<SEC-DOCUMENT>0001047469-19-002652.txt : 20190429
<SEC-HEADER>0001047469-19-002652.hdr.sgml : 20190429
<ACCEPTANCE-DATETIME>20190429060836
ACCESSION NUMBER:		0001047469-19-002652
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20190429
DATE AS OF CHANGE:		20190429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-230837
		FILM NUMBER:		19773584

	BUSINESS ADDRESS:	
		STREET 1:		13503 SANDERLING PLACE
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874
		BUSINESS PHONE:		240-418-1773

	MAIL ADDRESS:	
		STREET 1:		13503 SANDERLING PLACE
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20874
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>a2238596zs-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg78701_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fa78701_index_to_financial_statements">  INDEX TO FINANCIAL STATEMENTS</A><BR></font>
</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>As filed with the Securities and Exchange Commission on April&nbsp;29, 2019.

 </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>


Registration No.&nbsp;333-230837

  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1><B> &nbsp;<BR>  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>


Amendment No.&nbsp;1<BR>
to

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>NextCure,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=1>(Exact Name of Registrant as Specified in its Charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 47-5231247</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>9000 Virginia Manor Road, Suite&nbsp;200<BR>
Beltsville, Maryland 20705<BR>
(240)&nbsp;399-4900</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Michael Richman<BR>
Chief Executive Officer<BR>
NextCure,&nbsp;Inc.<BR>
9000 Virginia Manor Road, Suite&nbsp;200<BR>
Beltsville, Maryland 20705<BR>
(240)&nbsp;399-4900</B></FONT><FONT SIZE=1><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="46%" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Asher M. Rubin<BR>
William I. Intner<BR>
Hogan Lovells US&nbsp;LLP<BR>
100 International Drive, Suite&nbsp;2000<BR>
Baltimore, Maryland 21202<BR>
(410)&nbsp;659-2700</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Divakar Gupta<BR>
Brent B. Siler<BR>
Joshua A. Kaufman<BR>
Madison A. Jones<BR>
Cooley&nbsp;LLP<BR>
1114 Avenue of the Americas<BR>
New York, New York 10036<BR>
(212)&nbsp;479-6000</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to public:<BR>
As soon as practicable after the effective date of this registration statement.  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933 check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="87pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="134pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE

 </B></FONT>

</P>

<div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="33%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="91" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be Registered<SUP>(1)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price<BR>
Per Share<SUP>(2)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price<SUP>(2)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee<SUP>(3)</SUP></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, par value $0.001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>5,750,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$16.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$92,000,000.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$11,150.40</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->


<DL compact>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
750,000 shares that the underwriters have an option to purchase.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Estimated
solely for the purpose of computing the amount of the registration fee pursuant to Rule&nbsp;457(a) under the Securities Act of 1933, as amended.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
registrant paid $10,453.50 of the registration fee in connection with the initial filing of this Registration Statement on April&nbsp;12, 2019.


</FONT></DD>

</DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file&nbsp;a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as
amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section&nbsp;8(a), may determine.  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;text-align:justify"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=507148,FOLIO='blank',FILE='DISK106:[19ZAH1.19ZAH78701]BA78701A.;22',USER='WWASSER',CD='26-APR-2019;12:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT COLOR="#F1665F" SIZE=2>The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and
Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is
not permitted.</FONT></P>

<P style="font-family:times;text-align:justify">


<FONT COLOR="#F1665F" SIZE=3><I>SUBJECT TO COMPLETION<BR>  </I></FONT><FONT COLOR="#F1665F" SIZE=2><I>DATE APRIL 29, 2019</I></FONT>


</P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=5><I>5,000,000 Shares

 </I></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>
<IMG SRC="g79071.jpg" ALT="LOGO" WIDTH="373" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>NextCure,&nbsp;Inc.  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>Common Stock  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


 </FONT> <FONT SIZE=4><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2><B><I>NextCure,&nbsp;Inc. is offering 5,000,000 shares of common stock. This is our initial public offering and no public market exists for
our common stock. We anticipate that the initial public offering price will be between $14.00 and $16.00 per share.

  </I></B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><B><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I>We have applied to list our common stock on the Nasdaq Global Market under the symbol "NXTC".  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><B><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=3><B><I>We are an "emerging growth company" as defined under U.S. federal securities laws and will be subject to reduced
public company reporting requirements. Investing in our common stock involves risks. See "Risk Factors" beginning on page 12.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p><div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </I></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Per&nbsp;Share

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Total

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B><I> </I></B></FONT><FONT SIZE=2><I>Initial Public Offering Price </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2><I> </I></FONT><FONT SIZE=2><I>Underwriting Discounts and Commissions<SUP>(1)</SUP> </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2><I> </I></FONT><FONT SIZE=2><I>Proceeds, before expenses, to us </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> We refer you to "Underwriters" for additional information regarding total underwriter compensation.</I></FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2><I>We have granted the underwriters an option for a period of 30&nbsp;days to purchase up to an additional 750,000 shares of our common stock.</I></FONT>

</P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2><I>Certain of our stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $35.0
million of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are
not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any of these stockholders, or any of these stockholders may
determine to purchase more, fewer or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other
shares sold to the public in this offering.</I></FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</I></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>The underwriters expect to deliver the shares to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Joint Booking-Running Managers  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p><div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>


<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


  </I></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="159pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="183pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="136pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=3><I>MORGAN STANLEY</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=3><I>BofA MERRILL LYNCH</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=3><I>PIPER JAFFRAY</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:times;"><font></FONT><FONT SIZE=2><I>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
 2019</I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=399178,FOLIO='blank',FILE='DISK106:[19ZAH1.19ZAH78701]BC78701A.;37',USER='CHE106319',CD='26-APR-2019;00:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_bg78701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="BG78701A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg78701_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<A NAME="BG78701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ca78701_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Prospectus Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca78701_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da78701_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da78701_risk_factors"><FONT SIZE=2>12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dm78701_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_special_note_regarding_forward-looking_statements"><FONT SIZE=2>63</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dm78701_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_use_of_proceeds"><FONT SIZE=2>65</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dm78701_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_dividend_policy"><FONT SIZE=2>66</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dm78701_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_capitalization"><FONT SIZE=2>67</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#do78701_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do78701_dilution"><FONT SIZE=2>69</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#do78701_selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do78701_selected_financial_data"><FONT SIZE=2>71</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dq78701_management_s_discussion_and_an__man03466"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq78701_management_s_discussion_and_an__man03466"><FONT SIZE=2>72</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ds78701_business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds78701_business"><FONT SIZE=2>83</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eg78701_management"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eg78701_management"><FONT SIZE=2>122</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ei78701_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ei78701_executive_compensation"><FONT SIZE=2>133</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#em78701_certain_relationships_and_related_party_transactions"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Party Transactions</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#em78701_certain_relationships_and_related_party_transactions"><FONT SIZE=2>145</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eo78701_principal_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eo78701_principal_stockholders"><FONT SIZE=2>150</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eq78701_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eq78701_description_of_capital_stock"><FONT SIZE=2>154</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#es78701_shares_eligible_for_future_sale"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#es78701_shares_eligible_for_future_sale"><FONT SIZE=2>159</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#es78701_material_u.s._federal_income_t__mat03024"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Common
Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#es78701_material_u.s._federal_income_t__mat03024"><FONT SIZE=2>162</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eu78701_underwriters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eu78701_underwriters"><FONT SIZE=2>166</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eu78701_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eu78701_legal_matters"><FONT SIZE=2>172</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eu78701_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eu78701_experts"><FONT SIZE=2>172</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#eu78701_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#eu78701_where_you_can_find_more_information"><FONT SIZE=2>172</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#fa78701_index_to_financial_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#fa78701_index_to_financial_statements"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor any of the underwriters has authorized anyone to provide you any information that is different than that contained in this prospectus or any free writing prospectus
prepared by or on behalf of us or to which we may have referred you in connection with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information in this
prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that
jurisdiction. Persons who come
into possession of this prospectus in jurisdictions outside the United States must inform themselves about, and observe any restrictions as to, this offering and the distribution of this prospectus
applicable to that jurisdiction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=887187,FOLIO='i',FILE='DISK106:[19ZAH1.19ZAH78701]BG78701A.;13',USER='CHE106319',CD='26-APR-2019;02:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ca78701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca78701_prospectus_summary"> </A>
<A NAME="toc_ca78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information
that you should consider in making your investment decision. Before investing in our common stock, you should read this entire prospectus carefully, including the sections entitled "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and related notes contained elsewhere in this prospectus. Unless the context
otherwise requires, references in this prospectus to the "company," "NextCure," "we," "us" and "our" refer to NextCure,&nbsp;Inc.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding
biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or
FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are
focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are
committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition, for these patients. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate, NC318, is a first-in-class immunomedicine against a novel immunomodulatory receptor called Siglec-15, or S15. In October 2018, we initiated a Phase 1/2
clinical trial of NC318 in patients with advanced or metastatic solid tumors. We expect completion of the Phase&nbsp;1 portion of this trial in the fourth quarter of 2019 and completion of the
Phase&nbsp;2 portion in the fourth quarter of 2020. Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called
Leukocyte-Associated Immunoglobulin-like Receptor 1, or LAIR-1. We expect to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for NC410 in the
first quarter of 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
approach to identifying targets for new immunomedicines is based on our FIND-IO platform. FIND-IO embodies a rational approach to the discovery of novel cell surface and secretory
molecules that drive functional immune responses. We use our immunology knowledge, experience, capabilities and tools we have developed, including our FIND-IO platform, to support our discovery
efforts. We are working to discover novel targets that play a key role in mediating immune dysfunction that allows tumors to evade the immune system. We are seeking to identify and develop
immunomedicines that counteract these outcomes and to further validate and advance our product candidates. We have identified multiple novel targets using our FIND-IO platform, including those for
which certain of our research programs are being designed to target. In addition, the immunosuppressive properties of&nbsp;S15, the target of&nbsp;NC318, were discovered using a predecessor of our
FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
advancement of cancer to late stages indicates a failure of the immune system to mount an effective anti-tumor immune response. Immuno-oncology, which focuses on stimulating the
immune system to respond to cancer and includes checkpoint inhibitors targeting PD-L1, PD-1 and CTLA-4, is one of the most significant advances in the history of cancer treatment. In 2011, the first
checkpoint inhibitor was approved, and today, despite only a modest breadth of efficacy, this class of therapies is estimated to have had global sales of more than $17&nbsp;billion in 2018 and is
predicted to reach more than $33&nbsp;billion in global sales by 2022. However, despite the recent success of checkpoint inhibitors, efficacy has been limited. It is estimated that up to 60% to 70%
of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer, non-small cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to
single-agent therapy with checkpoint inhibitors. In addition, some patients </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=396964,FOLIO='1',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_2"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>develop
resistance after initial treatment with these therapies. As a result, the standard of care in cancer today leaves many patients underserved. We believe broader efficacy and more meaningful
clinical responses in oncology may be obtained by focusing on the tumor microenvironment, or TME. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are using our FIND-IO platform as our discovery engine to identify targets and develop immunomedicines that restore normal immune function in the TME through novel mechanisms of
action. Since our founding in 2015, we have developed, industrialized and optimized our FIND-IO platform based on the immunological expertise of our management team and the scientific leadership of
our scientific founder, Dr.&nbsp;Lieping Chen. Our approach in creating the FIND-IO platform, and how we apply it, reflects our belief in the importance of understanding biological pathways of all
cells in the
immune system and restoring normal immune function. The platform uses our proprietary approaches to assess the suppressive or stimulatory function of immune pathways in T cells and other immune cells,
as measured by effects on proliferation or induction of molecules known to impact immune responses, such as cytokines, which are signaling molecules secreted by cells in the immune system that mediate
and regulate immunity and inflammation. We study primary immune cells from healthy donors and from patients with various diseases, as well as established cell lines from immune and non-immune cell
lineages, including T cell subsets, monocytes, macrophage subpopulations and cancer cell lines. In oncology, we are using the FIND-IO platform to discover immunomedicines with the potential to
intervene or modulate interactions of immune cells within the TME to restore anti-tumor activity. We are also expanding the functional screening approach of our FIND-IO platform for the identification
of novel targets in other serious illnesses outside of oncology, including autoimmune, inflammatory and neuro-inflammatory diseases. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, we entered into a multi-year collaboration agreement with Eli Lilly and Company, or Lilly, focused on the discovery and development of immunomedicines for oncology
using our FIND-IO platform. The collaboration seeks to discover novel cancer targets utilizing our platform and provides that we and Lilly will each receive options to exclusively develop antibodies
resulting from the collaboration. In connection with the agreement, we received an upfront payment of $25.0&nbsp;million in cash and an equity investment of $15.0&nbsp;million and are eligible to
receive development and regulatory milestones and sales milestones in an aggregate of up to $1.4&nbsp;billion, as well as royalty payments. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=450254,FOLIO='2',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Pipeline  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are leveraging our understanding of biological pathways and our FIND-IO platform to discover, validate and build a proprietary pipeline of
immunomedicine candidates. The figure below details our pipeline of product candidates and principal discovery and research programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g57012.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="370">
  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Programs  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC318, our lead immunomedicine program, is a monoclonal antibody targeting S15, which is expressed on highly immunosuppressive cells called M2
macrophages and on tumor cells. The immunosuppressive properties of S15 were discovered in 2015 at Yale University by Dr.&nbsp;Chen. Dr.&nbsp;Chen was also the first to discover a molecule he
called B7-H1, which is now more widely known as PD-L1, or programmed cell death protein ligand 1, which is the ligand for PD-1, or programmed cell death 1. In preclinical research, we and others
observed that S15 promotes suppression of T cell proliferation and negatively regulates T cell function. NC318 is designed to block this S15-mediated immune suppression and restore T&nbsp;cell
function and anti-tumor immunity in the TME, which we believe will reduce and kill tumors. We believe NC318 has the potential to treat multiple cancer indications because S15 is expressed in multiple
tumor types and has a unique ability to modulate immune responses in the TME. In addition, because S15 and PD-L1 expression in tumors generally appear to be non-overlapping, we believe NC318 may be
well suited to treat patients who are not responding to PD-1/PD-L1 directed cancer therapies. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
preclinical studies, we evaluated the safety and efficacy of 5G12, the murine parent antibody of NC318, which has similar overall functional properties to NC318, and observed that
blocking the effects of S15 with 5G12 restored immune function and anti-tumor immunity, reduced tumor growth and increased survival. Our ongoing first-in-human trial is an open-label, Phase 1/2
clinical trial designed to assess the safety and tolerability of NC318, to define the maximal tolerable dose or pharmacologically active dose and to assess preliminary efficacy. Patients receive NC318
on day one of each cycle. We have initiated the trial with 14-day cycles; however, we may explore alternate dose administration schedules depending on pharmacokinetics, pharmacodynamics, biomarker
data, safety results and feedback from investigators. We designed this clinical trial with a robust biomarker strategy to help evaluate clinical activity throughout the trial by focusing on markers of
pharmacodynamics. We are initially evaluating NC318 for the treatment of </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=368902,FOLIO='3',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_4"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>advanced
or metastatic solid tumors, which could include ovarian cancer, non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma. As of March&nbsp;31, 2019, we have dosed 21
patients in the Phase&nbsp;1 portion of the trial across four dose cohorts. To date, NC318 has been well tolerated, with no drug-related severe adverse events or dose limiting toxicities observed.
We have observed one confirmed partial response and six instances of stable disease in 13 patients who have had at least one on-treatment radiologic assessment as of March&nbsp;31, 2019. We expect
to complete the Phase&nbsp;1 portion of the trial in the fourth quarter of 2019 and to complete the Phase&nbsp;2 portion in the fourth quarter of 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC410,
our second immunomedicine program, is a fusion protein designed to block immune suppression mediated by LAIR-1. LAIR-1 is expressed on T cells and antigen-presenting cells, known
as dendritic cells, that present tumor antigens to immune cells in order to generate immune responses. The binding of LAIR-1 to collagen or C1q results in loss of immune function in the TME and a
reduction in T cell function and dendritic cell activity. By blocking the binding of LAIR-1, NC410 can promote T cell function and dendritic cell activity, which could result in anti-tumor immune
responses that eliminate cancer cells. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have conducted multiple preclinical studies to assess the activity of NC410 across a variety of preclinical models. These studies support our understanding that eliminating or
blocking the binding of LAIR-1 to collagen or C1q can restore normal immune function in multiple immune cells, including T cells and myeloid cells, resulting in activation of T cells and anti-tumor
immunity. We and others have analyzed genomic and protein databases and observed that LAIR-1 expression levels negatively correlate with survival rates for several cancers, including brain, renal,
colorectal, glioma, lung, urothelial and ovarian cancers. These analyses support possible targeting of these tumor types as primary indications for therapeutic treatment with NC410. We are currently
conducting IND-enabling studies for NC410 and expect to submit an IND and initiate a Phase&nbsp;1/2 clinical trial in patients with advanced or metastatic solid tumors in the first quarter of 2020.
We are currently focused on opportunities for NC410 in ovarian cancer, NSCLC and renal cancer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to NC318 and NC410, we are also pursuing discovery and preclinical evaluation of other potential novel immunomodulatory molecules. Among these is an antibody that targets a
novel member of the B7-family of immunomodulatory proteins. We also have an antibody in preclinical development targeting an immune modulator that is highly expressed in inflamed tissue and the TME in
multiple tumor types. In addition, based on our understanding of the LAIR pathway, including through our development of NC410, we are also pursuing monoclonal antibodies that target LAIR-1 and
directly block LAIR-1 signaling to prevent tumor growth or to eliminate the tumor. These novel LAIR-1
antibodies have unique functional properties that may provide additional opportunities in both cancer and autoimmune disorders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our FIND-IO Discovery Engine  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our FIND-IO platform is the result of our industrialization, expansion and optimization of a predecessor platform that Dr.&nbsp;Chen used to
discover the immunosuppressive properties of S15. Our FIND-IO platform applies a function-based screening approach to identify human proteins and to determine whether those proteins alter or stop an
immune response resulting in immune evasion. The platform is designed to identify novel cell surface molecular interactions that drive functional immune responses. Our FIND-IO platform broadly and
quantitatively evaluates interactions between relevant protein components and different cellular types over time in order to identify novel targets that either increase or decrease immune-related
functional responses associated with desired immune responses against tumors. By identifying novel immune modulators, proteins or other molecules through the FIND-IO platform, we aim to develop
next-generation immunomedicines that restore normal immune function in the TME. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1017680,FOLIO='4',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy is to use our fully integrated discovery and product development infrastructure to build a sustainable pipeline of product
candidates to treat cancer patients who are not adequately served by currently available therapies. The key elements of our strategy include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Advancing the clinical development of our lead product candidates, NC318 and NC410. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Building an oncology pipeline of novel targets for new immunomedicines focused on non-responders. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Leveraging our fully integrated development, quality systems and cGMP manufacturing capabilities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Expanding our current focus and creating new opportunities outside of the oncology field, including through strategic partnerships. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Team  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have assembled an experienced management team to execute on our mission to create novel immunomedicines. Our scientific founder and members
of our management team collectively have extensive experience in drug discovery and product development and are leaders in the immuno-oncology field. Members of our management team have experience
discovering, developing, manufacturing and commercializing biologics, including some of the earliest approved monoclonal antibodies, such as Synagis, as well as some of the first immune checkpoint
inhibitor monoclonal antibodies and fusion proteins targeting the PD-1/PD-L1 pathway and CTLA-4. Within three years, we advanced our company from formation to antibody generation to the clinic, and
constructed a manufacturing facility that complies with current good manufacturing practice, or cGMP, and that we have used to manufacture our preclinical and clinical drug supply. We have received
financial support from leading healthcare investors, including OrbiMed Advisors, Canaan Partners, Sofinnova Investments, Pfizer Ventures, Lilly Asia Ventures, Quan Capital, Bay City
Capital&#150;GF Xinde, Surveyor Capital (a Citadel Company), Ping An Ventures, Taiho Ventures, ArrowMark Partners, NS Investment and Alexandria Venture Investments. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Members
of our management team have a longstanding relationship with our scientific founder Dr.&nbsp;Chen, who is the United Technologies Corporation Professor in Cancer Research and
Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) at Yale, and the Co-Director of the Cancer Immunology Program at Yale Cancer Center. Dr.&nbsp;Chen was the first to
discover PD-L1 and to show that it is expressed by multiple tumor types and its activity can cause the death of T cells, preventing those T cells from eliminating cancer cells. He also showed that
blocking the interaction between PD-1 and PD-L1 with monoclonal antibodies improved the immune system's ability to eliminate tumors. Dr.&nbsp;Chen's work provided an important foundation for the
subsequent development of immunotherapies that enable more effective immune treatments against cancer. Since then, his laboratory has identified and characterized various molecules in two of the major
families of immune modulating proteins, the B7-CD28 and the tumor necrosis factor receptor/ligand superfamilies, and elucidated their interactions and functions in controlling immune responses. The
immunosuppressive properties of S15, the target of our lead product candidate, NC318, were discovered in Dr.&nbsp;Chen's lab using a predecessor of our FIND-IO platform. In December 2015, we entered
into a license agreement with Yale, pursuant to which we obtained an exclusive, royalty-bearing, sublicensable worldwide license to products that either incorporate certain licensed patents used in
the discovery of targets or arise out of research and development of Dr.&nbsp;Chen's laboratory at Yale, including S15. We continue to collaborate with Dr.&nbsp;Chen on discovering novel
immunomedicines through an exclusive sponsored research agreement with Yale. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the combination of our team's capabilities and focus on understanding the biological pathways of the immune system, our product development expertise and manufacturing
infrastructure, our partnership with Lilly and our relationship with Dr.&nbsp;Chen and Yale positions us to build a sustainable portfolio of first-in-class immunomedicines. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1048147,FOLIO='5',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Associated with Our Business  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to implement our business strategy is subject to numerous risks and uncertainties. You should carefully consider all of the
information set forth in this prospectus and, in
particular, the information in the section entitled "Risk Factors" beginning on page&nbsp;12 before making an investment decision. Risks include, among others, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue
to incur significant losses for the foreseeable future and may never achieve or maintain profitability. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Even if this offering is successful, we will require substantial additional financing to pursue our business objectives, which may not be
available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercial efforts or
other operations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing
approval and ultimately commercialize them. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our approach to the discovery and development of product candidates based on our FIND-IO platform is unproven and may not result in marketable
products. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays or
an inability in developing and commercializing our current and future product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and
we may ultimately be unable to obtain regulatory approval for our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The results of preclinical studies and early-stage clinical trials may not be predictive of future results. We have only recently initiated our
first-in-human clinical trial of NC318 and do not expect to complete the Phase 1 portion of that trial until the fourth quarter of 2019. Initial success in our ongoing clinical trial may not be
indicative of results obtained when these trials are completed or in later stage trials. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel,
we may not be able to successfully implement our business strategy. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Given our limited operating history, our manufacturing experience as an organization and with our manufacturing facility is limited. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We have filed patent applications for our lead product candidates, but no patent has yet issued from these applications. If we are unable to
obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize
products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We may depend on Lilly, Yale or other third-party collaborators for the discovery, development and commercialization of our current and future
product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to
compete effectively. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
additional information about the risks we face, see the section entitled "Risk Factors." </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=134117,FOLIO='6',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ca78701_1_7"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in Delaware in September 2015. Our primary executive offices are located at 9000 Virginia Manor Road, Suite&nbsp;200,
Beltsville, Maryland 20705 and our telephone number is (240)&nbsp;399-4900. Our website address is </FONT><FONT SIZE=2><I>www.nextcure.com</I></FONT><FONT SIZE=2>. The information contained on, or
that can be accessed through, our website is not part of this prospectus and should not be considered as part of this prospectus or in deciding whether to purchase our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NextCure,
FIND-IO and our logo are some of our trademarks used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other
organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus may appear without the &reg; and &#153; symbols, but those references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and tradenames. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, we have elected
to comply with certain reduced public company reporting requirements for this prospectus and future filings. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being
required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive
compensation related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from
other public companies in which you hold stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will remain an emerging growth company until the earliest of (i)&nbsp;December&nbsp;31, 2024, (ii)&nbsp;the last day of the first fiscal year in which we have total annual gross
revenues of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the first fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0&nbsp;million
on June&nbsp;30th&nbsp;and (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This
provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of
this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we
(i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS act. As a result, our financial
statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company," which would allow us to take advantage of many of the same
exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=50957,FOLIO='7',FILE='DISK106:[19ZAH1.19ZAH78701]CA78701A.;24',USER='CHE106319',CD='26-APR-2019;01:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_cc78701_1_8"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc78701_the_offering"> </A>
<A NAME="toc_cc78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> Common stock offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 5,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Common stock to be outstanding immediately after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 21,935,381 shares (or 22,685,381 shares if the underwriters exercise their option to purchase additional shares in full)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Option to purchase additional shares offered by us</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 750,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 We estimate that the net proceeds from the sale of shares of our common stock in this offering will be approximately $66.6&nbsp;million, or approximately $77.0 million if the underwriters exercise their option to purchase additional shares in full,
 assuming an initial offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by
 us.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 We intend to use the net proceeds from this offering to advance NC318 through completion of our ongoing Phase&nbsp;1/2 clinical trial and into a Phase&nbsp;3 clinical trial, to advance NC410 through completion of a Phase&nbsp;1/2 clinical trial and
 for research and development activities related to our FIND-IO platform and discovery programs, including advancement of two discovery programs through submission of INDs, personnel expenses, working capital and other general corporate purposes. See
 the section entitled "Use of Proceeds" on page&nbsp;65 for a more complete description of the intended use of proceeds from this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 You should carefully read the section entitled "Risk Factors" on page 12 for a discussion of factors that you should consider before deciding to invest in shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Proposed Nasdaq Global Market symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 "NXTC"</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of common stock to be outstanding after this offering is based on 16,935,381 shares of common stock outstanding as of December&nbsp;31, 2018, which includes
272,802 shares of restricted common stock that were unvested or subject to repurchase at December&nbsp;31, 2018 and gives effect to the conversion of all outstanding shares of our preferred stock
into 15,560,569 shares of our common stock upon the closing of this offering, and excludes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,056,891 shares of our common stock issuable upon the exercise of stock options outstanding under our 2015 Omnibus Incentive Plan, or the 2015
Plan, as of December&nbsp;31, 2018, with a weighted average exercise price of $4.74 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 699,590 shares of our common stock reserved for issuance pursuant to future awards under our 2015 Plan as of December&nbsp;31, 2018, which
shares will cease to be available for issuance at the time our 2019 Omnibus Incentive Plan, or the 2019 Plan, becomes effective;

</FONT></DD>

</DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1035076,FOLIO='8',FILE='DISK106:[19ZAH1.19ZAH78701]CC78701A.;13',USER='WWASSER',CD='26-APR-2019;19:11' -->
<A NAME="page_cc78701_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,900,000 shares of our common stock that will become available for future issuance under our 2019 Plan upon the effectiveness of the
registration statement of which this prospectus forms&nbsp;a part; and</FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 240,000 shares of our common stock that will become available for future issuance under our 2019 Employee Stock Purchase Plan, or the ESPP,
upon the effectiveness of the registration statement of which this prospectus forms&nbsp;a part.


</FONT></DD>

</DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, unless we specifically state otherwise, all information in this prospectus reflects or assumes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a 1-for-8.0338 reverse stock split to be effected prior to the effectiveness of the registration statement of which this prospectus forms a
part; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the conversion of all outstanding shares of our preferred stock into 15,560,569 shares of our common stock upon the closing of this offering; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> no exercise of outstanding stock options subsequent to December&nbsp;31, 2018; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> no exercise by the underwriters of their option to purchase up to an additional 750,000 shares of our common stock in this offering; and </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the filing and effectiveness of our amended and restated certificate of incorporation in Delaware and the adoption of our amended and restated
bylaws, which will occur upon the closing of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise specified and unless the context requires, we refer to our Series&nbsp;A-1, Series&nbsp;A-2, Series&nbsp;A-3, Series&nbsp;B-1, Series&nbsp;B-2 and
Series&nbsp;B-3 Preferred Stock collectively as "preferred stock" in this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indications of Interest

  </B></FONT>

</P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an
aggregate of approximately $35.0&nbsp;million of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering.
However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any of these
stockholders, or any of these stockholders may determine to purchase more, fewer or no shares in this offering.

 </FONT>

</P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=81324,FOLIO='9',FILE='DISK106:[19ZAH1.19ZAH78701]CC78701A.;13',USER='WWASSER',CD='26-APR-2019;19:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ce78701_1_10"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce78701_summary_financial_data"> </A>
<A NAME="toc_ce78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following tables present summary financial data for our business. We derived the statement of operations and
comprehensive loss data for the years ended December&nbsp;31, 2018 and 2017 and the balance sheet data as of December&nbsp;31, 2018 from our audited financial statements appearing elsewhere in
this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. You should read this data together with our financial statements and related
notes, as well as the information included in the sections entitled "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," which appear
elsewhere in this prospectus.</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands,&nbsp;except share<BR>
and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations and Comprehensive Loss Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,954</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,409</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,595 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,549 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,038,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>See
Note&nbsp;12 to our financial statements included elsewhere in this prospectus for further details on the calculations of our basic and diluted net loss per
share, basic and diluted pro forma net loss per share and the weighted average number of shares used in the computation of the per share amounts.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table below presents our balance sheet data as of December&nbsp;31, 2018:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on a pro forma basis to give effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of
15,560,569 shares of common stock upon the closing of this offering; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to the sale of 5,000,000 shares of common stock in this offering, assuming an initial
offering price of $15.00 per share (the midpoint of the

 </FONT></DD>

</DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=187738,FOLIO='10',FILE='DISK106:[19ZAH1.19ZAH78701]CE78701A.;30',USER='WWASSER',CD='26-APR-2019;19:12' -->
<A NAME="page_ce78701_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>



<P style="font-family:times;text-align:justify"><FONT SIZE=2>estimated
price range set forth on the cover of this prospectus), and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

</FONT></P>


 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 </UL>
</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma<BR>
As Adjusted<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>201,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,628</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,628</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>213,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,065</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>162,223</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(46,944</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,279</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>181,829</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and the other terms of this offering
determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this
prospectus) would increase or decrease, respectively, the pro forma as adjusted amounts of cash and cash equivalents, working capital, total assets and total stockholders' equity by
$4.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are
offering in this offering would increase or decrease, respectively, the pro forma as adjusted amounts of cash and cash equivalents, working capital, total assets and total stockholders' equity by
$14.0&nbsp;million, assuming the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>We
define working capital as current assets less current liabilities. See our audited financial statements and related notes included elsewhere in this prospectus
for details regarding our current assets and current liabilities.  </FONT></DD></DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=791098,FOLIO='11',FILE='DISK106:[19ZAH1.19ZAH78701]CE78701A.;30',USER='WWASSER',CD='26-APR-2019;19:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_da78701_1_12"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da78701_risk_factors"> </A>
<A NAME="toc_da78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below
together with all of the other information in this prospectus, including our financial statements and the related notes and the information described in the section entitled "Management's Discussion
and Analysis of Financial Condition and Results of Operations," before deciding whether to invest in our common stock. If any of the events described below actually occurs, our business,
results of operations, financial conditions, cash flows or prospects could be harmed. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of
your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Additional Capital  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history and no products approved for commercial sale. We have a history of
significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company with a limited operating history. Since our inception in 2015, we have incurred significant
net losses. Our net losses were $22.8&nbsp;million and $15.5&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively. As of December&nbsp;31, 2018, we had an accumulated
deficit of $47.3&nbsp;million. We have funded our operations to date primarily with proceeds from the sale of preferred stock and upfront fees received in connection with our collaboration with
Lilly. Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development
opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and
development activities for our product candidates, our discovery programs and our FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that it will be several years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses and operating losses for the foreseeable
future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if, and as,
we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continue to advance the preclinical and clinical development of our existing product candidates and our research programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> leverage our FIND-IO platform to advance additional product candidates into preclinical and clinical development; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> seek regulatory approvals for any product candidates that successfully complete clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> hire additional clinical, quality control, regulatory, scientific and administrative personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expand our operational, financial and management systems and increase personnel, including to support our clinical development, manufacturing
and commercialization efforts and our operations as a public company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> establish a marketing, sales, distribution and medical affairs infrastructure to commercialize any products for which we may obtain marketing
approval and commercialize, whether on our own or jointly with a partner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> acquire or in-license other technologies or engage in strategic partnerships; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a
public company. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=868220,FOLIO='12',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
become and remain profitable, we, whether on our own or jointly with Lilly or any potential future collaborator, must develop and eventually commercialize products with significant
market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product
candidates, manufacturing, marketing and selling products and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never
generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or
continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have never generated revenue from product sales and may never be profitable.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners,
to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for the
next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, or our existing or future collaborators', success
in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> completing preclinical studies and clinical trials of our product candidates, including our ongoing Phase 1/2 clinical trial for NC318 and
other planned clinical trials for NC318 and NC410; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> seeking and obtaining marketing approvals for any product candidates that we or our collaborators develop; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> receiving acceptance of the INDs for NC410 and future product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> identifying and developing new product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> launching and commercializing product candidates for which we obtain marketing approval by establishing a marketing, sales, distribution and
medical affairs infrastructure or, alternatively, collaborating with a commercialization partner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> achieving coverage and adequate reimbursement by hospitals and third-party payors, including governmental authorities, such as Medicare and
Medicaid, private insurers and managed care organizations, for product candidates, if approved. that we or our collaborators develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> manufacturing cGMP supply of our product candidates for clinical trials and, if approved, commercial sales; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtaining market acceptance of product candidates, if approved, that we develop as viable treatment options; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> addressing any competing technological and market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under
such arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> defending against third-party interference or infringement claims, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attracting, hiring and retaining qualified personnel. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate incurring significant costs associated with commercializing any product candidate that is approved for commercial sale. Our expenses could increase beyond expectations if
we are required by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=467407,FOLIO='13',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>FDA
or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved
products, we may not become profitable and may need to obtain additional funding to continue operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if this offering is successful, we will require substantial additional financing to pursue our business
objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product
development, commercialization efforts or other operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the
preclinical and clinical development of our current and future programs. If we receive marketing approval for any product candidates, including NC318 and NC410, we will require significant additional
amounts of cash in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and outcomes of our planned and anticipated clinical
trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development of and commercialize any product candidate we develop. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
future capital requirements depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the scope, progress, timing, results and costs of researching and developing NC318, NC410 and our other product candidates, including targets
identified through our FIND-IO platform, and of conducting preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing of, and the costs involved in, obtaining marketing approval for NC318, NC410 and any future product candidates we develop, if
clinical trials are successful; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of our collaboration with Lilly, including whether Lilly exercises its licensing options under its collaboration agreement with us,
each of which would trigger additional payments to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of manufacturing NC318, NC410 and any future product candidates for preclinical studies and clinical trials and in preparation for
marketing approval and commercialization; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of commercialization activities, including marketing, sales and distribution costs, for NC318, NC410 and any future product
candidates we develop, whether alone or with a collaborator, if any of these product candidates are approved for sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of our corporate sponsored research agreement, or SRA, with Yale University; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to establish and maintain additional strategic collaborations, licensing or other arrangements on favorable terms, if at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs
and the outcome of any such litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone
payments we are required to make, or that we may be eligible to receive, under those agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing, receipt and amount of sales of, or royalties on, our future products, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the emergence of competing therapies and other adverse developments in the oncology market. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of
public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. As of December&nbsp;31, 2018, we
had $135.2&nbsp;million in cash and cash equivalents. Based on our research and development plans, we expect that the net proceeds from this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=129204,FOLIO='14',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2022. This estimate is based
on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available
capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates and changes in regulation.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise additional capital through marketing, sales and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may
have to relinquish certain valuable rights to our product candidates, future revenue streams or research programs, technologies or grant licenses on terms that may not be favorable to us. If we raise
additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. Further, to
the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise
additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring dividends. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adequate
additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain additional financing on favorable terms when needed, we may be
required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the Discovery and Development of Our Product Candidates  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business is dependent on our ability to advance our current and future product candidates through
clinical trials, obtain marketing approval and ultimately commercialize them.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are early in our development efforts. We have only recently initiated our first clinical trial for NC318, our lead product candidate, and our
second product candidate, NC410, is in preclinical development. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the
successful development and eventual commercialization of NC318, NC410 and any future product candidates we develop, which may never occur. Our current product candidates, including NC318 and NC410,
and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the
United States and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient cGMP manufacturing supply for both preclinical and clinical development and
commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
clinical and commercial success of our current and future product candidates will depend on several factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> timely and successful completion of preclinical studies and our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> acceptance of the INDs for NC410 and future product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> successful enrollment in and completion of clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient
populations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=903533,FOLIO='15',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers, if
needed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> whether we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond
those planned or anticipated to support approval of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the
FDA and comparable foreign regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> receipt and maintenance of timely marketing approvals from applicable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> successfully launching commercial sales of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> entry into collaborations to further the development of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> maintaining a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> competing effectively with other therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to identify targets and immunomedicines, whether through our FIND-IO platform, through our relationships with Yale or otherwise;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> enforcing and defending intellectual property rights and claims. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future
product candidates, and could otherwise materially harm our business. Successful completion of clinical trials does not mean that NC318, NC410 or any future product candidates we develop will receive
regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we
develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our
business operations or achieve profitability. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming
and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and
amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions. We have not obtained regulatory approval
for any product candidate. Neither we nor any future collaborator is permitted to market any product candidates in the United States until we receive regulatory approval of a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1991,FOLIO='16',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>biologics
license application, or BLA, from the FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval in the United States or elsewhere. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe,
pure and potent for its proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
authorities for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or
regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or
the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our
clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we
develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in
determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates
are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we
request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims we believe
are necessary or desirable for the successful commercialization of such product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the FDA or comparable foreign regulatory authorities may change their policies, issue additional regulations, revise existing regulations or take other actions that may
prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to
obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=20,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=815244,FOLIO='17',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur
additional costs and experience delays or an inability in developing and commercializing our current and future product candidates.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take many years to complete, and its outcome is highly uncertain.
Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical
studies and initiating or completing additional clinical trials. Although we initiated a Phase 1/2 clinical trial of NC318 in October 2018, we may experience delays in initiating or completing our
planned clinical trials and development efforts. Additionally, we cannot be certain the ongoing and planned preclinical studies or clinical trials for NC318, NC410 or any future product candidates
will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. We may also experience numerous unforeseen events during our clinical
trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or other regulatory authorities, Institutional Review Boards, or IRBs, or independent ethics committees may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other
requirements on us, before permitting us to initiate a clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract
research organizations, or CROs, as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> clinical trials of any product candidates may fail to show safety, purity or potency, or may produce negative or inconclusive results, which
may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the number of patients required for clinical trials may be larger than we anticipate, or we may have difficulty adding a sufficient number of
clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> it may be difficult to enroll a sufficient number of patients, enrollment in these clinical trials may be slower than we anticipate or
participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a
timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or
trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=21,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=926666,FOLIO='18',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<A NAME="page_da78701_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators,
IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product
candidates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the supply or quality of materials for product candidates we develop or other materials necessary to conduct clinical trials may be
insufficient or inadequate. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
could encounter delays if a clinical trial is suspended or terminated by us, or by the IRBs of the institutions in which such trials are being conducted, ethics committees or the Data
Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of marketing approval of our product candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our
interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal
investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with
such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have
affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized,
which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product
candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our
ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development
and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring
products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. Any such events would impair our ability to successfully
commercialize our product candidates and may harm our business and results of operations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=22,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=382097,FOLIO='19',FILE='DISK106:[19ZAH1.19ZAH78701]DA78701A.;19',USER='WWASSER',CD='26-APR-2019;21:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dc78701_1_20"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to
clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With the exception of NC318, all of our product candidates are still in the preclinical discovery stage, and the risk of failure for such
product candidates is high. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and
potency, including efficacy, in humans. To meet these requirements we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate,
we must complete extensive preclinical testing and studies that support our planned INDs in the United States. We cannot be certain of the timely completion or outcome of our preclinical testing and
studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our current
or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we
cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conducting
preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty
of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional
operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain programs that are the responsibility of Lilly or our potential future
collaborators over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but
not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an inability to generate sufficient preclinical or other </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> data to support the initiation of clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delays in reaching a consensus with regulatory agencies on study design; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA not permitting the reliance on preclinical or other data from published scientific literature. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The results of preclinical studies and early-stage clinical trials may not be predictive of future results.
We have only recently initiated our first-in-human clinical trial of NC318 and do not expect to complete the Phase&nbsp;1 portion of that trial until the fourth quarter of 2019. Initial success in
our ongoing clinical trial may not be indicative of results obtained when these trials are completed or in later stage trials.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials
are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules, and the results of any
early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results
obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our
product candidates. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered
significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our
business and operating results. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical
activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of
outcomes in human clinical trials. For example, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=668548,FOLIO='20',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dc78701_1_21"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>our
current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human
biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy
results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain
regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of
our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Interim and preliminary results from our clinical trials that we announce or publish from time to time may
change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data
and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data
being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with
caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common
stock to fluctuate significantly. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our approach to the discovery and development of product candidates using our FIND-IO platform is unproven
and may not result in marketable products.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The success of our business depends in part upon our ability to identify targets based on our proprietary FIND-IO platform and to develop and
commercialize immunomedicines. Our approach to the discovery of targets using the FIND-IO platform is novel. We have not yet initiated or completed a clinical trial of any product candidate developed
for a target identified from the FIND-IO platform. The platform may fail to accurately identify targets that modulate the immune system and are appropriate for immunomedicines. Even if we are able to
identify targets from the FIND-IO platform and to develop corresponding product candidates, we cannot assure that such product candidates will achieve marketing approval to safely and effectively
treat cancer or other disease states. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we uncover any previously unknown risks related to our FIND-IO platform, or if we experience unanticipated problems or delays in developing our FIND-IO product candidates, we may be
unable to achieve our strategy of building an oncology pipeline of novel targets for new immunomedicines focused on non-responders, or meet our obligations under the Lilly Agreement. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our current or future product candidates may cause undesirable side effects or have other properties when
used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their commercial potential or
result in significant negative consequences.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and
expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most
biologics, use of our current or future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from
infrequent to prevalent. There have been serious adverse side effects reported in response to immunotherapies in oncology. Immune-related adverse events that represent immune effects on normal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=958855,FOLIO='21',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dc78701_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>tissue
that can result from misdirected stimulation of the immune system are the most likely class of toxicity, and additional adverse side effects could develop. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have only recently initiated a Phase&nbsp;1/2 clinical trial of NC318, and it is likely that there will be side effects associated with its use. NC318 is an immunomedicine, and
although no specific toxicities were identified during preclinical testing, it is possible that immune-related adverse events associated with other immunotherapies may occur in patients treated with
NC318. Possible adverse side effects that could occur with treatment with immunotherapeutic products include an immunologic reaction early after administration which, while not necessarily adverse to
the patient's health, could substantially limit the effectiveness of the treatment. In addition to any potential side effects caused by the product or product candidate, the administration process or
related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the DSMB could suspend or
terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted
indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability
claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to
understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects
of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
our current and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with
regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Immunomedicines and their method of action of harnessing the body's immune system are powerful and could lead
to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates
have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that NC318, NC410 or any
other product candidate is safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates fail to demonstrate safety and
efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, even if we successfully advance one of our product candidates into and through clinical trials, such trials will likely only include a limited number of subjects and limited
duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients
are exposed to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant
negative consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory authorities may withdraw their approval of the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may be required to recall a product or change the way such product is administered to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any
component thereof; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=77915,FOLIO='22',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dc78701_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory authorities may require the addition of labeling statements, such as a "black box" warning or a contraindication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such
side effects for distribution to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the product may become less competitive; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant
revenues, which would materially harm our business. In addition, if one or more of our product candidates or our immunotherapeutic development approach generally prove to be unsafe, our entire
technology platform and pipeline could be affected, which would also materially harm our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As an organization, we have limited experience designing and implementing clinical trials and we have never
conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll
patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials,
and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may
delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis
of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally,
a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the
costs to implement the clinical trial, which could lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. See "&#151;Risks
Related to Reliance on Third Parties&#151;We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for NC318, NC410 and any future
product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to
obtain marketing approval for or commercialize NC318, NC410 and any future product candidates we develop, and our business could be materially harmed." Consequently, we may be unable to successfully
and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of NC318, NC410 or future product candidates. We may require more time and incur
greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we or our collaborators encounter difficulties enrolling patients in our clinical trials, our clinical
development activities could be delayed or otherwise be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll
a sufficient number of patients who remain in the trial until the trial's conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a
variety of reasons. The enrollment of patients depends on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the patient eligibility criteria defined in the protocol; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the nature and size of the patient population required for analysis of the trial's primary endpoints and the process for identifying patients; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=991651,FOLIO='23',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dc78701_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the number and location of participating clinical sites or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the design of the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to recruit clinical trial investigators with the appropriate competencies and experience; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> clinicians' and patients' perceptions as to the potential advantages and risks of the product candidate being studied in relation to other
available therapies, including any new products that may be approved for the indications we are investigating; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the availability of competing commercially available therapies and other competing drug candidates' clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to obtain and maintain patient informed consents for participation in our clinical trials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer
patients, will not survive the full terms of the clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product
candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial
conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce
the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used
methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future
clinical trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delays
of difficulties in patient enrollment may result in increased costs or may affect the timing, outcome or completion of clinical trials, which would adversely affect our ability to
advance the development of the product candidates we develop. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because the number of subjects in our Phase&nbsp;1/2 clinical trial of NC318 is small, the results from
this trial, once completed, may be less reliable than results achieved in larger clinical trials.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A study design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as proper
control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes, such as our ongoing Phase&nbsp;1/2 clinical trial of NC318, can be
disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, thus making the study results less
reliable than studies with a larger number of subjects. As a result, there may be less certainty that NC318 would achieve a statistically significant effect in any future clinical trials. If we
conduct any future clinical trials of NC318, we may not achieve a statistically significant result or the same level of statistical significance seen, if any, in our Phase&nbsp;1/2 clinical trial.
Similarly, if we conduct a clinical trial of any other product candidate we develop, including NC410, with a smaller sample size, the results of any such trial may be less reliable than results
achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects in any future clinical trials. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in
accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials must be conducted in accordance with the FDA's current good clinical practices requirements, or cGCP, or analogous requirements
of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=551952,FOLIO='24',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dc78701_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>committees
at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced in accordance with applicable cGMP. Clinical
trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements
or study protocols; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deficiencies in the clinical trial operations or trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unforeseen adverse side effects or the emergence of undue risks to study subjects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deficiencies in the trial design necessary to demonstrate efficacy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the product candidate may not appear to offer benefits over current therapies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the quality or stability of the product candidate may fall below acceptable standards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have chosen to prioritize development of NC318 and NC410. We may expend our limited resources on product
candidates or indications that do not yield a successful product and fail to capitalize on other candidates or indications for which there may be a greater likelihood of success or may be more
profitable.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited resources, we have strategically determined to prioritize development of NC318 and NC410 rather than other product
candidates based, in part, on the significant resources required for developing and manufacturing immunomedicines. To date, no regulatory authority has granted approval for an immunomedicine targeting
S15 or the LAIR pathway. As a result, we may be foregoing other potentially more profitable immunomedicines or therapies or those with a greater likelihood of success. Our decisions concerning the
allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable
commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties with respect to, certain programs
may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our current or
future product candidates or misread trends in the oncology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a
result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other
diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration,
licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may need to develop, or enter into a collaboration or partnership to develop, complementary or companion
diagnostics for our current or future product candidates. If we, or our future collaborators, are unable to successfully develop such complementary or companion diagnostics, or experience significant
delays in doing so, we may not realize the full commercial potential of our current or future product candidates.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of the key elements of our product development strategy is to identify cancer patient populations who may derive meaningful benefit from our
current or future product candidates. Because predictive biomarkers may be used to identify the right patients for current or future product candidates, we believe that our success may depend, in
part, on our ability to develop complementary or companion diagnostics in collaboration with partners. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have limited experience in the development of diagnostics and, as such, we expect to rely on future collaborators in developing appropriate diagnostics to pair with our current or
future product candidates. We have not yet begun substantial discussions with any potential partners with respect to the development of complementary or companion diagnostics and may be unsuccessful
in entering into
collaborations for the development of any such diagnostics for our current or future product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=322384,FOLIO='25',FILE='DISK106:[19ZAH1.19ZAH78701]DC78701A.;17',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_de78701_1_26"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Complementary or companion diagnostics are subject to regulation by the FDA and similar comparable foreign regulatory authorities as medical devices and require
separate regulatory approval or clearance prior to commercialization. If we, our collaborators, or any third parties that we engage to assist us, are unable to successfully develop complementary or
companion diagnostics for our current or future product candidates or experience delays in doing so:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> development of our current or future product candidates may be adversely affected if we are unable to appropriately select patients for
enrollment in our clinical trials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may not realize the commercial potential of our current or future product candidates if, among other reasons, we are unable to appropriately
identify, or it takes us longer to identify, patients who are likely to benefit from therapy with our products, if approved. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these events were to occur, our business could be materially harmed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to the Regulatory Approval and Commercialization of Product Candidates and Other Legal
Compliance Matters  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to obtain FDA approval of our product candidates under applicable regulatory requirements.
The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of
operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To gain approval to market our product candidates in the United States, we must provide the FDA with clinical data that adequately demonstrate
the safety, purity and potency, including efficacy, of the product candidate for the intended indication applied for in the applicable regulatory filing. Product development is a long, expensive and
uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered
significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings
made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory
filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and
potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
research, testing, manufacturing, labeling, approval, marketing, sale and distribution of biological products are subject to extensive regulation by the FDA and other regulatory
authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign
countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or comparable foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our inability to demonstrate to the satisfaction of the FDA or a comparable foreign regulatory authority that our product candidates are safe
and effective for the requested indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or a comparable foreign regulatory authority's disagreement with our trial protocol or the interpretation of data from preclinical
studies or clinical trials; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=980720,FOLIO='26',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our inability to demonstrate that the clinical and other benefits of our product candidates outweigh any safety or other perceived risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or a comparable foreign regulatory authority's requirement for additional preclinical studies or clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or a comparable foreign regulatory authority's non-approval of the formulation, labeling, or specifications of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or a comparable regulatory authority's failure to approve our manufacturing processes and facilities or the manufacturing processes and
facilities of third-party manufacturers upon which we rely; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> potential for approval policies or regulations of the FDA or a comparable foreign regulatory authority to significantly change in a manner
rendering our clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we eventually complete clinical testing and receive approval from the FDA or comparable foreign regulatory authorities for any of our product candidates, the FDA or comparable
foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or comparable foreign regulatory
authorities also may approve any of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or comparable foreign regulatory
authorities may not approve any of our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of any such product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies' approval processes and are
commercialized. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially harm our
business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree
of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other
therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, current approved immunotherapies,
and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. Our approach to targeting
different components of the tumor microenvironment is novel and unproven. In addition, adverse events in clinical trials testing our product candidates or in clinical trials of others developing
similar product candidates and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for our
current or future product candidates. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our immunomedicines or our competitors'
products, our products may not be accepted by the general public or the medical community. Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater
governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our current and any future product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become
profitable. The degree of market acceptance of our current and any future product candidates, if approved for commercial sale, will depend on a number of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> efficacy and potential advantages compared to alternative treatments, including those that are not yet approved; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=760999,FOLIO='27',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_28"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to offer our products, if approved, for sale at competitive prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> convenience and ease of administration compared to alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the strength of marketing, sales and distribution support; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as
a combination therapy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the regulatory approval and adoption of a companion or complementary diagnostic, if needed; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the prevalence and severity of any side effects. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The market opportunities for any current or future product candidate we develop, if approved, may be limited
to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the United
States and any other jurisdiction for
which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues
from sales of such products, even if approved. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer
therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected
early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure.
Second- and third-line therapies are administered to patients when prior therapy is not effective. We may initially seek approval for NC318, NC410 and any other product candidates we develop as a
therapy for patients who have received one or more prior treatments. If we do so, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a
first-line therapy, but there is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to
conduct additional clinical trials. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of patients who have the types of cancer we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current
or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are
small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may develop NC318, NC410 and future product candidates in combination with other therapies, which exposes
us to additional regulatory risks.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may develop NC318, NC410 and future product candidates in combination with one or more currently approved cancer therapies. Even if any
product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or
comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with
these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of
cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also evaluate NC318, NC410, or any future product candidate in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or
comparable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=801286,FOLIO='28',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>foreign
regulatory authorities. We will not be able to market and sell NC318, NC410 or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately
obtain marketing approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues
arise with, the biologics we choose to evaluate in combination with NC318, NC410 or any product candidate we develop, we may be unable to obtain approval of or market any such product candidate. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our products, if approved.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses
for which the product may be marketed or the conditions of approval, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the
product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable
foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, adverse event and deviation reporting, storage, advertising, promotion,
import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other
post-marketing information and reports, registration, as well as continued compliance with cGMP and cGCP, for any clinical trials that we may conduct post-approval. Later discovery of previously
unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers' manufacturing processes or facilities, or
failure to comply with regulatory requirements, may result in, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Warning Letters or Untitled Letters, or holds on clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved
biologics licenses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> permanent injunctions and consent decrees including the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
the FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, an approved product may not be promoted for uses that are
not approved by the FDA as reflected in the product's approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label
uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm's product communication is consistent with the FDA-required labeling for that product, and those
factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil,
criminal and administrative penalties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We
cannot </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=593305,FOLIO='29',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>predict
the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to
adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have
obtained and we may not achieve or sustain profitability. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to
comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if
regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
policies of the Trump Administration may impact our business and industry. President Trump has taken several executive actions, including the issuance of a number of Executive
Orders, that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance
of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA's ability to exercise
its regulatory authority. If these executive actions impose restrictions on the FDA's ability to engage in oversight and implementation activities in the normal course, our business may be negatively
impacted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction
does not mean that we will be successful in obtaining and maintaining marketing approval of our current and future product candidates in other jurisdictions.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be
able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the
manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from, and greater than, those in the United
States, including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside
the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is
also subject to approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates
with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays,
difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail
to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=688707,FOLIO='30',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_31"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend on our information technology systems, and any failure of these systems could harm our business.
Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability,
which could adversely affect our business, results of operations and financial condition.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We collect and maintain information in digital form that is necessary to conduct our business, and we are dependent on our information
technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including
intellectual property, proprietary business information and personal information, and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to
maintain data security and data integrity of such information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise. We
have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal
information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage
from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, phishing, persons inside our organization or persons
with access to systems inside our organization. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
risk of a security breach or disruption or data loss, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and
sophistication of
attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security
breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software
programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address
these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an
event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed
or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third
parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Moreover, if a computer security breach affects our
systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental
agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA,
as amended, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of
loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The successful commercialization of our product candidates will depend in part on the extent to which
third-party payors including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product
candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to
generate revenue.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The availability of coverage and adequacy of reimbursement by third-party payors, including managed care plans, governmental healthcare
programs, such as Medicare and Medicaid and private health insurers is essential for most patients to be able to afford medical services and pharmaceutical products such as our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=673069,FOLIO='31',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>product
candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by third-party payors will have
an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices
often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be
available. A decision by a third-party payor not to cover or not to separately reimburse for our products or
procedures using our products, could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates by a
third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in
the United States, the European Union or elsewhere will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may
become available may not be adequate or may be decreased or eliminated in the future. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to successfully commercialize any product candidate, whether as a single agent or combination therapy, will also depend in part on the extent to which coverage and
reimbursement for these product candidates and related treatments will be available from third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement
levels. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our current and future product candidates. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, third-party payors are increasingly challenging prices charged for pharmaceutical and biological products and services, and many third-party payors may refuse to provide
coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider
our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our
product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These third-party payors may deny or revoke the
reimbursement status of our product candidates, if approved, or establish prices for our product candidates at levels that are too low to enable us to realize an appropriate return on our investment.
If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory
financial return on our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products, especially novel products like our immunomedicines. To date, no
regulatory authority has granted approval for an immunomedicine targeting S15 or the LAIR pathway. The Medicare and Medicaid programs are increasingly used as models in the United States for how
private third-party payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new
or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the
coverage and reimbursement for our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
uniform policy for coverage and reimbursement for products exist among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ
significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the
use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules
and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=35,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=617252,FOLIO='32',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_33"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
if we or our collaborators develop companion diagnostic tests for use with our product candidates, we, or our collaborators, will be required to obtain coverage and
reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. While we and our collaborators have not yet developed any
companion diagnostic test for our product candidates, if we or our collaborators do, there is significant uncertainty regarding the ability to obtain coverage and adequate reimbursement for the same
reasons applicable to our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of
reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the
sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on
healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected
to the entry of new products. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Enacted healthcare legislation, changes in healthcare law and implementation of regulations, as well as
changes in healthcare policy, may increase the difficulty and cost for us to commercialize our product candidates, may impact our business in ways that we cannot currently predict, could affect the
prices we may set, and could have a material adverse effect on our business and financial condition.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. In particular, there
have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was passed, which substantially changes the way healthcare
is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by
lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed
care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs and creates a new Medicare Part&nbsp;D coverage gap discount program in which, as a
condition of coverage of its products under Medicare
Part&nbsp;D, manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges, as well as efforts by President
Trump's administration to repeal or replace certain aspects of the ACA, and to alter the implementation of the ACA and related laws. For example, Congress has considered legislation that would repeal
or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into
law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, includes a provision repealing, effective January&nbsp;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate." On January&nbsp;22, 2018, the President signed a
continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called "Cadillac" tax on certain high cost
employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share
and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January&nbsp;1, 2019, to reduce the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=36,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=20593,FOLIO='33',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>coverage
gap in most Medicare drug plans, commonly referred to as the "donut hole." Also, in July 2018, the Centers for Medicare and Medicaid Services, or CMS, issued a final rule permitting further
collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court
litigation regarding the method CMS uses to determine this risk adjustment. In December 2018, a United&nbsp;States District Court Judge for the Northern District of Texas ruled that the entire ACA
is unconstitutional because the tax penalty associated with the "individual mandate" was repealed by Congress as part of the Tax Act. This ruling is under appeal and stayed pending appeal. While the
United&nbsp;States District Court Judge for the Northern District of Texas, as well as the Trump Administration and CMS, have stated that the ruling will have no effect while this appeal is pending,
it is unclear how this decision, subsequent appeals and other efforts to invalidate the ACA, regulations promulgated under the ACA and related laws, or portions thereof will impact the ACA, its
implementation and our business. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things,
created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to
providers of 2% per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless
additional congressional action is
taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, effective January&nbsp;1, 2014, CMS began bundling into the
hospital outpatient prospective payment rate the Medicare payments for most laboratory tests ordered while a patient received services in a hospital outpatient setting. We expect that additional state
and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could
result in reduced demand for any product candidate we develop or complementary or companion diagnostics or additional pricing pressures. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CMS
may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation that legislators intend to,
among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient
programs. For example, the Trump Administration released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer
competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug
products paid by consumers. On January 31, 2019, the Department of Health and Human Services, HHS Office of Inspector General, proposed modifications to the federal Anti-Kickback Statute discount safe
harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will remove safe harbor protection from rebates paid by manufacturers to Medicare
Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. Although a number of these and other proposed measures may require additional
authorization to become effective, Congress and the Trump Administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which the U.S. federal government covers particular healthcare
products and services and could limit the amounts that the U.S. federal government </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=37,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=131978,FOLIO='34',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_35"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
pay for healthcare products and services. This could result in reduced demand for our product candidates or additional pricing pressures. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual
states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party
payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could
reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The
law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase&nbsp;1 clinical trial and that are
undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA
expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third
parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain
regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with customers, third-party payors, and others may be subject to applicable anti-kickback,
fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished
profits and future earnings.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and
prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to
broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell,
market and distribute any products for which we obtain marketing approval. The applicable federal and state healthcare laws and regulations that may affect our ability to operate include, but are not
limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any
remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs or other federal healthcare
programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory
exceptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=38,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=665248,FOLIO='35',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_de78701_1_36"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>prosecution
or regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and
biological products, including certain discounts, or engaging such individuals as speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor.
Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational
and research grants or patient or product assistance programs. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or FCA, which
prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be
made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government. Private individuals, commonly
known as "whistleblowers," can bring FCA qui tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement. In
addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. FCA liability is
potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement for violations. Criminal penalties,
including imprisonment and criminal fines, are also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The HIPAA fraud provisions, which prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including
private third-party payors, and prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or
representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of or
payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the HIPAA fraud provisions without actual
knowledge of the statutes or specific intent to violate them. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective
implementing regulations, also impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, which include
health plans, healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that
involve the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly
applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys' fees and costs
associated with pursuing federal civil actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information
related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their
immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse
practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=39,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=710888,FOLIO='36',FILE='DISK106:[19ZAH1.19ZAH78701]DE78701A.;27',USER='CHE106319',CD='26-APR-2019;01:41' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dg78701_1_37"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Analogous U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply
with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; state laws that require drug manufacturers to report
information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require
drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; and state laws governing
the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of
healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between
healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our business
arrangements with third parties comply with applicable healthcare laws, as well as responding to investigations by government authorities, can be time and resource consuming and can divert
management's attention from the business. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil,
criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages
and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve
allegations of non-compliance with these laws. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they
may be subject to criminal, civil and administrative sanctions, including exclusion from government funded healthcare programs. In addition, the approval and commercialization of any product candidate
we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to operate
our business and our financial results. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions
and other trade laws and regulations. We can face serious consequences for violations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations,
which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other
partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public
or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract
and fraud litigation, reputational harm and other consequences. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
business is heavily regulated and therefore involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of government
agencies or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=477078,FOLIO='37',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_38"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>government-affiliated
hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. Additionally, in many other countries, the health care providers who
prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to
regulation under the FCPA. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held
liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. In particular, our
operations will be subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing,
promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and
foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. Recently, the SEC and Department of Justice have increased
their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or
collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations
could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export
licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could also result in
prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation,
our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this
insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection
with our storage or disposal of biological or hazardous materials. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Manufacturing  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Given our limited operating history, our manufacturing experience as an organization and with our
manufacturing facility is limited.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing is a critical component of our approach to developing immunomedicines and we have invested significantly in our manufacturing
facility. We currently manufacture our product candidates for preclinical and clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=830279,FOLIO='38',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_39"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
manufacture of drugs for clinical trials and for commercial sale is subject to oversight by the FDA to ensure compliance with cGMP and by other regulatory authorities under other
laws, regulations and standards. We cannot assure you that we can successfully manufacture our products in compliance with cGMP and with any other applicable laws, regulations and standards in
sufficient quantities for clinical trials or for commercial sale, or in a timely or economical manner. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
manufacturing facility requires specialized personnel and is expensive to operate and maintain. Validation is an ongoing process that must be maintained to allow us to manufacture
under cGMP guidelines. We cannot guarantee that our facility will remain in compliance with cGMP. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
manufacture of pharmaceutical products is a highly complex process in which a variety of difficulties may arise from time to time. We are currently the sole manufacturer of NC318 and
NC410 and if anything were to interfere with our continuing manufacturing operations in our facility, it could materially adversely affect our business and financial condition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to develop manufacturing capacity and experience, whether internally or with a third party, or fail to manufacture our product candidates economically or on reasonable scale
or volumes, or in accordance with cGMP, our development programs and commercialization of any approved products will be materially adversely affected. This may result in delays in commencing or
continuing our clinical trials for NC318 or filing our IND for NC410. Any such delays could materially adversely affect our business and financial condition. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The loss of our third-party manufacturing partners or our, or our partners', failure to comply with
applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we currently manufacture our product candidates for preclinical and clinical trials, certain elements of manufacturing, including
Master Cell Bank manufacturing and fill-finish services, take place at qualified third-party contract manufacturing organizations, or CMOs. If approved, commercial supply of NC318, NC410 and any
future product candidates may be manufactured at a CMO or CMOs. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
facilities used by our CMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory
authorities. We do not control the manufacturing process at our CMOs, and are completely dependent on them for compliance with current regulatory requirements. If we or our CMOs cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on
their manufacturing facilities for the manufacture of elements of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for the manufacture of our product candidates or
if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability
to develop, obtain regulatory approval for or market our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
our CMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our CMOs were to
encounter any of these difficulties, our ability to provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be
jeopardized. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is
common that various aspects of the development program, such as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=600430,FOLIO='39',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_40"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>manufacturing
methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured
using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical
trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit
supply of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The process of manufacturing immunomedicines, including our product candidates, is complex, time-consuming, highly regulated and subject to
several risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation
of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral
or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of
time to investigate and remedy the contamination; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material
shortages, natural disasters, power failures and numerous other factors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures,
product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing
time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product
candidates to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo
comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development
may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of
these third-party suppliers or their inability to supply us with adequate materials could harm our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence on
these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and quality and
delivery schedules. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors that are larger than we are. We cannot be certain that our
suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited
or sole </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=827131,FOLIO='40',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_41"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>sourced
raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a
sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential
commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and
quantity, which would delay or prevent us from developing and, if approved, commercializing our product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. If one or more of our
product candidates progress to late-stage development, we may incur significant expenses in the expansion and/or construction of manufacturing facilities and increases in personnel in order to
manufacture product candidates. Currently, our product candidates are manufactured in small quantities for use in various preclinical studies and our ongoing Phase 1/2 clinical trial of NC318. We
cannot assure you that we will be able to successfully manufacture additional product candidates at a larger scale in a timely or economical manner, or at all. If we are unable to successfully
increase our manufacturing scale or capacity, the development, testing, and clinical trials of our current or future product candidates may be delayed or infeasible, and regulatory approval or
commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Intellectual Property  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have filed patent applications for our lead product candidates, but no patent has yet issued from these
applications. If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our
competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to
our product candidates and technology that are important to our business. No patent has yet issued from our patent applications. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject
of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result
in patents being issued that protect our technology or product candidates or that effectively prevent others from commercializing competitive technologies and product candidates. Because patent
applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the
first to file&nbsp;a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, we may challenge their ownership,
for example in a derivation proceeding before the U.S. Patent and Trademark Office, or USPTO, to determine who has the right to the claimed subject matter in the applications. Similarly, if our patent
applications are challenged in a derivation proceeding, the USPTO may hold that a third-party is entitled to certain patent ownership rights instead of us. We may then be forced to seek a license from
the third party that may not be available on commercially favorable terms, or at all. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent
applications at a reasonable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=449652,FOLIO='41',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_42"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cost
or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other
third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or
alternative technologies or products that do not infringe our patents. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are party to a license agreement with Yale University under which we acquired rights to intellectual
property related to certain of our product candidates. If we breach our obligations under this agreement, the agreement could be terminated, which would adversely affect our business and prospects.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to a license agreement with Yale pursuant to which we in-license patents and technology for certain of our product candidates.
This license imposes various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these and other obligations or otherwise materially breach this
license agreement, Yale may have the right to terminate the license. If this agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates or products
covered by the agreement, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our intellectual property agreements with third parties may be subject to disagreements over contract
interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract
interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant
agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have
licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to
the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we own or may own in the future. We
rely, in part, on our outside counsel or our licensing partners to pay these fees due to the USPTO and to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require
compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late
fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse
effect on our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=45,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1002945,FOLIO='42',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dg78701_1_43"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States are and could remain less extensive than those in the United States. In addition, the laws of some foreign countries do not
protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our
patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our
technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent
protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or
sufficient to prevent them from competing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of
patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of
our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition,
results of operations and prospects may be adversely affected. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United
States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&nbsp;a patent application was entitled to the patent. After March
2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other
requirements for patentability are met, the first inventor to file&nbsp;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to
invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These
include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity or ownership of a patent by USPTO administered post-grant
proceedings, including post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review and derivation proceedings. The America Invents Act and its implementation could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our
business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of
Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress, the federal courts and the
USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce
our intellectual property in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=46,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=858620,FOLIO='43',FILE='DISK106:[19ZAH1.19ZAH78701]DG78701A.;24',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_di78701_1_44"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive,
time-consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents or the patents of our licensors, or we may be required to defend against claims of infringement. Countering
infringement or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating
to intellectual property claims may
cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price
of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales or
distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the
initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages
or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we own, develop or license. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Issued patents covering our product candidates could be found invalid or unenforceable if challenged in
court. We may not be able to protect our trade secrets in court.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or one of our licensing partners initiate legal proceedings against a third party to enforce any patent that is issued covering one of our
product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if
successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a
terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the
patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in
the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review and
equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of
or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=471301,FOLIO='44',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_45"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cannot
be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal
assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a
material adverse impact on our business. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we
elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how,
information or technology that is not covered by patents, including portions of our FIND-IO platform. However, trade secrets can be difficult to protect, and some courts inside and outside the United
States are less willing or unwilling to protect trade secrets. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may initiate legal proceedings alleging that we are infringing their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business and financial condition.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product
candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not
exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or,
with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future
become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including post grant review
and </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates
approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may
be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us.
Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely
affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are found to infringe a third party's valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing,
manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain
a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and
royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found
liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could
prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have
misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=173801,FOLIO='45',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_46"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Others may claim an ownership interest in our intellectual property and our product candidates, which could
expose us to litigation and have a significant adverse effect on our prospects.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we
cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of
our, or our licensors', patents or other proprietary or intellectual property rights. A third party could bring legal actions against us to seek monetary damages or enjoin clinical testing,
manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant
diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to
continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however,
assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business
operations as a result of claims of patent infringement or violation of other intellectual
property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of
witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may
reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our proprietary information, the value of our technology
and products could be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter
into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential
information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. Our
agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we
cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we
have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized
use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential
information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties
as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may
need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual's assignee. Such assignment or license may not be available on
commercially reasonable terms or at all. We also seek to preserve the integrity and confidentiality of our trade secrets by other means, including maintaining physical security of our premises and
physical and electronic security of our information technology systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=921636,FOLIO='46',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_47"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adequate
remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position
and may materially harm our business, financial condition and results of operations. Costly and time-consuming
litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In
addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent
discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble
a team of scientists having backgrounds similar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or
disclosed alleged trade secrets of their current or former employers.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of
any such individual's current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates,
are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We
may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times,
competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential
trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over
the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our
efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial
costs and diversion of resources and could adversely impact our financial condition or results of operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not necessarily address all potential threats.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we
own or license or may own in the future; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=892805,FOLIO='47',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_48"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent
application that we license or may own in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or
licensed intellectual property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
learned from such activities to develop competitive products for sale in our major commercial markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may not develop additional proprietary technologies that are patentable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the patents of others may have an adverse effect on our business; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may choose not to file&nbsp;a patent for certain trade secrets or know-how, and a third party may subsequently file&nbsp;a patent
covering such intellectual property. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Reliance on Third Parties  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and
clinical trials for NC318, NC410 and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or
meet expected deadlines, we may not be able to obtain marketing approval for or commercialize NC318, NC410 and any future product candidates we develop, and our business could be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently do not have the ability to independently conduct preclinical studies that comply with the regulatory requirements known as current
good laboratory practice, or GLP, requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions
require us to comply with regulations and standards, including cGCP, or requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the
data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical
institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and cGCP-compliant clinical trials on our product
candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The
third parties with whom we contract for execution of our GLP-compliant preclinical studies and our cGCP-compliant clinical trials play a significant role in the conduct of these studies and trials and
the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to
control the amount or timing of resources that they devote to our current or future product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and
cGCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=485444,FOLIO='48',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_49"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>applicable
laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as
10&nbsp;days' prior written notice. Some of these agreements may also be terminated by such third parties under certain other circumstances. If the third parties conducting our preclinical studies
or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate
their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and cGCP, or for any
other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be
extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and
the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may depend on Lilly, Yale or other third-party collaborators for the discovery, development and
commercialization of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, we entered into the Lilly Agreement, which is focused on using our FIND-IO platform to identify novel oncology targets for
additional research and drug discovery by ourselves and Lilly. Pursuant to the Lilly Agreement, we granted Lilly the exclusive right to obtain worldwide exclusive licenses to research, develop,
manufacture and commercialize compounds and products directed to oncology targets identified through our research collaboration. Lilly will have the exclusive ability to control the development and
commercialization of any targets it chooses to license on a global basis. Our lack of control over the clinical development of certain programs under the Lilly Agreement could result in delays or
other difficulties in the development and commercialization of product candidates. Our right to receive certain milestone and royalty payments may be subsequently delayed, if we receive any at all. In
the event Lilly terminates the Lilly Agreement, we would be prevented from receiving any milestone payments, royalty payments and other benefits under that agreement, which would have a materially
adverse effect on our results of operations. Furthermore, in the event Lilly does not purchase and exercise any of its options, we will not be eligible to receive any future milestone payments under
the Lilly Agreement, which could require us to seek additional funding in order to avoid delaying, reducing the scope of, or suspending, one or more of our research and development programs or
clinical trials. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into the SRA with Yale in which we agreed to provide funding for a research program aimed at discovering new targets for immunomedicines. We have and would expect to
have limited control over the amount and timing of resources that are employed in the research program. The research program may not be successful, and as a result, we may not be able to identify,
develop and commercialize products from this collaboration. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will
complement or augment our development and commercialization efforts with respect to product candidates we develop. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
collaborations pose, and potential future collaborations involving our product candidates may pose, the following risks to us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=493415,FOLIO='49',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_50"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way
that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other
intellectual property proceedings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the
product candidate, or that result in costly litigation or arbitration that diverts management attention and resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product
development or commercialization program under such collaboration could be delayed, diminished or terminated; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> collaboration agreements may restrict our right to independently pursue new product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of
such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain
that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays in entering into new
collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our product candidates, which would harm our
business prospects, financial condition and results of operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may seek to establish additional collaborations, and, if we are not able to establish them on commercially
reasonable terms, we may have to alter our development and commercialization plans.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The advancement of our product candidates and development programs and the potential commercialization of our current and future product
candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide
to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring
and other charges, increase our near and long term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other
collaborations will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the collaborator's
evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory
authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the
potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=53,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=114875,FOLIO='50',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_51"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>regard
to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may
be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at
too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our
ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that
have resulted in a reduced number of potential future collaborators. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product
candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope
of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund
development or commercialization
activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further
develop our product candidates or bring them to market and generate product revenue. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Business  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and
retaining highly qualified personnel, we may not be able to successfully implement our business strategy.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our
objectives. Any of our executive officers could leave our employment at any time, as all of our employees are "at-will" employees. We currently only have "key person" insurance on Michael Richman, our
President and Chief Executive Officer, and on Dr.&nbsp;Lieping Chen, our scientific founder, in his role as consultant to us. The loss of the services of Mr.&nbsp;Richman, Dr.&nbsp;Chen or one
or more of our other executive officers could impede the achievement of our research, development and commercialization objectives. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continue to work with Dr.&nbsp;Chen on discovering novel immunomedicines through his consulting agreement and our SRA with Yale. If we are no longer able to leverage our
relationships with Dr.&nbsp;Chen and Yale, our ability to discover additional targets for immunomedicines may be impeded, which may adversely impact the achievement of our objectives. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recruiting
and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. Competition
for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and
biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it
more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of
our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=54,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=66157,FOLIO='51',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_di78701_1_52"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face significant competition from other biotechnology and pharmaceutical companies, and our operating
results will suffer if we fail to compete effectively  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our current or future product
candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently
exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product
development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients
and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with
leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds
that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among
a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA or other regulatory approval or discovering, developing
and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
competitors may obtain FDA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights
that limit our ability to develop or commercialize our product candidates or platform technologies. Our competitors may also develop drugs or discovery platforms that are more effective, more
convenient, more widely used or less costly than our product candidates or our FIND-IO platform or, in the case of drugs, have a better safety profile than our product candidates. These competitors
may also be more successful than us in manufacturing and marketing their products, and have significantly greater financial resources and expertise in research and development. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Currently marketed oncology drugs
and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech's Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as
BMS' Yervoy, and PD-1/PD-L1, such as BMS' Opdivo, Merck&nbsp;&amp;&nbsp;Co.'s Keytruda and Genentech's Tecentriq, to T cell-engager immunotherapies, such as Amgen's Blincyto. In addition, numerous
compounds are in clinical development for cancer treatment. In addition, numerous compounds are in
clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience. See "Business&#151;Competition." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smaller
and other early stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our current and future product
candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete
effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=55,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=449740,FOLIO='52',FILE='DISK106:[19ZAH1.19ZAH78701]DI78701A.;10',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dk78701_1_53"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less
severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also
obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Even if our product candidates
achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete
successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to grow the size of our organization, and we may experience difficulties in managing this
growth.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;1, 2019, we had 44&nbsp;full-time employees, including 35&nbsp;employees engaged in research and development. As our
development plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, marketing, sales, financial and other
personnel. Future growth would impose significant added responsibilities on members of management, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> identifying, recruiting, integrating, maintaining and motivating additional employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> managing our internal development efforts effectively, including the clinical and FDA review process for NC318, NC410 and any future product
candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> improving our operational, financial and management controls, reporting systems and procedures. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
future financial performance and our ability to advance development of and, if approved, commercialize NC318, NC410 and any future product candidates we develop will depend, in part,
on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a
substantial amount of time to managing these growth activities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services.
We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified
replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our
clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product
candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically
reasonable terms, or at all. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement
the tasks necessary to further develop and commercialize NC318, NC410 and any future product candidates we develop and, accordingly, may not achieve our research, development and commercialization
goals. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to establish marketing, sales and distribution capabilities for NC318, NC410 or any other
product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have sales or marketing infrastructure. To achieve commercial success for NC318, NC410 and any other product candidate for which we
may obtain marketing approval, we will need to establish a sales and marketing organization. In the future, we expect to build a focused sales and marketing infrastructure to market some of our
product candidates in the United States, if and when they are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=56,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=867000,FOLIO='53',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_54"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>approved.
There are risks involved with establishing our own marketing, sales and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and
could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we
would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that may inhibit our efforts to market our products on our own include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the inability of sales personnel to obtain access to physicians in order to educate physicians about our product candidates, once approved; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with
more extensive product lines; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unforeseen costs and expenses associated with creating an independent sales and marketing organization. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to establish our own marketing, sales and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services,
our revenue and our profitability, if any, are likely to be lower than if we had developed such capabilities ourselves. In addition, we may not be successful in entering into arrangements with third
parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them
may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish marketing, sales and distribution capabilities successfully, either on our
own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Product liability lawsuits against us could cause us to incur substantial liabilities and to limit
commercialization of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater
risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using,
administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims
may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> decreased demand for any product candidate we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> withdrawal of trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> termination of clinical trial sites or entire trial programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> initiation of investigations by regulators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> significant time and costs to defend the related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> substantial monetary awards to trial subjects or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> diversion of management and scientific resources from our business operations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the inability to commercialize any product candidates that we may develop. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=57,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=360960,FOLIO='54',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_55"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may
not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the
sale of commercial products if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance. A successful product
liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following this offering, we will be subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and
procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally,
controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations
in our control system, misstatements due to error or fraud may occur and not be detected. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to
certain limitations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. As of
December&nbsp;31, 2018, we had federal and state net operating loss carryforwards of $43.5&nbsp;million and $43.0&nbsp;million, respectively. The federal and state net operating loss
carryforwards will begin to expire, if not utilized, by 2036. Limitations imposed by the applicable jurisdictions on our ability to utilize net operating loss carryforwards could cause income taxes to
be paid earlier than would be paid if such limitations were not in effect and could cause such net operating loss carryforwards to expire unused, in each case reducing or eliminating the benefit of
such net operating loss carryforwards. Furthermore, we may not be able to generate sufficient taxable income to utilize our net operating loss carryforwards before they expire. If any of these events
occur, we may not derive some or all of the expected benefits from our net operating loss carryforwards. In addition, we may experience ownership changes in the future as a result of subsequent shifts
in our stock ownership, including this offering, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit
carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Common Stock and this Offering  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active trading market for our common stock may not develop, and you may not be able to sell your shares at
or above the initial public offering price, or at all.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for shares of our common stock. The initial public offering price of our common stock
was determined through negotiations between us and the underwriters and may not be indicative of the price at which our common stock will trade after the closing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=58,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=519701,FOLIO='55',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_56"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
this offering. Although we have applied to list our common stock on the Nasdaq Global Market, or Nasdaq, an active trading market for our shares may never develop or be sustained following this
offering. In the absence of an active trading market for our common stock, you may not be able to sell your common stock at or above the initial public offering price or at the time that you would
like to sell. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and fluctuate substantially, which could result in substantial
losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or
above the initial public offering price, or at all. The market price for our common stock may be influenced by many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the commencement, enrollment or results of our ongoing or future clinical trials, or changes in the development status of our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the
applicable regulatory authority's review of such filings, including without limitation the FDA's issuance of a "refusal to file" letter or a request for additional information; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> adverse results or delays in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our failure to commercialize our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unanticipated serious safety concerns related to the use of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the size and growth of our target markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of competitive products or technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory actions with respect to our product candidates or our competitors' products or product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital
commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory or legal developments in the United States and other countries applicable to our product candidates, including but not limited to
clinical trial requirements for approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the level of expenses related to our product candidates or clinical development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the results of our efforts to discover, develop, acquire or in-license product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or
publications of research reports about us or our industry; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=59,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=600679,FOLIO='56',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_57"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> variations in our annual or quarterly financial results or those of companies that are perceived by investors to be similar to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our cash position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> sales of our common stock by us, our directors, officers or their affiliated funds or our other stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> significant lawsuits, including patent or stockholder litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> general economic, industry and market conditions; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> other events or factors, many of which are beyond our control. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the stock market in general, and Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this "Risk Factors" section, could have a dramatic and material adverse
impact on the market price of our common stock. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities analysts do not publish research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or
our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we
do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease
to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the
book value of your shares.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible book value per
share of our common stock. Therefore, if you purchase our common stock in this offering, you will pay a price per share that substantially exceeds the pro forma as adjusted net tangible book value per
share after the closing of this offering. To the extent outstanding options are exercised, you will incur further dilution. Assuming an initial public offering price of $15.00 per share, which is the
midpoint of the estimated price range set forth on the cover of this prospectus, and our pro forma net tangible book value as of December&nbsp;31, 2018, you will experience immediate dilution of
$6.73 per share, representing the difference between our pro forma net tangible book value per share after giving effect to this offering at the assumed initial public offering price. In addition,
purchasers of common stock in this offering will have contributed approximately 40.7% of the aggregate price paid by all purchasers of our stock through December&nbsp;31, 2018, but will own only
approximately 22.8% of our common stock

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=60,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=365249,FOLIO='57',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_58"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


outstanding after this offering. See the section entitled "Dilution" for a more detailed description of the dilution to new investors in the offering.


</FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock in the public market could cause our stock price
to fall.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the
lock-up and other legal restrictions on resale discussed in this prospectus lapse, the market price of our common stock could decline. Based upon the number of shares of common stock, on an
as-converted basis, outstanding as of December&nbsp;31, 2018, upon the closing of this offering, we will have outstanding a total of 21,935,381 shares of common stock, assuming no exercise of the
underwriters' option to purchase an additional 750,000 shares. Of these shares, only the shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters'
option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
lock-up agreements pertaining to this offering will expire 180&nbsp;days from the date of this prospectus, subject to earlier release of all or a portion of the shares subject to
such agreements by Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Piper Jaffray&nbsp;&amp;&nbsp;Co. in their joint discretion, on behalf
of the underwriters. After the lock-up agreements expire, substantially all of the shares of common stock outstanding prior to this offering will be eligible for sale in the public market, subject to
the applicable volume, manner of sale and other limitations imposed under the federal securities laws. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, 2,824,317 shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans as of
December&nbsp;31, 2018 will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule&nbsp;144 and
Rule&nbsp;701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock
could decline.

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After this offering, the holders of 15,560,569 shares, or approximately 91.9%, of our common stock outstanding as of December&nbsp;31, 2018 will be entitled to rights with respect to
the registration of their shares under the Securities Act, subject to the lock-up agreements described above. See "Description of Capital Stock&#151;Registration Rights." Registration of these
shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by
these stockholders could have a material adverse effect on the market price of our common stock.

</FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us,
which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as they will be in effect upon the closing
of this offering, may delay or prevent an acquisition of us or a change in our management. For example, our board of directors will have the authority to issue up to 10,000,000 shares of preferred
stock. The board of directors can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares
of preferred stock may delay or prevent a change of control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely
affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
provisions also include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue
preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=61,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=35231,FOLIO='58',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_59"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>provisions
of Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.
Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they
would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace
or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our executive officers, directors and their affiliates will continue to exercise significant influence over
our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately following the closing of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common
stock and their respective affiliates will beneficially own, in the aggregate, approximately 62.6% of our outstanding common stock. As a result, these stockholders, if they act together, will be able
to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or
substantially all of our assets. These stockholders acquired their shares of common stock for substantially less than the price of the shares of common stock being acquired in this offering, and these
stockholders may have interests, with respect to their common stock, that are different from those of investors in this offering, and the concentration of voting power among these stockholders may
have an adverse effect on the price of our common stock. In addition, certain of our stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in
purchasing an aggregate of approximately $35.0&nbsp;million of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this
offering. If such stockholders purchase all shares they have indicated an interest in purchasing, our executive officers, directors and current beneficial owners of 5% or more of common stock and
their respective affiliates will beneficially own, in the aggregate, approximately 73.1% of our outstanding common stock upon the closing of this offering, assuming an initial public offering price of
$15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus) and assuming no exercise of the underwriters' option to purchase additional shares. This
concentration of ownership might adversely affect the market price of our common stock by:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delaying, deferring or preventing a change of control of us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> impeding a merger, consolidation, takeover or other business combination involving us; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
the section entitled "Principal Stockholders" for more information regarding the ownership of our outstanding common stock by our executive officers, directors and their affiliates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable
to emerging growth companies will make our common stock less attractive to investors.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy
statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=62,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=942014,FOLIO='59',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_60"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>approved.
We could be an emerging growth company for up to five years following the year in which we complete this offering, although circumstances could cause us to lose that status earlier. We will
remain an emerging growth company until the earliest of (i)&nbsp;December&nbsp;31, 2024, (ii)&nbsp;the last day of the first fiscal year in which we have total annual gross revenues of at least
$1.07&nbsp;billion, (iii)&nbsp;the last day of the first fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0&nbsp;million on
June&nbsp;30th&nbsp;and (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. We cannot predict if
investors will find our common stock less attractive because we may rely on these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected
to take advantage of this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the
earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS act. As a result,
our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to maintain proper and effective internal control over financial reporting, our ability to produce
accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, our management will be required to report upon the effectiveness of our internal
control over financial reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2020. When we lose our status as an "emerging growth company," our independent
registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to
assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company
under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Our independent registered
public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an "emerging growth
company," which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal control over
financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over
financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial
reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or
investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective
control systems required of public companies, could also restrict our future access to the capital markets. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=63,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=15440,FOLIO='60',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_61"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in how we use the net proceeds from this offering and may not use these proceeds
effectively, which could affect our results of operations and cause our stock price to decline.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described
in the section entitled "Use of Proceeds," and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity, as part of your
investment decision, to assess whether we are using the proceeds appropriately. Our management might not use the net proceeds from this offering in ways that ultimately increase the value of your
investment. If we do not use these proceeds in ways that enhance stockholder value, we may fail to achieve expected financial results or cause delays to our clinical development timelines, which could
cause our stock price to decline. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our
stock.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur significantly increased costs as a result of operating as a public company, and our management
will be required to devote substantial time to new compliance initiatives.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a public company, and particularly after we are no longer an emerging growth company, we expect to incur significant legal, accounting,
investor relations and other expenses that we did not incur as a private company, which we anticipate could be between $2.0&nbsp;million and $3.0&nbsp;million annually. The Sarbanes-Oxley Act, the
Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies,
including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount
of time to these compliance initiatives. Moreover, we expect these rules
and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations
may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot
predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and
retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations are often subject to varying interpretations, in many
cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in
continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to securities litigation, which is expensive and could divert management attention.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of their
stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and
divert our management's attention from other business concerns, which could seriously harm our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=64,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=656270,FOLIO='61',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<A NAME="page_dk78701_1_62"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our amended and restated bylaws designate the Court of Chancery of the State of Delaware or the United States
District Court for the District of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability
to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws, to be in effect upon the closing of this offering, provide that, unless we consent in writing to an alternative
forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction over the matter that is the subject of such action is vested exclusively in the federal courts, the United
States District Court for the District of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our
behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii)&nbsp;any action asserting a claim arising
pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the
validity of our certificate of incorporation or the bylaws or (v)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery
or the United&nbsp;States District Court for the District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person
holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does
not apply to any actions arising under the Securities Act or the Exchange Act. These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful,
might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery or the United States District Court for the District of Delaware could face additional litigation costs in
pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Court of Chancery or the United States District Court for the District of Delaware may also reach different
judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may
be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more
of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=65,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=111111,FOLIO='62',FILE='DISK106:[19ZAH1.19ZAH78701]DK78701A.;19',USER='WWASSER',CD='26-APR-2019;19:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dm78701_1_63"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm78701_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dm78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements, including with respect to our plans, objectives and expectations for our business,
operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. The forward-looking
statements are contained principally in the sections entitled "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and "Business," but are also contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terminology such as "aim,"
"anticipate," "assume," "believe," "continue," "could," "due," "estimate," "expect," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will,"
"would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. These forward-looking statements include,
but are not limited to, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations regarding the timing, progress and results of preclinical studies and clinical trials for NC318, NC410 and any other product
candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will
become available and our research and development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing or likelihood of regulatory filings for NC318, NC410 and any other product candidates we develop and our ability to obtain and
maintain regulatory approvals for such product candidates for any indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations regarding the potential benefits, activity, effectiveness and safety of NC318, NC410 and any other product candidates we
develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our intentions and ability to successfully commercialize our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations regarding the nature of the biological pathways we are targeting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the potential benefits of and our ability to maintain our relationships and collaborations with Yale, Dr.&nbsp;Lieping Chen and Lilly; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our estimates regarding our expenses, future revenues, capital requirements and our needs for or ability to obtain additional financing and the
period over which we expect the proceeds of this offering, together with our current cash and cash equivalents, to be sufficient to fund our operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party
manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developments and projections relating to our competitors and our industry, including competing therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the impact of current and future laws and regulations; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our intended use of proceeds from this offering. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=526396,FOLIO='63',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<A NAME="page_dm78701_1_64"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
statements are based on management's current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our or our industry's actual results, levels of activity, performance or
achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail in the section entitled "Risk Factors" and elsewhere
in this prospectus. While we believe that our internal expectations, estimates, forecasts and projections are reasonable, no independent source has verified such expectations, estimates, forecasts and
projections, as a result we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate,
the inaccuracy may be material. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this
prospectus, and except as required by law, after the date of this prospectus, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information,
future events or otherwise. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part,
completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by the foregoing cautionary
statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=67,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=45064,FOLIO='64',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<A NAME="page_dm78701_1_65"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm78701_use_of_proceeds"> </A>
<A NAME="toc_dm78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds from the sale of shares of our common stock in this offering will be approximately $66.6&nbsp;million, or
approximately $77.0&nbsp;million if the underwriters
exercise their option to purchase additional shares in full, assuming an initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this
prospectus), and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus)
would increase or decrease, respectively, the net proceeds from this offering by approximately $4.7&nbsp;million, assuming the number of shares offered by us, as set forth on the cover of this
prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares
we are offering. An increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease, respectively, the net proceeds from this offering, after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $14.0&nbsp;million, assuming the initial public offering price remains the same. We
do not expect that a change in the initial public offering price or the number of shares offered by us by these amounts would have a material effect on our intended use of the net proceeds from this
offering, although it may impact the amount of time prior to which we may need to seek additional capital.


</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, we had $135.2&nbsp;million in cash and cash equivalents. We intend to use the net proceeds from this offering, together with our existing cash and cash
equivalents, as follows:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $113.0&nbsp;million to advance NC318 through completion of our ongoing Phase&nbsp;1/2 clinical trial in patients with
advanced or metastatic solid tumors and into a Phase&nbsp;3 clinical trial; </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $31.0&nbsp;million to advance NC410 through completion of a Phase&nbsp;1/2 clinical trial;
and</FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the remainder for research and development activities related to our FIND-IO platform and discovery programs, including advancement of two
discovery programs through submission of INDs, personnel expenses, working capital and other general corporate purposes, including a $500,000 payment to Yale University that is due upon the closing of
this offering. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and
business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the
amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of our research and development activities may vary significantly
depending on numerous factors, including the progress of our development efforts, the timing and costs associated with the manufacture and supply of any of our product candidates, and any unforeseen
cash needs. As a result, our management will have broad discretion over the use of the net proceeds from this offering. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
the uses described above, we intend to invest the net proceeds from this offering in interest-bearing, investment-grade securities, certificates of deposit or government
securities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our planned operations into the second half of 2022.
We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. After this offering, we will require
substantial additional capital in order to continue to advance NC318, NC410 and future product candidates through preclinical studies, clinical trials, regulatory approval and commercialization.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=68,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=290180,FOLIO='65',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<A NAME="page_dm78701_1_66"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm78701_dividend_policy"> </A>
<A NAME="toc_dm78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable
future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=69,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1025993,FOLIO='66',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<A NAME="page_dm78701_1_67"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm78701_capitalization"> </A>
<A NAME="toc_dm78701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our cash and cash equivalents and our capitalization as of December&nbsp;31,
2018:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on a pro forma basis to give effect to: </FONT> <FONT SIZE=2>


<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'>

<FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the automatic conversion of all outstanding shares of our preferred stock into 15,560,569 shares of common stock upon the closing
of this offering; and

</FONT>

<FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the filing and effectiveness of our amended and restated certificate of incorporation, which will occur upon the closing of this
offering; and</FONT><FONT SIZE=2>

<BR><BR></FONT></DD></DL>
</DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to the sale of 5,000,000 shares of common stock in this offering, assuming an initial
public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus), after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us.

 </FONT></DD></DL>
</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this table together with the sections entitled "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and
our financial statements and the related notes and other financial information appearing elsewhere in this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma<BR>
As Adjusted<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share<BR>
and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>201,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Preferred Stock, par value of $0.001 per share; 68,181,819 and 64,545,455 shares authorized at December&nbsp;31, 2018 and 2017, respectively,
 68,181,819 and 40,000,000 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B Preferred Stock, par value $0.001 per share; 56,828,852 and 0 shares authorized at December&nbsp;31, 2018 and 2017, respectively, 56,828,851
and 0 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:36pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>162,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' (deficit) equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, par value $0.001 per share&#151;158,745,671 shares authorized, 1,374,812 shares issued and outstanding, actual; 158,745,671&nbsp;shares
authorized, 16,935,381&nbsp;shares issued and outstanding, pro forma; 100,000,000&nbsp;shares authorized, 21,935,381&nbsp;shares issued and outstanding, pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>141</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock, par value $0.001 per share&#151;no shares authorized, issued and outstanding, actual; 10,000,000 shares authorized, pro forma and pro
forma as adjusted; no shares issued or outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>162,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>228,985</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,279</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181,829</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>182,289</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
pro forma as adjusted information is illustrative only, and our cash and cash equivalents and our capitalization following the closing of this offering will
depend on the actual initial public offering price and the </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=70,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=39274,FOLIO='67',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<A NAME="page_dm78701_1_68"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>other
terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the estimated price range set
forth on the cover of this prospectus) would increase or decrease, respectively, our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders' equity and total
capitalization by $4.7&nbsp;million, assuming the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we
are offering would increase or decrease, respectively, our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders' equity and total capitalization by
$14.0&nbsp;million, assuming the assumed initial public offering price remains the same. </FONT>

</P>

</UL>


 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
actual, pro forma and pro forma as adjusted information set forth in the table above excludes the following:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,056,891 shares of our common stock issuable upon the exercise of stock options outstanding under our 2015 Plan as of December&nbsp;31,
2018, with a weighted average exercise price of $4.74 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 699,590 shares of our common stock reserved for issuance pursuant to future awards under our 2015 Plan as of December&nbsp;31, 2018, which
shares will cease to be available for issuance at the time our 2019 Plan becomes effective; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,900,000 shares of our common stock that will become available for future issuance under our 2019 Plan upon the effectiveness of the
registration statement of which this prospectus forms&nbsp;a part; and</FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 240,000 shares of our common stock that will become available for future issuance under our ESPP upon the effectiveness of the registration
statement of which this prospectus forms&nbsp;a part.

</FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=71,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=9888,FOLIO='68',FILE='DISK106:[19ZAH1.19ZAH78701]DM78701A.;33',USER='WWASSER',CD='26-APR-2019;19:16' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_do78701_1_69"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do78701_dilution"> </A>
<A NAME="toc_do78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between
the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, we had a historical net tangible book value (deficit) of $47.4&nbsp;million, or $34.43 per share of our common stock. Our net tangible book value
(deficit) per share represents total tangible assets less total liabilities and preferred stock (which is not included in stockholders' deficit), divided by the number of shares of common stock
outstanding on December&nbsp;31, 2018, including 272,802 shares of restricted common stock that were unvested or subject to repurchase.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pro forma net tangible book value as of December&nbsp;31, 2018, before giving effect to this offering, was $114.8&nbsp;million, or $6.78 per share. Pro forma net tangible book
value gives effect to the conversion of all outstanding shares of our preferred stock into 15,560,569 shares of our common stock upon the closing of this offering.


</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After giving further effect to the sale of 5,000,000 shares of common stock in this offering, assuming an initial public offering price of $15.00 per share (the midpoint of the estimated
price range set forth on the cover of this prospectus) after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net
tangible book value as of December&nbsp;31, 2018 would have been $181.3&nbsp;million, or $8.27 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of
$1.49 per share to existing stockholders and an immediate dilution of $6.73 per share to new investors participating in this offering. The following table illustrates this per share dilution to new
investors:

</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assumed initial public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value (deficit) per share as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(34.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma increase in historical net tangible book value per share attributable to conversion of preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in pro forma net tangible book value per share attributable to investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pro forma as adjusted information is illustrative only, and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00
increase or decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus) would increase or decrease,
respectively, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2018 after this offering by $4.7&nbsp;million, or $0.21 per share, and would increase or decrease,
respectively, dilution to investors in this offering by $0.79 per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Assuming the
assumed initial public price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus) remains the same, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us, each increase of 1,000,000 in the number of shares we are offering would increase our pro forma as adjusted net tangible book
value as of December&nbsp;31, 2018 after this offering by $14.0&nbsp;million, or $0.25 per share, and would decrease dilution to investors in this offering by $0.25 per share, and a decrease of
1,000,000 in the number of shares we are

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=72,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=33870,FOLIO='69',FILE='DISK106:[19ZAH1.19ZAH78701]DO78701A.;50',USER='MKEANE',CD='26-APR-2019;19:17' -->
<A NAME="page_do78701_1_70"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


offering would decrease our pro forma as adjusted net tangible book value as of December&nbsp;31, 2018 after this offering by $14.0&nbsp;million, or $0.27 per share, and would increase dilution to
investors in this offering by $0.27 per share.

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters exercise their option to purchase 750,000 additional shares of our common stock in full, the pro forma as adjusted net tangible book value after this offering would
be $8.45&nbsp;per share, the increase in pro forma net tangible book value per share would be $0.19 and the dilution per share to new investors would be $0.19 per share, in each case assuming an
initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of this prospectus), and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us.

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows, as of December&nbsp;31, 2018, on the pro forma as adjusted basis described above, the number of shares of common stock purchased from us, the total
consideration paid to us and the average price paid per share by existing stockholders and by investors purchasing common stock in this offering, assuming an initial public offering price of $15.00
per share (the midpoint of the
estimated price range set forth on the cover of this prospectus), before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us:

</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total Consideration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Existing stockholders before this offering</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
16,935,381</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
77.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>164,447,874</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investors participating in this offering</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,935,381</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>239,447,874</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that outstanding options with an exercise price per share that is less than the pro forma as adjusted net tangible book value per share are exercised, new investors will
experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to
our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our stockholders, including certain of our stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $35.0
million of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are
not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any of these stockholders, or any of these stockholders may
determine to purchase more, fewer or no shares in this offering. The presentation in this table regarding ownership by existing stockholders does not give effect to any purchases in this offering by
such investors.

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our common stock reflected in this discussion is based on 21,935,381 shares of our common stock outstanding as of December&nbsp;31, 2018, which gives effect to
the pro forma transactions and adjustments described above, and excludes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,056,891 shares of our common stock issuable upon the exercise of stock options outstanding under our 2015 Plan as of December&nbsp;31,
2018, with a weighted average exercise price of $4.74 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 699,590&nbsp;shares of our common stock reserved for issuance pursuant to future awards under our 2015 Plan as of December&nbsp;31, 2018,
which shares will cease to be available for issuance at the time our 2019 Plan becomes effective; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,900,000 shares of our common stock that will become available for future issuance under our 2019 Plan upon the effectiveness of the
registration statement of which this prospectus forms&nbsp;a part; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 240,000 shares of our common stock that will become available for future issuance under our ESPP upon the effectiveness of the registration
statement of which this prospectus forms&nbsp;a part.

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=73,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=403091,FOLIO='70',FILE='DISK106:[19ZAH1.19ZAH78701]DO78701A.;50',USER='MKEANE',CD='26-APR-2019;19:17' -->
<A NAME="page_do78701_1_71"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do78701_selected_financial_data"> </A>
<A NAME="toc_do78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following tables present our selected financial data for the periods and as of the dates indicated. We derived the
statement of operations and comprehensive loss data for the years ended December&nbsp;31, 2018 and 2017 and the balance sheet data as of December&nbsp;31, 2018 and 2017 from our audited financial
statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period. You should read the following data
together with our financial statements and the related notes appearing elsewhere in this prospectus and the section entitled "Management's Discussion and Analysis of Financial Condition and Results of
Operations." The selected financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the audited financial statements and related notes
appearing elsewhere in this prospectus.</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share<BR>
and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations and Comprehensive Loss Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,954</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,409</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,595 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,549 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,038,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>See
Note&nbsp;12 to our financial statements included elsewhere in this prospectus for further details on the calculations of our basic and diluted net loss per
share and the weighted average number of shares used in the computation of the per share amounts. The unaudited pro forma basic and diluted net loss per share has been computed using the weighted
average number of shares of common stock outstanding after giving effect to the automatic conversion of all outstanding shares of our preferred stock into shares of common stock upon the closing of
this offering. For purposes of pro forma basic and diluted net loss per share, all shares of convertible preferred stock have been treated as though they have been converted to common stock at the
later of the issuance date or on January 1, 2018. The pro forma net loss per share does not give effect to the sale of shares of our common stock in this offering. </FONT>

</DD></DL>


 </DIV>

 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,427</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,296</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,628</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,467</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,879</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>162,223</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24,498</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(46,944</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>We
define working capital as current assets less current liabilities. See our audited financial statements and related notes included elsewhere in this prospectus
for details regarding our current assets and current liabilities. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=74,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1034884,FOLIO='71',FILE='DISK106:[19ZAH1.19ZAH78701]DO78701A.;50',USER='MKEANE',CD='26-APR-2019;19:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dq78701_1_72"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq78701_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_dq78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS<BR>  OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations together with
the section entitled "Selected Financial Data" and our financial statements and the related notes appearing elsewhere in this prospectus. This discussion and other parts of this prospectus contain
forward-looking statements that involve risk and uncertainties, such as statements of
our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed in the section entitled "Risk Factors."</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding
biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or
FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are
focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are
committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition, for these patients. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate, NC318, is a first-in-class immunomedicine against a novel immunomodulatory receptor called Siglec-15, or S15. In October 2018, we initiated a Phase&nbsp;1/2
clinical trial of NC318 in patients with advanced or metastatic solid tumors. We expect completion of the Phase&nbsp;1 portion of this trial in the fourth quarter of 2019 and completion of the
Phase&nbsp;2 portion in the fourth quarter of 2020. Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called
Leukocyte-Associated Immunoglobulin-like Receptor&nbsp;1, or LAIR-1. We expect to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for NC410
in the first quarter of 2020. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financial Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our
company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing
capabilities and conducting discovery, research and development activities for our product candidates, discovery programs and FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not generated any revenue from product sales or otherwise and, as a result, we have never been profitable and have incurred net losses since the commencement of our operations.
Our net losses for the years ended December&nbsp;31, 2018 and 2017 were $22.8&nbsp;million and $15.5&nbsp;million, respectively. As of December&nbsp;31, 2018, we had an accumulated deficit of
$47.3&nbsp;million, primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing
approval for and commercialize a product candidate, and we cannot assure you that we will ever generate significant revenue or profits. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have funded our operations to date primarily through private placements of preferred stock and proceeds from our multi-year research and development collaboration agreement with Eli
Lilly and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=75,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=540189,FOLIO='72',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_73"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Company,
or Lilly. Since our inception through December&nbsp;31, 2018, we received gross proceeds of $164.4&nbsp;million through private placements of preferred stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2018, we received gross proceeds of $31.0&nbsp;million from the sale and issuance of shares of our Series&nbsp;A-3 Preferred Stock, and in November 2018, we received gross
proceeds of $93.4&nbsp;million from the sale and issuance of shares of our Series&nbsp;B Preferred Stock, including $15.0&nbsp;million from Lilly as described below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, we entered into a multi-year research and development collaboration agreement with Lilly, or the Lilly Agreement, pursuant to which we will use our FIND-IO platform to
identify novel oncology targets for additional collaborative research and drug discovery by us and Lilly. Under this agreement, we granted Lilly the exclusive option to obtain worldwide exclusive
licenses to research, develop, manufacture and commercialize multiple compounds and products directed to oncology targets identified through our research collaboration. In addition, Lilly granted us
the exclusive option to obtain worldwide exclusive licenses to research, develop, manufacture and commercialize an equal number of compounds and products directed to oncology targets for which Lilly
does not exercise its option. The Lilly Agreement will expire upon the earlier of the exercise of all options granted to Lilly or four years from the date of the agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
received an upfront payment of $25.0&nbsp;million in cash and an equity investment of $15.0&nbsp;million from Lilly upon entering into the Lilly Agreement, and we are eligible for
quarterly research and development support payments during a portion of the term of the Lilly Agreement, option exercise payments upon option exercises by Lilly and milestone payments in an aggregate
of up to $1.4&nbsp;billion, as well as mid to high single-digit royalty payments on net sales for all products directed to each target optioned by Lilly. The milestone payment amount assumes that
Lilly exercises all of the options available to it, as well as the successful achievement of all clinical development and sales milestones for each target optioned by Lilly pursuant to the Lilly
Agreement. If Lilly obtains approval in additional
indications in different therapeutic areas, then additional amounts may become due. Upon our exercise of an option with respect to a given target, we will owe Lilly option exercise, milestone and
royalty payments in amounts equivalent to a portion of the amounts payable by Lilly were Lilly to exercise an option. For more information on the Lilly Agreement, see "Business&#151;Our
Collaboration Agreements&#151;Research and Development Collaboration with Lilly." We expect to record collaboration and licensing revenue beginning in 2019 related to the Lilly Agreement. We
expect to recognize revenue from this agreement, including deferred revenue included on our balance sheets as of December&nbsp;31, 2018 of $26.7&nbsp;million, which consists of the
$25.0&nbsp;million upfront payment plus $1.7&nbsp;million attributed as a premium on the proceeds from Lilly's investment in shares of our Series&nbsp;B-3 Preferred Stock, on a proportional
performance basis over the term of the Lilly Agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2015, we entered into a license agreement with Yale University, or the Yale Agreement, pursuant to which we obtained a license to products that either incorporate certain
licensed patents used in the discovery of targets or arise out of research and development of Dr.&nbsp;Chen's laboratory at Yale, including S15. We are obligated to pay Yale low single-digit
royalties on sales of products, including NC318, that are either covered by the patents licensed to us under the Yale Agreement or arise out of Dr.&nbsp;Chen's laboratory, subject to minimum annual
royalty payments in the low to mid hundreds of thousands of dollars. Until we are required to pay royalties under the Yale Agreement, we must also pay an annual license maintenance fee in the mid to
high tens of thousands of dollars. In addition, we are obligated to pay Yale milestone payments in an aggregate of up to approximately $3.0&nbsp;million per product. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Yale Agreement, we also entered into a corporate sponsored research agreement with Yale, or the SRA, in which we agreed to provide an aggregate of up to
$12.4&nbsp;million to fund a research program under the direction and supervision of Dr.&nbsp;Chen aimed at discovering new targets for immunomedicines. As of December&nbsp;31, 2018, we have
made payments in an aggregate of $7.4&nbsp;million under the SRA, including $2.5&nbsp;million in the year ended December&nbsp;31, 2018. Pursuant to the SRA, we have </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=76,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=497093,FOLIO='73',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_74"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
option to add any patents invented pursuant to the research program as a licensed patent under the Yale Agreement and the right to obtain a royalty-bearing, exclusive, worldwide license to any
such patents. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, we had cash and cash equivalents of $135.2&nbsp;million. We believe that our existing cash and cash equivalents, together with the net proceeds from
this offering, will be sufficient to fund our planned operations into the second half of 2022. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available
capital resources sooner than we currently expect.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect to incur substantial expenditures in the foreseeable future as we advance our product candidates through clinical development, the regulatory approval process and, if approved,
commercialization, and as we expand our pipeline through research and development activities related to our FIND-IO platform and discovery programs. Specifically, in the near term, we expect to incur
substantial expenses relating to our ongoing Phase&nbsp;1/2 clinical trial of NC318, preclinical studies and our planned Phase&nbsp;1/2 clinical trial of NC410 and other research and development
activities. Furthermore, upon the closing of this offering, we expect to incur significantly increased costs as a result of operating as a public company, including significant legal, accounting,
investor relations and other expenses that we did not incur as a private company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales
of our product candidates, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings, marketing and distribution arrangements, other
collaborations, strategic alliances and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as
and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Components of Our Results of Operations  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through December&nbsp;31, 2018, we have not generated any revenue from product sales or otherwise. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating Expenses  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of costs incurred for our discovery efforts, research activities, development and testing of
our product candidates as well as for clinical trials, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or
clinical trials on our behalf, such as the SRA and the Yale Agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other
operating costs. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=77,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1033453,FOLIO='74',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_75"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated
costs are based on several factors, including patient enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under
contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical
trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or contracts are modified based upon changes in the
clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been
material. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to the early-stage nature of our programs and the discovery-related nature of our efforts, we do not track costs on a program-by-program basis. However, as our current and future
product candidates proceed along a development path towards evaluation in clinical trials, we intend to track the costs of each program. We will measure costs incurred under the Lilly Agreement as an
input to recording revenue from the Lilly Agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable
future as we advance our product candidates through development, including conducting our Phase&nbsp;1/2 clinical trial of NC318 and conducting preclinical studies and a Phase&nbsp;1/2 clinical
trial of NC410, and as we expand our pipeline through research and development activities related to our FIND-IO platform and discovery programs. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot determine with certainty the duration and costs of future clinical trials of NC318, NC410 or any other product candidate we may develop or if, when or to what extent we will
generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product
candidate. The duration, costs and timing of clinical trials and development of NC318, NC410 and any other product candidate we may develop will depend on a variety of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the scope, progress, results and costs of clinical trials of NC318 and NC410, as well as of any future clinical trials of other product
candidates and other research and development activities that we may conduct; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> uncertainties in selection of indications, clinical trial design and patient enrollment rates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of
manufacturing and commercial viability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> significant and changing government regulation and regulatory guidance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing and receipt of any development or marketing approvals, including the IND for NC410; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the
development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the
completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend
significant additional financial resources and time to complete clinical development for any such product candidate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=78,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=733827,FOLIO='75',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_76"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses consist primarily of personnel-related costs, including payroll and stock-based compensation, for personnel
in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services,
rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include
all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that our general and administrative expenses will increase substantially during the next few years as a result of staff expansion and additional occupancy costs, as well as
costs associated with being a public company, including higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs associated with being a public
company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Income, Net  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net consists primarily of interest income earned on our short-term investments in U.S. Treasury obligations and payment of
interest on our term loan with a commercial bank, or the Term Loan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of the Years Ended December&nbsp;31, 2017 and 2018  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the periods indicated (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,787</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,954</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,833</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,595</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>814 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(23,196</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,549</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>397</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>317 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses for the year ended December&nbsp;31, 2018 increased by $6.8&nbsp;million to $19.8&nbsp;million compared
to $13.0&nbsp;million for the year ended December&nbsp;31, 2017. The increase was driven primarily by $2.7&nbsp;million of increased expenses for product development and clinical research costs,
which related to advancing NC318 through IND-enabling activities, the initiation of our Phase&nbsp;1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors, clinical material
production costs, commencement of NC410 preclinical studies and advancement of our
other early-stage programs and discovery activities, including payments pursuant to the SRA and other sponsored research agreements. Other significant components of the increase in research and
development expenses, each as a result of increased product development and clinical research costs, included the following: research and development compensation expense by $2.0&nbsp;million;
reflecting higher headcount; depreciation and amortization expense by $1.1 million; lab supplies and services by $0.7 million; facility-related expenses by $0.3&nbsp;million; and research and
development license costs by $0.1 million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=79,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=73670,FOLIO='76',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_77"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses for the year ended December&nbsp;31, 2018 increased by $0.8&nbsp;million to $3.4&nbsp;million as
compared to $2.6&nbsp;million for the year ended December&nbsp;31, 2017. The increase was driven primarily by an increase of $0.2&nbsp;million in personnel-related costs due to an increase in
headcount and an increase of $0.3&nbsp;million for professional fees related to legal and audit services. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Income, Net  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net for the year ended December&nbsp;31, 2018 increased by $0.3&nbsp;million to $0.4&nbsp;million from $80,000 for the year
ended December&nbsp;31, 2017. The increase was driven primarily by interest income earned on the proceeds of our Series&nbsp;A and B Preferred Stock financing, partially offset by interest expense
related to the Term Loan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have financed our operations primarily through private placements of preferred stock and proceeds pursuant to the Lilly Agreement.
Since inception, we have received aggregate gross proceeds of $164.4&nbsp;million from the sale and issuance of shares of our preferred stock. In addition, in November 2018, we received an upfront
payment of $25.0&nbsp;million in cash from Lilly pursuant to the Lilly Agreement. Our cash and cash equivalents are held in money market funds and U.S. Treasury obligations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in April 2016, we entered into the Term Loan to finance laboratory equipment purchases. In January 2019, we amended the Term Loan to increase our borrowing capacity from
$1.0&nbsp;million to $5.0&nbsp;million. As amended, the Term Loan matures in January 2023. Our obligations under the Term Loan are secured by a security interest in our certificates of deposit,
money market accounts, cash, securities, investment property and deposit or investment accounts. The Term Loan bears interest at a rate equal to the greater of (i)&nbsp;the prime rate less 1.0% and
(ii)&nbsp;4.25% and is subject to mandatory prepayment upon the occurrence of specified events, including failure to pay the Term Loan when due, uncured breach, bankruptcy or dissolution. Under the
Term Loan, we will make interest-only payments through January 2020 and 36 equal monthly payments of principal plus accrued interest thereafter through January 2023. As of December&nbsp;31, 2018,
our outstanding borrowings under the Term Loan were $0.5&nbsp;million. Upon amending the Term Loan in January 2019, our outstanding borrowings under the Term Loan were $5.0&nbsp;million. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt
financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such
agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates or delay our efforts to expand our pipeline of product
candidates. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the scope, progress, results and costs of researching and developing NC318, NC410 and our other programs, including targets identified through
our FIND-IO platform, and of conducting preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing of, and the costs involved in, obtaining marketing approvals for NC318, NC410 and any future product candidates we develop, if
clinical trials are successful; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of our collaboration with Lilly, including whether Lilly exercises its licensing options under its collaboration agreement with us,
each of which would trigger additional payments to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of manufacturing NC318, NC410 and any future product candidates we develop for preclinical studies and clinical trials in preparation
for marketing approval and commercialization; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=80,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=584121,FOLIO='77',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_78"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of commercialization activities, including marketing, sales and distribution costs, for NC318, NC410 and any future product
candidates we develop, whether alone or with a collaborator, if any such product candidates are approved for sale, including marketing, sales and distribution costs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of our SRA with Yale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to establish and maintain additional collaborations, licenses or other arrangements on favorable terms, if at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs
and the outcome of any such litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone
payments we are required to make, or that we may be eligible to receive, under those agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing, receipt and amount of sales of, or royalties on, our future products, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the emergence of competing therapies and other adverse developments in the oncology market. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants
that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger,
consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional
funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our
product candidates in certain territories or indications that we would prefer to retain for ourselves. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
the section entitled "Risk Factors" for additional risks associated with our substantial capital requirements. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Flows  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,992</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,514</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,860 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,346</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,694 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Used in Operating Activities  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities was $8.0&nbsp;million for the year ended December&nbsp;31, 2018, which was primarily due to
deferred revenue, including the $25.0&nbsp;million upfront payment pursuant to the Lilly Agreement, as well as a non-cash charge for depreciation and amortization and the timing of cash payments,
partially offset by our net loss of $22.8&nbsp;million as we continued our research and development activities. Net cash used in operating activities was $12.5&nbsp;million for the year ended
December&nbsp;31, 2017, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=81,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=740909,FOLIO='78',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_79"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>which
was primarily due to our net loss of $15.5&nbsp;million in connection with our research and development activities, partially offset by a $1.6&nbsp;million increase in accrued liabilities
caused by the growth of our business as well as timing of cash payments. The amount of cash used in operating activities in any period is influenced by the timing of cash payments for research-related
expenses. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Used in Investing Activities  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used in investing activities for the years ended December&nbsp;31, 2018 and 2017 was $3.1&nbsp;million and $8.7&nbsp;million,
respectively, which consisted in each case primarily of purchases of laboratory equipment. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Provided by Financing Activities  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by financing activities was $121.4&nbsp;million for the year ended December&nbsp;31, 2018, which consisted primarily of net
proceeds from the issuance and sale of shares of our Series&nbsp;A and B Preferred Stock, partially offset by issuance costs, deferred offering costs and payments under the Term Loan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
provided by financing activities was $24.9&nbsp;million for the year ended December&nbsp;31, 2017, which consisted primarily of net proceeds from the issuance and sale of shares
of our Series&nbsp;A Preferred Stock, partially offset by payments under the Term Loan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual Obligations and Commitments  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our contractual obligations as of December&nbsp;31, 2018 (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payments Due by Period </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than 1 Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>1&nbsp;-&nbsp;3 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3&nbsp;-&nbsp;5 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More Than<BR>
5 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>325</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>690</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,275</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>712</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>690</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,735</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
had operating lease obligations consisting of an operating lease for our corporate headquarters, which includes both office and laboratory space, for approximately 25,000 square feet
as of December&nbsp;31, 2018. The term of the lease commenced in February 2016 and expires in August 2025. Under the terms of the lease as of December&nbsp;31, 2018, we will have lease obligations
aggregating $2.3&nbsp;million through 2025. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
contractual obligations table does not include any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty
payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed intellectual property, including our license
agreements with Lilly and Yale and our SRA with Yale. We excluded the contingent payments given that the timing and amount (if any) of any such payments cannot be reasonably estimated at this time.
See "Business&#151;Our Collaboration Agreements" for additional information. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
enter into contracts in the normal course of business with third-party contract organizations for clinical trials, non-clinical studies and testing, manufacturing and other services
and products for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these
agreements are not material. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies, Significant Judgments and Use of Estimates  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial
statements, as well as the reported expenses incurred during the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=82,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=926768,FOLIO='79',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_80"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>reporting
periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas
involving management's judgments and estimates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies are most important to
understanding and evaluating our reported financial results. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenditures, including payroll, contractor expenses and supplies, for research and development of product candidates are expensed as incurred.
Development costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements,
the milestone payment obligations are expensed when the milestone results are probable of being achieved. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We account for stock-based compensation, including stock options and restricted stock units, based on the fair value of the award as of the
grant date. We utilize the Black-Scholes option-pricing model as the method for estimating the fair value of our stock option grants. The Black-Scholes option-pricing model requires the use of highly
subjective and complex assumptions, including the options' expected term and the price volatility of the underlying stock. The fair value of the portion of the award that is ultimately expected to
vest is recognized as compensation expense over the award's requisite service period. We recognize stock-based compensation to expense using the straight-line method. If there are any modifications or
cancelations of stock-based awards, we may be required to accelerate, increase or decrease any remaining unrecognized stock-based compensation expense. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
compensation expense, net of estimated forfeitures, is reflected in the statements of operations and comprehensive loss as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>178</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, total unamortized stock-based compensation was $6.0&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The intrinsic value of all outstanding stock options as of December&nbsp;31, 2018 was $21.1&nbsp;million based on a hypothetical common stock fair value of $15.00 per share, the
midpoint of the estimated price range set forth on the cover of this prospectus.

</FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock Valuations  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board
of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock, and our board of directors' assessment of
additional objective and subjective factors that it believed were </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=83,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=428688,FOLIO='80',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_81"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>relevant
and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in
the American Institute of Certified Public Accountants' Accounting and Valuation Guide, </FONT><FONT SIZE=2><I>Valuation of Privately-Held-Company Equity Securities Issued as
Compensation</I></FONT><FONT SIZE=2>. Our common stock valuations were prepared using an option pricing method, or OPM, which used market approaches to estimate our enterprise value. The OPM treats
common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a
company's securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation
preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for
the common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the closing of this offering, our board of directors intends to determine the fair value of our common stock based on the closing price of our common stock on the Nasdaq Global
Market as reported on the date of grant. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated
future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and
liabilities, which relate primarily to the carrying amount of our property and equipment and our net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities.
Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more likely than not that the deferred tax
assets will not be realized. In evaluating our ability to recover deferred tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning
and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, we have recorded a full valuation allowance
against our deferred tax assets. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reserves
are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more likely than not to be
sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the
provision of income taxes; however, we currently have no interest or penalties related to uncertain income tax benefits. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, our gross deferred tax assets were $15.8&nbsp;million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future
taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating losses, or NOLs.
Utilization of NOLs may be limited by the "ownership change" rules, as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws. Our
ability to use our remaining NOLs may be further limited if we experience an ownership change in connection with this offering, future offerings or as a result of future changes in our stock
ownership. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the U.S. Securities
and Exchange Commission. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=84,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=977122,FOLIO='81',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_dq78701_1_82"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


JOBS Act Accounting Election  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an "emerging growth company" such as us to take advantage of an
extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to take advantage of this extended transition period to enable us to
comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth
company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that
comply with new or revised accounting pronouncements as of public company effective dates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being
required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002. We will
remain an emerging growth company until the earliest of (i)&nbsp;December&nbsp;31, 2024, (ii)&nbsp;the last day of the first fiscal year in which we have total annual gross revenues of at least
$1.07&nbsp;billion, (iii)&nbsp;the last day of the first fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0&nbsp;million on
June&nbsp;30th&nbsp;and (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Accounting Pronouncements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Note&nbsp;2 to our audited financial statements included elsewhere in this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=85,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=49813,FOLIO='82',FILE='DISK106:[19ZAH1.19ZAH78701]DQ78701A.;24',USER='MKEANE',CD='26-APR-2019;19:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ds78701_1_83"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ds78701_business"> </A>
<A NAME="toc_ds78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer
and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding
biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or
FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are
focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are
committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition, for these patients. Our lead
product candidate, NC318, is a first-in-class immunomedicine against a novel immunomodulatory receptor called Siglec-15, or S15. In October 2018, we initiated a Phase 1/2 clinical trial of NC318 in
patients with advanced or metastatic solid tumors. We expect completion of the Phase&nbsp;1 portion of this trial in the fourth quarter of 2019 and completion of the Phase&nbsp;2 portion in the
fourth quarter of 2020. Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated
Immunoglobulin-like Receptor 1, or LAIR-1. We expect to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for NC410 in the first quarter of
2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
approach to identifying targets for new immunomedicines is based on our FIND-IO platform. FIND-IO embodies a rational approach to the discovery of novel cell surface and secretory
molecules that drive functional immune responses. We use our immunology knowledge, experience, capabilities and tools we have developed, including our FIND-IO platform, to support our discovery
efforts. We are working to discover novel targets that play a key role in mediating immune dysfunctions that allow tumors to evade the immune system. We are seeking to identify and develop
immunomedicines that counteract these outcomes and to further validate and advance our product candidates. We have identified multiple novel targets using our FIND-IO platform, including those for
which certain of our research programs are being designed to target. In addition, the immunosuppressive properties of&nbsp;S15, the target of NC318, were discovered using a predecessor of our
FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC318,
our lead immunomedicine program, is a monoclonal antibody targeting S15, which is expressed on highly immunosuppressive cells called M2 macrophages and on tumor cells. The
immunosuppressive properties of S15 were discovered in 2015 at Yale University by our scientific founder Dr.&nbsp;Lieping Chen. Dr.&nbsp;Chen was also the first to discover a molecule he called
B7-H1, which is now more widely known as PD-L1, or programmed cell death protein ligand&nbsp;1, which is the ligand for PD-1, or programmed cell death 1. In preclinical research, we and others have
observed that S15 promotes suppression of T&nbsp;cell proliferation and negatively regulates T&nbsp;cell function. NC318 is designed to block this S15-mediated immune suppression and restore T
cell function and anti-tumor immunity in the tumor microenvironment, or TME, which we believe will reduce and kill tumors. We believe NC318 has the potential to treat multiple cancer indications
because S15 is expressed in multiple tumor types and has a unique ability to modulate immune responses in the TME. In addition, because S15 and PD-L1 expression in tumors generally appear to be
non-overlapping, we believe NC318 may be well suited to
treat patients who are not responding to PD-1/PD-L1 directed cancer therapies. We are initially evaluating NC318 for the treatment of advanced or metastatic solid tumors, which could include ovarian
cancer, non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma, or HNSCC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC410,
our second immunomedicine program, is a fusion protein designed to block immune suppression mediated by LAIR-1. LAIR-1 is expressed on T cells and antigen-presenting cells, known
as dendritic cells, that present tumor antigens to immune cells in order to generate immune responses. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=86,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=389761,FOLIO='83',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ds78701_1_84"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>binding
of LAIR-1 to collagen or C1q results in loss of immune function in the TME and a reduction in T&nbsp;cell function and dendritic cell activity. By blocking the binding of LAIR-1, NC410 can
promote T&nbsp;cell function and dendritic cell activity, which could result in anti-tumor immune responses that eliminate cancer cells. We are currently conducting IND-enabling studies for NC410
and expect to submit an IND and initiate a Phase&nbsp;1/2 clinical trial in patients with advanced or metastatic solid tumors in the first quarter of 2020. We are currently focused on opportunities
for NC410 in ovarian cancer, NSCLC and renal cancer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
advancement of cancer to late stages indicates a failure of the immune system to mount an effective anti-tumor immune response. Immuno-oncology, which focuses on stimulating the
immune system to respond to cancer and includes checkpoint inhibitors targeting PD-L1, PD-1 and cytotoxic T-lymphocyte antigen-4, or CTLA-4, is one of the most significant advances in the history of
cancer treatment. In 2011, the first checkpoint inhibitor was approved, and today, despite only a modest breadth of efficacy, this class of therapies is estimated to have had global sales of more than
$17&nbsp;billion in 2018 and is predicted to reach more than $33&nbsp;billion in global sales by 2022. However, despite the recent success of checkpoint inhibitors, efficacy has been limited. It
is estimated that up to 60% to 70% of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer, NSCLC, urothelial cancer and HNSCC, do not respond to single-agent therapy
with checkpoint inhibitors. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care in cancer today leaves many patients
underserved. We believe broader efficacy and more meaningful clinical responses in oncology may be obtained by focusing on the TME. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are using our FIND-IO platform as our discovery engine to identify targets and develop immunomedicines that restore normal immune function in the TME through novel mechanisms of
action. Since our founding in 2015, we have developed, industrialized and optimized our FIND-IO platform based on the immunological expertise of our management team and the scientific leadership of
Dr.&nbsp;Chen. Our approach in creating the FIND-IO platform, and how we apply it, reflects our belief in the importance of understanding biological pathways of all cells in the immune system and
restoring normal immune function. The platform uses our proprietary approaches to assess the suppressive or stimulatory function of immune pathways in T cells and other immune cells, as measured by
effects on
proliferation or induction of molecules known to impact immune responses, such as cytokines, which are signaling molecules secreted by cells in the immune system that mediate and regulate immunity and
inflammation. We study primary immune cells from healthy donors and from patients with various diseases, as well as established cell lines from immune and non-immune cell lineages, including T cell
subsets, monocytes, macrophage subpopulations and cancer cell lines. In oncology, we are using the FIND-IO platform to discover immunomedicines with the potential to intervene or modulate interactions
of immune cells within the TME to restore anti-tumor activity. We are also expanding the functional screening approach of our FIND-IO platform for the identification of novel targets in other serious
illnesses outside of oncology, including autoimmune, inflammatory and neuro-inflammatory diseases. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, we entered into a multi-year collaboration agreement with Eli Lilly and Company, or Lilly, focused on the discovery and development of immunomedicines for oncology
using our FIND-IO platform. The collaboration seeks to discover novel cancer targets utilizing our platform and provides that we and Lilly will each receive options to exclusively develop antibodies
resulting from the collaboration. In connection with the agreement, or the Lilly Agreement, we received an upfront payment of $25.0&nbsp;million in cash and an equity investment of
$15.0&nbsp;million and are eligible to receive development and regulatory milestones and sales milestones in an aggregate of up to $1.4&nbsp;billion, as well as royalty payments. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have assembled an experienced management team to execute on our mission to create novel immunomedicines. Our scientific founder and members of our management team collectively have
extensive experience in drug discovery and product development and are leaders in the immuno-oncology field. Members of our management team have experience discovering, developing, manufacturing and
commercializing biologics, including some of the earliest approved monoclonal antibodies, such as Synagis, as well as some of the first immune checkpoint inhibitor monoclonal antibodies and fusion
proteins targeting the PD-1/PD-L1 pathway and CTLA-4. Within three years, we advanced our company from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=87,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=46650,FOLIO='84',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ds78701_1_85"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>formation
to antibody generation to the clinic, and constructed a manufacturing facility that complies with current good manufacturing practice, or cGMP, and that we have used to manufacture our
preclinical and clinical drug supply. We have received financial support from leading healthcare investors, including OrbiMed Advisors, Canaan Partners, Sofinnova Investments, Pfizer Ventures, Lilly
Asia Ventures, Quan Capital, Bay City Capital&#150;GF Xinde, Surveyor Capital (a Citadel Company), Ping An Ventures, Taiho Ventures, ArrowMark Partners, NS Investment and Alexandria Venture
Investments. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Members
of our management team have a longstanding relationship with our scientific founder Dr.&nbsp;Chen, who is the United Technologies Corporation Professor in Cancer Research and
Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) at Yale, and the Co-Director of
the Cancer Immunology Program at Yale Cancer Center. Dr.&nbsp;Chen was the first to discover PD-L1, and to show that it is expressed by multiple tumor types and its activity can cause the death of T
cells, preventing those T cells from eliminating cancer cells. He also showed that blocking the interaction between PD-1 and PD-L1 with monoclonal antibodies improved the immune system's ability to
eliminate tumors. Dr.&nbsp;Chen's work provided an important foundation for the subsequent development of immunotherapies that enable more effective immune treatments against cancer. Since then, his
laboratory has identified and characterized various molecules in two of the major families of immune modulating proteins, the B7-CD28 and the tumor necrosis factor, or TNF, receptor/ligand
superfamilies, and elucidated their interactions and functions in controlling immune responses. The immunosuppressive properties of S15, the target of our lead product candidate, NC318, were
discovered in Dr.&nbsp;Chen's lab using a predecessor of our FIND-IO platform. We continue to collaborate with Dr.&nbsp;Chen on discovering novel immunomedicines through an exclusive sponsored
research agreement with Yale. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the combination of our team's capabilities and focus on understanding the biological pathways of the immune system, our product development expertise and manufacturing
infrastructure, our partnership with Lilly and our relationship with Dr.&nbsp;Chen and Yale positions us to build a sustainable portfolio of first-in-class immunomedicines. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Pipeline  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are leveraging our understanding of biological pathways and our FIND-IO platform to discover, validate and build a proprietary pipeline of
immunomedicine candidates. The figure below details our pipeline of product candidates and principal discovery and research programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g57012.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="370">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=88,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=634682,FOLIO='85',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ds78701_1_86"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy is to use our fully integrated discovery and product development infrastructure to build a sustainable pipeline of product
candidates to treat cancer patients who are not adequately served by currently available therapies. The key elements of our strategy include: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B><I> Advancing the clinical development of our lead product candidates, NC318 and
NC410.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;In October 2018, we initiated a Phase 1/2 clinical trial evaluating NC318 in patients with advanced or metastatic solid tumors. We expect
completion of the Phase&nbsp;1 portion of this trial in the fourth quarter of 2019 and completion of the Phase&nbsp;2 portion in the fourth quarter of 2020. For NC410, we are currently conducting
IND-enabling studies, with the expectation of submitting an IND and initiating a Phase&nbsp;1/2 clinical trial in the first quarter of 2020.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B><I> Building an oncology pipeline of novel targets for new immunomedicines focused on
non-responders</I></B></FONT><FONT SIZE=2>.&nbsp;&nbsp;We are leveraging our immunological expertise and our FIND-IO platform to identify novel targets relevant to overcoming immune
suppression. We believe our relationship with Lilly will promote the efficient development of antibodies for novel cancer targets identified using our FIND-IO platform. In addition to our internal
discovery efforts, we also expect to leverage our relationship with Dr.&nbsp;Chen's laboratory at Yale for the discovery of additional targets for immunomedicines.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B><I> Leveraging our fully integrated development, quality systems and cGMP manufacturing
capabilities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Our approach is to integrate key aspects of product development within our organization. We have assembled a team with extensive
experience in identifying, characterizing and developing novel immunomedicines. We seek to couple discovery of important targets with the capability to rapidly streamline target validation and conduct
key IND-enabling studies, leading to clinical development of lead candidates. Our purpose-built, dedicated, state-of-the-art cGMP manufacturing facility utilizes single-use technology to support
development of our pipeline and advancement of our product candidates into and through clinical development. The facility has an initial production capacity of 1,000 liters with additional room for
expansion and is designed to operate as a multi-product facility. Compared to working with third-party manufacturers, we believe our facility provides better quality assurance, greater control in
scheduling and prioritizing manufacturing activities and enhanced capital efficiency. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B><I> Expanding our current focus and creating new opportunities outside of the oncology
field, including through strategic partnerships</I></B></FONT><FONT SIZE=2>.&nbsp;&nbsp;While our primary focus is oncology, the functional screening approach and proprietary
technology of our FIND-IO platform are broadly applicable to the identification of positive and negative immune modulators, and therefore can be used and expanded to discover novel targets in other
inflammatory diseases. Our goal is to enable next-generation immunomedicines for other serious inflammatory diseases with significant unmet medical needs in fields beyond oncology. For example, we are
developing our FIND-AI platform, a new platform focused on discovery efforts in autoimmunity and inflammation. We expect to explore a variety of alternatives for our platforms and future product
candidates outside of oncology, including the pursuit of strategic partnerships. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Immuno-Oncology Background  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The immune system has powerful biological mechanisms to defend and protect the body from pathogens, such as viruses, parasites and bacteria. It
also provides surveillance against cancers by recognizing and responding to antigens that are uniquely or highly expressed on cancer cells. In cancer, complex interactions between immune cells and
growing tumor cells can prevent an immune response by blocking cellular interactions, resulting in immunosuppression in the TME. This phenomenon, referred to as immune evasion, is a hallmark of cancer
where the tumor can prevent tumor-specific immune cells called T cells from functioning within the TME or gaining access to the tumor site, which allows the tumor to continue to grow, leading to
disease progression. Tumors in advanced cancer have multiple mechanisms of evasion in the TME that can differ from tumor to tumor. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=89,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=36752,FOLIO='86',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ds78701_1_87"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
TME is the cellular environment in which the tumor exists and encompasses the surrounding blood vessels, a variety of immune cells, fibroblasts, bone marrow-derived inflammatory
cells, lymphocytes, signaling molecules and the extracellular matrix, or ECM. Immune cell types in the TME include T cells, natural killer, or NK, cells, dendritic cells, macrophages, suppressive
myeloid cells and neutrophils. The tumor and the surrounding microenvironment interact constantly. Tumors and immune cells can express co-inhibitory proteins known as checkpoints that lead to immune
tolerance by the tumor and/or immune cells, allowing the tumor to grow by evading the host immune response. In addition to modulating immune function, immune cells in the TME can also promote a
pro-tumorigenic environment that fosters the growth and evolution of cancer cells. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remodeling
the TME and overcoming its immunosuppressive properties is a major focus of cancer research and drug development. Checkpoint inhibitors are a drug class designed to counteract
certain tumor defenses against the immune system. Currently approved checkpoint inhibitors were developed for the treatment of cancer based on the belief that inactivation of the immune system by
checkpoints could be reversed to reactivate the immune system to recognize and attack the tumor. Therapies against checkpoints, such as PD-L1, PD-1 and CTLA-4, have produced impressive results in the
clinic across an array of cancers and have been approved for several malignancies. However, despite the recent success of these checkpoint inhibitors, efficacy has been limited. It is estimated that
up to 60% to 70% of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer, NSCLC, urothelial cancer and HNSCC, do not respond to single-agent therapy with checkpoint
inhibitors. Many of the patients who are non-responders possess so called "cold" tumors that do not contain meaningful numbers of T cells that recognize their tumors. In addition, some patients
develop resistance after initial treatment with these checkpoint inhibitors. This limited efficacy highlights the importance of our effort to identify novel targets and molecular pathways responsible
for tumor immune evasion mechanisms that we believe will work independently from current targets for cancer immunotherapy. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Approach to Developing Immunomedicines for Cancer  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our approach to identifying targets for new immunomedicines in cancer is based on the combination of our FIND-IO platform, our immunological
expertise and our belief in the importance of understanding biological pathways and the normal function of the immune system in the TME. Rather than focusing on a specific type of immune cell, we are
targeting molecules that modulate the immune system in ways that we believe may provide new treatment opportunities for patients that are differentiated from currently marketed targeted therapies as
well as those in development. Our primary goal is to develop immunomedicines that increase response rates, efficacy and durable overall survival among patients who do not respond to current therapies,
patients whose cancer progresses despite treatment and patients with cancer types that are not adequately addressed by currently available therapies. We design our product candidates either to restore
the normal effects of the immune system to promote elimination of the tumors or to counteract tumor immune evasion mechanisms. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
FIND-IO platform applies a function-based screening approach to identify human proteins and to determine whether those proteins alter or stop an immune response resulting in immune
evasion. The platform is designed to identify novel cell surface molecular interactions that drive functional immune responses. Our FIND-IO platform broadly and quantitatively evaluates interactions
between relevant protein components and different cellular types over time in order to identify novel targets that either increase or decrease immune-related functional responses associated with
desired immune responses against tumors. By identifying novel immune modulators through the FIND-IO platform, we aim to develop next-generation immunomedicines that restore normal immune function in
the TME. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
create our FIND-IO platform, we industrialized, expanded and optimized the T&nbsp;Cell Activity Array, or the TCAA, a predecessor of the FIND-IO platform that Dr.&nbsp;Chen used
to discover the immunosuppressive properties of S15. Our work in developing the FIND-IO platform beyond the
TCAA includes using different and expanded gene libraries, adding biological pathways and reporters, expanding immune cell types and, most importantly, increasing the repertoire of functional assay
readouts. We also broadened the platform to look at signaling within both the immune cell and the cell expressing the library </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=90,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=26258,FOLIO='87',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ds78701_1_88"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>gene.
By transfecting cells with library genes, which encode membrane-bound or soluble proteins, FIND-IO is designed to determine whether the genes have signaling functions when interacting with an
immune cell. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
FIND-IO technology includes proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines from immune lineages, including T
cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines and cells isolated from diseased patients. This platform allows us to identify proteins that can be targeted with
novel immunomedicines to repair and maintain anti-tumor immunity. By focusing on understanding the TME in oncology, we believe we can identify multiple new positive and negative modulators of immune
cells, including T cells, NK cells, macrophages and myeloid-derived suppressor cells. As shown in the figure below, our product candidates target a variety of cell types in the immune system. For
example, NC318 targets macrophages and tumor cells and prevents suppressive myeloid cells from negatively regulating T cells. NC410 targets the negative signaling from dendritic cells and macrophages
on T cells. We also have earlier stage discovery programs that are investigating the negative effects of NK cells and other immune cells in the TME on T cells. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ds78701_expanding_t&#97;rgets_beyond_t_cells"> </A>
<A NAME="toc_ds78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Expanding Targets Beyond T&nbsp;Cells    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g195482.jpg" ALT="GRAPHIC" WIDTH="480" HEIGHT="465">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=91,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=21689,FOLIO='88',FILE='DISK106:[19ZAH1.19ZAH78701]DS78701A.;44',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_du78701_1_89"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Programs  </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NC318  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC318 is a monoclonal antibody that binds specifically to human S15 with high affinity. We have observed in preclinical studies that blocking
S15 improved the immune response in multiple animal models. We believe that NC318 may help promote an effective anti-tumor immune response by targeting multiple cell types in the TME that express S15,
including macrophages and S15-positive tumor cells. Based on the results of our preclinical studies, we initiated a Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid
tumors in October 2018. We expect completion of the Phase&nbsp;1 portion of the trial in the fourth quarter of 2019 and completion of the Phase&nbsp;2 portion in the fourth quarter of 2020. We
have exclusive worldwide rights to NC318. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


S15 Background  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S15 is a member of the sialic acid-binding immunoglobulin lectins, or Siglec, family, a distinct subgroup of the immunoglobulin superfamily of
proteins. Siglecs are expressed on most white blood cells of the immune system, except for T cells. Siglecs recognize and bind to a sugar structure called sialic acid that coats proteins and fatty
acids found on the surface of all mammalian cells. This binding can affect cell signaling on immune cells. Several Siglecs play key roles in helping immune cells distinguish between self and non-self
and modulating immune responses. In 2015, Dr.&nbsp;Chen discovered the immunosuppressive properties of S15 using the TCAA. S15 is expressed on tumor cells and, importantly, on M2 macrophages, which
are highly immunosuppressive in the TME. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S15
molecules on M2 macrophages, as well as on tumors themselves, appear to interact with unidentified receptors on T cells and inhibit T cell proliferation and functions, leading to
decreased anti-tumor immune response. It also appears that S15 interacts with myeloid cells to promote their survival and differentiation so that they contribute to the overall immunosuppressive tumor
environment through production of cytokines, such as IL-6, IL-1<FONT FACE="SYMBOL">b</FONT> and TNF-<FONT FACE="SYMBOL">a</FONT>, that are tumor-promoting and immunosuppressive
in the context of the TME. As shown in the figure below, the presence of S15 on either tumor cells or M2 macrophages can lead to an immunosuppressive TME, resulting in tumor growth. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_s15_is_highly_immunosuppressive_in_the_tme"> </A>
<A NAME="toc_du78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  S15 is Highly Immunosuppressive in the TME    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g748691.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="391">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=92,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=669377,FOLIO='89',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_du78701_1_90"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
mechanism of action of NC318 prevents immune suppression caused by S15 and promotes anti-tumor activity. As the figure below shows, by targeting M2 macrophages, S15-induced myeloid
cells and S15-positive tumors, NC318 is engineered to decrease inflammatory cytokines associated with enhanced tumor growth, promote T cell proliferation and restore T cell function, which we believe
will reduce and kill tumors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_nc318_is_designed_to_block_imm__nc302536"> </A>
<A NAME="toc_du78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  NC318 is Designed to Block Immunosuppressive Activity Induced by S15    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g449255.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="360">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
preclinical studies, we have observed that S15 is highly expressed on both tumor cells and M2 macrophages in the TME in multiple tumor types, including human lung cancer, ovarian
cancer, breast cancer and melanoma. In contrast, S15 expression on normal tissues is minimal. Our analysis shows that S15 exhibits&nbsp;a distinct expression pattern on tumors and functions
independently from the PD-L1 pathway. The left panel of the following figure illustrates the expression of S15 relative to PD-L1 among more than 200 NSCLC tumor samples across multiple microarrays.
Three distinct populations are identified: S15-positive and PD-L1-negative tumors; PD-L1-positive and S15-negative tumors; and tumors that express neither S15 nor PD-L1. This observation suggests that
the expression of S15 is generally non-overlapping from PD-L1 on tumors. As reflected in the right panel of the following figure, we believe NC318 may provide a therapeutic solution for patients who
have S15-positive and PD-L1-negative tumors, a patient population that is less likely to respond to a PD-1/PD-L1 directed therapy. This is consistent with our goal to develop immunomedicines that
restore normal immune function in ways that differ from existing immunotherapies in order to provide effective therapies for patients who are not adequately served by currently available therapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=93,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=512731,FOLIO='90',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_du78701_1_91"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g308280.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="337">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


S15 Target Validation  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe S15 represents a novel target for the treatment of cancer. We and others have conducted multiple preclinical studies in various
animal models evaluating the effect of inhibiting S15 by knocking out the gene responsible for producing S15 in mice. Across these studies, we observed that mice in which S15 is absent have generally
developed normally, suggesting that the inhibition of S15 is not associated with adverse effects on normal cells. In subsequent studies, we observed that S15 knockout mice mounted enhanced
antigen-specific T cell responses </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> as compared with wild-type mice, as shown in the following figure. In addition, when S15 was knocked out in
myeloid-derived cells, reflected as conditional knockout in the figure below, the mice mounted an enhanced antigen-specific T cell response similar to that of the knockout mice, which suggests the key
role that macrophages play in S15-mediated immunosuppression. The data show a statistically significant increase in antigen-specific T cells in knockout and conditional knockout mice as compared to
wild-type mice, and the increase is prolonged and maintained over a longer period than in the wild-type mice. In addition, we observed a significant increase in antigen-specific T cells in the spleen,
as measured by the percentage of OVA+ CD8+ cells among CD8+ cells. The knockout mice showed an increase of nearly 20% as compared to less than 2% in wild-type mice. This suggests that S15 plays
a key role in mediating immune suppression and the absence or inhibition of S15 could restore normal immune function. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=94,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=567758,FOLIO='91',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_du78701_1_92"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_increase_in_t_cells_observed_when_s15_is_absent"> </A>
<A NAME="toc_du78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Increase in T Cells Observed When S15 is Absent    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g296577.jpg" ALT="GRAPHIC" WIDTH="465" HEIGHT="279">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1><SUP>(1)</SUP></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The p-value, or probability value, cited in figures in this prospectus as "p," is the likelihood that an
observed result occurred by chance. The smaller the p-value, the less likely that chance caused the result. A result that is sufficiently unlikely to have occurred by chance is referred to as being
statistically significant. The FDA generally considers a p-value of less than or equal to 0.05, meaning that there is a 5% or less chance that the results occurred by chance, to be statistically
significant.</FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also evaluated tumor progression in S15 knockout mice compared to wild-type mice in a glioma tumor model. As shown in the figures below, the knockout group showed delayed tumor
progression as well as a corresponding increase in survival as compared to the wild-type group. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_knocking_out_s15_delayed_tumor__kno03245"> </A>
<A NAME="toc_du78701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Knocking Out S15 Delayed Tumor Progression and Prolonged Survival in Glioma Model    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g212626.jpg" ALT="GRAPHIC" WIDTH="676" HEIGHT="244">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to study the potential benefit of S15 inhibition in non-responders to PD-1/PD-L1 therapies, we conducted a preclinical study evaluating S15 knockout mice in a frequently used
melanoma model, the B16.GMCSF tumor model, which has been demonstrated to be resistant to PD-1/PD-L1 therapy. We observed that S15 knockout mice demonstrated greater anti-tumor effect and, as shown in
the following figure, had better overall survival than wild-type mice. We believe that this study suggests NC318 may have therapeutic potential in patients who do not respond to checkpoint inhibitors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=95,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=133937,FOLIO='92',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_du78701_1_93"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_knocking_out_s15_prolonged_sur__kno02582"> </A>
<A NAME="toc_du78701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Knocking Out S15 Prolonged Survival in PD-1/PD-L1 Resistant Tumor Model    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g831763.jpg" ALT="GRAPHIC" WIDTH="433" HEIGHT="253">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase 1/2 Clinical Trial  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2018, we initiated a Phase 1/2 clinical trial to evaluate NC318 as a monotherapy in patients with advanced or metastatic solid
tumors. This ongoing first-in-human trial is an open-label Phase 1/2 clinical trial designed to assess the safety and tolerability of NC318, to define the maximal tolerable dose and/or
pharmacologically active dose and to assess preliminary efficacy. Patients receive NC318 on day one of each cycle. We have initiated the trial with 14-day cycles; however, we may explore alternate
dose administration schedules depending on pharmacokinetics, pharmacodynamics, biomarker data, safety results and feedback from investigators. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
trial is being conducted in two phases. The Phase&nbsp;1 portion, which is designed for dose escalation and safety expansion, is intended to determine the pharmacologically active
dose, defined as the dose that provides a maximal biologic effect, such as an increase in biomarkers of immune activation or a reduction of biomarkers associated with immune suppression, and/or the
maximal tolerable dose of NC318, including defining the optimal dose administration schedule and the maximum number of tolerated doses. We expect to complete this portion of the trial in in the fourth
quarter of 2019. As of March&nbsp;31, 2019, we have dosed 21 patients with 10 different tumor types in the Phase&nbsp;1 portion of the trial across four dose cohorts: 8 mg, 24 mg, 80 mg and 240
mg. We plan to dose patients in two additional dose cohorts of 400 mg and 800 mg if no dose limiting toxicities are observed in the current dose cohorts. To date, NC318 has been well tolerated, with
no drug-related severe adverse events or dose limiting toxicities observed. In one subject, during an on-study assessment, we observed a transient asymptotic elevation of amylase (grade&nbsp;3) and
lipase (grade&nbsp;4) that was deemed probably related to NC318. The patient was asymptomatic and both elevations resolved without any interventions within 72 hours. All other safety signals that
were deemed at least possibly related to NC318 have been limited to transient asymptomatic laboratory findings or grade 1 events, as determined by the investigator. We have observed one confirmed
partial response and six instances of stable disease in 13 patients who have had at least one on-treatment radiologic assessment as of March&nbsp;31, 2019. The patient with the partial response is
in the 8 mg cohort and remains on treatment. The six patients with stable disease are in the 8 mg and 80 mg cohorts, and four of these six patients remain on treatment. We have observed progressive
disease in six patients, and there are eight additional patients on study who have not had on-treatment radiologic assessment as of March&nbsp;31, 2019. The Phase&nbsp;2 portion of the trial is
intended to detect a relevant efficacy signal, or response rate, for each of the tumor types. In this portion, we will enroll patients with tumor types that have been shown to have elevated S15
expression, including ovarian cancer, NSCLC and HNSCC, as well as other malignancies where PD-L1 expression is low. We expect to complete the Phase&nbsp;2 portion of the trial in the fourth quarter
of 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
designed our ongoing clinical trial for NC318 with a robust biomarker strategy to help evaluate clinical activity throughout the trial by focusing on markers of pharmacodynamics.
During the trial, we will </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=96,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=728104,FOLIO='93',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_du78701_1_94"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>obtain
a series of peripheral blood and whole blood samples from patients before and during treatment. These blood samples will be used for the analysis and characterization of the immune cell
population. T&nbsp;cell receptor clones will also be analyzed to detect evidence of therapy-induced clonal expansion of a subpopulation of antigen-specific T cells. Other assays relevant to the
objectives of the study, such as flow cytometry analysis of intracellular cytokines, may be performed based upon emerging data. In the Phase&nbsp;2 portion of this trial, we will also obtain tumor
biopsy samples before the first dose of NC318 and at least once more after the third dose. The biopsy samples will be used to investigate molecular signatures associated with response or resistance to
treatment with NC318. We may also examine tissue by histology and immunohistochemistry or by exploratory methods to evaluate markers of inflammation and effector T cell populations, growth, signaling,
apoptosis and similar markers that may be associated with safety, response or resistance to treatment with NC318. We believe our biomarker strategy will allow us to better monitor the clinical trial
and could help shape the treatment strategy of NC318 in future clinical trials and, if approved, in clinical practice. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Data  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most syngeneic mouse tumor cell lines, which are common mouse models used to test immunotherapies, do not express S15. In order to study the
effects of our S15-targeted antibody, we generated a tumor model where the mouse expresses S15. The model was initiated by differentiating mouse bone marrow cells into S15-positive M2 macrophages </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT
SIZE=2>. These cells were then implanted into mice with an S15-negative mouse colon cancer cell line called CT26. The mice were then treated with
either the S15-targeted antibody 5G12, the murine parent antibody of NC318, which has similar overall functional properties to NC318, or a control antibody. Across multiple preclinical studies, we
evaluated the safety and efficacy of 5G12 and observed that blocking the effects of S15 with 5G12 restored immune function and anti-tumor immunity. For example, as the figure below shows, mice treated
with 5G12 every four days for seven doses had smaller tumors and increased survival when compared to the mice treated with a control antibody. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="du78701_treatment_with_5g12_reduced_tu__tre02451"> </A>
<A NAME="toc_du78701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Treatment with 5G12 Reduced Tumor Growth and Increased Survival    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g333345.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="207">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=97,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=308292,FOLIO='94',FILE='DISK106:[19ZAH1.19ZAH78701]DU78701A.;40',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dw78701_1_95"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also generated murine tumors expressing S15 on their surface. In our preclinical studies of an S15-positive murine colon cancer cell line, we observed that
5G12 delayed tumor growth and tumor metastasis, which was demonstrated by fewer lung nodules measured 28&nbsp;days after treatment in the mice treated with 5G12 as compared to the mice treated with
a control antibody, as shown in the figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dw78701_treatment_with_5g12_de__dw702289"> </A>
<A NAME="toc_dw78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Treatment with 5G12 Delayed Tumor Metastasis in Lung Model    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g162259.jpg" ALT="GRAPHIC" WIDTH="312" HEIGHT="328">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, we understand that S15 drives an increase in pro-inflammatory and pro-tumorigenic cytokines, such as
IL-1<FONT FACE="SYMBOL">b</FONT>, IL-6 and TNF-<FONT FACE="SYMBOL">a</FONT>. As indicated in the figure below, when human peripheral blood mononuclear cells, or PBMCs, which are
blood cells that are critical components in the immune system, were cultured in the presence of S15, the amount of pro-inflammatory and pro-tumorigenic cytokines increased, indicating an
immunosuppressive environment. However, when human PBMCs were cultured with S15 protein and 5G12 or NC318, the amount of pro-inflammatory and pro-tumorigenic cytokines was reduced relative to when
cultured with S15 and a control antibody. In addition, 5G12 and NC318 promoted the ability of human T cells to proliferate and produce interferon-gamma, or
IFN-<FONT FACE="SYMBOL">g</FONT>. These data, which are shown in the figures below, suggest that 5G12 and NC318 have the potential to block immune suppression mediated by S15. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dw78701_nc318_decreased_inflammatory_cytokines"> </A>
<A NAME="toc_dw78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  NC318 Decreased Inflammatory Cytokines    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g634913.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="193">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=98,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=23218,FOLIO='95',FILE='DISK106:[19ZAH1.19ZAH78701]DW78701A.;32',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dw78701_1_96"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g361630.jpg" ALT="GRAPHIC" WIDTH="495" HEIGHT="264">
  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NC410  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1, and is designed to block immune
suppression mediated by LAIR-1. Multiple preclinical studies support our understanding that eliminating or blocking the binding of LAIR-1 restores normal immune function in multiple immune cells. Our
translational work has shown that NC410 blocks the interaction of LAIR-1 with its binding partners, thereby promoting T cell function and dendritic cell activity to contribute to restoring anti-tumor
immune activity. Consistent with our strategy, we believe NC410 has the potential to address the needs of patients who are not adequately addressed by currently available therapies. We are currently
conducting IND-enabling studies and expect to file an IND and initiate a Phase&nbsp;1/2 clinical trial in patients with advanced or metastatic solid tumors in the first quarter of 2020. We have
exclusive worldwide rights to NC410. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background of LAIR Pathway in Cancer  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LAIR-1 is a co-inhibitory receptor expressed on T cells and several other immune cell subsets, including monocytes, macrophages and dendritic
cells. Its binding partners include certain types of collagen and complement component 1q, or C1q. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
normal conditions, collagen forms&nbsp;a scaffold to provide strength and structure to tissues. C1q is part of the innate immune system to protect the host from infection and
other foreign agents. Both collagen and C1q are highly upregulated and expressed under pathologic conditions, such as in the TME and in the immune organelles close to the tumor site known as lymph
nodes, which are
important sites for mounting immune responses to the tumor. However, binding of LAIR-1 to collagen or C1q leads to immune suppression. Our preclinical studies have shown that LAIR-1 and LAIR-2 bind to
similar ligands, including collagen and C1q. LAIR-2, which is a secreted protein as opposed to a membrane-bound protein like LAIR-1, binds to the same regions of these ligands with stronger affinity
than LAIR-1. However, because LAIR-2 does not induce immune suppression when binding to these ligands, LAIR-2 functions as an efficient decoy for LAIR-1. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the harsh conditions of the TME, collagen and C1q are overexpressed as a membrane protein on many types of tumor cells and in the ECM surrounding the tumor. This increased
expression of collagen and C1q, combined with insufficient levels of natural LAIR-2, leads to increased binding of LAIR-1, resulting in immune suppression, tumor immune evasion and tumor growth. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NC410
is a novel immunotherapeutic protein that was developed to block LAIR-1-mediated immune suppression by mimicking the natural decoy effects of LAIR-2. Our approach of using NC410 as
a therapeutic is intended to take advantage of the natural LAIR-2 regulatory system in humans, which maintains human immune function under normal non-pathologic conditions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=99,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=587471,FOLIO='96',FILE='DISK106:[19ZAH1.19ZAH78701]DW78701A.;32',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dw78701_1_97"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
mechanism of action of NC410 prevents immune suppression caused by LAIR-1 binding to collagen or C1q and promotes anti-tumor immune activity. As the figure below shows, when LAIR-2
and NC410 are present in the TME, they bind to collagen or C1q preferentially compared to LAIR-1 given their higher binding affinity. This has the effect of blocking the collagen or C1q from binding
to LAIR-1, which otherwise would have resulted in an immunosuppressive effect. By blocking this interaction with LAIR-1 and its binding partners, T cell function and dendritic cell activity is
promoted in order to restore anti-tumor immune activity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dw78701_nc410_is_designed_to_prevent_i__nc402351"> </A>
<A NAME="toc_dw78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  NC410 is Designed to Prevent Immune Suppression Caused by LAIR-1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g505554.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="333">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Data  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have conducted multiple preclinical studies to assess the activity of NC410 across a variety of preclinical models. These studies support our
understanding that eliminating or blocking the binding of LAIR-1 to collagen or C1q can restore normal immune function in multiple immune cells, including T cells and myeloid cells, resulting in
activation of T cells and anti-tumor immunity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have observed </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> with human cells that using NC410 to block LAIR-1 from binding with collagen or C1q reverses immune suppression
and restores normal immune cell function for both peripheral blood monocytes, including T cells, and myeloid cells. In one study of peripheral blood monocytes, we added
0&nbsp;&micro;g/mL, 10 &micro;g/mL and 100 &micro;g/mL of NC410 to 20 &micro;g/mL of collagen peptide </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>. Similarly, we also evaluated the addition of 0 &micro;g/mL, 2.5 &micro;g/mL and 10
&micro;g/mL of NC410 to 10 &micro;g/mL of C1q on human myeloid cells. As shown in the figures below, NC410 promoted the activation of immune cells in the presence
of high levels of collagen in peripheral blood monocytes and high levels of C1q in myeloid cells in a dose-dependent manner. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=100,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=530145,FOLIO='97',FILE='DISK106:[19ZAH1.19ZAH78701]DW78701A.;32',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dw78701_1_98"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g859618.jpg" ALT="GRAPHIC" WIDTH="666" HEIGHT="388">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
another preclinical study with human cells, we observed that NC410 promoted increases in the cytokines IL-2 and TNF-<FONT FACE="SYMBOL">a</FONT>, as shown in the left-hand
panel of the following figure, which is indicative of increased immune function. In addition,
simultaneous </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> injections of NC410 and human T cells in immune-deficient mice resulted in increased amounts of CD4+ and CD8+ T cells, as shown in
the right-hand panel of the figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g988525.jpg" ALT="GRAPHIC" WIDTH="660" HEIGHT="264">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
multiple preclinical studies in several additional tumor models, we observed that eliminating or blocking LAIR-1-mediated immune suppression prolonged survival. In addition,
anti-tumor activity of NC410 correlated with a local increase in antigen-specific T cells in the TME </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> using an engineered mouse model to measure
localized antigen-specific responses. We used an antigen-specific tumor model of EL4, a murine lymphoma cell line. We measured the weight of the animals daily as a proxy for tumor </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=101,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=506779,FOLIO='98',FILE='DISK106:[19ZAH1.19ZAH78701]DW78701A.;32',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_dw78701_1_99"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>growth.
As shown in the figure below, we observed that mice treated with NC410 had smaller tumors than mice treated with a control, suggesting that NC410 has potential anti-tumor activity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dw78701_nc410_showed_anti-tumor_activity"> </A>
<A NAME="toc_dw78701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  NC410 Showed Anti-Tumor Activity    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g809974.jpg" ALT="GRAPHIC" WIDTH="411" HEIGHT="310">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also measured T cells specific for ovalbumin, and as shown in the figures below, we observed systemic and local increases, as measured in the spleen and lymph node, respectively, in
mice treated with NC410 compared to those treated with control. We believe that these data support an immune response in and around the TME. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dw78701_nc410_increased_t_cell__dw702027"> </A>
<A NAME="toc_dw78701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  NC410 Increased T Cells Both Systemically and Locally    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g248496.jpg" ALT="GRAPHIC" WIDTH="552" HEIGHT="283">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=102,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=757227,FOLIO='99',FILE='DISK106:[19ZAH1.19ZAH78701]DW78701A.;32',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dy78701_1_100"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, when human PBMCs were implanted into mice with mouse P815 mastocytoma tumor cells, we observed that NC410 mediated an increase in human T cells </FONT> <FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> and that the increase in human T cells correlated with a delay in tumor growth. As shown in the figures below, NC410 increased the number of
CD8+ T cells on day 13 in a dose-dependent manner and that increase corresponded to a decrease in tumor volume. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g902545.jpg" ALT="GRAPHIC" WIDTH="666" HEIGHT="246">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Clinical Development Plan for NC410  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and others have analyzed genomic and protein databases and observed that LAIR-1 expression levels negatively correlate with survival rates
for several cancers, including brain, renal, colorectal, glioma, lung, urothelial and ovarian cancers. These analyses support possible targeting of these tumor types as primary indications for
therapeutic treatment with NC410. We are conducting expansive screening efforts on tumor samples from different solid tumor types to identify tumors that express LAIR-1 on the surface of either cancer
cells or infiltrating immune cells to guide our ultimate selection of patients for planned clinical trials of NC410 in humans. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently conducting IND-enabling studies for NC410 and plan to file an IND and initiate a Phase&nbsp;1/2 clinical trial in patients with advanced or metastatic solid tumors in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Research Programs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to NC318 and NC410, we are also pursuing preclinical evaluation of other potential novel immunomodulatory molecules. Among these is
an antibody that targets a novel member of the B7-family of immunomodulatory proteins. In our preclinical studies, this antibody has shown highly reproducible and potent anti-tumor activity with </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>
modeling and appears to involve an important immunomodulatory pathway in the TME that may complement the activity of NC318 and NC410. Consistent
with our focus on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types that are not adequately addressed by currently
available therapies, the target of this antibody appears to be non-overlapping with the expression of both S15 and PD-L1 on tumor cells. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have an antibody in preclinical development targeting an immune modulator that is highly expressed in inflamed tissue and the TME in multiple tumor types. In our preclinical
research, we observed that disrupting inhibitory signaling by this molecule with our antibody increased T cell and NK&nbsp;cell effector functions. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our understanding of the LAIR pathway, including through our development of NC410, we are also pursuing monoclonal antibodies that target LAIR-1 and directly block LAIR-1
binding and signaling to prevent tumor growth or to eliminate the tumor. These novel LAIR-1 antibodies have unique functional properties that may provide additional opportunities in both cancer and
autoimmune disorders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=779175,FOLIO='100',FILE='DISK106:[19ZAH1.19ZAH78701]DY78701A.;36',USER='CHE107555',CD='26-APR-2019;00:19' -->
<A NAME="page_dy78701_1_101"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our FIND-IO Discovery Engine  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our FIND-IO platform uses proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines
from immune lineages, including T cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines, and cells isolated from diseased patients. This platform allows us to identify
proteins that can be targeted with novel immunomedicines to repair and maintain anti-tumor immunity. We have identified multiple novel targets using our FIND-IO platform, including those for which
certain of our research programs are being designed to target. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are three integrated components to our FIND-IO platform. The first component consists of gene libraries, also called target libraries, comprising genes that are expressed and
queried for immune or other functions. Our target libraries are composed of genes that encode a structurally diverse set of protein molecules and that are either inserted into the plasma membrane on
the host cell surface or secreted outside of the host cell. The second component encompasses a variety of immune and non-immune cell types, called responder cells, used to evaluate the functional
effects of the target libraries. The immune responder cell types include primarily immune cells obtained from human volunteers and multiple immune cell lines that have been grown in culture, and the
non-immune responder cell types include tumor cell lines. The third component utilizes a broad set of outputs indicative of whether a newly discovered target inhibits or stimulates functional immune
responses. We utilize a cube to illustrate these three components as shown in the figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g767357.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="372">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unlike
other screening platforms that often focus on a single parameter or cell type, our approach uses a broad search across multiple cell types and multiple functions and is
purposefully designed to produce physiologically relevant results. Although the orchestration of an immune response is complex and dynamic within the TME, we have designed the FIND-IO platform to be
simple yet functional. The platform integrates multiple components to assess immune function resulting from cellular interactions in order to identify new immune modulators in an approach that mimics
physiological interactions. The goal is to identify proteins that can be targeted with immunomedicines, such as monoclonal antibodies or fusion proteins. Potential targets that are preliminarily
identified through the FIND-IO platform undergo reproducible, robust, relevant and comprehensive characterization resulting in functional readouts that improve the likelihood of developing
immunomedicines against novel immune modulatory molecules. This approach is intended to meet our goal of extending beyond the success of current immunotherapies to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=104,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=155157,FOLIO='101',FILE='DISK106:[19ZAH1.19ZAH78701]DY78701A.;36',USER='CHE107555',CD='26-APR-2019;00:19' -->
<A NAME="page_dy78701_1_102"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>treat
patients who are not adequately addressed by currently available therapies and to enhance overall survival in these patients. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
first step in the application of our FIND-IO platform is to transfect the target library into a host cell on a gene-by-gene basis. The host cells then express the library genes and
the proteins are present on the cell surface or secreted into the surrounding space. In addition, the host cell has been engineered to express a reporter of transcriptional activity associated with a
cellular function. For example, we engineer the host cells to report transcription factor activity in a cellular pathway by linking a selected DNA with a different fluorescent reporter, such as red
fluorescent protein, or RFP. Thus, if the library gene expresses a protein that can signal via the applicable pathway, then the RFP gene is transcribed, expressed as a protein and the cell will glow
red. The immune or non-immune responder cells are also engineered to express a reporter of transcriptional activity associated with a cellular function. For example, we engineer the responder cells to
report transcription factor activity in a cellular pathway by linking a selected DNA with a fluorescent reporter such as green fluorescent protein, or GFP. Therefore, when transcription occurs in the
responder cell, the GFP gene is transcribed, expressed as a protein and the cell will glow green. The red and/or green glow of the cells can be measured quantitatively. This is called bi-directional
signaling as the FIND-IO platform was designed to look at signaling events in the host cells as well as the immune and non-immune responder cells. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g454639.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="355">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FIND-IO platform allows us to select and screen multiple immune and non-immune responder cell types, including T cells, myeloid cells, leukemia cells, epithelial cancer cells, plasma
B cells and multiple myeloma cells, as well as primary immune cells from healthy donors. For each of these cell types, we undertake functional screening, including activity of many reporter pathways,
effector function activity and effects on cell death, in order to identify novel immunomodulatory targets with common or differentiating effects across multiple cell types. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
with our FIND-IO technology we can test for combination screens to search for synergistic or additive combinations with certain pathways, including immune checkpoint
pathways, like the PD-1/PD-L1 pathway, that are currently approved for treating cancer patients. We expect that this screening will help with the identification of potential combination treatments to
enhance response rates. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
goal of our FIND-IO platform is to sustain a pipeline of novel immunomedicines that restore normal immune function to treat cancer and other immune-related diseases. While we are
primarily </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=105,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=684527,FOLIO='102',FILE='DISK106:[19ZAH1.19ZAH78701]DY78701A.;36',USER='CHE107555',CD='26-APR-2019;00:19' -->
<A NAME="page_dy78701_1_103"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>focused
on cancer treatment, we believe that our proprietary technology, our approach, our understanding of biological pathways and the convergence of immunology and inflammation provide us with
opportunity to explore novel immunomedicines for other significant unmet medical needs. To maximize the full potential of our platform and expertise, we are expanding the functional screening approach
of our FIND-IO platform to the identification of novel targets in autoimmunity and inflammation, where we are using this approach to develop our FIND-AI platform, as well as in neuro-inflammatory
diseases. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Collaboration Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreements with Yale University  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


License Agreement with Yale  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2015, we entered into a license agreement with Yale, or the Yale Agreement, pursuant to which we obtained an exclusive,
royalty-bearing, sublicensable worldwide license to products that either incorporate certain licensed patents used in the discovery of targets or arise out of research and development of
Dr.&nbsp;Chen's laboratory at Yale, including S15. We are obligated to pay Yale low single-digit royalties on sales of products, including NC318, that are either covered by the patents licensed to
us under the Yale Agreement or arise out of Dr.&nbsp;Chen's laboratory, subject to minimum annual royalty payments in the low to mid hundreds of thousands of dollars. Until we are required to pay
royalties under the Yale Agreement, we must pay an annual license maintenance fee to Yale in the mid to high tens of thousands of dollars. In addition, with respect to each product covered by licenses
under the Yale Agreement, we are obligated to pay Yale milestone payments upon (i)&nbsp;the initiation of each of a Phase&nbsp;1 clinical trial, Phase&nbsp;2 clinical trial and Phase&nbsp;3
clinical trial or a pivotal trial, (ii)&nbsp;first commercial sale in the United States and (iii)&nbsp;first commercial sale in China, Japan or a major European country, in an aggregate amount of
up to $2,975,000. The term of the license agreement with Yale runs, on a country-by-country basis, until the later of the expiration of all licensed patents or 10&nbsp;years from the first
commercial sale in such country, unless Yale has cause to terminate earlier for our material breach of the license, bankruptcy or if we or any sublicensee bring a challenge against Yale in relation to
the licensed patents. We have the right to terminate the Yale Agreement for Yale's material breach or at any time during the term with six months' prior written notice to Yale. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sponsored Research Agreement with Yale  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Yale Agreement, we also entered into a corporate sponsored research agreement, or SRA, with Yale, in which we agreed to
provide an aggregate of up to $12.4&nbsp;million to fund a research program aimed at discovering new targets for immunomedicines. The research program is under the direction and supervision of
Dr.&nbsp;Chen. Pursuant to the SRA, we have the option to add any patents invented pursuant to the research program as a licensed patent under the Yale Agreement and the right to obtain a
royalty-bearing, exclusive, worldwide license to any such patents. If we do not exercise our option within the exercise period, Yale is permitted to license any such patents to any third party. The
SRA will expire on December&nbsp;31, 2020, and we have the option of extending the term upon mutual agreement with Yale. We can terminate the SRA at any time upon
90&nbsp;days' written notice to Yale. Yale can terminate for an uncured breach or with 90&nbsp;days' written notice for cause. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Collaboration with Lilly  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, we entered into the Lilly Agreement, pursuant to which we will use our FIND-IO platform to identify novel oncology targets for
additional collaborative research and drug discovery by us and Lilly. Under this agreement, we granted Lilly the exclusive option to obtain worldwide exclusive licenses to research, develop,
manufacture and commercialize multiple compounds and products directed to oncology targets identified through our research collaboration. Lilly currently has all options remaining eligible for
exercise. In addition, Lilly granted us the exclusive option to obtain worldwide exclusive licenses to research, develop, manufacture and commercialize an equal number of compounds and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=106,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=234984,FOLIO='103',FILE='DISK106:[19ZAH1.19ZAH78701]DY78701A.;36',USER='CHE107555',CD='26-APR-2019;00:19' -->
<A NAME="page_dy78701_1_104"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>products
directed to oncology targets for which Lilly does not exercise its option. We currently have all options remaining eligible for exercise. Under the Lilly Agreement, we retain all rights to
our intellectual property outside of oncology for any targets that are not actively being researched and developed pursuant to the Lilly Agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Lilly Agreement, we and Lilly have agreed to engage in a multi-year research collaboration, which will be managed by a joint steering committee formed by an equal number of
members from each party and expire upon the earlier of the exercise of all options granted to Lilly or four years from the date of the agreement, subject to certain extensions. We have granted Lilly
exclusivity with respect to targets identified through our FIND-IO platform that can be used in the oncology field during the research term or until Lilly has exercised all of its options. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the research term, as a part of target discovery, we will be responsible for providing Lilly with oncology targets identified using our FIND-IO platform. From the targets provided
by us, Lilly may select targets to advance to target validation using criteria developed by both parties. Following completion of the agreed upon target validation plan with respect to a given target,
either party may propose to advance that target to compound discovery. For each target that has been advanced to compound discovery, Lilly will have the option to obtain an exclusive license in all
fields of use with respect to the compounds and products directed to the target. If Lilly does not exercise its option with respect to a given target that has advanced through compound discovery, or
has previously exercised all of its options, we have the option to obtain licenses with respect to compounds and products directed
to the target. Lilly and we may each exercise our respective options with respect to targets during the research term. Following option exercise by a party, the development and commercialization of
any compounds and products directed to the target will be conducted by the exercising party. The exercising party must use commercially reasonable efforts to develop, seek regulatory approval for and
commercialize any such products under mutually agreed work plans. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
received an upfront, non-refundable payment of $25.0&nbsp;million in cash and a $15.0&nbsp;million equity investment from Lilly upon entering into the agreement. Lilly is also
required to pay us quarterly research and development support payments in an aggregate in the mid single digit millions of dollars during a portion of the research term as well as option exercise fees
in an aggregate of up to the high single digit millions of dollars upon the exercise of options by Lilly. For the first product directed to each target optioned by Lilly, Lilly will pay development
and regulatory milestones. For the first additional indication in a different therapeutic area for such product, Lilly will pay regulatory milestones upon regulatory approval in each of the United
States, European Union and Japan. Additionally, regardless of indication, Lilly will pay sales milestones as well as mid to high single-digit royalties on net sales for all products directed to each
target optioned by Lilly. The milestone payments could amount to an aggregate of up to $1.4&nbsp;billion. This amount assumes that Lilly exercises all of the options available to it, as well as the
successful achievement of all development and regulatory milestones and sales milestones for each target optioned by Lilly. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
our exercise of an option with respect to a given target, we will owe Lilly option exercise, milestone and royalty payments in amounts equivalent to a portion of the amounts payable
by Lilly were Lilly to exercise an option, including an aggregate of up to $710 million in development and regulatory milestones and sales milestones and low to mid single-digit royalties. Unless
terminated earlier, the term of the Lilly Agreement will continue in effect, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Either party may
terminate the agreement, in whole or in part, for the other's material breach that has not been cured within a certain period or general assignment for the benefit of creditors or in connection with
the other's bankruptcy or insolvency. In addition, Lilly has the right to terminate the agreement in its entirety or with respect to one or more specified products or targets at any time with
60&nbsp;days prior notice. To the extent that we terminate for Lilly's material breach or insolvency or Lilly terminates for convenience, all licenses and rights granted by us to Lilly will
automatically terminate and the licenses and rights granted by Lilly to us will survive. Similarly, if Lilly terminates for our material breach or insolvency, all licenses and rights granted by Lilly
to us will automatically terminate, and the licenses and rights granted by us to Lilly will survive. In such cases, all future royalties and milestones will be reduced in an amount to be reasonably
agreed by the parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=107,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=231677,FOLIO='104',FILE='DISK106:[19ZAH1.19ZAH78701]DY78701A.;36',USER='CHE107555',CD='26-APR-2019;00:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ea78701_1_105"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a purpose-built, dedicated, state-of-the-art cGMP manufacturing facility that utilizes single-use technology to support our pipeline and
advance our product candidates into and through clinical development. The facility has an initial production capacity of 1,000 liters and was designed with additional room for expansion to support
multiple product candidates. The investment in our manufacturing facility is a critical element of our ability to quickly identify whether a candidate will
be successful and to facilitate an efficient development path. While other companies may need to work with third parties for antibody production, we can do so in our own facility. Compared to working
with third-party manufacturers, we believe our facility provides better quality assurance, greater control in scheduling and prioritizing manufacturing activities and enhanced capital efficiency. We
are currently manufacturing all of the drug supply for our preclinical studies and our Phase 1/2 clinical trial of NC318. As we advance the development of our growing pipeline of product candidates,
we will continue to evaluate the merits of expanding our internal manufacturing capabilities, including for the production of commercial drug supply, as compared to collaborating with third-party
manufacturers. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies, fierce
competition and strong defense of intellectual property. We believe that our programs, platforms, technology, knowledge, experience and scientific resources provide us with competitive advantages, but
we also face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our competitors
include larger and better funded biopharmaceutical, biotechnology and therapeutics companies, including companies focused on cancer immunotherapies, such as Amgen,&nbsp;Inc., AstraZeneca&nbsp;plc,
Bristol-Myers Squibb Company, or BMS, Genentech,&nbsp;Inc., GlaxoSmithKline&nbsp;PLC, Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., Novartis AG, Pfizer&nbsp;Inc., Roche Holding&nbsp;Ltd and
Sanofi&nbsp;S.A. Moreover, we may also compete with smaller or earlier-stage companies, universities and other research institutions that have developed, are developing or may be developing current
and future cancer therapeutics. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
candidates that we successfully develop and commercialize will compete with a range of therapies that are currently approved and any new therapies that may become available in
the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Currently marketed oncology
drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&nbsp;Inc.'s Kadcyla, to immune checkpoint inhibitors targeting
CTLA-4, such as BMS' Yervoy, and PD-1/PD-L1, such as BMS' Opdivo, Merck&nbsp;&amp;&nbsp;Co.'s Keytruda and Genentech's Tecentriq, to T cell-engager immunotherapies, such as Amgen's Blincyto. In
addition to these marketed therapies, numerous compounds are in clinical development for the potential treatment of cancer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also
obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are
able to enter the market. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, methods and manufacturing
processes, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. We rely on a combination of patent applications and trade
secrets, as well as contractual protections, to establish and protect our intellectual property rights. We seek to protect our proprietary position by, among other things, filing

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=108,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=353090,FOLIO='105',FILE='DISK106:[19ZAH1.19ZAH78701]EA78701A.;25',USER='CHE106795',CD='27-APR-2019;09:19' -->
<A NAME="page_ea78701_1_106"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


patent applications in the United States and internationally. Our patent estate includes patent applications with claims relating to our product candidates, methods of use and manufacturing processes,
and claims for potential future products and developments. As of April&nbsp;29, 2019, our intellectual property portfolio includes, on a worldwide basis, 18 pending foreign patent applications
relating to NC318 and NC410, one pending U.S. patent application relating to NC318, one pending U.S. patent application relating to NC410 and additional pending patent applications for other discovery
and research programs. Patents resulting from our patent applications for NC318 and NC410, if issued, are expected to expire beginning in 2037 absent any patent term adjustments or extensions.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as described above, under the Yale Agreement, we have an exclusive, royalty-bearing, sublicensable worldwide license from Yale for an intellectual property portfolio,
including patent applications, relating to methods of use for S15 that covers the use of NC318. Any patents from these patent applications, if issued, are expected to expire no earlier than 2036
absent any patent term adjustments or extensions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all patent applications, we determine strategy for claim scope on a case-by-case basis, taking into account advice of counsel and our business model and needs. We file patents
containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and
products, based on our assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum
coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our
intellectual property and business needs. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position, including with respect to our FIND-IO platform. We
seek to protect
our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. In addition, in
the ordinary course of our business, we enter into agreements with other third parties for non-exclusive rights to intellectual property directed to other technologies that are ancillary to our
business, including laboratory information management software and research and development tools. In addition, we have filed for trademark registration with the U.S. Patent and Trademark Office, or
the USPTO, for "NextCure," our logo and our FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation and Product Approval  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other
things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising,
promotion, marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various preclinical, clinical
and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The processes
for obtaining regulatory approvals in the United States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require
the expenditure of substantial time and financial resources. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
policies may change and additional government regulations may be enacted that could prevent or delay further development or regulatory approval of any product candidates,
product or manufacturing changes, additional disease indications, or label changes. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative
or administrative action. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=109,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=688924,FOLIO='106',FILE='DISK106:[19ZAH1.19ZAH78701]EA78701A.;25',USER='CHE106795',CD='27-APR-2019;09:19' -->
<A NAME="page_ea78701_1_107"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review and Approval for Licensing Biologics in the United States  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates our current product candidates as biological products, or biologics, under the Federal Food, Drug, and
Cosmetic Act, or FDCA, the Public Health Service Act and associated implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In
contrast to chemically synthesized small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human,
animal, or microorganism) are complex in structure, and thus are usually not fully characterized. Biologics include immunomedicines for cancer and other diseases. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biologics
are also subject to other federal, state and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the
product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or
termination of clinical trials by the FDA, the FDA's refusal to approve pending applications or supplemental applications, withdrawal of an approval, Warning Letters or Untitled Letters, product
recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or
civil or criminal investigations and penalties brought by the FDA, the Department of Justice, or the DOJ, or other governmental entities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> completion of non-clinical laboratory tests and animal studies performed in accordance with the FDA's good laboratory practice, or GLP,
regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> manufacture, labeling and distribution of investigational drug in compliance with cGMP; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> submission to the FDA of an IND application, which must become effective before clinical trials may begin and must be updated annually or when
significant changes are made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each clinical trial may be
initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with the FDA's current Good Clinical Practices requirements, or
cGCP, to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all pivotal clinical trials requesting
marketing approval for one or more proposed indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtain satisfactory completion of an FDA Advisory Committee review, where appropriate or if applicable, as may be requested by the FDA to
assist with its review; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or components
thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic's identity, safety,
quality, purity and potency; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP requirements and the integrity of
the clinical data; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> payment of user fees under the Prescription Drug User Fee Act for the relevant year; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtain FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the
United States; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=110,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=603480,FOLIO='107',FILE='DISK106:[19ZAH1.19ZAH78701]EA78701A.;25',USER='CHE106795',CD='27-APR-2019;09:19' -->
<A NAME="page_ea78701_1_108"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or
REMS, and the potential requirement to conduct post-approval studies. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and
marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our
business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the
effect of such changes, if any, may be. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical and Clinical Development  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before an applicant can begin testing the potential candidate in human subjects, the applicant must first conduct preclinical studies.
Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and animal studies to assess the
potential
safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical studies are subject to federal regulations and requirements, including GLP
regulations. The results of an applicant's preclinical studies are submitted to the FDA as part of an IND. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be
shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment and administration of a biologic that is not subject of an
approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA raises safety concerns or
questions about the proposed clinical trial within the 30-day time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns
or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to
the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the
IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&nbsp;days after imposition of a clinical hold or partial
clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after
the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or
otherwise satisfying the FDA that the investigation can proceed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations, which
include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each
successive clinical trial conducted during product development and for any subsequent protocol amendments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=111,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=882739,FOLIO='108',FILE='DISK106:[19ZAH1.19ZAH78701]EA78701A.;25',USER='CHE106795',CD='27-APR-2019;09:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ec78701_1_109"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND
requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with cGCP regulations in order to use the study
as support for an IND or application for marketing approval, including cGCP regulations, including review and approval by an independent ethics committee and informed consent from subjects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the
clinical trial begins at
that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. DSMBs provide
authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an
unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or
competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trials  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of BLA approval, clinical trials are typically conducted in the following sequential
phases:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;1: The investigational product is initially introduced into healthy human subjects or patients with the target disease or
condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with
increasing doses. These trials may also yield early evidence of effectiveness. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;2: The investigational product is administered to a limited patient population with a specified disease or condition to evaluate
the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&nbsp;2 clinical trials may be conducted to obtain
information prior to beginning larger and more expensive Phase&nbsp;3 clinical trials. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;3: The investigational product is administered to an expanded patient population to further evaluate dosage, to provide
statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to
generate sufficient data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an
adequate basis for product approval by the FDA. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
phases may overlap or be combined. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more
information about the product, referred to as Phase&nbsp;4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and
information relating to the biological characteristics of the product and treatment of patients in the intended therapeutic indication. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety
reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT
SIZE=2> testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=112,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=880107,FOLIO='109',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_110"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>sponsor,
that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol
or investigator brochure. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its
institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to
patients. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes, or PROs, and outcome
reported outcomes, or OROs, the process typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on
optimizing
PRO and ORO instruments during the clinical development process, the FDA usually reserves final judgment until it reviews the BLA. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and
finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug
candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BLA Submission and Review  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may
submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, nonclinical studies and clinical
trials; detailed information on the product's chemistry, manufacture, controls; and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application
user fee, unless a waiver or exemption applies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA's procedures, the agency has 60&nbsp;days from its receipt of a BLA to determine
whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the
application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of the biologic in relevant pediatric
populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor's request or by the agency's initiative. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and if the facility in which it is
manufactured, processed, packed or held meets standards designed to assure the product's continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to
provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or
facilities where the product is manufactured. The FDA will not approve an application unless it determines that the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=113,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=484116,FOLIO='110',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_111"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>manufacturing
processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be
reliable and accurate, and requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor's responsibility
to ensure the safety, efficacy and quality of its product or products. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA determines that the application, manufacturing
process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of
any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA
performance goals generally provide for action on a BLA within 10&nbsp;months of filing, which (as discussed above) typically occurs within 60&nbsp;days of submission, but that
deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA requests for additional information or clarification. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists
of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA
is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, the FDA may issue an approval
letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all
of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL
without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to the FDA's satisfaction in a
resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including
requests for
additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, and may require additional testing or information
and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is a safety strategy to manage a known or potential serious
risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a
proposed REMS and the FDA will not approve the BLA without a REMS that the agency has determined is acceptable. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings or precautions be included in the product
labeling. The FDA may also require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug's safety after approval. The FDA may prevent or limit
further marketing of a product based on the results of post-market studies or surveillance programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=114,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=117141,FOLIO='111',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_112"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include official lot release, which requires
the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA,
together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer's tests performed on the lot. The FDA may also perform certain
confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing
requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not
maintained or if problems occur after the product reaches the marketplace. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric Studies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act, a BLA or BLA supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product
is safe and effective. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver
requests and any other information required by regulation. The applicant, the FDA and the FDA's internal review committee must then review the information submitted, consult with each other, and agree
upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. In addition, the FDA Reauthorization Act of 2017 requires the FDA to meet early in the development process
to discuss pediatric study plans with drug sponsors. The law requires the FDA to meet with drug sponsors by no later than the end-of-Phase&nbsp;1 meeting for serious or life-threatening diseases and
by no later than 90&nbsp;days after the FDA's receipt of the study plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults,
or full or partial waivers from the pediatric data requirements. For example, the requirement for such studies or clinical trials may be waived if necessary studies or clinical trials in children are
impossible, there is strong evidence suggesting the drug will not be effective or safe in children, the drug does not represent a meaningful therapeutic benefit over existing therapies for children,
or the drug is not likely to be used in a substantial number of children. Such studies or clinical trials may also be deferred if the drug is ready for approval in adults before pediatric studies or
clinical trials are completed or due to concerns about the safety or effectiveness of the drugs in pediatric populations. When such studies or clinical trials are deferred, they will be reported as
post-marketing requirements. Pediatric data requirements do not apply to products with orphan designation. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product sampling and distribution and advertising and promotion
of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. There also are continuing user
fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party contractors are required to register their
establishments with the FDA and certain state agencies. These establishments are subject to routine and periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose certain procedural and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=115,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=68581,FOLIO='112',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_113"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>documentation
requirements to assure quality of manufacturing and product. FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of
its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail
functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-approval
changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA
regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance and other aspects of
regulatory compliance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS. Other potential consequences include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> product seizure or detention, or refusal of the FDA to permit the import or export of products or Import Alert; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> permanent injunctions and consent decrees, including the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company can make only those claims relating to safety
and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA's regulation includes, among other things, standards and regulations
for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social
media. Promotional claims relating to a product's safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not
approved by the FDA, as reflected in the product's prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the
drug's labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers' communications,
prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding
off-label information, such as distributing scientific or medical journal information. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of
the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant
commercial impact, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=116,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=396580,FOLIO='113',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_114"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>including
civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil and criminal
fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed
or curtailed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of prescription drug and biologic are subject to the Drug Supply Chain Security Act, or DSCSA, which requires manufacturers and other stakeholders to comply with product
identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, and
state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription
drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Marketing Exclusivity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After approval, owners of relevant drug or biological product patents may apply for up to a five year patent extension to restore a portion of
patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient
under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as one-half of the product's testing
phase, which is the time between IND and BLA submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if
the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed more than 14&nbsp;years from the date of FDA approval of
the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&nbsp;days of approval. The USPTO, in consultation
with the FDA, reviews and approves the application for patent term restoration. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year
and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the
product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which a BLA has not been
submitted. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biosimilars and Marketing Exclusivities  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Biologics Price Competition and Innovation Act, or BPCIA, created an abbreviated approval pathway for biological product candidates shown to
be highly similar to or interchangeable with an FDA licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in
conditions of use, route of administration, dosage form and strength, and no clinically meaningful differences between the biological product candidate and the reference product in terms of safety,
purity and potency. Biosimilarity must be shown through analytical trials, animal trials and at least one clinical trial, unless the Secretary of Health and Human Services waives a required element. A
biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as
the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks
or risks of diminished efficacy relative to exclusive use of the reference biologic. To date, a handful of biosimilar products and no interchangeable products have been approved under the BPCIA.
Complexities associated with the larger, and often more complex, structures of biologics, as well as the process by which such products are manufactured, pose significant hurdles to implementation of
the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=117,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=976482,FOLIO='114',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<A NAME="page_ec78701_1_115"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reference biologic is granted 12&nbsp;years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four
years from the date of licensure of the reference product. The first biological product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the
reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&nbsp;one year after first commercial marketing of
the first interchangeable biosimilar, (ii)&nbsp;18&nbsp;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&nbsp;18&nbsp;months after
resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&nbsp;42&nbsp;months after the first interchangeable
biosimilar's application has been approved if a patent lawsuit is ongoing within the 42&nbsp;month period. At this time, it is unclear whether products deemed "interchangeable" by the FDA will, in
fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a biologic is designated and approved for an orphan indication, it will be granted seven years of orphan drug exclusivity. An orphan indication is granted to biological products and
drugs designated and approved to treat diseases or conditions affecting fewer than 200,000 individuals in the United States, or if there is no reasonable expectation that the sponsor will be able to
recover the costs of
developing and marketing the drug or biological product in the United States. A biosimilar may not be licensed by FDA for the protected orphan indication until after the expiration of the seven year
orphan drug exclusivity period or the 12&nbsp;year reference product exclusivity, whichever is later. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity adds an additional six month exclusivity period to any marketing exclusivities and patents that a biological product has obtained. In order to obtain pediatric
exclusivity, a BLA sponsor must conduct pediatric studies as requested by the FDA in a Written Request. The data do not need to show the product to be effective in the pediatric population studied;
rather, if the clinical trial is deemed to fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA
within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. While pediatric exclusivity is not an
actual extension on a patent term, it effectively extends the preclusive effect of the patent on FDA's authority to approve another application that relies on the product with pediatric exclusivity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
BPCIA is complex and continues to be interpreted and implemented by the FDA. The FDA has issued several guidance documents outlining an approach to review and approval of
biosimilars. In July 2018, the FDA released its Biosimilars Action Plan to improve the efficiency of the biosimilar and interchangeable product development and approval process. Other aspects of the
BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and impact of the BPCIA is subject
to significant uncertainty. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulation of Companion Diagnostics and Laboratory Developed Tests  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A companion diagnostic is an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic that can: identify the patients most likely to
benefit from a particular therapeutic product; identify those likely to be at an increased risk for serious side effects; or monitor responses to treatment with a particular therapeutic product for
the purpose of adjusting treatment to achieve improved safety or effectiveness. Under the FDCA, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostics are generally regulated
as medical devices. The FDA has generally classified </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostics as high-risk, Class&nbsp;III devices, which require FDA approval
of a premarket approval application, or PMA, but recognizes the possibility of a moderate-risk IVD companion diagnostic (</FONT><FONT SIZE=2><I>i.e</I></FONT><FONT SIZE=2>., Class&nbsp;II device),
which would require clearance of a 510(k) premarket notification or grant of a </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> request. Approval or clearance of the </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=118,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=101208,FOLIO='115',FILE='DISK106:[19ZAH1.19ZAH78701]EC78701A.;13',USER='CHE106319',CD='26-APR-2019;01:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ee78701_1_116"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For those </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostics that require PMA approval, the process involves gathering and submitting
clinical and preclinical data on the device for review by the FDA. It involves a rigorous premarket review, during which the applicant must provide the FDA with reasonable assurance of the device's
safety and effectiveness, as well as information regarding the device's design, manufacturing and labeling. In addition, the FDA will typically inspect the device manufacturer's facilities for
compliance with the Quality System Regulation, which imposes testing, control, documentation and other quality assurance requirements. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has issued guidance on the approval of therapeutic products and </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic devices. According to the FDA's
guidance, for novel therapeutic products including biologics, an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device and its corresponding therapeutic should be
approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product's labeling. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some cases, information from a diagnostic test may be useful to a prescriber, but not necessary for the safe and effective administration of the therapeutic product. In those cases,
health care providers may employ information derived from a laboratory developed test, or LDT, when administering a therapeutic product. An LDT is a type of </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> diagnostic test that is designed, manufactured and used within a single laboratory. LDTs can be used to measure or detect a wide variety of analytes (substances such as
proteins, chemical compounds like glucose or cholesterol, or DNA), in a sample taken from a human body. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently
the Centers for Medicare and Medicaid Services, or CMS, regulates LDTs and the laboratories that develop them, and enforces the Clinical Laboratories Improvement Amendments, or
CLIA. CMS evaluates whether there is clinical utility for each specific test, and also performs postmarket oversight of laboratory operational processes. CMS's oversight through the CLIA program is
designed to confirm that a lab assesses analytical validity, but does not confirm whether it had results from an analytical validity assessment that were sufficient to support the claimed intended use
of the test. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically
the FDA has generally not enforced premarket review and other FDA requirements on LDTs because LDTs were relatively simple lab tests and generally available on a limited
basis. Due to advances in technology, however, some LDTs are now much more complex, have a nationwide reach and present higher risks, such as detection of risk for breast cancer and Alzheimer's
disease, which are similar to those of other IV </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostics that have undergone premarket review. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has announced that in the future it intends to assert jurisdiction over LDTs and proposed increasing regulatory requirements for LDTs through a risk-based framework. The FDA
received considerable resistance to its proposal, and to date generally exercises enforcement discretion with respect to LDTs, leaving responsibility to CMS. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New
laws, regulations or changes to existing laws, regulations and policies may result in changes to the requirements for LDTs or </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>
diagnostic devices and to the FDA's compliance and enforcement policies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Regulation  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmaceutical Coverage and Reimbursement  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to successfully commercialize any of our product candidates for which we may receive regulatory approval will depend in significant
part on the availability of coverage and reimbursement from third-party payors, including governmental healthcare programs such as the Medicare and Medicaid programs in the U.S.; private health
insurers; managed care organizations; and other entities. Third-party payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for
which we may receive regulatory approval for commercial sale depends on those payors' coverage policies and reimbursement rates. Third-party payors may limit coverage to specific products on an
approved list, or formulary, which might not include one or more of our product candidates. Third-party payors, together with regulators and others, are increasingly challenging the prices </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=119,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1040006,FOLIO='116',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ee78701_1_117"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>charged
for pharmaceutical products and health services, in addition to their cost-effectiveness, safety and efficacy. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting
their own coverage and reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary
significantly from payor to payor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product
to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of
our products. We cannot be certain that our product candidates will be considered cost-effective by third-party
payors. This process could delay the market acceptance of any product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other U.S. Healthcare Laws and Compliance Requirements  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, our business may be subject to healthcare fraud and abuse regulation and enforcement by both the federal government and
the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may
affect our ability to operate include but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any
remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal
healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has
been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of
statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Law protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the
exceptions and safe harbors are drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain
discounts, or engaging such individuals as speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices may not in all cases meet
all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or patient or
product assistance programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or FCA, which
prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be
made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government. Private individuals, commonly
known as "whistleblowers," can bring FCA </FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2> actions, on behalf of the government and such individuals and may share in amounts paid by the entity
to the government in recovery or settlement. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the FCA. FCA liability is potentially significant in the healthcare industry </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=120,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=369904,FOLIO='117',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ee78701_1_118"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>because
the statute provides for treble damages and significant mandatory penalties per false claim or statement for violations. Criminal penalties, including imprisonment and criminal fines, are also
possible for making or presenting a false, fictitious or fraudulent claim to the federal government; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, prohibits executing a scheme to
defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&nbsp;knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement or representation and (ii)&nbsp;making or using any false writing or document knowing the same to contain any materially false, fictitious or
fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found
guilty of violating the HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective
implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans,
healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or
disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to
business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys' fees and costs associated
with pursuing federal civil actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information
related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their
immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse
practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Analogous U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply
with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; state laws that require drug manufacturers to report
information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require
drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; and state laws governing
the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then,
governmental authorities may conclude that our business practices do not comply with current or future statutes, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=121,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=300047,FOLIO='118',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ee78701_1_119"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from
government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to
resolve allegations of non-compliance with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and
regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any product candidate we develop outside the United States will
also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care
fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Reform  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare
system to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have
significantly affected the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or
collectively, the ACA, was passed in March 2010, substantially changing the way healthcare is financed by both governmental and private insurers and significantly impacting the U.S. pharmaceutical
industry. Among other things, the ACA subjects biologics to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program
and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a
new Medicare Part&nbsp;D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part&nbsp;D, manufacturers must now agree to offer 70% point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In addition, there have been
efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the ACA and related laws. For example, Congress has considered legislation that
would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal
legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, includes a provision repealing, effective
January&nbsp;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year commonly
referred to as the "individual mandate." On January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain
ACA-mandated fees, including the so-called "Cadillac" tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the
annual fee imposed on certain health insurance providers based on market share and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, or the BBA, among
other things, amends the ACA, effective January&nbsp;1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole." Also, in July 2018, CMS issued a final
rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal
district court litigation regarding the method CMS uses to determine this risk adjustment. Additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=122,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=686552,FOLIO='119',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ee78701_1_120"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>legislative
changes or regulatory changes related to the ACA remain possible. In December 2018, a United States District Court Judge for the Northern District of Texas ruled that the entire ACA is
unconstitutional because the tax penalty associated with the "individual mandate" was repealed by Congress as part of the Tax Act. This ruling is under appeal and stayed pending appeal. While the
United States District Court Judge for the Northern District of Texas, as well as the Trump Administration and CMS, have stated that the ruling will have no effect while this appeal is pending, it is
unclear how this decision, subsequent appeals and other efforts to invalidate the ACA, regulations promulgated under the ACA or portions thereof, will impact the ACA and its implementation. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several
recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing; reduce the cost of prescription
drugs under Medicare; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, the Trump
Administration released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating
power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On January 31,
2019, the Department of Health and Human Services, HHS Office of Inspector General, proposed modifications to the federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the
cost of drug products to consumers which, among other things, if finalized, will remove safe harbor protection from rebates paid by manufacturers to Medicare Part D plans, Medicaid managed care
organizations and pharmacy benefit managers working with these organizations. Although a number of these, and other proposed measures may require additional authorization to become effective, Congress
and the Trump Administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed
to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what
pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain
investigational new drug products that have completed a Phase&nbsp;1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek
treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug
products available to eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;1, 2019, we had 44 full-time employees, of which 35 were primarily engaged in research and development activities and 21 hold
M.D. or Ph.D. degrees. None of our employees is represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our corporate headquarters are currently located in Beltsville, Maryland and consist of 11,329 square feet of office space and 13,579 square
feet of laboratory and manufacturing space, as well as an additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=123,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=511955,FOLIO='120',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<A NAME="page_ee78701_1_121"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>10,209&nbsp;square
feet to be used for office space, under a lease that expires in August 2025. In January 2019, we entered into a new lease for an additional 14,075 square feet to be used for
office, laboratory and manufacturing space that we expect to take possession of in June 2019. The new lease is expected to expire in March 2030 and will also cover our existing space after the
expiration of our current lease.
We believe that these facilities are adequate for our current needs and that suitable additional or substitute space will be available in the future if needed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we may become involved in litigation or other legal proceedings as part of our ordinary course of business. We are not
currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=124,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=999876,FOLIO='121',FILE='DISK106:[19ZAH1.19ZAH78701]EE78701A.;18',USER='CHE106319',CD='26-APR-2019;01:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_eg78701_1_122"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eg78701_management"> </A>
<A NAME="toc_eg78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers and Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name and position of each of our executive officers and directors, and their ages as of April&nbsp;29,
2019:

</FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B><I>Executive Officers and Employee Directors</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Michael Richman</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Steven P. Cobourn, CPA</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Kevin N. Heller, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>James B. Bingham, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Development Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Sol Langermann, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Timothy Mayer, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Corporate Development</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Linda Liu, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Research</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B><I>Non-Employee Directors</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>David Kabakoff, Ph.D.<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chair of our Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Elaine V. Jones, Ph.D.<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Chau Q. Khuong<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Judith J. Li<SUP>(1)(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Briggs Morrison, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Timothy M. Shannon, M.D.<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Stephen W. Webster<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Stella Xu, Ph.D.<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of the audit committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of the compensation committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of the nominating and corporate governance committee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I>Michael Richman</I></B></FONT><FONT SIZE=2> co-founded our company and has served as our President, Chief Executive Officer
and a member of our board of directors since October 2015. Mr.&nbsp;Richman served as President and Chief Executive Officer of Amplimmune,&nbsp;Inc. (now MedImmune,&nbsp;LLC), a
biopharmaceutical company focused on immuno-oncology, from 2007 to August&nbsp;2015, including through Amplimmune's acquisition by AstraZeneca&nbsp;plc in October 2013. Before Amplimmune,
Mr.&nbsp;Richman served as Executive Vice President and Chief Operating Officer of MacroGenics,&nbsp;Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007.
Mr.&nbsp;Richman joined MacroGenics with approximately 20&nbsp;years' experience in corporate business development within the biotechnology industry. Mr.&nbsp;Richman has served as a director of
Pieris Pharmaceuticals,&nbsp;Inc., a public company, since December 2014 and as a director of Madison Vaccines,&nbsp;Inc., a private company, since May&nbsp;2014. Mr.&nbsp;Richman was
previously a member of the board of directors of GenVec,&nbsp;Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017 and Opexa Therapeutics,&nbsp;Inc. from June 2006 until
its acquisition by Acer Therapeutics in September 2017. Mr.&nbsp;Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international
business from San Francisco State University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Mr.&nbsp;Richman is qualified to serve on our board of directors because of his service as our President and Chief Executive Officer, his service on the boards of other
private and public life sciences companies and his extensive knowledge of our company and industry, including comprehensive experience in financing, corporate management, research and business
development. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=125,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=742342,FOLIO='122',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_123"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Steven P. Cobourn, CPA</I></B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since January 2018. Previously, he served as Chief Financial Officer of
Vaccinex,&nbsp;Inc., a biotechnology company, from May 2014 to January 2018. Prior to joining Vaccinex, Mr.&nbsp;Cobourn was the Vice President of Finance and Treasurer of Otsuka America
Pharmaceutical,&nbsp;Inc., a private pharmaceutical company, from 2003 to April 2014, and served in other roles at Otsuka America Pharmaceutical from 1993 to 2003. Prior to joining Otsuka
America Pharmaceutical, Mr.&nbsp;Cobourn was a Certified Public Accountant at Hass&nbsp;&amp; Company&nbsp;LLC, an accounting firm. Mr.&nbsp;Cobourn received a B.S. in business administration from
Drexel University and is a Certified Public Accountant. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kevin N. Heller, M.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Medical Officer since April 2018. He has also served as an Adjunct Professor at the Yale
University School of Medicine since October&nbsp;2018. Dr.&nbsp;Heller served as head of antibody clinical development at Incyte Corporation, a biotechnology company, from May 2015 to April 2018
and as Global Medical Lead for the vandetanib program at AstraZeneca&nbsp;plc from May 2013 to May 2015. Prior to joining AstraZeneca&nbsp;plc, Dr.&nbsp;Heller served as an early clinical
development lead for multiple programs, clinical strategy lead for ipilumumab and global lead for oncology search and evaluation in the business development group at Bristol-Meyers Squibb Company from
2007 to 2013. Dr.&nbsp;Heller received a B.S. in molecular biophysics and biochemistry from Yale University and an M.D. from George Washington University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>James B. Bingham, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Development Officer since December 2018 and previously served as our Senior Vice
President, Development and Manufacturing from October 2015 to December 2018. Dr.&nbsp;Bingham has also served as President of MMG&nbsp;Biopharmaceuticals Consulting,&nbsp;LLC since
November&nbsp;2008. Prior to joining NextCure, Dr.&nbsp;Bingham held various positions at Amplimmune from 2007 to July 2015, including Senior Vice President of Development, Manufacturing and
Quality from January 2013 to July 2015. Dr.&nbsp;Bingham served as Associate Director of Microbial Research&nbsp;&amp; Development at Cambrex Corporation and, after its acquisition of Cambrex, Lonza
Group AG from 2006 to 2007. Dr.&nbsp;Bingham also worked for Human Genome Sciences,&nbsp;Inc. (acquired by GlaxoSmithKline&nbsp;plc), or HGS, from 2000 to 2006. Prior to joining HGS,
Dr.&nbsp;Bingham was also employed at MedImmune and Integrated Genetics (now part of Laboratory Corporation of America Holdings). Dr.&nbsp;Bingham received a B.S. in biology from
St.&nbsp;Michael's College and a Ph.D. in biological chemistry from The Johns Hopkins University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Sol Langermann, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since December 2018 and previously served as our Senior Vice President,
Research from October&nbsp;2015 to December 2018. Prior to joining NextCure, Dr.&nbsp;Langermann served as Senior Vice President and Chief Scientific Officer of Amplimmune from 2007 to July 2015.
Dr.&nbsp;Langermann previously served as Chief Scientific Officer at PharmAthene,&nbsp;Inc., which was later acquired by Altimmune,&nbsp;Inc., from 2004 to 2007. Prior to PharmAthene, he held
several positions at MedImmune,&nbsp;LLC, including Senior Director of Cell Biology, Director of Immunology and Molecular Genetics and Research Scientist in Immunology. Dr.&nbsp;Langermann
received a B.A. in philosophy of science from Columbia College, an M.L.A. in immunology from Harvard University and a Ph.D. in microbiology and molecular biology from Tufts University. He completed
his postdoctoral fellowship in mucosal immunology at Harvard University. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Timothy Mayer, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Corporate Development since December 2018 and previously served as our Vice
President, Business Development from February 2016 to December 2018. Prior to joining NextCure, Dr.&nbsp;Mayer held several positions at MacroGenics,&nbsp;Inc., a biopharmaceutical company focused
on the treatment of cancer, from 2004 to February 2016, including Senior Director, Intellectual Property from 2009 to February 2016. Prior to that, Dr.&nbsp;Mayer worked on biotechnology and
pharmaceutical patent matters as a Technical Specialist at Banner&nbsp;&amp; Witcoff,&nbsp;Ltd., an intellectual property law firm, from 2000 to 2004. Dr.&nbsp;Mayer received a B.S. in microbiology
and a B.S.
in biochemistry from California Polytechnic State University and a Ph.D. in microbiology and immunology from the Pennsylvania State University College of Medicine. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=126,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=400949,FOLIO='123',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_124"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Linda N. Liu, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Research since December 2018 and previously served as our Vice President,
Translational Research from October 2015 to December 2018. Prior to joining NextCure, Dr.&nbsp;Liu held several positions at Amplimmune from 2007 to August 2015, including Executive Director of
Translational Science/Scientific Affairs and Vice President of New Product Development from January 2013 to August 2015. She served as a Senior Director of Biological Product Development at
MaxCyte,&nbsp;Inc., a clinical stage biotechnology company aimed at commercializing cell loading technology, from 2000 to 2007 and as a Senior Scientist at Osiris Therapeutics,&nbsp;Inc. from 1999
to 2000. Dr.&nbsp;Liu received a B.S. in virology and molecular biology from Wuhan University in China and a Ph.D. in virology and cell biology from the University of Texas at Austin. She conducted
her postdoctoral training in tumor cell biology at the St.&nbsp;Jude Children's Research Hospital. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I>David Kabakoff, Ph.D.</I></B></FONT><FONT SIZE=2> has served as Chair of our board of directors since December 2015.
Dr.&nbsp;Kabakoff has served as Executive Partner at Sofinnova Investments,&nbsp;Inc. since May 2007 and became a founding Partner of HealthQuest Capital in 2012. Dr.&nbsp;Kabakoff currently
serves on the board of directors of several privately held life sciences companies, including Dauntless Pharmaceuticals,&nbsp;Inc., Rainier Therapeutics, Neurana Pharmaceuticals,
Lineagen,&nbsp;Inc., where he serves as chairman, bioTheranostics,&nbsp;Inc., Castle Biosciences,&nbsp;Inc. and Antiva Biosciences,&nbsp;Inc. Mr.&nbsp;Kabakoff has previously served as a
director of several other publicly traded and privately held life sciences companies, including Principia Biopharma,&nbsp;Inc. from June 2016 until August 2018 in advance of Principia's September
2018 initial public offering, publicly traded lnterMune,&nbsp;Inc. from November 2005 to September 2014 and Amplimmune. In 2001, Dr.&nbsp;Kabakoff co-founded Salmedix,&nbsp;Inc., a company that
developed cancer drug treatments, and served as the company's Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon,&nbsp;Inc. Previously, Dr.&nbsp;Kabakoff held
the positions of Executive Vice President of Dura Pharmaceuticals,&nbsp;Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies, Chief Executive Officer of Corvas
International,&nbsp;Inc., a developer of biotherapeutics, and held senior executive positions with Hybritech, a biotechnology company. Dr.&nbsp;Kabakoff received a B.A. in chemistry from Case
Western Reserve University and a Ph.D. in chemistry from Yale University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Kabakoff is qualified to serve as a member of our board of directors due to his extensive experience in the biotechnology industry and his investing experience. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Elaine V. Jones, Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since December 2015. Dr.&nbsp;Jones has served as Vice
President, Worldwide Business Development and Senior Partner at Pfizer Ventures, where she is responsible for making and managing venture investments of strategic interest to Pfizer&nbsp;Inc., since
December 2008. Prior to joining Pfizer, Dr.&nbsp;Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund. Before
that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist for SmithKline Beecham Pharmaceutical R&amp;D. Dr.&nbsp;Jones currently serves on the board of directors
for various privately held companies and also serves as a trustee of Juniata College. Dr.&nbsp;Jones previously served on the boards of directors of several publicly traded healthcare companies,
including Mersana Therapeutics,&nbsp;Inc. from February 2015 to June 2018, Mirna Therapeutics,&nbsp;Inc. from December 2012 to June 2016, CytomX Therapeutics,&nbsp;Inc. from December 2014 to
June 2016, Aquinox Pharmaceuticals,&nbsp;Inc. from June 2010 to February 2015 and Flexion Therapeutics,&nbsp;Inc. from December 2009 to June 2014. Dr.&nbsp;Jones received a B.S. in biology from
Juniata College and a Ph.D. in microbiology from the University of Pittsburgh. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Dr.&nbsp;Jones is qualified to serve as a member of our board of directors due to her scientific and pharmaceutical industry background, as well as her extensive
experience in the venture capital industry. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Chau Q. Khuong</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since December 2015. Mr.&nbsp;Khuong has served as a Private Equity
Partner at OrbiMed Advisors&nbsp;LLC, a venture capital and asset management </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=127,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=890436,FOLIO='124',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_125"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>firm,
since 2003. Mr.&nbsp;Khuong currently serves as a director of several publicly traded companies, including Bellus Health since December 2018, Synlogic,&nbsp;Inc. since February 2016, Inspire
Medical Systems,&nbsp;Inc. since May 2014 and Aerpio Pharmaceuticals,&nbsp;Inc. since April 2014, and previously served as a director of Nabriva Therapeutics&nbsp;plc (formerly Nabriva
Therapeutics AG) from April 2015 to August 2017, Otonomy,&nbsp;Inc. from August 2013 to July 2016 and as chairman of the board of directors of Pieris Pharmaceuticals,&nbsp;Inc. from December 2014
to November 2017. Mr.&nbsp;Khuong has also served on the board of directors for several privately held companies. Mr.&nbsp;Khuong received a B.S. in molecular biology with concentration in
biotechnology and a M.P.H. with concentration in infectious diseases from Yale University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Mr.&nbsp;Khuong is qualified to serve as a member of our board of directors due to his extensive directorship and healthcare industry experience. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Judith J. Li</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since December 2015. Ms.&nbsp;Li has served as a Partner at Lilly Asia
Ventures, which focuses on early- and growth-stage life sciences investments, since April 2015 and prior to that served as Principal at Lilly Asia Ventures from November 2013 to April 2015.
Ms.&nbsp;Li has served as a director of publicly traded Gritstone Oncology,&nbsp;Inc. since September 2017 and holds board appointments at a variety of Lilly Asia Ventures' private portfolio
companies, including Just Biotherapeutics,&nbsp;Inc. and Veritas Genetics&nbsp;Inc. From April 2014 to December 2017, she served on the board of Crown BioScience&nbsp;Inc., a biotechnology
company that was publicly listed on the Taiwan Stock Exchange until it was acquired in December 2017. Prior to joining Lilly Asia Ventures, Ms.&nbsp;Li served as a senior business analyst at
McKinsey&nbsp;&amp; Company, worked in hospital administration at Partners Healthcare, and co-founded an interventional nephrology medical device venture. Ms.&nbsp;Li received a B.A. in biology from
Harvard University and an M.B.A. from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Ms.&nbsp;Li is qualified to serve on our board of directors due to her experience as a board member of biotechnology and pharmaceutical companies and her experience as
an investor in early-stage life sciences companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Briggs Morrison, M.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since April&nbsp;2019. Dr.&nbsp;Morrison has served as
Executive Partner at MPM Capital,&nbsp;Inc. since June 2015 and as Chief Executive Officer and a member of the board of directors of Syndax Pharmaceuticals,&nbsp;Inc., a publicly traded
biopharmaceutical company, since June&nbsp;2015. Dr.&nbsp;Morrison has served as a member of the board of directors of Arvinas Holding Company,&nbsp;LLC, a publicly traded biopharmaceutical
company, since June 2018 and prior to that as a member of its Scientific Advisory Board from August 2016 to June 2018. Before that, Dr.&nbsp;Morrison was the Chief Medical Officer and Head of Global
Medicines Development at AstraZeneca&nbsp;plc from January 2012 to June 2015. Before joining AstraZeneca, Dr.&nbsp;Morrison held several positions at Pfizer&nbsp;Inc., including Head, Medical
Affairs, Safety and Regulatory Affairs for Pfizer's human health business. Dr.&nbsp;Morrison also previously held several positions at Merck Research Laboratories, a division of
Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., including Vice President, Clinical Sciences, Oncology. Dr.&nbsp;Morrison was a member of the executive committee of the Clinical Trials Transformation
Initiative sponsored by the FDA and is on the board of the Alliance for Clinical Research Excellence and Safety. Dr.&nbsp;Morrison also serves on the board of directors for multiple private
pharmaceutical companies. Dr.&nbsp;Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in
internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Morrison is qualified to serve as a member of our board of directors due to his extensive executive leadership experience, his medical background and training and
his service on the boards of other public and private biopharmaceutical and biotechnology companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Timothy M. Shannon, M.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since December 2015. Dr.&nbsp;Shannon has served as a General
Partner at Canaan Partners since November 2009. Dr.&nbsp;Shannon has also served as the chairman of the board of directors at Arvinas,&nbsp;Inc., a publicly traded biopharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=128,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=710291,FOLIO='125',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_126"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>company
focused on therapies to degrade disease-causing proteins, since July 2013. Dr.&nbsp;Shannon was the President and Chief Executive Officer of Aldea Pharmaceuticals, a biopharmaceutical
company focused on the treatment of toxic aldehyde-related diseases, from November 2010 to September 2013. Dr.&nbsp;Shannon also served as Chief Executive Officer of CuraGen Corporation from 2007 to
2009 and as CuraGen's Chief Medical Officer from 2004 to 2007. From 1992 to 2002, Dr.&nbsp;Shannon served in various senior research and development roles at Bayer Healthcare, including Senior Vice
President of Worldwide Clinical Development. Dr.&nbsp;Shannon previously served as a member of the boards of directors of publicly traded CytomX Therapeutics,&nbsp;Inc. from July 2012 to March
2017, Celldex Therapeutics,&nbsp;Inc. from October 2009 to December 2014 and CuraGen Corporation from September 2007 until its acquisition by Celldex in October 2009. Dr.&nbsp;Shannon received a
B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Shannon is qualified to serve on our board of directors due to his extensive experience in the venture capital industry, his executive leadership experience, his
medical background and training and his service on the boards of other public and private biopharmaceutical companies. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Stephen W. Webster</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since April 2019. Mr.&nbsp;Webster has served as the Chief Financial
Officer of Spark Therapeutics,&nbsp;Inc., a publicly traded biotechnology company, since July 2014. He was previously Senior Vice President and Chief Financial Officer of Optimer
Pharmaceuticals,&nbsp;Inc., a publicly traded biotechnology company, from July&nbsp;2012 until its acquisition by Cubist Pharmaceuticals, Inc. in October&nbsp;2013. Prior to joining Optimer,
Mr.&nbsp;Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals,&nbsp;Inc. in 2011. From
2007 until joining Adolor Corporation in 2008, Mr.&nbsp;Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital&nbsp;Inc. (formerly First Albany
Capital). Mr.&nbsp;Webster served as co-founder, President and Chief Executive Officer for Neuronyx,&nbsp;Inc., a biopharmaceutical company, from 2000 to 2006. Mr.&nbsp;Webster previously served
in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. Mr.&nbsp;Webster has served as a director of Nabriva
Therapeutics&nbsp;plc, a publicly traded biopharmaceutical company, since August&nbsp;2016 and Viking Therapeutics,&nbsp;Inc., a publicly traded biopharmaceutical company, since May 2014.
Mr.&nbsp;Webster received an A.B. in economics from Dartmouth College and an M.B.A. in finance from The Wharton School of the University of Pennsylvania. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Mr.&nbsp;Webster is qualified to serve as a member of our board of directors due to his extensive experience in the biopharmaceutical industry, particularly his service
as chief financial officer and on the boards of other public companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Stella Xu, Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since November 2018. Dr.&nbsp;Xu has served as Managing Director of
Quan Capital, a life sciences venture fund with offices in China and
the United States, since August 2017. Prior to joining Quan Capital, Dr.&nbsp;Xu served as Vice President and site head of Roche Innovation Center Shanghai, and a member of the global management
team for Roche's Immunology, Inflammation&nbsp;&amp; Infectious Diseases Discovery and Translation Area, from September 2012 to August 2017. Dr.&nbsp;Xu joined Roche from McKinsey&nbsp;&amp; Company.
Dr.&nbsp;Xu has served as a director of Centrexion Therapeutics Corporation, a biopharmaceutical company focused on the treatment of chronic pain, since January 2018 and previously served as a
director of ARMO BioSciences,&nbsp;Inc., a late-stage biopharmaceutical company focused on immuno-oncology, from August 2017 to July 2018 when it was acquired by Eli Lilly and Company. Dr.&nbsp;Xu
received a B.S. in biophysics from Peking University and a Ph.D. in immunology from Northwestern University. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that Dr.&nbsp;Xu is qualified to serve on our board of directors due to her extensive, global experience in the development and commercialization of innovative therapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=129,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=968778,FOLIO='126',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_127"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Composition and Diversity  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors currently consists of nine members, each of whom except Dr.&nbsp;Jones and Mr.&nbsp;Webster currently serves pursuant
to the terms of an amended and restated voting agreement entered into in November 2018. The agreement will terminate upon the closing of this offering. Upon the termination of these provisions, there
will be no further contractual obligations regarding the election of our directors. Thereafter, each of our current directors will continue to serve until the election and qualification of his or her
successor, or his or her earlier death, resignation or removal.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate
characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and
current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such
candidates, may take into account many factors, including but not limited to the following:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> personal and professional integrity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> ethics and values; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> experience in corporate management, such as serving as an officer or former officer of a publicly traded company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> experience in the industries in which we compete; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> experience as a board member or executive officer of another publicly traded company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> diversity of background and perspective, including, but not limited to, with respect to race, gender or national origin; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> conflicts of interest; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> practical and mature business judgment. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding board diversity. Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context
of the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound
judgment using its diversity of experience in these various areas. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has determined that none of our directors other than Mr.&nbsp;Richman has a relationship that would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under Nasdaq rules. There are no family
relationships among any of our directors or executive officers. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director
has with our company and all other facts and circumstances deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director and
the transactions involving them described in the section entitled "Certain Relationships and Related Party Transactions." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=130,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=396886,FOLIO='127',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_128"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Kabakoff currently serves as Chair of our board of directors. Our board of directors believes that separation of the positions of
Chair and Chief Executive Officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of management's performance and
enhances the effectiveness of our board of directors as a whole, and has concluded that our current board leadership structure is appropriate at this time. However, our amended and restated bylaws and
corporate governance guidelines to be in effect upon the closing of this offering will provide our board of directors with flexibility to combine or separate the positions of Chair and Chief Executive
Officer and to appoint a lead director in accordance with its determination that utilizing one or the other structure would be in the best interests
of our company. Our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Classified Board of Directors  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with our amended and restated certificate of incorporation to be in effect upon the closing of this offering, our board of
directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from
the time of election and qualification until the third annual meeting following election. Effective upon the closing of this offering, we expect that our directors will be divided among the three
classes as follows:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Class&nbsp;I directors will be Ms.&nbsp;Li, Dr.&nbsp;Shannon and Dr.&nbsp;Xu, and their terms will expire at the annual meeting of
stockholders to be held in 2020; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Class&nbsp;II directors will be Dr.&nbsp;Jones, Mr.&nbsp;Khuong and Dr.&nbsp;Morrison, and their terms will expire at the annual
meeting of stockholders to be held in 2021; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Class&nbsp;III directors will be Dr.&nbsp;Kabakoff, Mr.&nbsp;Richman and Mr.&nbsp;Webster, and their terms will expire at the
annual meeting of stockholders to be held in 2022.


</FONT></DD>

</DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional
directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.
The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages management to
promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings
and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these
risks with the board of directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies and presents the steps taken by
management to mitigate or eliminate such risks. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as
through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure and our audit committee is responsible for overseeing our major financial risk exposures and the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=131,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=432150,FOLIO='128',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_129"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>steps
our management has taken to monitor and control these exposures. The audit committee also monitors compliance with legal and regulatory requirements and considers and approves or disapproves any
related person transactions. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance practices and of our board of directors. Our compensation
committee assesses and monitors whether any of our compensation policies and programs have the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain
risks and overseeing the management of such risks, our entire board of directors is regularly informed about such risks through committee reports. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each of
these committees will
operate under a written charter approved by our board of directors that satisfies applicable SEC and Nasdaq standards, to be effective upon the effectiveness of the registration statement of which
this prospectus forms&nbsp;a part. From time to time, our board of directors may establish other committees to facilitate the management of our business. Upon our listing on Nasdaq, each committee's
charter will be available under the Corporate Governance section of our website at </FONT><FONT SIZE=2><I>www.nextcure.com</I></FONT><FONT SIZE=2>. The reference to our website address does not
constitute incorporation by reference of the information contained at or available through our website. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The primary function of our audit committee is to oversee our corporate accounting and financial reporting process. Our audit committee's
responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> appointing and retaining, approving the compensation of, overseeing and evaluating the independence, qualification and performance of our
independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related
disclosures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> coordinating our board of directors' oversight of our internal control over financial reporting, disclosure controls and procedures and the
prompt reporting of violations of our code of business conduct and ethics </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing our critical accounting policies and estimates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> discussing our risk management policies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving or ratifying any related person transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparing the audit committee report required to be included in our annual proxy statement </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, the members of our audit committee will be Dr.&nbsp;Kabakoff, Ms.&nbsp;Li and Mr.&nbsp;Webster and Mr.&nbsp;Webster will serve as the chair of
the committee. Our board of directors has determined that each of the members of our audit committee satisfies the financial literacy and sophistication requirements of the SEC and the Nasdaq listing
rules. In addition, our board of directors has determined that Mr.&nbsp;Webster qualifies as an audit committee financial expert under SEC rules. Under SEC rules, members of our audit committee must
also meet heightened independence standards. Our board of directors has determined that each of the members of our audit committee is independent under the applicable SEC and Nasdaq listing rules.

</FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee oversees policies relating to compensation and benefits of our officers and employees. The compensation committee
reviews and approves or recommends corporate goals and


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=132,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=626559,FOLIO='129',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_130"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


objectives relevant to compensation of our executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based
on such evaluations. The compensation committee also reviews and approves or makes recommendations
to our board of directors regarding the issuance of stock options and other awards to our executive officers. The compensation committee will review and evaluate, at least annually, the performance of
the compensation committee and its members, including compliance by the compensation committee with its charter. Upon the closing of this offering, the members of our compensation committee will be
Dr.&nbsp;Shannon, Mr.&nbsp;Khuong, Dr.&nbsp;Kabakoff and Dr.&nbsp;Morrison and Dr.&nbsp;Shannon will serve as chair of the committee. Each of the members of our compensation committee is
independent under the applicable Nasdaq listing rules and is a "non-employee director" as defined in Rule&nbsp;16b-3 promulgated under the Securities Exchange Act of 1934, as amended, or the
Exchange Act.

 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for making recommendations to our board of directors regarding candidates for
directorships and the size and composition of our board of directors. In addition, our nominating and corporate governance committee is responsible for overseeing our corporate governance policies and
reporting and making recommendations to our board of directors concerning governance matters. Upon the closing of this offering, the members of our nominating and corporate governance committee will
be Dr.&nbsp;Jones, Mr.&nbsp;Khuong and Dr.&nbsp;Shannon and Dr.&nbsp;Xu and Dr.&nbsp;Jones will serve as chair of the committee. Each of the members of our nominating and corporate
governance committee is independent under the applicable Nasdaq listing rules.

</FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the members of our compensation committee has ever served as one of our officers or employees. None of our executive officers serves, or
has served during the last three fiscal years, as a member of the board of directors, compensation committee or other board committee performing equivalent functions of any entity that has one or more
executive officers serving as one of our directors or on our compensation committee. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective upon the effectiveness of the registration statement of which this prospectus forms&nbsp;a part, we will adopt a code of business
conduct and ethics that applies to all of our
directors, officers and employees, including those officers responsible for financial reporting. Following this offering, a current copy of the code of business conduct and ethics will be available
under the Corporate Governance section of our website. We intend to disclose future amendments to the code or any waivers of its requirements on our website. The reference to our website address does
not constitute incorporation by reference of the information contained at or available through our website. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on Liability and Indemnification Matters  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation, which will become effective upon the closing of offering, will contain provisions that
limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for
monetary damages for any breach of fiduciary duties as directors, except liability for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any breach of the duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any act or omission not in good faith that involves intentional misconduct or a knowing violation of law; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=133,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=949230,FOLIO='130',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_131"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General
Corporation Law; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated bylaws, which will become effective upon the closing of this offering, will provide that we are required to indemnify our directors and officers, in each case to
the fullest extent permitted by Delaware law. Our amended and restated bylaws will also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any
action or proceeding and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of such person's actions in that capacity regardless of
whether we would otherwise be permitted to indemnify such person under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and
other employees as determined by our board of directors. These indemnification agreements generally require us, among other things, to indemnify our directors, executive officers and these employees
against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also
generally require us to advance any expenses incurred by the directors, executive officers and employees as a result of any proceeding against them as to which they could be indemnified. We believe
that these provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors' and officers' liability insurance that
insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from
bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though
an action, if successful, might benefit us and our stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damage. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Director Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, we have not had a formalized non-employee director compensation program. In the year ended December&nbsp;31, 2018, we did not
pay any fees to, or make any equity or non-equity awards to, or pay any other compensation to the non-employee members of our board of directors for their services as directors, except that we granted
Dr.&nbsp;Kabakoff an option to purchase 37,342 shares of our common stock at an exercise price of $7.63 per share. We do not currently compensate any of our other non-employee directors for service
on our board of directors. We do reimburse our non-employee directors for travel and other necessary business expenses incurred in the performance of their service as directors.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has approved a compensation program for our non-employee directors, or the Non-Employee Director Compensation Program, to be effective upon the closing of this
offering. Pursuant to this program, our non-employee directors will receive annual cash compensation as follows:</FONT>


</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Chair of our board of directors will receive a $65,000 annual retainer and each other non-employee director will receive $35,000; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the chair of our audit committee will receive a $15,000 annual retainer and each other member will receive $7,500; </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the chair of our compensation committee will receive a $10,000 annual retainer and each other member will receive $5,000; and </FONT> <FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the chair of our nominating and corporate governance committee will receive a $8,000 annual retainer and each other member will receive $4,000.

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=134,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=28995,FOLIO='131',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<A NAME="page_eg78701_1_132"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


All fees under the Non-Employee Director Compensation Program will be paid quarterly in arrears and will be pro-rated for any partial quarters of service, and no per meeting fees will be paid, except
that we will reimburse non-employee directors for reasonable expenses incurred in connection with attending board and committee meetings.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Non-Employee Director Compensation Program, each non-employee director will also be entitled to receive an annual stock option award to purchase 11,000 shares of our common
stock that vests on the earlier of one year from the grant date of the award or the date of the next annual meeting of the stockholders, subject to continued service through the vesting date. Annual
stock option grants for non-employee directors who were initially elected in the 12&nbsp;months preceding the annual
grant date will be pro-rated on a monthly basis for time in service. In addition, each non-employee director who is elected or appointed to our board of directors after the closing of this offering
will be entitled to receive an initial stock option award to purchase 22,000 shares of our common stock that vests in three equal annual installments commencing on the grant date of the award, subject
to continued service through the applicable vesting date. All stock options granted pursuant to the Non-Employee Director Compensation Program will be subject to the terms and provisions of the 2019
Omnibus Incentive Plan.

 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation Table  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described above, we did not pay any cash or grant any stock awards or other compensation to our non-employee directors during 2018 for their
services as non-employee directors, except for the option granted to Dr.&nbsp;Kabakoff. Except as described below for Dr.&nbsp;Kabakoff, there were no outstanding stock awards or option awards
held by our non-employee directors as of December&nbsp;31, 2018. The table below sets forth information on the compensation of all our non-employee directors for the year ended December&nbsp;31,
2018. Michael Richman, our President and Chief Executive Officer, is also a member of our board of directors, but did not receive any additional compensation for his service as a director. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Kabakoff, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>182,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>182,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All other non-employee directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
in this column reflect the full grant date fair value of stock option awards granted during the year as measured pursuant to Financial Accounting Standards
Board Accounting Standards Codification Topic 718 and do not correspond to the actual value that may be recognized by the director in connection with the applicable awards. See Note&nbsp;11 to our
financial statements included elsewhere in this prospectus regarding assumptions underlying the valuation of equity awards.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
of December&nbsp;31, 2018, Dr.&nbsp;Kabakoff held 62,237 shares of restricted common stock that were purchased in May 2016 and are subject to repurchase
following termination, of which 10,372 shares were unvested and will vest in equal monthly installments through December&nbsp;29, 2019, subject to Dr.&nbsp;Kabakoff's continued service with us
through the applicable vesting date.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
of December&nbsp;31, 2018, Dr.&nbsp;Kabakoff held an option to purchase 37,342 shares of our common stock. The option vests 25% on December&nbsp;21, 2019
and, thereafter, 1/36th&nbsp;of the remaining option will vest on each monthly anniversary of the grant date.

</FONT></DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=135,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=508248,FOLIO='132',FILE='DISK106:[19ZAH1.19ZAH78701]EG78701A.;33',USER='MKEANE',CD='26-APR-2019;17:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ei78701_1_133"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ei78701_executive_compensation"> </A>
<A NAME="toc_ei78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section discusses the material components of the executive compensation program for our named executive officers, or NEOs, who are named in
the "Summary Compensation Table" below. As an "emerging growth company" as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to
comply with the scaled
disclosure requirements applicable to emerging growth companies. In 2018, our NEOs and their positions were as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Michael Richman, President and Chief Executive Officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Steven P. Cobourn, Chief Financial Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Sol Langermann, Ph.D., Chief Scientific Officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual
compensation programs that we adopt following the closing of this offering may differ materially from the currently planned programs summarized in this discussion. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information concerning the compensation of our NEOs for the year ended December&nbsp;31, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Richman<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>383,400</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,963,224</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>154,480</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>493</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2,501,597</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steven P. Cobourn, CPA<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>239,583</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>58,800</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>694,465</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>493</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>993,341</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sol Langermann, Ph.D.<BR></FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>340,976</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>455,022</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>85,800</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>493</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>882,291</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
in this column reflect the full grant date fair value of stock option awards granted during the year as measured pursuant to Financial Accounting Standards
Board Accounting Standards Codification Topic 718 and do not correspond to the actual value that may be recognized by the director in connection with the applicable awards. See Note&nbsp;11 to our
financial statements included elsewhere in this prospectus regarding assumptions underlying the valuation of equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Mr.&nbsp;Cobourn's
employment commenced with us on January&nbsp;22, 2018. The 2018 salary reported reflects the pro rata portion of Mr.&nbsp;Cobourn's annual
salary of $250,000 earned during 2018 from commencement of his employment through December&nbsp;31, 2018.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Base Salary  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into employment agreements with each of our NEOs that establish annual base salaries, which are generally determined, approved
and reviewed periodically by our board of directors in order to compensate our NEOs for services rendered to our company. The base salary payable to each NEO is intended to provide a fixed component
of compensation reflecting the executive's skill set, experience, role and responsibilities. Base salaries for our NEOs have generally been set at levels deemed necessary to attract and retain
individuals with superior talent. In March 2018, the annual base salaries of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=136,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=885089,FOLIO='133',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_134"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Mr.&nbsp;Richman
and Dr.&nbsp;Langermann were increased by 3% and 2.5% to $386,200 and $343,050, respectively. Mr.&nbsp;Cobourn's annual base salary for 2018 was $250,000. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Bonus and Non-Equity Incentive Plan Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs are eligible to receive annual bonuses, which are determined at the discretion of our board of directors based upon, among other
things, the achievement of pre-determined performance milestones. For 2018, Mr.&nbsp;Richman and Dr.&nbsp;Langermann were each eligible to receive a target bonus of up to 35% and 25%,
respectively, of his base salary. Our board of directors reviewed performance for the fiscal year 2018 and based on the level of achievement of performance milestones determined to pay these bonuses
at target with the exception of Mr. Richman, who received a bonus of 40% of his base salary, which was above his target. At the time Mr.&nbsp;Cobourn joined our company in 2018, our board of
directors did not set a target bonus percentage for Mr.&nbsp;Cobourn. Mr.&nbsp;Cobourn's bonus was determined by our board of directors using the same pre-determined performance milestones used
for our other NEOs and represented 25% of his base salary pro rated to reflect his start date of January&nbsp;22, 2018. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Awards  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our NEOs, we believe that equity grants provide
our NEOs with a strong link to our long-term performance, create an ownership culture and help to align the interests of our NEOs and our stockholders. Our board of directors and compensation
committee has historically been responsible for approving NEO equity grants, Following the closing of this offering, our compensation committee will generally be responsible for approving NEO equity
grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional retention measure. Our NEOs generally are awarded an initial new hire grant upon
commencement of employment. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain goals or to reward NEOs for exceptional
performance. Prior to this offering, we have granted all awards pursuant to the 2015 Plan, the terms of which are described below under "&#151;Equity Compensation Plans&#151;2015 Omnibus
Incentive Plan." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2018, our board of directors awarded Mr.&nbsp;Richman an option to purchase 118,249&nbsp;shares of our common stock, Mr.&nbsp;Cobourn an option to purchase 74,684 shares
of our common stock and Mr.&nbsp;Langermann an option to purchase 24,894 shares of our common stock, each at an exercise price of $1.77&nbsp;per share. In December 2018, our board of directors
awarded Mr.&nbsp;Richman an option to purchase 373,422 shares of our common stock, Mr.&nbsp;Cobourn an option to purchase 124,474 shares of our common stock and Dr.&nbsp;Langermann an option to
purchase 87,131 shares of our common stock, each at an exercise price of $7.63 per share. With respect to each of the grants disclosed above, 25% vest on the one-year anniversary of the grant date,
and, thereafter, 1/36th&nbsp;of the remaining options vest on each monthly anniversary of the grant date.

 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Fiscal Year-End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding equity awards held by our NEOs that were outstanding as of December&nbsp;31, 2018. All of
the awards listed in this table were granted under our 2015 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=137,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=493685,FOLIO='134',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_135"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Omnibus
Incentive Plan, the terms of which are described below under "&#151;Equity Compensation Plans&#151;2015 Omnibus Incentive Plan." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($/sh) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael Richman</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/15/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,565</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/15/2027</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>118,249</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>373,422</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7.63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>64,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>2</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>964,665</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>3</SUP><SUP>)</SUP></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Steven P. Cobourn,&nbsp;CPA</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>74,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>124,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7.63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Sol Langermann, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/1/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,891</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/1/2026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/15/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,891</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/15/2027</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>24,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/27/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>87,131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><SUP>(</SUP><SUP>1</SUP><SUP>)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7.63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/21/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>On
the one-year anniversary of the grant date, 25% of these options vested and, thereafter, 1/36th&nbsp;of the remaining options vest on each monthly anniversary
of the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Represents
unvested restricted common stock purchased by the NEO on October&nbsp;1, 2015 in connection with our founding. On December&nbsp;29, 2015, the NEO
entered into a stock restriction agreement pursuant to which 25% of the stock vested on the agreement date, 25% vested on the one-year anniversary of the agreement date and, thereafter,
1/36th&nbsp;of the remaining shares vest on each monthly anniversary of the agreement date.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
market value of the stock award assumes an initial public offering price of $15.00 per share (the midpoint of the estimated price range set forth on the cover of
this prospectus). </FONT>


</DD>

</DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements with Named Executive Officers and Potential Payments Upon Termination or Change
in Control  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into employment agreements with each of our NEOs, as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
entered into a letter agreement with Michael Richman, our President and Chief Executive Officer, in August 2016 that governs the current terms of his employment with us. Pursuant to
that agreement, Mr.&nbsp;Richman (i)&nbsp;was entitled to an initial annual base salary of $375,000, which has since increased, (ii)&nbsp;is eligible to receive an annual bonus of up to 35% of
his base salary, (iii)&nbsp;in our board of directors' sole discretion, from time to time, is entitled to equity compensation awards under our 2015 Omnibus Incentive Plan and (iv)&nbsp;receives
health insurance benefits and other benefits approved by our board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a letter agreement with Steven P. Cobourn, our Chief Financial Officer, in December 2017 that governs the current terms of his employment with us. Pursuant to that
agreement, Mr.&nbsp;Cobourn (i)&nbsp;was entitled to an initial annual base salary of $250,000, (ii)&nbsp;received an option to purchase 74,684 shares of our common stock under our 2015 Omnibus
Incentive Plan and (iii)&nbsp;receives health insurance benefits and other benefits approved by our board of directors.


</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a letter agreement with Sol Langermann, Ph.D., our Chief Scientific Officer, in August 2016 that governs the current terms of his employment with us. Pursuant to that
agreement, Dr.&nbsp;Langermann (i)&nbsp;was entitled to an initial annual base salary of $325,000, which has since increased, (ii)&nbsp;is eligible to receive an annual bonus of up to 25% of his
base salary, (iii)&nbsp;received an option to purchase 24,894 shares of our common stock under our 2015 Omnibus Incentive Plan and (iv)&nbsp;receives health insurance benefits and other benefits
approved by our board of directors.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=138,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=546301,FOLIO='135',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_136"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event Mr.&nbsp;Richman or Dr.&nbsp;Langermann's employment with us is terminated by us for any reason other than Cause (as defined in the employment agreements) or by the NEO
for Good Reason (as defined in the employment agreements), then he will be entitled to: (i)&nbsp;any unpaid salary for services rendered prior to the date of termination of employment;
(ii)&nbsp;any earned but unpaid annual bonus for any fiscal year prior to the year in which termination of employment occurs; (iii)&nbsp;reimbursement of any unreimbursed business expenses;
(iv)&nbsp;accrued but unused vacation; (v)&nbsp;any other payments, benefits or fringe benefits to which the NEO is entitled under the terms of any applicable compensation
arrangement or benefit, equity, program or grant; (vi)&nbsp;12&nbsp;months' base salary, in the case of Mr.&nbsp;Richman, and six months' base salary, in the case of Dr.&nbsp;Langermann,
subject to certain conditions and terms set forth in the employment agreement, including the execution of a release of claims; and (vii)&nbsp;health insurance coverage until the earlier of
(a)&nbsp;six months following the effective termination date or (b)&nbsp;the date upon which the NEO commences full-time employment. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have also entered into standard confidentiality and proprietary rights agreements with each of our NEOs pursuant to which each NEO has agreed
to protect our confidential, proprietary information and trade secret information indefinitely. Pursuant to these agreements, each NEO has agreed not to compete with us during his employment and for a
period of one year after the termination of his employment and not to solicit our employees during his employment and for a period of one year after the termination of his employment. In addition,
each NEO has agreed that there is a presumption that we own all inventions or works created by the NEO (i)&nbsp;using our facilities, supplies, information, trade secrets or time, (ii)&nbsp;that
are indirectly related to or arise out of our actual or proposed business, (iii)&nbsp;that relate to any task assigned or performed by the NEO on our behalf or (iv)&nbsp;that are based on our
confidential information. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plans  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Omnibus Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors adopted, and our stockholders approved the 2015 Plan on December&nbsp;29, 2015, which was subsequently amended to
increase the number of shares issuable under the 2015 Plan. The 2015 Plan is intended to enhance our company's ability to attract and retain highly qualified officers, directors, key employees and
other persons, and to motivate such persons to serve us and our affiliates and to expend maximum effort to improve the business results and our earnings, by providing to such persons an opportunity to
acquire or increase a direct proprietary interest in our operations and our future success. The 2015 Plan provides for the grant of stock options, restricted stock and stock units. No further awards
will be made under the 2015 Plan upon the effectiveness of
our 2019 Omnibus Incentive Plan, or the 2019 Plan; however, awards outstanding under the 2015 Plan will continue to be governed by their existing terms. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Reserve  </I></FONT></P>


</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, we have reserved 2,824,317 shares of our common stock for issuance under the 2015 Plan. As of
December&nbsp;31, 2018, options to purchase 2,056,891 shares of our common stock were outstanding under the 2015 Plan, 10,372 unvested shares of restricted stock were outstanding under the 2015 Plan
and 699,590&nbsp;shares of our common stock remained available for future issuance. If any shares covered by an award granted under the 2015 Plan are not purchased or are forfeited, expire or
otherwise terminate without delivery of any shares subject to the award, or are settled in cash in lieu of shares, then the number of shares subject to such award will, to the extent of any such
forfeiture, termination, expiration or settlement, again be available for future issuance under the 2015 Plan or, following the effectiveness of the registration statement of which this prospectus is
a part, under our 2019 Plan.

 </FONT></P>


<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=139,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=477134,FOLIO='136',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_137"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has administered the 2015 Plan since its adoption; however, following the completion of this offering, the compensation
committee of our board of directors will generally administer the 2015 Plan. The administrator has complete discretion to make all decisions relating to the 2015 Plan and outstanding awards. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our employees, officers and directors or any of our affiliates and consultants, contractors and advisers who provide services to us or any of
our affiliates are eligible to receive awards under the 2015 Plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in Capitalization  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of shares, exchange of shares,
stock dividend or other distribution payable in capital stock, or other increase or decrease in our shares of common stock effected without the receipt of consideration by us, then the number and kind
of shares for which grants of options and other awards may be made under the 2015 Plan will be adjusted proportionately and accordingly by the administrator of the 2015 Plan. In addition, the number
and kind of shares for which awards are outstanding, as well as the exercise price of outstanding options will be adjusted proportionately and accordingly by the administrator of the 2015 Plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Transaction  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the discretion to determine the effect of a "corporate transaction" (as defined in the 2015 Plan) on any outstanding
awards. Without limiting the generality of the foregoing, in connection with a corporate transaction, our board of directors may elect, in its sole discretion,
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cancel any outstanding awards and pay or deliver, or cause to be paid or delivered, to the holder of the award an amount in cash or securities
having a value (as determined by our board of directors acting in good faith) equal to the product of the number of shares subject to the award, or the Grant Shares, multiplied by, (i)&nbsp;in the
case of options, the amount, if any, by which (a)&nbsp;the formula or fixed price per share paid to holders of shares of our common stock pursuant to such transaction exceeds (b)&nbsp;the exercise
price applicable to such Grant Shares and (ii)&nbsp;in the case of restricted stock and stock units, the formula or fixed price per share paid to holders of shares of our common stock pursuant to
the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> provide in connection with such corporate transaction for the assumption or continuation of the options previously granted, or for the
substitution for such awards for new common stock options relating to the stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustments as to the number of shares
(disregarding any consideration that is not common stock) and exercise prices, such that awards previously granted will continue in the manner and under the terms so provided; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cancel any outstanding awards that are unvested (or any unvested portion thereof) without payment to the holders of such awards; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cancel any outstanding awards to the extent the exercise price applicable to the Grant Shares issuable under such awards is greater than the
formula or fixed price per share paid to holders of shares of our common stock pursuant to such transaction, with or without any payment to the holders of such awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we establish an exercise window in connection with a scheduled consummation of a corporate transaction, any exercise of an option during such period will be conditioned upon the
consummation of the event and will be effective only immediately before the consummation of the event. Upon the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=140,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1020903,FOLIO='137',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_138"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>consummation
of any corporate transaction, the 2015 Plan and all outstanding but unexercised options will terminate. Our board of directors will send written notice of an event that will result in
such a termination to all individuals who hold options not later than the time at which we give notice of the event to the holders of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may, in its sole discretion, provide for the accelerated vesting or lapse of restrictions of awards at any time. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Plan Amendment and Termination  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may amend or terminate the 2015 Plan or any outstanding award under the 2015 Plan at any time; provided that no amendment
may adversely impair a participant's rights under outstanding awards without his or her consent. Our stockholders must approve any amendment if such approval is required under applicable law or Nasdaq
listing rules. Unless terminated sooner by our board of directors or extended with stockholder approval, the 2015 Plan will terminate on December&nbsp;29, 2025. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Omnibus Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors adopted the 2019 Plan in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019 and our stockholders approved the 2019
Plan in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019. The
2019 Plan will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. The purpose of the 2019 Plan is to provide eligible individuals with an
incentive to contribute to our success and to operate and manage our business in a manner that will provide for our long-term growth and profitability and that will benefit our stockholders and other
important stakeholders, including our employees and customers. The 2019 Plan is also intended to provide a means of recruiting, rewarding and retaining key personnel. The 2019 Plan provides for the
grant of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash
bonus awards. The 2019 Plan will replace our 2015 Plan; however, awards outstanding under the 2015 Plan will continue to be governed by their existing terms.

</FONT>

</P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Reserve  </I></FONT></P>


</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our common stock reserved for issuance under the 2019 Plan is equal to the sum of (i)&nbsp;2,900,000 shares plus
(ii)&nbsp;up to 2,056,891 shares related to awards outstanding under our 2015 Plan on the effective date of the registration statement to which this prospectus is a part that subsequently terminate
by expiration or forfeiture, cancellation, or otherwise without the issuance of such shares. The number of shares reserved for issuance under our 2019 Plan will automatically increase on
January&nbsp;1st&nbsp;of each year during the term of the 2019 Plan, by a number equal to 4% of the shares of common stock outstanding on December&nbsp;31st&nbsp;of the prior calendar year;
however, our board of directors may provide that there will be no increase, or a smaller increase, in the share reserve for a given calendar year.

 </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any shares covered by an award granted under the 2019 Plan are not purchased or are forfeited or expire or otherwise terminate without delivery of any shares subject to the award, or
are settled in cash in lieu of shares, then the number of shares subject to such award will, to the extent of any such forfeiture, termination, expiration or settlement, again be available for future
issuance under the 2019 Plan. In addition, if shares subject to an award are applied to the exercise price or tax withholding obligations related to the award, such shares will again be available for
future issuance under the 2019 Plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan will be administered by our board of directors or a committee of our board of directors to which our board of directors delegates
such administration (as applicable, the administrator). Subject to the terms of the 2019 Plan, the administrator has the complete discretion to determine the eligible individuals who are to receive
awards under the 2019 Plan, to determine the terms and conditions of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=141,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=196969,FOLIO='138',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_139"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>awards
granted under the 2019 Plan and to make all decisions related to the 2019 Plan and awards granted thereunder. The administrator will also interpret the provisions of the 2019 Plan. Our board of
directors has delegated full authority to administer the 2019 Plan to its compensation committee. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our employees and the employees of our affiliates are eligible to receive awards under the 2019&nbsp;Plan. In addition, our
non-employee directors and certain consultants and advisors who perform services for us and our affiliates may receive awards under the 2019 Plan. However, only our employees and our subsidiaries are
eligible to receive incentive stock options. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options  </I></FONT></P>


</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan authorizes our compensation committee to grant incentive stock options (under Section&nbsp;422 of the Internal Revenue Code of
1986, as amended, or the Code) and stock options that do not qualify as incentive stock options, or non-qualified stock options. The maximum number of shares that may be issued under the 2019 Plan
pursuant to the exercise of incentive stock options is 8,700,000. The compensation committee will determine the exercise price of each stock option, provided that the price must be equal to at least
the fair market value of our shares of common stock on the date on which the stock option is granted. If we were to grant incentive stock options to any 10% stockholder, the exercise price may not be
less than 110% of the fair market value of our shares of common stock on the date of grant.

 </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of a stock option cannot exceed 10&nbsp;years from the date of grant. If we were to grant incentive stock options to any 10% stockholder, the term cannot exceed five years
from the date of grant. The compensation committee will determine at what time or times each stock option may be exercised and the period of time, if any, after death, disability or termination of
employment during which stock options may be exercised. Stock options may be made exercisable in installments. The compensation committee may accelerate the exercisability of stock options. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate fair market value, determined at the time of grant, of our common stock with respect to incentive stock options that are exercisable for the first time by a grantee during
any calendar year under all of our stock plans may not exceed $100,000. We will generally treat stock options or portions thereof that exceed such limit as non-qualified stock options. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Appreciation Rights  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan authorizes our compensation committee to grant stock appreciation rights that provide the recipient with the right to receive,
upon exercise of the stock appreciation right, cash, shares of our common stock or a combination of the two. The amount that the recipient will receive upon exercise of the stock appreciation right
generally will equal the excess of the fair market value of our common stock on the date of exercise over the shares' fair market value on the date of grant. Stock appreciation rights will become
exercisable in accordance with terms determined by our compensation committee. Stock appreciation rights may be granted in tandem with a stock option grant or independently from a stock option grant.
The term of a stock appreciation right cannot exceed 10&nbsp;years from the date of grant. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock, Restricted Stock Units and Deferred Stock Units  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan authorizes our compensation committee to grant restricted stock, restricted stock units and deferred stock units. Restricted stock
is an award of our common stock on which vesting restrictions are imposed that subject such shares of our common stock to a substantial risk of forfeiture, as defined in Section&nbsp;83 of the Code.
A restricted stock unit is an award that represents the right to receive a compensation amount, based on the value of our shares of common stock, if vesting criteria established by the compensation
committee are met. If the vesting criteria are met, we will settle restricted stock units in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=142,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=670741,FOLIO='139',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<A NAME="page_ei78701_1_140"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cash,
shares of our common stock or a combination of the two. A deferred stock unit is a restricted stock unit that may be settled at some point in the future at a time or times consistent with the
requirements of Section&nbsp;409A of the Code. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisions of the 2019 Plan, our compensation committee will determine the terms and conditions of each award of restricted stock, restricted stock units and deferred
stock units, including the restricted period for all or a portion of the award, the restrictions applicable to the award and the purchase price, if any, for the shares of our common stock subject to
the award. A grantee of restricted stock will have all the rights of a stockholder, including the right to vote the shares and receive dividends, except to the extent limited by our compensation
committee. However, all cash dividends declared or paid on shares of restricted stock will not vest or become payable unless and until the shares of restricted stock to which the dividends apply
become vested and nonforfeitable. In addition, all stock dividend payments or distributions, if any, received by a grantee with respect to shares of restricted stock as a result of any stock split,
stock dividend, combination of stock or other similar transaction will be subject to the same vesting conditions and restrictions as applicable to such underlying shares of restricted stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grantees
of restricted stock units and deferred stock units will have no voting or dividend rights or other rights associated with stock ownership, although our compensation committee
may award dividend equivalent rights on such units. Dividend equivalent rights granted as a component of another award will not vest or become payable unless and until the award to which the dividend
equivalent rights correspond becomes vested and settled. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend Equivalent Rights  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan authorizes our compensation committee to grant dividend equivalent rights in connection with the grant of any equity-based award
other than stock options and stock appreciation rights. Dividend equivalent rights entitle the grantee to receive, or to receive credits for the future payment of, cash, shares of our common stock or
other property equal in value to dividend payments or distributions declared or paid by us with respect to a number of shares of our common stock specified in such dividend equivalent right (or other
award to which such right relates), as if such shares had been issued to and held by the grantee as of the record date of such dividend or distribution. Dividend equivalent rights may be paid
currently or may be deemed to be reinvested in additional shares of stock, which may thereafter accrue additional dividend equivalent rights and may be payable in cash, shares of our common stock or a
combination of the two; however, dividend equivalent rights granted as a component of another award will not vest or become payable unless and until the award to which the dividend equivalent rights
correspond becomes vested and settled. Our compensation committee will determine the terms of any dividend equivalent rights. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Equity-Based Awards  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan authorizes our compensation committee to grant other types of equity-based awards under the 2019 Plan. Other equity-based awards
may be granted with vesting, value and/or payment contingent upon the achievement of one or more performance goals or other vesting conditions, and may be payable in cash, shares of our common stock
or a combination thereof. The terms and conditions that apply to other equity-based awards will be determined by our compensation committee. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Director Compensation Limitation  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan provides that the aggregate value of all awards granted under the plan and all other cash compensation paid by us to any of our
non-employee directors in any calendar year may not exceed $750,000; however, such amount will be $1,000,000 for the calendar year in which the non-employee director is initially elected or appointed
to our board of directors. Our board of directors may make exceptions to these limitations for individual non-employee directors in extraordinary circumstances, provided that the non-employee director
receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=143,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1027267,FOLIO='140',FILE='DISK106:[19ZAH1.19ZAH78701]EI78701A.;47',USER='VRIVERA',CD='26-APR-2019;22:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ek78701_1_141"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in Capitalization  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of shares, exchange of shares,
stock dividend or other distribution payable in capital stock, or other increase or decrease in our shares of common stock effected without the receipt of consideration by us, then the number and kind
of shares for which grants of options and other
awards may be made under the 2019 Plan, including the maximum number of shares that may be issued upon the exercise of incentive stock options, will be adjusted proportionately and accordingly by our
compensation committee. In addition, the number and kind of shares for which awards are outstanding, as well as the exercise price of outstanding options and stock appreciation rights, will be
adjusted proportionately and accordingly by our compensation committee. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in Control  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the applicable award agreement, in another agreement with a grantee, or as otherwise set forth in writing, upon
the occurrence of a "change in control" (as defined in the 2019 Plan) in which outstanding awards are not being assumed, continued or substituted for, the following provisions will apply to the
awards: (i)&nbsp;except for performance-based awards, all shares of restricted stock, restricted stock units, deferred stock units and dividend equivalent rights will be deemed to have vested and
any underlying shares of our common stock will be deemed delivered immediately before the change in control; and (ii)&nbsp;at our compensation committee's discretion, either all options and stock
appreciation rights will become exercisable 15&nbsp;days before the change in control (with any exercise of an option or stock appreciation right during such 15&nbsp;day period to be contingent
upon the consummation of the change in control) and terminate upon the change in control to the extent not exercised, or all options, stock appreciation rights, shares of restricted stock, restricted
stock units, deferred stock units and/or dividend equivalent rights will be canceled and cashed out in connection with the change in control. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of performance-based awards, if less than half of the performance period has lapsed, the award will be treated as though target performance has been achieved. If at least
half of the performance period has lapsed, actual performance to date will be determined as of a date reasonably proximal to the date of the consummation of the change in control, as determined by our
compensation committee in its sole discretion, and that level of performance will be treated as achieved immediately prior to the occurrence of the change in control. If our compensation committee
determines that actual performance is not determinable, the award will be treated as though target performance has been achieved. Any awards that arise after performance is determined in accordance
with this paragraph will be treated as set forth in the preceding paragraph. Other equity-based awards will be governed by the terms of the applicable award agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we experience a change in control in which outstanding awards will be assumed, continued or substituted for by the surviving entity, then, except as otherwise provided in the
applicable award agreement, in another agreement with a grantee, or as otherwise set forth in writing, upon the occurrence of the change in control, the 2019 Plan and the awards granted under the 2019
Plan will continue in the manner and under the terms so provided in the event of the change in control to the extent that provision is made in writing in connection with such change in control for the
assumption or continuation of such awards, or for the substitution for such awards with new awards, with appropriate adjustments as to the number of shares (disregarding any consideration that is not
common stock) and exercise prices of options and stock appreciation rights. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in the applicable award agreement, in another agreement with a grantee, or as otherwise set forth in writing, in the event a grantee's award is assumed,
continued, or substituted upon the consummation of any change in control and the service of such grantee with us or an affiliate of ours is terminated without "cause" (as defined in the 2019 Plan)
within 12&nbsp;months following the consummation of such change in control, such award will become fully vested and may be exercised in full, to the extent applicable, beginning on the date of such
termination and for the one-year period, or such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=144,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=41562,FOLIO='141',FILE='DISK106:[19ZAH1.19ZAH78701]EK78701A.;22',USER='WWASSER',CD='26-APR-2019;14:47' -->
<A NAME="page_ek78701_1_142"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>longer
period as may be determined by our compensation committee, immediately following such termination. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback; Transferability  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All awards will be subject to mandatory repayment to us by a grantee to the extent the grantee is, or in the future becomes, subject to
(i)&nbsp;any "clawback" or recoupment policy by us or any of our affiliates that is adopted to comply with the requirements of any applicable laws, or (ii)&nbsp;any applicable laws which impose
mandatory recoupment, under circumstances set forth in such applicable laws. Except in limited circumstances, awards granted under our 2019 Plan may generally not be transferred in any manner prior to
vesting other than by will or by the laws of descent and distribution. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Plan Amendment and Termination  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee may amend or terminate the 2019 Plan at any time; provided that no amendment may materially impair a participant's
rights under outstanding awards without his or her consent. Our stockholders must approve any amendment if such approval is required under applicable law or Nasdaq listing rules. Unless terminated
sooner by our board of directors or extended with stockholder approval, the 2019 Plan will terminate on the day before the tenth anniversary of the effective date of the registration statement of
which this prospectus is a part. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Repricing without Stockholder Approval  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except in connection with certain corporate transactions, we may not, without obtaining stockholder approval: (i)&nbsp;amend the terms of
outstanding options or stock appreciation rights to reduce the applicable exercise price; (ii)&nbsp;cancel outstanding options or stock appreciation rights in exchange for or substitution of options
or stock appreciation rights with an exercise price that is less than the exercise price of the original options or stock appreciation rights; or (iii)&nbsp;cancel outstanding options or stock
appreciation rights with an exercise price above the current stock price in exchange for cash or other securities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors adopted the ESPP in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019 and our stockholders
approved the ESPP in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;2019. The ESPP will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. The purpose of the ESPP is to encourage and to enable
eligible employees to acquire proprietary interests in our company through the purchase and ownership of shares of our common stock. The ESPP is intended to benefit us and our stockholders by
incentivizing participants to contribute to our success and to operate and manage our business in a manner that will provide for our long-term growth and profitability and that will benefit our
stockholders and other important stakeholders. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&nbsp;423 of the Code.

</FONT>

</P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Share Reserve  </I></FONT></P>


</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP will authorize the issuance of up to 240,000 shares of our common stock pursuant to purchase rights granted to our employees or to
employees of any of our participating affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1st&nbsp;of each year, commencing on
January&nbsp;1, 2020 and continuing until the expiration of the ESPP, in an amount equal to the least of (i)&nbsp;1% of the total number of shares of our common stock outstanding on
December&nbsp;31st&nbsp;of the preceding calendar year, (ii)&nbsp;480,000 shares of our common stock (subject to adjustment as provided in the ESPP) and (iii)&nbsp;a number of shares of our
common stock determined by our board of directors or our compensation committee, as applicable; however, our board of directors or our compensation committee, as applicable, may act prior to the first
day of any calendar year to provide that there will be no increase in the share reserve for such calendar year.


</FONT></P>


<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=145,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=415765,FOLIO='142',FILE='DISK106:[19ZAH1.19ZAH78701]EK78701A.;22',USER='WWASSER',CD='26-APR-2019;14:47' -->
<A NAME="page_ek78701_1_143"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP will be administered under the direction of our board of directors, our compensation committee, or any other committee designated by
our board of directors. Our board of directors has delegated full authority to administer the ESPP to its compensation committee. Among other things, the compensation committee will have the authority
to determine eligibility for participation in the ESPP, designate separate offerings under the plan and construe, interpret and apply the terms of the plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our employees who are employed by us or our participating affiliates may be eligible to participate in the ESPP, provided that the
following employees are among those that are ineligible under the ESPP: (i)&nbsp;employees whose customary employment is 20&nbsp;hours or less per week; (ii)&nbsp;employees whose customary
employment is for not more than five months in any calendar year; and (iii)&nbsp;employees who, after exercising their rights to purchase our common stock under the ESPP, would own 5% or more of our
total combined voting power. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
employee may purchase shares of our common stock in any calendar year under the ESPP and under all other employee stock purchase plans having an aggregate fair market value in excess
of $25,000, determined as of the first trading day of the offering period. In addition, unless otherwise determined by our compensation committee, no employee may purchase more than 5,000 shares of
our common stock in any one offering period. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Offering Periods  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP will be implemented through a series of offerings under which eligible employees are granted purchase rights to purchase our common
stock on specified dates during such offerings. Our compensation committee will determine offering periods of not more than 27&nbsp;months and may permit periodic purchases of our common stock
within a single offering period. Unless otherwise established by our compensation committee prior to the start of an offering period, the plan will have two offering periods (with concurrent purchase
periods) that commence each calendar year, and each offering period will be of approximately six months' duration, with the first such offering period beginning on the first trading day of April and
ending on the last trading day of the immediately following September, and the second such offering period beginning on the first trading day of October and ending on the last trading day of the
immediately following March. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payroll Deductions and Purchase Price  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, all employees, including executive officers, employed by us or by any of our participating affiliates, may participate in the ESPP
and may contribute, normally through payroll deductions, up to 15% of their eligible compensation for the purchase of our common stock under the ESPP. Unless otherwise determined by our compensation
committee, the purchase price per share of our common stock under the ESPP will be 85% of the lesser of the average of the high and low sales price of our common stock on (i)&nbsp;the first trading
day of the relevant offering period and (ii)&nbsp;the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the
relevant purchase period). </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on the Sale of Shares  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee has the right to (i)&nbsp;require that an employee not request that all or a part of the shares of our common stock
purchased by the employee be reissued in the employee's own name and shares be delivered to the employee until two years have elapsed since the offering date of the offering period in which the shares
of our common stock were purchased and one year has elapsed since the day the shares of our common stock were purchased, or the holding period, (ii)&nbsp;require that any sales of our common stock
during the holding period be performed through a licensed broker acceptable to us </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=146,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=334865,FOLIO='143',FILE='DISK106:[19ZAH1.19ZAH78701]EK78701A.;22',USER='WWASSER',CD='26-APR-2019;14:47' -->
<A NAME="page_ek78701_1_144"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
(iii)&nbsp;limit sales or other transfers of shares of our common stock for up to two years from the date the employee purchases shares of our common stock under the ESPP. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Transactions  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that there occurs a change in our capital structure through such actions as a recapitalization, stock split, reverse stock split,
spin-off, combination of shares, exchange of shares, stock dividend or other distribution payable in capital stock, our compensation committee will make appropriate adjustments to the number and kind
of shares that may be purchased, and the number and kind of shares for which options are outstanding, under the ESPP. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of certain significant corporate transactions, including (i)&nbsp;a dissolution or liquidation, (ii)&nbsp;a merger, consolidation or reorganization where we are not the
surviving entity, (iii)&nbsp;a sale of all or substantially all of our assets, or (iv)&nbsp;a merger or consolidation resulting in any person or entity owning more than 50% of the combined voting
power of all classes of our capital stock, the ESPP and all elections outstanding under the ESPP will terminate, except for certain situations where, for instance, the parties make arrangements for
the continuation or assumption of the ESPP. In the event of any such termination of the ESPP, the offering period and the purchase period will be deemed to have ended on the last trading day prior to
such termination, and the options of each participant then outstanding will be deemed to be automatically exercised on such last trading day. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment, Suspension, or Termination  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP will terminate on the day before the 10th&nbsp;anniversary of the date of adoption of the ESPP by our board of directors, unless
earlier terminated. Our compensation committee may amend, suspend, or terminate the ESPP; however, any such amendment, suspension, or termination may not impair any vested rights without the
employee's consent. Our compensation committee may not increase the number of shares reserved for issuance under the ESPP without stockholder approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=147,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1024217,FOLIO='144',FILE='DISK106:[19ZAH1.19ZAH78701]EK78701A.;22',USER='WWASSER',CD='26-APR-2019;14:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_em78701_1_145"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="em78701_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_em78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2016 to which we have been or are to be a participant, in which the
amount exceeds $120,000, and in which any of our directors, executive officers or beneficial owners of more than 5% of any class of our voting securities, or any immediate family member of or person
sharing a household with any of the foregoing persons, had or will have a direct or indirect material interest, other than employment relationships with our
executive officers and compensation to our directors. Employment relationships with and compensation paid to our NEOs are described under the section entitled "Executive Compensation" and compensation
to our directors is described in "Management&#151;Non-Employee Director Compensation." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Relationships with Yale University and Dr.&nbsp;Lieping Chen  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consulting Agreement with Lieping Chen, M.D., Ph.D.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2015, we entered into a consulting agreement for advisory services with our scientific founder, Dr.&nbsp;Lieping Chen, who
beneficially owns more than 5% of our outstanding common stock. The term of the consulting agreement expires December&nbsp;31, 2020. Under the agreement, Dr.&nbsp;Chen receives $5,000 per month in
consulting fees until the expiration of the agreement. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Yale License Agreement and Sponsored Research Agreement  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2015, we entered into a license agreement with Yale University, which beneficially owns more than 5% of our outstanding common
stock. Under the Yale Agreement, we obtained a license to products that either incorporate certain licensed patents used in the discovery of targets or arise out of research and development of
Dr.&nbsp;Chen's laboratory at Yale, including S15. We are obligated to pay Yale low single-digit royalties on sales of products, including NC318, that are either covered by the patents licensed to
us under the Yale Agreement or arise out of Dr.&nbsp;Chen's laboratory, subject to minimum annual royalty payments in the low to mid hundreds of thousands of dollars. Until we are required to pay
royalties under the Yale Agreement, we must pay an annual license maintenance fee to Yale in the mid to high tens of thousands of dollars. In addition, with respect to each product covered by licenses
under the Yale Agreement, we are obligated to pay Yale milestone payments in an aggregate amount of up to approximately $3.0&nbsp;million. Upon the closing of this offering, we are obligated to pay
Yale $500,000 pursuant to the terms of the Yale Agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Yale Agreement, we also entered into the SRA with Yale, in which we agreed to provide an aggregate of up to $12.4&nbsp;million to fund a research program aimed
at discovering new targets for immunomedicines. The research program is under the direction and supervision of Dr.&nbsp;Chen. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Chen
is the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) at Yale, and the
Co-Director of the Cancer Immunology Program at the Yale Cancer Center. For more information about the Yale Agreement and the SRA, see "Business&#151;Our Collaboration
Agreements&#151;Agreements with Yale University." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gift to Yale University  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, we made a charitable contribution to Dr.&nbsp;Chen at Yale University of $500,000 to be used at Dr.&nbsp;Chen's discretion to
support research activities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Relationship with Eli Lilly  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, we entered into the Lilly Agreement, which is focused on the discovery and development of immunomedicines for oncology using
our FIND-IO platform. Lilly beneficially owns more than 5% of our outstanding common stock. We received an upfront payment of $25.0&nbsp;million in cash and an equity investment of
$15.0&nbsp;million from Lilly upon entering into the Lilly Agreement and are eligible for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=148,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=884786,FOLIO='145',FILE='DISK106:[19ZAH1.19ZAH78701]EM78701A.;30',USER='CHE106319',CD='26-APR-2019;01:11' -->
<A NAME="page_em78701_1_146"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>support,
option exercise and milestone payments of an aggregate of up to $1.4&nbsp;billion, as well as mid to high single-digit royalties under the Lilly Agreement. Upon our exercise of an option
with respect to a given target, we will owe Lilly option exercise, milestone and royalty payments in amounts equivalent to a portion of the amounts payable by Lilly were Lilly to exercise an option.
For more information on the Lilly Agreement, see "Business&#151;Our Collaboration Agreements&#151;Research and Development Collaboration with Lilly." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sales and Purchases of Securities  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A-2 and Series&nbsp;A-3 Preferred Stock Financings  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, we issued and sold an aggregate of 25,000,000 shares of our Series&nbsp;A-2 Preferred Stock, at a purchase price of $1.00 per
share, for aggregate proceeds to us of $25&nbsp;million. In April 2018, we issued and sold an aggregate of 28,181,819 shares of our Series&nbsp;A-3 Preferred Stock, at a purchase price of $1.10
per share, for aggregate proceeds to us of approximately $31&nbsp;million. Each share of Series&nbsp;A-2 and Series&nbsp;A-3 Preferred Stock is convertible into 0.1245&nbsp;shares of common
stock.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
owners of 5% or more of a class of our voting stock and entities that may be deemed to beneficially own 5% or more of a class of our voting stock purchased shares of our
Series&nbsp;A-2 and Series&nbsp;A-3 Preferred Stock in these financings. The following table summarizes those purchases: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Participants

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;A-2<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;A-3<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments VI,&nbsp;LP<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,970,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,861,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,417,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canaan X&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.970,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,861,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,417,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Venture Partners IX,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,732,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,301,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,763,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,477,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,396,091</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,313,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with Lilly Asia Ventures<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,477,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,396,091</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,313,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alexandria Venture Investments,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>372,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>365,727</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>774,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chau
Q. Khuong, a member of our board of directors, is a Partner at OrbiMed Advisors&nbsp;LLC, which is associated with OrbiMed Private Investments VI,&nbsp;LP.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Timothy
M. Shannon, M.D., a member of our board of directors, is a managing member of Canaan Partners X&nbsp;LLC, the general partner of Canaan X&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>David
Kabakoff, Ph.D., the Chair of our board of directors, is an Executive Partner at Sofinnova Investments,&nbsp;Inc., the management company of Sofinnova
Venture Partners&nbsp;IX,&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>These
shares are directly owned by Pfizer Ventures (US)&nbsp;LLC. Pfizer&nbsp;Inc. is the parent company to Pfizer Ventures (US)&nbsp;LLC and may be deemed to
beneficially own the shares directly owned by Pfizer Ventures (US)&nbsp;LLC. Elaine V. Jones, a member of our board of directors, is Vice President, Worldwide Business Development and Senior Partner
at Pfizer Ventures, which is associated with Pfizer&nbsp;Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 1,492,500 shares of Series&nbsp;A-2 Preferred Stock and 1,465,364 shares of Series&nbsp;A-3 Preferred Stock purchased by Lilly Asia Ventures Fund
III,&nbsp;L.P. and 2,985,000 shares of Series&nbsp;A-2 Preferred Stock and 2,930,727 shares of Series&nbsp;A-3 Preferred Stock purchased by LAV Biosciences Fund III,&nbsp;L.P. Judith J. Li, a
member of our board of directors, is a Partner at Lilly Asia Ventures, which is associated with Lilly Asia Ventures Fund III,&nbsp;L.P. and LAV Biosciences Fund III.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=149,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=882867,FOLIO='146',FILE='DISK106:[19ZAH1.19ZAH78701]EM78701A.;30',USER='CHE106319',CD='26-APR-2019;01:11' -->
<A NAME="page_em78701_1_147"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B Preferred Stock Financing  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, we issued and sold an aggregate of 15,052,117 shares of our Series&nbsp;B-1 Preferred Stock at a purchase price of $1.59 per
share, 34,276,734 shares of our Series&nbsp;B-2 Preferred Stock at a purchase price of $1.59 per share and 7,500,000 shares of our Series&nbsp;B-3 Preferred Stock at a purchase price of $2.00 per
share. We received aggregate gross proceeds of approximately $93.4&nbsp;million for the sale of our Series&nbsp;B Preferred Stock. Each share of Series&nbsp;B Preferred Stock is convertible into
0.1245&nbsp;shares of common stock.

</FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
owners of 5% or more of a class of our voting stock and entities that may be deemed to beneficially own 5% or more of a class of our voting stock purchased shares of our
Series&nbsp;B-1, B-2 and B-3 Preferred Stock in these financings. The following table summarizes that participation: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Participants

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;B-1<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;B-2<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;B-3<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments&nbsp;VI,&nbsp;LP<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,554,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,651,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canaan X&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,296,605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,651,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Venture Partners&nbsp;IX,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,773,585</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,665,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,238,702</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with Lilly Asia Ventures<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,132,680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,390,961</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alexandria Venture Investments,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>628,931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HH NCure Holdings&nbsp;LLC<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,861,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,500,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quan Venture Fund&nbsp;II,&nbsp;L.P.<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,861,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,500,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bay City Capital GF Xinde International Life Sciences USD Fund,&nbsp;L.P.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,716,982</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Citadel Multi-Strategy Equities Master Fund&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,144,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taiho Ventures,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,144,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ling Tong Investment Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,144,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with ArrowMark Partners</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,515,723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with NS Investment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,886,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eli Lilly and Company</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chau
Q. Khuong, a member of our board of directors, is a Partner at OrbiMed Advisors&nbsp;LLC, which is associated with OrbiMed Private Investments VI,&nbsp;LP.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Timothy
M. Shannon, M.D., a member of our board of directors, is a managing member of Canaan Partners X&nbsp;LLC, the general partner of Canaan X&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>David
Kabakoff, Ph.D., the Chair of our board of directors, is an Executive Partner at Sofinnova Investments,&nbsp;Inc., the management company of Sofinnova
Venture Partners&nbsp;IX,&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Elaine
V. Jones, a member of our board of directors, is Vice President, Worldwide Business Development and Senior Partner at Pfizer Ventures, which is associated
with Pfizer&nbsp;Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 710,893 shares of Series&nbsp;B-1 Preferred Stock purchased by Lilly Asia Ventures Fund III,&nbsp;L.P. and 1,421,787 shares of Series&nbsp;B-1
Preferred Stock purchased by LAV Biosciences Fund III,&nbsp;L.P. Judith J. Li, a member of our board of directors, is a Partner at Lilly Asia Ventures, which is associated with Lilly Asia Ventures
Fund III,&nbsp;L.P. and LAV Biosciences Fund&nbsp;III.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Qingqing
Yi, a former member of our board of directors, is a Partner at Hillhouse Capital Group, which is associated with HH NCure Holdings LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Stella
Xu, a member of our board of directors, is a Managing Director at Quan Capital, which is associated with Quan Venture Fund II,&nbsp;L.P. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=150,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=168409,FOLIO='147',FILE='DISK106:[19ZAH1.19ZAH78701]EM78701A.;30',USER='CHE106319',CD='26-APR-2019;01:11' -->
<A NAME="page_em78701_1_148"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Series&nbsp;B Preferred Stock financing, we reimbursed (i)&nbsp;counsel for HH NCure Holdings&nbsp;LLC in the amount of $150,000, (ii)&nbsp;counsel for
Quan Venture Fund II,&nbsp;L.P., in the amount of $10,000 and (iii)&nbsp;counsel for Pfizer&nbsp;Inc., OrbiMed Private Investments VI,&nbsp;LP, Lilly Asia Ventures and Sofinnova Venture
Partners IX,&nbsp;L.P., collectively, in an aggregate amount of $45,000 for legal fees incurred by them. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amended and Restated Investors' Rights Agreement  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our Series&nbsp;B Preferred Stock financing in November 2018, we entered into an amended and restated investors' rights
agreement with the holders of our preferred stock. These stockholders are entitled to rights with respect to the registration of their shares under the Securities Act in certain circumstances. For a
more detailed description of these registration rights, see the section entitled "Description of Capital Stock&#151;Registration Rights." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Agreement  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our Series&nbsp;A Preferred Stock financing, we entered into a voting agreement with the holders of our preferred stock and
the holders of our common stock with respect to election of our directors and certain other matters, which voting agreement was amended and restated in connection with our Series&nbsp;B Preferred
Stock financing in November 2018. All of our current directors except Stephen&nbsp;W.&nbsp;Webster and Elaine&nbsp;V.&nbsp;Jones, Ph.D. currently serve pursuant to the terms of the amended and
restated voting agreement. The agreement will terminate upon the closing of this offering. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Management Rights Letters  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our preferred stock financings, we entered into management rights letters with purchasers of our preferred stock with which
certain of our directors are affiliated, pursuant to which such purchasers were granted certain management rights, including the right to consult with and advise our management on significant business
issues, review our operating plans, examine our books and records and inspect our facilities. These management rights will terminate upon the closing of this offering. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Participation in this Offering

  </I></B></FONT>

</P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our stockholders, including beneficial owners of more than 5% of a class of our voting stock and stockholders affiliated with certain
of our directors, have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million of shares of our common stock in this offering at the initial public offering price and on
the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more,
fewer or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, fewer or no shares in this offering.

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into indemnification agreements with each of our directors and executive officers. These indemnification agreements generally
require us, among other things, to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service as directors or officers, other than
liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors and executive officers as a result of any
proceeding against them as to which they could be indemnified. For more information regarding these agreements, see "Management&#151;Limitation on Liability and Indemnification Matters." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures Regarding Transactions with Related Persons  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this offering, setting forth
the policies and procedures for the review and approval or ratification </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=151,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=371998,FOLIO='148',FILE='DISK106:[19ZAH1.19ZAH78701]EM78701A.;30',USER='CHE106319',CD='26-APR-2019;01:11' -->
<A NAME="page_em78701_1_149"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
related person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of Regulation&nbsp;S-K under the Securities Act, any transaction, arrangement or
relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or
will have a direct or indirect material interest. Types of transactions covered by this policy include, without limitation, purchases of goods or services by or from the related person or entities in
which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit
committee is tasked to consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to those that could be obtained in an arm's length
transaction with an unrelated third party and the extent of the related person's interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this
policy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=152,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=920352,FOLIO='149',FILE='DISK106:[19ZAH1.19ZAH78701]EM78701A.;30',USER='CHE106319',CD='26-APR-2019;01:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_eo78701_1_150"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eo78701_principal_stockholders"> </A>
<A NAME="toc_eo78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information relating to the beneficial ownership of our common stock as of April&nbsp;29, 2019,
by:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> each of our NEOs; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> all of our directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares beneficially owned prior to this offering by each entity, person, director or executive officer is determined in accordance with SEC rules, and the information is
not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or
investment power as well as any shares that the individual has the right to acquire within 60&nbsp;days of April&nbsp;29, 2019 through the exercise of any stock option or other rights. Except as
otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that
person.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our stockholders, including 5% stockholders and stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately
$35.0&nbsp;million of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of
interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any of these stockholders, or any of these
stockholders may determine to purchase more, fewer or no shares in this offering. The figures in the table below do not reflect the purchase of any shares in this offering by these stockholders.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The percentage of shares beneficially owned is computed on the basis of 16,964,765 shares of our common stock deemed to be outstanding on April&nbsp;29, 2019, after giving effect to
the conversion of all outstanding shares of our preferred stock into 15,560,569 shares of our common stock. The percentage of beneficial ownership after this offering in the table below is based on
21,964,765 shares of common stock assumed to be outstanding after the closing of this offering, assuming no exercise of the underwriters' option to purchase additional shares. Shares of our common
stock that a person has the
right to acquire within 60&nbsp;days of April&nbsp;29, 2019 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but not for purposes of
computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=153,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=22149,FOLIO='150',FILE='DISK106:[19ZAH1.19ZAH78701]EO78701A.;35',USER='CHE106204',CD='26-APR-2019;02:02' -->
<A NAME="page_eo78701_1_151"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


as a group. Except as set forth below, the address for each beneficial owner listed is c/o NextCure,&nbsp;Inc., 9000 Virginia Manor Road, Suite&nbsp;200, Beltsville, Maryland 20705.

 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Before<BR>
Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>After<BR>
Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% Stockholders:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments VI,&nbsp;LP<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,361,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Canaan X&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,204,442</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.99</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sofinnova Venture Partners IX,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,121,856</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with Pfizer&nbsp;Inc.<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,770,759</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities associated with Lilly Asia Ventures<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,704,391</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HH NCure Holdings&nbsp;LLC<SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>978,570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quan Venture Fund II,&nbsp;L.P.<SUP>(7)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>978,570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eli Lilly and Company<SUP>(8)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>933,555</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Richman<SUP>(9)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>478,835</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steven P. Cobourn, CPA<SUP>(10)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sol Langermann, Ph.D.<SUP>(11)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,240</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Kabakoff, Ph.D.<SUP>(12)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elaine V. Jones, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chau Q. Khuong</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Judith J. Li<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,704,391</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Briggs Morrison, M.D.<SUP>(13)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,356</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Timothy M. Shannon, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stephen W. Webster</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stella Xu, Ph.D.<SUP>(7)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>978,570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All executive officers and directors as a group (15&nbsp;persons)</B></FONT><FONT SIZE=2><SUP>(</SUP><SUP>14</SUP><SUP>)
</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,576,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Indicates
beneficial ownership of less than 1% of the total outstanding common stock.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;445,866 shares of common stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock, (b)&nbsp;743,110 shares of common stock
issuable upon conversion of Series&nbsp;A-2 Preferred Stock, (c)&nbsp;729,599 shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock and (d)&nbsp;442,438 shares of
common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock. OrbiMed Advisors is the general partner of OrbiMed Capital&nbsp;GP VI&nbsp;LLC, which is general partner of OrbiMed
Private Investments VI,&nbsp;LP. Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein as members of OrbiMed Advisors' management committee share voting and dispositive power over the shares
directly owned by OrbiMed Private Investments VI,&nbsp;LP. The address for OrbiMed Private Investments VI,&nbsp;LP is c/o OrbiMed Advisors&nbsp;LLC, 601 Lexington Ave. 54th&nbsp;Floor, New
York, NY&nbsp;10022.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;445,866 shares of common stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock, (b)&nbsp;743,110 shares of common stock
issuable upon conversion of Series&nbsp;A-2 Preferred Stock, (c)&nbsp;729,599 shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock and (d)&nbsp;285,867 shares of
common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock. Canaan Partners X&nbsp;LLC is the sole general partner of Canaan X&nbsp;L.P. and may be deemed to have sole voting and
dispositive power over the shares held by Canaan X&nbsp;L.P. Investment, voting and dispositive decisions with respect to the shares held by Canaan X&nbsp;L.P. are made by the managers of Canaan
Partners X&nbsp;LLC, collectively. None of the managers of Canaan Partners X&nbsp;LLC has beneficial ownership (within the meaning of Rule&nbsp;13d-3 promulgated under the Exchange Act) of any
shares

</FONT></DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=154,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=682751,FOLIO='151',FILE='DISK106:[19ZAH1.19ZAH78701]EO78701A.;35',USER='CHE106204',CD='26-APR-2019;02:02' -->
<A NAME="page_eo78701_1_152"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>held
by Canaan X&nbsp;L.P. The address for Canaan X&nbsp;L.P. is 285 Riverside Ave., Suite&nbsp;250, Westport, CT&nbsp;06880.


</FONT></P>


</UL>

<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;278,759 shares of common stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock, (b)&nbsp;464,599 shares of common stock
issuable upon conversion of Series&nbsp;A-2 Preferred Stock, (c)&nbsp;908,785 shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock and (d)&nbsp;469,713 shares of
common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock. Sofinnova Management IX, L.L.C., or SM IX, the general partner of Sofinnova Venture Partners IX,&nbsp;L.P., may be deemed
to have sole voting and dispositive power, and Dr.&nbsp;Michael F. Powell, Dr.&nbsp;James I. Healy and Dr.&nbsp;Anand Mehra, the managing members of SM IX, may be deemed to have shared power to
vote and dispose of the shares owned by Sofinnova Venture Partners IX,&nbsp;L.P. The address for Sofinnova Venture Partners IX,&nbsp;L.P. is 3000 Sand Hill Rd. Bldg. 4, Suite&nbsp;250, Menlo
Park, CA 94025.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of: (a)&nbsp;(i)&nbsp;334,399 shares of common stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock; (ii)&nbsp;557,332 shares of common
stock issuable upon conversion of Series&nbsp;A-2 Preferred Stock; and (iii)&nbsp;547,199 shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock directly owned by
Pfizer Ventures (US)&nbsp;LLC; and (b)&nbsp;331,829 shares of common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock directly owned by Pfizer&nbsp;Inc. As of April&nbsp;29,
2019, the board of directors of Pfizer&nbsp;Inc. is comprised of the following individuals: Dennis&nbsp;A. Ausiello, Ronald&nbsp;E. Blaylock, Albert Bourla, W.&nbsp;Don Cornwell,
Joseph&nbsp;J. Echevarria, Helen&nbsp;H. Hobbs, James&nbsp;M. Kilts, Dan&nbsp;R. Littman, Shantanu Narayen, Suzanne Nora Johnson, Ian&nbsp;C. Read and James&nbsp;C. Smith.
Pfizer&nbsp;Inc. is a publicly traded company. The address for Pfizer&nbsp;Inc. is 235 East 42nd&nbsp;St., New York, NY&nbsp;10017.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of: (a)&nbsp;(i)&nbsp;111,466 shares of common stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock, (ii)&nbsp;185,777 shares of common
stock issuable upon conversion of Series&nbsp;A-2 Preferred Stock, (iii)&nbsp;182,399 shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock and (iv)&nbsp;88,487
shares of common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock directly owned by Lilly Asia Ventures Fund III,&nbsp;L.P.; and (b)&nbsp;(i)&nbsp;222,933 shares of common
stock issuable upon conversion of Series&nbsp;A-1 Preferred Stock, (ii)&nbsp;371,555 shares of common stock issuable upon conversion of Series&nbsp;A-2 Preferred Stock, (iii)&nbsp;364,799
shares of common stock issuable upon conversion of Series&nbsp;A-3 Preferred Stock and (iv)&nbsp;176,975 shares of common stock issuable upon conversion of Series&nbsp;B-1 Preferred Stock
directly owned by LAV Biosciences Fund III,&nbsp;L.P. Ms.&nbsp;Li is a Partner at Lilly Asia Ventures and shares voting and dispositive power over the shares owned by the entities associated with
Lilly Asia Ventures. The address for Lilly Asia Ventures is Unit 1109-10, Two Chinachem Central, 26 Des Voeux Road Central, Hong Kong.



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 978,570 shares of common stock issuable upon conversion of Series&nbsp;B-2 Preferred Stock. HH NCure Holdings&nbsp;LLC is beneficially owned and
controlled by Hillhouse Fund IV,&nbsp;L.P. Hillhouse Capital Management,&nbsp;Ltd. acts as the sole management company of Hillhouse Fund IV,&nbsp;L.P., which is in turn ultimately controlled by
Mr.&nbsp;Lei Zhang. The registered address of HH NCure Holdings&nbsp;LLC is Citco Trustees (Cayman) Limited, 89 Nexus Way, Camana Bay, PO Box&nbsp;31106, Grand Cayman KY1-1205, Cayman Islands.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 978,570 shares of common stock issuable upon conversion of Series&nbsp;B-2 Preferred Stock. Dr.&nbsp;Xu is a Managing Director at Quan Capital, has
voting and dispositive power over the shares directly owned by Quan Venture Fund II,&nbsp;L.P. The address for Quan Venture Fund II,&nbsp;L.P. is c/o Quan Capital, Jinchuang Plaza, 4560 Jinke Rd.,
Bldg. 1N, Suite&nbsp;401, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai, China 201210.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 933,555 shares of common stock issuable upon conversion of Series&nbsp;B-3 Preferred Stock. The address for Eli Lilly and Company is Lilly Corporate
Center, Indianapolis, IN 46285.

 </FONT></DD>

</DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=155,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=450261,FOLIO='152',FILE='DISK106:[19ZAH1.19ZAH78701]EO78701A.;35',USER='CHE106204',CD='26-APR-2019;02:02' -->
<A NAME="page_eo78701_1_153"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;385,869 shares of common stock, including up to 42,874 shares of restricted common stock subject to repurchase by us upon certain terminations
and (b)&nbsp;92,966 shares of common stock issuable upon the exercise of stock options within 60&nbsp;days of April&nbsp;29, 2019. Our right of repurchase lapses in equal monthly installments
through December&nbsp;29, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 26,450 shares of common stock issuable upon the exercise of stock options within 60&nbsp;days of April&nbsp;29, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;37,342 shares of common stock, including up to 6,223 shares of restricted common stock subject to repurchase by us upon certain terminations,
and (b)&nbsp;38,898 shares of common stock issuable upon the exercise of stock options within 60&nbsp;days of April&nbsp;29, 2019. Our right of repurchase lapses in equal monthly installments
through December&nbsp;29, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 62,237 shares of restricted common stock subject to repurchase following termination, 6,915 of which are unvested and subject to forfeiture following
termination for any reason other than death or disability prior to December&nbsp;29, 2019. The unvested restricted common stock will vest in equal monthly installments through December&nbsp;29,
2019, subject to Dr.&nbsp;Kabakoff's continued service with us.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 4,356 shares of common stock issuable upon the exercise of stock options within 60 days of April&nbsp;29, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of (a)&nbsp;594,361&nbsp;shares of common stock, including 125,855&nbsp;shares subject to repurchase or forfeiture, (b)&nbsp;298,941&nbsp;shares
of common stock issuable upon the exercise of stock options within 60&nbsp;days of April&nbsp;29, 2019 and (c)&nbsp;2,682,961&nbsp;shares of common stock issuable upon conversion of preferred
stock.

</FONT></DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=156,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=732503,FOLIO='153',FILE='DISK106:[19ZAH1.19ZAH78701]EO78701A.;35',USER='CHE106204',CD='26-APR-2019;02:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_eq78701_1_154"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eq78701_description_of_capital_stock"> </A>
<A NAME="toc_eq78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary describes our capital stock and the material provisions of our amended and restated certificate of
incorporation and our amended and restated bylaws, each of which will become effective upon the closing of this offering, and of the Delaware General Corporation Law. Because the following is only a
summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation and
amended and restated bylaws, copies of which have been filed as exhibits to the registration statement of which this prospectus is part.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, we will file our amended and restated certificate of incorporation that authorizes 158,745,671 shares of
common stock, $0.001 par value per share, and 10,000,000&nbsp;shares of preferred stock, $0.001 par value per share, all of which shares of preferred stock will be undesignated. Our board of
directors may establish the rights and preferences of the preferred stock from time to time.

</FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, there were outstanding:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 16,935,381 shares of our common stock, on an as-converted basis, held by approximately 33 stockholders of record; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,056,891 shares of our common stock issuable upon exercise of outstanding stock options.


</FONT></DD>

</DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, we intend to effect a 1-for-8.0338 reverse stock split of our outstanding common stock prior to the effectiveness of the registration statement of which
this prospectus forms a part.

 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the
directors. In addition, the affirmative vote of holders of 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including
amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to the classified board. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive
dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then
outstanding shares of preferred stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rights and Preferences  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=157,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=957462,FOLIO='154',FILE='DISK106:[19ZAH1.19ZAH78701]EQ78701A.;25',USER='MKEANE',CD='26-APR-2019;19:13' -->
<A NAME="page_eq78701_1_155"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>privileges
of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the
future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fully Paid and Nonassessable  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and
nonassessable. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, options to purchase 2,056,891 shares of our common stock were outstanding under our 2015 Plan, with a weighted
average exercise price of $4.74 per share, and 699,590&nbsp;shares of our common stock remained available for future issuance. For additional information regarding the terms of the 2015 Plan, see
"Executive Compensation&#151;Equity Incentive Plans&#151;2015 Omnibus Incentive Plan."

</FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of this offering, all outstanding shares of our preferred stock will be converted into 15,560,569 shares of our common stock.
Upon the closing of this offering, our amended and restated certificate of incorporation will be amended and restated to delete all references to such shares of preferred stock. From and after the
closing of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to
fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption,
liquidation preferences, sinking fund terms and the number of shares
constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of
holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of our preferred stock could have the effect of
delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after the closing of this offering, no shares of preferred stock will be outstanding, and we
have no present plan to issue any shares of preferred stock.

</FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our amended and restated investors' rights agreement, following the closing of this offering, the holders of 15,560,569 shares of common
stock, or their transferees, will have the right to require us to register their shares, or the registrable shares, under the Securities Act so that those shares may be publicly resold, and the right
to include their shares in any registration statement we file, in each case as described below.

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After the closing of this offering, the holders of the registrable shares will be entitled to certain demand registration rights. Beginning six
months following the effectiveness of the registration statement of which this prospectus forms a part, the holders of at least 20% of these shares can, on not more than two occasions, request that we
register all or a portion of their shares if the aggregate offering price of the shares would exceed $10&nbsp;million (after deductions of underwriters' commissions and expenses).

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Piggyback Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After the closing of this offering, in the event that we determine to register any of our securities under the Securities Act (subject to
certain exceptions), either for our own account or for the account of other security holders, the holders of the registrable shares will be entitled to certain "piggyback" registration </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=158,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=739390,FOLIO='155',FILE='DISK106:[19ZAH1.19ZAH78701]EQ78701A.;25',USER='MKEANE',CD='26-APR-2019;19:13' -->
<A NAME="page_eq78701_1_156"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>rights
allowing the holders to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file&nbsp;a registration statement
under the Securities Act, other than with respect to a registration related to employee benefit plans, registration on a form that does not include substantially the same information as would be
required to be included in a registration statement covering the registrable shares, a registration in which the only common stock being registered is common stock issuable upon conversion of debt
securities also being registered, or corporate reorganizations or certain other transactions, the holders of these shares are entitled to notice of the registration and have the right, subject to
limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration. In an underwritten offering, the underwriters have the
right, subject to specified conditions, to exclude or limit the number of shares such holders may include. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-3 Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we become and are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, the holders of the registrable shares can make a
written request that we register their shares on Form&nbsp;S-3 if we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3 and if the aggregate offering price of the shares is at
least $1&nbsp;million (after deductions of underwriters' commissions and expenses). These stockholders may make an unlimited number of requests for registration on Form&nbsp;S-3, but in no event
shall we be required to file more than two registrations on Form&nbsp;S-3 in any given 12-month period. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of Registration  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay the registration expenses of the holders of the shares registered pursuant to the demand, piggyback and Form&nbsp;S-3 registration
rights described above, including the reasonable expenses of one counsel for the selling holders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expiration of Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The demand, piggyback and Form&nbsp;S-3 registration rights described above will expire, with respect to any particular stockholder, upon the
earlier of five years after the closing of this offering and when that stockholder can sell all of its shares under Rule&nbsp;144 under the Securities Act without limitation during any three-month
period without registration. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our
Amended and Restated Bylaws and Delaware Law  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws that will
become effective upon to the closing of this offering could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest
or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may
otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly
or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=159,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=246802,FOLIO='156',FILE='DISK106:[19ZAH1.19ZAH78701]EQ78701A.;25',USER='MKEANE',CD='26-APR-2019;19:13' -->
<A NAME="page_eq78701_1_157"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Anti-Takeover Statute  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed "interested stockholders" from
engaging in a "business combination" with a publicly traded Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or
the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an "interested stockholder" is a person
who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a
"business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an
anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our
common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Undesignated Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other
rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control
or management of our company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special Stockholder Meetings  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our board of directors, our Chair,
President or Chief Executive Officer. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Requirements for Advance Notification of Stockholder Nominations and Proposals  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for
election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elimination of Stockholder Action by Written Consent  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Classified Board; Election and Removal of Directors; Filling Vacancies; Board Size  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each
year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder
of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect
all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a
66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of the then outstanding voting stock. For more information on the classified board, see "Management&#151;Classified Board of Directors." Any vacancy on
our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of
directors determines that such vacancies shall be filled by the stockholders. Furthermore, the authorized number of directors may be changed only by a resolution of the board of directors. This system
of electing and removing directors, filling vacancies and fixing the size of the board may tend to discourage a third party from making a tender </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=160,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=224923,FOLIO='157',FILE='DISK106:[19ZAH1.19ZAH78701]EQ78701A.;25',USER='MKEANE',CD='26-APR-2019;19:13' -->
<A NAME="page_eq78701_1_158"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>offer
or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Choice of Forum  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws, to be in effect upon the closing of this offering, provide that unless we consent in writing to an alternative
forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction of such action is vested exclusively in the federal courts, the United States District Court for the District
of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a
claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware
General Corporation Law, our certificate of incorporation or our bylaws, (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation
or the bylaws or (v)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery or the United States District Court for the
District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person holding, owning or otherwise acquiring any
interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does not apply to any actions arising under the
Securities Act or the Exchange Act. Although our amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is
inapplicable for a particular claim or action or that such provision is unenforceable. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment of Charter Provisions  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The amendment of any of the above provisions that are in our amended and restated certificate of incorporation, except for the provision making
it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the voting power of the
then outstanding voting stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging
others from
attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that
stockholders may otherwise deem to be in their best interests. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation of Liability and Indemnification Matters  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For a discussion of liability and indemnification, see "Management&#151;Limitation on Liability and Indemnification Matters." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to list our common stock on the Nasdaq Global Market under the symbol "NXTC". </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock will be American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC. The transfer agent and
registrar's address is 6201&nbsp;15th&nbsp;Avenue, Brooklyn, New York&nbsp;11219. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=161,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=234462,FOLIO='158',FILE='DISK106:[19ZAH1.19ZAH78701]EQ78701A.;25',USER='MKEANE',CD='26-APR-2019;19:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_es78701_1_159"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="es78701_shares_eligible_for_future_sale"> </A>
<A NAME="toc_es78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock. Future sales of our common stock, including shares issued upon the
exercise of outstanding options or warrants, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to
fall or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be
available for sale in the public market for a period of several months after the closing of this offering due to contractual and legal restrictions on resale described below. Future sales of our
common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price
of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale of Restricted Shares  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of shares of our common stock outstanding as of December&nbsp;31, 2018, upon the closing of this offering, we will have
outstanding an aggregate of 21,935,381 shares of common stock. Of these shares, all of the shares of common stock to be sold in this offering and any shares sold upon exercise of the underwriters'
option to purchase additional shares, will be freely tradable in the public market without restriction or further registration under the Securities Act, unless the shares are held by any of our
"affiliates" as such term is defined in Rule&nbsp;144 under the Securities Act. All remaining shares of common stock held by existing stockholders immediately prior to the closing of this offering
will be "restricted securities" as such term is defined in Rule&nbsp;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are
eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by
Rule&nbsp;144 or Rule&nbsp;701, which rules are summarized below.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the lock-up agreements referred to below and the provisions of Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act, based on the number of shares of our common
stock outstanding as of December&nbsp;31, 2018, the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="145pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Approximate Number of Shares


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First Date Available for Sale into Public Market </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> 16,935,381 shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 180&nbsp;days after the date of this prospectus upon expiration of the lock-up agreements referred to below, subject in some cases to applicable volume limitations under Rule&nbsp;144 under the Securities Act</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lock-Up Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, we, our directors, our executive officers and the holders of all of our outstanding stock and stock options
have agreed, subject to certain exceptions, with the underwriters not to dispose of any shares of our common stock or securities convertible into or exchangeable for shares of common stock during the
period from the date of the lock-up agreement continuing through the date 180&nbsp;days after the date of this prospectus, except with the prior written consent of Morgan
Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Piper Jaffray&nbsp;&amp;&nbsp;Co., on behalf of the underwriters. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the closing of this offering, certain of our employees, including our executive officers and directors may enter into written trading plans that are intended to comply with
Rule&nbsp;10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=162,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=234777,FOLIO='159',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_160"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the lock-up periods set forth in the agreements described above, all of the shares of our common stock that are restricted securities or are held by our affiliates as of the
date of this prospectus will be eligible for sale in the public market in compliance with Rule&nbsp;144 under the Securities Act. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the
Exchange Act for at least 90&nbsp;days, a person (or
persons whose shares are required to be aggregated) who is not deemed to have been one of our "affiliates" for purposes of Rule&nbsp;144 at any time during the three months preceding a sale, and who
has beneficially owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including the holding period of any prior owner other than one of our "affiliates," is
entitled to sell those shares in the public market (subject to the lock-up agreement referred to above, if applicable) without complying with the manner of sale, volume limitations or notice
provisions of Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially owned the shares proposed to be sold for at
least one year, including the holding period of any prior owner other than "affiliates," then such person is entitled to sell such shares in the public market without complying with any of the
requirements of Rule&nbsp;144 (subject to the lock-up agreement referred to above, if applicable). In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public
company reporting requirements of the Exchange Act for at least 90&nbsp;days, our "affiliates," as defined in Rule&nbsp;144, who have beneficially owned the shares proposed to be sold for at least
six months are entitled to sell in the public market, upon expiration of any applicable lock-up agreements and within any three-month period, a number of those shares of our common stock that does not
exceed the greater of:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will equal approximately 219,354 immediately after this offering; or </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a
notice on Form&nbsp;144 with respect to such sale. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
sales under Rule&nbsp;144 by our "affiliates" or persons selling shares on behalf of our "affiliates" are also subject to certain manner of sale provisions, notice requirements
and to the availability of current public information about us. Notwithstanding the availability of Rule&nbsp;144, the holders of substantially all of our restricted securities have entered into
lock-up agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under Rule&nbsp;144) upon the expiration of the restrictions
set forth in those agreements. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common
stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule&nbsp;701 under the
Securities Act before the effective date of the registration statement of which this prospectus is a part (to the extent such common stock is not subject to a lock-up agreement) is entitled to rely on
Rule&nbsp;701 to resell such shares beginning 90&nbsp;days after we become subject to the public company reporting requirements of the Exchange Act in reliance on Rule&nbsp;144, but without
compliance with the holding period requirements contained in Rule&nbsp;144. Accordingly, subject to any applicable lock-up agreements, beginning 90&nbsp;days after we become subject to the public
company reporting requirements of the Exchange Act, under Rule&nbsp;701 persons who are not our "affiliates," as defined in Rule&nbsp;144, may resell those shares without complying with the
minimum holding period or public information requirements of Rule&nbsp;144, and persons who are our "affiliates" may resell those shares without compliance with Rule&nbsp;144's minimum holding
period requirements (subject to the terms of the lock-up agreement referred to above). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=163,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=812565,FOLIO='160',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_161"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of shares outstanding as of December&nbsp;31, 2018, after the closing of this offering, the holders of 15,560,569 shares
of our common stock, or their transferees, will, subject to the lock-up agreements referred to above, be entitled to certain rights with respect to the registration of the offer and sale of those
shares under the Securities Act. For a description of these registration rights, see "Description of Capital Stock&#151;Registration Rights." If the offer and sale of these shares are
registered, they will be freely tradable without restriction under the Securities Act.

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incentive Plans  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to file with the SEC a registration statement under the Securities Act covering the shares of common stock that we may issue upon
exercise of outstanding options reserved for issuance under the 2015 Plan, the 2019 Plan and the ESPP. Such registration statement is expected to be filed and become effective as soon as practicable
after the closing of this offering. Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to
Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=164,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1027448,FOLIO='161',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_162"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="es78701_material_u.s._federal_income_t__mat03024"> </A>
<A NAME="toc_es78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired in
this offering by a Non-U.S. Holder (as defined below). For purposes of this discussion, a Non-U.S. Holder is a beneficial owner of our common stock that is not a "U.S. person" or partnership,
including any entity or arrangement treated as a partnership and the equity holders therein, for U.S. federal income tax purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. person is any of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an individual citizen or resident of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United
States, any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a trust (i)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have
the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes, the U.S. federal income tax treatment of a partner will generally depend on
the status of the partner and your activities. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors as to particular U.S. federal income
tax consequences to them of holding and disposing of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is based on the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, changes to any of which subsequent to the
date of this prospectus supplement may affect the tax consequences described herein, possibly with retroactive effect. We have not sought and will not seek any rulings from the Internal Revenue
Service, or IRS, regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the
ownership and disposition of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is limited to Non-U.S. Holders who hold our common stock as a "capital asset" within the meaning of Section&nbsp;1221 of the Code (generally, property held for
investment). This discussion does consider any specific facts or circumstances that may be relevant to holders subject to special rules under the U.S. federal income tax laws, including, without
limitation, certain former citizens or long-term residents of the United States, a person who holds or receives our common stock pursuant to the exercise of an employee stock option or otherwise as
compensation, partnerships (or arrangements classified as partnerships for U.S. federal income tax purposes) or other pass-through entities and the equity holders therein, "controlled foreign
corporations," "passive foreign investment companies," corporations that accumulate earnings to avoid U.S. federal income tax, banks, financial institutions, investment funds, insurance companies,
brokers, dealers or traders in securities, tax-exempt organizations, tax-qualified retirement plans or foreign pension funds, persons subject to the alternative minimum tax, persons subject to special
tax accounting rules under Section&nbsp;451(b) of the Code, persons that own, or have owned, actually or constructively, more than 5% of our common stock and persons holding our common stock as part
of a hedging or conversion transaction or straddle, or a constructive sale, or other risk reduction strategy. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion does not describe all of the U.S. federal income tax consequences that may be relevant to you in light of your particular circumstances, and does not address the
potential application of the alternative minimum tax, Medicare contribution tax, estate or gift taxes and does not address any aspect of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=165,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=789313,FOLIO='162',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_163"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>state,
local or non-U.S. taxation, or any taxes other than income taxes. You should consult your tax adviser with regard to the application of the U.S. federal tax laws to your particular situation,
as well as any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROSPECTIVE
INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS
WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributions of cash or other property paid on our common stock will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed our current and accumulated earnings and
profits, they will constitute a return of capital, which will first reduce your basis in our common stock, but not below zero, and any excess will be treated as gain from the sale or other disposition
of our common stock, as described below under "&#151;Gain on Disposition of Our Common Stock." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
paid to you generally will be subject to withholding tax at a 30% rate or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of
withholding, subject to the discussion below under "&#151;FATCA," you will be required to provide to us or our paying agent a properly executed IRS Form&nbsp;W-8BEN or IRS
Form&nbsp;W-8BEN-E (or applicable successor form) certifying your entitlement to benefits under a treaty. This certification must be provided to us or our paying agent prior to the payment of
dividends and must be updated periodically. If you hold the stock through a financial institution or other agent acting on your behalf, you will be required to provide appropriate documentation to the
agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you do not timely provide the required certification, but qualify for a reduced treaty rate, you may obtain a refund of any excess amounts withheld by timely filing an appropriate
claim for refund with the IRS. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
dividends paid to you are effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to
a permanent establishment or fixed base maintained by you in the United States), you will generally be taxed on the dividends on a net income basis in the same manner as a U.S. person. If you are a
foreign corporation you also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of your effectively connected earnings
and profits for the taxable year, as adjusted for certain items. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
dividends paid to you are effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to
a permanent establishment or fixed base maintained by you in the United States), you will be exempt from the withholding tax discussed in the preceding paragraph, although you will be required to
provide a properly executed IRS Form&nbsp;W-8ECI in order to claim an exemption from withholding. You should consult your tax advisors regarding any applicable income tax treaties that may provide
for different rules. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=166,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=106559,FOLIO='163',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_164"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on Disposition of Our Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussions below under "&#151;Information Reporting and Backup Withholding" and "&#151;FATCA," you generally will
not be subject to U.S. federal income or withholding tax on gain realized on a sale or other taxable disposition of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax
treaty, is attributable to a permanent establishment or fixed base maintained by you in the United States); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> you are a nonresident alien individual present in the United States for 183&nbsp;days or more during the taxable year of the disposition, and
certain other requirements are met; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we are or have been a "United States real property holding corporation," as defined in the Code, or a USRPHC, at any time within the five-year
period ending on the date of the taxable disposition or your holding period for such common stock, whichever period is shorter, and our common stock is not regularly traded on an established
securities market or you hold more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the taxable disposition or the
holding period for such common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain
described in the first bullet point above will generally be taxed on such gain in the same manner as a U.S. person. If you are a foreign corporation, you also may be subject to an
additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of your effectively connected earnings and profits for the taxable year, as adjusted for
certain items. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain
described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may
be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that you have timely filed U.S. federal income tax returns with
respect to such losses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
a corporation is a USRPHC only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real
property interests plus any of its assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a UPRHC, or that we are likely
to become one in the future. Even if we are a USRPHC, for so long as our common stock is regularly traded on an established securities market, sales of our common stock generally will not be subject
to tax if you have not held more than 5% of our common stock, actually or constructively, during the five-year period preceding such sale or other disposition of our common stock (or your holding
period, if shorter). If we are a USRPHC and either our common stock is not regularly traded on an established securities market or you hold, or are treated as holding, more than 5% of our outstanding
common stock, directly or indirectly, during the applicable testing period, you will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S.
trade or business, except that the branch profits tax generally will not apply. No assurance can be provided that our common stock will be regularly traded on an established securities market for
purposes of the rules described above. You are encouraged to consult your own tax advisors regarding the possible consequences to you if we are, or were to become, a USRPHC. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information returns are required to be filed with the IRS in connection with payments of dividends on our common stock. Unless you comply with
certification procedures to establish that you are not a U.S. person, information returns may also be filed with the IRS in connection with the proceeds from a sale or other disposition of our common
stock. You may be subject to backup withholding on payments on our common stock or on the proceeds from a sale or other disposition of our common stock unless the applicable withholding agent does not
have actual knowledge or reason to know that you are a U.S. person and you comply with certification procedures to establish that you are not a U.S. person or otherwise </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=167,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=768704,FOLIO='164',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<A NAME="page_es78701_1_165"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>establish
an exemption. Your provision of a properly executed applicable IRS Form&nbsp;W-8 certifying your non-U.S. status will permit you to avoid backup withholding, provided the applicable
withholding agent does not have actual knowledge or reason to know that you are a U.S. person. Amounts withheld under the backup withholding rules are not additional taxes and may be refunded or
credited against your U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FATCA  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, require withholding of 30% on payments of
dividends on our common stock, and, subject to the discussion of certain proposed Treasury Regulations below, gross proceeds of dispositions of our common stock, to "foreign financial institutions"
(which is broadly defined for this purpose and in general includes investment vehicles) and certain other non-U.S. entities unless various U.S. information reporting and due diligence requirements
(generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied, or an exemption applies. An intergovernmental agreement between the United States
and an applicable foreign country may modify these requirements. Under certain circumstances, you may be eligible for refunds or credits of such taxes. The U.S. Treasury recently released proposed
Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock.
In its preamble to such proposed Treasury Regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. You should consult
your tax adviser regarding the effects of FATCA on your investment in our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=168,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=460357,FOLIO='165',FILE='DISK106:[19ZAH1.19ZAH78701]ES78701A.;18',USER='JLAWRENA',CD='26-APR-2019;12:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_eu78701_1_166"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu78701_underwriters"> </A>
<A NAME="toc_eu78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for
whom Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Piper Jaffray&nbsp;&amp;&nbsp;Co. are acting as
representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Piper Jaffray&nbsp;&amp;&nbsp;Co.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the
obligations of the
several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other
conditions. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to
take or pay for the shares covered by the underwriters' option to purchase additional shares described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover of this prospectus and part to certain
dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share under the public offering price. After the initial offering of the shares of common stock, the
offering
price and other selling terms may from time to time be varied by the representatives. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted the underwriters an option for a period of 30&nbsp;days from the date of this prospectus to purchase up to an additional 750,000 shares of our common stock. To the
extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number
listed next to the underwriter's name in the preceding table bears to the total number of shares of common stock listed next to the names of all underwriters in the preceding table.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $35.0&nbsp;million
of shares of our common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not
binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares in this offering to any of these stockholders, or any of these stockholders may determine
to purchase more, fewer or no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these stockholders as they will on any other shares sold
to the public in this offering.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=169,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1027835,FOLIO='166',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_167"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per share and total public offering price, underwriting discounts and commissions and proceeds before expenses to us. These amounts are shown assuming both
no exercise and full exercise of the underwriters' option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per<BR>
Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No<BR>
Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Full<BR>
Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions to be paid by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $3.2&nbsp;million. We have agreed to reimburse the
underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority of up to $35,000.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have applied to list our common stock on the Nasdaq Global Market under the trading symbol "NXTC." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and all directors and officers and the holders of all of our outstanding stock and stock options have agreed that, without the prior written consent of the representatives, on behalf
of the underwriters, we and they will not, during the period ending 180&nbsp;days after the date of this prospectus, or the restricted period:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares
of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or
exercisable or exchangeable for shares of common stock; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the
common stock, </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;whether
any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees
that, without the prior written consent of the representatives, on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any
right with respect to, the registration of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
restrictions described in the immediately preceding paragraph to do not apply to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the sale of shares to the underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the issuance by us of shares of common stock upon the exercise of an option or a warrant or the conversion of a security outstanding on the
date of this prospectus of which the underwriters have been advised in writing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> transactions by any person other than us relating to shares of common stock or other securities acquired in open market transactions after the
closing of this offering; provided that no filing under Section&nbsp;16(a) of the Exchange Act is required or voluntarily made in connection with subsequent sales of the common stock or other
securities acquired in such open market transactions; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=170,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=108617,FOLIO='167',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_168"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> transfers of shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock (i)&nbsp;as
a bona fide gift or (ii)&nbsp;to any corporation, partnership, limited liability company, investment fund or other entity controlled or managed, or under common control or management by, the holder,
provided that, (a)&nbsp;each transferee shall sign and deliver a lock-up agreement and (b)&nbsp;no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in the beneficial
ownership of shares of common stock shall be required or shall be voluntarily made during the restricted period; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of common stock, provided
that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any,
is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such
plan during the restricted period. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representatives, in their joint discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock.
Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no
greater than the number of shares available for purchase by the underwriters under the option. The underwriters can close out a covered short sale by exercising the option or purchasing shares in the
open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available
under the option. The underwriters may also sell shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the
open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing
that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the
open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in
the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The
representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters that may make Internet distributions on the same basis as other allocations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and
expenses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively
trade debt and equity </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=171,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=56080,FOLIO='168',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_169"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short
positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make
investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or
short positions in such securities and instruments. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2> or subsection&nbsp;73.3(1) of the </FONT><FONT SIZE=2><I>Securities
Act</I></FONT><FONT SIZE=2> (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103 </FONT><FONT SIZE=2><I>Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I></FONT><FONT SIZE=2>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National
Instrument&nbsp;33-105 </FONT><FONT SIZE=2><I>Underwriting Conflicts</I></FONT><FONT SIZE=2> (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of
NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or each, a Relevant Member State,
an offer to the public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common
stock may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>to
any legal entity which is a qualified investor as defined in the Prospectus Directive;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>to
fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive,
subject to obtaining the prior consent of the representatives for any such offer; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock shall result
in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to any shares of our common stock in any Relevant Member State means the communication in any form
and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our common stock,
as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=172,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=427384,FOLIO='169',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_170"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>expression
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes
any relevant implementing measure in the Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each underwriter has represented and agreed that: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>it
has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment
activity within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or FSMA, received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>it
has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in,
from or otherwise involving the United Kingdom. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii)&nbsp;to "professional investors" within the meaning of the Securities and Futures Ordinance
(Cap.571, Laws of Hong Kong) and any rules made thereunder or (iii)&nbsp;in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance
(Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to shares of our common stock may be issued or may be
in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the
public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside
Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No registration pursuant to Article&nbsp;4, paragraph&nbsp;1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of
1948, as amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or
re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the
FIEL and the other applicable laws and regulations of Japan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


For Qualified Institutional Investors, or QII  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please note that the solicitation for newly issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the
FIEL) in relation to the shares of common stock constitutes either a "QII only private placement" or a "QII only secondary distribution" (each as described in Paragraph&nbsp;1, Article&nbsp;23-13
of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=173,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=148024,FOLIO='170',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_171"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Paragraph&nbsp;1,
Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred to QIIs. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


For Non-QII Investors  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please note that the solicitation for newly issued or secondary securities (each as described in Paragraph&nbsp;2, Article&nbsp;4 of the
FIEL) in relation to the shares of common stock constitutes either a "small number private placement" or a "small number private secondary distribution" (each as is described in Paragraph&nbsp;4,
Article&nbsp;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the
shares of common stock. The shares of common stock may only be transferred en bloc without subdivision to a single investor. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our common stock may not be circulated or distributed, nor may the shares of our
common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A),
and in accordance with the conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the
SFA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
shares of our common stock are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (i)&nbsp;a corporation (which is not an accredited investor) the
sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (ii)&nbsp;a trust (where the
trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that
corporation or the beneficiaries' rights and interest in that trust shall not be transferable for 6&nbsp;months after that corporation or that trust has acquired shares of our common stock under
Section&nbsp;275 except: (a)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or
to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (b)&nbsp;where no consideration is given
for the transfer; or (c)&nbsp;by operation of law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=174,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=721057,FOLIO='171',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<A NAME="page_eu78701_1_172"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu78701_legal_matters"> </A>
<A NAME="toc_eu78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of our common stock to be issued in this offering will be passed upon for us by our counsel, Hogan Lovells
US&nbsp;LLP, Baltimore, Maryland. As of the date of this prospectus, a partner of Hogan Lovells US&nbsp;LLP owns 37,342 shares of our common stock. Cooley&nbsp;LLP, New York, New York, is acting
as counsel for the underwriters in connection with this offering.

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu78701_experts"> </A>
<A NAME="toc_eu78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our financial statements at December&nbsp;31, 2018
and 2017, and for the years then ended, as set forth in their report. We have included our financial statements in this prospectus and elsewhere in the registration statement in reliance on
Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eu78701_where_you_can_find_more_information"> </A>
<A NAME="toc_eu78701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of common stock
offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules
filed therewith. For further information with respect to us and the common stock offered hereby, reference is made to the registration statement
and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration
statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration
statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address
is&nbsp;</FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the closing of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file
periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the website of the
SEC referred to above. We maintain a website at </FONT><FONT SIZE=2><I>www.nextcure.com</I></FONT><FONT SIZE=2>. Upon the closing of this offering, you may access our annual reports on
Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the
Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website
address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider the contents of our website in making an investment
decision with respect to our common stock.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=175,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=203044,FOLIO='172',FILE='DISK106:[19ZAH1.19ZAH78701]EU78701A.;24',USER='CHE106319',CD='26-APR-2019;01:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fa78701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fa78701_index_to_financial_statements"> </A>
<BR></FONT><FONT SIZE=2><B>  INDEX TO FINANCIAL STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<A NAME="FA78701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fc78701_report_of_independent___fc702287"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fc78701_report_of_independent___fc702287"><FONT SIZE=2>F-2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fe78701_nextcure,_inc._balance_sheets___nex02934"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fe78701_nextcure,_inc._balance_sheets___nex02934"><FONT SIZE=2><BR>
F-3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fg78701_nextcure,_inc._statements_of_o__nex04364"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Operations and Comprehensive Loss</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fg78701_nextcure,_inc._statements_of_o__nex04364"><FONT SIZE=2><BR>
F-4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fi78701_nextcure,_inc._statements_of_p__nex03919"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Preferred Stock and Stockholders' Deficit</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fi78701_nextcure,_inc._statements_of_p__nex03919"><FONT SIZE=2><BR>
F-5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fk78701_nextcure,_inc._stateme__fk702044"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fk78701_nextcure,_inc._stateme__fk702044"><FONT SIZE=2><BR>
F-6</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fm78701_nextcure,_inc._notes_to_financial_statements"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fm78701_nextcure,_inc._notes_to_financial_statements"><FONT SIZE=2><BR>
F-7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=176,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=904342,FOLIO='F-1',FILE='DISK106:[19ZAH1.19ZAH78701]FA78701A.;12',USER='CHE106319',CD='26-APR-2019;01:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fc78701_1_2"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fc78701_report_of_independent___fc702287"> </A>
<A NAME="toc_fc78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>To
the Stockholders and the Board of Directors of NextCure,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying balance sheets of NextCure,&nbsp;Inc. (the "Company") as of December&nbsp;31, 2018 and 2017, the related
statements of operations and comprehensive loss, preferred stock and stockholders' equity and cash flows for the years then ended and the related notes (collectively referred to as the "financial
statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2018 and 2017, and the results of its
operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


Ernst &amp;&nbsp;Young&nbsp;LLP

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


We have served as the Company's auditor since 2017.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


Tysons, VA<BR>
March&nbsp;5, 2019, except as to the seventh paragraph of Note 1, as to which the date is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019.


</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


The foregoing report is in the form that will be signed upon the completion of the reverse stock split described in the seventh paragraph of Note 1 to the financial statements.

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


/s/ Ernst &amp; Young LLP

</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


Tysons, VA<BR>
April&nbsp;29, 2019

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=177,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=233892,FOLIO='F-2',FILE='DISK106:[19ZAH1.19ZAH78701]FC78701A.;25',USER='WWASSER',CD='26-APR-2019;18:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fe78701_1_3"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fe78701_nextcure,_inc._balance_sheets___nex02934"> </A>
<A NAME="toc_fe78701_1"> </A></FONT> <FONT SIZE=2><B><BR>  NEXTCURE,&nbsp;INC.    <BR>    <BR>    BALANCE SHEETS    <BR>    <BR>    (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,427</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>860</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>152</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>133 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,785</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,420</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,407</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>436</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>147,628</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,467 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, Preferred Stock and Stockholders' Deficit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,483</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,141</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,564</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent, current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term loan, current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred revenue from related party, current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,989</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,124</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>295</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term loan, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred revenue from related party, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,349</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,879 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Preferred Stock, par value of $0.001 per share; 68,181,819 and 64,545,455 shares authorized at December 31, 2018 and 2017, respectively,
68,181,819 and 40,000,000 shares issued and outstanding at December 31, 2018 and 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B Preferred Stock, par value $0.001 per share; 56,828,852 and 0 shares authorized at December&nbsp;31, 2018 and 2017, respectively, 56,828,851
and 0 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>162,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' deficit:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, par value of $0.001 per share; 158,745,671 and 84,045,455 shares authorized as of December&nbsp;31, 2018 and 2017, respectively, 1,374,812
and 1,369,212 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(47,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(24,498</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(24,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, preferred stock and stockholders' deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>147,628</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,467 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=178,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=334574,FOLIO='F-3',FILE='DISK106:[19ZAH1.19ZAH78701]FE78701A.;16',USER='CHE109572',CD='25-APR-2019;23:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fg78701_1_4"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fg78701_nextcure,_inc._statements_of_o__nex04364"> </A>
<A NAME="toc_fg78701_1"> </A></FONT> <FONT SIZE=2><B><BR>  NEXTCURE,&nbsp;INC.    <BR>    <BR>    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    <BR>    <BR>    (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,954</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,409</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,595 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,549 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
80 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=179,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1015067,FOLIO='F-4',FILE='DISK106:[19ZAH1.19ZAH78701]FG78701A.;14',USER='WWASSER',CD='26-APR-2019;12:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fi78701_1_5"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fi78701_nextcure,_inc._statements_of_p__nex03919"> </A>
<A NAME="toc_fi78701_1"> </A></FONT> <FONT SIZE=2><B><BR>  NEXTCURE,&nbsp;INC.    <BR>    <BR>    STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' DEFICIT    <BR>    <BR>    (in thousands, except share data)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stockholders' Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B><BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-in<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stockholders'<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1> Balance as of December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(9,029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(9,018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;A-2 preferred stock, net of issuance costs of $0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(24,498</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(24,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series A-3 preferred stock, net of issuance costs of $0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,181,819</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>31,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series B preferred stock, net of issuance costs of $485</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,828,851</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,181,819</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,828,851</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
1,374,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(47,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(46,944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=180,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=762912,FOLIO='F-5',FILE='DISK106:[19ZAH1.19ZAH78701]FI78701A.;34',USER='CHE111663',CD='25-APR-2019;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fk78701_1_6"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fk78701_nextcure,_inc._stateme__fk702044"> </A>
<A NAME="toc_fk78701_1"> </A></FONT> <FONT SIZE=2><B><BR>  NEXTCURE,&nbsp;INC.    <BR>    <BR>    STATEMENTS OF CASH FLOWS    <BR>    <BR>    (in thousands)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash flows from operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash provided by (used) in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,677</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>767</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>847</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,557</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred revenue from related party</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used) in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,514</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash flows from investing activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchase of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,063</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,652</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,063</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,652</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash flows from financing activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of preferred stock, net of issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>122,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payments of the term loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred financing costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(410</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>121,417</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,860 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase in cash, cash equivalents and restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,694</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash&#151;beginning of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,593 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash&#151;end of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>135,633</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,287 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Supplemental disclosures of cash flow information:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for interest</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for income taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Supplemental disclosures of noncash investing and financing activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchase of property and equipment included in accrued liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>515</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred financing costs in accrued liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=181,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=862234,FOLIO='F-6',FILE='DISK106:[19ZAH1.19ZAH78701]FK78701A.;10',USER='CHE106319',CD='26-APR-2019;01:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fm78701_1_7"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fm78701_nextcure,_inc._notes_to_financial_statements"> </A>
<A NAME="toc_fm78701_1"> </A></FONT> <FONT SIZE=2><B><BR>  NEXTCURE,&nbsp;INC.    <BR>    <BR>    NOTES TO FINANCIAL STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of the Business and Basis of Presentation  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Organization  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NextCure,&nbsp;Inc. ("NextCure" or the "Company") was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland.
The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring
normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology ("FIND-IO") platform, the Company studies various immune cells in order to discover and
understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts
and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company's product
candidates, building and optimizing the Company's manufacturing capabilities and conducting discovery, research and development activities for the Company's product candidates, discovery programs and
its FIND-IO platform. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks and Uncertainties  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited
operating history and no products approved for commercial sale; having a history of significant losses; our need to obtain additional financing; dependence on its ability to advance its current and
future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company's FIND-IO
platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the
results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization
and with its manufacturing facility; risks related to patent protection and our pending patent applications; dependence on third-party collaborators for the discovery, development and
commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company's business efforts will require
significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's development efforts are successful, it is uncertain
when, if ever, the Company will realize significant revenue from product sales. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. As of the issuance date of the
financial statements for the year ended December&nbsp;31, 2018, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure
requirements through at least two years from the issuance date of the financial statements. The future viability of the Company beyond that date is dependent on its ability to raise additional capital
to finance its operations. On April&nbsp;5, 2018, the Company issued 28,181,819 shares of Series&nbsp;A-3 Preferred Stock at an issuance price of $1.10 per share for cash proceeds of
$31.0&nbsp;million (Note&nbsp;9). On November&nbsp;5, 2018, the Company entered into a Series&nbsp;B Preferred Stock Purchase Agreement and issued 15,052,117 shares of Series&nbsp;B-1
Preferred Stock at an issuance price of $1.59 per share, 34,276,734 shares of Series&nbsp;B-2 Preferred Stock at an issuance price of $1.59 per share and 7,500,000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=182,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=504997,FOLIO='F-7',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_8"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of the Business and Basis of Presentation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>shares
of Series&nbsp;B-3 Preferred Stock at an issuance price of $2.00 per share for aggregate cash proceeds of $93.4&nbsp;million (Note&nbsp;9). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic
alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other
arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the
Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business
prospects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company,
if at all, to fund continuing operations past two years from the issuance date of these financial statements. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying financial statements include the accounts of the Company. The Company's financial statements have been prepared in accordance
with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting
Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reverse Stock Split

 </I></B></FONT>

</P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company intends to effect a 1-for-8.0338 reverse stock split of its outstanding common stock prior to the effectiveness of the registration
statement pursuant to which the Company intends to effect its initial public offering. The par value and authorized shares of common stock will not be adjusted as a result of the reverse stock split.
All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as
of all dates presented.

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, revenue recognition, the valuation of
equity-based compensation, including incentive stock options, common stock and restricted common stock, as well as income taxes. The Company bases its estimates on various assumptions that the Company
believes to be reasonable under the circumstances. Actual results could differ from those estimates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment and Geographic Information  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=183,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=833044,FOLIO='F-8',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of the Business and Basis of Presentation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>how
to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and Cash Equivalents  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Cash  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its Term Loan
(Note&nbsp;8) equal to the principal portion on a quarterly basis. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required reserve totaled $460,000 as of
December&nbsp;31, 2018. This amount is presented as restricted cash on the accompanying balance sheet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,173</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,427</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>860 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,633</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,287 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentration of Credit Risk  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The
Company maintains its cash and cash equivalents at one accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual
credit risk beyond the normal credit risk associated with commercial banking relationships. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair Value of Financial Instruments  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC Topic 820, </FONT><FONT SIZE=2><I>Fair Value Measurement</I></FONT><FONT SIZE=2> ("ASC 820"), establishes a fair value hierarchy for
instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs
that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's
assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies
fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
As a basis for considering market participant </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=184,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=875495,FOLIO='F-9',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>assumptions
in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&#151;Quoted
market prices in active markets for identical assets or liabilities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&#151;Inputs
other than Level&nbsp;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&#151;Unobservable
inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the
degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument's level within the fair value hierarchy is based
on the lowest level of any input that is significant to the fair value measurement. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property and Equipment, Net  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are recorded at cost. Depreciation is computed over the estimated useful lives of the related assets using the
straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related
accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and
comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated
useful lives for property and equipment are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="308pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Useful Life </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Computers and peripherals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>Lesser of estimated useful life or remaining lease term</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Construction in Progress  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction in progress (Note&nbsp;4) is carried at cost and consists of specifically identifiable direct and indirect development and
construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the
appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of Long-Lived Assets  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the
carrying value of the asset group may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset group from the expected future cash
flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such asset group, an impairment loss for the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=185,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=671358,FOLIO='F-10',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>difference
between the estimated fair value and carrying value is recorded. There was no impairment loss recognized during the years ended December&nbsp;31, 2018 or 2017. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's preferred stock is classified outside of stockholders' deficit because the shares contain deemed liquidation rights that are a
contingent redemption feature not solely within the control of the Company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Costs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenditures, including payroll, contractor expenses and supplies, for research and development of products are expensed as incurred.
Development costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements,
the milestone payment obligations are expensed when the milestone results are probable of being achieved. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Costs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty
about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </FONT><FONT SIZE=2><I>Compensation-Stock
Compensation</I></FONT><FONT SIZE=2> ("ASC 718"). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock
options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations
and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model ("Black-Scholes") for stock option
grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recognizes forfeitures as they occur as allowed by ASU No.&nbsp;2016-09, </FONT><FONT SIZE=2><I>Improvements to Employee Share-Based Payment
Accounting</I></FONT><FONT SIZE=2> ("ASU&nbsp;2016-09"). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&nbsp;the expected stock price volatility, (ii)&nbsp;the expected term of
the award, (iii)&nbsp;the risk-free interest rate and (iv)&nbsp;expected dividends. Due to the lack of a public market for the Company's common stock and lack of company-specific historical and
implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the
Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The
Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does
not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=186,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=169942,FOLIO='F-11',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_12"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>expected
term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its
employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a
treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current
plans to pay any dividends on its common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are significant judgments and estimates inherent in the determination of the fair value of the Company's common stock. These estimates and assumptions include a number of objective
and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common
stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the
estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax
assets and liabilities, which relate primarily to the carrying amount of the Company's property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets
and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that
the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating
results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has
recorded a full valuation allowance against its deferred tax assets. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reserves
are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be
sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the
provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue Recognition  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted ASC Topic&nbsp;606, Revenue from Contracts with Customers ("ASC 606"). Under ASC&nbsp;606, an entity recognizes
revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To
determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&nbsp;606, the Company performs the following five steps:
(i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=187,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=373697,FOLIO='F-12',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>promised
goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&nbsp;measurement of the transaction price, including the constraint
on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations; and (v)&nbsp;recognition of revenue when (or as) the Company satisfies each performance
obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it
transfers to the customer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company evaluates customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to
represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&nbsp;the customer can
benefit from the good or service on its own or together with other readily available resources and (ii)&nbsp;the promised good or service is separately identifiable from other promises in the
contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the
customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services
in the contract. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. Consideration generally may
include fixed consideration or variable consideration. Should an arrangement include variable consideration, the Company will evaluate the amount of potential payments and the likelihood that the
payments will be received. The Company will utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts
the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and will be included in the transaction price only to the extent
that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's contracts may include development and regulatory milestone payments which would be assessed under the most likely amount method and constrained if it is probable that a
significant revenue reversal would occur. Milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, will not be considered probable of being
achieved until those approvals are received. At the end of each reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint,
and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period
of adjustment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties
relate, the Company will recognize revenue at the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated
has been satisfied (or partially satisfied). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require
judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for
service obligations, which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=188,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=481649,FOLIO='F-13',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>may
include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the
Company may reference comparable transactions, clinical trial success probabilities and estimates of option exercise likelihood. Variable consideration will be allocated specifically to one or more
performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the
amounts the Company would expect to receive for the satisfaction of each performance obligation. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which
consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied
over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the
measure of performance and related revenue recognition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upfront
payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts expected to be recognized
as revenue within the 12&nbsp;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to
be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts are recorded as accounts receivable when the
Company's right to consideration is unconditional. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive Loss  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company did not have any other comprehensive income or loss for any of the periods presented and, therefore, comprehensive loss did not
differ from net loss. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss per Share  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required
for participating securities. The Company considers its Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock to be participating securities because in the event a dividend is paid on
common stock, the holders of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock would be entitled to receive dividends on a basis consistent with the common stockholders. Under the
two-class method, the net loss attributable to common stockholders is not allocated to the preferred stock as the holders of the preferred stock do not have a contractual obligation to share in
losses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average
number of shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently Adopted Accounting Pronouncements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the FASB issued ASU&nbsp;No.&nbsp;2016-08, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers (Topic&nbsp;606):
Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</I></FONT><FONT SIZE=2> ("ASU 2016-08"), which clarified the revenue recognition implementation guidance on principal versus
agent considerations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=189,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=807754,FOLIO='F-14',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>In
April 2016, the FASB issued ASU No.&nbsp;2016-10, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and
Licensing</I></FONT><FONT SIZE=2> ("ASU 2016-10"), which clarified the revenue recognition guidance regarding the identification of performance obligations and the licensing implementation. In May
2016, the FASB issued ASU No.&nbsp;2016-12, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</I></FONT><FONT SIZE=2>
("ASU 2016-12"), which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition. ASU No.&nbsp;2016-08, ASU
No.&nbsp;2016-10 and ASU 2016-12 are effective during the same period as ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2> ("ASU
2014-09"), which is effective for the Company for fiscal years beginning after December&nbsp;15, 2018 and interim periods within fiscal years beginning after December&nbsp;15, 2019. Early adoption
is permitted. The Company adopted ASU 2016-08, ASU 2016-10, ASU&nbsp;2016-12 and ASU&nbsp;2014-09 as of January&nbsp;1, 2018 on a retrospective basis. There was no revenue in previous years and
the adoption of ASC&nbsp;606 did not have any impact on prior year financial statements. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2016, the FASB issued ASU No.&nbsp;2016-15, </FONT><FONT SIZE=2><I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments</I></FONT><FONT SIZE=2> ("ASU 2016-15"). ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or
extinguishment costs, the maturing of a zero-coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain
equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate
certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods
presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively applied as of the earliest date practicable. ASU 2016-15 is
effective for the Company for fiscal years beginning after December&nbsp;15, 2018 and interim periods within fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted. The
Company adopted ASU&nbsp;2016-15 as of January&nbsp;1, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2016, the FASB issued ASU No.&nbsp;2016-18, </FONT><FONT SIZE=2><I>Statement of Cash Flows (Topic 230): Restricted Cash</I></FONT><FONT SIZE=2> ("ASU&nbsp;2016-18'),
which requires that a statement of cash flows explain the change during the period in the total cash, cash equivalents and amounts generally described as restricted cash or restricted cash
equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning and ending
balances shown on the statement of cash flows. The guidance is effective for the Company for fiscal years beginning after December&nbsp;15, 2018 and interim periods within fiscal years beginning
after December&nbsp;15, 2019. Early adoption is permitted. The Company adopted ASU&nbsp;2016-18 as of January&nbsp;1, 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the FASB issued ASU No.&nbsp;2017-09, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification
Accounting</I></FONT><FONT SIZE=2> ("ASU 2017-09"), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance,
modification accounting is required only if the fair value, the vesting conditions, or the
classification of the award (as equity or liability) changes as a result of the change in terms or conditions of the agreement. The standard is effective for fiscal years, and interim periods within
those years, beginning after December&nbsp;15, 2017. The Company adopted ASU 2017-09 as of the required effective date of January&nbsp;1, 2018. In June&nbsp;2018, the FASB issued ASU
No.&nbsp;2018-07 </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I></FONT><FONT SIZE=2> ("ASU
No.&nbsp;2018-07"). ASU No.&nbsp;2018-07 expands the guidance in ASC718 to include share-based payments for goods and services to non-employees </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=190,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=21806,FOLIO='F-15',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
generally aligns it with the guidance for share-based payments to employees. The amendments are effective for the Company for fiscal years beginning after December&nbsp;15, 2019 and interim
periods within fiscal years beginning after December&nbsp;15, 2020, with early adoption permitted for entities that have adopted ASC&nbsp;606. The Company adopted this new standard on
January&nbsp;1, 2018. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently Issued Accounting Pronouncements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February&nbsp;2016, the FASB issued ASU No.&nbsp;2016-02, </FONT><FONT SIZE=2><I>Leases</I></FONT><FONT SIZE=2> ("ASU 2016-02"). The new
guidance requires lessees to record most leases on their balance sheets and recognize the related expenses on their income statements in a manner similar to current practice. ASU&nbsp;2016-02 states
that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is
effective for the Company for fiscal years beginning after December&nbsp;15, 2019 and interim periods fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted. The Company
is currently evaluating the effect of this standard on its financial statements. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Fair Value of Financial Instruments  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the fair value of the Company's financial assets by level within the fair value hierarchy (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value Measurement Based on </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Assets

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Carrying<BR>
Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Quoted Prices in<BR>
Active Markets<BR>
(Level&nbsp;1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Significant<BR>
Other<BR>
Observable<BR>
Inputs (Level&nbsp;2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Significant<BR>
Unobservable<BR>
Inputs (Level&nbsp;3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds (cash equivalents)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value Measurement Based on </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Assets

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Carrying<BR>
Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Quoted Prices in<BR>
Active Markets<BR>
(Level&nbsp;1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Significant<BR>
Other<BR>
Observable<BR>
Inputs (Level&nbsp;2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Significant<BR>
Unobservable<BR>
Inputs (Level&nbsp;3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds (cash equivalents)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company did not transfer any assets measured at fair value on a recurring basis to or from Level&nbsp;1 during the years ended December&nbsp;31, 2018 and 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=191,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=495689,FOLIO='F-16',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Property and Equipment, Net  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consist of the following (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,787</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,825</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>111</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Construction in progress</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,892 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, gross</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,876</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,407</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,021 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction
in progress at December&nbsp;31, 2018 consists of the costs incurred for research equipment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
and amortization expense was $1.7&nbsp;million and $582,000 for the years ended December&nbsp;31, 2018 and 2017, respectively. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Accrued Liabilities  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities consist of the following (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued construction in progress</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>515</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued payroll and related benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>493</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued clinical trial costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>271</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>719</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued financing costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>284</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued office lease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,411</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,564 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Agreement with Eli Lilly and Company  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the "Lilly Agreement") with Eli Lilly and Company ("Lilly"), pursuant to
which the Company will use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Under the Lilly
Agreement, Lilly and the Company have granted one another an equal number of exclusive options to research, develop, manufacture and commercialize compounds and products directed to oncology targets
identified through the Lilly Agreement. Both Lilly and the Company each have all options remaining eligible for exercise. The research collaboration with Lilly will be managed by a joint steering
committee formed by an equal number of members from the Company and Lilly and will expire upon the earlier of the exercise of all options granted to Lilly or four years from the date of the agreement,
subject to certain extensions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=192,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=407720,FOLIO='F-17',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<A NAME="page_fm78701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Agreement with Eli Lilly and Company (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the research term under the Lilly Agreement, as a part of target discovery, the Company will be responsible for providing Lilly with oncology targets identified using the
Company's FIND-IO platform. From the targets provided by the Company, Lilly may select targets to advance to target validation using criteria developed by both parties. Following completion of the
agreed upon target validation plan with respect to a given target, either party may propose to advance that target to compound discovery. For each target that has been advanced to compound discovery,
Lilly will have the option to obtain an exclusive license with respect to the compounds and products directed to the target. If Lilly does not exercise its option with respect to a given target or has
previously exercised all of its options, the Company will have the option to obtain licenses with respect to compounds and products directed to that target. Following option exercise by a party, the
development and commercialization of any products directed to the target will be conducted by the exercising party. The exercising party must use commercially reasonable efforts to develop, seek
regulatory approval for and commercialize any such products under mutually agreed upon work plans. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company received an upfront, non-refundable payment of $25.0&nbsp;million under the Lilly Agreement and a concurrent $15.0&nbsp;million equity investment (Note&nbsp;9). In
addition, the Company will receive quarterly research and development support payments during a portion of the research term as well as option exercise fees upon option exercises by Lilly. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Lilly Agreement, Lilly will owe an aggregate of up to $1.4&nbsp;billion in development and regulatory milestones and sales milestones. Additionally, Lilly will pay mid
to high single-digit royalties on net sales for all products directed to each target optioned by Lilly. Upon the Company's exercise of an option with respect to a given target, the Company will pay
Lilly option exercise, milestone and royalty payments. The company will owe an aggregate of up to $710.0&nbsp;million in development and regulatory milestones and sales milestones. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
company has evaluated the Lilly Agreement under ASC&nbsp;606. Two performance obligations were identified as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> research and development services; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> material right related to an optional term extension by Lilly. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Lilly Agreement was executed in November 2018, however, the performance obligations were initiated in January 2019; accordingly no revenue was recorded under the Lilly Agreement in
2018. As of December&nbsp;31, 2018, deferred revenue included in the Company's balance sheets in connection with the Lilly Agreement was $26.7&nbsp;million, which consisted of the $25.0 million
upfront payment plus $1.7&nbsp;million attributed as a premium on the proceeds from Lilly's equity investment in the Company (Note&nbsp;9). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Commitments and Contingencies  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating Leases  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company subleases its facilities under a non-cancelable operating sublease agreement. The sublease commenced on February&nbsp;9, 2016 and
expires on August&nbsp;31, 2025. The Company is also responsible for its prorated share of the sublandlord's operating expense. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=193,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=552034,FOLIO='F-18',FILE='DISK106:[19ZAH1.19ZAH78701]FM78701A.;47',USER='WWASSER',CD='26-APR-2019;12:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_fo78701_1_19"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Commitments and Contingencies (Continued)  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The future minimum payments for the operating leases are as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Year Ending December&nbsp;31,

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>325</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>317</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>635 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total future minimum payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,275 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent
expense incurred under operating leases was approximately $420,000 and $376,000 for the years ended December&nbsp;31, 2018 and 2017, respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contingencies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a
liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and
the estimated amount. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been
incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better
estimate than any other amount within the range, the minimum amount in the range is accrued. As of December&nbsp;31, 2018 and 2017, the Company was not involved in any material legal proceedings. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Term Loan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2016, the Company entered into a $1.0&nbsp;million term loan (the "Term Loan"). The Term Loan bears interest at the prime rate less 1%. The interest rate in effect was 4.5%
and 3.5% for the years ended December&nbsp;31, 2018 and 2017, respectively. The Term Loan is secured by all certificates of deposit, money market accounts, cash, securities, investment property and
deposit or investment accounts. The Term Loan requires monthly payments of interest only before May 2017, and equal monthly payments of principal and interest thereafter, as defined in the agreement.
Interest expense under the Term Loan was approximately $25,000 and $30,000 for the years ended December&nbsp;31, 2018
and 2017, respectively. The outstanding balance on the Term Loan totaled $460,000 as of December&nbsp;31, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=194,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=98967,FOLIO='F-19',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_20"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Term Loan (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future
maturities of the Term Loan as of December&nbsp;31, 2018 are as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>387</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: current portion of term loan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>387 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Term loan, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Preferred Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, the Company's certificate of incorporation, as amended and restated, authorized the Company to issue 125,010,671 shares of $0.001 par value preferred
stock. The Company's preferred stock is classified outside of stockholders' deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the
control of the Company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series A Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, the Company has issued 68,181,819 shares of Series&nbsp;A Preferred Stock as follows: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2015, the Company issued 15,000,000 shares of Series&nbsp;A-1 Preferred Stock at an issuance price of $1.00 per share for cash proceeds of $15.0&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017, the Company issued 25,000,000 shares of Series&nbsp;A-2 Preferred Stock at an issuance price of $1.00 per share for cash proceeds of $25.0&nbsp;million. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2018, the Company issued 28,181,819 shares of Series A-3 Preferred Stock at an issuance price of $1.10 per share for cash proceeds of approximately $31.0&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series B Preferred Stock  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, the Company has issued 56,828,851 shares of Series&nbsp;B Preferred Stock as follows: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2018, the Company issued 15,052,117 and 34,276,734 shares of Series&nbsp;B-1 Preferred Stock and Series&nbsp;B-2 Preferred Stock, respectively, at an issuance price of
$1.59 per share for aggregate cash proceeds of approximately $78.4&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with the issuance of the Series B-1 Preferred Stock and Series&nbsp;B-2 Preferred Stock, in November 2018, the Company issued 7,500,000 shares of Series&nbsp;B-3 Preferred
Stock at an issuance price of $2.00 per share for cash proceeds of $15.0&nbsp;million in connection with the execution of the Collaboration Agreement with Lilly. The Company allocated
$13.3&nbsp;million of the proceeds to Series&nbsp;B-3 Preferred Stock and $1.7&nbsp;million to deferred revenue. The $1.7 million was determined to be a premium over the fair value of the
Series&nbsp;B-3 Preferred Stock and attributed as additional consideration of the Collaboration Agreement (Note&nbsp;6). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimated the premium of the Series&nbsp;B-3 Preferred Stock based on a valuation of the Company's preferred stock prepared by an unrelated third-party valuation firm in
accordance with the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=195,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=844299,FOLIO='F-20',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_21"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Preferred Stock (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>guidance
provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The $1.7&nbsp;million
premium on the Series&nbsp;B-3 Preferred Stock will be recognized as revenue on a proportional performance basis over the term of the Collaboration Agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's Preferred Stock has the following rights and preferences, privileges and restrictions: </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Preferred Stock are entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration
or payment of any dividend on the common stock, on an as-converted basis when, as and if declared by the Board of Directors. As of December&nbsp;31, 2018, no dividends have been declared. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Preferred Stock represents such number of votes as is equal to the number of shares of common stock into which such share is
convertible. The holders of Preferred Stock vote together with the holders of common stock on an as-converted basis on all matters in which stockholders are entitled to vote. The holders of
Series&nbsp;A Preferred Stock, exclusively and as a separate class, are entitled to elect five directors, the holders of the Series&nbsp;B Preferred Stock, exclusively and as a separate class, are
entitled to elect two directors of the Company as of December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of the Preferred Stock are entitled to convert each share into 0.1245&nbsp;shares of common stock on demand. The Preferred Stock
is mandatorily convertible upon the closing of a qualified public offering in which gross proceeds to the Company of not less than $75.0&nbsp;million or on the date specified by a majority vote of
the outstanding shares of Preferred Stock voting on an as-converted basis.

</FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation Preference  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of the Company's Series B
Preferred Stock are entitled to receive, before any payment of any of the assets of the Company to the holders of the Series A Preferred Stock and holders of common stock, $12.77&nbsp;per share with
respect to shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock and $16.07 per share with respect to shares of Series B-3 Preferred Stock (as adjusted for any stock dividend, stock
split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of
common stock, the holders of Series&nbsp;A Preferred Stock are entitled to receive $8.03&nbsp;per share with respect to shares of Series&nbsp;A-1 Preferred Stock and Series&nbsp;A-2 Preferred
Stock and $8.84 per share with respect to shares of Series&nbsp;A-3 Preferred Stock (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but
unpaid dividends).

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=196,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=836734,FOLIO='F-21',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2018, the Company's Certificate of Incorporation, as amended and restated, authorized the Company to issue 158,745,671 shares of $0.001 par value common stock,
of which 1,374,812 were issued and outstanding.

 </FONT>

</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are entitled to receive dividends, as may
be declared by the board of directors, if any, subject to the preferential dividend rights of the preferred stock. When dividends are declared on shares of common stock, the Company must declare at
the same time a dividend payable to the holders of preferred stock equivalent to the dividend amount they would receive if each share of preferred stock was converted into common stock. The Company
may not pay dividends to common stockholders until all dividends accrued or declared but unpaid on the preferred stock have been paid in full. No dividends have been declared or paid by the Company
through December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after
the payment of the full liquidation preference for the preferred stock. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Stock-Based Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Omnibus Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The NextCure,&nbsp;Inc. 2015 Omnibus Incentive Plan (the "2015 Plan") provides for the Company to grant incentive stock options or
nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company. The 2015&nbsp;Plan is administered by
the board of directors, or at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion
of the board of directors or its committee if so delegated, except that the exercise price per share of the stock options may not be less than 100% of the fair market value of
a share of the Company's common stock on the date of grant and the term of the stock options may not be greater than 10&nbsp;years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the 2015 Plan, the Company had initially reserved on December&nbsp;29, 2015, 311,185 shares of common stock, which number of shares was automatically increased pursuant to the
terms of the 2015&nbsp;Plan by 373,422 as of the second closing of the Series&nbsp;A Preferred Stock financing on January&nbsp;24, 2017. The total number of shares of common stock that may be
issued under the 2015 Plan was 2,824,317 as of December&nbsp;31, 2018. As of December&nbsp;31, 2018, there were 2,056,891&nbsp;stock options and 62,237&nbsp;shares of registered stock
outstanding and 699,590&nbsp;shares of common stock available for future issuance under the 2015 Plan.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
options granted under the 2015 Plan generally vest over four years and expire after 10&nbsp;years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
exercise price for stock options granted is not less than the fair value of common shares as determined by the board of directors as of the date of grant. The board of directors
determines the value the Company's common stock taking into consideration the most recently available third-party valuation of common shares, as well as additional factors, which may have changed
since the date of the most recent contemporaneous valuation through the date of grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=197,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=708667,FOLIO='F-22',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Stock-Based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of stock option activity for awards under the 2015 Plan is presented below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Outstanding and Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value<SUP>(1)</SUP><BR>
(in thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Outstanding as of January&nbsp;1, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>189,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>317,397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>506,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,570,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.92</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,599</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeitures</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of December 31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,056,891</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,946 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,056,891</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable as of December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>242,079</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,634</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock
for the options that were in the money at December&nbsp;31, 2018 and 2017.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted average grant date fair value per share of stock options granted during the years ended December&nbsp;31, 2018 and 2017 was $3.80 and $0.94, respectively. The aggregate
intrinsic value of stock options exercised during the years ended December&nbsp;31, 2018 and 2017 was $38,000 and $0, respectively.

 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate grant date fair value of stock options and restricted stock vested during the year ended December&nbsp;31, 2018 and 2017 was approximately $157,000 and $29,000,
respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded stock-based compensation expense of $263,000 and $75,000 during the years ended December&nbsp;31, 2018 and 2017,
respectively. As of December&nbsp;31, 2018, there was $6.0&nbsp;million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the 2015 Plan.
This remaining compensation expense is expected to be recognized over a weighted average period of three&nbsp;years as of December&nbsp;31, 2018. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>178</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=198,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=972798,FOLIO='F-23',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Stock-Based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.1 years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Common Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2016, the Company issued 62,237 shares of restricted common stock from the 2015 Plan, which are restricted as to sale or transferability.
These restrictions lapse over a four-year period.

 </FONT>

</P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Net Loss Per Share Attributable to Common Stockholders  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share
amounts): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(22,799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of common shares, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,369,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per common share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's potential dilutive securities, which include preferred stock and common stock options, have been excluded from the computation of diluted net loss per share as the effect
would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.
The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders
for the period indicated because including them would have had an anti-dilutive effect: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,560,569</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,978,957</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>242,079</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,802,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,043,746</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=199,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=578991,FOLIO='F-24',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 U.S. Tax Reform  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;22, 2017, the U.S. government signed into law the Tax Cuts and Jobs Act (the "Tax Act") that significantly reforms the
Internal Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate
of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018; limitation of the tax deduction for interest expense; limitation of the deduction for net operating losses to 80% of annual
taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such tax losses may be carried
forward indefinitely); and modifying or repealing many business deductions and credits, including reducing the business tax credit for certain clinical testing expenses incurred in the testing of
certain drugs for rare diseases or conditions generally referred to as "orphan drugs". </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2018, the Company finished its analysis of the impact of the Tax Act. Where the Company made reasonable estimates in 2017 of the effects related to the Tax Act, the Company recorded
provisional amounts. After the completed analysis, the resulting impact to the Company's financial statements did not differ from the recorded provisional amounts. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The reconciliation of federal statutory income tax rate to the Company's effective income tax rate is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected income tax benefit at the federal statutory rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State taxes, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development credit, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-deductible items</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prior year provision to return adjustments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax rate reduction due to the Tax Act</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for
income tax purposes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=200,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=717993,FOLIO='F-25',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_26"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal components of the Company's deferred tax assets consisted of the following as of December&nbsp;31, 2018 and 2017 (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal and state net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,176</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development tax credits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,393</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,283</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charitable contribution carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>165</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,817</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,751</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,491</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(260</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross deferred tax liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(260</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Company's history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&nbsp;31, 2018. The Company increased its
valuation allowance by approximately $8.0&nbsp;million for the year ended December&nbsp;31, 2018.The Company intends to maintain a valuation allowance until sufficient positive evidence exists to
support a reversal of the allowance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, the Company had federal and state net operating loss carryforwards of $43.5&nbsp;million and $43.0&nbsp;million, respectively, some of which begin to
expire in the year ending December&nbsp;31, 2036. Approximately $20.8&nbsp;million of the federal and state net operating loss carryforwards do not expire. The Company had federal and state
research and development tax credit carryforwards
of approximately $2.5&nbsp;million and $1.1&nbsp;million, respectively, as of December&nbsp;31, 2018. The federal credits begin to expire in the year ending December&nbsp;31, 2036 and the
state credits begin to expire in the year ending December&nbsp;31, 2024. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the provisions of Sections&nbsp;382 and 383 of the Internal Revenue Code (the "IRC"), net operating loss and credit carryforwards and other tax attributes may be subject to
limitation if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts, including an initial public offering, could result in limitations
on net operating loss and credit carryforwards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax years 2015 to 2017 remain open to examination by the major jurisdictions in which
the Company are subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been
carried forward and may be audited in subsequent years when utilized. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=201,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=628101,FOLIO='F-26',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest
amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of
December&nbsp;31, 2018, the Company had no unrecognized income tax benefits that would affect the Company's effective tax rate if recognized. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. Employee Benefit Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company sponsors a 401(k) plan that stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory
maximum or 100% of eligible compensation on a pre-tax basis. Through December&nbsp;31, 2018, the Company has not provided any contributions to this plan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. Related Party Transactions  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lilly Agreement  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, the Company entered into the Lilly Agreement with a stockholder of the Company, Lilly, pursuant to which the Company will use
its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Lilly provided to the Company a cash upfront
payment of $25.0&nbsp;million upon entering into the Collaboration Agreement and made a concurrent $15.0&nbsp;million equity investment in the Company (Note&nbsp;6 and Note&nbsp;9). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consulting Agreement with Scientific Founder  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2015, the Company entered into a consulting agreement for scientific advisory services with a founder of the Company (the
"Scientific Founder"), who is also a stockholder of the Company. The term of the consulting agreement expires December&nbsp;31, 2020. Under the agreement, the Scientific Founder is entitled to
receive $5,000&nbsp;per month in consulting fees until the expiration of the agreement. As of December&nbsp;31, 2018, the amount due under this agreement is $120,000. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Yale License Agreement and Sponsored Research Agreement  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2015, the Company entered into a license agreement with Yale University (the "Yale Agreement"), which is also a stockholder of the
Company. Under the Yale Agreement, the Company obtained a license to products that either incorporate certain licensed patents used in the discovery of targets or arise out of research and development
of the Scientific Founder's laboratory at Yale, including a proprietary target. The Company is obligated to pay Yale low single-digit royalties on sales of products that are either covered by the
patents licensed to the Company under the Yale Agreement or arise out of the Scientific Founder's laboratory, subject to minimum annual royalty payments in the low to mid hundreds of thousands of
dollars, an annual license maintenance fee in the mid to high tens of thousands of dollars and milestone payments of up to $3.0&nbsp;million per product. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Yale Agreement, the Company also entered into the Corporate Sponsored Research Agreement with Yale (the "SRA"), in which the Company agreed to provide an aggregate
of up to $12.4&nbsp;million to fund a research program aimed at discovering new targets for immunomedicines.
The research program is under the direction and supervision of the Scientific Founder. As of December&nbsp;31, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=202,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=585699,FOLIO='F-27',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<A NAME="page_fo78701_1_28"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
NEXTCURE,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. Related Party Transactions (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>2018,
the Company has made payments in an aggregate of $7.4&nbsp;million under the SRA, including $2.5&nbsp;million and $2.1&nbsp;million in the years ended December&nbsp;31, 2018 and 2017,
respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


16. Subsequent Events  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has evaluated subsequent events through March&nbsp;5, 2019. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
January&nbsp;25, 2019, the Company amended its Term Loan to an aggregate principal amount of $5.0&nbsp;million, which remains secured by the Company's certificates of deposit,
money market account, investment property and deposit or investment accounts. As amended, the Term Loan bears interest at the greater of the prime rate less 1% and 4.25%. Under the agreement, the
Company is required to make monthly interest-only payments through January 2020 and is required to make 36 equal monthly payments of principal plus accrued interest thereafter through January 2023. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
January&nbsp;30, 2019, the Company entered into a new lease for 14,075 square feet to be used for office, manufacturing and laboratory space, which the Company expects to take
possession of in June 2019. The new lease is expected to expire in March 2030 and will also cover the Company's existing space after expiration of the Company's current lease. Base rent for the first
10&nbsp;months is abated, after which the base rent of the lease is $19,650 per month, with an increase in annual rent of 3.0% in each subsequent year of the lease term. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


17. Subsequent Event (Unaudited)  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;15, 2019, the Company entered into an amended and restated lease that covers the Company's existing space plus additional square footage to be used as office space, which
the Company took possession of upon entering into the amended and restated lease. The amended and restated lease expires in August 2025. The total remaining commitment under the amended and restated
lease is approximately $3.0&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=203,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=291976,FOLIO='F-28',FILE='DISK106:[19ZAH1.19ZAH78701]FO78701A.;56',USER='MKEANE',CD='26-APR-2019;21:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=5><I>5,000,000 Shares

 </I></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>
<IMG SRC="g79071.jpg" ALT="LOGO" WIDTH="373" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>Common Stock  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>PROSPECTUS  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="172pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="172pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=3><I>MORGAN STANLEY</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>BofA MERRILL LYNCH</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=3><I>PIPER JAFFRAY</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, all dealers that effect transactions in these securities,
 whether or not participating in this offering, may be required to deliver a prospectus.
This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.  </I></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:times;"><font></FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019  </I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=1011056,FOLIO='blank',FILE='DISK106:[19ZAH1.19ZAH78701]HO78701A.;19',USER='C905689',CD='25-APR-2019;23:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ja78701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ja78701_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II    <BR>    <BR>    INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="ja78701_item_13._other_expense__ja701996"> </A>
<A NAME="toc_ja78701_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by us in connection with
the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority,&nbsp;Inc., or FINRA, filing fee and the Nasdaq
Global Market listing fee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount to<BR>
be Paid </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Market listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and engraving expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>235,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,702,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>803,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer agent and registrar fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="ja78701_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja78701_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated under the laws of the State of Delaware. As permitted by Section&nbsp;102 of the Delaware General Corporation Law, we have
adopted provisions in our amended and restated certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a
director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to
them. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability
for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any breach of the duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any act or omission not in good faith that involves intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General
Corporation Law; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also
authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws provide that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we will indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited
exceptions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we will advance expenses to our directors in connection with legal proceedings to the fullest extent permitted by the Delaware General
Corporation Law, subject to limited exceptions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the rights provided in our amended and restated bylaws are not exclusive. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=205,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=79166,FOLIO='II-1',FILE='DISK106:[19ZAH1.19ZAH78701]JA78701A.;18',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_ja78701_1_2"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation, attached as Exhibit&nbsp;3.1 hereto, and our amended and restated bylaws, attached as Exhibit&nbsp;3.2 hereto, will provide for
the indemnification provisions described above and elsewhere herein. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. These
indemnification agreements generally require us, among other things, to indemnify our directors, executive officers and these employees against liabilities that may arise by reason of their status or
service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors,
executive officers and employees as a result of any proceeding against them as to which they could be indemnified. We also maintain directors' and officers' liability insurance that insures our
directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
form of Underwriting Agreement, attached as Exhibit&nbsp;1.1 hereto, provides for indemnification by the underwriters named in this registration statement of our executive
officers, directors and us, and by us of the underwriters named in this registration statement, for specified liabilities, including liabilities arising under the Securities Act. Our amended and
restated investors' rights agreement with certain stockholders, attached as Exhibit&nbsp;4.2 hereto, also provides for cross-indemnification in connection with the registration of our common stock
on behalf of such investors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
the undertakings set forth in response to Item&nbsp;17 herein.  </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="ja78701_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja78701_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following list sets forth information regarding all securities sold or granted by us within the last three years that were not registered
under the Securities Act and the consideration, if any, received by us for such securities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuances of Capital Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>

<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
January 2017, we issued an aggregate of 25,000,000 shares of our Series&nbsp;A-2 Preferred Stock to seven accredited investors at a price per share of $1.00 for
aggregate proceeds of $25&nbsp;million. Upon the closing of this offering, each share of Series&nbsp;A-2 Preferred Stock will convert into 0.1245 shares of our common stock.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
April 2018, we issued an aggregate of 28,181,819 shares of our Series&nbsp;A-3 Preferred Stock to seven accredited investors at a price per share of $1.10 for
aggregate proceeds of $31&nbsp;million. Upon the closing of this offering, each share of Series&nbsp;A-3 Preferred Stock will convert into one share of our common stock. Upon the closing of this
offering, each share of Series&nbsp;A-2 Preferred Stock will convert into 0.1245 shares of our common stock.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
November 2018, we issued an aggregate of 15,052,117 shares of our Series&nbsp;B-1 Preferred Stock to seven accredited investors at a price per share of $1.59
for aggregate proceeds of approximately $23.9&nbsp;million. Upon the closing of this offering, each share of Series&nbsp;B-1 Preferred Stock will convert into 0.1245 shares of our common stock.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
November 2018, we issued an aggregate of 34,276,734 shares of our Series&nbsp;B-2 Preferred Stock to 14 accredited investors at a price per share of $1.59 for
aggregate proceeds of approximately $54.5&nbsp;million. Upon the closing of this offering, each share of Series&nbsp;B-2 Preferred Stock will convert into 0.1245 shares of our common stock.


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
November 2018, we issued an aggregate of 7,500,000 shares of our Series&nbsp;B-3 Preferred Stock to Eli Lilly and Company at a price per share of $2.00 for
aggregate proceeds of $15&nbsp;million. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=206,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=665566,FOLIO='II-2',FILE='DISK106:[19ZAH1.19ZAH78701]JA78701A.;18',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_ja78701_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>



<UL>
<UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Upon
the closing of this offering, each share of Series&nbsp;B-3 Preferred Stock will convert into 0.1245 shares of our common stock.

</FONT></P>

</UL>
</UL>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grants of Stock Options and Restricted Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>

<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
May 2016, we issued 62,237 shares of restricted common stock to David Kabakoff, Ph.D., pursuant to a restricted stock agreement under the 2015 Plan at a price per
share of $0.48 for aggregate proceeds of $30,000.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Since
April&nbsp;29, 2016, we have granted to our directors, officers, employees, consultants and other service providers stock options to purchase an aggregate of
2,030,671&nbsp;shares of our common stock under our 2015 Plan at exercise prices ranging from $0.48 to $7.63 per share. Of these, stock options covering an aggregate of 14,232 shares were cancelled
without being exercised.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Since
April&nbsp;29, 2016, we have issued an aggregate of 34,984 shares of our common stock to our directors, officers and employees pursuant to the exercise of
stock options under our 2015 Plan at exercise prices ranging from $0.48 to $1.76 per share for aggregate proceeds of approximately $48,431.


</FONT></DD>

</DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
deemed the offers, sales and issuances of the securities described in paragraphs&nbsp;(1) through (5)&nbsp;above to be exempt from registration under the Securities Act, in
reliance on Section&nbsp;4(a)(2) of the Securities Act, including Regulation&nbsp;D and Rules&nbsp;504 and 506 promulgated thereunder, relative to
transactions by an issuer not involving a public offering. All purchasers of securities in transactions exempt from registration pursuant to Regulation&nbsp;D represented to us that they were
accredited investors and were acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of
the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered under the Securities Act and that
any resale must be made pursuant to a registration statement or an available exemption from such registration. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
deemed the issuance of restricted common stock and grants and exercises of stock options described in paragraphs&nbsp;(6) through (8)&nbsp;above to be exempt from registration
under the Securities Act in reliance on Rule&nbsp;701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation in compliance
with Rule&nbsp;701. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to
information about us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing securities issued in the transactions described in this
Item&nbsp;15 included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer
of the securities. There were no underwriters employed in connection with any of the transactions set forth in this Item&nbsp;15.  </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="ja78701_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja78701_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Exhibits
</FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
the Index to Exhibits attached to this registration statement, which is incorporated by reference herein.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Financial
Statement Schedules </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
financial statement schedules are provided, because the information called for is not required or is shown either in the financial statements or the notes thereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=207,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=242770,FOLIO='II-3',FILE='DISK106:[19ZAH1.19ZAH78701]JA78701A.;18',USER='MKEANE',CD='26-APR-2019;19:11' -->
<A NAME="page_ja78701_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="ja78701_item_17._undertakings."> </A>
<A NAME="toc_ja78701_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
registrant will provide to the underwriters at the closing as specified in the underwriting agreement, certificates in such denominations and registered in such
names as required by the underwriters to permit prompt delivery to each purchaser.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to
be part of this registration statement as of the time it was declared effective.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona
fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=208,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=468528,FOLIO='II-4',FILE='DISK106:[19ZAH1.19ZAH78701]JA78701A.;18',USER='MKEANE',CD='26-APR-2019;19:11' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_jc78701_1_5"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="jc78701_index_to_exhibits"> </A>
<A NAME="toc_jc78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INDEX TO EXHIBITS    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-1_1.htm">Form of Underwriting Agreement.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-3_1.htm">Form of Third Amended and Restated Certificate of Incorporation, to be in effect upon the closing of this offering.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-3_2.htm">Form of Amended and Restated Bylaws, to be in effect upon the closing of this offering.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-3_3.htm">Second Amended and Restated Certificate of Incorporation, as currently in effect.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Certificate of Amendment to Second Amended and Restated Certificate of Incorporation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-3_4.htm">Bylaws, as amended to date, and as currently in effect.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-4_1.htm">Amended and Restated Investors' Rights Agreement, dated as of November&nbsp;5, 2018, by and among the Company and the investors party
 thereto.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Opinion of Hogan Lovells US&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_1.htm">License Agreement, dated as of December&nbsp;29, 2015, by and between the Company and Yale University.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_2.htm">Corporate Sponsored Research Agreement, dated as of December&nbsp;29, 2015, by and between the Company and Yale University.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_3.htm">Research and Development Collaboration Agreement, dated as of November&nbsp;2, 2018, by and between the Company and Eli Lilly and
 Company.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_4.htm">Amended and Restated Sublease Agreement, dated as of March&nbsp;15, 2019, by and between the Company and Lupin,&nbsp;Inc.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_5.htm">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_6.htm">NextCure,&nbsp;Inc. 2015 Omnibus Incentive Plan, as amended.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_7.htm">Form of Stock Option Agreement under the NextCure,&nbsp;Inc. 2015 Omnibus Incentive Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_8.htm">NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_9.htm">Forms of Stock Option Agreement under the NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_10.htm">Form of Restricted Stock Agreement under the NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_11.htm">Form of Restricted Stock Unit Agreement under the NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_12.htm">NextCure,&nbsp;Inc. 2019 Employee Stock Purchase Plan.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-10_13.htm">Non-Employee Director Compensation Program.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_14.htm">Lease Agreement, dated as of January&nbsp;30, 2019, by and between the Company and ARE-8000/9000/10000 Virginia Manor,&nbsp;LLC.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_15.htm">Employment Letter, dated as of September&nbsp;12, 2016, by and between the Company and Michael Richman.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_16.htm">Employment Letter, dated as of December&nbsp;18, 2017, by and between the Company and Steven&nbsp;P. Cobourn.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=792599,FOLIO='II-5',FILE='DISK106:[19ZAH1.19ZAH78701]JC78701A.;34',USER='SMENEZE',CD='26-APR-2019;23:14' -->
<A NAME="page_jc78701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_17.htm">Employment Letter, dated as of September&nbsp;12, 2016, by and between the Company and Sol Langermann, Ph.D.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="a2238596zex-23_1.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Consent of Hogan Lovells US&nbsp;LLP (included in Exhibit&nbsp;5.1).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 <A HREF="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zs-1.htm#SIG">Power of Attorney.</A></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>#</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To
be filed by amendment.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Previously
filed.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>+</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Indicates
a management contract or compensatory plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#134;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Portions
of this exhibit have been omitted in compliance with Item&nbsp;601 of Regulation S-K. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=210,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=339505,FOLIO='II-6',FILE='DISK106:[19ZAH1.19ZAH78701]JC78701A.;34',USER='SMENEZE',CD='26-APR-2019;23:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_je78701_1_7"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="SIG"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> SIGNATURES  </B></FONT></P>

<P style="font-family:times;text-align:justify">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in Beltsville, Maryland, on this 29th day of April, 2019.

 </FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> NEXTCURE,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/ Michael Richman<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Richman<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated:


</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2> /s/ Michael Richman<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Richman</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director<BR></FONT> <FONT SIZE=2><I>(Principal Executive Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
/s/ Steven P. Cobourn<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Steven P. Cobourn</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer<BR></FONT> <FONT SIZE=2><I>(Principal Financial and Accounting Officer)</I></FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David Kabakoff, Ph.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chair of the Board</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Elaine V. Jones, Ph.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Chau Q. Khuong</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Judith J. Li</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Briggs Morrison, M.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=211,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=830530,FOLIO='II-7',FILE='DISK106:[19ZAH1.19ZAH78701]JE78701A.;30',USER='JLAWRENA',CD='26-APR-2019;14:55' -->
<A NAME="page_je78701_1_8"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Tim Shannon, M.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Stephen Webster</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Stella Xu, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>April&nbsp;29, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>*By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2> /s/ Michael Richman<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Richman<BR>
Attorney-in-Fact</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=212,EFW="2238596",CP="NEXTCURE, INC.",DN="1",CHK=46953,FOLIO='II-8',FILE='DISK106:[19ZAH1.19ZAH78701]JE78701A.;30',USER='JLAWRENA',CD='26-APR-2019;14:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a2238596zex-1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 1.1<a name="3387-2-KA-01_Exhibit1_1_112714"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[</font></b><b><font face="Symbol" style="font-weight:bold;">&#183;</font></b><b>] Shares</b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMMON STOCK, PAR VALUE $0.001 PER SHARE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNDERWRITING AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:35.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=761037,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan Stanley&nbsp;&amp; Co. LLC<br>  </font>Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</p>
<p style="margin:0in 0in .0001pt 52.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper Jaffray&nbsp;&amp; Co.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Morgan Stanley&nbsp;&amp; Co. LLC</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1585 Broadway<br> New York, New York 10036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Bryant Park</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, New York 10036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Piper Jaffray&nbsp;&amp; Co.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800 Nicollet Mall</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis, Minnesota 55402</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the &#147;<b>Underwriters</b>&#148;) [</font><font face="Symbol">&#183;</font>] shares of its common stock, par value $0.001 per share (the &#147;<b>Firm Shares</b>&#148;).&#160; The Company also proposes to issue and sell to the several Underwriters not more than an additional [<font face="Symbol">&#183;</font>] shares of its common stock, par value $0.001 per share (the &#147;<b>Additional Shares</b>&#148;) if and to the extent that you, as representatives of the several Underwriters (the &#147;<b>Representatives</b>&#148;) of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof.&#160; The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<b>Shares.</b>&#148; The shares of common stock, par value $0.001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<b>Common Stock.</b>&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has filed with the Securities and Exchange Commission (the &#147;<b>Commission</b>&#148;) a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-230837) including a prospectus, relating to the Shares.&#160; The registration statement as amended at the time it becomes effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act of 1933, as amended (the &#147;<b>Securities Act</b>&#148;), is hereinafter referred to as the &#147;<b>Registration Statement</b>&#148;; the prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company to meet requests of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="3387-2-KA-01_PB_1_112911_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=114089,FOLIO='1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">purchasers pursuant to Rule&nbsp;173 under the Securities Act) is hereinafter referred to as the &#147;<b>Prospectus.</b>&#148;&#160; If the Company has filed an abbreviated registration statement to register additional shares of Common Stock pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act (a &#147;<b>Rule&nbsp;462 Registration Statement</b>&#148;), then any reference herein to the term &#147;<b>Registration Statement</b>&#148; shall be deemed to include such Rule&nbsp;462 Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Agreement, &#147;<b>free writing prospectus</b>&#148; has the meaning set forth in Rule&nbsp;405 under the Securities Act, &#147;<b>Time of Sale Prospectus</b>&#148; means the preliminary prospectus contained in the Registration Statement at the time of its effectiveness together with the documents and pricing information set forth in Schedule II hereto, and &#147;<b>broadly available road show</b>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule&nbsp;433(h)(5)&nbsp;under the Securities Act that has been made available without restriction to any person.&#160; As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and &#147;Prospectus&#148; shall include the documents, if any, incorporated by reference therein as of the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.65in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Representations and Warranties</i>.&#160; The Company represents and warrants to and agrees with each of the Underwriters that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the Company&#146;s knowledge, threatened by the Commission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;The Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply, as of the date of such amendment or supplement, in all material respects with the applicable requirements of the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (iv)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (v)&nbsp;the Prospectus, as of its date, does not contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KA-01_PB_2_112933_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=407426,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act.&#160; Any free writing prospectus that the Company is required to file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the Commission in accordance with the applicable requirements of the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder.&#160; Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or, if filed after the date of this Agreement, will comply, when filed, in all material respects with the requirements of the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder.&#160; Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any free writing prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company has been duly incorporated, is validly existing as a corporation and in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own or lease its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a material adverse effect on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company does not have any subsidiaries.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Agreement has been duly authorized, executed and delivered by the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the sections entitled &#147;Capitalization&#148; and &#147;Description of Capital Stock&#148; in each of the Time of Sale Prospectus and the Prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and non-assessable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KA-01_PB_3_112948_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=206642,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights that have not been validly waived.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene (i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or by-laws of the Company, (iii)&nbsp;any agreement or other instrument binding upon the Company that is material to the Company, or (iv)&nbsp;any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company, except in the case of clauses (i), (iii)&nbsp;and (iv)&nbsp;as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as have been obtained or waived or as may be required by the securities or blue sky laws of the various states in connection with the offer and sale of the Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There has not occurred any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, management or operations of the Company from that set forth in the Time of Sale Prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There are no legal or governmental proceedings pending or, to the Company&#146;s knowledge, threatened to which the Company is a party or to which any of the properties of the Company is subject (i)&nbsp;other than (A)&nbsp;proceedings accurately described in all material respects in the Time of Sale Prospectus and (B)&nbsp;proceedings that would not reasonably, individually or in the aggregate, be expected to have a material adverse effect on the Company or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus or (ii)&nbsp;that are required to be described in the Registration Statement or the Prospectus and are not so described in all material respects; and there are no statutes, regulations, contracts or other documents to which the Company or its property are subject or bound that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement that are not described in all material respects or filed as required.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act, complied when so filed in all material respects with the applicable requirements of the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KA-01_PB_4_113010_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=158017,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company (i)&nbsp;is in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<b>Environmental Laws</b>&#148;), (ii)&nbsp;has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its business and (iii)&nbsp;is in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) that would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement, except those contracts, agreements and understandings described in the Time of Sale Prospectus and the Prospectus as have been validly waived in connection with the issuance and sale of the Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;None of the Company or its controlled affiliates, any director or officer, thereof, or, to the Company&#146;s knowledge, any employee, agent or representative of the Company or of any of its controlled affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to improperly influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and its controlled affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KA-01_PB_5_113025_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=734815,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">representations and warranties contained herein; and (iii)&nbsp;the Company will not use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The operations of the Company are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company conducts business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<b>Anti-Money Laundering Laws</b>&#148;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;None of the Company or any director or officer thereof, or, to the Company&#146;s knowledge, any employee, agent, affiliate or representative of the Company, is an individual or entity (&#147;<b>Person</b>&#148;) that is, or is owned or controlled by one or more Persons that are:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.6in;text-align:justify;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<b>Sanctions</b>&#148;), or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.6in;text-align:justify;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba,&nbsp;Iran, North Korea and Syria).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-align:justify;text-indent:.35in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.6in;text-align:justify;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.6in;text-align:justify;text-indent:.9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KA-01_PB_6_113608_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=160132,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-align:justify;text-indent:.35in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For the past five years, the Company has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subsequent to the respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company has not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding capital stock, other than in connection with the termination of service of employees, directors or other service providers pursuant to equity compensation plans described in the Time of Sale Prospectus or existing agreements or in connection with the exercise of the Company&#146;s right of first refusal upon a proposed transfer, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and (iii)&nbsp;there has not been any material change in the capital stock (other than the exercise of equity awards or grants of equity awards or repurchase or forfeiture of equity awards or restricted stock outstanding as of such respective dates as of which information is given in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, in each case granted pursuant to the equity compensation plans described in the Time of Sale Prospectus or subject to an existing agreement), short-term debt or long-term debt of the Company, except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company does not own any real property.&#160; The Company has good and marketable title to all personal property owned by it that is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do not materially diminish the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company; and any real property and buildings held under lease by the Company is held by the Company under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company, in each case except as described in the Time of Sale Prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company owns, has obtained licenses or can acquire on reasonable terms all material patent rights, inventions, trademarks, trade names, service marks, logos, trade dress, designs, data, database rights,&nbsp;Internet domain names, copyrights, works of authorship, trade secrets, know-how and proprietary information (including unpatented and unpatentable proprietary or confidential information, systems or procedures) and other intellectual property rights (collectively, &#147;<b>Intellectual Property Rights</b>&#148;) necessary to the current conduct of the business as described in the Registration Statement, the Time of Sale Prospectus, and the Prospectus, except where any failure to own, possess or acquire such</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KA-01_PB_7_113740_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=210010,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Intellectual Property Rights would not reasonably be expected to have a material adverse effect on the Company.&#160; Such Intellectual Property Rights owned by or licensed to the Company have not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part.&#160; To the Company&#146;s knowledge: (i)&nbsp;there are no third parties that have rights to any Intellectual Property Rights of the Company except for (a)&nbsp;customary retained and reversionary rights of third-party licensors with respect to Intellectual Property Rights licensed to the Company, (b)&nbsp;non-exclusively licensed Intellectual Property Rights, where the licensor may provide licenses to a third party and (c)&nbsp;third parties that have been explicitly granted licenses by the Company; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property Rights of the Company.&#160; Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by any third party: (A)&nbsp;challenging the Company&#146;s rights in or to any of their Intellectual Property Rights; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property Rights of the Company; or (C)&nbsp;asserting that the Company infringes, misappropriates, or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe, misappropriate, or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others.&#160; The Company has complied in all material respects with the terms of each agreement pursuant to which Intellectual Property Rights have been licensed to the Company, and all such agreements are in full force and effect.&#160; The Company has taken all reasonable steps necessary to secure its interests in the Company-owned Intellectual Property Rights from its employees and contractors and to protect the confidentiality of all of its confidential information and trade secrets, including the execution of appropriate nondisclosure, confidentiality agreements, invention assignment agreements and invention assignments with its employees, and to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company.&#160; The product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company fall within the scope of one or more claim of one or more patents or patent applications owned by, or exclusively licensed to, the Company.&#160; To the Company&#146;s knowledge, the duties of candor and good faith required by the United States Patent and Trademark Office, including citation of material prior art that the Company is aware of, during the prosecution of Company-owned United States patents and patent applications included in the Intellectual Property Rights have been complied with.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To the Company&#146;s knowledge, none of the Company-owned Intellectual Property Rights or technology (including information technology and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KA-01_PB_8_113801_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=815657,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">outsourced arrangements) employed by the Company in the conduct of the business in the manner described in the Registration Statement, the Time of Sale Prospectus or the Prospectus has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or any of its officers, directors or employees or otherwise in violation of the rights of any persons.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as would not reasonably be expected to result in a material adverse effect on the Company, (A)&nbsp;each Plan (as defined below) has been maintained in compliance with its terms and in all material respects with the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but not limited to the Employee Retirement Income Security Act of 1974, as amended (&#147;<b>ERISA</b>&#148;) and the Internal Revenue Code of 1986, as amended (the &#147;<b>Code</b>&#148;); (B)&nbsp;no non-exempt prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan; (C)&nbsp;for each Plan, no failure to satisfy the minimum funding standards (within the meaning of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA), whether or not waived, has occurred or is reasonably expected to occur; (D)&nbsp;no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c)&nbsp;of ERISA, other than those events as to which notice is waived) has occurred or is reasonably expected to occur; and (E)&nbsp;neither the Company nor any member of its &#147;Controlled Group&#148; (defined as any organization that is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of the Code) has incurred, nor is reasonably expected to incur, any liability under Title IV of ERISA (other than contributions to any Plan or any Multiemployer Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan or a Multiemployer Plan. For purposes of this paragraph, (x)&nbsp;the term &#147;<b>Plan</b>&#148; means an employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of ERISA, subject to Title IV of ERISA, but excluding any Multiemployer Plan, for which the Company or any member of its &#147;Controlled Group&#148; has any liability and (y)&nbsp;the term &#147;Multiemployer Plan&#148; means a multiemployer plan within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No material labor dispute with the employees of the Company exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that would reasonably be expected to have a material adverse effect on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are, in the reasonable judgment of the Company, prudent and customary in the businesses in which it is engaged; the Company has not been refused any insurance coverage sought or applied for; and the Company does not have any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KA-01_PB_9_113814_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=826389,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">necessary to continue its business at a cost that would not have a material adverse effect on the Company, except as described in the Time of Sale Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(bb)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct its business, except where failure to obtain such certificates, authorizations and permits would not, singly or in the aggregate, reasonably by expected to have a material adverse effect on the Company, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit that, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a material adverse effect on the Company, except as described in the Time of Sale Prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(cc)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles in the United States (&#147;<b>U.S. GAAP</b>&#148;) and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.&#160; Except as described in the Time of Sale Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (i)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial reporting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(dd)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The financial statements (including the related notes thereto) of the Company included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and present fairly in all material respects the consolidated financial position of the Company as of the dates indicated and the results of its operations and cash flows for the periods specified.&#160; Such financial statements have been prepared in conformity with U.S. GAAP applied on a consistent basis throughout the periods involved.&#160; The other financial information of the Company included in the Registration Statement, the Time of Sale Prospectus and the Prospectus has been derived from the accounting or other records of the Company and presents fairly in all material respects the information shown thereby.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ee)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Ernst&nbsp;&amp; Young LLP, independent public accountants, who have expressed their opinion with respect to certain financial statements (which term as used in this Agreement includes the related notes thereto) of the Company</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="3387-2-KA-03_PB_10_114859_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=433348,FOLIO='10',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">included in the Registration Statement, are independent with respect to the Company within the applicable rules&nbsp;and regulations of the Commission and as required by the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ff)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To the extent required under applicable rules: (i)&nbsp;the Company maintains disclosure controls and procedures that comply with the requirements of the Securities Exchange Act of 1934, as amended (the &#147;<b>Exchange Act</b>&#148;); (ii)&nbsp;such disclosure controls and procedures have been designed to ensure that material information relating to the Company is made known to the Company&#146;s principal executive officer and principal financial officer by others within the Company; and (iii)&nbsp;such disclosure controls and procedures are effective.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(gg)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as described in the Time of Sale Prospectus, the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(hh)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company has taken all necessary actions to ensure that, upon the effectiveness of the Registration Statement, it will be in compliance, to the extent required, with all provisions of the Sarbanes-Oxley Act of 2002, as amended (the &#147;<b>Sarbanes-Oxley Act</b>&#148;), and all rules&nbsp;and regulations promulgated thereunder applicable to the Company at such time, and is taking steps designed to ensure that it will be in compliance, at all times, with the other provisions of the Sarbanes-Oxley Act when they become applicable to the Company after the effectiveness of the Registration Statement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company has filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or has requested extensions thereof, except where the failure to file would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the Company, and has paid all taxes required to be paid thereon, except for cases in which the failure to file or pay would not reasonably be expected to have a material adverse effect on the Company, or, except as currently being contested in good faith and for which reserves required by U.S. GAAP have been created in the financial statements of the Company, and no tax deficiency has been determined adversely to the Company that has had (nor does the Company have any notice or knowledge of any tax deficiency that would reasonably be expected to be determined adversely to the Company and that would reasonably be expected to have) a material adverse effect on the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(jj)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication) through the date hereof, the Company has</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="3387-2-KA-03_PB_11_114859_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=234170,FOLIO='11',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &#147;<b>Emerging Growth Company</b>&#148;).&#160; &#147;<b>Testing-the-Waters Communication</b>&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d)&nbsp;of the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(kk)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company (i)&nbsp;has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule&nbsp;144A under the Securities Act or institutions that are accredited investors within the meaning of Rule&nbsp;501 under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications.&#160; The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications.&#160; The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule III hereto.&#160; &#147;<b>Written Testing-the-Waters Communication</b>&#148; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule&nbsp;405 under the Securities Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ll)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers, none of (A)&nbsp;the Time of Sale Prospectus, (B)&nbsp;any free writing prospectus, when considered together with the Time of Sale Prospectus, and (C)&nbsp;any individual Written Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(mm)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160; </font>The Company has complied, and is presently in compliance, in all material respects with its privacy and security policies, and with all obligations, laws and regulations regarding the collection, use, transfer, storage, protection, disposal or disclosure of personally identifiable information or any other information collected from or provided by third parties.&#160; The Company has taken commercially reasonable steps to protect the information technology systems and data used in connection with the operation of the Company.&#160; The Company has used reasonable efforts to establish, and has established, commercially reasonable disaster recovery and security plans, procedures and facilities for the business, including, without limitation, for the information technology systems and data held or used by or for the Company.&#160; To its knowledge, there has been no material security breach or attack or other compromise of or relating to any such information technology system or data.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(nn)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The statistical, industry and market-related data included in the Registration Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="3387-2-KA-03_PB_12_114859_7672"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=14767,FOLIO='12',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">be reliable and accurate.&#160; To the Company&#146;s knowledge, it does not</font>  </font>require the consent of any third party for the use of any such data except as already obtained.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(oo)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company has not taken, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares to facilitate the sale or resale thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(pp)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The preclinical tests and clinical trials, and other studies (collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company has no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company has made all such filings and obtained all such approvals or authorizations as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug regulatory agency, or health care facility Institutional Review Board (collectively, the &#147;<b>Regulatory Agencies</b>&#148;), except where the failure to make such filing or obtain such approval would not reasonably be expected to result in a material adverse effect on the Company; except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has not received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus; and the Company has operated and currently is in compliance in all material respects with all applicable rules&nbsp;and regulations of the Regulatory Agencies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(qq)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company is, and at all times has been, in compliance with all applicable Health Care Laws except where failure to be in compliance would not be reasonably expected to have a material adverse effect on the Company.&#160; For purposes of this Agreement, &#147;<b>Health Care Laws</b>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.) and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the U.S. False Statements Law (42 U.S.C. &#167; 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. &#167;1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), all applicable federal, state, local and foreign criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167;&#167; 286 and 287, and the health care fraud criminal provisions under the U.S.</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="3387-2-KA-03_PB_13_114859_536"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=886051,FOLIO='13',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Health Insurance Portability and Accountability Act of 1996 (&#147;<b>HIPAA</b>&#148;) (42 U.S.C. &#167;&#167; 1320d et seq.), the Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h), the exclusion law (42 U.S.C. &#167;1320a-7), the statutes, regulations and directives of applicable federal healthcare programs (as defined in 42 U.S.C. &#167; 1320a-7b(f)), and the regulations promulgated pursuant to such statutes, including but not limited to Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act); (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), and the regulations promulgated thereunder, including without limitation, the Standards for Privacy of Individually Identifiable Health Information (the &#147;<b>Privacy Rule</b>&#148;), the Security Standards, and the Standards for Electronic Transactions and Code Sets, and any state or non-U.S. counterpart thereof or other law or regulation the purpose of which is to protect the privacy of individuals or prescribers; (iv)&nbsp;the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; and (v)&nbsp;any and all other applicable health care laws and regulation applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company.&#160; The Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that it is in violation of any Health Care Laws, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened.&#160; Neither the Company nor its officers, directors, or, to the Company&#146;s knowledge, its employees, contractors or agents, is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.&#160; Additionally, neither the Company nor any of its officers, directors, or to the Company&#146;s knowledge, its employees, contractors or agents has been excluded, suspended or debarred from participation in any federal health care program (as defined in 42 U.S.C. &#167; 1320a-7b(f)) or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in such debarment, suspension, or exclusion.&#160; The Company has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), except as would not reasonably be expected to have a material adverse effect on the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Agreements to Sell and Purchase.&#160; </i>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="3387-2-KA-03_PB_14_114859_5926"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=397090,FOLIO='14',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth in Schedule&nbsp;I hereto opposite its name at $[</font><font face="Symbol">&#183;</font>] a share (the &#147;<b>Purchase Price</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly, up to [</font><font face="Symbol">&#183;</font>] Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not payable on such Additional Shares.&#160; You may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice to the Company not later than 30 days after the date of this Agreement.&#160; Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased.&#160; Each purchase date must be at least one business day after the written notice is given and may not be earlier than the Closing Date nor later than ten business days after the date of such notice.&#160; Additional Shares may be purchased as provided in Section&nbsp;4 hereof solely for the purpose of covering over-allotments made in connection with the offering of the Firm Shares.&#160; On each day, if any, that Additional Shares are to be purchased (an &#147;<b>Option Closing Date</b>&#148;), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule&nbsp;I hereto opposite the name of such Underwriter bears to the total number of Firm Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Terms of Public Offering</i>.&#160; The Company is advised by you that the Underwriters propose to make a public offering of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in your judgment is advisable.&#160; The Company is further advised by you that the Shares are to be offered to the public initially at $[<font face="Symbol">&#183;</font>] a share (the &#147;<b>Public Offering Price</b>&#148;) and to certain dealers selected by you at a price that represents a concession not in excess of $[<font face="Symbol">&#183;</font>] a share under the Public Offering Price, and that any Underwriter may allow, and such dealers may reallow, a concession, not in excess of $[<font face="Symbol">&#183;</font>] a share, to any Underwriter or to certain other dealers.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Payment and Delivery.&#160; </i>Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2019, or at such other time on the same or such other date, not later than [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2019, as shall be designated in writing by you.&#160; The time and date of such payment are hereinafter referred to as the &#147;<b>Closing Date</b>&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery of such Additional</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="3387-2-KA-03_PB_15_114859_4688"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=879585,FOLIO='15',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section&nbsp;2 or at such other time on the same or on such other date, in any event not later than [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2019, as shall be designated in writing by you.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Firm Shares and Additional Shares shall be registered in such names and in such denominations as you shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be.&#160; The Firm Shares and Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters designated by you through the facilities of the Depository Trust Company, with any transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Conditions to the Underwriters&#146; Obligations</i>.&#160; The obligations of the Company to sell the Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition that the Registration Statement shall have become effective not later than 4:00pm (New York City time) on the date hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The several obligations of the Underwriters are subject to the following further conditions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.05in;text-indent:.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>no order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.05in;text-indent:.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the Company by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.05in;text-indent:.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160; </font>there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business, management or operations of the Company from that set forth in the Time of Sale Prospectus that, in your judgment, is material and adverse and that makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed on behalf of the Company by an</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="3387-2-KA-03_PB_16_114859_2983"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=231819,FOLIO='16',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">executive officer of the Company, to the effect set forth in Section&nbsp;5(a)(i)&nbsp;above and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Hogan Lovells US LLP, outside counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Smith, Gambrell&nbsp;&amp; Russell, LLP, intellectual property counsel for the Company, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters, dated the Closing Date, in form and substance reasonably satisfactory to the Underwriters.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to the opinion and negative assurance letters to be delivered pursuant to Sections 5(c)&nbsp;and 5(e)&nbsp;above, Hogan Lovells US LLP and Cooley LLP, respectively, may state that their opinions and beliefs are based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus and the Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except as specified.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The opinion of Hogan Lovells US LLP described in Section&nbsp;5(c)&nbsp;above shall be rendered to the Underwriters at the request of the Company and shall so state therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date, as the case may be, in form and substance reasonably satisfactory to the Underwriters, from Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <i>provided</i> that the letter delivered on the Closing Date shall use a &#147;cut-off date&#148; not earlier than the date hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The &#147;lock-up&#148; agreements, each substantially in the form of Exhibit&nbsp;A hereto, between you and the shareholders, officers and directors of the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="3387-2-KA-03_PB_17_114859_6228"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=982046,FOLIO='17',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Underwriters shall have received, on each of the date hereof and the Closing Date, a certificate of the accuracy of certain financial information included in the Time of Sale Prospectus and the Prospectus, in form and substance reasonably satisfactory to the Underwriters, signed by the Chief Financial Officer of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to you on the applicable Option Closing Date of the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a certificate, dated the Option Closing Date and signed on behalf of the Company by an executive officer of the Company, confirming that the certificate delivered on the Closing Date pursuant to Section&nbsp;5(b)&nbsp;hereof remains true and correct as of such Option Closing Date;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an opinion of Hogan Lovells US LLP, outside counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(c)&nbsp;hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an opinion of Smith, Gambrell&nbsp;&amp; Russell, LLP, intellectual property counsel for the Company, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(d)&nbsp;hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an opinion of Cooley LLP, counsel for the Underwriters, dated the Option Closing Date, relating to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section&nbsp;5(e)&nbsp;hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a letter dated the Option Closing Date, in form and substance reasonably satisfactory to the Underwriters, from Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, substantially in the same form and substance as the letter furnished to the Underwriters pursuant to Section&nbsp;5(e)&nbsp;hereof; <i>provided</i> that the letter delivered on the Option Closing Date shall use a &#147;cut-off date&#148; not earlier than three business days prior to such Option Closing Date; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such other documents as you may reasonably request with respect to the good standing of the Company, the due authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="3387-2-KA-03_PB_18_114859_6479"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=479397,FOLIO='18',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Covenants of the Company</i>.&#160; The Company covenants with each Underwriter as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To furnish to you, without charge and upon request, four conformed copies of the Registration Statement (including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to you in New York City, without charge, prior to 10:00&nbsp;a.m.&nbsp;New York City time on the business day next succeeding the date of this Agreement and during the period mentioned in Section&nbsp;6(e)&nbsp;or 6(f)&nbsp;below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to you a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which you reasonably object in writing, and to file with the Commission within the applicable period specified in Rule&nbsp;424(b)&nbsp;under the Securities Act any prospectus required to be filed pursuant to such Rule.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To furnish to you a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which you reasonably object.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement then on file, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="3387-2-KA-03_PB_19_114859_2639"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=870170,FOLIO='19',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:21 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160; If, during such period after the first date of the public offering of the Shares as in the reasonable opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule&nbsp;173(a)&nbsp;of the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule&nbsp;173(a)&nbsp;of the Securities Act) is delivered to a purchaser, not misleading, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule&nbsp;173(a)&nbsp;of the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160; To endeavor to qualify the Shares for offer and sale under the securities or blue sky laws of such jurisdictions as you shall reasonably request, provided, however, that nothing contained herein shall require the Company to qualify to do business in any jurisdiction, to execute a general consent to service of process in any jurisdiction, or to subject itself to taxation in any jurisdiction in which it is not otherwise subject.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)&#160;&#160;&#160;&#160;&#160; To make generally available (which may be satisfied by filing with the Commission on its Electronic Data Gathering, Analysis, and Retrieval system) to the Company&#146;s security holders and to you as soon as practicable an earnings statement covering a period of at least 12 months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement that shall satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and the rules&nbsp;and regulations of the Commission thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and the Company&#146;s accountants in connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="3387-2-KA-05_PB_20_113618_235"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=640139,FOLIO='20',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii)&nbsp;the reasonable cost of printing or producing any blue sky or legal investment memorandum in connection with the offer and sale of the Shares under state securities laws and all expenses incurred in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section&nbsp;6(g)&nbsp;hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the blue sky or legal investment memorandum, (iv)&nbsp;all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering of the Shares by the Financial Industry Regulatory Authority,&nbsp;Inc. provided that the amount payable by the Company with respect to fees and disbursements of the Underwriters and counsel for the Underwriters pursuant to subsections (iii)&nbsp;and (iv)&nbsp;shall not exceed $35,000 in the aggregate, (v)&nbsp;all fees and expenses in connection with the preparation and filing of the registration statement on Form&nbsp;8-A relating to the Common Stock and all costs and expenses incident to listing the Shares on the Nasdaq Global [Select] Market, (vi)&nbsp;the cost of printing certificates representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or depositary, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show (the remaining 50% of the cost of such aircraft to be paid by the Underwriters), (ix)&nbsp;the document production charges and expenses associated with printing this Agreement and (x)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section.&#160; It is understood, however, that except as provided in this Section, Section 8(a) entitled &#147;Indemnity and Contribution&#148; and the last paragraph of Section&nbsp;10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any advertising expenses connected with any offers they may make and all travel and other expenses of the Underwriters, their representatives, their counsel or any of their employees incurred by them in connection with their participation in investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="3387-2-KA-05_PB_21_113813_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=990452,FOLIO='21',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160; To promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (a)&nbsp;completion of the distribution of the Shares within the meaning of the Securities Act and (b)&nbsp;completion of the Restricted Period (as defined in this Section&nbsp;6).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)&#160;&#160;&#160;&#160;&#160; If at any time during the period in which delivery of a prospectus is required by the Securities Act following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication, as then amended or supplemented, included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, to promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; To deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the foregoing Certification.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company also covenants with each Underwriter that, without the prior written consent of the Representatives, on behalf of the Underwriters, it will not, during the period ending 180 days after the date of the Prospectus (the &#147;<b>Restricted Period</b>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause&nbsp;(1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3)&nbsp;file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The restrictions contained in the preceding paragraph shall not apply to (a)&nbsp;the Shares to be sold hereunder, (b)&nbsp;the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof, as described in the Time of Sale Prospectus and the Prospectus or of which the Underwriters have been advised in writing, (c)&nbsp;the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of Common Stock, <i>provided</i> that (i)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="3387-2-KA-05_PB_22_113827_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=663031,FOLIO='22',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period, (d)&nbsp;the grant or issuance by the Company of options, restricted stock awards, restricted stock units or any other type of equity award to employees, officers, directors, advisors or consultants of the Company pursuant to employee benefit plans described in the Time of Sale Prospectus, (e)&nbsp;the filing by the Company of one or more registration statements with the Commission on Form&nbsp;S-8 with respect to employee benefit plans in described in the Time of Sale Prospectus and the Prospectus, or (f)&nbsp;the sale or issuance of or entry into an agreement to sell or issue shares of Common Stock or securities convertible into or exercisable for Common Stock in connection with any (i)&nbsp;merger, (ii)&nbsp;acquisition of securities, businesses, technology, property or any other assets, (iii)&nbsp;joint venture, (iv)&nbsp;strategic alliance or (v)&nbsp;equipment leasing arrangement, provided that the aggregate number of shares of Common Stock or securities convertible into or exercisable for Common Stock (on an as-converted or as exercised basis, as the case may be) that the Company may sell or issue or agree to sell or issue pursuant to this clause (f)&nbsp;shall not exceed 5% of the total number of shares of the Company&#146;s Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement, and provided further, that each recipient of shares of Common Stock or securities convertible into or exercisable for Common Stock pursuant to clauses (d)&nbsp;and (f)&nbsp;shall execute a lock-up letter substantially in the form of Exhibit&nbsp;A hereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the Representatives, in their joint discretion, agree to release or waive the restrictions set forth in a lock-up letter described in Section&nbsp;5(g)&nbsp;hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit&nbsp;B hereto through a major news service at least two business days before the effective date of the release or waiver.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.65in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Covenants of the Underwriters</i>.&#160; Each Underwriter severally covenants with the Company not to take any action that would result in the Company being required to file with the Commission under Rule&nbsp;433(d)&nbsp;a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.65in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Indemnity and Contribution.</i>&#160; (a)&nbsp;The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of any Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other reasonable expenses incurred in connection with defending or investigating any such action or claim) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any issuer free writing prospectus as defined in Rule&nbsp;433(h)&nbsp;under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="3387-2-KA-05_PB_23_113933_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=7371,FOLIO='23',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities Act, any road show as defined in Rule&nbsp;433(h)&nbsp;under the Securities Act (a &#147;road show&#148;), or the Prospectus or any amendment or supplement thereto, or any Written Testing-the-Waters Communication arising out of or based upon any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities arising out of or based upon such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through you expressly for use therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160; Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to information relating to such Underwriter furnished to the Company in writing by such Underwriter through you expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road show or the Prospectus or any amendment or supplement thereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160; In case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity may be sought pursuant to Section&nbsp;8(a)&nbsp;or 8(b), such person (the &#147;<b>indemnified party</b>&#148;) shall promptly notify the person against whom such indemnity may be sought (the &#147;<b>indemnifying party</b>&#148;) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to such proceeding.&#160; In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed in writing to the retention of such counsel, (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them (iii)&nbsp;the indemnified party shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party, or (iv)&nbsp;the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party.&#160; It is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred.&#160; Such firm shall be</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="3387-2-KA-05_PB_24_114400_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=1009667,FOLIO='24',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">designated in writing by the Representatives, in the case of parties indemnified pursuant to Section&nbsp;8(a), and by the Company, in the case of parties indemnified pursuant to Section&nbsp;8(b).&#160; The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.&#160; Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.&#160; No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160;&#160;&#160;&#160; To the extent the indemnification provided for in Section&nbsp;8(a)&nbsp;or 8(b)&nbsp;is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause&nbsp;8(d)(i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;8(d)(i)&nbsp;above but also the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.&#160; The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares (before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares.&#160; The relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="3387-2-KA-05_PB_25_114416_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=458966,FOLIO='25',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.&#160; The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;8(a)&nbsp;are several in proportion to the respective number of Shares they have purchased hereunder, and not joint.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160; The Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section&nbsp;8(a)&nbsp;were determined by <i>pro rata</i> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in Section&nbsp;8(d)(i).&#160; The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section&nbsp;8(d)(i)&nbsp;shall be deemed to include, subject to the limitations set forth above, any legal or other reasonable expenses incurred by such indemnified party in connection with investigating or defending any such action or claim.&#160; Notwithstanding the provisions of this Section&nbsp;8(a), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&#160; The remedies provided for in this Section&nbsp;8(a)&nbsp;are not exclusive and shall not limit any rights or remedies that may otherwise be available to any indemnified party at law or in equity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160; The indemnity and contribution provisions contained in this Section&nbsp;8(a)&nbsp;and the representations, warranties and other statements of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Termination</i>.&#160; The Underwriters may terminate this Agreement by notice given by you to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE MKT, the Nasdaq Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade or other relevant exchanges, (ii)&nbsp;trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the United States or other relevant jurisdiction shall have occurred, (iv)&nbsp;any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v)&nbsp;there shall have occurred any</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="3387-2-KA-05_PB_26_114501_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=36304,FOLIO='26',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause&nbsp;(v), makes it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Effectiveness; Defaulting Underwriters</i>.&#160; This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares that such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite their respective names in Schedule&nbsp;I bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as you may specify, to purchase the Shares that such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; <i>provided</i> that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section&nbsp;10 by an amount in excess of one-ninth of such number of Shares without the written consent of such Underwriter.&#160; If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to you and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter or the Company.&#160; In any such case either you or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected.&#160; If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default.&#160; Any action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement required to be complied with or fulfilled by the Company, or if for any reason the Company shall be unable to perform its</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="3387-2-KA-05_PB_27_114517_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=508099,FOLIO='27',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligations under this Agreement (other than by reason of a default by the Underwriters or the occurrence of any of the events described in clauses (i), (iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;10), the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, for all reasonable and documented out-of-pocket expenses (including the reasonable and documented fees and disbursements of their counsel) incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Entire Agreement</i>.&#160; (a)&nbsp;This Agreement together with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160; The Company acknowledges that in connection with the offering of the Shares: (i)&nbsp;the Underwriters have acted at arm&#146;s length, are not agents of, and owe no fiduciary duties to, the Company or any other person; (ii)&nbsp;the Underwriters owe the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any; and (iii)&nbsp;the Underwriters may have interests that differ from those of the Company.&#160; The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Recognition of the U.S. Special Resolution Regimes</i>.&#160; (a)&nbsp;In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160; In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Section: (i)&nbsp;a &#147;<b>BHC Act Affiliate</b>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (ii)&nbsp;&#147;<b>Covered Entity</b>&#148; means any of the following: (A)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (B)&nbsp;a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (C)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="3387-2-KA-05_PB_28_114619_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=13499,FOLIO='28',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">with, 12 C.F.R. &#167; 382.2(b); (iii)&nbsp;&#147;<b>Default Right</b>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (iv)&nbsp;&#147;<b>U.S. Special Resolution Regime</b>&#148; means each of (A)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (B)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Counterparts</i>.&#160; This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Applicable Law</i>.&#160; This Agreement and any claim, controversy or dispute arising out of this Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Headings</i>.&#160; The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>Notices</i>.&#160; All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed or sent to you in care of Morgan Stanley&nbsp;&amp;&nbsp;Co. LLC, 1585&nbsp;Broadway, New York, New York&nbsp;10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, One Bryant Park, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; Piper Jaffray&nbsp;&amp; Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: Equity Syndicate Desk, with a copy to the Legal Department, and in each case with a copy (which shall not constitute notice) to Cooley LLP, 55 Hudson Yards, New York, New York 10001, Attention: Div Gupta, Brent Siler and Josh Kaufman; and if to the Company shall be delivered, mailed or sent to 9000 Virginia Manor Road, Suite&nbsp;200, Beltsville, Maryland 20705, with a copy (which shall not constitute notice) to Hogan Lovells US LLP, 100 International Drive, Suite&nbsp;2000, Baltimore, Maryland 21202, Attention: William I. Intner.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="3387-2-KA-05_PB_29_114802_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=938088,FOLIO='29',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:23 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accepted as of the date   hereof</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan   Stanley&nbsp;&amp; Co. LLC<br>   Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith<br>   Incorporated</font><br> Piper Jaffray&nbsp;&amp; Co.</p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt .3in;text-indent:-.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acting severally on behalf of themselves and<br>   the several Underwriters named in<br>   Schedule I hereto.</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan   Stanley&nbsp;&amp; Co. LLC</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merrill Lynch, Pierce,   Fenner&nbsp;&amp; Smith</font></p>
<p style="margin:0in 0in .0001pt 52.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper   Jaffray&nbsp;&amp; Co.</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">30<a name="3387-2-KA-07_PB_30_120520_6373"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=176778,FOLIO='30',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE I</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="48%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Underwriter</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;To&nbsp;<br>   Be&nbsp;Purchased</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan   Stanley&nbsp;&amp; Co. LLC</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:47.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt 52.55pt;text-indent:-52.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merrill Lynch,   Pierce, Fenner&nbsp;&amp; Smith<br>   Incorporated</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper   Jaffray&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:47.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.76%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:47.66%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I-</font>1<a name="3387-2-KA-07_PB_1_120710_3480"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=62300,FOLIO='I-1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE II</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Time of Sale Prospectus</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Preliminary Prospectus issued [date]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Price per share to the public: [<font face="Symbol">&#183;</font>]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of shares offered: [</font><font face="Symbol">&#183;</font>]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Underwriters&#146; option to purchase additional shares: [</font><font face="Symbol">&#183;</font>]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">II-</font>1<a name="3387-2-KA-07_PB_1_120804_5467"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=53428,FOLIO='II-1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCHEDULE III</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Written Testing-the-Waters Communication</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[None]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">III-</font>1<a name="3387-2-KA-07_PB_1_120832_1832"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=187420,FOLIO='III-1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;OF LOCK-UP LETTER</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:354.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan Stanley&nbsp;&amp; Co. LLC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</font></p>
<p style="margin:0in 0in .0001pt 52.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper Jaffray&nbsp;&amp; Co.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>Morgan Stanley&nbsp;&amp; Co. LLC</p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1585 Broadway</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, New York 10036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</font></p>
<p style="margin:0in 0in .0001pt 65.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Bryant Park</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, New York 10036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o Piper Jaffray&nbsp;&amp; Co.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">800 Nicollet Mall</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Minneapolis, Minnesota 55402</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned understands that Morgan Stanley&nbsp;&amp; Co. LLC (&#147;<b>Morgan Stanley</b>&#148;), Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (&#147;<b>Merrill Lynch</b>&#148;) and Piper Jaffray and Co. (together with Morgan Stanley and Merrill Lynch, the &#147;<b>Representatives</b>&#148;), propose to enter into an Underwriting Agreement (the &#147;<b>Underwriting Agreement</b>&#148;) with NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), providing for the public offering (the &#147;<b>Public Offering</b>&#148;) by the several Underwriters, including the Representatives (the &#147;<b>Underwriters</b>&#148;), of a number of&#160; shares (the &#147;<b>Shares</b>&#148;) of the common stock, par value $0.001 per share, of the Company (the &#147;<b>Common Stock</b>&#148;) in an amount to be determined.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To induce the Underwriters that may participate in the Public Offering to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representatives, on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending 180 days after the date of the final prospectus (the &#147;<b>Restricted Period</b>&#148;) relating to the Public Offering (the &#147;<b>Prospectus</b>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>1<a name="3387-2-KA-07_PB_1_121011_1623"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=1031177,FOLIO='A-1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common Stock beneficially owned (as such term is used in Rule&nbsp;13d-3 of the Securities Exchange Act of 1934, as amended (the &#147;<b>Exchange Act</b>&#148;)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock (together, with Common Stock, &#147;<b>Securities</b>&#148;) or make any public announcement of its intention to enter into any of the foregoing or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Securities, in cash or otherwise.&#160; The foregoing sentence shall not apply to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>transactions relating to Securities acquired in open market transactions after the completion of the Public Offering, <i>provided</i> that no filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall be required, or shall be voluntarily made during the Restricted Period, in connection with subsequent sales of Securities acquired in such open market transactions;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>transfers of Securities</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>as a bona fide gift or charitable contribution;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>upon death or by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or an immediate family member (as defined below) of the undersigned;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to an immediate family member of the undersigned or to any trust, partnership or limited liability company for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this agreement, &#147;immediate family&#148; shall mean any relationship by blood, current or former marriage or adoption, not more remote than first cousin);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>not involving a change in beneficial ownership;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the undersigned is a trust, to any beneficiary of the undersigned or the estate of any such beneficiary;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>as forfeitures to satisfy tax withholding obligations of or pursuant to a net or cashless exercise by the undersigned in connection with the vesting or exercise of equity awards by the undersigned to the extent such equity awards are outstanding as of the date of the Prospectus and granted pursuant to any equity incentive plan of the Company existing as of the date of the Prospectus and described in the Prospectus and so long as such net or cashless exercise is effected solely by the surrender of outstanding equity awards and the Company&#146;s cancellation of all or a portion thereof to pay the exercise price (including the payment of taxes due as a result of such vesting event or exercise) and/or withholding tax obligations, but for the avoidance of doubt, excluding all methods of exercise that would</p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>2<a name="3387-2-KA-07_PB_2_121106_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=510065,FOLIO='A-2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">involve a sale of any Securities related to such equity awards, whether to cover the applicable exercise price, withholding tax obligations or otherwise; <i>provided</i> that no filing under Section&nbsp;16(a)&nbsp;of the Exchange Act or any other public filing or disclosure of such receipt or transfer by or on behalf of the undersigned shall be required or shall be voluntarily made within 90 days after the date of the Prospectus, and after such 90th day, any filing under Section&nbsp;16(a)&nbsp;of the Exchange Act shall clearly indicate in the footnotes thereto that no shares were sold by the undersigned and the purpose of such transfer was to cover tax obligations of the undersigned or to pay the exercise price in connection with such exercise;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#146;s Securities involving a Change of Control (as defined below) of the Company (including, without limitation, the entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Securities in connection with such transaction, or vote any Securities in favor of any transaction), <i>provided</i> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such Securities held by the undersigned shall remain subject to the provisions of this letter agreement, <i>provided further</i> that if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Restricted Period, the undersigned shall include a statement that such transfer is being made pursuant to the circumstances described in this clause (b)(vii)&nbsp;(as used herein, &#147;<b>Change of Control</b>&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than any Underwriters pursuant to the Public Offering), of the Company&#146;s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity));</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>by operation of law pursuant to an order of a court or regulatory agency, <i>provided</i> that if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Restricted Period, the undersigned shall include a statement that such transfer is being made pursuant to the circumstances described in this clause (b)(viii);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the undersigned is a corporation, partnership, limited liability company or other entity, (A)&nbsp;distributions of Securities to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&nbsp;405 under the Securities Act of 1933, as amended), current or former partners (general or limited), members or managers of the undersigned, as applicable, or to the</p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>3<a name="3387-2-KA-07_PB_3_121202_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=1037241,FOLIO='A-3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">estates of any such stockholders, affiliates, partners, members or managers or (B)&nbsp;sales or transfers of any Securities to another such entity that is a direct or indirect affiliate of the undersigned, or to any investment fund or other entity controlled or managed by, or under common control or management with, the undersigned; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to the Company pursuant to any contractual arrangement that provides for the repurchase by the Company or forfeiture to the Company of the undersigned&#146;s Securities upon termination of the undersigned&#146;s employment or service with the Company, <i>provided</i> that if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Restricted Period, the undersigned shall include a statement that such transfer is being made pursuant to the circumstances described in this clause (b)(x);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of Common Stock, <i>provided</i> that (i)&nbsp;such plan does not provide for the transfer of Common Stock during the Restricted Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>dispositions or transfers to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a)&nbsp;and (b)&nbsp;above;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">provided</font></i> that in the case of any transfer or distribution pursuant to clause&nbsp;(b), (i)&nbsp;each transferee, recipient, donee, distributee, trustee or beneficiary shall sign and deliver a lock-up letter substantially in the form of this letter and (ii)&nbsp;no filing under Section&nbsp;16(a)&nbsp;of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Restricted Period except as otherwise provided in clauses (b)(vi), (b)(vii), (b)(viii)&nbsp;and (b)(x).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the undersigned agrees that, without the prior written consent of the Representatives, on behalf of the Underwriters, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any Securities.&#160; The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing restrictions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed shares of Common Stock the undersigned may purchase in the Public Offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>4<a name="3387-2-KA-07_PB_4_121229_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=834342,FOLIO='A-4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:25 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives, on behalf of the Underwriters, agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, the Representatives, on behalf of the Underwriters, will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver.&#160; Any release or waiver granted by the Representatives, on behalf of the Underwriters, hereunder to any such officer or director shall only be effective two business days after the publication date of such press release.&#160; The provisions of this paragraph will not apply if (a)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned understands that, if (a)&nbsp;the Underwriting Agreement does not become effective by December&nbsp;31, 2019, (b)&nbsp;the Company informs the undersigned that the Board of Directors has determined not to proceed with the Public Offering prior to the execution of the Underwriting Agreement or the registration statement filed with the U.S. Securities and Exchange Commission in connection with the Public Offering is withdrawn, (c)&nbsp;a Representative informs the Company that the Representatives have determined not to proceed with the Public Offering prior to the execution of the Underwriting Agreement, or if (d)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities, this agreement shall terminate and the undersigned shall be released from all obligations hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned understands that the Company and the Underwriters are relying upon this agreement in proceeding toward consummation of the Public Offering.&#160; The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns. This letter agreement and any claim, controversy or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature Page&nbsp;Follows]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>5<a name="3387-2-KA-09_PB_5_113028_1580"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=718102,FOLIO='A-5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions.&#160; Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Name)</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>6<a name="3387-2-KA-09_PB_6_113206_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=550189,FOLIO='A-6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;B</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;OF WAIVER OF LOCK-UP</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt 3.0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Name and Address of <br> Officer or Director <br> Requesting Waiver]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Mr./Ms.&nbsp;[Name]:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This</font> letter is being delivered to you in connection with the offering by NextCure,&nbsp;Inc. (the &#147;<b>Company</b>&#148;) of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.001 par value (the &#147;<b>Common Stock</b>&#148;), of the Company and the lock-up letter dated &nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the &#147;Lock-up Letter&#148;), executed by you in connection with such offering, and your request for a [waiver] [release] dated &nbsp;&nbsp;&nbsp;&nbsp;, 2019, with respect to &nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock (the &#147;<b>Shares</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan Stanley&nbsp;&amp; Co. LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Piper Jaffray&nbsp;&amp; Co. hereby agree to [waive] [release] the transfer restrictions set forth in the Lock-up Letter, but only with respect to the Shares, effective &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019; provided, however, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver] [release].&#160; This letter will serve as notice to the Company of the impending [waiver] [release].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as expressly [waived] [released] hereby, the Lock-up Letter shall remain in full force and effect.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Morgan   Stanley&nbsp;&amp; Co. LLC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Merrill Lynch, Pierce,   Fenner&nbsp;&amp; Smith</font></p>
<p style="margin:0in 0in .0001pt 49.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Piper   Jaffray&nbsp;&amp; Co.<br>   Acting severally on behalf of themselves and the several Underwriters named   in Schedule I hereto</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B-</font>1<a name="3387-2-KA-09_PB_1_113757_423"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=877155,FOLIO='B-1',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc: The Company</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 5.4pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B-</font>2<a name="3387-2-KA-09_PB_2_113836_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=667649,FOLIO='B-2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;OF PRESS RELEASE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Date]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc. (the &#147;<b>Company</b>&#148;) announced today that Morgan Stanley&nbsp;&amp; Co. LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Piper Jaffray&nbsp;&amp; Co., the lead book-running managers in the Company&#146;s recent public sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock are [waiving][releasing] a lock-up restriction with respect to &nbsp;&nbsp;&nbsp;&nbsp; shares of the Company&#146;s common stock held by [certain officers or directors] [an officer or director] of the Company.&#160; The [waiver][release] will take effect on &nbsp;&nbsp;&nbsp;&nbsp;, 2019, and the shares may be sold on or after such date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B-</font>3<a name="3387-2-KA-09_PB_3_113930_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2238596",CP="NEXTCURE, INC.",DN="2",CHK=408126,FOLIO='B-3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KA-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:29 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>a2238596zex-3_1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.1<a name="3387-2-KC_Exhibit3_1_110937"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIRD AMENDED AND RESTATED<br> CERTIFICATE OF INCORPORATION<br> OF<br> NEXTCURE,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Pursuant to Sections 242 and 245 of the<br> General Corporation Law of the State of Delaware)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#147;<b>General Corporation Law</b>&#148;),</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DOES HEREBY CERTIFY:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1. The name of the Corporation is NextCure,&nbsp;Inc. The Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of the State of Delaware on September&nbsp;3, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2. The Third Amended and Restated Certificate of Incorporation of the Corporation attached hereto as <u>Exhibit&nbsp;A</u> is incorporated herein by reference, and amends, integrates and restates the Second Amended and Restated Certificate of Incorporation of the Corporation, as amended.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3. The Third Amended and Restated Certificate of Incorporation was duly adopted and approved by the Corporation&#146;s Board of Directors and by written consent of the Corporation&#146;s stockholders in accordance with Sections 228, 242 and 245 of the Delaware General Corporation Law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF</font></b>, the Corporation has caused this Third Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer and the foregoing facts stated herein are true and correct.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael   Richman</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=410012,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;A</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIRD AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATE OF INCORPORATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The name of the corporation is NextCure,&nbsp;Inc. (the &#147;<b>Corporation</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;2</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Corporation&#146;s registered office in the State of Delaware shall be located at The Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, in the City of Wilmington, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The purposes for which the Corporation is formed are to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (&#147;<b>DGCL</b>&#148;) and to possess and exercise all of the powers and privileges granted by such law and any other law of Delaware.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;4</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Authorized Capital</b>. The total number of shares of all classes of stock that the Corporation shall have authority to issue is 110,000,000 shares, consisting of (i)&nbsp;100,000,000 shares of Common Stock, $0.001 par value per share (&#147;<b>Common Stock</b>&#148;), and (ii)&nbsp;10,000,000 shares of Preferred Stock, $0.001 par value per share (&#147;<b>Preferred Stock</b>&#148;). Except as otherwise provided in any certificate of designations of any series of Preferred Stock, the number of authorized shares of Preferred Stock and Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) from time to time by the affirmative vote of the holders representing at least a majority of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, irrespective of the provisions of Section&nbsp;242(b)(2)&nbsp;of the DGCL (or any successor provision thereto), and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class or series shall be required therefor.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Common Stock</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.1.</font></b>&#160;&#160;&#160;&#160;&#160; <b>General</b>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the board of directors of the Corporation (the &#147;<b>Board</b>&#148;) upon any issuance of the Preferred Stock of any series.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=750740,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.2.</font></b>&#160;&#160;&#160;&#160;&#160; <b>Voting</b>. Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; <i>provided</i>,<i> however</i>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (this &#147;<b>Certificate of Incorporation</b>&#148;) (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.3.</font></b>&#160;&#160;&#160;&#160;&#160; <b>No Cumulative Voting</b>. There shall be no cumulative voting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.4.</font></b>&#160;&#160;&#160;&#160;&#160; <b>Dividends and Distributions</b>. Dividends and other distributions in cash, securities and other property of the Corporation may be declared and paid on the Common Stock from assets or funds lawfully available therefor as and when determined by the Board and subject to any preferential dividend or other rights of any then outstanding Preferred Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2.5.</font></b>&#160;&#160;&#160;&#160;&#160; <b>Liquidation</b>. Subject to the rights, if any, of the holders of any series of Preferred Stock, in the event of any liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or involuntary, the net assets of the Corporation shall be distributed to the holders of shares of Common Stock ratably in proportion to the number of shares held by them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Preferred Stock</b>. The Board is hereby expressly authorized to issue Preferred Stock from time to time in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the DGCL, to determine and fix the number of shares of such series and the designation of such series, the voting powers, if any, of the shares of such series, the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, including without limitation, dividend rights, conversion rights, redemption privileges and liquidation preferences, of the shares of such series. Without limiting the generality of the foregoing, the powers, preferences, and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Any shares of Preferred Stock that may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;5</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>General Powers</b>. The business and affairs of the Corporation shall be managed by or under the direction of the Board except as otherwise provided herein or required by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Election of Directors</b>. Unless and to the extent that the bylaws of the Corporation, as may be amended and/or restated from time to time (the &#147;<b>Bylaws</b>&#148;), shall so provide, the election of directors of the Corporation need not be by written ballot.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=191055,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Number of Directors</b>. The number of directors that shall constitute the whole Board shall be fixed from time to time solely by resolutions adopted by the Board; <i>provided</i>, <i>however</i>, that the Board shall consist of no fewer than three directors. Each director shall be entitled to one vote on each matter presented to the Board of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.4.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Classification</b>. Subject to the rights, if any, of the holders of any series of Preferred Stock, and effective upon the effectiveness of this Certificate of Incorporation (the &#147;<b>Effective Time</b>&#148;), the Board of the Corporation shall be divided into three classes designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board. The term of office of the initial Class&nbsp;I directors shall expire at the first annual meeting of the stockholders following the Effective Time; the term of office of the initial Class&nbsp;II directors shall expire at the second annual meeting of the stockholders following the Effective Time; and the term of office of the initial Class&nbsp;III directors shall expire at the third annual meeting of the stockholders following the Effective Time. At each annual meeting occurring after the Effective Time, each director elected to the class of directors expiring at such annual meeting shall be elected to hold office until the third annual meeting following his or her election and until his or her successor shall have been duly elected and qualified, or until his or her earlier death, resignation, removal or retirement. Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the whole Board shall shorten the term of any incumbent director.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.5.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Removal of Directors</b>. Subject to the rights, if any, of the holders of any series of Preferred Stock, for so long as this Certificate of Incorporation provides for a classified Board, any director may be removed from office at any time but only with cause, at a meeting called for that purpose, by the affirmative vote of the holders representing at least 66 2/3% of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.6.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Vacancies</b>. Subject to the rights, if any, of the holders of any series of Preferred Stock, any and all vacancies in the Board, however occurring, including, without limitation, by reason of an increase in the size of the Board, or the death, resignation, disqualification or removal of a director, shall be filled solely by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum of the Board, and not by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director&#146;s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal. In the event of a vacancy in the Board, the remaining directors, except as otherwise provided by law, shall exercise the powers of the whole Board until the vacancy is filled.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;6</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Director Indemnification</b>. To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=288406,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a director. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article&nbsp;6 to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended, automatically and without further action, upon the date of such amendment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Expenses</b>. The Corporation, to the fullest extent permitted by law, shall indemnify and advance expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate, is or was a director or officer of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as a director or officer at the request of the Corporation or any predecessor to the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Employee Indemnification</b>. The Corporation, to the fullest extent permitted by law, may indemnify and advance expenses to any person made or threatened to be made a party to an action, suit or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he or she, or his or her testator or intestate, is or was an employee or agent of the Corporation or any predecessor of the Corporation, or serves or served at any other enterprise as an employee or agent at the request of the Corporation or any predecessor to the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.4.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment</b>. Neither any amendment nor repeal of this Article&nbsp;6, nor the adoption by amendment of this certificate of incorporation of any provision inconsistent with this Article&nbsp;6, shall eliminate or reduce the effect of this Article&nbsp;6 in respect of any matter occurring, or any action or proceeding accruing or arising (or that, but for this Article&nbsp;6, would accrue or arise) prior to such amendment or repeal or adoption of an inconsistent provision.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;7</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Action by Written Consent</b>. Subject to the rights of any series of Preferred Stock, no action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be effected by written consent of stockholders in lieu of a meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Annual Meetings of Stockholders</b>. The annual meeting of stockholders for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held at such date, time and place, if any, as shall be determined exclusively by resolution of the Board in its sole and absolute discretion and stated in the notice of the meeting. Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders at any meeting of stockholders shall be given in the manner provided in the Bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Special Meetings of Stockholders</b>. Subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of stockholders of the Corporation shall be called only (i)&nbsp;by the chair of the Board or (ii)&nbsp;by or at the direction of a majority of the Board. Any business transacted at any special meeting of stockholders shall be limited to matters properly brought before the meeting by or at the direction of the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=885572,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;8</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment of Certificate of Incorporation</b>. Notwithstanding any other provision of this Certificate of Incorporation or the Bylaws and in addition to any affirmative vote of the holders of any particular class of stock required by the DGCL, this Certificate of Incorporation or the Bylaws, the affirmative vote of the holders of at least 66 2/3% of the voting power of the shares of the then outstanding voting stock of the Corporation, voting together as a single class, shall be required to amend, repeal, or adopt any provisions of this Certificate of Incorporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Bylaws</b>. In furtherance and not in limitation of the powers conferred by law, the Board is expressly authorized to adopt, alter, amend or repeal the Bylaws without any action on the part of the stockholders. Any adoption, alteration, amendment or repeal of the Bylaws by the Board shall require the approval of a majority of the Board then in office, <i>provided</i> a quorum is otherwise present. Any Bylaws adopted or amended by the Board, and any powers conferred thereby, may be amended, altered or repealed by the stockholders. In addition to any other vote otherwise required by law or this Certificate of Incorporation, with respect to the adoption, alteration, amendment or repeal of the Bylaws by the stockholders, the affirmative vote of the holders representing at least a majority of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote with respect thereto, voting together as a single class, shall be required to adopt, alter, amend or repeal the Bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;9</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any provision (or any part thereof) of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any section of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii)&nbsp;to the fullest extent possible, the provisions of this Certificate of Incorporation (including, without limitation, any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit of the Corporation to the fullest extent permitted by law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=644404,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, this Third Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this &nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Michael Richman</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   President and CEO</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="3",CHK=376894,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 23:25 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>a2238596zex-10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.8</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=216912,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 03:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="81%" colspan="3" valign="bottom" style="padding:0in 0in 0in 0in;width:81.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PURPOSE</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DEFINITIONS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADMINISTRATION OF THE   PLAN</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Committee</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.1</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Powers and Authorities</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.2</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Composition of the   Committee</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.3</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other Committees</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.4</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delegation by the   Committee</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Board</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Terms of Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.1</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Committee Authority</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.2</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forfeiture; Recoupment</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Repricing Without   Stockholder Approval</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.5</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferral Arrangement</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.6</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Liability</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.7</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration; Share   Certificates</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">STOCK SUBJECT TO THE   PLAN</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of Shares of   Stock Available for Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments in   Authorized Shares of Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Share Usage</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERM; AMENDMENT AND   TERMINATION</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Term</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment, Suspension,   and Termination</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AWARD ELIGIBILITY AND   LIMITATIONS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eligible Grantees</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Limitation on Shares of   Stock Subject to Awards to Non-Employee Directors</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stand-Alone,   Additional, Tandem, and Substitute Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AWARD AGREEMENT</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   OPTIONS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option Price</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting and Exercisability</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Term</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination of Service</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.5</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Limitations on Exercise   of Option</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.6</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Method of Exercise</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.7</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of Holders of   Options</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.8</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delivery of Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.9</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Transferability of   Options</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">i<a name="3387-2-KS-01_PB_i_005526_6126"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=540234,FOLIO='i',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 03:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.10</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Family Transfers</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.11</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Limitations on   Incentive Stock Options</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.12</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notice of Disqualifying   Disposition</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   STOCK APPRECIATION RIGHTS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Right to Payment and   SAR Price</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other Terms</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Term</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of Holders of   SARs</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.5</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Transferability of SARs</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.6</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Family Transfers</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   RESTRICTED STOCK, RESTRICTED STOCK UNITS, AND DEFERRED STOCK UNITS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant of Restricted   Stock, Restricted Stock Units, and Deferred Stock Units</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restrictions</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration;   Restricted Stock Certificates</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of Holders of   Restricted Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights of Holders of Restricted   Stock Units and Deferred Stock Units</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5.1</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Voting and Dividend   Rights</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5.2</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Creditor&#146;s Rights</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.6</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination of Service</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.7</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of Restricted   Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.8</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delivery of Shares of   Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   UNRESTRICTED STOCK AWARDS AND OTHER EQUITY-BASED AWARDS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unrestricted Stock   Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other Equity-Based   Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   DIVIDEND EQUIVALENT RIGHTS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dividend Equivalent   Rights</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination of Service</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TERMS AND CONDITIONS OF   PERFORMANCE-BASED AWARDS</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant of   Performance-Based Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Value of   Performance-Based Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Earning of   Performance-Based Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;and Timing of   Payment of Performance-Based Awards</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.5</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Performance Conditions</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FORMS OF PAYMENT</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General Rule</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Surrender of Shares of   Stock</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.3</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cashless Exercise</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.4</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other Forms of Payment</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font></p>    </td>
<td width="81%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">REQUIREMENTS OF LAW</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.1</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.2</font></p>    </td>
<td width="75%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rule&nbsp;16b-3</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">ii<a name="3387-2-KS-01_PB_ii_005545_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=894825,FOLIO='ii',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 03:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font></p>    </td>
<td width="81%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:81.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EFFECT OF CHANGES IN   CAPITALIZATION</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in Stock</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reorganization in Which   the Company Is the Surviving Entity Which Does not Constitute a Change in   Control</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in Control in   which Awards are not Assumed</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.4</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in Control in   which Awards are Assumed</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.5</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.6</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Limitations on   Company</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:81.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font></p>    </td>
<td width="81%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:81.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PARACHUTE LIMITATIONS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:81.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font></p>    </td>
<td width="81%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:81.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GENERAL PROVISIONS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Disclaimer of Rights</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.2</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nonexclusivity of the   Plan</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.3</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Withholding Taxes</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.4</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Captions</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.5</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Construction</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.6</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other Provisions</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.7</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number and Gender</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.8</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Severability</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.9</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Governing Law</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.10</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;409A of   the Code</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.98%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">iii<a name="3387-2-KS-01_PB_iii_005552_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=135387,FOLIO='iii',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 03:50 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PURPOSE</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan is intended to (a)&nbsp;provide eligible individuals with an incentive to contribute to the success of the Company and to operate and manage the Company&#146;s business in a manner that will provide for the Company&#146;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders, including its employees and customers, and (b)&nbsp;provide a means of recruiting, rewarding, and retaining key personnel.&#160; To this end, the Plan provides for the grant of Awards of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Unrestricted Stock, Dividend Equivalent Rights, Other Equity-Based Awards, and cash bonus awards.&#160; Any of these Awards may, but need not, be made as performance incentives to reward the holders of such Awards for the achievement of performance conditions in accordance with the terms of the Plan.&#160; Options granted under the Plan may be Nonqualified Stock Options or Incentive Stock Options, as provided herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEFINITIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of interpreting the Plan documents, including the Plan and Award Agreements, the following capitalized terms shall have the meanings specified below, unless the context clearly indicates otherwise:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Affiliate</b>&#148; shall mean any Person that controls, is controlled by, or is under common control with the Company within the meaning of Rule&nbsp;405 of Regulation C under the Securities Act, including any Subsidiary.&#160; For purposes of grants of Options or Stock Appreciation Rights, an entity may not be considered an Affiliate unless the Company holds a Controlling Interest in such entity.&#160; &#147;Controlling Interest&#148; shall have the meaning set forth in Treasury Regulation Section&nbsp;1.414(c)-2(b)(2)(i); provided that (a)&nbsp;except as specified in clause (b)&nbsp;below, an interest of &#147;at least 50 percent&#148; shall be used instead of an interest of &#147;at least 80 percent&#148; in each case where &#147;at least 80 percent&#148; appears in Treasury Regulation Section&nbsp;1.414(c)-2(b)(2)(i), and (b)&nbsp;where a grant of Options or Stock Appreciation Rights is based upon a legitimate business criterion, an interest of &#147;at least 20 percent&#148; shall be used instead of an interest of &#147;at least 80 percent&#148; in each case where &#147;at least 80 percent&#148; appears in Treasury Regulation Section&nbsp;1.414(c)-2(b)(2)(i).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Applicable Laws</b>&#148; shall mean the legal requirements relating to the Plan and the Awards under (a)&nbsp;applicable provisions of the Code, the Securities Act, the Exchange Act, any rules&nbsp;or regulations thereunder, and any other laws, rules, regulations, and government orders of any jurisdiction applicable to the Company or its Affiliates, (b)&nbsp;applicable provisions of the corporate, securities, tax, and other laws, rules, regulations, and government orders of any jurisdiction applicable to Awards granted to residents thereof, and (c)&nbsp;the rules&nbsp;of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Award</b>&#148; shall mean a grant under the Plan of an Option, a Stock Appreciation Right, Restricted Stock, a Restricted Stock Unit, a Deferred Stock Unit, Unrestricted Stock, a Dividend Equivalent Right, an Other Equity-Based Award, or cash.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Award Agreement</b>&#148; shall mean the written agreement, in such written, electronic, or other form as determined by the Committee, between the Company and a Grantee that evidences and sets forth the terms and conditions of an Award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=15745,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Benefit Arrangement</b>&#148; shall mean any formal or informal plan or other arrangement for the direct or indirect provision of compensation to a Grantee (including groups or classes of Grantees or beneficiaries of which the Grantee is a member), whether or not such compensation is deferred, is in cash, or is in the form of a benefit to or for the Grantee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Board</b>&#148; shall mean the Board of Directors of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Cause</b>&#148; shall have the meaning set forth in an applicable agreement between a Grantee and the Company or an Affiliate, and in the absence of any such agreement, shall mean, with respect to any Grantee and as determined by the Committee, (a)&nbsp;gross negligence or willful misconduct in connection with the performance of duties; (b)&nbsp;conviction of a criminal offense (other than minor traffic offenses); (c)&nbsp;material breach of any term of any employment, independent contractor, consulting or other services, confidentiality, intellectual property or non-competition agreements, if any, between the Grantee and the Company or an Affiliate thereof that the Grantee has failed to cure, if curable, as determined by the Committee, within twenty (20) days following the Grantee&#146;s receipt of written notice from the Company setting forth such breach; (d)&nbsp;breach of any material policy of the Company or any of its Affiliates that the Grantee has failed to cure, if curable, as determined by the Committee, within twenty (20) days following the Grantee&#146;s receipt of written notice from the Company setting forth such breach; or (e)&nbsp;commission of an act of embezzlement or fraud.&#160; For purposes of the Plan, no act or failure to act on a Grantee&#146;s part shall be considered &#147;willful&#148; unless done or omitted to be done by the Grantee not in good faith and without reasonable belief that the Grantee&#146;s action or omission was in the best interests of the Company.&#160; Any determination by the Committee regarding whether an event constituting Cause shall have occurred shall be final, binding, and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Capital Stock</b>&#148; shall mean, with respect to any Person, any and all shares, interests, participations, or other equivalents (however designated, whether voting or non-voting) in equity of such Person, whether outstanding on the Effective Date or issued thereafter, including, without limitation, all shares of Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Change in Control</b>&#148; shall mean, subject to <b>Section&nbsp;18.10</b>, the occurrence of any of the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A transaction or series of transactions (other than an offering of Stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d)&nbsp;and 14(d)(2)&nbsp;of the Exchange Act) directly or indirectly acquires beneficial ownership (within the meaning of Rules&nbsp;13d-3 and 13d-5 under the Exchange Act) of the Company&#146;s securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; provided, however, that the following acquisitions shall not constitute a Change in Control: (i)&nbsp;any acquisition by the Company or any Affiliate; (ii)&nbsp;any acquisition by an employee benefit plan maintained by the Company or any Affiliate, or (iii)&nbsp;any acquisition which complies with Sections 2.9(c)(i), 2.9(c)(ii)&nbsp;and 2.9(c)(iii);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Individuals who, as of the Effective Date, constitute the Board (the &#147;<b>Incumbent Board</b>&#148;) cease for any reason to constitute at least a majority of the members of the Board over a period of twelve (12) months; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a vote of at least two-thirds (2/3) of the members of the Incumbent Board then still in office, such new member shall, for purposes of the Plan, be considered a member of the Incumbent Board;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KS-03_PB_2_005744_733"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=750875,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of a merger, consolidation, reorganization, or business combination, in each case other than a transaction:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<b>Successor Entity</b>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>after which no person or group beneficially owns voting securities representing fifty percent (50%) or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this Section&nbsp;2.9(c)(ii)&nbsp;as beneficially owning fifty percent (50%) or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>after which at least a majority of the members of the board of directors (or the analogous governing body) of the Successor Entity were Board members at the time of the Board&#146;s approval of the execution of the initial agreement providing for such transaction;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The consummation of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization, merger, consolidation or business combination), in one transaction or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any person or group (other than the Company or any Affiliate); or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The liquidation, winding up, or dissolution of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board shall have full and final authority, in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control, and any incidental matters relating thereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Code</b>&#148; shall mean the Internal Revenue Code of 1986, as now in effect or as hereafter amended, and any successor thereto.&#160; References in the Plan to any Code Section&nbsp;shall be deemed to include, as applicable, regulations and guidance promulgated under such Code Section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.11</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Committee</b>&#148; shall mean a committee of, and designated from time to time by resolution of, the Board, which shall be constituted as provided in <b>Section&nbsp;3.1.2</b> and <b>Section&nbsp;3.1.3</b> (or, if no Committee has been so designated, the Board).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.12</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Company</b>&#148; shall mean NextCure,&nbsp;Inc., a Delaware corporation, and any successor thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.13</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Deferred Stock Unit</b>&#148; shall mean a Restricted Stock Unit, the terms of which provide for delivery of the underlying shares of Stock, cash, or a combination thereof subsequent to the date of vesting, at a time or times consistent with the requirements of Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KS-03_PB_3_005954_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=240723,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.14</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Disability</b>&#148; shall mean the inability of a Grantee to perform each of the essential duties of such Grantee&#146;s position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than twelve (12) months; provided that, with respect to rules&nbsp;regarding the expiration of an Incentive Stock Option following termination of a Grantee&#146;s Service, Disability shall mean the inability of such Grantee to engage in any substantial gainful activity by reason of a medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.15</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Disqualified Individual</b>&#148; shall have the meaning set forth in Code Section&nbsp;280G(c).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.16</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Dividend Equivalent Right</b>&#148; shall mean a right, granted to a Grantee pursuant to <b>Section&nbsp;12</b>, entitling the Grantee thereof to receive, or to receive credits for the future payment of, cash, Stock, other Awards, or other property equal in value to dividend payments or distributions, or other periodic payments, declared or paid with respect to a number of shares of Stock specified in such Dividend Equivalent Right (or other Award to which such Dividend Equivalent Right relates) as if such shares of Stock had been issued to and held by the Grantee of such Dividend Equivalent Right as of the record date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.17</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Effective Date</b>&#148; shall mean the date on which the Registration Statement covering the initial public offering of the Stock is declared effective by the Securities and Exchange Commission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.18</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Employee</b>&#148; shall mean, as of any date of determination, an employee (including an officer) of the Company or an Affiliate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.19</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Exchange Act</b>&#148; shall mean the Securities Exchange Act of 1934, as now in effect or as hereafter amended, and any successor thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.20</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Fair Market Value</b>&#148; shall mean the fair market value of a share of Stock for purposes of the Plan, which shall be, as of any date of determination:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If on such date the shares of Stock are listed on a Stock Exchange, or are publicly traded on another Securities Market, the Fair Market Value of a share of Stock shall be the closing price of the Stock on such date as reported on such Stock Exchange or such Securities Market (provided that, if there is more than one such Stock Exchange or Securities Market, the Committee shall designate the appropriate Stock Exchange or Securities Market for purposes of the Fair Market Value determination).&#160; If there is no such reported closing price on such date, the Fair Market Value of a share of Stock shall be the closing price of the Stock on the next preceding day on which any sale of Stock shall have been reported on such Stock Exchange or such Securities Market.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If on such date the shares of Stock are not listed on a Stock Exchange or publicly traded on a Securities Market, the Fair Market Value of a share of Stock shall be the value of the Stock as determined by the Committee by the reasonable application of a reasonable valuation method, in a manner consistent with Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding this <b>Section&nbsp;2.20&nbsp;</b>or <b>Section&nbsp;18.3</b>, for purposes of determining taxable income and the amount of the related tax withholding obligation pursuant to <b>Section&nbsp;18.3</b>, the Fair Market Value will be determined by the Committee in good faith using any reasonable method as it deems appropriate, to be applied consistently with respect to Grantees; provided, further, that the Committee shall determine the Fair Market</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KS-03_PB_4_010056_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=229900,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Value of shares of Stock due in connection with sales, by or on behalf of a Grantee, of such shares of Stock subject to an Award to pay the Option Price, SAR Price, and/or any tax withholding obligation on the same date on which such shares may first be sold pursuant to the terms of the applicable Award Agreement (including</font>  </font>broker-assisted cashless exercises of Options and Stock Appreciation Rights, as described in <b>Section&nbsp;14.3</b>, and sell-to-cover transactions) in any manner consistent with applicable provisions of the Code, including but not limited to using the sale price of such shares on such date (or if sales of such shares are effectuated at more than one sale price, the weighted average sale price of such shares on such date) as the Fair Market Value of such shares, so long as such Grantee has provided the Company, or its designee or agent, with advance written notice of such sale.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.21</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Family Member</b>&#148; shall mean, with respect to any Grantee as of any date of determination, (a)&nbsp;a Person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of such Grantee, (b)&nbsp;any Person sharing such Grantee&#146;s household (other than a tenant or employee), (c)&nbsp;a trust in which any one or more of the Persons specified in clauses (a)&nbsp;and (b)&nbsp;above own more than fifty percent (50%)&nbsp;of the beneficial interest, (d)&nbsp;a foundation in which any one or more of the Persons specified in clauses (a)&nbsp;and (b)&nbsp;above (or such Grantee) control the management of assets, and (e)&nbsp;any other entity in which one or more of the Persons specified in clauses (a)&nbsp;and (b)&nbsp;above (or such Grantee) own more than fifty percent (50%)&nbsp;of the voting interests.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.22</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Grant Date</b>&#148; shall mean, as determined by the Committee, the latest to occur of (a)&nbsp;the date as of which the Committee approves the Award, (b)&nbsp;the date on which the recipient of an Award first becomes eligible to receive an Award under <b>Section&nbsp;6</b> hereof, or (c)&nbsp;such subsequent date specified by the Committee in the corporate action approving the Award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.23</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Grantee</b>&#148; shall mean a Person who receives or holds an Award under the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.24</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Incentive Stock Option</b>&#148; shall mean an &#147;incentive stock option&#148; within the meaning of Code Section&nbsp;422.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.25</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Nonqualified Stock Option</b>&#148; shall mean an Option that is not an Incentive Stock Option.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.26</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Non-Employee Director</b>&#148; shall have the meaning set forth in Rule&nbsp;16b-3 under the Exchange Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.27</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Officer</b>&#148; shall have the meaning set forth in Rule&nbsp;16a-1(f)&nbsp;under the Exchange Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.28</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Option</b>&#148; shall mean an option to purchase one or more shares of Stock at a specified Option Price awarded to a Grantee pursuant to <b>Section&nbsp;8</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.29</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Option Price</b>&#148; shall mean the per share exercise price for shares of Stock subject to an Option.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.30</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Other Agreement</b>&#148; shall mean any agreement, contract, or understanding heretofore or hereafter entered into by a Grantee with the Company or an Affiliate, except an agreement, contract, or understanding that expressly addresses Code Section&nbsp;280G and/or Code Section&nbsp;4999.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KS-03_PB_5_010214_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=22273,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.31</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Other Equity-Based Award</b>&#148; shall mean an Award representing a right or other interest that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to Stock, other than an Option, a Stock Appreciation Right, Restricted Stock, a Restricted Stock Unit, a Deferred Stock Unit, Unrestricted Stock, or a Dividend Equivalent Right.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.32</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Parachute Payment</b>&#148; shall mean a &#147;parachute payment&#148; within the meaning of Code Section&nbsp;280G(b)(2).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.33</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Performance-Based Award</b>&#148; shall mean an Award made subject to the achievement of performance conditions over a Performance Period specified by the Committee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.34</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Performance Period</b>&#148; shall mean the period of time, up to ten (10)&nbsp;years, during or over which the performance goals under Performance-Based Awards must be met in order to determine the degree of payout and/or vesting with respect to any such Performance-Based Awards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.35</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Person</b>&#148; shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust, or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.36</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Plan</b>&#148; shall mean this NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan, as amended from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.37</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Prior Plan</b>&#148; shall mean the NextCure,&nbsp;Inc. 2015 Omnibus Incentive Plan, as amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.38</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Restricted Period</b>&#148; shall mean a period of time established by the Committee during which an Award of Restricted Stock, Restricted Stock Units, or Deferred Stock Units is subject to restrictions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.39</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Restricted Stock</b>&#148; shall mean shares of Stock awarded to a Grantee pursuant to <b>Section&nbsp;10</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.40</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Restricted Stock Unit</b>&#148; shall mean a bookkeeping entry representing the equivalent of one (1)&nbsp;share of Stock awarded to a Grantee pursuant to <b>Section&nbsp;10</b> that may be settled, subject to the terms and conditions of the applicable Award Agreement, in shares of Stock, cash, or a combination thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.41</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>SAR Price</b>&#148; shall mean the per share exercise price of a SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.42</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Securities Act</b>&#148; shall mean the Securities Act of 1933, as now in effect or as hereafter amended, and any successor thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.43</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Securities Market</b>&#148; shall mean an established securities market.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.44</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Separation from Service</b>&#148; shall have the meaning set forth in Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.45</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Service</b>&#148; shall mean service qualifying a Grantee as a Service Provider to the Company or an Affiliate.&#160; Unless otherwise provided in the applicable Award Agreement, a Grantee&#146;s change in position or duties shall not result in interrupted or terminated Service, so long as such Grantee continues to be a Service Provider to the Company or an Affiliate.&#160; Subject to the preceding sentence, any determination by the Committee whether a termination of Service shall have occurred for purposes of the Plan shall be final, binding, and conclusive.&#160; If a Service Provider&#146;s employment or other Service relationship is with an Affiliate</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KS-03_PB_6_010246_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=1013074,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and the applicable entity ceases to be an Affiliate, a termination of Service shall be deemed to have occurred when such entity ceases to be an Affiliate unless the Service Provider transfers his or her employment or other Service relationship to the Company or any other Affiliate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.46</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Service Provider</b>&#148; shall mean (a)&nbsp;an Employee or director of the Company or an Affiliate, or (b)&nbsp;a consultant or adviser to the Company or an Affiliate (i)&nbsp;who is a natural person, (ii)&nbsp;who provides bona fide services to the Company or an Affiliate, and (iii)&nbsp;whose services are not in connection with the Company&#146;s offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#146;s Capital Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.47</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Service Recipient Stock</b>&#148; shall have the meaning set forth in Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.48</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Share Limit</b>&#148; shall have the meaning set forth in <b>Section&nbsp;4.1</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.49</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Short-Term Deferral Period</b>&#148; shall have the meaning set forth in Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.50</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Stock</b>&#148; shall mean common stock, par value $0.001 per share, of the Company, or any security into which shares of Stock may be changed or for which shares of Stock may be exchanged as provided in <b>Section&nbsp;16.1</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.51</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Stock Appreciation Right</b>&#148; or &#147;<b>SAR</b>&#148; shall mean a right granted to a Grantee pursuant to <b>Section&nbsp;9</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.52</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Stock Exchange</b>&#148; shall mean the NASDAQ Stock Market, the New York Stock Exchange, or another established national or regional stock exchange.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.53</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Subsidiary</b>&#148; shall mean any corporation (other than the Company) or non-corporate entity with respect to which the Company owns, directly or indirectly, fifty percent (50%)&nbsp;or more of the total combined voting power of all classes of stock, membership interests or other ownership interests of any class or kind ordinarily having the power to vote for the directors, managers, or other voting members of the governing body of such corporation or non-corporate entity; provided however, for purposes of Incentive Stock Options, Subsidiary means any &#147;subsidiary corporation&#148; of the Company within the meaning of Code Section&nbsp;424(f).&#160; In addition, any other entity may be designated by the Committee as a Subsidiary, provided that (a)&nbsp;such entity could be considered as a subsidiary according to generally accepted accounting principles in the United States of America and (b)&nbsp;in the case of an Award of Options or Stock Appreciation Rights, such Award would be considered to be granted in respect of Service Recipient Stock under Code Section&nbsp;409A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.54</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Substitute Award</b>&#148; shall mean an Award granted under the Plan in substitution for outstanding awards previously granted under a compensatory plan of a business entity acquired or to be acquired by the Company or an Affiliate or with which the Company or an Affiliate has combined or will combine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.55</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Ten Percent Stockholder</b>&#148; shall mean a natural Person who owns more than ten percent (10%)&nbsp;of the total combined voting power of all classes of voting Capital Stock of the Company, the Company&#146;s parent (if any), or any of the Company&#146;s Subsidiaries.&#160; In determining stock ownership, the attribution rules&nbsp;of Code Section&nbsp;424(d)&nbsp;shall be applied.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.56</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Unrestricted Stock</b>&#148; shall mean Stock that is free of any restrictions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KS-03_PB_7_010317_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=27418,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>ADMINISTRATION OF THE PLAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Committee.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Powers and Authorities.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">The Committee shall administer the Plan and shall have such powers and authorities related to the administration of the Plan as are consistent with the Company&#146;s certificate of incorporation and bylaws and</font>  </font>Applicable Laws.&#160; Without limiting the generality of the foregoing, the Committee shall have full power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award, or any Award Agreement and shall have full power and authority to take all such other actions and to make all such other determinations not inconsistent with the specific terms and provisions of the Plan which the Committee deems to be necessary or appropriate to the administration of the Plan, any Award, or any Award Agreement.&#160; All such actions and determinations shall be made by (a)&nbsp;the affirmative vote of a majority of the members of the Committee present at a meeting at which a quorum is present, or (b)&nbsp;the unanimous consent of the members of the Committee executed in writing or evidenced by electronic transmission in accordance with the Company&#146;s certificate of incorporation and bylaws and Applicable Laws.&#160; Unless otherwise expressly determined by the Board, the Committee shall have the authority to interpret and construe all provisions of the Plan, any Award, and any Award Agreement, and any such interpretation or construction, and any other determination contemplated to be made under the Plan or any Award Agreement, by the Committee shall be final, binding, and conclusive on all Persons, whether or not expressly provided for in any provision of the Plan, such Award, or such Award Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event that the Plan, any Award, or any Award Agreement provides for any action to be taken by the Board or any determination to be made by the Board, such action may be taken or such determination may be made by the Committee constituted in accordance with this <b>Section&nbsp;3.1</b> if the Board has delegated the power and authority to do so to such Committee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Composition of the Committee.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee shall be a committee composed of not fewer than two (2)&nbsp;directors of the Company designated by the Board to administer the Plan.&#160; Each member of the Committee shall be (a)&nbsp;a Non-Employee Director and (b)&nbsp;an independent director in accordance with the rules&nbsp;of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded; provided that any action taken by the Committee shall be valid and effective whether or not members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in this <b>Section&nbsp;3.1.2</b> or otherwise provided in any charter of the Committee.&#160; Without limiting the generality of the foregoing, the Committee may be the Compensation Committee of the Board or a subcommittee thereof, if the Compensation Committee of the Board or such subcommittee satisfies the foregoing requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Committees.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board also may appoint one or more committees of the Board, each composed of one or more directors of the Company who need not satisfy the requirements for membership set forth in <b>Section&nbsp;3.1.2</b>, which (a)&nbsp;may administer the Plan with respect to Grantees who are not Officers or directors of the Company, (b)&nbsp;may grant Awards under the Plan to such Grantees, and (c)&nbsp;may determine all terms of such Awards, in each case, subject, if applicable, to the requirements of Rule&nbsp;16b-3 under the Exchange Act and the rules&nbsp;of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KS-03_PB_8_010339_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=52727,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Delegation by the Committee.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">To the extent permitted by Applicable Laws, the Committee may, by resolution, delegate some or all of its authority with respect to the Plan and Awards to the President and Chief Executive Officer of the Company and/or any other officer of the Company designated by the Committee, provided that the Committee may not delegate its authority hereunder (a)&nbsp;to make Awards to directors of the Company, (b)&nbsp;to make Awards to Employees who are (i)&nbsp;Officers or (ii)&nbsp;officers of the Company who are delegated authority by the Committee pursuant to this <b>Section&nbsp;3.1.4</b>, or (c)&nbsp;to interpret the Plan, any Award, or any Award Agreement.&#160; Any delegation</font>  </font>hereunder will be subject to the restrictions and limits that the Committee specifies at the time of such delegation or thereafter.&#160; Nothing in the Plan will be construed as obligating the Committee to delegate authority to any officer of the Company, and the Committee may at any time rescind the authority delegated to an officer of the Company appointed hereunder and delegate authority to one or more other officers of the Company.&#160; At all times, an officer of the Company delegated authority pursuant to this <b>Section&nbsp;3.1.4</b> will serve in such capacity at the pleasure of the Committee.&#160; Any action undertaken by any such officer of the Company in accordance with the Committee&#146;s delegation of authority will have the same force and effect as if undertaken directly by the Committee, and any reference in the Plan to the &#147;Committee&#148; will, to the extent consistent with the terms and limitations of such delegation, be deemed to include a reference to each such officer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Board.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board, from time to time, may exercise any or all of the powers and authorities related to the administration and implementation of the Plan, as set forth in <b>Section&nbsp;3.1</b> and other applicable provisions of the Plan, as the Board shall determine, consistent with the Company&#146;s certificate of incorporation and bylaws and Applicable Laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Terms of Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Committee Authority.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the other terms and conditions of the Plan, the Committee shall have full and final authority to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>designate Grantees;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>determine the type or types of Awards to be made to a Grantee;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>determine the number of shares of Stock to be subject to an Award or to which an Award relates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establish the terms and conditions of each Award (including the Option Price, the SAR Price, and the purchase price for applicable Awards; the nature and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer, or forfeiture of an Award or the shares of Stock subject thereto; the treatment of an Award in the event of a Change in Control (subject to applicable agreements); and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>accelerate the exercisability or vesting of an Award or a portion thereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KS-03_PB_9_010401_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=191355,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prescribe the form of each Award Agreement evidencing an Award;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>subject to the limitation on repricing in <b>Section&nbsp;3.4</b>, amend, modify, or supplement the terms of any outstanding Award, which authority shall include the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to make Awards or to modify outstanding Awards made to eligible natural Persons who are foreign nationals or are natural Persons who are employed outside the United States to reflect differences in local law, tax policy, or custom; provided that, notwithstanding the foregoing, no amendment, modification, or supplement of the terms of any outstanding Award shall, without the consent of the Grantee thereof, materially impair such Grantee&#146;s rights under such Award; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>make Substitute Awards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Forfeiture; Recoupment.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Committee may reserve the right in an Award Agreement to cause a forfeiture of the gain realized by a Grantee with respect to an Award thereunder on account of actions taken by, or failed to be taken by, such Grantee in violation or breach of, or in conflict with, any (i)&nbsp;employment agreement, (ii)&nbsp;non-competition agreement, (iii)&nbsp;agreement prohibiting solicitation of Employees or clients of the Company or an Affiliate, (iv)&nbsp;confidentiality obligation with respect to the Company or an Affiliate, (v)&nbsp;Company or Affiliate policy or procedure, (vi)&nbsp;other agreement, or (vii)&nbsp;other obligation of such Grantee to the Company or an Affiliate, as and to the extent specified in such Award Agreement.&#160; If the Grantee of an outstanding Award is an Employee of the Company or an Affiliate and such Grantee&#146;s Service is terminated for Cause, the Committee may annul such Grantee&#146;s outstanding Award as of the date of the Grantee&#146;s termination of Service for Cause.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any Award granted pursuant to the Plan shall be subject to mandatory repayment by the Grantee to the Company (i)&nbsp;to the extent set forth in this Plan or an Award Agreement or (ii)&nbsp;to the extent the Grantee is, or in the future becomes, subject to (A)&nbsp;any Company or Affiliate &#147;clawback&#148; or recoupment policy that is adopted to comply with the requirements of any Applicable Laws, or (B)&nbsp;any Applicable Laws which impose mandatory recoupment, under circumstances set forth in such Applicable Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>No Repricing Without Stockholder Approval</b><b>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, distribution (whether in the form of cash, shares of Stock, other securities, or other property), stock split, extraordinary dividend, recapitalization, Change in Control, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of shares of Stock, or other securities or similar transaction), the Company may not: (a)&nbsp;amend the terms of outstanding Options or SARs to reduce the Option Price or SAR Price, as applicable, of such outstanding Options or SARs; (b)&nbsp;cancel or assume outstanding Options or SARs in exchange for or substitution of Options or SARs with an Option Price or SAR Price, as applicable, that is less than the Option Price or SAR Price, as applicable, of the original Options or SARs; or (c)&nbsp;cancel or assume outstanding Options or SARs with an Option Price or SAR Price, as applicable, above the current Fair Market Value in exchange for cash, Awards, or other securities, in each case, unless such action is subject to and approved by the Company&#146;s stockholders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="3387-2-KS-03_PB_10_010418_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=1043794,FOLIO='10',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:12 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Deferral Arrangement</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may permit or require the deferral of any payment pursuant to any Award into a deferred compensation arrangement, subject to such rules&nbsp;and procedures as it may establish, which may include provisions for the payment or crediting of interest or Dividend Equivalent Rights and, in connection therewith, provisions for converting such credits into Deferred Stock Units and for restricting deferrals to comply with hardship distribution rules&nbsp;affecting tax-qualified retirement plans subject to Code Section&nbsp;401(k)(2)(B)(IV); provided that no Dividend Equivalent Rights may be granted in connection with, or related to, an Award of Options or SARs.&#160; Any such deferrals shall be made in a manner that complies with Code Section&nbsp;409A, including, if applicable, with respect to when a Separation from Service occurs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>No Liability.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No member of the Board or the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any Award, or any Award Agreement.&#160; Notwithstanding any provision of the Plan to the contrary, neither the Company, an Affiliate, the Board, the Committee, nor any person acting on behalf of the Company, an Affiliate, the Board, or the Committee will be liable to any Grantee or to the estate or beneficiary of any Grantee or to any other holder of an Award under the Plan by reason of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Code Section&nbsp;422 or Code Section&nbsp;409A or by reason of Code Section&nbsp;4999, or otherwise asserted with respect to the Award; provided, that this <b>Section&nbsp;3.6</b> shall not affect any of the rights or obligations set forth in an applicable agreement between the Grantee and the Company or an Affiliate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Registration; Share Certificates.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding any provision of the Plan to the contrary, the ownership of the shares of Stock issued under the Plan may be evidenced in such a manner as the Committee, in its sole discretion, deems appropriate, including by book-entry or direct registration (including transaction advices) or the issuance of one or more share certificates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK SUBJECT TO THE PLAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Number of Shares of Stock Available for Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to such additional shares of Stock as shall be available for issuance under the Plan pursuant to <b>Section&nbsp;4.2</b>, and subject to adjustment pursuant to <b>Section&nbsp;16</b>, the maximum number of shares of Stock reserved for issuance under the Plan shall be equal to the sum of (a)&nbsp;two million nine hundred thousand (2,900,000) shares of Stock, plus (b)&nbsp;the number of shares of Stock related to awards outstanding under the Prior Plan as of the Effective Date that thereafter terminate by expiration or forfeiture, cancellation, or otherwise without the issuance of such shares of Stock and become available for issuance under the Plan (the &#147;<b>Share Limit</b>&#148;).&#160; The Share Limit shall automatically increase on January&nbsp;1st of each year during the term of the Plan, as set forth in <b>Section&nbsp;5.1</b>, commencing on January&nbsp;1 of the year following the year in which the Effective Date occurs, in an amount equal to four percent (4%) of the total number of shares of Stock outstanding on December&nbsp;31st of the preceding calendar year. The Board may provide that there will be no January&nbsp;1st increase in the Share Limit for such year or that the increase in the Share Limit for such year will be a smaller number of shares of Stock than would otherwise occur pursuant to the preceding sentence.&#160; Shares of Stock issued under the Plan may be authorized and unissued shares of Stock, treasury shares of Stock, or any combination of the foregoing, as may</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="3387-2-KS-05_PB_11_005559_9944"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=736764,FOLIO='11',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">be determined from time to time by the Board or by the Committee.&#160; Any of the shares of Stock reserved and available for issuance under the Plan may be used for any type of Award under the Plan.&#160; Notwithstanding the foregoing, subject to adjustment pursuant to <b>Section&nbsp;16</b>, the aggregate maximum number of shares of Stock that may be issued pursuant to the exercise of Incentive Stock Options is eight million seven hundred thousand (8,700,000) shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Adjustments in Authorized Shares of Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with mergers, reorganizations, separations, or other transactions to which Code Section&nbsp;424(a)&nbsp;applies, the Committee shall have the right to cause the Company to assume awards previously granted under a compensatory plan of another business entity that is a party to such transaction and/or to grant Substitute Awards under the Plan for such awards.&#160; Assumed awards shall not, but Substitute Awards shall, reduce the number of shares of Stock otherwise available for issuance under the Plan, and shares available for issuance under a stockholder-approved plan of a business entity that is a party to such transaction (as appropriately adjusted, if necessary, to reflect such transaction) may be used for Awards under the Plan and shall not reduce the number of shares of Stock otherwise available for issuance under the Plan, subject to applicable rules&nbsp;of any Stock Exchange or Securities Market on which the Stock is listed or publicly traded.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Share Usage.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Shares of Stock covered by an Award shall be counted as used as of the Grant Date for purposes of calculating the number of shares of Stock available for issuance under <b>Section&nbsp;4.1</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any shares of Stock that are subject to Awards, including shares of Stock acquired through dividend reinvestment pursuant to <b>Section&nbsp;10</b>, will be counted against the Share Limit as one (1)&nbsp;share of Stock for every one (1)&nbsp;share of Stock subject to the Award.&#160; The number of shares of Stock subject to an Award of SARs will be counted against the Share Limit as one (1)&nbsp;share of Stock for every one (1)&nbsp;share of Stock subject to such Award, regardless of the number of shares of Stock actually issued to settle such SARs upon the exercise of the SARs.&#160; A number of shares of Stock equal to the maximum number of shares issuable under a Performance-Based Award shall be counted against the Share Limit as of the Grant Date, but such number shall be adjusted to equal the actual number of shares issued upon settlement of the Performance-Based Award to the extent different from such number of shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If any shares of Stock covered by an Award under the Plan or any award outstanding under the Prior Plan as of the Effective Date are not purchased or are forfeited or expire or otherwise terminate without delivery of any Stock subject thereto or are settled in cash in lieu of shares, then the number of shares of Stock with respect to such Award or award shall, to the extent of any such forfeiture, termination, expiration, or settlement, again be available for making Awards under the Plan.&#160; In addition, the following shares of Stock shall again be available for making awards under the Plan: (i)&nbsp;shares of Stock tendered, withheld, or subject to an Award granted under the Plan surrendered in connection with the purchase of shares of Stock upon exercise of an Option, (ii)&nbsp;shares of Stock that were not issued upon the net settlement or net exercise of a Stock-settled SAR granted under the Plan, or (iii)&nbsp;shares of Stock deducted or delivered from payment of an Award granted under the Plan in connection with the Company&#146;s tax withholding obligations as provided in <b>Section&nbsp;18.3</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="3387-2-KS-05_PB_12_005608_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=828802,FOLIO='12',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERM; AMENDMENT AND TERMINATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Term.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall be effective as of the Effective Date.&#160; The Plan shall terminate on the first to occur of (a)&nbsp;11:59pm ET on the day before the tenth (10th)&nbsp;anniversary of the Effective Date, (b)&nbsp;the date determined in accordance with <b>Section&nbsp;5.2</b>, and (c)&nbsp;the date determined in accordance with <b>Section&nbsp;16.3</b>; provided, however, that Incentive Stock Options may not be granted under the Plan more than ten (10)&nbsp;years after the date of the Board&#146;s adoption of the Plan (which was&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019).&#160; No Awards may be granted after termination of the Plan, and upon such termination of the Plan, all then-outstanding Awards shall continue to have full force and effect in accordance with the provisions of the terminated Plan and the applicable Award Agreement (or other documents evidencing such Awards).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment, Suspension, and Termination.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may, at any time and from time to time, amend or suspend the Plan; provided that, with respect to Awards theretofore granted under the Plan, no amendment or suspension of the Plan shall, without the consent of the Grantee, materially impair the rights or obligations under any such Award.&#160; The effectiveness of any amendment to the Plan shall be contingent on approval of such amendment by the Company&#146;s stockholders to the extent provided by the Board or required by Applicable Laws; </font>provided that no amendment shall be made to the no-repricing provisions of <b>Section&nbsp;3.4</b>, the Option pricing provisions of <b>Section&nbsp;8.1</b>, or the SAR pricing provisions of <b>Section&nbsp;9.1 </b>without the approval of the Company&#146;s stockholders.&#160; The Board may, at any time, terminate the Plan; provided that, with respect to Awards theretofore granted under the Plan, no termination of the Plan shall, without the consent of the Grantee, materially impair the rights or obligations under any such Award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>AWARD ELIGIBILITY AND LIMITATIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Eligible Grantees.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to this <b>Section&nbsp;6</b>, Awards may be made under the Plan to any Service Provider, as the Committee shall determine and designate from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Limitation on Shares of Stock Subject to Awards to Non-Employee Directors.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to adjustment as provided in <b>Section&nbsp;16</b>, the aggregate value of all Awards granted under the Plan and all other cash compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed Seven-Hundred Fifty Thousand Dollars ($750,000) (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes); provided, however, that such amount shall be One Million Dollars ($1,000,000) for the calendar year in which the applicable Non-Employee Director is initially elected or appointed to the Board.&#160; The Board may make exceptions to the foregoing limitations for individual Non-Employee Directors in extraordinary circumstances, as the Board may determine in its discretion, provided that the Non-Employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving Non-Employee Directors.&#160; Awards granted to an individual while he or she was serving in the capacity as an Employee or a consultant or advisor to the Company or an Affiliate (but not a Non-Employee Director) will not count for purposes of the limitations set forth in this <b>Section&nbsp;6.2</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="3387-2-KS-05_PB_13_005636_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=792269,FOLIO='13',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Stand-Alone, Additional, Tandem, and Substitute Awards</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to <b>Section&nbsp;3.4</b>, Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or in substitution or exchange for, (a)&nbsp;any other Award, (b)&nbsp;any award granted under another plan of the Company, an Affiliate, or any business entity that has been a party to a transaction with the Company or an Affiliate, or (c)&nbsp;any other right of a Grantee to receive payment from the Company or an Affiliate.&#160; Such additional, tandem, exchange, or Substitute Awards may be granted at any time.&#160; If an Award is granted in substitution or exchange for another Award, or for an award granted under another plan of the Company, an Affiliate, or any business entity that has been a party to a transaction with the Company or an Affiliate, the Committee shall require the surrender of such other Award or award under such other plan in consideration for the grant of such exchange or Substitute Award.&#160; In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash payments under other plans of the Company or an Affiliate.&#160; Notwithstanding <b>Section&nbsp;8.1</b> and <b>Section&nbsp;9.1</b>, but subject to <b>Section&nbsp;3.4</b>, the Option Price of an Option or the SAR Price of a SAR that is a Substitute Award may be less than one hundred percent (100%)&nbsp;of the Fair Market Value of a share of Stock on the original Grant Date; provided that such Option Price or SAR Price is determined in accordance with the principles of Code Section&nbsp;424 for any Incentive Stock Option and consistent with Code Section&nbsp;409A for any other Option or SAR.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>AWARD AGREEMENT</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Award granted pursuant to the Plan shall be evidenced by an Award Agreement, which shall be in such form or forms as the Committee shall from time to time determine.&#160; Award Agreements utilized under the Plan from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan.&#160; Each Award Agreement evidencing an Award of Options shall specify whether such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and, in the absence of such specification, such Options shall be deemed to constitute Nonqualified Stock Options.&#160; In the event of any inconsistency between the Plan and an Award Agreement, the provisions of the Plan shall control.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF OPTIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Option Price.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Option Price of each Option shall be fixed by the Committee and stated in the Award Agreement evidencing such Option.&#160; Except in the case of Substitute Awards, the Option Price of each Option shall be at least the Fair Market Value of one (1)&nbsp;share of Stock on the Grant Date; provided that, in the event that a Grantee is a Ten Percent Stockholder, the Option Price of an Option granted to such Grantee that is intended to be an Incentive Stock Option shall be not less than one hundred ten percent (110%) of the Fair Market Value of one (1)&nbsp;share of Stock on the Grant Date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Vesting and Exercisability.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to <b>Sections 8.3</b> and <b>16.3</b>, each Option granted under the Plan shall become vested and/or exercisable at such times and under such conditions as shall be determined by the Committee and stated in the Award Agreement, in another agreement with the Grantee, or otherwise in writing; </font>provided that no Option shall be granted to Grantees who are entitled to overtime under Applicable Laws that will vest or be exercisable within a six (6)-month period starting on the Grant Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="3387-2-KS-05_PB_14_005653_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=16786,FOLIO='14',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Term.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Option granted under the Plan shall terminate, and all rights to purchase shares of Stock thereunder shall cease, on the day before the tenth (10</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>)&nbsp;anniversary of the Grant Date of such Option, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Committee and stated in the Award Agreement relating to such Option; provided that, in the event that the Grantee is a Ten Percent Stockholder, an Option granted to such Grantee that is intended to be an Incentive Stock Option shall terminate, and all rights to purchase shares of Stock thereunder shall cease, on the day before the fifth (5<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>)&nbsp;anniversary of the Grant Date of such Option; and provided, further, that, to the extent deemed necessary or appropriate by the Committee to reflect differences in local law, tax policy, or custom with respect to any Option granted to a Grantee who is a Service Provider who is employed or providing services outside the United States, such Option may terminate, and all rights to purchase shares of Stock thereunder may cease, upon the expiration of a period longer than ten (10)&nbsp;years from the Grant Date of such Option as the Committee shall determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Service.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Award Agreement with respect to the grant of an Option shall set forth the extent to which the Grantee thereof, if at all, shall have the right to exercise such Option following termination of such Grantee&#146;s Service.&#160; Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Limitations on Exercise of Option.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding any provision of the Plan to the contrary, in no event may any Option be exercised, in whole or in part, after the occurrence of an event referred to in <b>Section&nbsp;16</b> which results in the termination of such Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Method of Exercise.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the terms of <b>Section&nbsp;14</b> and <b>Section&nbsp;18.3</b>, an Option that is exercisable may be exercised by the Grantee&#146;s delivery to the Company or its designee or agent of written notice of exercise on any business day, at the Company&#146;s principal office or the office of such designee or agent, on the form specified by the Company and in accordance with any additional procedures specified by the Committee.&#160; Such notice shall specify the number of shares of Stock with respect to which such Option is being exercised and shall be accompanied by payment in full of the Option Price of the shares of Stock for which such Option is being exercised, plus the amount (if any) of federal and/or other taxes which the Company may, in its judgment, be required to withhold with respect to the exercise of such Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights of Holders of Options.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising an Option shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares of Stock subject to such Option, to direct the voting of the shares of Stock subject to such Option, or to receive notice of any meeting of the Company&#146;s stockholders) until the shares of Stock subject thereto are fully paid and issued to such Grantee or other Person.&#160; Except as provided in <b>Section&nbsp;16</b>, no adjustment shall be made for dividends, distributions, or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="3387-2-KS-05_PB_15_005757_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=119335,FOLIO='15',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">other rights with respect to any shares of Stock subject to an Option for which the record date is prior to the date of issuance of such shares of Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Delivery of Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Promptly after the exercise of an Option by a Grantee and the payment in full of the Option Price with respect thereto, such Grantee shall be entitled to receive such evidence of such Grantee&#146;s ownership of the shares of Stock subject to such Option as shall be consistent with <b>Section&nbsp;3.7</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.9</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Transferability of Options.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as provided in <b>Section&nbsp;8.10</b>, during the lifetime of a Grantee of an Option, only such Grantee (or, in the event of such Grantee&#146;s legal incapacity or incompetency, such Grantee&#146;s guardian or legal representative) may exercise such Option.&#160; Except as provided in <b>Section&nbsp;8.10</b>, no Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.10</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Family Transfers.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee, in its sole discretion, may provide either in an applicable Award Agreement or by the subsequent approval of the Committee that a Grantee may transfer, not for value, all or part of an Option which is not an Incentive Stock Option to any Family Member.&#160; For the purpose of this <b>Section&nbsp;8.10</b>, a transfer &#147;not for value&#148; is a transfer which is (a)&nbsp;a gift, (b)&nbsp;a transfer under a domestic relations order in settlement of marital property rights, or (c)&nbsp;unless Applicable Laws do not permit such transfer, a transfer to an entity in which more than fifty percent (50%)&nbsp;of the voting interests are owned by Family Members (and/or the Grantee) in exchange for an interest in such entity.&#160; Following a transfer under this <b>Section&nbsp;8.10</b>, any such Option shall continue to be subject to the same terms and conditions as were applicable immediately prior to such transfer.&#160; Subsequent transfers of transferred Options shall be prohibited except to Family Members of the original Grantee in accordance with this <b>Section&nbsp;8.10</b> or by will or the laws of descent and distribution.&#160; The provisions of <b>Section&nbsp;8.4</b> relating to termination of Service shall continue to be applied with respect to the original Grantee of the Option, following which such Option shall be exercisable by the transferee only to the extent, and for the periods specified, in <b>Section&nbsp;8.4</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.11</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Limitations on Incentive Stock Options.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An Option shall constitute an Incentive Stock Option only (a)&nbsp;if the Grantee of such Option is an Employee of the Company or any Subsidiary, (b)&nbsp;to the extent specifically provided in the related Award Agreement, (c)&nbsp;to the extent that the aggregate Fair Market Value (determined at the time such Option is granted) of the shares of Stock with respect to which all Incentive Stock Options held by such Grantee become exercisable for the first time during any calendar year (under the Plan and all other plans of the Company and its Affiliates) does not exceed one hundred thousand dollars ($100,000), and (d)&nbsp;to the extent such Option fulfills all other requirements under Code Section&nbsp;422.&#160; Except to the extent provided under Code Section&nbsp;422, this limitation shall be applied by taking Options into account in the order in which they were granted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.12</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notice of Disqualifying Disposition.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any Grantee shall make any disposition of shares of Stock issued pursuant to the exercise of an Incentive Stock Option under the circumstances provided in Code Section&nbsp;421(b)&nbsp;(relating to certain</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="3387-2-KS-05_PB_16_005844_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=152093,FOLIO='16',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">disqualifying dispositions), such Grantee shall notify the Company of such disposition immediately but in no event later than ten (10)&nbsp;days thereafter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Right to Payment and SAR Price.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A SAR shall confer on the Grantee to whom it is granted a right to receive, upon exercise thereof, the excess of (a)&nbsp;the Fair Market Value of one (1)&nbsp;share of Stock on the date of exercise, over (b)&nbsp;the SAR Price as determined by the Committee.&#160; The Award Agreement for a SAR shall specify the SAR Price, which shall be no less than the Fair Market Value of one (1)&nbsp;share of Stock on the Grant Date of such SAR.&#160; SARs may be granted in tandem with all or part of an Option granted under the Plan or at any subsequent time during the term of such Option, in combination with all or any part of any other Award, or without regard to any Option or other Award; provided that a SAR that is granted in tandem with all or part of an Option will have the same term, and expire at the same time, as the related Option; provided, further, that a SAR that is granted subsequent to the Grant Date of a related Option must have a SAR Price that is no less than the Fair Market Value of one (1)&nbsp;share of Stock on the Grant Date of such SAR.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Terms.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to <b>Sections 9.3</b> and <b>16.3</b>, the Committee shall determine, on the Grant Date or thereafter, the time or times at which, and the circumstances under which, a SAR may be exercised in whole or in part (including based on achievement of performance goals and/or future Service requirements); the time or times at which SARs shall cease to be or become exercisable following termination of Service or upon other conditions; the method of exercise, method of settlement, form of consideration payable in settlement, method by or forms in which shares of Stock shall be delivered or deemed to be delivered to Grantees, whether or not a SAR shall be granted in tandem or in combination with any other Award; and any and all other terms and conditions of any SAR; </font>provided that no SARs shall be granted to Grantees who are entitled to overtime under Applicable Laws that will vest or be exercisable within a six (6)-month period starting on the Grant Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Term.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each SAR granted under the Plan shall terminate, and all rights thereunder shall cease, on the day before the tenth (10th)&nbsp;anniversary of the Grant Date of such SAR or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Committee and stated in the Award Agreement relating to such SAR.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights of Holders of SARs</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise stated in the applicable Award Agreement, a Grantee or other Person holding or exercising a SAR shall have none of the rights of a stockholder of the Company (for example, the right to receive cash or dividend payments or distributions attributable to the shares of Stock underlying such SAR, to direct the voting of the shares of Stock underlying such SAR, or to receive notice of any meeting of the Company&#146;s stockholders) until the shares of Stock underlying such SAR, if any, are issued to such Grantee or other Person.&#160; Except as provided in <b>Section&nbsp;16</b>, no adjustment shall be made for dividends, distributions, or other rights with respect to any shares of Stock underlying a SAR for which the record date is prior to the date of issuance of such shares of Stock, if any.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="3387-2-KS-05_PB_17_005924_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=961921,FOLIO='17',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Transferability of SARs.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as provided in <b>Section&nbsp;9.6</b>, during the lifetime of a Grantee of a SAR, only the Grantee (or, in the event of such Grantee&#146;s legal incapacity or incompetency, such Grantee&#146;s guardian or legal representative) may exercise such SAR.&#160; Except as provided in <b>Section&nbsp;9.6</b>, no SAR shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Family Transfers.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee, in its sole discretion, may provide either in an applicable Award Agreement or by the subsequent approval of the Committee that a Grantee may transfer, not for value, all or part of a SAR to any Family Member.&#160; For the purpose of this <b>Section&nbsp;9.6</b>, a transfer &#147;not for value&#148; is a transfer which is (a)&nbsp;a gift, (b)&nbsp;a transfer under a domestic relations order in settlement of marital property rights, or (c)&nbsp;unless Applicable Laws do not permit such transfer, a transfer to an entity in which more than fifty percent (50%)&nbsp;of the voting interests are owned by Family Members (and/or the Grantee) in exchange for an interest in such entity.&#160; Following a transfer under this <b>Section&nbsp;9.6</b>, any such SAR shall continue to be subject to the same terms and conditions as were in effect immediately prior to such transfer.&#160; Subsequent transfers of transferred SARs shall be prohibited except to Family Members of the original Grantee in accordance with this <b>Section&nbsp;9.6</b> or by will or the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF RESTRICTED STOCK, RESTRICTED STOCK UNITS, AND DEFERRED STOCK UNITS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Grant of Restricted Stock, Restricted Stock Units, and Deferred Stock Units</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Awards of Restricted Stock, Restricted Stock Units, and Deferred Stock Units may be made for consideration or for no consideration, which shall be deemed paid by past Service or, if so provided in the related Award Agreement or a separate agreement, the promise by the Grantee to perform future Service to the Company or an Affiliate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Restrictions.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to <b>Sections 16.3</b> and <b>18.10</b>, at the time a grant of Restricted Stock, Restricted Stock Units, or Deferred Stock Units is made, the Committee may, in its sole discretion, (a)&nbsp;establish a Restricted Period applicable to such Restricted Stock, Restricted Stock Units, or Deferred Stock Units and (b)&nbsp;prescribe restrictions in addition to or other than the expiration of the Restricted Period, including the achievement of corporate or individual performance goals, which may be applicable to all or any portion of such Restricted Stock, Restricted Stock Units, or Deferred Stock Units as provided in <b>Section&nbsp;13</b>.&#160; Awards of Restricted Stock, Restricted Stock Units, and Deferred Stock Units may not be sold, transferred, assigned, pledged, or otherwise encumbered or disposed of during the Restricted Period or prior to the satisfaction of any other restrictions prescribed by the Committee with respect to such Awards.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Registration; Restricted Stock Certificates.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to <b>Section&nbsp;3.7</b>, to the extent that ownership of Restricted Stock is evidenced by a book-entry registration or direct registration (including transaction advices), such registration shall be notated to evidence the restrictions imposed on such Award of Restricted Stock under the Plan and the applicable Award Agreement.&#160; Subject to <b>Section&nbsp;3.7</b> and the immediately following sentence, the Company may issue, in the</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="3387-2-KS-05_PB_18_010050_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=626194,FOLIO='18',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">name of each Grantee to whom Restricted Stock has been granted, certificates representing the total number of shares of Restricted Stock granted to the Grantee, as soon as reasonably practicable after the Grant Date of such Restricted Stock.&#160; The Committee may provide in an Award Agreement with respect to an Award of Restricted Stock that either (a)&nbsp;the Secretary of the Company shall hold such certificates for such Grantee&#146;s benefit until such time as such shares of Restricted Stock are forfeited to the Company or the restrictions applicable thereto lapse and such Grantee shall deliver a stock power to the Company with respect to each certificate, or (b)&nbsp;such certificates shall be delivered to such Grantee, provided that such certificates shall bear legends that comply with Applicable Laws and make appropriate reference to the restrictions imposed on such Award of Restricted Stock under the Plan and such Award Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights of Holders of Restricted Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the Committee provides otherwise in an Award Agreement and subject to the restrictions set forth in the Plan, any applicable Company program, and the applicable Award Agreement, holders of Restricted Stock shall have the right to vote such shares of Restricted Stock and the right to receive any dividend payments or distributions declared or paid with respect to such shares of Restricted Stock.&#160; Notwithstanding the foregoing, cash dividends declared or paid on shares of Restricted Stock shall not vest or become payable unless and until the shares of Restricted Stock to which the dividends apply become vested and nonforfeitable.&#160; The Committee may provide in an Award Agreement evidencing a grant of Restricted Stock that any cash dividend payments or distributions paid on Restricted Stock shall be reinvested in shares of Stock, which shall be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock.&#160; All stock dividend payments or distributions, if any, received by a Grantee with respect to shares of Restricted Stock as a result of any stock split, stock dividend, combination of stock, or other similar transaction shall be subject to the same vesting conditions and restrictions as applicable to such underlying shares of Restricted Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights of Holders of Restricted Stock Units and Deferred Stock Units.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.5.1</font></b>&#160;&#160;&#160;&#160; <b>Voting and Dividend Rights.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holders of Restricted Stock Units and Deferred Stock Units shall have no rights as stockholders of the Company (for example, the right to receive dividend payments or distributions attributable to the shares of Stock underlying such Restricted Stock Units and Deferred Stock Units, to direct the voting of the shares of Stock underlying such Restricted Stock Units and Deferred Stock Units, or to receive notice of any meeting of the Company&#146;s stockholders); provided, however, that the Committee may provide in an Award Agreement evidencing a grant of Restricted Stock Units or Deferred Stock Units that the holder of such Restricted Stock Units or Deferred Stock Units shall be entitled to receive Dividend Equivalent Rights in accordance with <b>Section&nbsp;12.1</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.5.2</font></b>&#160;&#160;&#160;&#160; <b>Creditor&#146;s Rights.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A holder of Restricted Stock Units or Deferred Stock Units shall have no rights other than those of a general unsecured creditor of the Company.&#160; Restricted Stock Units and Deferred Stock Units represent unfunded and unsecured obligations of the Company, subject to the terms and conditions of the applicable Award Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="3387-2-KS-05_PB_19_010126_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=777112,FOLIO='19',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Service.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, but prior to termination of Grantee&#146;s Service, upon the termination of such Grantee&#146;s Service, any Restricted Stock, Restricted Stock Units, or Deferred Stock Units held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited.&#160; Upon forfeiture of such Restricted Stock, Restricted Stock Units, or Deferred Stock Units, the Grantee thereof shall have no further rights with respect thereto, including any right to vote such Restricted Stock or any right to receive dividends or Dividend Equivalent Rights, as applicable, with respect to such Restricted Stock, Restricted Stock Units, or Deferred Stock Units.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Purchase of Restricted Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Grantee of an Award of Restricted Stock shall be required, to the extent required by Applicable Laws, to purchase such Restricted Stock from the Company at a purchase price equal to the greater of (x)&nbsp;the aggregate par value of the shares of Stock represented by such Restricted Stock or (y)&nbsp;the purchase price, if any, specified in the Award Agreement relating to such Restricted Stock.&#160; Such purchase price shall be payable in a form provided in <b>Section&nbsp;14</b> or, in the sole discretion of the Committee, in consideration for Service rendered or to be rendered by the Grantee to the Company or an Affiliate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Delivery of Shares of Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon the expiration or termination of any Restricted Period and the satisfaction of any other conditions prescribed by the Committee, including, without limitation, any performance goals or delayed delivery period, the restrictions applicable to Restricted Stock, Restricted Stock Units, or Deferred Stock Units settled in shares of Stock shall lapse, and, unless otherwise provided in the applicable Award Agreement, a book-entry or direct registration (including transaction advices) or a certificate evidencing ownership of such shares of Stock shall, consistent with <b>Section&nbsp;3.7</b>, be issued, free of all such restrictions, to the Grantee thereof or such Grantee&#146;s beneficiary or estate, as the case may be.&#160; Neither the Grantee, nor the Grantee&#146;s beneficiary or estate, shall have any further rights with regard to a Restricted Stock Unit or Deferred Stock Unit once the shares of Stock represented by such Restricted Stock Unit or Deferred Stock Unit have been delivered in accordance with this <b>Section&nbsp;10.8</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS AND OTHER EQUITY-BASED AWARDS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Unrestricted Stock Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may, in its sole discretion, grant (or sell at the par value of a share of Stock or at such other higher purchase price as shall be determined by the Committee) an Award to any Grantee pursuant to which such Grantee may receive shares of Unrestricted Stock under the Plan.&#160; Awards of Unrestricted Stock may be granted or sold to any Grantee as provided in the immediately preceding sentence in respect of Service rendered or, if so provided in the related Award Agreement or a separate agreement, to be rendered by the Grantee to the Company or an Affiliate or other valid consideration, in lieu of or in addition to any cash compensation due to such Grantee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="3387-2-KS-05_PB_20_010151_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=684766,FOLIO='20',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-05_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:49 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Equity-Based Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may, in its sole discretion, grant Awards in the form of Other Equity-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan.&#160; Awards granted pursuant to this <b>Section&nbsp;11.2</b> may be granted with vesting, value, and/or payment contingent upon the achievement of one or more performance goals.&#160; The Committee shall determine the terms and conditions of Other Equity-Based Awards on the Grant Date or thereafter.&#160; Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, but prior to termination of Grantee&#146;s Service, upon the termination of a Grantee&#146;s Service, any Other Equity-Based Awards held by such Grantee that have not vested, or with respect to which all applicable restrictions and conditions have not lapsed, shall immediately be deemed forfeited.&#160; Upon forfeiture of any Other Equity-Based Award, the Grantee thereof shall have no further rights with respect to such Other Equity-Based Award.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Dividend Equivalent Rights.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A Dividend Equivalent Right may be granted hereunder, provided that no Dividend Equivalent Rights may be granted in connection with, or related to, an Award of Options or SARs.&#160; The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement therefor.&#160; Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently (with or without being subject to forfeiture or a repayment obligation) or may be deemed to be reinvested in additional shares of Stock or Awards, which may thereafter accrue additional Dividend Equivalent Rights (with or without being subject to forfeiture or a repayment obligation).&#160; Any such reinvestment shall be at the Fair Market Value thereof on the date of such reinvestment.&#160; Dividend Equivalent Rights may be settled in cash, shares of Stock, or a combination thereof, in a single installment or in multiple installments, all as determined in the sole discretion of the Committee.&#160; A Dividend Equivalent Right granted as a component of another Award may (a)&nbsp;provide that such Dividend Equivalent Right shall be settled upon exercise, settlement, or payment of, or lapse of restrictions on, such other Award and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award or (b)&nbsp;contain terms and conditions which are different from the terms and conditions of such other Award, provided that, notwithstanding the foregoing, Dividend Equivalent Rights granted as a component of another Award shall not vest or become payable unless and until the Award to which the Dividend Equivalent Rights correspond become vested and settled.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Service.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the Committee provides otherwise in an Award Agreement, in another agreement with the Grantee, or otherwise in writing after such Award Agreement is issued, a Grantee&#146;s rights in all Dividend Equivalent Rights shall automatically terminate upon such Grantee&#146;s termination of Service for any reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS AND CONDITIONS OF PERFORMANCE-BASED AWARDS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Grant of Performance-Based Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the terms and provisions of the Plan, the Committee, at any time and from time to time, may grant Performance-Based Awards in such amounts and upon such terms as the Committee shall determine.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="3387-2-KS-07_PB_21_010259_3562"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=851608,FOLIO='21',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Value of Performance-Based Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each grant of a Performance-Based Award shall have an initial cash value or an actual or target number of shares of Stock that is established by the Committee as of the Grant Date.&#160; The Committee shall set performance goals in its discretion which, depending on the extent to which they are achieved, shall determine the value and/or number of shares of Stock subject to a Performance-Based Award that will be paid out to the Grantee thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Earning of Performance-Based Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the terms of the Plan, after the applicable Performance Period has ended, the Grantee of a Performance-Based Award shall be entitled to receive a payout of the value earned under such Performance-Based Award by such Grantee over such Performance Period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Form&nbsp;and Timing of Payment of Performance-Based Awards.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment of the value earned under Performance-Based Awards shall be made, as determined by the Committee, in the form, at the time, and in the manner described in the applicable Award Agreement.&#160; Subject to the terms of the Plan, the Committee, in its sole discretion, (a)&nbsp;may pay the value earned under Performance-Based Awards in the form of cash, shares of Stock, other Awards, or a combination thereof, including shares of Stock and/or Awards that are subject to any restrictions deemed appropriate by the Committee, and (b)&nbsp;shall pay the value earned under Performance-Based Awards at the close of the applicable Performance Period, or as soon as reasonably practicable after the Committee has determined that the performance goal or goals relating thereto have been achieved; provided that, unless specifically provided in the Award Agreement for such Performance-Based Awards, such payment shall occur no later than the fifteenth (15</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day of the third (3<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">rd</font>) month following the end of the calendar year in which such Performance Period ends.&#160; The applicable Award Agreement shall specify the circumstances in which Performance-Based Awards shall be paid or forfeited in the event of termination of Service by the Grantee prior to the end of a Performance Period or settlement of such Performance-Based Awards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Performance Conditions.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The right of a Grantee to exercise or to receive a grant or settlement of any Performance-Based Award, and the timing thereof, may be subject to such performance conditions as may be specified by the Committee.&#160; The Committee may use such performance goals, business criteria, and other measures of performance, with or without adjustment, as it may deem appropriate in establishing any performance conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>FORMS OF PAYMENT</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>General Rule.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment of the Option Price for the shares of Stock purchased pursuant to the exercise of an Option or the purchase price, if any, for Restricted Stock shall be made in cash or in cash equivalents acceptable to the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="3387-2-KS-07_PB_22_010317_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=146688,FOLIO='22',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Surrender of Shares of Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that the applicable Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option or the purchase price, if any, for Restricted Stock may be made all or in part through the tender or attestation to the Company of shares of Stock, which shall be valued, for purposes of determining the extent to which such Option Price or purchase price has been paid thereby, at their Fair Market Value on the date of such tender or attestation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Cashless Exercise.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent permitted by Applicable Laws and to the extent the Award Agreement so provides, payment of the Option Price for shares of Stock purchased pursuant to the exercise of an Option and payment of any withholding taxes described in <b>Section&nbsp;18.3 </b>may be made all or in part by delivery (on a form acceptable to the Committee) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell shares of Stock and to deliver all or part of the proceeds of such sale to the Company in payment of such Option Price and/or any withholding taxes described in <b>Section&nbsp;18.3</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Forms of Payment.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that the applicable Award Agreement so provides and/or unless otherwise specified in an Award Agreement, payment of the Option Price for shares of Stock purchased pursuant to exercise of an Option, for the purchase price, if any, for Restricted Stock, or for any withholding taxes described in <b>Section&nbsp;18.3</b> may be made in any other form that is consistent with Applicable Laws, including (a)&nbsp;with respect to the purchase price of Restricted Stock only, Service rendered or to be rendered by the Grantee thereof to the Company or an Affiliate and (b)&nbsp;with the consent of the Committee, by withholding the number of shares of Stock that would otherwise vest or be issuable in an amount equal in value to the Option Price or purchase price and/or the applicable tax withholding amount.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>REQUIREMENTS OF LAW</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>General.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company shall not be required to offer, sell, or issue any shares of Stock under any Award, whether pursuant to the exercise of an Option, a SAR, or otherwise, if the offer, sale, or issuance of such shares of Stock would constitute a violation by the Grantee, the Company, an Affiliate, or any other Person of any provision of the Company&#146;s certificate of incorporation or bylaws or of Applicable Laws, including any federal or state securities laws or regulations.&#160; If at any time the Company shall determine, in its discretion, that the listing, registration, or qualification of any shares of Stock subject to an Award upon any Stock Exchange or Securities Market or under any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the offering, sale, issuance, or purchase of shares of Stock in connection with any Award, no shares of Stock may be offered, sold, or issued to the Grantee or any other Person under such Award, whether pursuant to the exercise of an Option, a SAR, or otherwise, unless such listing, registration, or qualification shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way affect the date of termination of such Award.&#160; Without limiting the generality of the foregoing, upon the exercise of any Option or any SAR that may be settled in shares of Stock or the delivery of any shares of Stock underlying an Award, unless a registration statement under the Securities Act is in effect with respect to the shares of Stock subject to such Award, the Company shall not be required to offer, sell, or issue such shares of Stock unless the Committee shall have received evidence satisfactory to it</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="3387-2-KS-07_PB_23_010417_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=821123,FOLIO='23',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that the Grantee or any other Person exercising such Option or SAR or accepting delivery of such shares may acquire such shares of Stock pursuant to an exemption from registration under the Securities Act.&#160; Any determination by the Committee in connection with the foregoing shall be final, binding, and conclusive.&#160; The Company may register, but shall in no event be obligated to register, any shares of Stock or other securities issuable pursuant to the Plan pursuant to the Securities Act.&#160; The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or a SAR or the issuance of shares of Stock or other securities issuable pursuant to the Plan or any Award to comply with any Applicable Laws.&#160; As to any jurisdiction that expressly imposes the requirement that an Option or SAR that may be settled in shares of Stock shall not be exercisable until the shares of Stock subject to such Option or SAR are registered under the securities laws thereof or are exempt from such registration, the exercise of such Option or SAR under circumstances in which the laws of such jurisdiction apply shall be deemed conditioned upon the effectiveness of such registration or the availability of such an exemption.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rule&nbsp;16b-3.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During any time when the Company has any class of common equity securities registered under Section&nbsp;12 of the Exchange Act, it is the intention of the Company that Awards pursuant to the Plan and the exercise of Options and SARs granted hereunder that would otherwise be subject to Section&nbsp;16(b)&nbsp;of the Exchange Act shall qualify for the exemption provided by Rule&nbsp;16b-3 under the Exchange Act.&#160; To the extent that any provision of the Plan or action by the Committee does not comply with the requirements of such Rule&nbsp;16b-3, such provision or action shall be deemed inoperative with respect to such Awards to the extent permitted by Applicable Laws and deemed advisable by the Committee and shall not affect the validity of the Plan.&#160; In the event that such Rule&nbsp;16b-3 is revised or replaced, the Committee may exercise its discretion to modify the Plan in any respect necessary or advisable in its judgment to satisfy the requirements of, or to permit the Company to avail itself of the benefits of, the revised exemption or its replacement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>EFFECT OF CHANGES IN CAPITALIZATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Changes in Stock.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the number of outstanding shares of Stock is increased or decreased or the shares of Stock are changed into or exchanged for a different number of shares or kind of Capital Stock or other securities of the Company on account of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of stock, exchange of stock, stock dividend or other distribution payable in capital stock, or other increase or decrease in shares of Stock effected without receipt of consideration by the Company occurring after the Effective Date, the number and kinds of shares of Capital Stock for which grants of Awards may be made under the Plan, including the maximum number of shares of Capital Stock that may be issued pursuant to the exercise of Incentive Stock Options, and the individual share limitation set forth in <b>Section&nbsp;6.2</b>, shall be adjusted proportionately and accordingly by the Committee. In addition, the number and kind of shares of Capital Stock for which Awards are outstanding shall be adjusted proportionately and accordingly by the Committee so that the proportionate interest of the Grantee therein immediately following such event shall, to the extent practicable, be the same as immediately before such event.&#160; Any such adjustment in outstanding Options or SARs shall not change the aggregate Option Price or SAR Price payable with respect to shares that are subject to the unexercised portion of such outstanding Options or SARs, as applicable, but shall include a corresponding proportionate adjustment in the per share Option Price or SAR Price, as the case may be.&#160; The conversion of any convertible securities of the Company shall not be treated as an increase in shares effected without receipt of consideration.&#160; Notwithstanding the foregoing, in the event of any distribution to the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="3387-2-KS-07_PB_24_010537_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=755741,FOLIO='24',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s stockholders of securities of any other entity or other assets (including an extraordinary dividend, but excluding a non-extraordinary dividend, declared and paid by the Company) without receipt of consideration by the Company, the Board or the Committee constituted pursuant to <b>Section&nbsp;3.1.2</b> shall, in such manner as the Board or the Committee deems appropriate, adjust (a)&nbsp;the number and kind of shares of Capital Stock subject to outstanding Awards and/or (b)&nbsp;the aggregate and per share Option Price of outstanding Options and the aggregate and per share SAR Price of outstanding SARs as required to reflect such distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Reorganization in Which the Company Is the Surviving Entity Which Does not Constitute a Change in Control.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to <b>Section&nbsp;16.3</b>, if the Company shall be the surviving entity in any reorganization, merger, or consolidation of the Company with one or more other entities which does not constitute a Change in Control, any Award theretofore granted pursuant to the Plan shall pertain to and apply to the Capital Stock to which a holder of the number of shares of Stock subject to such Award would have been entitled immediately following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the per share Option Price or SAR Price of any outstanding Option or SAR so that the aggregate Option Price or SAR Price thereafter shall be the same as the aggregate Option Price or SAR Price of the shares of Stock remaining subject to the Option or SAR as in effect immediately prior to such reorganization, merger, or consolidation. Subject to any contrary language in an Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing, any restrictions applicable to such Award shall apply as well to any replacement shares of Capital Stock subject to such Award, or received by the Grantee, as a result of such reorganization, merger, or consolidation.&#160; In the event of any reorganization, merger, or consolidation of the Company referred to in this <b>Section&nbsp;16.2</b>, Performance-Based Awards shall be adjusted, including any adjustment to the performance conditions applicable to such Awards deemed appropriate by the Committee and including any adjustment so as to apply to the Capital Stock that a holder of the number of shares of Stock subject to the Performance-Based Awards would have been entitled to receive immediately following such reorganization, merger, or consolidation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Change in Control in which Awards are not Assumed.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing, upon the occurrence of a Change in Control in which outstanding Awards are not being assumed, continued, or substituted for, the following provisions shall apply to such Award, to the extent not assumed, continued, or substituted for:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immediately prior to the occurrence of such Change in Control, in each case with the exception of Performance-Based Awards, all outstanding shares of Restricted Stock, and all Restricted Stock Units, Deferred Stock Units, and Dividend Equivalent Rights shall be deemed to have vested, and all shares of Stock and/or cash subject to such Awards shall be delivered; and either or both of the following two (2)&nbsp;actions shall be taken:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At least fifteen (15)&nbsp;days prior to the scheduled consummation of such Change in Control, all Options and SARs outstanding hereunder shall become immediately exercisable and shall remain exercisable for a period of fifteen (15)&nbsp;days.&#160; Any exercise of an Option or SAR during this fifteen (15)-day period shall be conditioned upon the consummation of the applicable Change in Control and shall be effective only immediately before the consummation thereof, and upon consummation of such Change in Control, the </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="3387-2-KS-07_PB_25_010620_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=577621,FOLIO='25',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Plan and all outstanding but unexercised Options and SARs shall terminate, with or without consideration (including, without limitation, consideration in accordance with clause (ii)&nbsp;below) as determined by the Committee in its sole discretion.&#160; The Committee shall send notice of an event that shall result in such a termination to all Persons who hold Options and SARs not later than the time at which the Company gives notice thereof to its stockholders;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and/or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Committee may elect, in its sole discretion, to cancel any outstanding Awards of Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock Units, and/or Dividend Equivalent Rights and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in cash or Capital Stock having a value (as determined by the Committee acting in good faith), in the case of Restricted Stock, Restricted Stock Units, Deferred Stock Units, and Dividend Equivalent Rights (for shares of Stock subject thereto), equal to the formula or fixed price per share paid to holders of shares of Stock pursuant to such Change in Control and, in the case of Options or SARs, equal to the product of the number of shares of Stock subject to such Options or SARs multiplied by the amount, if any, by which (x)&nbsp;the formula or fixed price per share paid to holders of shares of Stock pursuant to such transaction exceeds (y)&nbsp;the Option Price or SAR Price applicable to such Options or SARs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For Performance-Based Awards, (i)&nbsp;if less than half of the Performance Period has elapsed, then such Performance-Based Awards shall be treated as though target performance has been achieved, and (ii)&nbsp;if at least half of the Performance Period has elapsed, then actual performance to date shall be determined as of a date reasonably proximal to the date of the consummation of the Change in Control, as determined by the Committee in its sole discretion, and that level of performance thus determined shall be treated as achieved immediately prior to occurrence of the Change in Control.&#160; For purposes of clause (ii)&nbsp;of the preceding sentence, if, based on the discretion of the Committee, actual performance is not determinable, the Performance-Based Awards shall be treated as though target performance has been achieved.&#160; After application of this <b>Section&nbsp;16.3(b)</b>, if any Awards arise from application of this <b>Section&nbsp;16.3(b)</b>, such Awards shall be settled under the applicable provision of <b>Section&nbsp;16.3(a)</b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other Equity-Based Awards shall be governed by the terms of the applicable Award Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Change in Control in which Awards are Assumed.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in the applicable Award Agreement, in another agreement with the Grantee, or as otherwise set forth in writing, upon the occurrence of a Change in Control in which outstanding Awards are being assumed, continued, or substituted for, the following provisions shall apply to such Award, to the extent assumed, continued, or substituted for:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Plan and the Awards granted under the Plan shall continue in the manner and under the terms so provided in the event of any Change in Control to the extent that provision is made in writing in connection with such Change in Control for the assumption or continuation of such Awards, or for the substitution for such Awards of new stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, dividend equivalent rights, or other equity-based awards relating to the Capital Stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustments as to the number of</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="3387-2-KS-07_PB_26_010713_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=89183,FOLIO='26',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares (disregarding any consideration that is not common stock) and exercise prices of options and stock appreciation rights. </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event a Grantee&#146;s Award is assumed, continued, or substituted upon the consummation of any Change in Control and the Grantee&#146;s employment is terminated by the Company (or its successor) without Cause within the twelve (12)-month period following the consummation of such Change in Control, the Grantee&#146;s Award will become fully vested as of such termination and may be exercised in full, to the extent applicable, beginning on the date of such termination and for the one-year period immediately following such termination or for such longer period as the Committee shall determine (but in no event later than the original expiration date of the Award).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Adjustments</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments under this <b>Section&nbsp;16</b> related to shares of Stock or other Capital Stock of the Company shall be made by the Committee, whose determination in that respect shall be final, binding, and conclusive.&#160; No fractional shares or other securities shall be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest whole share.&#160; The Committee may provide in the applicable Award Agreement as of the Grant Date, in another agreement with the Grantee, or otherwise in writing at any time thereafter with the consent of the Grantee, for different provisions to apply to an Award in place of those provided in <b>Sections 16.1, 16.2, 16.3, </b>and<b> 16.4</b>.&#160; This <b>Section&nbsp;16</b> shall not limit the Committee&#146;s ability to provide for alternative treatment of Awards outstanding under the Plan in the event of a change in control event involving the Company that is not a Change in Control.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>No Limitations on Company.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The making of Awards pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve, or liquidate, or to sell or transfer all or any part of its business or assets (including all or any part of the business or assets of any Subsidiary or other Affiliate) or to engage in any other transaction or activity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PARACHUTE LIMITATIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any Grantee is a Disqualified Individual, then, notwithstanding any other provision of the Plan or of any Other Agreement to the contrary and notwithstanding any Benefit Arrangement, any right of the Grantee to any exercise, vesting, payment, or benefit under the Plan shall be reduced or eliminated:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent that such right to exercise, vesting, payment, or benefit, taking into account all other rights, payments, or benefits to or for the Grantee under the Plan, all Other Agreements, and all Benefit Arrangements, would cause any exercise, vesting, payment, or benefit to the Grantee under the Plan to be considered a Parachute Payment; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if, as a result of receiving such Parachute Payment, the aggregate after-tax amounts received by the Grantee from the Company under the Plan, all Other Agreements, and all Benefit Arrangements would be less than the maximum after-tax amount that could be received by the Grantee without causing any such payment or benefit to be considered a Parachute Payment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="3387-2-KS-07_PB_27_010758_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=1046784,FOLIO='27',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-07_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 24 01:08 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as required by Code Section&nbsp;409A or to the extent that Code Section&nbsp;409A permits discretion, the Committee shall have the right, in the Committee&#146;s sole discretion, to designate those rights, payments, or benefits under the Plan, all Other Agreements, and all Benefit Arrangements that should be reduced or eliminated so as to avoid having such rights, payments, or benefits be considered a Parachute Payment; provided, however, to the extent any payment or benefit constitutes deferred compensation under Code Section&nbsp;409A, in order to comply with Code Section&nbsp;409A, the Company shall instead accomplish such reduction by first reducing or eliminating any cash payments, then by reducing or eliminating any accelerated vesting of Performance-Based Awards, then by reducing or eliminating any accelerated vesting of Options or SARs, then by reducing or eliminating any accelerated vesting of Restricted Stock, Restricted Stock Units, or Deferred Stock Units, then by reducing or eliminating any other remaining Parachute Payments, in each case with the payments to be made furthest in the future being reduced first.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GENERAL PROVISIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.1</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Disclaimer of Rights.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No provision in the Plan, any Award, or any Award Agreement shall be construed (a)&nbsp;to confer upon any individual the right to remain in the Service of the Company or an Affiliate, (b)&nbsp;to interfere in any way with any contractual or other right or authority of the Company or an Affiliate either to increase or decrease the compensation or other payments to any Person at any time, or (c)&nbsp;to terminate any Service or other relationship between any Person and the Company or an Affiliate.&#160; In addition, notwithstanding any provision of the Plan to the contrary, unless otherwise stated in the applicable Award Agreement, in another agreement with the Grantee, or otherwise in writing, no Award granted under the Plan shall be affected by any change of duties or position of the Grantee thereof, so long as such Grantee continues to provide Service.&#160; The obligation of the Company to pay any benefits pursuant to the Plan shall be interpreted as a contractual obligation to pay only those amounts provided herein, in the manner and under the conditions prescribed herein.&#160; The Plan and Awards shall in no way be interpreted to require the Company to transfer any amounts to a third-party trustee or otherwise hold any amounts in trust or escrow for payment to any Grantee or beneficiary under the terms of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.2</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Nonexclusivity of the Plan.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither the adoption of the Plan nor the submission of the Plan to the stockholders of the Company for approval shall be construed as creating any limitations upon the right and authority of the Board or the Committee to adopt such other incentive compensation arrangements (which arrangements may be applicable either generally to a class or classes of individuals or specifically to a particular individual or particular individuals) as the Board or the Committee in their discretion determine desirable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.3</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Withholding Taxes.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any federal, state, or local taxes of any kind required by Applicable Laws to be withheld with respect to the vesting of or other lapse of restrictions applicable to an Award or upon the issuance of any shares of Stock upon the exercise of an Option or pursuant to any other Award.&#160; At the time of such vesting, lapse, or exercise, the Grantee shall pay in cash to the Company or an Affiliate, as the case may be, any amount that the Company or such Affiliate may reasonably determine to be necessary to satisfy such withholding obligation; provided that if there is a same-day sale of shares of Stock subject to an Award, the Grantee shall pay such withholding obligation on the day on which such same-day</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="3387-2-KS-09_PB_28_010903_15"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=705413,FOLIO='28',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">sale is completed.&#160; Subject to the prior approval of the Company or an Affiliate, which may be withheld by the Company or such Affiliate, as the case may be, in its sole discretion, the Grantee may elect to satisfy such withholding obligation, in whole or in part, (a)&nbsp;by causing the Company or such Affiliate to withhold shares of Stock otherwise issuable to the Grantee or (b)&nbsp;by delivering to the Company or such Affiliate shares of Stock already owned by the Grantee.&#160; The shares of Stock so withheld or delivered shall have an aggregate Fair Market Value equal to such withholding obligation.&#160; The Fair Market Value of the shares of Stock used to satisfy such withholding obligation shall be determined by the Company or such Affiliate as of the date on which the amount of tax to be withheld is to be determined.&#160; A Grantee who has made an election pursuant to this <b>Section&nbsp;18.3</b> may satisfy such Grantee&#146;s withholding obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting, or other similar requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The maximum number of shares of Stock that may be withheld from any Award to satisfy any federal, state, or local tax withholding requirements upon the exercise, vesting, or lapse of restrictions applicable to any Award or payment of shares of Stock pursuant to such Award, as applicable, may not exceed such number of shares of Stock having a Fair Market Value equal to the minimum statutory amount required by the Company or the applicable Affiliate to be withheld and paid to any such federal, state, or local taxing authority with respect to such exercise, vesting, lapse of restrictions, or payment of shares of Stock; provided, however, for so long as Accounting Standards Update 2016-09 or a similar rule&nbsp;remains in effect, the Board or the Committee has full discretion to choose, or to allow a Grantee to elect, to withhold a number of shares of Stock having an aggregate Fair Market Value that is greater than the applicable minimum required statutory withholding obligation (but such withholding may in no event be in excess of the maximum required statutory withholding amount(s)&nbsp;in such Grantee&#146;s relevant tax jurisdictions).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.4</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Captions.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The use of captions in the Plan or any Award Agreement is for convenience of reference only and shall not affect the meaning of any provision of the Plan or such Award Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.5</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Construction.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the context otherwise requires, all references in the Plan to &#147;including&#148; shall mean &#147;including without limitation.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.6</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Provisions.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Award granted under the Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Committee, in its sole discretion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.7</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Number and Gender.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to words used in the Plan, the singular form shall include the plural form, and the masculine gender shall include the feminine gender, as the context requires.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.8</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Severability.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="3387-2-KS-09_PB_29_010944_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=308830,FOLIO='29',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.9</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Governing Law.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The validity and construction of the Plan and the instruments evidencing the Awards hereunder shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, other than any conflicts or choice of law rule&nbsp;or principle that might otherwise refer construction or interpretation of the Plan and the instruments evidencing the Awards granted hereunder to the substantive laws of any other jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.10</font></b>&#160;&#160;&#160;&#160;&#160; <b>Section&nbsp;409A of the Code.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Plan is intended to comply with Code Section&nbsp;409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan will be interpreted and administered to be in compliance with Code Section&nbsp;409A.&#160; Any payments described in the Plan that are due within the Short-Term Deferral Period will not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding any provision of the Plan to the contrary, to the extent required to avoid accelerated taxation and tax penalties under Code Section&nbsp;409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6)-month period immediately following the Grantee&#146;s Separation from Service will instead be paid on the first payroll date after the six (6)-month anniversary of the Grantee&#146;s Separation from Service (or the Grantee&#146;s death, if earlier).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Furthermore, notwithstanding anything in the Plan to the contrary, in the case of an Award that is characterized as deferred compensation under Code Section&nbsp;409A, and pursuant to which settlement and delivery of the cash or shares of Stock subject to the Award is triggered based on a Change in Control, in no event will a Change in Control be deemed to have occurred for purposes of such settlement and delivery of cash or shares of Stock if the transaction is not also a &#147;change in the ownership or effective control of&#148; the Company or &#147;a change in the ownership of a substantial portion of the assets of&#148; the Company as determined under Treasury Regulation Section&nbsp;1.409A-3(i)(5)&nbsp;(without regard to any alternative definition thereunder).&#160; If an Award characterized as deferred compensation under Code Section&nbsp;409A is not settled and delivered on account of the provision of the preceding sentence, the settlement and delivery shall occur on the next succeeding settlement and delivery triggering event that is a permissible triggering event under Code Section&nbsp;409A.&#160; No provision of this paragraph shall in any way affect the determination of a Change in Control for purposes of vesting in an Award that is characterized as deferred compensation under Code Section&nbsp;409A.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the foregoing, neither the Company nor the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Grantee under Code Section&nbsp;409A, and neither the Company or an Affiliate nor the Board or the Committee will have any liability to any Grantee for such tax or penalty.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">30<a name="3387-2-KS-09_PB_30_011012_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=860363,FOLIO='30',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:50 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To record adoption of the Plan by the Board as of&#160;&#160;&#160;&#160;&#160;&#160; , 2019 and approval of the Plan by the Company&#146;s stockholders as of&#160;&#160;&#160;&#160;&#160;&#160; , 2019, the Company has caused its authorized officer to execute the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page&nbsp;to the NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2238596",CP="NEXTCURE, INC.",DN="4",CHK=269858,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KS-09_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:50 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>5
<FILENAME>a2238596zex-10_9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.9</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Option No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCENTIVE STOCK OPTION AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COVER SHEET</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), hereby grants an option (the &#147;<b>Option</b>&#148;) to purchase shares of its common stock, par value $0.001 (the &#147;<b>Stock</b>&#148;), to the individual named below as Grantee, subject to the vesting and other conditions set forth below.&#160; The terms and conditions of the Option are set forth in this cover sheet and in the attachment (collectively, the &#147;<b>Agreement</b>&#148;) and in the Company&#146;s 2019 Omnibus Incentive Plan (as it may be amended from time to time, the &#147;<b>Plan</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of Shares of Stock Covered by Option:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option Price per Share of Stock:&#160; U.S. $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Start Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of which has been provided or made available to you.&#160; You acknowledge that you have carefully reviewed the Plan, and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with the Plan.&#160; Certain capitalized terms used in this Agreement are defined in the Plan, and have the meaning set forth in the Plan.</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grantee:</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company:</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:40.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="70" style="border:none;"></td>
<td width="42" style="border:none;"></td>
<td width="246" style="border:none;"></td>
<td width="98" style="border:none;"></td>
<td width="252" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=785637,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Attachment</font></u></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This document is not a stock certificate or a negotiable instrument.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KM-01_PB_2_132625_1863"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=508323,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCENTIVE STOCK OPTION AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Incentive Stock Option</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement evidences an award of an Option   exercisable for that number of shares of Stock set forth on the cover sheet   and subject to the vesting and other conditions set forth in this Agreement   and in the Plan. This Option is intended to be an incentive stock option   under Section&nbsp;422 of the Code and will be interpreted accordingly. If   you cease to be an employee of the Company, its parent or a subsidiary (&#147;<b>Employee</b>&#148;) but continue to provide Service, this option   will be deemed a Nonqualified Stock Option three (3)&nbsp;months after you   cease to be an Employee. In addition, to the extent that all or part of this   Option exceeds the one hundred thousand dollar ($100,000) rule&nbsp;of   Section&nbsp;422(d)&nbsp;of the Code, this Option or the lesser excess part   will be deemed to be a Nonqualified Stock Option.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Vesting&nbsp;&amp; Exercisability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is only exercisable before it expires   and then only with respect to the vested portion of the Option. This Option   shall vest in accordance with the vesting schedule set forth on the cover   sheet of this Agreement; provided, however, that for purposes of vesting,   fractional numbers of shares of Stock shall be rounded to the nearest whole   number, and you cannot vest in more than the number of shares covered by this   Option. Subject to the preceding sentence, you may exercise this Option, in whole   or in part, to purchase a whole number of vested shares of not less than one   hundred (100) shares, unless the number of shares purchased is the total   number available for purchase under the Option, by following the procedures   set forth in the Plan and below in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the termination of your Service triggers   accelerated vesting or other treatment of your Option pursuant to the terms   of this Agreement or the Plan, you shall immediately and automatically   forfeit the unvested portion of the Option to the Company in the event your   Service terminates for any reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Change in Control</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a Change in Control, your Option   will be treated in the manner provided in Sections 16.3 or 16.4 of the Plan,   as applicable.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Term</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything in this Agreement to the   contrary, the Option shall expire and you shall immediately and automatically   forfeit the Option to the Company in any event at the close of business at   Company headquarters on the Expiration Date, as shown on the cover sheet.   Your Option will expire earlier (but never later) if your Service terminates,   as described below.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Regular Termination</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates for any reason, other   than due to death or Disability or for Cause, then your Option will expire at   the close of business at Company headquarters on the ninetieth (90</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day after your </p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KM-01_PB_3_122608_4545"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=953011,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">termination date.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination for Cause</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service is terminated for Cause, then you   shall immediately forfeit all rights to your Option (including to any vested   portion of the Option) and the Option shall immediately expire.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination due to Death or Disability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your death or Disability,   then upon such termination you will be automatically credited with an   additional twelve (12) months of Service for vesting purposes.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Death</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your death, then   your Option will expire at the close of business at Company headquarters on   the date that is twelve (12) months after the date of your death. During such   twelve (12) month period, your estate or heirs may exercise the vested   portion of your Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, if you die during the ninety (90) day   period described in connection with a regular termination (i.e., a   termination of your Service other than due to death or Disability or for   Cause), and a vested portion of your Option has not yet been exercised, then   such vested portion of your Option will instead expire on the date that is   twelve (12) months after your termination date. In such a case, during the   period following your death up to the date that is twelve (12) months after   your termination date, your estate or heirs may exercise the vested portion   of your Option.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Disability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your Disability,   then your Option will expire at the close of business at Company headquarters   on the date that is twelve (12) months after your termination date. During   such twelve (12) month period, you (or your guardian or legal representative,   as applicable) may exercise the vested portion of your Option.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Leaves of Absence</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Option, your Service does not   terminate when you go on a <i>bona fide</i>   employee leave of absence that was approved by the Company in writing, if the   terms of the leave provide for continued Service crediting, or when continued   Service crediting is required by applicable law. However, in all other cases,   your Service will be treated as terminating ninety (90) days after you went   on employee leave, unless your right to return to active work is guaranteed   by law or by a contract. Your Service terminates in any event when the   approved leave ends unless you immediately return to active employee work.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company determines, in its sole discretion,   which leaves count for this purpose, and when your Service terminates for all   purposes under the Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notice of Exercise</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">When you wish to exercise this Option, you must   notify the Company by filing the proper &#147;Notice of Exercise&#148; form at the   address given on the form. Your notice must specify how many shares you wish   to purchase. Your notice must also specify how your shares of Stock should be   registered (in your name only or in your and your spouse&#146;s names as joint   tenants with right of survivorship). The notice will be effective when it is   received by the Company. </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KM-01_PB_4_123008_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=10815,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If someone else wants to exercise this Option after   your death, that person must prove to the Company&#146;s satisfaction that he or   she is entitled to do so.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;of Payment</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">When you submit your notice of exercise, you must   include payment of the option price indicated on the cover sheet for the   shares you are purchasing. Payment may be made in one (or a combination) of   the following forms:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Cash, your   personal check, a cashier&#146;s check, a money order, or another cash equivalent   acceptable to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Shares of   Stock which are owned by you and which are surrendered to the Company and   which are not subject to any repurchase, forfeiture, unfulfilled vesting, or   other similar requirements. The Fair Market Value of the shares of Stock as   of the effective date of the Option exercise will be applied to the Option   Price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>By delivery   (on a form prescribed by the Company) of an irrevocable direction to a   licensed securities broker acceptable to the Company to sell shares of Stock   and to deliver all or part of the sale proceeds to the Company in payment of   the aggregate Option Price and any withholding taxes (if approved in advance   by the Committee or the Board if you are either an executive officer or a   director of the Company).</p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Evidence of Issuance</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of the shares of Stock upon exercise of   your Option shall be evidenced in such a manner as the Company, in its   discretion, will deem appropriate, including, without limitation, book-entry,   direct registration, or issuance of one or more Stock certificates.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Withholding Taxes</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree as a condition of this Agreement that you   will make acceptable arrangements to pay any withholding or other taxes that   may be due relating to the exercise of this Option, the sale of shares of   Stock acquired under this Option, or as otherwise arising under this Option.   In the event that the Company or any Affiliate determines that any federal,   state, local, or foreign tax or withholding payment is required relating to   the exercise of this Option, the sale of shares of Stock acquired under this   Option, or as otherwise arising under this Option, the Company or any   Affiliate shall have the right to (i)&nbsp;require you to tender a cash   payment, (ii)&nbsp;deduct from payments of any kind otherwise due to you, or   (iii)&nbsp;withhold the delivery of vested shares of Stock otherwise deliverable   under this Agreement to meet such obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any shares of Stock so withheld will have an   aggregate Fair Market Value not exceeding the minimum amount of tax required   to be withheld by applicable laws; provided, however, for so long as   Accounting Standards Update 2016-09 or a similar rule&nbsp;is otherwise in   effect, the Board or the Committee has full discretion to choose, or to allow   you to elect, to withhold a number of shares of Stock having an aggregate   Fair Market Value that is greater than the applicable minimum required   statutory withholding obligation (but such withholding may in no event</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KM-01_PB_5_123015_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=136793,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">be in excess of the maximum statutory withholding   amount(s)&nbsp;in your relevant tax jurisdictions).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree that the Company or any Affiliate shall be   entitled to use whatever method it may deem appropriate to recover such   taxes. You further agree that the Company or any Affiliate may, as it   reasonably considers necessary, amend or vary this Agreement to facilitate   such recovery of taxes.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Transfer of Option</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as provided in Section&nbsp;8.10 of the Plan,   during your lifetime, only you (or, in the event of your legal incapacity or   incompetency, your guardian or legal representative) may exercise the Option.   Except as provided in Section&nbsp;8.10 of the Plan, you may not transfer,   assign, pledge, hypothecate, or otherwise encumber this Option. For instance,   you may not sell this Option or use it as security for a loan. If you attempt   to do any of these things, this Option will immediately become forfeited. You   may, however, dispose of this Option in your will or it may be transferred   upon your death by the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regardless of any marital property settlement agreement,   the Company is not obligated to honor a notice of exercise from your spouse,   nor is the Company obligated to recognize your spouse&#146;s interest in your   Option in any other way.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Retention Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither your Option nor this Agreement gives you the   right to be retained or employed by the Company (or any Affiliate) in any   capacity. Unless otherwise specified in any written employment or other   agreement between the Company or any Affiliate and you, the Company (and any   Affiliate) reserves the right to terminate your Service at any time and for   any reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stockholder Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You, or your estate or heirs, have no rights as a   stockholder of the Company until the shares of Stock have been issued upon   exercise of your Option and either a certificate evidencing your shares of   Stock has been issued or an appropriate entry has been made on the Company&#146;s   books. No adjustments are made for dividends or other rights if the   applicable record date occurs before your stock certificate is issued (or an   appropriate book entry has been made).</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you should take actions in violation or breach of   or in conflict with any agreement prohibiting solicitation of employees or   clients of the Company or any Affiliate, any non-competition obligation with   respect to the Company or any Affiliate, any Company policy or procedure, any   other agreement with or obligation to the Company or any Affiliate, or any   confidentiality obligation with respect to the Company or any Affiliate, the   Company has the right to cause an immediate forfeiture of your rights to this   Option and the immediate expiration of the Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting the generality of the foregoing,   if, during your Service or the twelve (12) month period following the   termination of your Service for any reason, you should take actions in   competition with the Company, the Company shall have the right, in its sole   discretion, (i)&nbsp;to cause a</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KM-01_PB_6_123238_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=841473,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">forfeiture of any portion of your Option that   remains outstanding, and, (ii)&nbsp;with respect to any shares of Stock that   you have acquired upon exercise of this Option during the period commencing   on the date that is twelve (12) months prior to your termination of Service,   to require you to make a cash payment to the Company (or to forfeit shares of   Stock to the Company) in an amount determined as follows: (1)&nbsp;for any   shares of Stock that you have sold prior to receiving notice from the   Company, the amount will be the proceeds received from the sale(s), and   (2)&nbsp;for any shares of Stock that you still own, the amount will be the   number of shares of Stock owned times the Fair Market Value of the shares of   Stock on the date you receive notice from the Company (provided, that, the   Company may require you to satisfy your payment obligations hereunder either   by forfeiting and returning to the Company such shares of Stock or any other   shares of Stock or making a cash payment or a combination of these methods,   as determined by the Company in its sole discretion).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise specified in an employment or other   agreement between the Company or any Affiliate and you, you take actions in   competition with the Company or any Affiliate if you directly or indirectly,   own, manage, operate, join or control, or participate in the ownership,   management, operation or control of, or are a proprietor, director, officer,   stockholder, member, partner or an employee or agent of, or a consultant to   any business, firm, corporation, partnership or other entity which competes   with any business in which the Company or any Affiliate is engaged during   your employment or other relationship with the Company or any Affiliate or at   the time of your termination of Service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If it is ever determined by the Board that your   actions have constituted wrongdoing that contributed to any material   misstatement or omission from any report or statement filed by the Company   with the U.S. Securities and Exchange Commission, gross misconduct, breach of   fiduciary duty to the Company, or fraud, then the Option shall be immediately   forfeited; provided, however, that if the Option was exercised within two   (2)&nbsp;years prior to the Board&#146;s determination, you shall be required to   pay to the Company an amount equal to the aggregate Fair Market Value of the   shares acquired upon such exercise at the date of the Board determination.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Clawback</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is subject to mandatory repayment by you   to the Company to the extent you are or in the future become subject to   (i)&nbsp;any Company or Affiliate &#147;clawback&#148; or recoupment policy that is   adopted to comply with the requirements of any Applicable Laws, or   (ii)&nbsp;any Applicable Laws which impose mandatory recoupment, under   circumstances set forth in such Applicable Laws.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adjustments</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a stock split, reverse stock split,   stock dividend, recapitalization, combination or reclassification of shares,   spin-off, or other similar change in capitalization or event, the number of   shares covered by this Option and the option price per share shall be adjusted   pursuant to Section&nbsp;16 of the Plan. Your Option shall be subject to the   terms of any applicable agreement of merger, liquidation or reorganization in   the event the Company is subject to such corporate</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KM-01_PB_7_123416_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=78379,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">activity.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Applicable Law</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement will be interpreted and enforced   under the laws of Delaware other than any conflicts or choice of law   rule&nbsp;or principle that might otherwise refer construction or   interpretation of this Agreement to the substantive law of another   jurisdiction.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Plan</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The text of the Plan is incorporated into this   Agreement by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement and the Plan constitute the entire   understanding between you and the Company regarding this Option. Any prior   agreements, commitments or negotiations concerning this grant are superseded;   except that any written employment, consulting, confidentiality,   non-solicitation, non-competition, and/or severance agreement between you and   the Company or any Affiliate shall supersede this Agreement with respect to   its subject matter.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Data Privacy</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to administer the Plan, the Company may   process personal data about you. Such data includes, but is not limited to   the information provided in this Agreement and any changes thereto, other   appropriate personal and financial data about you such as home address and   business addresses and other contact information, payroll information and any   other information that might be deemed appropriate by the Company to   facilitate the administration of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting this Option, you give explicit consent   to the Company to process any such personal data. You also give explicit   consent to the Company to transfer any such personal data outside the country   in which you work or are employed, including, with respect to non-U.S.   resident grantees, to the United States, to transferees who shall include the   Company and other persons who are designated by the Company to administer the   Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consent to Electronic Delivery</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting the Option, you consent to receive   documents related to the Option by electronic delivery (including e-mail or   reference to a website or other URL) and, if requested, agree to participate   in the Plan through an on-line or electronic system established and   maintained by the Company or another third party designated by the Company,   and your consent shall remain in effect throughout your term of Service and   thereafter until you withdraw such consent in writing to the Company.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certain Dispositions</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you sell or otherwise dispose of Stock acquired   pursuant to the exercise of this Option prior to the later of (i)&nbsp;the   second (2</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">nd</font>)   anniversary of the Grant Date or (ii)&nbsp;the one (1)&nbsp;year anniversary   of the date you acquired the Stock, then you agree to notify the Company in   writing of the date of sale or disposition, the number of shares of Stock   sold or disposed of and the sale price per share within thirty (30) days of   such sale or disposition.</p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Code Section&nbsp;409A</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is intended to be exempt from, or to   comply with, Code Section&nbsp;409A to the extent subject thereto, and,   accordingly, to the maximum extent permitted, this Agreement will be   interpreted and administered to be in compliance with Code Section&nbsp;409A.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KM-01_PB_8_123518_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=170703,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything to the contrary in the Plan   or this Agreement, neither the Company, any Affiliates, the Board, nor the   Committee will have any obligation to take any action to prevent the assessment   of any excise tax or penalty on you under Code Section&nbsp;409A, and neither   the Company, any Affiliates, the Board, nor the Committee will have any   liability to you for such tax or penalty.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Severability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any provision of this Agreement is held invalid   or unenforceable by any court of competent jurisdiction, the other provisions   of this Agreement will remain in full force and effect. Any provision of this   Agreement held invalid or unenforceable only in part or degree will remain in   full force and effect to the extent not held invalid or unenforceable.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KM-01_PB_9_123530_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=631051,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 16:29 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Option No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NONQUALIFIED STOCK OPTION AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COVER SHEET</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), hereby grants an option (the &#147;<b>Option</b>&#148;) to purchase shares of its common stock, par value $0.001 (the &#147;<b>Stock</b>&#148;), to the individual named below as Grantee, subject to the vesting and other conditions set forth below.&#160; The terms and conditions of the Option are set forth in this cover sheet and in the attachment (collectively, the &#147;<b>Agreement</b>&#148;) and in the Company&#146;s 2019 Omnibus Incentive Plan (as it may be amended from time to time, the &#147;<b>Plan</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of Shares of Stock Covered by Option:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option Price per Share of Stock:&#160; U.S. $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Start Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of which has been provided or made available to you.&#160; You acknowledge that you have carefully reviewed the Plan, and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with the Plan.&#160; Certain capitalized terms used in this Agreement are defined in the Plan, and have the meaning set forth in the Plan.</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grantee:</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company:</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="30%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="37%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:37.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="30%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=444908,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Attachment</font></u></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This document is not a stock certificate or a negotiable instrument.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KM-03_PB_2_122348_6018"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=508323,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NONQUALIFIED STOCK OPTION AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Nonqualified Stock Option</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement evidences an award of an Option   exercisable for that number of shares of Stock set forth on the cover sheet   and subject to the vesting and other conditions set forth in this Agreement   and in the Plan. This Option is not intended to be an incentive stock option   under Section&nbsp;422 of the Code and will be interpreted accordingly.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Vesting&nbsp;&amp; Exercisability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is only exercisable before it expires   and then only with respect to the vested portion of the Option. This Option   shall vest in accordance with the vesting schedule set forth on the cover   sheet of this Agreement; provided, however, that for purposes of vesting,   fractional numbers of shares of Stock shall be rounded to the nearest whole   number, and you cannot vest in more than the number of shares covered by this   Option. Subject to the preceding sentence, you may exercise this Option, in   whole or in part, to purchase a whole number of vested shares of not less   than one hundred (100) shares, unless the number of shares purchased is the   total number available for purchase under the Option, by following the   procedures set forth in the Plan and below in this Agreement.<br><br></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the termination of your Service triggers   accelerated vesting or other treatment of your Option pursuant to the terms   of this Agreement or the Plan, you shall immediately and automatically   forfeit the unvested portion of the Option to the Company in the event your   Service terminates for any reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Change in Control</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a Change in Control, your Option   will be treated in the manner provided in Sections 16.3 or 16.4 of the Plan,   as applicable.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Term</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything in this Agreement to the   contrary, the Option shall expire and you shall immediately and automatically   forfeit the Option to the Company in any event at the close of business at   Company headquarters on the Expiration Date, as shown on the cover sheet.   Your Option will expire earlier (but never later) if your Service terminates,   as described below.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Regular Termination</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates for any reason, other   than due to death or Disability or for Cause, then your Option will expire at   the close of business at Company headquarters on the   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   after your termination date.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination for Cause</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service is terminated for Cause, then you   shall immediately forfeit all rights to your Option (including to any vested   portion of the Option) and the Option shall immediately expire.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination due to Death or Disability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your death or   Disability, then upon such termination you will be automatically credited   with an additional twelve </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KM-03_PB_3_122506_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=1034577,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12) months of Service for vesting purposes.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Death</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your death, then   your Option will expire at the close of business at Company headquarters on   the date that is twelve (12) months after the date of your death. During such   twelve (12) month period, your estate or heirs may exercise the vested   portion of your Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, if you die during the ninety (90) day   period described in connection with a regular termination (i.e., a   termination of your Service other than due to death or Disability or for   Cause), and a vested portion of your Option has not yet been exercised, then   such vested portion of your Option will instead expire on the date that is   twelve (12) months after your termination date. In such a case, during the   period following your death up to the date that is twelve (12) months after   your termination date, your estate or heirs may exercise the vested portion   of your Option.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Disability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service terminates due to your Disability,   then your Option will expire at the close of business at Company headquarters   on the date that is twelve (12) months after your termination date. During   such twelve (12) month period, you (or your guardian or legal representative,   as applicable) may exercise the vested portion of your Option.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Leaves of Absence</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Option, your Service does not   terminate when you go on a <i>bona fide</i>   employee leave of absence that was approved by the Company in writing, if the   terms of the leave provide for continued Service crediting, or when continued   Service crediting is required by applicable law. However, in all other cases,   your Service will be treated as terminating ninety (90) days after you went   on employee leave, unless your right to return to active work is guaranteed   by law or by a contract. Your Service terminates in any event when the   approved leave ends unless you immediately return to active employee work.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company determines, in its sole discretion,   which leaves count for this purpose, and when your Service terminates for all   purposes under the Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notice of Exercise</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">When you wish to exercise this Option, you must   notify the Company by filing the proper &#147;Notice of Exercise&#148; form at the   address given on the form. Your notice must specify how many shares you wish   to purchase. Your notice must also specify how your shares of Stock should be   registered (in your name only or in your and your spouse&#146;s names as joint   tenants with right of survivorship). The notice will be effective when it is   received by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If someone else wants to exercise this Option after   your death, that person must prove to the Company&#146;s satisfaction that he or   she is entitled to do so.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;of Payment</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">When you submit your notice of exercise, you must   include payment of the option price indicated on the cover sheet for the   shares you are purchasing. Payment may be made in one (or a combination) of   the </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KM-03_PB_4_122628_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=400756,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">following forms:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Cash, your personal check, a   cashier&#146;s check, a money order, or another cash equivalent acceptable to the   Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Shares of   Stock which are owned by you and which are surrendered to the Company and   which are not subject to any repurchase, forfeiture, unfulfilled vesting, or   other similar requirements. The Fair Market Value of the shares of Stock as   of the effective date of the Option exercise will be applied to the Option   Price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>By delivery   (on a form prescribed by the Company) of an irrevocable direction to a   licensed securities broker acceptable to the Company to sell shares of Stock   and to deliver all or part of the sale proceeds to the Company in payment of   the aggregate Option Price and any withholding taxes (if approved in advance   by the Committee or the Board if you are either an executive officer or a   director of the Company).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>If permitted   by Applicable Law and if approved in advance by the Committee or the Board,   by the Company&#146;s withholding a number of shares of Stock that would otherwise   be issuable to you upon your exercise of your Option. The Fair Market Value   of the shares as of the effective date of the Option exercise will be applied   to the Option Price.</p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Evidence of Issuance</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of the shares of Stock upon exercise of   your Option shall be evidenced in such a manner as the Company, in its   discretion, will deem appropriate, including, without limitation, book-entry,   direct registration, or issuance of one or more Stock certificates.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Withholding Taxes</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree as a condition of this Agreement that you   will make acceptable arrangements to pay any withholding or other taxes that   may be due relating to the exercise of this Option, the sale of shares of   Stock acquired under this Option, or as otherwise arising under this Option.   In the event that the Company or any Affiliate determines that any federal,   state, local, or foreign tax or withholding payment is required relating to   the exercise of this Option, the sale of shares of Stock acquired under this   Option, or as otherwise arising under this Option, the Company or any   Affiliate shall have the right to (i)&nbsp;require you to tender a cash   payment, (ii)&nbsp;deduct from payments of any kind otherwise due to you, or   (iii)&nbsp;withhold the delivery of vested shares of Stock otherwise   deliverable under this Agreement to meet such obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any shares of Stock so withheld will have an   aggregate Fair Market Value not exceeding the minimum amount of tax required   to be withheld by applicable laws; provided, however, for so long as   Accounting Standards Update 2016-09 or a similar rule&nbsp;is otherwise in   effect, the Board or the Committee has full discretion to choose, or to allow   you to elect, to withhold a number of shares of Stock having an aggregate   Fair Market Value that is greater than the applicable minimum required   statutory withholding obligation (but such withholding may in no event</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KM-03_PB_5_122947_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=213404,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">be in excess of the maximum statutory withholding   amount(s)&nbsp;in your relevant tax jurisdictions).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree that the Company or any Affiliate shall be   entitled to use whatever method it may deem appropriate to recover such   taxes. You further agree that the Company or any Affiliate may, as it   reasonably considers necessary, amend or vary this Agreement to facilitate   such recovery of taxes.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Transfer of Option</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as provided in Section&nbsp;8.10 of the Plan,   during your lifetime, only you (or, in the event of your legal incapacity or   incompetency, your guardian or legal representative) may exercise the Option.   Except as provided in Section&nbsp;8.10 of the Plan, you may not transfer,   assign, pledge, hypothecate, or otherwise encumber this Option. For instance,   you may not sell this Option or use it as security for a loan. If you attempt   to do any of these things, this Option will immediately become forfeited. You   may, however, dispose of this Option in your will or it may be transferred upon   your death by the laws of descent and distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regardless of any marital property settlement   agreement, the Company is not obligated to honor a notice of exercise from   your spouse, nor is the Company obligated to recognize your spouse&#146;s interest   in your Option in any other way.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Retention Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither your Option nor this Agreement gives you the   right to be retained or employed by the Company (or any Affiliate) in any   capacity. Unless otherwise specified in any written employment or other agreement   between the Company or any Affiliate and you, the Company (and any Affiliate)   reserves the right to terminate your Service at any time and for any reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stockholder Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You, or your estate or heirs, have no rights as a   stockholder of the Company until the shares of Stock have been issued upon   exercise of your Option and either a certificate evidencing your shares of   Stock has been issued or an appropriate entry has been made on the Company&#146;s   books. No adjustments are made for dividends or other rights if the   applicable record date occurs before your stock certificate is issued (or an   appropriate book entry has been made).</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you should take actions in violation or breach of   or in conflict with any agreement prohibiting solicitation of employees or   clients of the Company or any Affiliate, any non-competition obligation with   respect to the Company or any Affiliate, any Company policy or procedure, any   other agreement with or obligation to the Company or any Affiliate, or any   confidentiality obligation with respect to the Company or any Affiliate, the   Company has the right to cause an immediate forfeiture of your rights to this   Option and the immediate expiration of the Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting the generality of the foregoing,   if, during your Service or the twelve (12) month period following the   termination of your Service for any reason, you should take actions in   competition with the Company, the Company shall have the right, in its sole   discretion, (i)&nbsp;to cause a</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KM-03_PB_6_123034_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=1045540,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">forfeiture of any portion of your Option that   remains outstanding, and, (ii)&nbsp;with respect to any shares of Stock that   you have acquired upon exercise of this Option during the period commencing   on the date that is twelve (12) months prior to your termination of Service,   to require you to make a cash payment to the Company (or to forfeit shares of   Stock to the Company) in an amount determined as follows: (1)&nbsp;for any   shares of Stock that you have sold prior to receiving notice from the   Company, the amount will be the proceeds received from the sale(s), and   (2)&nbsp;for any shares of Stock that you still own, the amount will be the   number of shares of Stock owned times the Fair Market Value of the shares of   Stock on the date you receive notice from the Company (provided, that, the   Company may require you to satisfy your payment obligations hereunder either   by forfeiting and returning to the Company such shares of Stock or any other   shares of Stock or making a cash payment or a combination of these methods,   as determined by the Company in its sole discretion).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise specified in an employment or other   agreement between the Company or any Affiliate and you, you take actions in   competition with the Company or any Affiliate if you directly or indirectly,   own, manage, operate, join or control, or participate in the ownership,   management, operation or control of, or are a proprietor, director, officer,   stockholder, member, partner or an employee or agent of, or a consultant to   any business, firm, corporation, partnership or other entity which competes   with any business in which the Company or any Affiliate is engaged during   your employment or other relationship with the Company or any Affiliate or at   the time of your termination of Service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If it is ever determined by the Board that your   actions have constituted wrongdoing that contributed to any material   misstatement or omission from any report or statement filed by the Company   with the U.S. Securities and Exchange Commission, gross misconduct, breach of   fiduciary duty to the Company, or fraud, then the Option shall be immediately   forfeited; provided, however, that if the Option was exercised within two   (2)&nbsp;years prior to the Board&#146;s determination, you shall be required to   pay to the Company an amount equal to the aggregate Fair Market Value of the   shares acquired upon such exercise at the date of the Board determination.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Clawback</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is subject to mandatory repayment by you   to the Company to the extent you are or in the future become subject to   (i)&nbsp;any Company or Affiliate &#147;clawback&#148; or recoupment policy that is   adopted to comply with the requirements of any Applicable Laws, or   (ii)&nbsp;any Applicable Laws which impose mandatory recoupment, under   circumstances set forth in such Applicable Laws.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adjustments</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a stock split, reverse stock split,   stock dividend, recapitalization, combination or reclassification of shares,   spin-off, or other similar change in capitalization or event, the number of   shares covered by this Option and the option price per share shall be   adjusted pursuant to Section&nbsp;16 of the Plan. Your Option shall be   subject to the terms of any applicable agreement of merger, liquidation or   reorganization in the event the Company is subject to such corporate</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KM-03_PB_7_123125_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=216904,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">activity.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Applicable Law</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement will be interpreted and enforced   under the laws of Delaware other than any conflicts or choice of law   rule&nbsp;or principle that might otherwise refer construction or   interpretation of this Agreement to the substantive law of another   jurisdiction.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Plan</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The text of the Plan is incorporated into this   Agreement by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement and the Plan constitute the entire   understanding between you and the Company regarding this Option. Any prior   agreements, commitments or negotiations concerning this grant are superseded;   except that any written employment, consulting, confidentiality,   non-solicitation, non-competition, and/or severance agreement between you and   the Company or any Affiliate shall supersede this Agreement with respect to   its subject matter.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Data Privacy</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to administer the Plan, the Company may process   personal data about you. Such data includes, but is not limited to the   information provided in this Agreement and any changes thereto, other   appropriate personal and financial data about you such as home address and   business addresses and other contact information, payroll information and any   other information that might be deemed appropriate by the Company to   facilitate the administration of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting this Option, you give explicit consent   to the Company to process any such personal data. You also give explicit   consent to the Company to transfer any such personal data outside the country   in which you work or are employed, including, with respect to non-U.S.   resident grantees, to the United States, to transferees who shall include the   Company and other persons who are designated by the Company to administer the   Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consent to Electronic Delivery</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting the Option, you consent to receive   documents related to the Option by electronic delivery (including e-mail or   reference to a website or other URL) and, if requested, agree to participate   in the Plan through an on-line or electronic system established and   maintained by the Company or another third party designated by the Company,   and your consent shall remain in effect throughout your term of Service and   thereafter until you withdraw such consent in writing to the Company.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Code Section&nbsp;409A</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Option is intended to be exempt from, or to   comply with, Code Section&nbsp;409A to the extent subject thereto, and,   accordingly, to the maximum extent permitted, this Agreement will be   interpreted and administered to be in compliance with Code Section&nbsp;409A.   Notwithstanding anything to the contrary in the Plan or this Agreement,   neither the Company, any Affiliates, the Board, nor the Committee will have   any obligation to take any action to prevent the assessment of any excise tax   or penalty on you under Code Section&nbsp;409A, and neither the Company, any   Affiliates, the Board, nor the Committee will have any liability to you for   such tax or penalty.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KM-03_PB_8_123209_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=421305,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" bgcolor="black" style="background:white;border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Severability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any provision of this Agreement is held invalid   or unenforceable by any court of competent jurisdiction, the other provisions   of this Agreement will remain in full force and effect. Any provision of this   Agreement held invalid or unenforceable only in part or degree will remain in   full force and effect to the extent not held invalid or unenforceable.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KM-03_PB_9_123220_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2238596",CP="NEXTCURE, INC.",DN="5",CHK=676851,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KM-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:45 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>6
<FILENAME>a2238596zex-10_10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.10<a name="3387-2-KU-01_Exhibit10_10_113923"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Grant No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COVER SHEET</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), hereby grants shares of its common stock, par value $0.001 (the &#147;<b>Stock</b>&#148;), to the individual named below as Grantee, subject to the vesting and other conditions set forth in the attachment.&#160; Additional terms and conditions of the grant are set forth in this cover sheet and in the attachment (collectively, the &#147;<b>Agreement</b>&#148;) and in the Company&#146;s 2019 Omnibus Incentive Plan (as it may be amended from time to time, the &#147;<b>Plan</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of Shares of Stock Covered by Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Price per Share of Stock:&#160; U.S. $0.001</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Start Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of which has been provided or made available to you.&#160; You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with the Plan.&#160; Certain capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grantee:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="55%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="55%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:55.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="55%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=573370,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Attachment</font></u></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This document is not a stock certificate or a negotiable instrument</font></i>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KU-01_PB_2_133230_4545"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=343289,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Restricted Stock</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This grant is an award of Stock in the number of   shares set forth on the cover sheet, at the purchase price set forth on the   cover sheet, and subject to the vesting conditions and other terms and   conditions described herein (&#147;<b>Restricted Stock</b>&#148;).   The purchase price is deemed paid by your Service to the Company and its   Affiliates. To the extent not yet vested, your Restricted Stock may not be   sold, assigned, transferred, pledged or otherwise encumbered, whether   voluntarily or by operation of law, except by will or the laws of descent and   distribution. If you attempt to do any of these things, you will immediately   and automatically forfeit your Restricted Stock.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Vesting</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will issue your Restricted Stock in your   name as of the Grant Date. Your Restricted Stock shall vest in accordance   with the vesting schedule set forth on the cover sheet of this Agreement;   provided, however, that for purposes of vesting, fractional numbers of shares   of Stock shall be rounded to the nearest whole number, and you may not vest   in more than the number of shares covered by this grant. Unless the   termination of your Service triggers accelerated vesting or other treatment   of your Restricted Stock pursuant to the terms of this Agreement or the Plan,   you shall immediately and automatically forfeit your unvested shares of   Restricted Stock to the Company in the event your Service terminates for any   reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Change in Control</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a Change in Control, your Restricted   Stock will be treated in the manner provided in Sections 16.3 or 16.4 of the   Plan, as applicable.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Unvested Stock</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event that your Service terminates for any reason   other than death or Disability, you will forfeit to the Company all of the   shares of Stock subject to this grant that have not yet vested or with   respect to which all applicable restrictions and conditions have not lapsed.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination due to Death or Disability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service is terminated due to your death or   Disability, the unvested portion of your grant shall become immediately   vested.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Issuance</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of the Stock under this grant shall be   evidenced in such a manner as the Company, in its discretion, will deem </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KU-01_PB_3_114802_3273"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=203191,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">appropriate, including, without limitation,   book-entry, direct registration or issuance of one or more stock   certificates, with any unvested Restricted Stock bearing a legend with the   appropriate restrictions imposed by this Agreement. As your interest in the   Stock vests as described above, the recordation of the number of shares of   Restricted Stock attributable to you will be appropriately modified. To the   extent certificates are issued with regard to unvested Stock, such   certificates will be held in escrow with the Secretary of the Company while   the Stock remains unvested.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Leaves of Absence</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this Agreement, your Service does   not terminate when you go on a <i>bona fide</i>   employee leave of absence that was approved by the Company in writing, if the   terms of the leave provide for continued Service crediting, or when continued   Service crediting is required by applicable law. However, in all other cases,   your Service will be treated as terminating ninety (90) days after you went   on employee leave, unless your right to return to active work is guaranteed   by law or by a contract. Your Service terminates in any event when the   approved leave ends unless you immediately return to active employee   work.&nbsp; The Company determines, in its   sole discretion, which leaves count for this purpose, and when your Service   terminates for all purposes under the Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Withholding Taxes</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree as a condition of this Agreement that you   will make acceptable arrangements to pay any withholding or other taxes that   may be due relating to the Restricted Stock and the issuance of shares of   Stock or cash with respect to the Restricted Stock. In the event that the   Company determines that any federal, state, local, or foreign tax or   withholding payment is required relating to the Restricted Stock and/or the   issuance of shares of Stock or cash with respect to the Restricted Stock, the   Company shall have the right to (i)&nbsp;require you to tender a cash payment,   (ii)&nbsp;deduct from payments of any kind otherwise due to you, or   (iii)&nbsp;withhold the delivery of vested shares of Stock otherwise   deliverable under this Agreement to meet such obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any shares of Stock so withheld will have an   aggregate Fair Market Value not exceeding the minimum amount of tax required   to be withheld by applicable laws; provided, however, for so long as   Accounting Standards Update 2016-09 or a similar rule&nbsp;is otherwise in   effect, the Board or the Committee has full discretion to choose, or to allow   you to elect, to withhold a number of shares of Stock having an aggregate   Fair Market Value that is greater than the applicable minimum required</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KU-01_PB_4_114901_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=776348,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">statutory withholding obligation (but such   withholding may in no event be in excess of the maximum statutory withholding   amount(s)&nbsp;in your relevant tax jurisdictions).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree that the Company or any Affiliate shall be   entitled to use whatever method it may deem appropriate to recover such   taxes. You further agree that the Company or any Affiliate may, as it   reasonably considers necessary, amend or vary this Agreement to facilitate   such recovery of taxes.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;83(b)</font></b>  <b>Election</b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under Section&nbsp;83 of the Code, the difference   between the purchase price paid for the shares of Stock and their fair market   value on the date any forfeiture restrictions applicable to such shares lapse   will be reportable as ordinary income at that time. For this purpose,   &#147;forfeiture restrictions&#148; include the forfeiture as to unvested Stock   described above. You may elect to be taxed at the time the shares are   acquired, rather than when such shares cease to be subject to such forfeiture   restrictions, by filing an election under Section&nbsp;83(b)&nbsp;of the Code   with the Internal Revenue Service within thirty (30) days after the Grant   Date. You will have to make a tax payment to the extent the purchase price is   less than the fair market value of the shares on the Grant Date. No tax   payment will have to be made to the extent the purchase price is at least   equal to the fair market value of the shares on the Grant Date. The form for   making this election is attached as <u>Exhibit&nbsp;A</u> hereto. Failure to   make this filing within the thirty (30) day period will result in the   recognition of ordinary income by you (in the event the fair market value of   the shares as of the vesting date exceeds the purchase price) as the   forfeiture restrictions lapse.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">YOU ACKNOWLEDGE THAT IT IS YOUR SOLE   RESPONSIBILITY, AND NOT THE COMPANY&#146;S, TO FILE A TIMELY ELECTION UNDER CODE   SECTION&nbsp;83(b), EVEN IF YOU REQUEST THE COMPANY OR ITS REPRESENTATIVES TO   MAKE THIS FILING ON YOUR BEHALF. YOU ARE RELYING SOLELY ON YOUR OWN ADVISORS   WITH RESPECT TO THE DECISION AS TO WHETHER OR NOT TO FILE ANY CODE SECTION&nbsp;83(b)&nbsp;ELECTION.</font></b></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Retention Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither the Restricted Stock nor this Agreement   gives you the right to be retained or employed by the Company (or any   Affiliate) in any capacity. Unless otherwise specified in any written   employment or other agreement between the Company or any Affiliate and you,   the Company (and any Affiliate) reserves the right to terminate your Service   at any time and for</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KU-01_PB_5_115035_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=1024102,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any reason.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Shareholder Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You have the right to vote the Restricted Stock and   to receive any dividends declared or paid on such Restricted Stock. Any   distributions you receive with respect to unvested Restricted Stock as a   result of any stock split, stock dividend, combination of shares or other   similar transaction shall be deemed to be a part of the Restricted Stock and   subject to the same conditions and restrictions applicable thereto. Any cash   dividends paid on unvested shares of Restricted Stock that you hold on the   record date for such dividend shall be held by the Company and subject to the   same conditions and restrictions applicable to your unvested shares of   Restricted Stock; provided that, within forty-five (45) days after the date   on which the applicable shares of Restricted Stock vest in accordance with   the terms of this Agreement, such dividends shall be paid to you, without   interest. You will immediately and automatically forfeit such dividends to   the extent that you forfeit the corresponding unvested shares of Restricted   Stock. Except as described in the Plan, no adjustments are made for dividends   or other rights if the applicable record date occurs before an appropriate   book entry is made (or your certificate is issued).</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Rights</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you should take actions in violation or breach of   or in conflict with any agreement prohibiting solicitation of employees or   clients of the Company or any Affiliate, any non-competition obligation with   respect to the Company or any Affiliate, any Company policy or procedure, any   other agreement with or obligation to the Company or any Affiliate, or any   confidentiality obligation with respect to the Company or any Affiliate, the   Company has the right to cause an immediate forfeiture of your unvested   Restricted Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting the generality of the foregoing,   if, during your Service or the twelve (12) month period following the   termination of your Service for any reason, you should take actions in   competition with the Company, the Company shall have the right, in its sole   discretion, to cause a forfeiture of your unvested Restricted Stock, and,   with respect to those shares of Restricted Stock that vested during the   period commencing on the date that is twelve (12) months prior to your   termination of Service and ending on (and including) the date of your   termination of Service, the Company shall have the right, in its sole   discretion, to require you to make a cash payment to the Company (or to   forfeit shares of Stock to the Company) in an amount determined as follows: (1)&nbsp;for   any shares of Stock that you have sold prior to receiving notice from the   Company, the</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KU-01_PB_6_115344_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=685431,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">amount will be the proceeds received from the   sale(s), and (2)&nbsp;for any shares of Stock that you still own, the amount   will be the number of shares of Stock owned times the Fair Market Value of   the shares of Stock on the date you receive notice from the Company   (provided, that, the Company may require you to satisfy your payment   obligations hereunder either by forfeiting and returning to the Company such   shares of Stock or any other shares of Stock or making a cash payment or a   combination of these methods, as determined by the Company in its sole   discretion).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise specified in an employment or other   agreement between the Company or any Affiliate and you, you take actions in   competition with the Company or any Affiliate if you directly or indirectly,   own, manage, operate, join or control, or participate in the ownership,   management, operation or control of, or are a proprietor, director, officer,   stockholder, member, partner or an employee or agent of, or a consultant to   any business, firm, corporation, partnership or other entity which competes   with any business in which the Company or any Affiliate is engaged during   your employment or other relationship with the Company or any Affiliate or at   the time of your termination of Service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If it is ever determined by the Board that your   actions have constituted wrongdoing that contributed to any material   misstatement or omission from any report or statement filed by the Company   with the U.S. Securities and Exchange Commission, gross misconduct, breach of   fiduciary duty to the Company, or fraud, then the Restricted Stock shall be   immediately forfeited; provided, however, that if the Restricted Stock has   vested within two (2)&nbsp;years prior to the Board&#146;s determination, you   shall be required to pay to the Company an amount equal to the aggregate Fair   Market Value of the shares acquired upon such vesting at the date of the   Board&#146;s determination.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Clawback</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Your Restricted Stock is subject to mandatory   repayment by you to the Company to the extent you are or in the future become   subject to (i)&nbsp;any Company or Affiliate &#147;clawback&#148; or recoupment policy   that is adopted to comply with the requirements of any Applicable Laws, or   (ii)&nbsp;any Applicable Laws which impose mandatory recoupment, under   circumstances set forth in such Applicable Laws.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adjustments</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a stock split, reverse stock split,   stock dividend, recapitalization, combination or reclassification of shares,   spin-</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KU-01_PB_7_115347_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=67391,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:33 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">off, or other similar change in capitalization or   event, the number of shares covered by this grant may be adjusted pursuant to   Section&nbsp;16 of the Plan. Your Restricted Stock shall be subject to the   terms of any applicable agreement of merger, liquidation or reorganization in   the event the Company is subject to such corporate activity in accordance   with the terms of the Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Legends</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All certificates representing the Stock issued in   connection with this grant shall, where applicable, have endorsed thereon the   following legend:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;THE SHARES REPRESENTED   BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING, FORFEITURE AND OTHER   RESTRICTIONS ON TRANSFER SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND   THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH   AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE   FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER   OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#148;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Applicable Law</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement will be interpreted and enforced   under the laws of Delaware, other than any conflicts or choice of law   rule&nbsp;or principle that might otherwise refer construction or interpretation   of this Agreement to the substantive law of another jurisdiction.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Plan</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The text of the Plan is incorporated into this   Agreement by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement and the Plan constitute the entire   understanding between you and the Company regarding this grant of Restricted   Stock. Any prior agreements, commitments or negotiations concerning this   grant are superseded; except that any written employment, consulting,   confidentiality, non-solicitation, non-competition, and/or severance   agreement between you and the Company or any Affiliate shall supersede this   Agreement with respect to its subject matter.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Data Privacy</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to administer the Plan, the Company may   process personal data about you. Such data includes but is not limited to the   information provided in this Agreement and any changes thereto, other   appropriate personal and financial data about you such as home address and   business addresses and other contact information, payroll information and any   other information that might be deemed appropriate by the Company to   facilitate the</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KU-03_PB_8_115655_8049"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=520963,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:43 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">administration of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting this grant, you give explicit consent   to the Company to process any such personal data. You also give explicit   consent to the Company to transfer any such personal data outside the country   in which you work or are employed, including, with respect to non-U.S.   resident grantees, to the United States, to transferees who shall include the   Company and other persons who are designated by the Company to administer the   Plan.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consent to Electronic Delivery</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting the option, you consent to receive   documents related to the option by electronic delivery (including e-mail or   reference to a website or other URL) and, if requested, agree to participate   in the Plan through an on-line or electronic system established and   maintained by the Company or another third party designated by the Company,   and your consent shall remain in effect throughout your term of Service and   thereafter until you withdraw such consent in writing to the Company.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Code Section&nbsp;409A</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Restricted Stock granted under this Agreement is   intended to be exempt from, or to comply with, Code Section&nbsp;409A to the   extent subject thereto, and, accordingly, to the maximum extent permitted,   this Agreement will be interpreted and administered to be in compliance with   Code Section&nbsp;409A. Notwithstanding anything to the contrary in the Plan   or this Agreement, neither the Company, any Affiliates, the Board, nor the   Committee will have any obligation to take any action to prevent the   assessment of any excise tax or penalty on you under Code Section&nbsp;409A,   and neither the Company, any Affiliates, the Board, nor the Committee will have   any liability to you for such tax or penalty.</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.06%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Severability</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="64%" valign="top" style="padding:0in 0in 0in 0in;width:64.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any provision of this Agreement is held invalid   or unenforceable by any court of competent jurisdiction, the other provisions   of this Agreement will remain in full force and effect. Any provision of this   Agreement held invalid or unenforceable only in part or degree will remain in   full force and effect to the extent not held invalid or unenforceable.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.35pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:36.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KU-03_PB_9_115715_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=449778,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:43 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Grant No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">U.S. GRANTEE ELECTION UNDER SECTION&nbsp;83(b)&nbsp;OF<br> THE INTERNAL REVENUE CODE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned U.S. Grantee hereby makes an election pursuant to Section&nbsp;83(b)&nbsp;of the Internal Revenue Code of 1986, as amended, with respect to the property described below and supplies the following information in accordance with the regulations promulgated thereunder:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The name, address and social security number of the undersigned:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Social Security No.:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Description of property with respect to which the election is being made:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of common stock, par value $0.001 per share, of NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The date on which the property was transferred is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The taxable year to which this election relates is calendar year 20&nbsp;&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nature of restrictions to which the property is subject:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The shares of stock are subject to the provisions of a Restricted Stock Agreement between the undersigned and the Company.&#160; The shares of stock are subject to forfeiture and transfer limitations under the terms of the Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The fair market value of the property at the time of transfer (determined without regard to any lapse restriction) was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, for a total of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The amount paid by taxpayer for the property was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; A copy of this statement has been furnished to the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&#160; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;, 20</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxpayer&#146;s Signature</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=836181,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:43 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxpayer&#146;s Name</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=566200,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:43 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROCEDURES FOR U.S. GRANTEE MAKING ELECTION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNDER&nbsp;INTERNAL&nbsp;REVENUE&nbsp;CODE&nbsp;SECTION&nbsp;83(b)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:100.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following procedures <b>must</b> be followed with respect to the attached form for making an election under Internal Revenue Code section 83(b)&nbsp;in order for the election to be effective:</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">(1)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:100.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; You must file one (1)&nbsp;copy of the completed election form with the IRS Service Center where you file your federal income tax returns within <u>thirty (30) days</u> after the Grant Date of your Restricted Stock.&#160; Please send this by certified mail, return receipt requested, and retain a copy of the receipt confirmation for your records.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:100.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; At the same time you file the election form with the IRS, you must also give a copy of the election form to the Secretary of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Whether or not to make the election is your decision and may create tax consequences for you.&#160; You are advised to consult your tax advisor if you are unsure whether or not to make the election.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="6",CHK=579410,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KU-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:43 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>7
<FILENAME>a2238596zex-10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.11<a name="3387-2-KV_Exhibit10_11_120314"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Grant No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK UNIT AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COVER SHEET</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NextCure,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), hereby grants Restricted Stock Units (&#147;<b>RSUs</b>&#148;) for shares of its common stock, par value $0.001 (the &#147;<b>Stock</b>&#148;), to the individual named below as Grantee, subject to the vesting and other conditions set forth in the attachment.&#160; Additional terms and conditions of the grant are set forth in this cover sheet and in the attachment (collectively, the &#147;<b>Agreement</b>&#148;) and in the Company&#146;s 2019 Omnibus Incentive Plan (as it may be amended from time to time, the &#147;<b>Plan</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Grantee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number of RSUs Covered by Grant:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Start Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing this cover sheet, you agree to all of the terms and conditions described in this Agreement and in the Plan, a copy of which has been provided or made available to you.&#160; You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with the Plan.&#160; Certain capitalized terms used in this Agreement are defined in the Plan and have the meaning set forth in the Plan.</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grantee:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>    </td>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date)</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="top" style="padding:0in 0in 0in 0in;width:15.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="56%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:56.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="56%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:56.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="56%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:56.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=286591,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Attachment</font></u></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This document is not a stock certificate or a negotiable instrument</font></i>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=129348,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 OMNIBUS INCENTIVE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK UNIT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Restricted Stock Units</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This grant is an   award of RSUs in the number set forth on the cover sheet. Each RSU represents   the right to receive one share of Stock, subject to the vesting conditions   and other terms and conditions described herein. Your RSUs may not be sold,   assigned, transferred, pledged or otherwise encumbered, whether voluntarily   or by operation of law, except by will or the laws of descent and   distribution. If you attempt to do any of these things, you will immediately   and automatically forfeit your RSUs.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Vesting</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Your RSUs shall   vest in accordance with the vesting schedule set forth on the cover sheet of   this Agreement; provided, however, that for purposes of vesting, fractional   numbers of RSUs shall be rounded to the nearest whole number, and you may not   vest in more than the number of RSUs covered by this grant.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless the   termination of your Service triggers accelerated vesting or other treatment   of your RSUs pursuant to the terms of this Agreement or the Plan, you shall   immediately and automatically forfeit your unvested RSUs to the Company in   the event your Service terminates for any reason.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Change in Control</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a   Change in Control, your RSUs will be treated in the manner provided in   Sections 16.3 or 16.4 of the Plan, as applicable.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Unvested RSUs</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event that   your Service terminates for any reason other than death or Disability, you   will forfeit to the Company all of your unvested RSUs.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Termination due to Death or   Disability</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If your Service is   terminated due to your death or Disability, the unvested portion of your   grant shall become immediately vested.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Issuance</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of the   Stock underlying your vested RSUs shall be made within forty-five (45) days   after the applicable vesting date of your RSUs. Any such issuance shall be   evidenced in such a manner as the Company, in its discretion, will deem   appropriate, including, without limitation, book-entry, direct registration   or issuance of one or more stock certificates.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Leaves of Absence</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of this   Agreement, your Service does not terminate</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=492170,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">when you go on a <i>bona fide</i> employee leave of absence that was approved by   the Company in writing, if the terms of the leave provide for continued   Service crediting, or when continued Service crediting is required by   applicable law. However, in all other cases, your Service will be treated as   terminating ninety (90) days after you went on employee leave, unless your   right to return to active work is guaranteed by law or by a contract. Your   Service terminates in any event when the approved leave ends unless you   immediately return to active employee work.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company determines,   in its sole discretion, which leaves count for this purpose, and when your   Service terminates for all purposes under the Plan.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Dividend Equivalent Rights</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the Company declares one or more cash dividends   on the Stock during the period commencing on the Grant Date and ending on and   including the day immediately preceding the day on which the shares of Stock   subject to the vested RSUs are issued to you, then, on the date each such   dividend is paid to the holders of Stock, you will be credited with dividend   equivalents in an amount equal to the product of (i)&nbsp;the amount of the   dividend declared and paid per share of Stock and (ii)&nbsp;the number of   RSUs granted to you under this Agreement that are outstanding as of the   record date of such dividend. The dividend equivalents that are credited to   you in respect of each cash dividend will be deemed to have been reinvested   into additional RSUs (rounded to the nearest whole unit) as of the dividend   payment date based on the closing price of the Stock on the dividend payment   date. Any such additional RSUs shall be subject to the same terms and   conditions which apply to the underlying RSUs to which they relate and shall   vest or be forfeited, as applicable, at the same time as the underlying RSUs   to which they relate. The foregoing does not obligate the Company to pay   dividends on the Stock and nothing in the Plan or in this Agreement shall be   interpreted as creating such an obligation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything to the contrary in this   Agreement, if the RSUs are scheduled to vest and be settled between a   dividend record date and a dividend payment date, then dividend equivalents   with respect to such dividend will be credited to you, will be deemed to have   been reinvested into additional RSUs (rounded to the nearest whole unit), and   will be paid to you on the earlier of (i)&nbsp;the dividend payment date for   such dividend and (ii)&nbsp;March&nbsp;15th following the date on which the   underlying RSUs vest.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=109348,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Withholding Taxes</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree as a condition of this Agreement that you   will make acceptable arrangements to pay any withholding or other taxes that   may be due relating to the RSUs and the issuance of shares of Stock or cash   with respect to the RSUs. In the event that the Company determines that any   federal, state, local, or foreign tax or withholding payment is required   relating to the RSUs and/or the issuance of shares of Stock or cash with   respect to the RSUs, the Company shall have the right to (i)&nbsp;require you   to tender a cash payment, (ii)&nbsp;deduct from payments of any kind   otherwise due to you, or (iii)&nbsp;withhold the delivery of vested shares of   Stock otherwise deliverable under this Agreement to meet such obligations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any shares of Stock so withheld will have an aggregate   Fair Market Value not exceeding the minimum amount of tax required to be   withheld by applicable laws; provided, however, for so long as Accounting   Standards Update 2016-09 or a similar rule&nbsp;is otherwise in effect, the   Board or the Committee has full discretion to choose, or to allow you to   elect, to withhold a number of shares of Stock having an aggregate Fair   Market Value that is greater than the applicable minimum required statutory   withholding obligation (but such withholding may in no event be in excess of   the maximum statutory withholding amount(s)&nbsp;in your relevant tax   jurisdictions).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You agree that the Company or any Affiliate shall be   entitled to use whatever method it may deem appropriate to recover such   taxes. You further agree that the Company or any Affiliate may, as it   reasonably considers necessary, amend or vary this Agreement to facilitate   such recovery of taxes.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Retention Rights</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither the RSUs   nor this Agreement gives you the right to be retained or employed by the   Company (or any Affiliate) in any capacity. Unless otherwise specified in any   written employment or other agreement between the Company or any Affiliate   and you, the Company (and any Affiliate) reserves the right to terminate your   Service at any time and for any reason.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Shareholder Rights</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You have no rights   as a shareholder of the Company until shares of Stock underlying the RSUs   have been issued to you upon vesting of the RSUs and either a certificate   evidencing the shares of Stock has been issued to you or an appropriate entry   has been made on the Company&#146;s books. Except as described in the Plan, no   adjustments are made for dividends or other rights if the applicable record   date occurs before an appropriate book entry is made (or your certificate is   issued).</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=639891,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forfeiture of Rights</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you should take   actions in violation or breach of or in conflict with any agreement   prohibiting solicitation of employees or clients of the Company or any   Affiliate, any non-competition obligation with respect to the Company or any   Affiliate, any Company policy or procedure, any other agreement with or   obligation to the Company or any Affiliate, or any confidentiality obligation   with respect to the Company or any Affiliate, the Company has the right to   cause an immediate forfeiture of your unvested RSUs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting   the generality of the foregoing, if, during your Service or the twelve (12)   month period following the termination of your Service for any reason, you   should take actions in competition with the Company, the Company shall have   the right, in its sole discretion, to cause a forfeiture of your unvested   RSUs, and, with respect to those shares of Stock that were issued to you in   respect of RSUs that vested during the period commencing on the date that is   twelve (12) months prior to your termination of Service and ending on (and   including) the date of your termination of Service, the Company shall have   the right, in its sole discretion, to require you to make a cash payment to   the Company (or to forfeit shares of Stock to the Company) in an amount   determined as follows: (1)&nbsp;for any shares of Stock that you have sold   prior to receiving notice from the Company, the amount will be the proceeds   received from the sale(s), and (2)&nbsp;for any shares of Stock that you   still own, the amount will be the number of shares of Stock owned times the   Fair Market Value of the shares of Stock on the date you receive notice from   the Company (provided, that, the Company may require you to satisfy your   payment obligations hereunder either by forfeiting and returning to the   Company such shares of Stock or any other shares of Stock or making a cash   payment or a combination of these methods, as determined by the Company in   its sole discretion).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise   specified in an employment or other agreement between the Company or any   Affiliate and you, you take actions in competition with the Company or any   Affiliate if you directly or indirectly, own, manage, operate, join or   control, or participate in the ownership, management, operation or control   of, or are a proprietor, director, officer, stockholder, member, partner or   an employee or agent of, or a consultant to any business, firm, corporation,   partnership or other entity which competes with any business in which the   Company or any Affiliate is engaged during your employment or other   relationship with the Company or any Affiliate or at the time of</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=40206,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">your termination   of Service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If it is ever   determined by the Board that your actions have constituted wrongdoing that   contributed to any material misstatement or omission from any report or   statement filed by the Company with the U.S. Securities and Exchange   Commission, gross misconduct, breach of fiduciary duty to the Company, or   fraud, then the RSUs shall be immediately forfeited; provided, however, that   if the RSUs have vested within two (2)&nbsp;years prior to the Board&#146;s   determination, you shall be required to pay to the Company an amount equal to   the aggregate Fair Market Value of the shares acquired upon such vesting at   the date of the Board&#146;s determination.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Clawback</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Your RSUs are   subject to mandatory repayment by you to the Company to the extent you are or   in the future become subject to (i)&nbsp;any Company or Affiliate &#147;clawback&#148;   or recoupment policy that is adopted to comply with the requirements of any   Applicable Laws, or (ii)&nbsp;any Applicable Laws which impose mandatory   recoupment, under circumstances set forth in such Applicable Laws.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adjustments</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of a   stock split, reverse stock split, stock dividend, recapitalization,   combination or reclassification of shares, spin-off, or other similar change   in capitalization or event, the number of shares subject to the RSUs covered   by this grant may be adjusted pursuant to Section&nbsp;16 of the Plan. Your RSUs   shall be subject to the terms of any applicable agreement of merger,   liquidation or reorganization in the event the Company is subject to such   corporate activity in accordance with the terms of the Plan.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Applicable Law</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement   will be interpreted and enforced under the laws of Delaware, other than any   conflicts or choice of law rule&nbsp;or principle that might otherwise refer   construction or interpretation of this Agreement to the substantive law of   another jurisdiction.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Plan</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The text of the   Plan is incorporated into this Agreement by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement and   the Plan constitute the entire understanding between you and the Company   regarding this grant of RSUs. Any prior agreements, commitments or   negotiations concerning this grant are superseded; except that any written   employment, consulting, confidentiality, non-solicitation, non-competition,   and/or severance agreement between you and the Company or any Affiliate shall   supersede this Agreement with respect to its</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=964020,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">subject matter.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Data Privacy</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to   administer the Plan, the Company may process personal data about you. Such   data includes but is not limited to the information provided in this   Agreement and any changes thereto, other appropriate personal and financial   data about you such as home address and business addresses and other contact   information, payroll information and any other information that might be   deemed appropriate by the Company to facilitate the administration of the   Plan.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting this   grant, you give explicit consent to the Company to process any such personal   data. You also give explicit consent to the Company to transfer any such   personal data outside the country in which you work or are employed, including,   with respect to non-U.S. resident grantees, to the United States, to   transferees who shall include the Company and other persons who are   designated by the Company to administer the Plan.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consent to Electronic Delivery</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By accepting the   option, you consent to receive documents related to the option by electronic   delivery (including e-mail or reference to a website or other URL) and, if   requested, agree to participate in the Plan through an on-line or electronic   system established and maintained by the Company or another third party   designated by the Company, and your consent shall remain in effect throughout   your term of Service and thereafter until you withdraw such consent in   writing to the Company.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Code   Section&nbsp;409A</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The   RSUs granted under this Agreement are intended to be exempt from, or to   comply with, Code Section&nbsp;409A to the extent subject thereto, and,   accordingly, to the maximum extent permitted, this Agreement will be   interpreted and administered to be in compliance with Code Section&nbsp;409A.   Notwithstanding anything to the contrary in the Plan or this Agreement,   neither the Company, any Affiliates, the Board, nor the Committee will have   any obligation to take any action to prevent the assessment of any excise tax   or penalty on you under Code Section&nbsp;409A, and neither the Company, any   Affiliates, the Board, nor the Committee will have any liability to you for   such tax or penalty.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For   purposes of this Agreement, a termination of Service only occurs upon an   event that would be a Separation from Service.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding   anything in this Agreement to the contrary, if at the time of the Grantee&#146;s   Separation from Service, (i)&nbsp;the Grantee is a specified employee (within   the meaning of Code</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=172308,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;409A   and using the identification methodology selected by the Company from time to   time), and (ii)&nbsp;the Company makes a good faith determination that an   amount payable on account of such separation from service to the Grantee   constitutes deferred compensation (within the meaning of Code   Section&nbsp;409A) the payment of which is required to be delayed pursuant to   the six (6)-month delay rule&nbsp;set forth in Code Section&nbsp;409A in   order to avoid taxes or penalties under Section&nbsp;409A (the &#147;<b>Delay Period</b>&#148;), then the Company will not pay such amount   on the otherwise scheduled payment date but will instead pay it in a lump sum   on the first payroll date after such Delay Period (or upon the Grantee&#146;s   death, if earlier), without interest thereupon.</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Severability</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If   any provision of this Agreement is held invalid or unenforceable by any court   of competent jurisdiction, the other provisions of this Agreement will remain   in full force and effect. Any provision of this Agreement held invalid or   unenforceable only in part or degree will remain in full force and effect to   the extent not held invalid or unenforceable.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.25pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">By signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="7",CHK=289641,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KV_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 26 13:38 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>a2238596zex-10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.12<a name="3387-2-KW-01_Exhibit10_12_010847"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 EMPLOYEE STOCK PURCHASE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=859298,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 EMPLOYEE STOCK PURCHASE PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PURPOSE AND INTERPRETATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The purpose of the NextCure,&nbsp;Inc. 2019 Employee Stock Purchase Plan is to encourage and to enable Eligible Employees of the Company and its Participating Affiliates, through after-tax payroll deductions or periodic cash contributions, to acquire proprietary interests in the Company through the purchase and ownership of shares of Stock.&#160; The Plan is intended to benefit the Company and its stockholders (a)&nbsp;by incentivizing Participants to contribute to the success of the Company and to operate and manage the Company&#146;s business in a manner that will provide for the Company&#146;s long-term growth and profitability and that will benefit its stockholders and other important stakeholders and (b)&nbsp;by encouraging Participants to remain in the employ of the Company or its Participating Affiliates. The Plan was adopted by the Board on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and was approved by the Company&#146;s stockholders on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Plan and the Options granted under the Plan are intended to satisfy the requirements for an &#147;employee stock purchase plan&#148; under Code Section&nbsp;423.&#160; Notwithstanding the foregoing, the Company makes no undertaking to, nor representation that it will, maintain the qualified status of the Plan or any Options granted under the Plan.&#160; In addition, Options that do not satisfy the requirements for an &#147;employee stock purchase plan&#148; under Code Section&nbsp;423 may be granted under the Plan pursuant to the rules, procedures, or sub-plans adopted by the Administrator, in its sole discretion, for certain Eligible Employees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEFINITIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Account</b>&#148; shall mean a bookkeeping account established and maintained to record the amount of funds accumulated pursuant to the Plan with respect to a Participant for the purpose of purchasing shares of Stock under the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Administrator</b>&#148; shall mean the Board, the Compensation Committee of the Board, or any other committee of the Board designated by the Board to administer the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Board</b>&#148; shall mean the Board of Directors of the Company.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Code</b>&#148; shall mean the Internal Revenue Code of 1986, as amended, as now in effect or as hereafter amended, and any successor thereto.&#160; References in the Plan to any Code Section&nbsp;shall be deemed to include, as applicable, regulations and guidance promulgated under such Code Section.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Company</b>&#148; shall mean NextCure,&nbsp;Inc., a Delaware corporation, and any successor thereto.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Custodian</b>&#148; shall mean the third-party administrator designated by the Administrator from time to time.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Effective Date</b>&#148; shall mean the date on which the Registration Statement covering the initial public offering of the Stock is declared effective by the United States Securities and Exchange Commission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="3387-2-KW-01_PB_2_011234_6122"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=57671,FOLIO='2',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Eligible Compensation</b>&#148; shall mean, unless otherwise established by the Administrator prior to the start of an Offering Period, regular base compensation (including any shift differentials), but excludes any bonus, overtime payment, sales commission, contributions to any Code Section&nbsp;125 or 401(k)&nbsp;plan, the cost of employee benefits paid for by the Company or a Participating Affiliate, education or tuition reimbursements, imputed income arising under any Company or Participating Affiliate group insurance or benefit program, traveling expense reimbursements, business and moving expense reimbursements, income received in connection with stock options and other equity awards, or other form of extra compensation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Eligible Employee</b>&#148; shall mean a natural person who is an employee (including an officer) of the Company or a Participating Affiliate as of an Offering Date, except the following, who shall not be eligible to participate under the Plan: (i)&nbsp;an employee whose customary employment is twenty (20)&nbsp;hours or less per week, (ii)&nbsp;an employee whose customary employment is for not more than five (5)&nbsp;months in any calendar year, (iii)&nbsp;an employee who, after exercising his or her rights to purchase shares of Stock under the Plan, would own (directly or by attribution pursuant to Code Section&nbsp;424(d)) shares of Stock (including shares that may be acquired under any outstanding Options) representing five percent (5%) or more of the total combined voting power of all classes of stock of the Company, (iv)&nbsp;an employee who is a citizen or resident of a foreign jurisdiction (without regard to whether such employee is also a U.S. citizen or resident alien), if the grant of an Option under the Plan or an Offering Period to such employee is prohibited under the laws of such foreign jurisdiction or compliance with the laws of such foreign jurisdiction would cause the Plan or an Offering Period to violate the requirements of Code Section&nbsp;423 and (v)&nbsp;any other natural person whom the Administrator determines to exclude from an offering designated to satisfy the requirements of Code Section&nbsp;423, provided such exclusion is permitted by Code Section&nbsp;423 and the guidance issued thereunder.&#160;&#160; The Administrator may, at any time in its sole discretion, if it deems it advisable to do so, exclude the participation of the employees of a particular Participating Affiliate from eligibility to participate in a future Offering Period. Notwithstanding the foregoing, for purposes of a Non-423(b)&nbsp;Offering under the Plan, if any, the Administrator shall have the authority, in its sole discretion, to establish a different definition of Eligible Employee as it may deem advisable or necessary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Enrollment Form</b>&#148; shall mean the agreement(s)&nbsp;between the Company and an Eligible Employee, in such written, electronic, or other format and/or pursuant to such written, electronic, or other process as may be established by the Administrator from time to time, pursuant to which an Eligible Employee elects to participate in the Plan or to which a Participant elects to make changes with respect to the Participant&#146;s participation as permitted by the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Enrollment Period</b>&#148; shall mean that period of time prescribed by the Administrator, which period shall conclude prior to the Offering Date, during which Eligible Employees may elect to participate in an Offering Period.&#160; The duration and timing of Enrollment Periods may be changed or modified by the Administrator from time to time.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Fair Market Value</b>&#148; shall mean the value of each share of Stock subject to the Plan on a given date determined as follows: (i)&nbsp;if on such date the shares of Stock are listed on an established national or regional stock exchange or are publicly traded on an established securities market, the Fair Market Value of the shares of Stock shall be the closing price of the shares of Stock on such exchange or in such market (the exchange or market selected by the Administrator if there is more than one such exchange or market) on such date or, if such date is not a Trading Day, on the Trading Day immediately</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="3387-2-KW-01_PB_3_011403_9810"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=66692,FOLIO='3',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">preceding such date, or, if no sale of the shares of Stock is reported for such Trading Day, on the next preceding day on which any sale shall have been reported; or (ii)&nbsp;if the shares of Stock are not listed on such an exchange or traded on such a market, the Fair Market Value of the shares of Stock shall be determined by the Administrator in good faith.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Holding Period</b>&#148; shall have the meaning set forth in <u>Section&nbsp;10(c)(i)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>NGM</b>&#148; shall mean the Nasdaq Global Market.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Non-423(b)&nbsp;Offering</b>&#148; shall mean the rules, procedures, or sub-plans, if any, adopted by the Administrator, in its sole discretion, as a part of the Plan, pursuant to which Options that do not satisfy the requirements for &#147;employee stock purchase plans&#148; that are set forth under Code Section&nbsp;423 may be granted to Eligible Employees as a separate offering under the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Offering Date</b>&#148; shall mean the first day of any Offering Period under the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Offering Period</b>&#148; shall mean the period determined by the Administrator pursuant to <u>Section&nbsp;7</u>, which period shall not exceed twenty-seven (27) months, during which payroll deductions or periodic cash contributions are accumulated for the purpose of purchasing Stock under the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Option</b>&#148; shall mean the right granted to Participants to purchase shares of Stock pursuant to an offering under the Plan.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Outstanding Election</b>&#148; shall mean a Participant&#146;s then-current election to purchase shares of Stock in an Offering Period, or that part of such an election which has not been cancelled (including any voluntary cancellation under <u>Section&nbsp;6(c)</u>&nbsp;and deemed cancellation under <u>Section&nbsp;11</u>) prior to the close of business on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period) or such other date as determined by the Administrator.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Participating Affiliate</b>&#148; shall mean any Subsidiary designated by the Administrator from time to time, in its sole discretion, whose employees may participate in the Plan or in a specific Offering Period under the Plan, if such employees otherwise qualify as Eligible Employees.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Participant</b>&#148; shall mean an Eligible Employee who has elected to participate in the Plan pursuant to <u>Section&nbsp;5</u>.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Plan</b>&#148; shall mean this NextCure,&nbsp;Inc. 2019 Employee Stock Purchase Plan, as it may be amended from time to time.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Purchase Period</b>&#148; shall mean the period during an Offering Period designated by the Administrator on the last Trading Day of which purchases of Stock are made under the Plan.&#160; An Offering Period may have one or more Purchase Periods.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Purchase Price</b>&#148; shall mean the purchase price at which shares of Stock may be purchased under the Plan, which shall be set by the Administrator from time to time;<i> provided, however</i>, that the Purchase Price shall not be less than the lesser of eighty-five percent (85%) of the average of the high and low sales price of the Stock on the NGM (or, if the Stock ceases to trade on the NGM, on the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="3387-2-KW-01_PB_4_011510_6734"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=391054,FOLIO='4',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">principal national securities exchange on which the Stock is then trading) on the Offering Date or the last Trading Day of the Offering Period (or, if an Offering Period has multiple Purchase Periods, on the last Trading Day of the Purchase Period).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Stock</b>&#148; shall mean the common stock, par value $0.001 per share, of the Company, or any security into which shares of Stock may be changed or for which shares of Stock may be exchanged as provided in <u>Section&nbsp;12</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Subsidiary</b>&#148; shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.&#160; A corporation that attains the status of a Subsidiary on a date after the Effective Date shall be considered a Subsidiary commencing as of such date.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Termination of Employment</b>&#148; shall mean, with respect to a Participant, a cessation of the employee-employer relationship between the Participant and the Company or a Participating Affiliate for any reason,</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>including, without limitation, (A)&nbsp;a termination by resignation, discharge, death, disability, retirement, or the disaffiliation of a Subsidiary, (B)&nbsp;unless otherwise determined or provided by the Administrator, a transfer of employment to a Subsidiary that is not a Participating Affiliate as of the first day immediately following the expiration of the then-current Offering Period (or, if an Offering Period has multiple Purchase Periods, the then-current Purchase Period), and (C)&nbsp;a termination of employment where the individual continues to provide certain services to the Company or a Subsidiary in a non-employee role, but</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>excluding (A)&nbsp;such termination of employment where there is a simultaneous reemployment of the Participant by the Company or a Participating Affiliate and (B)&nbsp;any bona fide and Company-approved or Participating Affiliate-approved leave of absence, such as family leave, medical leave, personal leave, and military leave, or such other leave that meets the requirements of Treasury Regulations section 1.421-1(h)(2); <i>provided</i>, <i>however</i>, where the period of leave exceeds three (3)&nbsp;months and the employee&#146;s right to reemployment is not guaranteed either by statute or by contract, the employee-employer relationship will be deemed to have terminated on the first day immediately following such three (3)-month period.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(bb)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Trading Day</b>&#148; shall mean a day on which the NGM (or, if the Stock ceases to trade on the NGM, the principal national securities exchange on which the Stock is then trading) is open for trading.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>SHARES SUBJECT TO THE PLAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Share Reserve</u>.&#160; Subject to adjustment as provided in <u>Section&nbsp;12</u>, the maximum number of shares of Stock that may be issued pursuant to Options granted under the Plan (including any Non-423(b)&nbsp;Offering established hereunder) is two hundred forty thousand (240,000) shares.&#160; In addition, the number of shares of Stock that may be issued pursuant to Options granted under the Plan shall automatically increase on January&nbsp;1st of each year, commencing on January&nbsp;1, 2020 and continuing until the expiration of the Plan,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="3387-2-KW-01_PB_5_011623_3574"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=313093,FOLIO='5',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in an amount equal to the least of (i)&nbsp;one percent (1%) of the total number of shares of Stock outstanding on December&nbsp;31st of the preceding calendar year, (ii) four hundred eighty thousand (480,000) shares of Stock (subject to adjustment as provided in Section&nbsp;12) and (iii)&nbsp;a number of shares of Stock determined by the Administrator.&#160; For the avoidance of doubt, the Administrator may act prior to the first day of any calendar year to provide that there shall be no increase in the share reserve for such calendar year.&#160; The shares of Stock reserved for issuance under the Plan may be authorized but unissued shares, treasury shares, or shares purchased on the open market.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Participation Adjustment as a Result of the Share Reserve</u>.&#160; If the Administrator determines that the total number of shares of Stock remaining available under the Plan is insufficient to permit the number of shares of Stock to be purchased by all Participants on the last Trading Day of an Offering Period (or if an Offering Period has multiple Purchase Periods, on the last Trading Day of the Purchase Period) pursuant to <u>Section&nbsp;9</u>, the Administrator shall make a participation adjustment, where the number of shares of Stock purchasable by all Participants shall be reduced proportionately in as uniform and equitable a manner as is reasonably practicable, as determined in the Administrator&#146;s sole discretion.&#160; After such adjustment, the Administrator shall refund in cash all affected Participants&#146; Account balances for such Offering Period as soon as practicable thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Applicable Law Limitations on the Share Reserve</u>.&#160; If the Administrator determines that some or all of the shares of Stock to be purchased by Participants on the last Trading Day of an Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period) would not be issued in accordance with applicable laws or any approval by any regulatory body as may be required or the shares of Stock would not be issued pursuant to an effective Form&nbsp;S-8 registration statement or that the issuance of some or all of such shares of Stock pursuant to a Form&nbsp;S-8 registration statement is not advisable due to the risk that such issuance will violate applicable laws, the Administrator may, without Participants&#146; consent, terminate any outstanding Offering Period and the Options granted thereunder and refund in cash all affected Participants&#146; Account balances for such Offering Period as soon as practicable thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>ADMINISTRATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Generally</u>.&#160; The Plan shall be administered under the direction of the Administrator.&#160; Subject to the express provisions of the Plan, the Administrator shall have full authority, in its sole discretion, to take any actions it deems necessary or advisable for the administration of the Plan, including, without limitation:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Interpreting and construing the Plan and Options granted under the Plan and the rules&nbsp;and regulations thereunder; prescribing, adopting, amending, suspending, waiving, and rescinding such rules&nbsp;and regulations as it deems appropriate to administer and implement the Plan, including amending any outstanding Option, as it may deem advisable or necessary to comply with applicable laws; correcting any defect or supplying any omission or reconciling any inconsistency in the Plan or Options granted under the Plan or any Enrollment Form; and making all other decisions and determinations necessary and advisable in administering the Plan, including, without limitation:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Making determinations relating to eligibility;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Determining the Purchase Price;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="3387-2-KW-01_PB_6_011820_2981"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=1047490,FOLIO='6',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Establishing the timing and length of Offering Periods and Purchase Periods;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Establishing minimum and maximum contribution rates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Establishing new or changing existing limits on the number of shares of Stock a Participant may elect to purchase with respect to any Offering Period, if such limits are announced prior to the first Offering Period to be affected;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Adopting such rules, procedures, or sub-plans as may be deemed advisable or necessary to comply with the laws of countries other than the United States, to allow for tax-preferred treatment of the Options or otherwise to provide for the participation by Eligible Employees who reside outside of the United States, including determining which Eligible Employees are eligible to participate in the Non-423(b)&nbsp;Offering or other sub-plans established by the Administrator;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Establishing the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars and permitting payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the processing of properly completed Enrollment Forms; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Furnishing to the Custodian such information as the Custodian may require.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Administrator&#146;s determinations under the Plan shall be final, binding, and conclusive upon all persons.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Custodian</u>.&#160; If the Administrator designates a Custodian for the Plan, the Custodian shall act as custodian under the Plan and shall perform such duties as requested by the Administrator in accordance with any agreement between the Company and the Custodian.&nbsp; The Custodian shall establish and maintain, as agent for each Participant, an Account and any subaccounts as may be necessary or desirable for the administration of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Administrative Provisions</u>. The Company will furnish information to the Custodian from its records as directed by the Administrator, and such records will be conclusive on all persons unless determined by the Administrator to be incorrect.&nbsp; Each Participant and other person claiming benefits under the Plan must furnish to the Company in writing an up-to-date mailing address and any other information as the Administrator or Custodian may reasonably request.&nbsp; The Plan will be administered on a reasonable and nondiscriminatory basis, and Plan provisions and rules&nbsp;thereunder will apply in a uniform manner to all persons similarly situated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Liability</u>.&#160; Neither the Board, the Compensation Committee of the Board, any other committee of the Board, the Administrator or the Custodian, nor any of their respective agents or designees, shall be liable to any person (i)&nbsp;for any act, failure to act, or determination made in good faith with respect to the Plan or Options granted under the Plan or (ii)&nbsp;for any tax (including any interest and penalties) by reason of the failure of the Plan, an Option, or an Offering Period to satisfy the requirements of Code Section&nbsp;423, the failure of the Participant to satisfy the requirements of Code Section&nbsp;423, or otherwise asserted with respect to the Plan, Options granted under the Plan, or shares of Stock purchased or deemed purchased under the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="3387-2-KW-01_PB_7_011932_849"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=424282,FOLIO='7',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-01_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:19 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PARTICIPATION IN THE PLAN IN AN OFFERING PERIOD</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Generally</u>.&#160; An Eligible Employee may become a Participant for an Offering Period under the Plan by completing the prescribed Enrollment Form&nbsp;and submitting such Enrollment Form&nbsp;to the Company (or the Company&#146;s designee), in the format and pursuant to the process as prescribed by the Administrator, during the Enrollment Period prior to the commencement of the Offering Period to which it relates.&#160; If properly completed and timely submitted, the Enrollment Form&nbsp;will become effective for the first Offering Period following submission of the Enrollment Form&nbsp;and all subsequent Offering Periods as provided by <u>Section&nbsp;5(b)</u>&nbsp;until (i)&nbsp;it is terminated in accordance with <u>Section&nbsp;11</u>, (ii)&nbsp;it is modified by filing another Enrollment Form&nbsp;in accordance with this <u>Section&nbsp;5(a)</u>&nbsp;(including an election is made to cease payroll deductions or periodic cash contributions in accordance with <u>Section&nbsp;6(c)</u>), or (iii)&nbsp;the Participant is otherwise ineligible to participate in the Plan or in a subsequent Offering Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Automatic Re-Enrollment</u>.&#160; Following the end of each Offering Period, each Participant shall automatically be re-enrolled in the next Offering Period at the applicable rate of payroll deductions or periodic cash contributions in effect on the last Trading Day of the prior Offering Period or otherwise as provided under <u>Section&nbsp;6</u>, unless (i)&nbsp;the Participant has experienced a Termination of Employment, or (ii)&nbsp;the Participant is otherwise ineligible to participate in the Plan or in the next Offering Period.&#160; Notwithstanding the foregoing, the Administrator may require current Participants to complete and submit a new Enrollment Form&nbsp;at any time it deems necessary or desirable to facilitate Plan administration or for any other reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PAYROLL DEDUCTIONS OR PERIODIC CASH CONTRIBUTIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Generally</u>.&#160; Each Participant&#146;s Enrollment Form&nbsp;shall contain a payroll deduction authorization pursuant to which he or she shall elect, unless otherwise established by the Administrator prior to the start of an Offering Period, to have a designated whole percentage of Eligible Compensation between one percent (1%) and fifteen percent (15%) deducted, on an after-tax basis, on each payday during the Offering Period and credited to the Participant&#146;s Account for the purchase of shares of Stock pursuant to the offering.&#160; The Administrator shall also have the authority, but not the obligation, to permit a Participant to elect to make periodic cash contributions, in lieu of payroll deductions, for the purchase of shares of Stock pursuant to the offering.&#160; Notwithstanding the foregoing, if local law prohibits payroll deductions, a Participant may elect to participate in an Offering Period through contributions to his or her Account in a format and pursuant to a process acceptable to the Administrator.&#160; In such event, any such Participant shall be deemed to participate in a separate offering under the Plan, unless the Administrator otherwise expressly provides.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insufficiency of Contributions</u>.&#160; Subject to <u>Section&nbsp;6(e)</u>, if in any payroll period a Participant has no pay or his or her pay is insufficient (after other authorized deductions) to permit deduction of the full amount of his or her payroll deduction election, then (i)&nbsp;the payroll deduction election for such payroll period shall be reduced to the amount of pay remaining, if any, after all other authorized deductions, and (ii)&nbsp;the percentage or dollar amount of Eligible Compensation shall be deemed to have been reduced by the amount of the reduction in the payroll deduction election for such payroll period.&#160; Deductions of the full amount originally elected by the Participant will recommence as soon as his or her pay is sufficient to permit such payroll deductions; <i>provided</i>, <i>however</i>, no additional amounts shall be deducted to satisfy the Outstanding Election.&#160; If the Administrator authorizes a Participant to elect to make periodic cash contributions in lieu of payroll deductions, the failure of a Participant to make</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="3387-2-KW-03_PB_8_012135_3418"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=256614,FOLIO='8',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any such contributions shall reduce, to the extent of the deficiency in such payments, the number of shares purchasable under the Plan by the Participant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Cessation after Offering Date</u>.&#160; A Participant may cease his or her payroll deductions or periodic cash contributions during an Offering Period by properly completing and timely submitting a new Enrollment Form&nbsp;to the Company (or the Company&#146;s designee), in the format and pursuant to the process as prescribed by the Administrator, at any time prior to the last day of such Offering Period (or if an Offering Period has multiple Purchase Periods, the last day of such Purchase Period). Any such cessation in payroll deductions or periodic cash contributions shall be effective as soon as administratively practicable thereafter and shall remain in effect for successive Offering Periods as provided in <u>Section&nbsp;5(b)</u>&nbsp;unless the Participant submits a new Enrollment Form&nbsp;for a later Offering Period in accordance with <u>Section&nbsp;5(a).</u>&#160; A Participant may only increase his or her rate of payroll deductions or periodic cash contributions in accordance with <u>Section&nbsp;6(d)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Modification Prior to Offering Date</u>.&#160; A Participant may increase or decrease his or her rate of payroll deductions or periodic cash contributions, to take effect on the Offering Date of the Offering Period following submission of the Enrollment Form, by properly completing and timely submitting a new Enrollment Form&nbsp;in accordance with <u>Section&nbsp;5(a)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Authorized Leave or Disability after Offering Date</u>.&#160; Subject to <u>Section&nbsp;11</u>, if a Participant is absent from work due to an authorized leave of absence or disability (and has not experienced a Termination of Employment), such Participant shall have the right to elect (i)&nbsp;to remain a Participant in the Plan for the then-current Offering Period (or if an Offering Period has multiple Purchase Periods, the then-current Purchase Period) but to cease his or her payroll deductions or periodic cash contributions in accordance with <u>Section&nbsp;6(c)</u>, or (ii)&nbsp;to remain a Participant in the Plan for the then-current Offering Period (or if an Offering Period has multiple Purchase Periods, the then-current Purchase Period) but to authorize payroll deductions to be made from payments made by the Company or a Participating Affiliate to the Participant during such leave of absence or disability and to undertake to make additional cash payments to the Plan at the end of each payroll period during the Offering Period to the extent that the payroll deductions from payments made by the Company or a Participating Affiliate to such Participant are insufficient to meet such Participant&#146;s Outstanding Election.&#160; Neither the Company nor a Participating Affiliate shall advance funds to a Participant if the Participant&#146;s payroll deductions and additional cash payments during the Participant&#146;s leave of absence or disability are insufficient to fund the Participant&#146;s Account at his or her Outstanding Election.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OFFERING PERIODS AND PURCHASE PERIODS; PURCHASE PRICE</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Administrator shall determine from time to time, in its sole discretion, the Offering Periods and Purchase Periods under the Plan.&#160; Each Offering Period shall consist of one or more Purchase Periods, as determined by the Administrator.&#160; Unless otherwise established by the Administrator prior to the start of an Offering Period, the Plan shall have two (2)&nbsp;Offering Periods (with concurrent Purchase Periods) that commence each calendar year, and each Offering Period shall be of approximately six (6)&nbsp;months&#146; duration, with the first such Offering Period beginning on the first Trading Day of April&nbsp;and ending on the last Trading Day of the immediately following September, and the second such Offering Period beginning on the first Trading Day of October&nbsp;and ending on the last Trading Day of the immediately following March.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="3387-2-KW-03_PB_9_012225_2275"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=702390,FOLIO='9',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Administrator shall determine from time to time, in its sole discretion, the Purchase Price of each share of Stock for an Offering Period.&#160; Unless otherwise established by the Administrator prior to the start of an Offering Period, the Purchase Price shall be the lesser of eighty-five percent (85%) of the average of the high and low sales price of the Stock on the NGM (or, if the Stock ceases to trade on the NGM, on the principal national securities exchange on which the Stock is then trading) on the Offering Date or the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, on the last Trading Day of the Purchase Period).</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GRANT OF OPTION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Grant of Option</u>.&#160; On each Offering Date, each Participant in such Offering Period shall automatically be granted an Option to purchase as many whole shares of Stock as the Participant will be able to purchase with the payroll deductions or periodic cash contributions credited to the Participant&#146;s Account during the applicable Offering Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>5% Owner Limit</u>.&#160; Notwithstanding any provisions of the Plan to the contrary, no Participant shall be granted an Option to purchase shares of Stock under the Plan if such Participant (or any other person whose Stock would be attributed to such Participant pursuant to Code Section&nbsp;424(d)), immediately after such Option is granted, would own or hold Options to purchase shares of Stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any of its Subsidiaries.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Limitation</u>.&#160; The Administrator may determine, as to any Offering Period, that the offering shall not be extended to &#147;highly compensated employees&#148; within the meaning of Code Section&nbsp;414(q).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PURCHASE OF SHARES OF STOCK; PURCHASE LIMITATIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Purchase</u>.&#160; Unless the Participant&#146;s participation in the Plan has otherwise been terminated as provided in <u>Section&nbsp;11</u>, such Participant will be deemed to have automatically exercised his or her Option to purchase Stock on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period) for the maximum number of shares of Stock that may be purchased at the Purchase Price with the Participant&#146;s Account balance at that time; <i>provided</i>, <i>however</i>, the number of shares of Stock purchased is subject to adjustment by <u>Section&nbsp;3</u>, this <u>Section&nbsp;9</u>, and <u>Section&nbsp;12</u>.&#160; The Administrator shall cause the amount credited to each Participant&#146;s Account to be applied to such purchase, and the amount applied to purchase shares of Stock pursuant to an Option shall be deducted from the applicable Participant&#146;s Account. Notwithstanding the foregoing, with respect to the first Offering Period, the exercise of each Option shall be conditioned on the closing of the Company&#146;s initial public offering on or before the last Trading Day of such Offering Period (or if such Offering Period has multiple Purchase Periods, the last Trading Day of the applicable Purchase Period).&#160; Notwithstanding any provisions of the Plan to the contrary, in the event (i)&nbsp;the Company&#146;s initial public offering does not close on or before the last Trading Day of such Offering Period (or if such Offering Period has multiple Purchase Periods, the last Trading Day of the applicable Purchase Period) or (ii)&nbsp;the Administrator terminates the Plan prior to the closing of the Company&#146;s initial public offering, then each Participant&#146;s outstanding Options to purchase shares of Stock under the Plan shall automatically terminate, and the Administrator shall refund in cash the Participant&#146;s Account balance as soon as practicable thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="3387-2-KW-03_PB_10_012321_2220"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=548740,FOLIO='10',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Limit on Number of Shares Purchased</u>.&#160; Notwithstanding <u>Section&nbsp;8(a)</u>&nbsp;or <u>Section&nbsp;9(a)</u>, in no event may a Participant purchase more than five thousand (5,000) shares of Stock in any one Offering Period; <i>provided</i>,<i> however</i>, that the Administrator may, in its sole discretion, prior to the start of an Offering Period, set a different limit on the number of shares of Stock a Participant may purchase during such Offering Period.</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Limit on Value of Shares Purchased</u>.&#160; Notwithstanding any provisions of the Plan to the contrary, excluding Options granted pursuant to any Non-423(b)&nbsp;Offering, no Participant shall be granted an Option to purchase shares of Stock under the Plan which permits the Participant&#146;s rights to purchase shares under all &#147;employee stock purchase plans&#148; (described in Code Section&nbsp;423) of the Company and its Subsidiaries to accrue at a rate which exceeds twenty-five thousand dollars ($25,000) of the aggregate Fair Market Value of such shares of Stock (determined at the time such Options are granted) for each calendar year in which such Options are outstanding at any time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Fractional Shares</u>.&#160; Notwithstanding any provisions of the Plan to the contrary, no Participant may exercise an Option to purchase less than one whole share of Stock, certificates representing fractional shares will not be delivered to Participants under any circumstances, and any Option to purchase less than one whole share of Stock shall be automatically terminated on the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the Purchase Period).&#160; Unless the Participant&#146;s participation in the Plan has otherwise been terminated as provided in <u>Section&nbsp;11</u>, the portion of a Participant&#146;s Account balance remaining as a result of a Participant&#146;s inability to exercise an Option to purchase less than one whole share of Stock shall be transferred to the Participant&#146;s brokerage account.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK ISSUANCE; STOCKHOLDER RIGHTS; AND SALES OF PLAN SHARES</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stock Issuance and Account Statements</u>.&#160; Shares of Stock purchased under the Plan will be held by the Custodian.&#160; The Custodian may hold the shares of Stock purchased under the Plan by book entry or in the form of stock certificates in nominee names and may commingle shares held in its custody in a single account without identification as to individual Participants.&#160; The Company shall cause the Custodian to deliver to each Participant a statement for each Offering Period during which the Participant purchases Stock under the Plan, which statement shall reflect, for each such Participant, (i)&nbsp;the transactions in his or her Account and the date thereof; (ii)&nbsp;the amount of payroll deductions withheld or periodic cash contributions made during the Offering Period; (iii)&nbsp;the number of shares of Stock purchased; (iv)&nbsp;the aggregate Purchase Price of the shares of Stock purchased; (v)&nbsp;the Purchase Price per share; (vi)&nbsp;the brokerage fees and commissions paid (if any); and (vii)&nbsp;the total number of shares of Stock held by the Custodian for the Participant as of the end of the Offering Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stockholder Rights</u>.&#160; A Participant shall not be a stockholder or have any rights as a stockholder with respect to shares of Stock subject to the Participant&#146;s Options under the Plan until the shares of Stock are purchased pursuant to the Options and such shares of Stock are transferred into the Participant&#146;s name on the Company&#146;s books and records.&#160; No adjustment will be made for dividends or other rights for which the record date is prior to such time.&#160; Following purchase of shares of Stock under the Plan and transfer of such shares of Stock into the Participant&#146;s name on the Company&#146;s books and records, a Participant shall become a stockholder with respect to the shares of Stock purchased during such Offering Period (or, if applicable, Purchase Period) and, except as otherwise provided in <u>Section&nbsp;10(c)</u>, shall thereupon have all dividend, voting, and other ownership rights incident thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="3387-2-KW-03_PB_11_012415_4466"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=859345,FOLIO='11',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Sales of Plan Shares</u>.&#160; The Administrator shall have the right to require any or all of the following with respect to shares of Stock purchased under the Plan:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that a Participant may not request that all or part of the shares of Stock be reissued in the Participant&#146;s own name and shares be delivered to the Participant until two (2)&nbsp;years (or such shorter period of time as the Administrator may designate) have elapsed since the Offering Date of the Offering Period in which the shares were purchased and one (1)&nbsp;year has elapsed since the day the shares were purchased (the &#147;<b>Holding Period</b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that all sales of shares of Stock during the Holding Period applicable to such purchased shares be performed through a licensed broker acceptable to the Company; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>that Participants abstain from selling or otherwise transferring shares of Stock purchased pursuant to the Plan for a period lasting up to two (2)&nbsp;years from the date the shares of Stock were purchased pursuant to the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEEMED CANCELLATION OR TERMINATION OF PARTICIPATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Employment Other than Death</u>.&#160; In the event a Participant who holds outstanding Options to purchase shares of Stock under the Plan experiences a Termination of Employment for any reason other than death prior to the last Trading Day of the Offering Period, the Participant&#146;s outstanding Options to purchase shares of Stock under the Plan shall automatically terminate, and the Administrator shall refund in cash the Participant&#146;s Account balance as soon as practicable thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Death</u>.&#160; In the event of the death of a Participant while the Participant holds outstanding Options to purchase shares of Stock under the Plan, the legal representatives of such Participant&#146;s estate (or, if the Administrator permits a beneficiary designation, the beneficiary or beneficiaries most recently designated by the Participant prior to his or her death) may, within three (3)&nbsp;months after the Participant&#146;s death (but no later than the last Trading Day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the then-current Purchase Period)) by written notice to the Company (or the Company&#146;s designee), elect one of the following alternatives.&#160; In the event the Participant&#146;s legal representatives (or, if applicable, beneficiary or beneficiaries) fail to deliver such written notice to the Company (or the Company&#146;s designee) within the prescribed period, the alternative in <u>Section&nbsp;11(b)(ii)</u>&nbsp;shall apply.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Participant&#146;s outstanding Options shall be reduced to the number of shares of Stock that may be purchased, as of the last day of the Offering Period (or if an Offering Period has multiple Purchase Periods, the last Trading Day of the then-current Purchase Period), with the amount then credited to the Participant&#146;s Account; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Participant&#146;s Options to purchase shares of Stock under the Plan shall automatically terminate, and the Administrator shall refund in cash, to the Participant&#146;s legal representatives, the Participant&#146;s Account balance as soon as practicable thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Termination of Participation</u>.&#160; If a Participant ceases to be eligible to participate in the Plan for any reason, the Administrator shall refund in cash the affected Participant&#146;s Account balance</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="3387-2-KW-03_PB_12_012549_7225"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=23892,FOLIO='12',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as soon as practicable thereafter.&#160; Once terminated, participation may not be reinstated for the then-current Offering Period, but, if otherwise eligible, the Eligible Employee may elect to participate in a subsequent Offering Period in accordance with <u>Section&nbsp;5</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>CHANGES IN CAPITALIZATION</b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Changes in Stock</u>.&#160; If the number of outstanding shares of Stock is increased or decreased or the shares of Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of any recapitalization, reclassification, stock split, reverse stock split, spin-off, combination of shares, exchange of shares, stock dividend, or other distribution payable in capital stock, or other increase or decrease in such shares effected without receipt of consideration by the Company occurring after the Effective Date, the number and kinds of shares that may be purchased under the Plan (including, for the avoidance of doubt, the numerical limits of Sections 3(a)&nbsp;and 9(b)) shall be adjusted proportionately and accordingly by the Administrator.&#160; In addition, the number and kind of shares for which Options are outstanding shall be similarly adjusted so that the proportionate interest of a Participant immediately following such event shall, to the extent practicable, be the same as immediately prior to such event.&#160; Any such adjustment in outstanding Options shall not change the aggregate Purchase Price payable by a Participant with respect to shares subject to such Options but shall include a corresponding proportionate adjustment in the Purchase Price per share.&#160; Notwithstanding the foregoing, in the event of a spin-off that results in no change in the number of outstanding shares of Stock, the Company may, in such manner as the Company deems appropriate, adjust (i)&nbsp;the number and kind of shares for which Options are outstanding under the Plan and (ii)&nbsp;the Purchase Price per share.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reorganization&nbsp;in&nbsp;Which&nbsp;the&nbsp;Company&nbsp;Is the&nbsp;Surviving Corporation</u>.&#160; Subject to <u>Section&nbsp;12(c)</u>, if the Company shall be the surviving corporation in any reorganization, merger, or consolidation of the Company with one or more other corporations, all outstanding Options under the Plan shall pertain to and apply to the securities to which a holder of the number of shares of Stock subject to such Options would have been entitled immediately following such reorganization, merger, or consolidation, with a corresponding proportionate adjustment of the Purchase Price per share so that the aggregate Purchase Price thereafter shall be the same as the aggregate Purchase Price of the shares subject to such Options immediately prior to such reorganization, merger, or consolidation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reorganization&nbsp;in&nbsp;Which&nbsp;the&nbsp;Company&nbsp;Is&nbsp;Not&nbsp;the Surviving Corporation, Sale of Assets or Stock, and Other Corporate Transactions</u>.&#160; Upon any dissolution or liquidation of the Company, or upon a merger, consolidation, or reorganization of the Company with one or more other corporations in which the Company is not the surviving corporation, or upon a sale of all or substantially all of the assets of the Company to another corporation, or upon any merger or consolidation in which the Company is the surviving corporation that results in any person or entity owning more than fifty percent (50%) of the combined voting power of all classes of stock of the Company, the Plan and all Options outstanding hereunder shall terminate, except to the extent provision is made in writing in connection with such transaction for the continuation of the Plan and/or the assumption of the Options theretofore granted, or for the substitution for such Option of new rights covering the stock of a successor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kinds of shares and purchase prices, in which event the Plan and rights theretofore granted shall continue in the manner and under the terms so provided.&#160; In the event of any such termination of the Plan, the Offering Period and the Purchase Period shall be deemed to have ended on the last Trading Day prior to such termination, and in accordance with <u>Section&nbsp;9</u>, the Options of each Participant then outstanding shall be deemed to be</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="3387-2-KW-03_PB_13_012655_4091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=1028545,FOLIO='13',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">automatically exercised on such last Trading Day.&#160; The Administrator shall send written notice of an event that will result in such a termination to all Participants at least five (5)&nbsp;days prior to the date upon which the Plan will be terminated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustments</u>.&#160; Adjustments under this <u>Section&nbsp;12</u> related to stock or securities of the Company shall be made by the Administrator, whose determination in that respect shall be final, binding, and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No&nbsp;Limitations&nbsp;on&nbsp;Company</u>.&#160; The grant of an Option pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or assets.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERM; AMENDMENT, SUSPENSION, AND TERMINATION OF THE PLAN</b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Term</u>.&#160; The Plan shall be effective as of the Effective Date. The Plan shall, without further action of the Board, terminate on the first to occur of (i)&nbsp;the day before the tenth (10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) anniversary of the date of adoption of the Plan by the Board (which was&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019), (ii)&nbsp;the date determined in accordance with <u>Section&nbsp;12</u>, and (iii)&nbsp;the date determined in accordance with <u>Section&nbsp;13(b)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment, Suspension, and Termination of the Plan</u>.&#160; The Administrator may, at any time and from time to time, amend, suspend, or terminate the Plan or an Offering Period under the Plan; <i>provided</i>, <i>however</i>, that no amendment, suspension, or termination shall, without the consent of the Participant, materially impair any rights of a Participant that have vested at the time of such amendment, suspension, or termination.&#160; The effectiveness of any amendment to the Plan shall be contingent on approval of such amendment by the Company&#146;s stockholders to the extent provided by the Board or required by applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GENERAL PROVISIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding of Taxes</u>.&#160; To the extent that a Participant recognizes ordinary income in connection with a sale or other transfer of any shares of Stock purchased under the Plan, the Company may withhold amounts needed to cover such taxes from any payments otherwise due and owing to the Participant or from shares that would otherwise be issued to the Participant under the Plan. Any Participant who sells or otherwise transfers shares of Stock purchased under the Plan within two (2)&nbsp;years after the beginning of the Offering Period in which the shares were purchased or within one (1)&nbsp;year from the date the shares of Stock were purchased, must, within ten (10)&nbsp;days of such transfer, notify the Company in writing of such transfer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Options Not Transferable or Assignable</u>.&#160; A Participant&#146;s Options under the Plan may not be sold, pledged, assigned, or transferred in any manner, whether voluntarily, by operation of law, or otherwise.&#160; If a Participant sells, pledges, assigns, or transfers his or her Options in violation of this <u>Section&nbsp;14(a)</u>, such Options shall immediately terminate, and the Participant shall immediately receive a refund of the amount then credited to the Participant&#146;s Account.&#160; Any payment of cash or issuance of shares of Stock under the Plan may be made only to the Participant (or, in the event of the Participant&#146;s death, to the Participant&#146;s estate or, if the Administrator permits a beneficiary designation, the beneficiary or beneficiaries most recently designated by the Participant prior to his or her death).&#160; During a Participant&#146;s lifetime, only such Participant may exercise his or her Options under the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="3387-2-KW-03_PB_14_012756_5192"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=808869,FOLIO='14',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Right to Continued Employment</u>.&#160; Neither the Plan nor any Option to purchase Stock under the Plan confers upon any Eligible Employee or Participant any right to continued employment with the Company or any of its Subsidiaries, nor will a Participant&#146;s participation in the Plan restrict or interfere in any way with the right of the Company or any of its Subsidiaries to terminate the Participant&#146;s employment at any time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Interest on Payments</u>.&#160; No interest shall be paid on sums withheld from a Participant&#146;s pay or otherwise contributed for the purchase of shares of Stock under the Plan unless otherwise determined necessary by the Administrator.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governmental Regulation</u>.&#160; The Company&#146;s obligation to issue, sell, and deliver shares of Stock pursuant to the Plan is subject to such approval of any governmental authority and any national securities exchange or other market quotation system as may be required in connection with the authorization, issuance, or sale of such shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Rule&nbsp;16b-3</u>.&#160; Transactions under this Plan are intended to comply with all applicable conditions of Rule&nbsp;16b-3 or any successor provision under the Securities Exchange Act of 1934, as amended.&#160; If any provision of the Plan or action by the Administrator fails to so comply, it shall be deemed null and void to the extent permitted by applicable law and deemed advisable by the Board.&#160; Moreover, in the event the Plan does not include a provision required by Rule&nbsp;16b-3 to be stated in the Plan, such provision (other than one relating to eligibility requirements or the price and amount of awards) shall be deemed automatically to be incorporated by reference into the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payment of Plan Expenses</u>.&#160; The Company shall bear all costs of administering and carrying out the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Application of Funds</u>.&#160; All funds received or held by the Company under the Plan may be used for any corporate purpose until applied to the purchase of Stock and/or refunded to Participants.&#160; Participants&#146; Accounts need not be segregated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; The validity and construction of the Plan and the Options granted hereunder shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware (other than any conflicts or choice of law rule&nbsp;or principle that might otherwise refer construction or interpretation of the Plan and the Options granted under the Plan to the substantive laws of any other jurisdiction), except to the extent superseded by applicable U.S. federal laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>*<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>*</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="3387-2-KW-03_PB_15_012904_7738"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2238596",CP="NEXTCURE, INC.",DN="8",CHK=973755,FOLIO='15',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-KW-03_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 07:20 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>9
<FILENAME>a2238596zex-10_13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.13<a name="3387-2-OC_Exhibit10_13_120935"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEXTCURE,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This NextCure,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) Non-Employee Director Compensation Program (this &#147;<u>Program</u>&#148;) sets forth the arrangements for compensation for members of the Board of Directors of the Company (the &#147;<u>Board</u>&#148;) who are not employees or consultants of the Company (the &#147;<u>Non-Employee Directors</u>&#148;).&#160; All compensation paid pursuant to this Program is subject to the terms and provisions of </font>the NextCure,&nbsp;Inc. 2019 Omnibus Incentive Plan (the &#147;<u>Plan</u>&#148;), including, but not limited to, the requirement under the Plan that all compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed $750,000, or $1,000,000 in the calendar year in which the applicable Non-Employee Director is elected or appointed to the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Cash Compensation</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-Employee Directors shall be entitled to receive the following annual cash compensation, payable quarterly in arrears:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $35,000 retainer for each member (non-Chair)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $65,000 retainer for the Chair of the Board</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $7,500 retainer for each member of the Audit Committee (non-Chair)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $15,000 retainer for the Chair of the Audit Committee</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $5,000 retainer for each member of the Compensation Committee (non-Chair)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $10,000 retainer for the Chair of the Compensation Committee</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A $4,000 retainer for each member of the Nominating and Corporate Governance Committee (non-Chair)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>An $8,000 retainer for the Chair of the Nominating and Governance Committee</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retainers shall be paid promptly after the conclusion of the applicable calendar quarter, but in no event later than 30 days after the end of the applicable calendar quarter.&#160; In the event a&nbsp;Non-Employee&nbsp;Director does not serve as a&nbsp;Non-Employee&nbsp;Director, or in the applicable positions described above, for an entire calendar quarter, the retainer paid to such&nbsp;Non-Employee&nbsp;Director shall be prorated for the portion of such calendar quarter actually served as a&nbsp;Non-Employee Director, or in such position, as applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Equity Compensation</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Non-Employee Director shall be entitled to receive the following awards under the Plan, to be granted annually, in connection with the Annual Meeting of the Stockholders:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>An annual stock option award for each Non-Employee Director that is exercisable for 11,000 shares of the Company&#146;s common stock, that vests on the earlier of one year from the grant date of the award or the day of the next Annual Meeting of the Stockholders, subject to the Non-Employee Director&#146;s continued service on the Board until such vesting date; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="9",CHK=837414,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-OC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:54 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>An initial stock option award for each Non-Employee Director newly elected to the Board that is exercisable for 22,000 shares of the Company&#146;s common stock, that vests in three equal, annual installments commencing on the grant date of the award, subject to the Non-Employee Director&#146;s continued service on the Board through the applicable vesting date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All stock option awards under this Program will be non-statutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock on the date of grant, and shall have a fixed term of 10 years (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for cause, the post termination exercise period will be 12 months from the date of termination). Annual stock option grants for Non-Employee Directors who were initially elected in the 12 months preceding the annual grant date will be pro-rated on a monthly basis for time in service.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Expenses</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The reasonable expenses incurred by Non-Employee Directors in connection with attendance at Board or committee meetings will be reimbursed upon submission of appropriate substantiation in accordance with the Company&#146;s policies and practices.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Effectiveness</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Program is effective upon the closing of the Company&#146;s initial public offering and may be amended at any time in the sole discretion of the Board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2238596",CP="NEXTCURE, INC.",DN="9",CHK=992914,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-OC_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 00:54 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>a2238596zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 23.1<a name="3387-2-NG_Exhibit23_1_101114"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;5, 2019 (except for the seventh paragraph of Note 1 to the financial statements, as to which the date is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2019), in Amendment 1 to the Registration Statement (Form&nbsp;S-1 No.&nbsp;333-230837) and related Prospectus of NextCure,&nbsp;Inc. for the registration of 5,000,000 shares of its common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ernst &amp; Young LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tysons, VA</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing consent is in the form that will be signed upon the completion of the reverse stock split described in the seventh paragraph of Note 1 to the financial statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Ernst&nbsp;&amp; Young LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tysons, VA</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;29, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2238596",CP="NEXTCURE, INC.",DN="10",CHK=594446,FOLIO='',FILE="DISK108:[19ZAH2.19ZAH78702]3387-2-NG_ZAH78702.CHC",USER="JTAYLORA",CD='Apr 27 05:10 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g79071.jpg
<DESCRIPTION>G79071.JPG
<TEXT>
begin 644 g79071.jpg
M_]C_X  02D9)1@ ! 0$!\0'Q  #__@ S35),3%]'4D%02$E#4SI;3D585$-5
M4D5?24Y#74Y%6%1#55)%7U!-4U],3T=/+D504__; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $$!=0,!(@ "
M$0$#$0'_Q  ?   " @(" P$             "@D+!P@!!@($!0/_Q !A$
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MQS#VP_"&N>8<N?L?A_!R\ON<O+JG''9>)WB/T1O_ )<<"(% 1$>0!\?E[@
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M2,HJ43B"3=LV*FDGZ3KB3[>6[E=!C&Y5F6R1C G)1](.DS<E*(@!VY9B:C)
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MHT%<$?!HT:-9QG!HT:-9QG!HT:-9QG!HT"(!Y1 /LZ-9QG!HT:\!43*/(RA
M'VA,4!_ (ZSC.//1K@IBF]"8IOM1 ?DUSK.,X-&C1K.,X27T:-?7K\(_LT]!
MUN*(DI*V&8BX&,376*W04D9A^WC6":S@X"1!)1VY1(HL<!(D0PJ'\Z41UT.,
MP6!L84  "1F93$"(#$D1%,^40,1,S,^41&_'YVTI;8:I"%FUSV E*EC),8UA
M0"U@,;R1F90(C$;S,Q$>?'R0$0$! 1 0$# 8IC%,4Q1 2F*8H@8ARF #$.02
MG(8 ,0Q3  @QEP]-XHYJK9<49%E2J96IT64\?)O%"E7OU69%20+*"<W+QBR0
MI3(M[$F'U9\@9O/%!05I06J\,Y!R]9FI>NV".=P\[ R;Z'F8I^B9!['2<<X4
M:O63I$W>19!=,Y!\I3EZ5$S'2.0YO=J5LL5$LT'<:E*N8.RUN2;RT+*M!Y+,
MWK81Z#&(/G'#99,RC9ZS6 S=ZR7<,W!3(KG 0_6>DZ.L\+-4B4%M8S9Q5^-C
MA+C&)'VPZI.I:"!%XCU00=#0B6*5,.#DSS8SG)?6H95:[+<588..U9@#ZE%=
MHJ:0LV2V0%.6QK)8VBQL 2V]ZHTPKVK0DZ*;R#]@?DTHUNQ]<[N ^%JY_E,^
MF0MIVYFO;F\9-K.T(VB[C" A$WZKI+=9H:=[#K!VS*H/;J5^;(0[Z#=' 1[(
M%X]<XOHYV +>[L?7.[@/A:N?Y3/I/\F:%O%ZKU)CKZ3KW*F,[+TG[P,;U;SB
M8W@@(9@UF,R#%D)A,B43-P_3.U!B-5<JN6VHL#=5D<1E]1E=HVTS/0U+,)>\
MB$H@U.4<&FPAH@ZN];$. &K,8P"CZ>W]\-_GB:=;9?K-I[V0^:)I*1'T]O[X
M;_/$TW1N"S7%;?<)V3)LBD@\=Q$4U:5R(<*F2+.VJ3*1I Q',ABJBDN\."[\
MR(]HC&-GS@O+L1$)+G?4L7[6C*519.M6WY:M74/X3'./$+6$;[1'411&\S$1
M'G,Q$3/ UZ#V6Q^!Q?.7-Y:R%/&8FAI3(Y"TS?HKTZ:=76+#2@8DBZ%+(H$8
MDRF($1DIB)Z/N<WBXNVQ1S=&PG<6:\2J!G$)0H!PT"86;AU%+*3+A<XH5Z#,
MJ444Y%XFJL\6*HE%,)%1!P5&$7)G$FW/W]PZ3@[-'8PA%53"WC*1&-AD4D ,
M I)N;/-HR,HX6*4.2J[%*(35$3"#5,O20NEMUN=GR):Y^[W*67G+/9I%:4F9
M-QW&<.5AY%302#SC1@S1!-I&L$0*W8,44&C<A4T@YY!P1@3(6XF\HT7'S)N9
MR1OYH3<Y)G60@:S$ J"(R<PY0276 JBP@W8L6J*SZ2=<T6J79I.G#8IT_P N
M-*:2Q<Y#/+I9"VA,6+]_) +:-:1B)(*M9T$D5K*8!;#6=EQ[2/1)@D%9S!](
M_FOS<U0. T)9S> Q-^[-# :?TVUM7-Y*#*16W)Y&F86V6'@,ML5D658RFGJ$
MX<*6W6^Z?=%N34=)O3Y\RZ+E("@F<+W/$( $ZND!;D=E:G]&/,5$#B?N$XF$
M"B&7L?<0?=90%R#],A2\, .F=6+R)&M+(DJ"?=V991((VPH <!$#'3F!YFY'
M,0PAK?-#@^0@PZ)'6=9PM@%,@KN&U'B3015A+S.FBP6F@E#)%-W%44EBJ&*'
M4*9!'H+&5N1VM9,VQV1I$W5%G)P,V=X-5N<**IH6>39B4ZS91%<I741--D%$
M5GD.\[02IG%=@\D6A%')-O&YCEEJQY8BG7PMMY"7;K/PXU#: 1)%-4K%-$D0
MB),Z$'WA 29TP(D40^I='^DWRFHKU9F+^M<30!JIL9.CK \LFHY\K !RJ\?E
M[T*!K"77[MU4TW.)=?NFPP64[.U??]C?<0[;TZ<9?2ZR>=$@MJ](OTG<-:%$
MTP%T-1F3$;&=.DQ 530,@W:S!&YA49EE4&[ITEI[OUR)NYV[9)).5',5L3Q+
M?U7#RKB6+JCA"L3*916E*8NZ6K:JPIHI@,G7U7:RKAU$G7;'6<N(AVNI"ZU=
M.6+IJ^9.7#-ZR<MWC)XT6.V=LWC14B[5XT<I"55NZ:KIIKMG"9BJ(K$(H00,
M4-,;8'MM<X@FTR;HF3U$3W.&,G6;9(LT$0D(^R,$@?4_(L8W$H)M74@B5-ZL
MDD*;9=^VL$4!2L%3HZ",_I+%\OLQ3U+7QU?):5M/&CF<9?K*R$XP;!#V[50K
M0.,@$QW#KGNP<16)QA;B5/#07-S57I!Z0RW+2_J*_IKFIBJ3,[HW5&"R5G3P
M:F9C@GQ&)S"L8VHD7-2R8;"1BJ2)G)A44[$E%J'D-]^[H! 0SC9>8" AU0]-
M.7F \PZB#6@ Y>8!U%YAU%YEYASYZ8;VH;A8C<CB&$N[<6[2S,NF O<(D<.<
M1;&#= ST44QY'"+EDE$IB&4$# 9@\(W.H9RT=%(K5D_&UKQ#?;-CFZL18V*K
MR*C%V!2*%:OFY@!:.F(TZA2F6BIEB="1CEPY]3=<J9Q!=)8A-@=EFY5UMLR\
MREY)PN;'=N\4KN0V)#F%-"-,XYQ]I11[RF?59RLHZ,(%[5>&<2[(@]HNAT$V
MN=!8?4&FQNZ:Q^/1>KJC(8\\95KUPR59BA,Z\S76$.[Z8%E4B@IAP@ R N;,
MK/D7S[UCR^YDSAN96H-17\%DK,Z=U C4V4R.0=IO(HLFA&1&,@]YT_ 6^Y6R
MJUR E38YS1:VG6&&@;O<ZYCNHV*\6V21B*W5XEY,S$@L8H @S9I"H<$R&$!6
M<K'Z&[-L3FJZ=K(-D2F56(45H[YQ"]SMGN=EGZQDB9I%;E)9RX@*DPCZPX;P
M$. @E'1YG+V"=NG3LC5-)61<*KG!:15=G1!-N**2>R7$[W2I7.=:X HLLDZJ
MM:683=_DH]5-9I.V8R*;Z$@4':)CD=1E?:.&\L\,F<47$VZ9IB FAAYQ'(HK
M.%DF[=%9PX75200;MTCK.'"ZZA4D&[=%,#*++KJG(B@BF4RBJIR)D 3F* Q/
M*S0%*OARS6?QU6W9RH =2M?K*L!4Q\>VMO:L 0"ZY.S9+IF1KPF!(>XX9*_2
MG]('-Y'6(:+Y?ZBRN(Q>E'M3E<E@,E:Q[\OJ ME6*L6J#U.;2Q$=5.%0<+=D
M2N$:VC7IMB1/!&X;?%G_ "=7,9U3-]H1<3"QUYB9-!T]9I6JXS$AYFP/@^AH
MI!39('*DS0.<GFA*N8^.3,!W747,6^?<YN&PSGUQ0:#EVRQ->B:'05R(*,*H
MZ6>23B/>%D)5ZJYKRW6^DUFQ'+PJ79,^W$X-VR"0@F$@^Q':RCMTQ@21LC)(
M,JWY!E*714P)JJ035,IU8BFM%PY@5&&37.M+&1,)'L\N\5ZU6S5AV>O&[[A^
M90W#9LDLF5:ZT&#AWM;J\(FPL 6/S3(XA47B+A8_F;%NFG8JF<D%$"K]IR*;
MM (/+G )U-H>SKMP/Q^GZ6F,;C[E2NXL14)-^^5BIUVB%-1DL&86P*<D)"*1
M-T2!63'@^N<L.>>-Y#TGT-0\P<WS.U'J+#9:]4#5N6"[@-/KH9/LXI3+N51"
M&P5A#\R(&!G<8FH8-#'*<4"#YZZDGKV1?+&<OI%X[D'KDX$*=P]?N57CQP<J
M92)E,NY655,5,A$RF.($(4H 4/<@)V7J\[#66 ?*QD[7I1C-0TD@1%1:/E(Q
MRF\8/4B.$EFYU&SE%-8A5T54C&( *)G((E'\YJ+7@YF8A'*B2SF%EY6&<+(=
M?8+.(B1<QJZJ/:%*IV*JS4ZB7:%*?LS%ZRE-S*'V*+4GU^NU0HL8Y:,I*YV:
M#JT>\?\ ;>(M7L](MXQJX>>+IJN/%45G)%%^P245[(INS(8W(!L4PZT5#8WM
M^#BN1LZ@ZE>&A<D?4OIG=?:WW#IG<=QZ9]W'.NNG)'E45ZWB/7!Y!*:_;;(6
M_6161!/;?UC(V/%2/0[N1(LV/N1MU<;#K[\-W94'!RYRLQ3%;KG*(1--[C%2
M.8H@ U@0[C  @'+E[FI8.)COJD]BO#4O>YEJHWD\HK4*E5/&*<@1+L)#+V3F
M<="UV4>($2*BNTK[E[(W:39$(F5VQKSIFGV0+%$FHRW")SHHDLF7)F)0%1%9
M,HB%S$ %1,Q $>4#Y $P"/+GW>3GJ+?PM^XSM,V[\/[ 7FN88^6M>0KA9&+0
MJ@,).4Q/CZFTR#?BH<Z:O9-%LASQVB"S<PJ>-@X,=%5J"9T'GDZ'U5J+1>+T
MW&()9Y*XS+!CJ$4Y94KH1:A3Y&M7E@M76L+'S+HZC+<9G>>FGH\8SG5I"IS$
MR'-.=70H\7A P!:ESQYD(M38R*K)4A;D\A%=@=^F3B@5RR(7$]R V%9_A0;'
M9WB7[\\>X;M"U@E:$XDI?+6XZVI/'*4P7&L'()25Q<KS9$G*S2Q9%LDK&U%E
M)]"CE.9MBTL3D9BJJG:!9LRG0MF6"Z[$TJJ0\>E$Q<5C?#>-H9!.,@V@0\,#
M6$C$6K0"#'5*JP[%)5Z+8@'39-V[%N(/G[<PJP^!Z8<B4:1O.W!.&HJSLI<\
M:X5B7AC(\F<+6ZX]R%/((E*<7!324I;X [D54DT3DB6?8G6,18J$P^]RQNKY
MNL+4UC]43C"J044T:@J8Z(2]H13L\R]Z.L2)N%6CJ#9''I(?LF! -S*8.>KJ
MN8U9S%]26I*<%I>GWW5@(@!O0JNU_D,CTDZS9JTF$/00(7,KD2]KAJ:JU%:Y
M>\KCS.*D U-JO)5\/BKC !DU;-^;!^*D2$Q.:6/IW[Z%L$U,M"D'@0$03@=C
M6;MF:V.\@9*EWMIM4L8#*R#TO9H,6XCS2BX9@F'BD-#M@Z2-8U@1- I0 ZXN
M79UG*NQ45@- 6I?U$'H/_+#V?8'N#V1]S\&LSX=I38S=K]2*/<G^U#G^UY]X
M=PB/X?8]L-;PPM#:BT*(HE]"'+S@![ #SY>7F/L>P/EU$9W5[:K8K5NFNA$"
MI*$#"TI4&P@M2PZ1  B-A&(B(B-HB/+@ T)RAJY&J60R$,R%^\16KMZX9VK=
MNRV8-UBS8=).>]AS)&QAD9%.Y3Q#Y=\"-_%5@,R*)1*)3 *?,#%Y<A 0$H@8
M# (@)1Y@(<_+S$-?;VR[DK/MNML5CN_RKN3PC-R!(TAY$YW2V-7K]8J+:5C7
M"QC+DJ1G!R$G803J-HM$ZDO$I-S(OFC^2.^T9J5JJ'9%$.D?VH>U]@?*'/OY
M>3E[0ZBSS]3&@MWY3H$,4Q52F*)>XQ1*(&+RY<_/%$0'W!]OR[^'RU;4]8\/
MEUQ8J6AZ8DMI;6;,=*[-8RC[U85,]0%&T%YK."49@4#K'2.2Y:Y.OK#2+BQV
M7QA0SV)(:]^L) ;L;DDKF(LT+0C .4>_3,B]!*LI2Y<J-2V,;0Z7N+ON[FK8
M"QQ'[B\GBP6MN7 A2OK.[69Q;2(\=A5GZKMC57LLP9-2V*2J;.%?VE9$CVPN
MI1T(K#E_.5GF:1A;+=QKCA-G/U/&&0++!NEFZ+Q)M+P%/FI:+<*M7)3H.DT'
MS-NJ=NN0Z*Y2"DJ4Q#F <1;(;X_R!MIQQ(2RZKJ7@6<C29)TLJ599VM3)-U
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M('0,0.IBI)X]?M$EDU%!(Y1736*B!F_;26;J&:]>WG7]=X0Z:-DBJ)88XZA
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M>.H9&M[;'U NU[>HF<,Z54;+;G2!.KK6;UB#?SJR)>@#'$54X\R8 4!,/5R
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MMB27!!(LB)(;(;Q)CUAPA,UICF?Z-FOZ>6FN['W<3=?.#U"%8K& SM1BV5V
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MC#F376*O%)66TMKV!$6%(04*,R2?F(R?-3TA>3NHN66M\WD1H6V:0S.5M93
MYVNII4T!?L,M1BK5D(D:F0Q[&'6 '&L[:4KN(WAABJ5K'?%SL$-66$7DG$Y+
M=8F+9!LO9:Y9V]?3FC(H F9^_AGT*]18OW2A 5=ECG9F)E#JJMVS4@E:EZGD
M;BU99GD'++&N/ZI04U>94I><>.KM-MRAZ!1!J+>#@D7 &#K SEI*H (  HG
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,AQYZ-&C2DX8''__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g57012.jpg
<DESCRIPTION>G57012.JPG
<TEXT>
begin 644 g57012.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]04D]$54-47S1#7T9,3U<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!<@*L P$B  (1 0,1 ?_$ !\  0 !! ,! 0$            ( 04'"00&
M"@(#"__$ &X0   & 0(! PP," 8,"@D"!P$" P0%!@< "!$)$A@3%!4A45B1
MEI?1UM<6%S$T-5=9871UDM49(D%2E)BTM453L\/%TB,R-D)55G&!DY6ATPH:
M)"4F,W>QMO H-SA#5&5SP=1B=B=$<HBRQ^'_Q  = 0$  @,! 0$!
M     @,$!08!!P@)_\0 81$  0," 00)"PT+" H# 0$  0(#!  %$08246$3
M%!4A99&5H? 6(C$R05)55G'4\0<C4W)S@9*4EK&RL]48)"4S0T1%8Y/#T@@F
M-#5"9+3"%S9&5%=B=-/6X6;!T8(G_]H # ,!  (1 Q$ /P#W\::H(\/" >$0
M /\ OUJ*BN6GVERF/K;D$]5W!13>!KD?<JK7)C%*;*R9?ITAG>$VV>R?$O\
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M&9;#CQ+0V$+&R@OQU2V0ILX+27(R5/)"@"4)5W00,VZ:::U]9]--0:W6[_\
M#>SZUU6IY+JV8+$XL.-\FYCEY3&./E;U%T'$^'7%90R-D*\)LI9I,LJ[62VV
M(=/SP</8'Z;(SEV+ $&QS#^9>40V[K1\U*LW-QD(Z$W;8QV9*/&%<1<H2&5\
MNL<?2=+E8HQ94!>4!['Y*KCM>S\$ED42R)DXE?K4@.-JW8[PZQ'E-6Z6Y'E!
M2H[R&E*;="7A'5FJ3B,0^I+>!P.<I. P4"=8Y>;4T\]'<GQD/QR \TMP)6WG
M-%\8@X8C8@5XC$  @G$$5.G36OYMRF6U-28WFP[RS62('8K$25@S7(R=5>DC
MWT#!)3K>S3&.1:+.WUZ85:RUF=HMA4CV+<\==HY:#,F<QT7"G6)7E,J/%(X4
M8J[9]XKB^9[-DUS1,4ML0UH,A'KF)V5%D[/<W[%WDAK 'J*\;D2NO867A+'-
M#) ,DS!LA)1CMD2Q.3UZ4H(W-E)40E0#B UUJH.Z6=ZZ4#,3 PEN+[5IA2%N
M% 6C.K7?K.A.>;A'*<2G%"BYUPF"!F^MI4<Y4P[6;3V770I+85FJ(V4::C'G
M3=IBS;W=<"T&^-;VM/;B<FU_%-&5K='FYR C;)95Q:12UVM*:3>M5!BZ>B5F
MT2DY7LY**@Z4A823:Q<PXCI-@/$ $/R@ ^'6M<C2&6H[[K+C;,I+BXSBTE*'
MT-.*:<4VH[RPAQ*D*(W@H$=D5L&Y+#SC[+3S;CL92$R&TJ!6RIUM+K:7 -])
M6VI*T@[Y20:KIIIJBKZ::@+N8Y1O NT_*L?BO*D-E<ZH8P:9GN5YJ%!5ME!Q
M=C!YD%+&*=RR))Q\J6<B89*W.&S-\YBJY.%BV:Y962ZUCTUUT;]';_L"2AZB
MFT&ZG&Z[R;WL9A!&MH@4^:L>!>#3KIP)94W4J*J2@3)XRSDZJH[(YBC'BD >
M'%OM18[P8[,L6V6J+(2I;#X946G$H0IQ>:L8C%+22ZI)P4&\UPC,6E2M6;U:
M1(>BFX1A)CJ2AYDN .-J6I+:<Y)P."G%I;"ABDN8H!SDJ FYIK7&?E4-I*4-
MO$GE[!;T(_9)/,J]E4QZDX56LCJ3LLC0XI]BM!L]74O4)(Y+A9S&:$TB$='(
MW6%DV#YPT8-PDS\ZP<HK4Z[-83ICK;7N[<Y0SA"9)L\1B5KB6O%R%3JSBFX5
MFF6^Q7N-?9$913"%1?V^!D8N1KTU9V\U"/22,:9<!(B>?4_>LX)5;9+:B2D!
MY 9WTP47)?XTHWFX#C4IP]AMEUI3A3LK85$WVT89PN$=8S0O%M2G>M,M<!)P
M;2L]?,;<CMC#%QQMP("@VLIV'::AON7WO8NVH6:@0^5:=F<:Q>9RH5Y]E>JX
MOF+%B7'LE?[BA0J8AD&[(.&[>+<6"TN6\>WC85I89ADBX:R<M'1\6]9/'$QP
M$![8=T0_S@(@/@$!#6 [#E,,1I+S#C<>6'#&>4GUM[82D.I0H8@J;V1LK0<%
M)2XTLC,<0I6<U*CO/2([3R%O12A,AH'KVBXDJ;*@<.M6 H)4,4E2%IQSD* K
MIIIK&K(IIJ!&X/E&<";9\UM,*9.B<J).4:+0,D7+(M>H:EBQ?C&G9.R9(8BI
M<UD2?8RO9F#8RM[CE(A9ZSK<LPBDUD'\NZ9,A561OM9W]X(M:^(FT66[@MFK
M<QFG:C3R.JRBB*64<#FR>6\*S7,EE>Q]64'$UE[!S:?7:L@#J%,M'LBOEA9[
M0V2[B.U*-NE[6?;+K+X:46W$)8<E**5#$8IC-+D*2<%!D)=(S%H4K6B\6LO.
MQQ.C[.PX&G6MD 6VLNH8"5)._OON)9"ABDN9R <Y"PF;6FM9\/RL>TBQ8LSG
MEF DK_,P^",RUW!<M ,:4J>W7N[7JT,*9C-SC2)5DT6UCJ>4;,^-%T6W/Y*"
MA)(\?*N7[F+91SAR';3\H93O;1Q)A9OMZW7.\GY4QVQRJ^IY,40K66Q-1763
M7&)W$]EM"2OC$8!I%VALHN^/7_9616 %"=BSR+%TU,M:K)Z]H*TN6V4TII3B
M7 \@,E!:CMRW<X.E& 1'>9=4H]:$O-#'%Q 54+]9U!!1<([@=2VILM*4Z%AV
M0N*WFEM*@2M]MQM*>V);<.&:A1&P/341,T[S<=8$R[BK$^0*3F9NURY;Z-CN
M!RQ%8V?R6&XO(.3)25A:%2IVZE>HK%GK')1*S8$X2&G6, #J.<VQ] M)!LN>
M78=O6N>B28[4=YYE;;4M"G(SBAUCR$JS5%"@2,4G#.2<%)"DJ("5I)SV9<:0
MY(99>0X[%6EN0VDG/:6I.<D*! ."ACFJ&*24J2"5(4 TTTUCUD4TTU%7=+O-
MP-LW:8FDL]6.2JT1F3*T'AZJR[2 D9J-:6N?9OGS-S974>0X5^NH(,%C2,Z\
M*9HP*)57($;E661R(L63-?;BPX[TJ2[G!IAAM3KSA0A3B@AM *E$(2I1"03@
MDGN51)DQX;*Y,I]J/';S=D>>6EMI 6M*$E:U$)2"M24XD@8D5*K6@_E&-_\
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M"?:+Y].J)_QA/M%\^M./X.W?E\M+NY\A.T7U7:?@[=^7RTN[GR$[1?5=IN=
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M=DTHZ3LN1[T]N"TVK!1K6:B63NM5*NA649E,%9%Y%H^Q4CXO5%T"&5?*I"V
MJ)#J8^K.V9G6X#',"G=)14,>Y>S)EA"1;Q;5B^?.,OI9C27B45"NEPC#USVW
M5UHV73!TLX<UYDJLT2Z\6*@I7X/MW&/X!K<E[K5\E8_=5"J0EV+%W"K-&$C9
M*Y8[06E0KV"38SDDW;KNK8LS@W47:759E85>09NYYE%Q9U7Z7:;!N"B:ZVK3
M9WC_ "8ZNEEBK?8"8TCX:NN;M$5RC.T&-CL$P0;8E5TXMN\?1#2+4C[1(N+.
M[FHMI5FTRY7510P7CW94OCQM,'C;U37DM)8HK^(U5WN%8)6'L4/#V9O/2D]D
MR(7M3AUD>U71KV3C;A*2<TP2?*2BTE&-(EQUPF[^T=D,3'Q^/#Q]AICZ;HB&
M5(LC*Z8@A;KC8];RA;D;H%9KF/I&R-W-,B:'+,8]I0$8BW+=AX$LA"/@E&;\
M@,U*E.WO*UZQ?%9 PT>O6T+C7(2P45S.R<A!UZ086)-DX924F[9Q4I+-6S6/
M>&?N(].,[(K+-C1)NL'*IG+;INV#)UCS+@7&N3+:VAF=DMD"H_F6]>;/6<*F
M^0E9*.4[&M9%])/6[4X,BJ$2<OW:I!.8#+G[0Z[N6I6&(QK'TVF3]?J]BB8"
M'B(JP$HS%:N,',:1FFNX;T&*EX!@VCG":#A-I"L9AFWC".$BH.%2M0!7H^VW
M#D]@7%L-BZ7O+6_,:P9=K795*HDJ+QM#KK*O192:"5AGT))V61=OEBR"(QQ.
MME4&IF(J-SNG"E9\TTTTI5KG/@68^JY#]D6US&GO1K]'1_DRZX<Y\"S'U7(?
MLBVN8T]Z-?HZ/\F74_R8]N?HIJK\N?<A]-5<C3334*MIIIII2FFFFE*::::4
MIIIII2J#[G^<O_>&M6UHPSDN,Q['2=5J4TX?7B:FJMDFL)LU"R)FL7F22N%%
MN760<!X,V*2K!P[-P 8>29JG/U #&)M*'M:PZ?.F.D&S9TY?2I$Y"4MD=%)-
M:[-33N40I4D,389QDQK[*7=^QQD_*9$9IR@V:&'FCSB@HF)_F/JD9+9+Y2L,
M(RCOHL);M5YA0Y8E0XCC#=UEV%F;*:>F)*$E266+,Z#ZV_&OC\)8*Y;0KN<B
M[]?;(ZZJS6H78*N-MF2(YCR9"'5V^/=78K#C<925J"5..W-LCKV7[6S*3@F.
MX:Q'6'-FQ/DC,+.4QS>;<CDB]-+75['5(AK+1;E@_C649V'G9%=\T3@AKZJ*
MA1&4$K3K'GKH"(&(FM:.M+98=QE*L\=7,G.HV!<7=E8B9(@&$=4J9%O6)F*+
MK'DC'%1)(/IE9N0J:O5Y]9S&.0(LNT+U1-O)<F3J(K9+#4DK V7GZK!JV*PL
M44':P144@9,JZCETFW,T!R@*J0KQR:YWZ)5$S*MB <O'K[7-]#?PB%C8J6!:
M$5FZM"'DG54L,(V1/<G:+&#DA/88^'ZYAEW3EJ1>2C^O46W7*!U0 B@&#4/6
M#)M+42VKR[83;;=E/*RFBP!(M6V&7[-?UY0W&(M]I:7)#=ON3BVIKDIA]<.&
M,'PBX(%R3GMW>\J=D34Y*.JFS;#'L3\LLS]A<:N-G;LT.0AM:2AAR; 2AR*B
M.ZTF3).+17"48*HMOD+/,EW3(P>(K>JCD*NU<U.B;-4'T+$/VM<K3.ORK/@9
MRQ(A(MCK+/8*,(Z;*R*C(O6IRCP*.2=L\#9(6<R*N^87=W7Y-O2S1MQR?#GA
M+[,R$7$N(N0AG;98R:[B @4T&YH9<[%J4AW[PA%I 3'=#+@ #\@!W/<#_.&J
MZVMJ]3)BW7ZTW]R]S)4FU2+S*;9$6+&8=<O4[*.X2$*2V%8,ID947'-2O9'&
MVV(*(ST8"X&XX,_+AZ;:;A:$VR,RQ/8MD=3I??>>;1:XECALJ2I9&+JFK!#*
ME)S$+6]+4^V^=I;1::::^H5PM---?DNN@U06<N5DF[=NDHNNNNH1%%!%$AE%
M5EE5#%32223*8ZBAS%(0A3&,8"@(@I6!MRV/;+D_%Q:K4T62\P&2,)V84W[T
ML>W[%4;,M$NM@4ZY.DJ7JZ4# 22K1OS.+MV1%J4Z8K H6,F>L)9SM4EN$J],
MJ=4G*OG"TX&N\?:Y"Y)P2U:-C-:BM;9!2L(M%O7<C(O6=!9.ZPY8'+&.#2[A
M&7?19XQ(LC.D<A4,J;I4;K4@28R,=$/5!LL(";.6F$R*Q,8Z.+X"MI&32524
MCF*PD=/B*$.U25*8!U='-GKC*;85MY/PK6PRB*CB,@G,M'H3,B@B!S++L8I5
MR1^[11*FH951NW4(F!#B8P 4P@I4%H';%9T'[)Y-5FH.CDW\7_<4Z667CWBR
ME&EH>\,ZS+&.HP$ZUB:N)6  D:8PN8XJ!3).^#%,-?G#X0RAC:[U7(D#C^KW
M1I6,A;NW"-';V2(@7;"&SSD*%NE4N=:=R<>2#:S#=K7W4#8XMPZ8ND8RWR*K
M!PY60?LY.=![=5DI"6B5;) )RD!'EEIR-4F8PDA#19R H22E61G0.8Y@<@@<
MCUZD@V,3\8%>:(#K@N<@T1FU1>N[I4VK-Q,KUQ!TYLD*@V6L+94R#F"275?$
M24F6ZY#HKQ9#F?(JD,FHW*<HE!2H1X!VNW3&60\:VBSP]*?-JG@/*]9$L>[3
M<-:Q=<G9T'*/L.K .XE-XG5(&OOEZDUG$6;07$;%MDSQA"+E;$RIM;Q]DC'*
M%GKT]$/:GC"/BJ9&8NHL];J_?YVFBQ"PJVB#C;?"Q,<]>8[8%>5]C1H^U/)N
MRL>M9LZKF-C'$;%-I+2-MJT.\;1TM9(",D'CME'M&$A,QK)ZZ?R15S1S)LU=
M.DG"[M^5JZ,R;))G7= V7%!-0$5.;C^LYLIUCR#D7&QG)(6QX^M\33@;S$C#
MM5+5(2F/ZOD05ZLR!^:0D&[")M+1J_*9JFX1>-G1@1%H"3A12H+,]OFY*R^S
M5Y>VL8M8'>V3<?B!LY+::@A5G5QR9(5AQ6"4*MUBGPJ]2H"C:O%%=6S/Y"Q)
MNCIFE6CEXBZFY:_7[:M?'T-#DJU1HCE>%VZ;?Z2[K\A*I14+:+)A7-E2R@YH
MS\S.-<))0,S$1$_!LIE=FY8-5IQ7KI@HR6=)GV(-K/7'DV^K32?A75BC&Y'4
MC MI6/7FF#542 DY>Q2+D[]HW4%0@)K.&Z:9Q.0"F$3%XVZ.OU&EW<HPB;E5
M)-]!HNG$RRCK'#/7<2W8J]0>KR;9J^56CT6BW]A=*O"(IMU?[&L8ANUI2H^[
M?\?7Z!R?N,R5=*=!T9KF*S8]L$%7XFP,; ^03K= 9U25<61Q&,&4>2>>OX_K
MUR#%63:F1<H$)+/E$55-2OUU0;Y20KR=M&X58*JJH1%*RC88<*^JJ=P+0B:<
MT+WL8HH=T MBD(Z$YG =1 !5_%UVDARJ%*<ABG(<I3%,4P&*8I@ Q3%,41 Q
M3 (" @(@(" @(@.E*ZW5?>+[Z\F?VY77S=_[C+;_ /MF?_=#S7U5?>+[Z\F?
MVY77S=_[C+;_ /MF?_=#S6+>_P"@W/\ Z.3]0JO;'^-MGN\/ZQJO..T257!H
M@@F=9=<&J""*8<5%EU^II(I$#\IU53D3('YQ@X]K4@B8AIQK>;%OM@R(Y-!R
M>#*0*HB%!-="$-QJ SYIH)WJO7Q30OL@[!%BAE@YA4A9B#D<"Q+Y:,=1,FV
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M(-T'76CAFL<H=?N5ZG+L2,_$>MAGMP<GHYM\Z[NLL3+PK("\W9^3(?,^.B/
MN&5#MIM-V0),=NUW"WN,N2;9%N02WS N.72)+[,IJ>(:Y=\>$V';$.O1;8G+
M.U6UB.RP(;RI$R'D^W<KE;5EAY=QA3D.ML7!^"<_'4;0J;+GL4\SNLRACRJ1
M,0_FYF0J!$K025G))>,BJFP@4)M6*D)B07;K.49 DZA#H1R:[IV=!5NHV&YL
M<40-D=XY=U"UR;^L7G($=C:3<3, VC+#4;$^.Q6 CR/9RLA&RK1U%O3R,4]9
M2"1' M'3-TFV62XF_6OR= BX*\XT=75VK"71G4)9.[HU&63C8FY5*4D7;9FM
M"'6-8G]:=QLFX9.90C)M((R74W"44HR1$RUXKMSHU =8Q@8V=7L[&#S% 91N
MEJ:PDG&QZ:<.5K%,X:O1DDFG,R";.,*_D'L@Z9LS/';E!JR:"F@8Y\6!;LDE
M)MBKI%R68C.MI5>WHN42G)D*]=5*HZ+? C-7^67[0NP"&Z]-3'E0T,S+C(%U
M3*B,MQ,J7.RC2J:+?(RB??;4H6IJ38@W%EVGJ?;>7-F/N6:-L-S3>%2FVHJW
MXTI;L:"R;<J/)=<DXWKU 3FK-;HI[.)PU>HK:Q2EFLBL>J^4:0L!+%ABJM8E
MNNDH^E9:0<,64;'%=HIG=O ZJZ3;HJJZO*V-XBP02,]C&9G;*=*UP%.EJ[88
M%E!3[&3MRSEO57K52,EYF*D(J8>-5HY10'#=U&OBD(Y2405(OKN3>6QK!S60
M&GMAJ3M=RW$V:%E)&*I-D8OJ6LXLC&V5R5783!6XS[(LBT*QE6<6H5X#0RZZ
M!>>"!#6Z)N58Q1$I-JE/-\@6-[?:%<)"10AIF"KD=&8[DG4U&0K7LXBUE9*0
MFY)Z8\@[!@W:1C-L1!$[MPL<Q:6+)DG%:2Q=7+ 8>QWQ5XN<3*.+.O-OF)<=
M5D^Q8XMNO$EBY17F=RRZZU;KDV#-N[4^1'<MP5;IO7;*.2X7;<B\B6%VE-L@
M2;%)AVN;%4EE-Z>NTF=:X[L&0V[N@&VW9\%13$MKD-AY$Y0F]4LE6QI7E9J
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MI*TI<4I*#]I=O(1L6QQPZI32WG4![!;*6FY#CB2E+2U*= C+0ALA&<X0E2D
M*4/5B19)4QRIJ$.9,W,4 I@,*:G-*?J:@ (BFIS#E-U,_-/S3 ;F\! =?KK0
M#@BDQT+N,VC26W=38#AX9Y.>GIUIMKW$98RG9=QVVEM39D+'[-H%'#5>A<AR
M$=9)6CW*MYMR=:1G(BW1SB,9V1\ZO,Y"2^_T./ .=PX\ X\/<X_EX?-Q]S6G
MN4!,!QI"75.AUHN8+;0VX@AUUHI4EMZ0V<2T2"AY0WRA02M"A6?#E;;0XHH"
M,QP(ZU2EI5BVVX"DK:95V%X8%L=@*!(4#0?<\';#AQ#M^[VP$.U[O; 0[6H!
MQ^.[Q-8JHT+5ZPM'9 HCB_UIC>FMQ=4J7IMB1MSYLN[>,QC'"=JJ4^V*WF9!
MBD+MK) "*39BF5P5RWG[IK@<ILD(>5#C)F2Y,9MNW7"W+$9N*IXHGS[%<1(8
M=EL2D19<6188JHLIM@R(ZUF1%=CRV8\AKK+)E%)L27-K,,O+7-AS1LZWPWGQ
M(EUA;"\W'=84_'?9NSZ7V%NAE]*0S(0]'<>9<C"YJ^2G&6GT^^IL/,5I;%3[
M&[J1-;6T4I-N5'"D\O+GBFT8NXBFTO)">(4;)+N'#$C@9,%%2H];&Q1/T/(4
M;CR^0+EC,0\+<97$50QOCUQ<)/(KBNO8^Q1I)243FW/51AX7K)NFY+'IN3M&
M+.'4>'49'4(W)/736EN'J:VZ>W,2N[7;999O_KK@MBEMHRBMKMKEQR_'MT6=
M(B,1WG'8T61-<97-3'ESDS7HL<M[2'EM-B+C%-OM^QQA:!L:#-2E:K--;GQW
M@V[,?BM2'GFDMOOLQ4.)C*=C13&:??#E ]S_ #B/A$1#5=--?1ZXNFFFFE*:
MZ+E"&D;%C;(,!#M@>2TW2+;$1;05$$0<R,G7I)BR;BLY.FW2ZNZ<))=474(B
M3G\Y4Y4P,8.]::4K5C#;+VY:U%14KA.DF.&PICBN4:G95 Z2V;"L>HNB.027
M%%U8R*.'Q4KP85!2!X^%M/D*^="M6P88SI8+CCKLSC1)8M2L6T"=:6N'98:%
M5ZTQO(TV5RH_R'>[ ]>Y5<VN$<L[/#UJ)I/8V&>P2Z?5)>7).3;-':;P#N![
MG#_-W/\ )IP#N!I2M8)\'7Q+#FXS%Y\")2.6+;4=VK:,SP,CC0@9"=95?V:5
MI;5"8/-)WAO)69E-0$!,QT_%PL!65:L5'LBM$,X-5;L-JV]IU*TP3MIMJ@<N
M8[)ML/C6%H,.7'31I2,CJ2[F0L[UW$W.6@85LQR;'NH6-L-WA%IBPIJTUN62
M:N6KINOK8[P#N!II2M(3[#-M6G\N8/?8@C\XY,:[$-K^*T+LK,4]!K1K\JRS
M!7$+0\E[8_BK*SAB238MA&T55M)VD_L-:":-4E7+%0)*6;:]9Y6;W"V]>BQ4
MQ?9O.6U:W8TO:BM>2M3F"Q9!8$9VZ;BYM5Z64KY&[ZLY .O&.7;!S*$5D$TF
M[U.62%WL>38,47CJ029M4GSU)J@\>IMT2.W2#$7 LD7+DI 772:"[="U354.
M1N+EP*)2=64YW+TI6IK(&-,J,\@6C+%EQ\2K0U#?;M;%+V2NQN,*_63X_G\7
MWJ-I$O&2M+&3SI;+=92DK\Q>UYA- C2R@92*K*RL5"O28,Q?0BWN@W6B4^'C
MI'+<K@K:^NHRI">%&M/G,2XDOD3)3E&=S=:LEYKB60+X1[8&+Q'(Z$=5[DS;
MQT>$4E5XRS%0WKB " @( /$. \0 >/:X=OC[O:'AV_R:L4%5JU5TG:%:KT'7
MT7[I1\^1@XB.B$GCU7_K7CM..;-B.72G_O'"Q3K'_OCCI2M:L_M]FQIT[-5W
M'N>5KK)95<Y$AF4VSVIKQL?;F>(EJ"$I+8L:2D7BY[2KG%NSUFT)]5"X*SJ)
M;:S<P:A&LYK9!1TIY"F5)&TQ\+$V9*L0"=BBZV!@KL;.IQ#,DNP@0.(G"%9R
M!7+:* XB<&*3<#"(AQUV?@'<#P:KI2NLU7WB^^O)G]N5U\W@0"F6WB/#_HS/
M^[]4/-?55]XOOKR9_;E==E,4IRF(8H&*8HE,4P 8IBF#@)3%$! 0$!$! 0$!
M#M"'#4+BQMEJ7'"LS9V76<_#.S=D;*,[-Q&.&..&(Q[&(JJUN[ B$_FYVPJ8
M=S<<,[8RA>;C@<,<,,<#AV<#7F9142ZBC_94O^I1_P#>I_Q9?_U:_3JB7\:E
M_I4_ZVO29['X(/<AHK_5K+_<:=@(/_ T5_JUE_N-?@T?R*Y8 '^D1C> '^JS
MG<P_^0=,#JQ_7Q_E1,DD]13F^?&!.K@76>+C\V?5$OXU+_2I_P!;3JB7\:E_
MI4_ZVO29V @_\#17^K67^XT[ 0?^!HK_ %:R_P!QI]Q9+_XB1_DLY_Y!TP.K
M%]U"SXE.=S_:!.K']"^7BX_-GU1+^-2_TJ?];3JB7\:E_I4_ZVO29V @_P#
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M_C4O]*G_ %M>DSL!!_X&BO\ 5K+_ '&G8"#_ ,#17^K67^XT^XLE_P#$2/\
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M<2IB!2B80 ;QKJ-_J#+(-%NE"DW#AI&W:IV.HR#IIS.NV[&RPSV%=KM14 2
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M,R>5.^^D&L3PK%W*&A8R/0.ZD),8B-CVJ?\ UCI_(F:LF+4G:'@=P[711*/
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M5G,Y#MTI,@JQJJ\FQ23?I%(50RK(ZBY2NTRIG*<QVXJE ABG$>:(#K7EET$
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MILFQ571XA1.3*D+$Y'!M2$+.."5'#''!).&&^<=[>P&^:WV<G>ZX;_8WQO\
M<WM._O;U=CTUU2N7NDV]Y.Q]4M]7LSZL/NQ=D9UZPP\V[K\GQ4#L=.-HQZZ7
MB'W%)4.LY%-LXXIJ!U/B0P!VO7BDJ2<U22E0P)"@0<" 0<#@=\$$:001O&@(
M4,4D$:001O=G?&BJ&,!0$QA   .(B(@   =L1$1[7 H<1'Y@'4/,$[M&.9Y^
MC0/L.>PALD8YR7E^KR)9-N]9!0*=E-ECRLGDDSHMGB4_:XV28V=9FW1480Z2
MAXXSUVX %-2]=-TG;9=JN43HN456ZQ0,)!,DNF9)0 ,7@8HB0YN E$! >V @
M/;UK4PEM3SE38W!=D8Y!KV.[QAG%]TV^RD79*&ED:(MM#0RBUF:]9(MU"9 J
MJL0O.UJL0#A!-V+A['%D%T'[)-ZW4(.^M+%H=A7$W%]IB2%LHA+=7(&:5P;J
MLG8HR'G'$&6U!2XO85):*FPHAMU9'-7N1?&;A:DVN._)BE#[EP;91%Q4ENXV
M5&;LTM;+3;FTGKBIIO9T*>2EU2,7&4"I U[=M3;#G7)N#T*]/-G./:_.RT?<
M'"L<%=O$G2D*XID6MUHH+@^&6HJUOK;28Z[230.X?K@@82,5S:P(^Y2&NL8R
ML64</7-S47V&</9MN$LVL]'+)T^LYEFY2 @F;6M/)5G+767C7T8;LDQJX.7"
MA%DBL$'*YT45^Q5;84WJ3[%]M8Y>MTAD2FW')=HN$Y-]E96KW9OF9G94<G1D
M?175C4BJ4K87DS$R)).+<.UD'-:CC.4GJAA53Z:3DVX8*["H*9#9*7JCX0V^
MXSQ?D0<?L5)S'MTP%9)RRL<BP@.)U=5-*U+R;2.GJLW>-$G$0R58NI9\1TGU
MKT+#>02'277W7F@W!8ZYNY(*G6Y+\:;+2&RE242(R8]P3G*48[CJVT0W0SM1
MSEI+OJE.,C8([+#VR7!\9KEI6 RY%C2[?#670M*W(TM4JV+S$MIDM,MN.3F2
M^9S4R=Q.;D-ON)[-E5S2+;?&E98NY)[#5-*.2=MH]A'NY1_+2C^:>1\?$P[!
MFR5,Z>+*+N174;,F3!Z^<I-Q_"/S2=?.$#B1_!),6=RPK[;=1G1D#'<OG$/8
MV,)<*T[CQ:E136AVMDJ4FT=MGJXO$W\BFLV;%9(JN<<Y@VGL+OC?,%+QU86>
M-YS/O7#7*UGE8^VY$;RL9*-IHLTE7*Y,7]A&U%^Y=S2[EBZBC=CV*8"V5AW@
M U59\*I8@R@EN(QA<;L\BYR&Q)MQLU!-=XB+;U=E<KK?KK6W+ELPJ)[%9Y2(
M95NK4*,5?+.Y R#N2FTACW"Q$WC9EI&&+$JW*)D(5+0BZ*7LPD1Y)P@Q%VXH
M;"W82DBXI?CA+;[C[C#I>>9;3@(_0R).4B;HA(BN(A..6=*-@,63$&-PEMW0
M./*0S/23:EQY14[&:CM260PP^ZH$RIFZ:::YJNNIIIII2FOR*LB<#F*HF8$U
M!2.(&(;F* 8"BF80$>:H!A !3'@<!$ $O$0 ;-:329*U83PD4C.3)(.7-$PK
MA]V,0EY,L<Y%A&+27$.QZ4@[!%FH^_\ Y0BQG'_N^.M,I<*Y=F\>9E:PV')B
MFDO&,=L[%S5:?CY#$$8M>*YF[LU?6<5$M;Q.2TU)U*I.TVCG(TJ^;3,_%QR:
MK&4ET639<BE;LA71ZD=85""D0#B8_.*)"]3X\_B?CS2\W@(&$P@!1 0,(" \
M,60&8ZO9XS*<I#1UH>EQ%<;+1;*Q:5YU(2\A/56(B)J02K,1%G?2$^FNUFV2
M<:1L@1X_==5;HM ,4@J0*R#@.5JTYD>"J^(IJ6V]JY^V^Y L&)Z@SCBUZV5%
MG1'\/D(L#2BKMF,_'-KHQH]KO%4*B0UJ-"R:YV<T\<K,G\A-FE"DJ'6<V-W&
M/I?&D'9]P=\N-'JDRBS;.FU*G*]2@A52,V3^2;QS=11H\22B0= ,,*!X@S=I
MUCUJBI62<5;D*/F*P3E=J4!D]NZK+V5B+"]M&++K4H:&GX4D6M(5I_-3T6SC
MT+"BA,1[HL2*PNE6RPK)$,1-02Y]ZHGS^I<\O5.:)^9SB\[F@/ 3@7CSA*!A
MX"?AS0-^*(\[M:C/MOJ-FJLAN15L<(^AB6K<Q?[96SO2I$"9K4G6*&T833(4
ME51%B[=1KY!$Z@)*BHT5YR10 HFCL..+86^[AP=8JM#W/EKL>4Y'".XDC&//
M 56J3^)%H3'#5"]KRI']4C:N\!6JOZ8TCUU#6=8+BE!O$W[F>;J5-[*.4:OB
M2CS&0+.$@X@H1_ 1SXD(U2D9 KJQ66&JC A&IG+8ANI2<XR,[ ZZ9V[0%EN8
M<R94CJ)E&L9"5OR4&$@W-CG(DSC&P'E6J3%-2R03&%?NS1QP<K@[CE$9YB1J
MZ/U!1=8%TP;%%,HJ:GQP'>'V(+RC6*+DN&L\A0L$UR9QP7%5=QS7Y:=JV;*;
M9)2?E'[6WSP9%R%!1C&R#(7=H[<M)2NN%7#R9EG:T<FCW2^X?NP1V6Y!UCFY
MSLV.Z_,^3,?5=YCN.RCC"_1\GC"HP,,VR!45+'".$(NR.22#&GW1L_C75-G6
M3N5</6;83MY%2MN>FK+6S21J]!&F8QO"RYH:+-*1#1YV0:Q<B+!N+Z.;/N:7
MKQNQ==6:(N^:7KE)$J_-#JG +UI2NLU7WB^^O)G]N5U8<N_^JK)?_9_=?_#,
MKJ_57WB^^O)G]N5U8\MD.IBS))"%,<YZ#<RD(0ICG.8U:E"E*0A0$QC&,(%*
M4H"8PB   B(!K-;_ *>S_P!2Q]-%:I7]4._]$OZDUX.JY*O8)W7)R-.1.1@W
M,#-QRBA 433D(==E)L#JICQ!1(KMHB*J8@('3 Q1 >.I_.,Q;:$,^.=W#*6R
MD_NZMU<YA9X$?T>+;Q#;+SA?L^1M(Y>);'#-UC)I=ECSB)V50"WNHANE!G8L
MUC#(Z@8TK%F!FS :U9 $&;4! :[.<0'K=/M#_P WZY'L8LW^+5D\79S[OU^^
M;E;X%R<"W)KC"C'E07MJR&&]M09BF3(B/%QMU00X66REZ.6);/7;7DM;(O._
MG!:KE<;4T&VH+4@"3#GL"7&?<VK<(*71%F,!MQE*G&@\O.9DB1#?ZS;$5[8V
M\V7$1NAC*Y5ML+)K'2,T_P :&W%Q69H!ZU195^]T?/MU3?66HM%NNUNNFLY4
MG,JBY%PW;)P\T$2X0.NHR(NGW+(6X7">2;=N.ITBID6!PUEV8PY:*'<&U>C)
MF[TZU86HC*E0B]HIRLY%MK%"V&(5F(J=0C[$TD&;DL;/1A5S"X:%@K[&+-_B
MU9/%V<^[]/8Q9O\ %JR>+LY]WZUIR:L.S[9;=6S(&V2AYJ4VE3;DF]HR@2ZA
M*D*:+D6Y)"XV>VMO8%&-(1(:5FUM!E3E#M?:CC+;T4F)GL/1'5)<;BV%>3:F
M5+2M+H;EVM>9*V-Q#FV$HE1G(SPSC*:H7O M:KV5,'.+5E)_BW*\)CJ4?9,+
M0(%K8*]E;&U@F9B#F(_&Y+@JO(X_7BYU]7I6,?6\MG674-.M$D02;,4^RU'.
M&'L/2>WZIT5W<[K3L>;E:EN+RC?9FJ-*G+V:3K/8Z"C*Y1Z2,],N6,'!59M*
M."O)^=3E;!/S)^>RB6+) BD-/8Q9O\6K)XNSGW?I[&+-_BU9/%V<^[]7.V.V
M/E\2+A*?:E*V:4PN5%2U)F;23;A.=V*.VL2$Q4,H0TTMN"EQII\0]F0EP4LW
M^ZQA',:W16'8:=AAOHBRU/186Z"KF;>T79+J#&5,6\M3KS;L]3;[[!FEAQ3=
M33:9&VW52V9;3C+UEFZT'<C7LA53)'.Q-#TRS8[3F[C%Y$I%FJB+O(LZQO"L
M':HY%";@7KFLEDH4KH$78.7+=)OUZ)S/CO %::0F")ZQ9(MLAE[%&5[->;I1
MDJ!7FC7"<R]LE'I==JI[!9YQZ65L$H[D;?/RK]@0C=JRBH6-6*9Q(#$WV,6;
M_%JR>+LY]WZ>QFR\>'L;L?'AQ$/8]-\0#CPXB'8_CP$>T ^X(]K418;8H%$B
MXRIC#AC+EQY#\$,3G880(;LI,:''45QT-1T)#"V&G41HYDMOJ05*DK**ZI*5
MQ[;$A/M)E-PY,>/<#(@-3LY4QF&N3,D)")*W9+BS(1(=:7+D[5<CH<S$S[B=
MP&%Z.EFF:QWE#/L34\O5#,+0NUMU64B4R'O&6:I(0 2,S<FM_3JE@K]/>217
M4!+!31MKB/BHQBY8-G" .S1=<919K;8X;"HO)TTK&9^G,GBT.!_8V2 D<9Q%
M42!$_70D[+C/-G[I1KUF4J:#@[PKD5G*I!Q-[&+-_BU9/%V<^[]/8Q9O\6K)
MXNSGW?JR)9+3%4'!*6^Z),64'7WHA<SX33S$8+4RPR7RVW(<!?D;+,=*DE^4
M[FIPKF7Z\3$%K:C<=HQ9<0M1V)@:V.<_'D2RA#TAY+ =<BM%,>/L,)@!0CQ&
M@I6-CT]WW-7SV,6;_%JR>+LY]WZV6<G_ ,G=8]RMA1ON48V8J^#:[(BF[(Y0
M>0\UDB39J!U>MP75TV[UE (* "5ELJ14S\!/"P2II([Q_#9-ZRAM%@MTBZ7*
M8TU&CI["%H6\\XH>ML1VPH%UYT[R$ @ 8K6I#:5K3BV')F]9276+9[5"=>ER
MEX K0MMEAH$!V3)=*<UF.R"%.+.)WTH;2MU;;:OPY/?D]YO=#-MLC9&;2$'@
M.#?F(NL45F,CDV19*B1S7*ZX+S%F]>;K$,WLUF;F P&!6#@U1E!?/H7U=04'
M#UF%B:Y7HQC"P,#&L8>&B(QLDSCHN*C6R;-A'L&B)2HMF;-JBDW;()%*1)),
MI"AP#7Q7Z_"56$BJW6XJ/@H""CVD5#P\4T18QL9&L42MV;%BS;E(BV:MD2%3
M113*!2E#\HB(C>-?B[+;+6Y9:7(RI1+$".5IMUN2HEJ*THC%2SO!V4Z$I+[Y
M *B$H0$-(0A/[UR R M60=I$2(!)N4E+:[I<UH"79;R4_BT#%19ALJ*A'CA1
M"05..%;SCCBFFFFN+KO:L<Y_!'UY'_SVKYJQSG\$?7D?_/:OFIGM$>5?^6J$
M?CWO(CZ(IIIIJ%7TTTTTI33332E625]^U[ZW4_<\KJ]ZLDK[]KWUNI^YY75[
MU-7:M^T/UCE5-]N_[JGZAFFFFFH5;33332E----*58Y+X5KOTQ_^Z7NKYJQR
M7PK7?IC_ /=+W5\U-7:M^T/UCE4M=O(]V3_AV*::::A5U----*4TTTTI5C>?
M#\)]#FOZ-U?-6-Y\/PGT.:_HW5\U-7:M^T/UCE5-]N_[JGZAFFK/8)QA68&:
ML<J=1.+@(F2FY%1%(RRI&$2R7D'ATD2?C*J%;-U3)I%_&4. $#MF#5XU;)J'
MC[##RL#+-P=Q4U&OHF2:F,<A7,?)-%F3UN8Z9BJ$!9LNJD)B&*<O.YQ3 8 '
M4*MJ#\9N%SI&U#%&<;S6<8-<-Y6L.-&*M:@W%G-D+'E=S3,1$%CZ?F;,\>J5
M:U.H^0LE:)=(>,KD$BQ)(OS0DO+=AT0E\M5?+N0Y#<Q<\,V:JU6%JD9B^.R'
M49.,FI*9LLHW<7Z=IAG,^51C'0\2F_2B D&4,P"5<L45$QD)A1RLI'L<(3FV
M3< PQUC;'D1ERAW^DX5M&/K#5*5::%*TJ=R!"XIEVTE1:=D+)T!:K!'MAA^Q
ML"Y-88+%B!9J7K<6K.1"L>^FFSO,L3AS*:6XQQG62R%1E(:0HK?'"U%;8WG$
M91K4F=@EK?'$)<C9+79N+(TG)<[9]-#4TXF3B6P)-ZW&/%^O45*_'<MD[,&'
M8-SD:IL\9R=$KB=53E:W8"VX]\NLU8;BPKOL:J#V'62AH25=HR<>VK O8RT*
M3]B>$CG+*(9I@^6QU<]SV085[DZ]0L)1U\-89S=2\+7!A(^R,<B3ZDT\H<3;
M[97WS5PG7HE&J2N18M.+KC^)EEK6T@YA<TY7SO(U(,DY<POE6_9-J-X@,DT!
MC7J(P([JE#O.*YVZ1$5D ZCU);)1UX7*-("2LC.)<EAJP63:.FU307F)"*($
MS+!(L^JSVU2;FI:[PY<BQ;7$N4<M4K,^0:2-%,YGWMGK!Z@]FX2 MY[25M$5
M.Z35"K4G*M7U;F9N.(:?8QDTFG+-58I2N;:,V90QEF&OU[(33'$ECRYQF9K!
M&-J8C;C7ZH5?%,"G9$K/8G$FNM!S["3:G:0DJFQBZX2#M%@K\8Q?3Z2RK@UK
MQ)N"R?/6O![+)$'0FD!N1Q58LFT%&FJ6,\U2G,"RJ=E"I6UY,KK1]H%[4+DR
M<C9H=E64&L]$248$$Y9NV,B%Y@=OV2TLE9!N5UR-CR\1&2@FZ[.H.L4V".N4
M9BMVA)HP.+:I:$\K.82OP$(H_P"R+]PC3EW-HGEY2=G 7?NV!HG]L3;;+)2;
M!BN3NV1X^]QF"<:3.+\4L6-("JOV\;-!7(QQ8[C)^R2<2GK02IU&!KB:D-'U
MJ%$3SLL:)ZXE6S>+4J6^FFFE*M<Y\"S'U7(?LBVN8T]Z-?HZ/\F77#G/@68^
MJY#]D6US&GO1K]'1_DRZG^3'MS]%-5?ES[D/IJK5CO'Q["Y5W:;;<?61)R:"
MME.R!$OE6HJ)K-3'1D7+-XDJ4.8"S%^W:O4DE1%)<R'4%B&15. P^=5?<E7,
MQW''TLK(RN4*/MNO-,H]BC$W)7]LI<=U-S&2<'(=M=]+.:\\EH^,4(IV70>M
MTHI83R[3JROH4,FF8Y5#)D,<G'F',0HG)Q]WFF$.)>/Y> AH*:8G!02$%0"B
M4#B4.>!1[8E W#G 41[8@ \!'7?6S+Y^W08EO-MCRXT.UN0FT27 M(E+FRI*
MIB!L.+;;S,D19<4*4)+;#2E/)*$)1\/RB]0^'E!>+I?!E!.MD^Z91Q[N\] 8
M+:E6YBTVRW)MCIVWFO2(LFWKN5LN10A4!^7)0F*ZEUU;GGFQ;$X_D9O$#IM9
M,55=2HP+]UEQA6,8Y7":DZ2@Q3]G]?SU*R"[FMJ.Y./"4CD7:J"#9Y)NTTFW
M4^?#IDS#M0@:>[RO6(O+E>M"E#M]%O</M)9Y!,W<1[2B2MDFT9Z">=223.VM
M$I!.N9$"Y4354AW"Z;( *]AC&W8$8,DS.#D:-2'=G*HZ,5NB4SE0O]J=P8I
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MS-6QO6Y";FJE/0#+.$:PFHW*=1:(56./;VL\B7T&!QX!Q'B/ .(@' !'AVQ
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M1,3$ YR$$H'.4G'G&*03E Q@ 2E$Q0,("8./RFLW5,H5-1(YDAX*E*8AC)B
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M?@(#S> AKTW2 HE1R?MA).)^^;UJTW75SFHHL5V;2E"<KKT$I  &TLFNP,.
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M$_5VBS4 +PMHA^**O.'B)>T'NF'@&N=TE,_]X]F;Q\PWZ7ZFKP#N!X TX!W
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M;/C-ZU<*ZN<Z:]W$O'C?>^Y^99,ZN =1Y].]"KI*9_[Q[,WCYAOTOTZ2F?\
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M>.0<N&#<KOL7,,CNVG5F#DRK)TY05Z/F#9IMKSO 8#K.3,:LI>(VO96QCFS
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MPYF\0\-^B&IK::;O3^\MG(EEU<'ZN<Z:=2=H]DO?RHRFU<+ZN<Z:A3T:\_\
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MT>R7OY493:N%]7.=-0??;=-P#-D\=]-_,IQ:M'#D"FH>'.!A01.J!1YM2*/
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M2'B,[8D+<S<<,[,1G88X'#'##' X=G ]BL2(<(C1T-)/$@&N_P#.#N&^P?\
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M8_H_R\7&ZJV_]R7^W3_VJ][W.#N&^P?^KJRDX^R-R;FGYHPC(H&YA^:)@?R
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MR$^E&XCM6,[=7%FSMB1\]D<5F;FKZ,RHK'JH.&;L6R?9=-FW8K..)NM5V8B
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M%WH6=X^M165('(<PYMC>VQU7P9CG;RS:OC.2(*)E>8ZQ=5D9-1N9)PZG2/[
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MWA[O^7M?Y=*5730! 0X@("'=#MAII2FFFFE*:::"(![H@'^7M:4IIH(@'NB
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M-;6EN>RXLX(;DLK6<"<$H6A2C@,2< "< "=%:U"%.6Q3:!G+7%*4C$#%2FL
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MVC2/:MF#!J@R9,T$FK1HT;IMFC5L@F5-%NW00(F@@@DF4J:221")IE*!"%*
M  :;H6NP^6]O& ()$'UHW+6.'088SR \L\ZYG<78;I68I<\/G&1FPG$C1\:U
MIS6)2CYWG=F<MV%[7ZTY5FF!Y$T5*6\4:FV;=-C]SC&-%MDNG79E?\ZY.:3D
MLHI7Z>>DRL) XDDU59<6SN2R05W$NF- 22/%0-8B']X?1K!^^K#B;4J>NFJ
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MU,5/;$M_/%,H\XI!-V8YPD*8QC%*(\T#&$0#B(CIIJ:.PKR#YD5%7]GVP_\
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M$A\S97.0X"0Y#9$MYBG(8.!BF*,P(&*8.T8H@("':$!#0,]9S   ,SY8
M  R+;P   .   =F.T     !V@ . :::G_83Y1_DJ/]O_ /G_ .Z>WUG/XZ,L
M>46X??&GM]9S^.C+'E%N'WQIIJ [GO?NZE3V^LY_'1ECRBW#[XT]OK.?QT98
M\HMP^^---!W/>_=TI[?6<_CHRQY1;A]\:>WUG/XZ,L>46X??&FF@[GO?NZ4]
MOK.?QT98\HMP^^-/;ZSG\=&6/*+</OC330=SWOW=*>WUG/XZ,L>46X??&GM]
49S^.C+'E%N'WQIIH.Y[W[NE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g195482.jpg
<DESCRIPTION>G195482.JPG
<TEXT>
begin 644 g195482.jpg
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MWD;7HHQB2.X/![(Y!$#%=9=QT@<HAV$#$5LI#!WY#N ?=J@&WX;/RB(?X36
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M9HOK3&+2LBE8G;92-=3"AJ_&I,7*$F=M&LG3E=)5^Q4$J!TVY7"HE(/,]/\
MY2^HZM<^YZ;[.YKZZ\&XN!;VW4#23&&T@>YN9%1=#+,(H(I96 R=J< FL='U
M&\K;([ NV&;:LY)VHNYCCP/)0Q/?MY^?L3^D8_\ GS/^DH?Z^GTC'_SYG_24
M/]?7B\E\6VN%Q-2\S/'L8>HWRTVBHP:+>4?*3)).I)>+)KOV9FR31O'JD WN
M3A&0=*K=/*S=L4Q#GQ>#D1 1!R80*4#F$':@@!!\E!$%NR8^A_U!]#:M7/\
M*>N[-XDNN@'A>:VM;N)7ZB(+VU[!'<VLR_\ 8,Y2>"5)8SYJRGUKQNI&0@/8
M[255P#<'E7565OZ#L5)(^6/O]R?TC'_SYG_24/\ 7T^D8_\ GS/^DH?Z^O#;
M[P8!* N3 )_U %TIRI_]&'C<G]/U.?,!]0UR"YQ$0!=01+P!@!RJ(E$0Y #
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MHFG5RS&?5N1IM7/9AO;"M0<4R=/(5S",$8B+CVRJS,[9H43#Z9[1MWVS2L?
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MZOL6^KMQN5AP_2H^TW"%FB(I2D%;+7-4]O(6*+E2H()R47.2CUG)%12*\07
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M!04!X<4Q.(\ 0#@MTB<1X "@/4(B   CJ7_N0K_E W_-8_ZQ^OY','^^%?\
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M<\ZQ2D]CGY$XY Q^/?N!@U\0^TSH"[]GVOFP:1[K2[U&N=(O67#36X;#Q38
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MJG$;!EA)6#4$5V7:8WA<W$@1B-UO%G. :]-NFNNT5*NV06*/(*)$/SSSSU%
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M6LL6X0H"S1SS.N3&%?1!LS !W?[5>P"/^$9A@ [ (\_G @1[>O/;GMWY -;
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ML^6,YR 32UBYP20<\@@ C#DX*MZ;3^ ')"YI:O!A4*50XE,4P)%3#D_48
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M)(BFW+((D+'DD@(H[NY[*/($^9/"J&=L*K$4BC^/O8S"PSA,&!SM<P;<'!L
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MB[--VBHS*X!)@J)Q;]+1<ZXN$N' &3<=1P14*<HDS!U:P"%U,DCY!\,IM)[
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M9::<*C%1KA5PJ>8734\)Q(RCCJ,Y1K<>MTA,29C@L\4 (*(.I+.NICZ9MI^
MF>%\?QZ#H =62412D9^25232</91VDFH\<*$3*!$0$_Z)!LB (,FB+9BV C9
MLB4N!$\3S/;(X:6-$>91_BUD)";L'@R;'VCO@;C@8SR_VX]>6NA=.KT!I]W'
M=:U?06R:Y+!M"V=C'X;K;L$.(Y[PHA:+ADM X=5%Q'4JVR)6Z"2)0 "I)E(
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MPS<I&U1]*Q"H-'Z"[<YB=:950$OB)&* D6;JE$4W"!RB!DG+8ZJ"@<'25,'
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MK,"R,P^20%R<Q1(B@@DFBFDV9LF:9Q181C!!K&QR'Z%DV2*)Q4VG@4I0 I0
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MTCL[L6=V9W9CEF9B2S$GN2223YDU%    X   'H , #Y <"H%3GM--F%<O\
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M7&;V2C))@WOP/&M!=660?712%;/#RSMPS/'*& DG''GZ@\8\C]1Y_P!E4LH
M)!/&,9Q@YP3C@9\_IZ$8)W"Z@C?3'VW[M*9F%GU-L6[K7==PSEU,#]#"!SY
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MX'C$ [R>2%1>(XT)P!CXA@XS5QR;&/1DD[XO-.4XM&,3-[J0#F;*(KH]")P
MIQ$04%8B@H@D)Q<](@<H /'X&/@YTC:P-4$G!W+(R#=^"9RJ@U.J(F0X,/)
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MLLJ<P];ATX4Y7<N%!$3'64.)C>10*4"E#*\1(ILX]:0=G$J#5 RZA@#DP@D
M")0 W &44$ (F7D ,8X  \CJ$M0LKB2DQ7=*@JH=V!14+P4!*(]0=92@  <
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M_P GD>W \A_WO0,K',' W#:?KP?OXQGOCTQR:UZ:V:,DJ=Z_](?4>??N._/
MJH#]O&FGGY:ZKMXW9)'6<*D3(0HF$3&  XXY\Q'@/ZM7JBD@=_.NR8 $H\^7
M @(_;J+N/]NN*L29]W*[CZ\\L7YQ]U@X6#*24I,M7E<3_,-1Y''M$"J1"48U
M=0HGK\DY-/ XDY;Z4D 3=( P(06YL4;D-]^*<*PTJV0FD)^WIM$RQ5;B2O9!
M5Y+2#X8F$C7KV*92#6'/*RX^XMPD3(KK'1=>[(N#M52%TJY;W%;E<D3U@^DK
MBSK==4L$:C-U^*4EI.JNZ6QDX B\)'M':<%*-+9+.8^P*O7AWZD;]#2";"4,
MZ1%%!IE],Z>U/6<M:0'P8\;IY2(T.YPFV+=@RL<-C;\!9"C2*Y53I'5WM#Z6
MZ*6)-;U!4N;DR+%90(]Q./!CCF=KA8E?W>,>+;Y\3],4GCEBADC$CIMFSM[/
MK!^7\ZSFYJE9PW/;4<]W*DP>.LF9'VGYE9XU=98I]30=M*G'Y,JUHJ.0:+9I
M:H,G[MC5K::KM+=!,SH-FDUX31H5&P([:9MVVW9YO^ZIENXW3T(N1,DL,FY=
MQHZSM6&^ LCWPF/(/%99"_4@<<!+SCN4@8&#7>HDM:#Q]-L6CX#E13(S+J'L
M4CN$B2-)6MY)+.V6DS8)UE>T+2)&T/54$)Y)I6HUY&(R4S).459]@ZG)>50$
M;%&P,;%2)$"H(N0H+^ERZKHDDA99!.8C/I-L*+:659QDF_) $BSVNSAXJA9N
MQ( ^F)!E,N%R.DGDY)$</)+F.0;[!:^SW4Y9@D]S;P1J(6:0 NK*\[)*(R&!
MW10*L^7559I%AX=6-<UU+^4=TC:60FL+:^U">0WT,5L<6[0R0:?9SVKW:RQ[
M5ANM1N9-/)@>:2-+.YO51T,,4NSS'GL=-JIMM [;ZWNKWP3^W1RCCB4QQ2G>
MXJG2M=Q6_P <Y5B,VTNV8@4;8B23KLTC;XM!8)1<9Q-S#O'C1!%%19!XAGG(
MOLM*UF;&3?#^1-]OM'[5CR2KMYIF2H%_N5JAR9MHV0)<LG.TS*;DF'$UG\0F
MQ,[J<:[JH5*>:TR3DJXM+.VSDJB6ENJ7G.F-HV/J<!D.ZUZF)*/^JN.9UV+I
M>/ZW"[&/C569TYVD1",H?I07KCERY<PA?H54&QCMI)K(2I;[MS%.80<8O=J]
M<)9D9!HFQE:H+4DG'I*^ 9:VV'\HT7!; =J*#OQH)K'LD>@ZTJS54>B@SLS>
MS[J&,GP8K:\'B2(!!<!6*I&DBNPE$:J9-Q14+D^(I'V"LAS&G_R@_9[>^'[Q
M?:CILC10NXN]-FF1)9)V@DB62P%X7,"(ERTFQ4>VE0J3<K+;1>ENG5*N4&HU
M6B4^*;P51I-:@*=58-H98[6&K56B&<! 1+8[E59P=O&Q$>S9(G<+++G30*=9
M510QCFN/U^7QU!_9KNXKFY/&T18CNF3*S@06UA@BIOF#N+?E4/X1%XF830F(
MX'K'W621;/TQ531=D)XR_AF5--\I@, &*("40Y 0\A#6H.C1.\3KM>-FC=3W
M5E.".#CCR[@C!&00:[+#-'<0PW$+;X;B*.>&0 @212JKHX# $;E89# ,#D$
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M0' Q@YZ>">8]AU'EE(RST6+* 9G>.I1;W:,*!'CA:6<?JBA!QL>U?2T\L03
M*H1C?W5L @I(R,:WZW2>>2;/]TZ< %V/$U$.2E>%J!W=F:60&@$ PE7LR$[.
M03*55#E0K0E:FHIB;H:*/)  5>ZP=W/9VC!9[@([$851XCJ/Z[JIRBCU8>6
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MN\;'K4JW.88Q_57P_P#\,F/U_P VFFFFHM7J::::4K"6XR?-5\(97L9%/"-
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M?G\^O[./VM---*?MII^SG]_W?[M--*?G^VG'<?/O^[[----*4TTTTI33301
M $1$   $1$1X  #N(B(_+2E:M_:L,O?-N4JU^C%U@>3,2V"?:M5W2]+5*9P\
M;VQ K5W'JINX]RT09QZQI*+9IR,BU^DY!M&B\$_D]L]K5</9N6@)<[6(AG[U
MH5!-0%'#1PN#1>0ACG4:M&Y73QM)-7SI5JF,<5@X%5BHX020 />O:(:-M$8Y
MC9!L1RT7242.0X (& X=)A'GR 0$0X$>X>?/(Z\@WM+MN<I@_)$K)-G;22K%
MT=6VW1;!%D[)+L'P24.!$7"(OUHYXR.,HW@&SE)BW<BLG7X\B:@J* '4O9GK
ML6GZD-*GC14U.9=LS":9I)\1Q1VXA >"(&/QF>=DR5S&Q&%(^?O;OT;<ZQI,
M?4]M+)+)H%N8Y;7-A;P6]@[33WE_)<2*EY=2&1;.&*RCD98R7EACS),'@DWS
M,T=*#%/7Z+J=9+.FJSD#J'2=-F'A)$<M5P 6[UH8!, > 8W0*X**!^@3Z[&M
M 3EK([>0SX(\2JIDDF)S)E;SX*>,!6Z;CI K5V0&BAQ>*\H&33'QA25ZE PK
M,K,8-8UE?JOXX[ALW%HB+$K@J;WWQXS.)4#K)*)@_4:E423Z3F7.R5(LB"9#
M+:X'(#T[U6 ;2XQ@NR(-I@Z1C+B@0Z@+$<(JM!,F^56147.[\#KZ2K*$323Z
MU6H_2=M"X %DFSMO>928XF1D,ZI&D>PI'N"*$!VX0*P<J6^/$NQ$<RR!9>RK
M$ZJTBOQ"&+NHW2$9P3\0#'!",5P+<;TE%/S()JR;"12<F.JD\**)$1(?GK;)
M.4U!4*J @J4Q13*<@IF$@"H($QI*Y'DIJ040^D@;,U'X.$%TE% 6]Y6$G28"
M>\%!(C4I3+*"55%-NF51<P]7?63[^^;O169(MI9^+1V*GNCE@U2:] =:[B4<
MG$ZZY&ZJG ,6@@8WA@95VHV,3W<<+6>2@VSLS2O-R&(X; +E0(Y%FZ [H3F7
MCB=/6<R0)&(BX/YN!!0P%%$Q!'>82K1PB- )PDGZ1P"$#;&+N"JA2V08T*8S
MN52V&88Z'$UP_C))*K,K/&DR* $8!@JC)4@AE9F+8#!V!W1K6+70S5H<*BD9
M19$IGCAS)$\0[0"-UN@RX*G*"JJ9P.54IP PB"I3G,7D-7?5&T:M,-XQDNK#
MME$ET5YE8S1\^$3-3D55Z3MFR/#@_(-FX"4K,IBG1<I* HY&ZF#=RI9#Q2[^
M%:UYZ=W!?2KDZJ$:HP%T"ZDH!A\,QU3"GX"#I1JN5,A@(4BQ4$SAC]RVC(NP
M.2QCD\J#9\[(S=MDE4F[E%!10B;LWBB!RI"CT*]!1( &, ^(8.#ZL2SQ.9$9
M\OX):)OB "N"-S @(K#&/#=6"C<"N,@[*)0%58T2.&)P1! PDVR(WB.CRHZ.
MRJI"B5<1DA6 W5?\Y1#5MM MGATB2UE41>,$@$B;4\2F[2:(+G=IG,0RGB]0
M+I"4HMTQ*L8IDO#,;(NWC'TY>;K$ I&QB;.+G5FC]THY;("NL^(H"R*?OBZP
MSQF;9L9\6,1\9HJT04(N@=M)'*XL^'J<SD.6BXJ,92$^D>3@D5K-X3YZ6$2?
MM2@O$JG2031*V:+KF6,HH1-$YV[9-,C8Y7)E_85['#9!&0599Y"N59<(E=U^
MOA7AE4&"*YD';,CV5>IM8YY(MFX2RPQBCEPL^<R3Q9B(*&;QR$:R1Y;U]UF.
MF-*9G,-YJ=[(T5K:NSQ+\0Q-.0C!E2"&0+PP<2-&X^ DUOGL^Z$;KW7IK")K
MBPTBPBBN=3U&)([F2$8=;2TC:56B::^GA,@$J>$L$,ZX+QHAVC>S0V^PV(\%
M5*40CG+"=LD-%2UB!_XPOUY,T:W;F,Z\<B:B)$B)%3:,2HMD(YIX3-!HV*F9
M$NS'5!@F<?$M$8QBB1L@D4"()D*!2B4H=B@ =@$ ^'F'<._;5>U\>R2/+(\L
MC,\DKM)([LSNSN2S,SL2S$D\LQ+'N237WC'!';1QV\4<<,,$:0PPQ1QPQ10Q
MJ$C2.&)(XHT51A4C144 !5   ::::HJNG/<//O\ N^W330.?7S^6E*::X'MW
M_< <C]W?7.E*::::4II^/Q^[332E----*?G\_G]M---/Q^/Q^S2E--/+SU^R
MI*F#J*DJ8OH8J2ABB'Q 0*("'S >-*5^/Q^/CIKZ^ O_ *!?_P E7_5T\!?_
M $"__DJ_ZFF1ZC\_[1^-,'\C\_DU\M?DX])3& .1*4P@'J/ <\??QK[^ O\
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MU"(>0AY=/_=$1 0X[!JX8V3(\ 45! '"8"(]_P#*D#GZX?\ >  _2%#CC]8
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M"DBY_5="&'ECC)(KY\ZBT&]Z:UJ_T6^0B>RN'B5@I"S19S#-'G)*31E9%QG
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M1*'S#]GIV^.K3E[@E,1[AM)(D?-'"1@4;+E*J02C]4> X'H.'F4Q.#%'@P&
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M%4#**)H.@9IHFDP:E 10(J4X*<)D*<$0U,+%#&I42PI/9)1=9Z2(8K/FK0C
M';8\JHP,E'^/[F9!*25(!79S*KJIL6W206:G47Q/(VW*T<=NJJK!B5!#G"QD
M*%)VJ7PNXXXQ@YW'&]MIEA8PM<6EJI89N$MX5R7F5HG3PG._PB)(HBS ;20"
MX)Y..+2X<T1*'I6*:U<<O92*];S5-J<;790CULI)1Z[9(9@KH@M:Q!H.G*,R
M>3F)QC6SIAXR[I)T@*)YL;=\TOMGC2M8ZM&2:N;-<X]3D[[",Z<^DJA!6.=5
M(K^3$K;OI9A,JO&K52.CEI2/B4&$<*2#<C%T"(D/(ZX9_9Q=2/3L8MD6T_-5
MDCTTJ\30?OTI:8;1LQ',8T@$,9HWC(0%5(U-0OO*CE,S@.DXB :8+9C_ "!<
M,D/+'8SO)64E[(E8U7;D423<P^ [)-,GTD\634418Q[9!-NW9MU%EN@$$&ZJ
M_6.H,ED^N1Q0W-LL=M V](FGVR2.5V&=V41X4 MX2J/ARQ)).*YAJG3-KU\6
MEZSB>#3+03-8627!AN'EE4)'?7*QJ$"*AF,04JP9CN09('M P%F%GE^G)31$
M!8RC1PXBYN*.L1PK%R[$X)/61ETRD(Y2ZA(Y:.RIID?1SAF^(FF5R"9<[Z\T
MNU3?27'DUD>'CHC\ITFKJJQ#R3<6>L5Z)&X1%0BV%K;^^RL@+AXK&/VZ47+O
MVD<Y:IRC)RT,L9PW633G-5/:1%5E2'LT14UX(C@I)=6DW<UIFJTU'D3R<G#/
M*Y7S2<<T2*=>36KKJ2=,6R:JY&#PB0AKF]UHNH037*I9W4D$#R;9A$Q5X58[
M9%. 7!3!W*"#W'!%?%NL^SKJ>QO=7:QT/5+K2;&ZN1#?BTE\*>SCE817,;E%
M$T;Q 2*\097!W+\+ UMTTU1X*9:3\4RE6*J:[5ZW2<H+(G*HDLDN0%$E4E""
M)#IJ)F*=,Y!$IR&*8HB40$:QK$UH----//[M*<^7Y_(S3336,\QY:IV"\9V[
M*U]</4:Q3XTCMRVB6WTA/SLD^>-8BNU.K18&(I-7*YV21B:G3X- 1<3-EF8N
M/2#_ !@QBU(C2.D:*7=V5$51EF9B%50/,DD #S)KPD*"20  22>  .23\AYU
M&G=U?IRU2-3V<8KF)*,RKN$BI)>YV>!!<'^&MM;)ZG"94R8>2204;PMKM:;I
M3%&'"N'+61>7FPR%LBD74?C6QJLYUXZHU=QQ3:W2JG#L8"MU:#BJ[ 0D:B5O
M'P\)",&\9%1;%$H?HVD?'M6[-L0>1*@@F!A,;DPQ3V?89N,&RM^<<V-68;@L
M]2S"XY&:M'";Z/H$/'L3QV.L(UI^0I4W-6P]5EQKY'K<A$;/<WU[OQR YN:X
M%G'JJZD3X+:)@T4!;<ZME9YV"B692!S&-JQ09)!B3Q0L;SRK4BWC('B."'D
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M6<13:>9B(^G+BL!^_C7C'K=A)6MQ=;D%%/=V\U)3<#XAA$@$"YPKYFP,)N>
MXDG;%/N8.#\AYAP'US["84N^ANIK:(9GD;68G !W'Q--ME0<')+(Q"^?EP:E
MI,D,O3TDQ @76;'QR>P'OL6XN>,!5"EL^7-;X+S;%'!UNE0H 43B83'YY#D?
M+CU$H!T\\B/80[\ZP(K9W;-PHLT<K(+*I*-U3(J 43-'(>$Z04-]7E-5/ZIP
M\C!^MK'K#(Q9Z+2*Y6Z9%NB5%VF<>E14Z( F*X\]AYZ !0O'4!^1'GSU1C3:
M(NB"L;J2.H *"'(\@("''3R B!> $0YY-ZB'D,J#26MP8GCY7((P""!]>&!
MR#CL1BOHVSN8TB[@K@=R!@$*,<]SQC![>=7@O)BWGDTD#%!G[ZU5*5P5(R*B
M9S)F BO4 ]9%.H$C !NX]0<]^06:QNT??"?HBKIG43 P= $%,3B =(!SP  ;
M@I>>  H"41X  QA(28@_04\81 %A O"8*^[MB@)B&, C]0#]A* B84QX$.>P
M:LJQW!9-NH4RX<$%7PQY*KUE-R/4<1#J+VX$#<^8\@(E#C66AL<F-BH(50&+
M @GMW]20,'\>!C,'4KQ-R-E6VKCD\DY&".QR1C()[C )J@W"T*MQ=IF=&,'0
M1)+@>L !3DP@3@! .!$> Y W/!A\A#4;;19?J*"8XAU%.00$W/< YY#RY#J#
MD.>/,..W;7[M5I!43B"AS<K=74)P$3" FZC=(CSQP/)>>W;OY!Q@"S6$5E#$
M*H(FZC< !N0$.> X !'X^7'(>7GK)E_#0J.,$$8^@'S !QP.XX/;MJ=]=^*C
M MDGRR !R#GSS^!R?*K'NLB!,DW!9(W269@ZW(K  \@961@623HX@'\I4[ 5
M#CR'48W4/<!$?7M_[.Q=7LH3(40JJ8Z)X6O.Q*)AX]X0D9]J8_'/'48J@ (]
MQ^IQYAQKQM33Q"0F+=(E,"BK*2K=40.40$IOHN 5(]X'MV3>=28\>0E'C7LD
M_P#9P*2^0JETMSA$X(O(Z#02.8O!1]\?3TR0H#P'(@P?1JG';ZBI!'GJUB/;
MM)$/9CHD4W_;(;0T3</B$GNZL,9&[(MXW!SVP1QDYXEI+%[GJ1U96@?5=4DA
M93E2IU:X[=L\@\C/!S7JUTTTU\55/III^/332E----*4_''QT_=^_0.>_(\]
M_P!@?#32E Y[\AQW_:'QTTTTI34>-P=-^E:^G;620FD:Z04WX)EZCN8)=3E4
MYN/K",6X.#HIN#=#59YR'!0U(?7S621<(JH.$DUVZZ2B"Z*I0,DL@L0R:R*A
M1["FJD8Z9P]2F$-5QN8W5QS@\CU'F/O%3=.O9-.O8+R+),+@LF<"2,\21D^C
MH2N<':2&'(%:BYTYCQKT!$>? 5 "AW[ 0>/M$..1$>._'EY:T65^$</TMP\:
MLBL61@+?8G,.]3["20<62QR8,53F[)D=HL_&2.(E#Q_ $3$*8#!OISQ&M\62
MMDBUUTB1C>/=3D>_=K%0:H5KI44,^D7:@@DV0B.E1E(.%C 'C-R%("B[INBK
MJ6Q(QAGM>S/8[$_:MC9(M+NR5UDL8C<RS6+^GFK<KE!<4W2+>14=L6":@%Y.
M[9/S&*4G08=[Z;F"SW,JJ60VL:DC.09+NV90,?K%(Y#MR"520_JFOJSV97P_
MGV&_LPT\7N,<KM$"S)#<75ILW!00K.L<WZ-OB=89QSX<FW FW'*UTQI7[W38
MUTLYAWM@D+(WAY@46[$BUF\9Y/L0Z5$U 6^D4W[]LXZ"+&.Y=(@/'AF''.2K
M78',D[^@86,* $.[7(T3!:8$KIL4J704H/C.0(5<.DS=1/JX3.*G28R9:S&5
M?P+K*N(FQLS1[M45T8]81-*$,V*JJNQ2!115DL":A%2M3++HE.(=8<""A!V)
M[<,%U5S:+-<#2)9&(6J4/D"*GW)2)JQ]>68+-+>HI$@4@@XBW+5V@>/5436@
M'+9P4Y7:+AHL;=;N>'3TEN5C*-*@+$+AB24 W>18@@C(+8#G#;2!](WTVC:+
M%<ZC);J)&43-X<;*TT@=%6-B%V;F,FX J9O#60HK[-HU+56J/JDVD,BV2NN(
MQ%(2,&I%FAXMZNM($)R5J4H"9J!TBD(JN"2BB:)S D(*&Z@[2%T9V>R-I=PH
M,,N5S'LU"B)'*:SMFJ844717*R15#O8Y$C,RA12, M&JJBBRY"E+.3)>YS:O
M<\C+TBT8YNJ]>6=>Y-+@%B:F<1R)R V9O_R*,T(Q\ B8E66$T@M)BB(%0,DL
M44QB_N#VH)8KNK=E49E1Y&SS-E*-VK [I),C)Z E:+*IBH<[?Z5(+AVU.#@@
MMDVRASF6 Y#C$L[B1YXHE1@S[R\4[J26&UY&$T9904&T%,1D$X*'&1DH-7W)
M%%?V,VE7DT+RV\4PB998D53(J/%+)&)(@4,T<ZP3 ,OZ+BLLUNW4M_+.4I9D
M_?NP%%-5RS?)1*;3Z/.F#,&JH)/E7KE'PC B91N!T$3>&18Q2%%3%>>;E9K#
MF%K7*U+/*CMT@:/4'-J1K;U&(M%YMLX]=C86$]>%")SR$%%I>XL#5^K/(.-6
M; ^>S /5'944+?KV-KI"O&;Y*4!Z@=HV:%;\K&%BW07*FY4;LE#\NP4 Z::C
MMR<JCA0H& >!$#7+=,2GMT8BR9RKEHY1(<!]]3:)/G1BG,JY1:IJO"MFXK*@
M45R=/A@D7H. "!>G-2VL!*L'RRJP6-G+1>(%PK.@;:5! *@XP2&(! -:Y>6N
MG7MY%/>RS26Z-GP!.? ;@ "5 3&JJ,8& NY 6!*U>-HP5^4D2TM6'I_$-9JC
M9NW(QH<L#R/5:]+=%!!9E*UU]*$6:F/U*&00KJ!_% 1?)O \1<]C1-%W45:Q
MM44L20\I37K@S25O$7E&FO7X!+,G34[BNU>7)2YAXE&H@H\2B2(G=JO46I00
M%NJZ5U&:U1](QXBQK[[<+$P3LJC?P8R6GV4,@T?F(F1ST/3KI%4(U4Y)U^-[
MN02G./!3B8URLJCF5_#*,H6WK7ADJMTH^ZW)E(M6;43F!59JS8/GZJRSGD1,
MX 2+MT43I)H 5<PAC)%N/#DMO>8PTL;J0K6K3JI3:=HD*R%AG"RLK%6;DDG)
MB:DUK?VLVC1]9C3Q=6\L$<!&GFZBMGC\/$ F+SO)&3A92K9^!F7<,GVD;4<C
MTZYXIJ[.JR0.DX&-8P+IHN*B4C&.8MBV1"/D6BY".&[I!M[N?](7H<(*(/&Z
MJ[1R@NI*77FF]D39<H%RE+5N80=*0+:J^YR[I=JNR,N_CI@ K+A9HJ!5"K'8
M/+(T;K.2).G<6Q9N!*9K[FJ?TL%\@^P-<?U2Q.F:A=6!D67W:0('4JV08TD5
M6VDJ)$#A) #@.K >E?GIU;H2=-]1ZKHL5TE[%8W)CBN4P/%C=%E0N 2!(J.J
M2*.%D5E' P.?C\_QVT_'Q_A]OXX'334"M<_///\ ']M/@  (B(@4I2AR8QC"
M!2E* =S&,80*4H=S&$  !$0UKZI9!WI;@4LBG,5]MBVS7*5B\-@@H+B$S7GV
M$([K]SSD58H^[2]'Q X<3F,<.J$*HQD;TGD?)+55RE'X[DD*QN N-JSID!YL
MVPU-24&"L7&/MU66*ZZ6:2.)<965K[VPQ73YIL(#&YTS9"&42:.VJOTGBC%#
MR3R0H#*R3^+PDI[X]H58QI4:]2:=!QE;K%6A8RO5^!AF:3"*A86&9(1T7%1K
M)$ 3:L8]BV09M$"=DVZ*9!$P@)C26/ND)_\ .KB/"CS@MI5&7//$MRA*QAA\
M-LSR[?T]O*OL2>,^3_11MGSQ)*A! SC!6)N6QWE 7/Z.1#>"")&Z*:*92E*F
M4"@!0  X*' =@ /(.P!Z!VU]M--8ZI]----*4TTTTI33332E----*4TTTTI3
M3332E----*5UW39%VB=!8A3D.42B @ \@(" AW >P\ZU@7^*E=B^1+1F:NL)
M"2VGY+G'EGW#4V(:.G[G!MTD3D/+;FZ+#LTUG#BDS'AE<;E:5%-S*D(D.=:T
MS7GH[(S"V;1]4^2C6THU5:N4R*$4(8@@8H& 0$/(0$! 0^'("'RX$=7X)S Q
MROB12+LFB)VB6/(.-V&V.I >*0*QC< E77<C6I8EE4 DJRG<C@9*MVSC(W C
M(9<@,"1D'!%@QDG&S4<PF(>082T3*L6<G%RL6\;R,9)QL@V2>1\E&R#-19H_
MCI!FN@\8/FBRK5XT61<ME5$%4SF[VM;4@G.>SPL0JH-%)/8?/S#AQ,LT2.E)
M#9E*S;A=PZLD(W117(\VIOYA4SJUU\ADGFWQ_+.+/7$W.'S34/C_ &.-';5^
MU;/F+AN]9/6[=VS=M'"+IH[:.D2.&KMJZ;J*MW35RW53<-G+=55NY0437044
M14(<TB:((%EC;Q+>7/A28 .5P6BE4%A'/'N7Q(\D89)(VDADBE>&"02CC:ZX
MW+W'/9E.!N1L':V/(JP5U=%[.FFFK%>U#G?)B(V8,!7&":,O?Y5FR&9B6H<=
M;M[$\NOH\G;DII5H#N(Z@\BOS<]N0U_.4W/4Z6IEMEHP#KMW\&^!:)?E*=)5
M5%)0DE#2*8ATB50R*K.3)SW3475;#^D:*%+_ %*';9)XV6;*AUIJD,0Q1\AZ
M@X'[P ?L_J\A/MG/9[NF$P^R;1HA4\?,KNG;=-HT,9-*2=.%'KVMF!$O!#/W
M;I[,U4!_RT@XGJV0#+R%<;Z[M[!NM[?I?J8Z9J4BQ:;K;PQK*Y C@U!#LA,A
M)PL=TC&!V. '6$DA<D47,'OUA<V.2'<,\!!PV_ R%/<-P"I'.Y0!]JM#-'S.
MC=:ZPMC98K:0$Y6=I8)&Z3Q5G0)Q(H" <=#61, RL88P FNR= F7E5HX*3(2
M63TE  JZP"(>9@-^MP/(^0\\?$2^OIZZU;33:Y8LLCR<@TU4R+IBG-0SDBWT
M=,QQ5!*87"2?2"A$50$4'[8?>8IV'B$43Y514O:"R<ULR)#Q#PR,D(""]??N
M$TI1 P"'(-@-X24FW]4G#+E0Q?\ G#5JJ IZ^LM>T6&P<W4,/BZ9(=\,\>6%
MNK8;P)L$[1%]E)6^&1-@+;R0<CTK[0IK@+HVL2>Z=06RK%(DQV)JBIB-;VR9
MB%=Y\!I[8?I8I2^Q&A7<NP]YDIN9,?\ &1["(G[@(FZP /KB8>1$OF7[@X[<
M:Q!:LC&<)G3!8# 8!X$O(")>1X 1+Q]G' !VY\]1=>7*30$4W)5T#!V,1P15
M(PCZ@)3@ ]^?/R'D.P<\!9K^VNEQ$J9CJ''L4I.HXB(CR'  !A^W@/3GGU#4
M)I;=%W(1C&1C&">//&#D\<@_3FMUFUB27ACALXQ@YSQ@8."/+C/UP*RC/6X!
M!0QU0$.#!P AR C^KQQZ@(CSV'MSSW\\+SER)%I+2IQ!51 P%CFX]P=R(@(M
M$0#OU)IJ #AUP @5LF8##R=,!LZP6@C/Q/?ES&<#_DX] X&>K&$0  %+O[N3
MOW57Z2@'<A%#!T#;T-#3-LD6[]XW.! /X$8P2*H*"(J&*/AIB8.I9=0P%.X6
M$.LW2'7X:9"$)7I.F3:M<1O*C1:?$P>:5AM\8+AC%#G!;?C:SJ"%4D@[OAK2
M.H^J#:H]AI["XUB==D4<>'%EOPOO5UM)5/"'Q1P-\<LFT%?#8N,HXVJTO;#U
MJKMCG4D[1873ARX, \E,J1(TG*K&XX*E'M0>OG!Q$.D"&+Y@(!_2;]DCM\'!
MVV*L%=QQHR3LR2<\X:K$Z7#5LX:MF\2R6Y* @JSA6L<U7*/'#E)?@!]?,M[(
M;V;DGD[(,)>[E!KDKL LT2>>]MU2ID09*%>A6R%.4$C.Y-^0DS;U3=1VC=2.
MJG258]A20]T\!#,Z_$L8ABD5)LR;)(ID(  4 3(!>P  <>7[>1#UU\^>W7K>
M#J+68=#T^59++1I96NGB(,+ZAM\%8(R"59+&$-&6''C2S*I945CB]/L$TG3;
M>P!+2[(S,6)+DHJC+DY.^1BTC^?Q#=\0.*SIIIK@U2.U//3RTTTI33332E--
M--*4UQSY\]N/GZ?'Y:Y_'X_'[-./Z_W^>E*?U?O\_P ?LU&;='GR.P!CB2MK
ME 'TB=1M%P$4"W@*2\])G,C',/'!)<S9 3E4=/G96[@S.-:/79$%SH%06DSK
M6C[2W!U^RYB6,D<;G67M5 LS&YQL0GX8A-FC6[E-2/*"ZS=N+L2K%79$<N6K
M5=1([!P\9)/C/6U^U2"2YMTN9/!MWGB6>7!/APM(HD?@$_"FXYVG'?!Q60TF
M*QN-5TZ#4YC;:=+>6\=].H),5JTJ"=Q@,01&6.0K$?:"G&#HCW);A\A9,OS*
M"RY='DG&-423\]4*V<:]6H=@#HZC>%;G;&=NWTZ#E$K!:0F'DDXAI!4!C%$I
M1(3(1LQ<E<<A3TG>K$Z5A:G[TA!LF;)U]%MXEDW$QXB.(HY3,@DFS1_YB@5
MRX^$!N#!]8:8G5LWO;+,UB>QB\7-+*2+:30DHB[KRHK/W /''N#).NA)IF.]
M12<(I*KC&IN $1DTT%#.B[/ML'LV+_D%C%2V2%92E5TI$W!(!NH 3HE,F!E
M?S"#ATA#G. >$NUK2Z[XQ"^&XMKY/] 7K4^H=/:!:QK%<VDV5#V]IIC17+2.
MX7=+,R2$!MH4>+<R[A\)"N% K[8FZ[]FOLXT&*WZ?ELI9I80%AT@PW%Q<N5&
M9994E(C+85?$NI"[*B -,RD&P,?8+C[E)OS5]PWM2IV[E!V68L\6Q(@1X443
MO!BF(LG:R:Y1.R<B!D < /C-U4%P#G,%4Q=EW$4TVE:Y"^-$QL1.5>\8VC;*
M@8;CCVQ0[^)G6D&XGY "EGHP[AM8JH9T*""\W#%A%WZ#>764"..YA&O[+=Q:
M X8-)*I4RNQ4G>X4\B_>QTL29=N$_HU0KYP]!%]),5V"*ATP [I1\P77(LJP
M(=.31_:+0$W41'\V\W 3Q"1I(2L,I/Z:D9=Y)F29-XGW1 $5A<R"RZ239HHL
M(J+*HIN$DDQ461B&[U#4+&*]BM@]E<P.TJ7,BAK>)))(6D<B15*%8S*DL:)X
M0PXV[59UMU+KO4G3,/4!L1'H=]#<-<B\N%1K&.VF>,W4C-+&AC*()XYH8(VB
M&7.S8&>!$KMUPBG>B6V;SC2BL6$@V1+!S;_Z.NJ;U J:*,0]QXB5:\#.)J%(
M(PQ8 [M9QRBV:N .GXT\0P==\G3DG<%((]!@G!JY&4YA=9B,CYEK0J?7H^'A
MY65@B2+E2OV.PR19FS2,"\2\6&;S#&'<BD^9O$PB5N(D\RSQ(Z0R#2)S%+B6
M9*%@+3'+L'!"D4$5PA%;)')MUD9 K4BRHQ"R231XW1<JQ$M(G;+-AP)6*A;J
M[**3J=FEY@'D"_&,&7D6$C!EL;R/6+ G?,U5#JJMB2!V*SKQ$Q1<MP5(<2IB
M8#3K9C?6\=[:WT,FQ9H\Q0)+LEQ&SJ0);<M.VQ/B>/[+C8@4[CLNEWDO6.E'
MJ&QZGM+X645TAM[>R9G658T>2-H1/:EKMXXU""2%0RR%EB"N&&WV+P16(HY1
ME6$E<730!,HO66W$>F<I1Y1=2HO(UB<%!Y45Z'J143 '0T5.0!#\*5RFUZ33
MES04 B=J5?W>-4=-!9M2*AR9-V=A[PX66Z ZE$B/T1'_ ":RR:(F(>"E4R1D
M:3J$!7+?<)$XJ1D:)%FY/HF'74F&:CJ'L!8>(%FWC0D5VLQ7I>/9F2CXRV5Z
M4(S3:M)*/8(_?&>*;/EW*=*J37)]N@UY21NB+MG'/$2(/$&E:K\G"O9"/?A*
MI/F2:Z<F#=G)HF353D!6,45A051QS2D:9)JTU[)+;"-7\.)'$ACDE6%U"ETC
MC=&)61/U2N [!@QTF?684Z4?JZ2\N;K35BAE,,&5NO#FNDM)8S&TJ01RVSNX
MGB)&UHV5975@SR-RNRH682%@[96HXU>9Q+QRO,,XEBJV*"+1P=HV21%JN D2
M<F1!(45&RKQ4YDS+G0ZQ-"K;UG? %>LJ.*,WXZCIRI-'I(EA.2,0UEIFLE2$
M4O<CKKH+/IJ*8%2[,E#!9XIH0I6)K0T2(FSR_N)VM;C<3.%_IZ)E<BU)053?
M34&UEW ,1*!EBO)"":.7DJT$1(!"+1J5K:-E?"4,VBVI!,E!"8G&70@P=U5A
M-.8\Z)P^F$()VFP79J!]&).7Q5VTF!6XIEZ59EZ19(/%/^A6$"$EV]EH?4%C
MX,=Y%.J#=&/&6VO+!PN6D59V5AN)!E#J;=Q&H5L@.$=O[/?:+TZ;8ZO \]NA
MDLI6E]SU/29MK&5REPVZ1)RRK< AK1Q#$8P2BO7LCVZ8GPQ2ZLPE\2Q4&UA9
MENC*,W4(DT!F]1?-TEDGJ2S0H)NBN4#)*)N@.H*J/A""ADP(!9,^H]OL[^?W
M?+6M+V6[>Z--ME>;V]%VW )&=7A&SM)P@9O .Y)9Q%I)(NP!RBT,55=S'(.
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M@ !V B3@'/1P(<=)0  [AV\M?@U&OST?^6;"]9-C<B(/Y5O& <!'^; JU7,
M\B'<A0_DCQK^AQ>?8/;?+([6<L9&1:E5.8W2Z95R3.'5SSRXD8)PZ4^U5PH?
MCN8PCSS2:?[ [;[77J+MP\<+&24 W+6*JT:H/' \@X8UY!T01'S,FN0X#Y&
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M,7!1-[L*)8M=$R"JI0$B:R9A$W)1#WNV"(0G(E[&.$R*I.D%43D.4#E,"A1
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MLTCTUEB)JN0:BY.B@*XH)S\UK]]J4\LNHPVUS.FF7=]/<+:JS) ZM.98V,/
M7.$8K@=AD<8'+-?ZIOKJ\ZALM,U"ZAZ=U/6+V]334DD2T9);MKB%O=R=L9XC
M8J%&&50V2@Q3'\/&RK<6TBR;ND3%Z3$62*H'''';J >/W_'S[ZP5,;6<(SDR
ME/2%#KR\HBJ59-ZK%,%729RCU 9-PHW,NF8# !@$BA1 0Y 0'4B. Y$?CY_=
MIZ@  (F,(% I2B8QC#V*4I2@)C&$>Q2E 1$>P!K%$ ]P#6H!B.Q(^A(JD0L'
M%UY@E'1+1)HT0*!2)IE H  !QZ?'S$1\Q[^HZC'G/<9*UNT-<$X&@8K)VY>Q
MQ;65;UZ17>%H.'*G)**MVN6<^2T2<KZ"J JHN0IU'C5T+_F.69+PE,2CX1G9
MKO5K"M^XC(&<K-,X?V9ECG_T3)O:QDW=;*L&5@Q'B659*^[SM:QG%N%@9YZS
M3#\+-%8Y@93$&.)X 3R78YB<C'6,Y*4^WS;A0]OU7<PU71DY*8GI9S:;S>;7
M)KV/(&2+K))IDEKOD"V/2A(66SR8))(G=K@@QC(Y!E UV-A*U&14*QEE([0!
MKA0\Y ,=J<_!D K)=@$,BG.4M\K+(/C?PHC&9Z45I_L$K%GXI?-L'D19^U_G
M2<H.57>X8);VV_;3$X783]AGIZ5R1F'(T@TL67,P6Q%D2VY"L;9J+1F*S9@0
MD96:A661S0F/\=UQ-K4Z#7"DBH1LJZ7F)>8E4  '8 X#X!IY>6FH$DCRNTDC
M%W<Y9B ,X     5550%1% 5$"H@"J )Z(J*$4 *!P!GZDDDDDDY)))))))))
M-----45533332E----*4TTTTI33332E----*4TTTTI33332E----*4TTTTI3
M3332E?-5%-<ADU"@<I@$! P (<#V$._H/J'KJ#&:]HZDA=7.=]O]O<X1W"D8
M-&;NWQ<>I,TC*$9%@)8^H9[QG](QD+E*L)(F,PC)99S#9+H[94RF.;]6!!9H
M]G7H( (<" " ^8#W ?NU=AFE@?Q(G*-@J> RNA(+1R(P9)(VP-\<BLC@892*
MH=$D7:ZAAW'D0?)E(P589X92&'<$5 7!^Z0ETM2F$<U50,&[F(TD@I^;:2E#
MRE9RE!Q)"'<Y%V]71TSC$\G491(PK2D*HSC,H8\6*HPR)3(A$8R;FY<@(#P(
M" @/J \_LU9N<-O.+=P%44J62JLRL$<F^:S,4OXSV+G*U8XXPJ1%KI]FAG,=
M8Z;;X58?>(2V5:6A['$+AUQ\FWZE /#<;%N;VE+%8Y%96_=IM_:\)MLD5F(;
M2&Z3&<8GR4GYP:3$-XZ.W%5V-;@ N;EC]G"9G2;-Q4E<>Y-DC.I\\T""Z.8=
MEO.1S;.Y$4AXYMII&.TGDB"X?=PJQ37#R")(3QR1?:S)'Y.HRZCC^D4#D9_Q
MB#'<LD:KO,^]<#SZ#Q\]6!C#*V-\TTV/R#BBZUZ_4R345;MI^M/R/F:+]L($
M>PTFEPF]@[#&+"+:8K<ZTC;!#/"J,Y6,9.DSHER!J.Z/&S(ZLCJ2K(ZE65AW
M#*0""/,$ BO 00"""",@@Y!'J"."*::::IKVFFFFE*::::4IIIII3]WY^7\:
M::::4I^/Q^/]S332E/Q^/+G[=-- Y[\CSW_8'PTI33332E-/4/G_ !] ^_33
M2E----*4TTTTI3SY_'\===5HV7$!6;HJ& >0$Y"F$H_$!,7L/W:[&FE>>?YP
M//\ '\\>?!2E( %*4"E#R H  !]P=M<Z=Q$"@ F,8>"E*43',/ CTE*4!,8W
M "(%* B/ \!J%MYWA,)"SS.*ML-+=[ELNP[Y2%L*E=E/H;!>+)H@%%9MF3.9
M&4K 0TG'%ZU'V/,?L<@Y7,8I&JU0B"KC(MKL4,DQ(1>%&Z1V*I'&N<;I)'*Q
MQKG@,[*"Q"@Y(!$A<#S/"J 2S'T50"S''.%!. 3C -2;R-DJ@XBIDYD/)UOK
M]%I-<;E<3-ELLDC&1;/QE"HLVH*JB*KR4DG1TF4/"QR+R:FY%9"-AH^0D%T&
MJD)643FO?09<UG8WO;KM)=JN6J% 5&1IVX'<5!%641*^R9),5VDY@K$%F; 5
MRABJ!=L\O6^#720RA8:"P?2N-'.6,8;0I69N<)FS=)<RYRS%!+K2%,:FB5*_
MAG";AV0Y54<'XL7?R[:!ER(*'9.LI6V2MF7YMJ)D%[C%0RQ:XUGBV:H-$RI(
M)E3(4   *   ?'C@.W/KJLW$5L"+5O%G\[LJ56/_ -TC<!@X/(N9525#@PQ0
MR1K.]Q+=I.9OA3RA!!+=C^E89!'<&)"58#XW=6,8M*B8_J..*S"5"F5Z%K%:
MKD8SAX& @(QE#PL+%,$@091D5%1R+9C'L&B103;,V;=%L@3DJ210$>;UTTUC
MSR23R2223W)/<D^9/F:F@ # & . !V ]*::::4IIIII2FFFFE*::::4IIIII
M2FFFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4IKKN&J#I,R2Z9%
M"&#@0,4!_C]FNQII2H/Y5V3TZQW&1R_B6RVK;]G5Z1$7F5L3.VL6\M1FA!(T
M9Y7I$DUD<=YFADT^&XL<DUF<DFC4 2K\]7ERH.T,7%W'YKP"/T9N^Q<>1J33
MZA=S.WFNV2TX]]T3*<32>5,,)J6+*V'S 'A^_2U;4R]CMI^E>/[36&10;([,
M==-TP;/"]*R13=^0,(?6*(>1BB' E, ]P,40, ^0AJ7'>.%6.=1<PJ J+(2)
M8E P!!. 7C"C(2-A+;*26-NS<U'>W1B60F)R<DJ 58^KIPK$_K,-LA  $@ K
M#](OE)R75HJ\8ZM]8OE,G$_%AK939V,LM;E" (E-[C-0[EY'KJ)G 4UFY5P<
MMU"F2<(I*E,0+LU%:_;&<?.[5+9/PQ/6_;=EV85*[F,A8/D&59_*UVCR9(V3
ML?2$=,8LRPCR(@J;(-*G);PA,1C-QR@E6)C!_ES>+@$$$<PX38[G*.V<((.\
MH[8VI*ME)A'& $1E[-MNNTTYC+"+("@[F%,2Y6D)=V0RAZ_C-13HC2WEBAG(
M]WF4.?\ $7+) X/F$F8BVE )"J3)#-*?LVRYQ4=EEC^VF1_7C!=?(<H!XBDG
M)X5T48+2=\3XTU@O$>Y?!.=7#Z,Q=DNO6.S1)3FG:$Y%_5\H5OH,!3EM&*K@
MRK^1JX8HCW-,5AHB/!O#64*43:SGV$1+ZE-TF#U*8![E,'F4P#Y@/ AZAJS)
M%)$Q26-XW !*.K(P! ()5@" 001D>=>*P894AE.?B4@C(X(R#W'GZ>=<Z::?
MC\?#5%>T\OX]QTU^5#D2(=50Y$TTR'4444.5----,HG4444,(%333(4QU%#"
M!2$*8YA H"(0$R7NIL#F4>1>.#-(R%:+*-T[$NT2?R<N*1C%,\8HNRG91T>J
M/(M!4;.7JR/2X4.W%0J!.>^T/VG=*>S'3;?4>IKJ</>R21:?IUA"MSJ5_)$J
MM,;>%Y8(EB@#IXUQ<SP6\;211F7Q9HHWV_H_H?7^M[V6ST2"+9;(DEY>W<C0
MV5HLC%8_&E5)7:24J_A00Q2S.$D<)X<<CI/SD/B'[0TY+\0_:&M4?^$%F3_K
MY)?T&!#]G_)';7/^$%F0/_GY)^O_ ,A@?7_^D:X;_?B>SO\ R>ZT_P"1Z'_U
M]74/[W3K'_TOTS_RG5?E_O1]?P^E;6^2_$/VAIR'Q#]H:U1_X0.9/^ODG\/^
M8P/^R/W^>G^$#F/_ *^2?]!@O]D:?WXGL[_R>ZT_Y'H?_7U/[W3K'_TOTSY?
M^$ZK\L_^*/+G\/G6USD/B'[0TY#XA^T-:H_\(',G_7R3_H,#_LC3_"!S'_U\
MD_Z#!?[(T_OQ/9W_ )/=:?\ (]#_ .OJ?WNG6/\ Z7Z9_P"4ZK\O]Z/F?P^=
M;7.0^(?M#7.M47^$#F3_ *^2?]!@O]D:O6F[I<AP<@B-I72N$*=0H/$%VC%A
M+I(B(=:L=(,4&J1ER!R8C=^@LW6$ 3%1OU>,6=IO\KKV9WM[!:W6G]5Z5#-(
ML;7][I^G2VEL&('B7"V&K7EWX2YRQ@M9W '$9J+>_P GSK:VMI9X+S0+^6)2
MZVEM>7B7$^!G9$UWI]M;^(>RB6>)2>[C(K91IJDP4Y%V6'C9^$=IOHJ6:)O&
M3I/D 424 0$IR#]9%=%0IT'+<_"C=PDJBH &(.JMKZ@M[B"[@@NK6:*XMKF&
M.XM[B%UEAG@F19(9HI$)22*6-E>-T)5T8,I((-<.FBEMY9()XWAGAD>&:&56
MCEBEC8I)'(C ,DB,K*Z, RL"" 0:?'\?\/MTTT_JU>JW335*G)V%K,-(6.R3
M$37J[$-UG<M89Z38PL%%-4  5G$G,RCAI&,$$@$!.J[=(D*'/)M0HF=\</<W
MS>N[2,86_=C-NGBS->[U-8*/MOJXH=/4\LVX*T1BT%86YC=:9(W"D!E^?44(
M)58YBD;WHMZ*WFF#,B? O#RNRQPQ\9'B32%8H\]E#N"QP%R2 :2R@@$Y8]D4
M%W;D<JB@NV#W(' Y. ,B=@<B)2@ B8P\%*4!,8P^?24H<F,8>.Q2@(CZ!J*>
M3MX.+J+:GN+Z8TLV>\XLP(5SA;"#)A;;57U%A$J"^2[$ZD(W'F&HL1X.I(93
MMU9=*(=1XF(FERD:*64AMHW#YR '&YO/<K#U-Z >]X)VR_36(* LS,4P#%7'
M*0OG&>LAHJ)J*(R(,K;C&MRR9C(N:01LH9 TQ\5X.Q9A6K,*7B^BU:B5:-,9
M1I 52$CX.+37./*SQ1M'H($<R+DW*CR3=>/(O51,J\=N%3&4'TM:0]V-W)_5
MC#Q6ZG@_'*ZK-+@Y5XXXHE(.Z.ZXJXL,S]\0KZG:\A'GA02BY&"&9G(.0T50
MM1P!N*W- +C=%=$,:8N>@!C;8\!6:>81TPQ/U@:.S7GI-"M7[)2*Z*@HRM/H
M4?BO'3H@J1\PTOD>(.%IVX_QA1<7UB%IM"JM?J%6KK)..@JY68>/@H*'8IE
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MD*@A-[%@BG]6,$XC3T1 JCR J^D:1C"(J ]]H )(\V/=C\R23YFN   #@
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..::4IIIII2FFFFE*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g748691.jpg
<DESCRIPTION>G748691.JPG
<TEXT>
begin 644 g748691.jpg
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M\=9O[/C_ .);P_T/G]<'"_K;H?\ =GIX_P S>_ZO[/'&='ZVZ)_=D/M://\
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MP''_ )O[?AUTWKG/^T;_ !A_'1SG_:-_C#^.GZ"7^LM_NA_[\3_':7^SX_\
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M1BRUU6NH/7U!>JRS1!)1R$8Y0,9RBF41.L=TU2 Y5DT2 8RKED X3+VITVX
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M$O*5TD!2.BEQ@I1/@2JE*']$BH'   0*!-?55 12$1,"9<9$PX*  'B(B.
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M;"UDMUN+38+?RH+V%*L)LHRO[/796SO6ES*WL,BX2>.TFS-%DPAF]@YFJYR
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MRJA2  !UR(F$,   /7RZ]>_38;_QJ<-NW+[Z'G=U*PXL)P5%O6(-X:RV9T9
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M8I%]D&\4+923>Q]<MD3..T(TL@\8,5WZ[%BNW;E</&J;ER9NFNZ03(*H.OW
MX";Q;]T]V%[WN'5-M=J*A0Z=Q(S>ZKZJWT'$91=R3.VM;A&^U$DC&7MK?'L]
M!V&/"GR0,W4:Y8JMUU5EY"*9+HL'!0S)LUN'Q%2/%118[:FB[EW+;"KRLGMK
M>HRS[E7""K4=8Z;$UVNNW!Y"->WF0?*UY=K.(D-5#1<A-O'$I'F(1%5YKE<L
M;DU#F*:)(G:."H8#[2I)AUK"R+/H)<(QU@[LH (QT2M]*?8#,LHJ:"HS6NFI
M<VH4H*B>ARK-9N[?.*)T2D$\>7RP19@87=DIW5I4MJDALK6=C<^)-A9>'SB
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M(#@C%=S=Q(BS>H59F].E L%QDQBX9LZD)";ES)J%(H^[#MA[%D!P!)%0.3F
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M<]/_ ')]-9ARA]%1WU0ZM$>GMY?+N]V._OU<Y22)92/^[ Y_M#Z^CC&]JO\
M-Z7_ %S_ /)]?ESQF[/V_+^.CL_;\OXZVA*'D'W=?#I^_ _=H$@=^/'SZ=_7
MV=/+6=UGG;W?OQI-CT/U_B/?C5[/V_+^.CL_;\OXZVN4N1''?\ ]VJ\H#X!]
MWW=^FL\@/KV_'GT&)L>%C?I;&IV?M^7\='9^WY?QUM\H=?JACN^/M[_/X:IR
M!\P'[/+4ZSX>[]^(L>GU]$8U>S]OR_CH[/V_+^.MKE+CN#'CU_(_NUJ+O634
MAE'"Z*)"@(B954A #IGJ)C '=IK.VU_KEN>=\#MQV\]L5[/V_+^.CL_;\OXZ
M2RR[[[.4\3!9MRJ/!F)GF)*6:(9G#'>'(Y>)CD.X>F?8'BF2G&SPJI*]D??7
M;$#9$!_WWPI@ ?>#P0$/: B'?C7L+*1=4)\E/#:W/G? ;\ Q_P#"K$>\ ]<.
M@[/V_+^.CL_;\OXZ0^O\3G#_ &E0B4#N[MY*K*"'(DRMT(NH;., "9'ICB8<
MA]4"^(9$!'2RL9J'DB$58/V;M,X )3H.45BF W<(=FH<! ?XAG7DEU-F6WA8
M^'CX['??$$@$@W!'$$$'IP(&-OL_;\OXZ.S]OR_CK:P4<<H .>[&/9W_ !\A
MT<A<]WV==>=9\/KV_7QQ/'AOC5[/V_+^.CL_;\OXZVP*4/ /MZ_?JG(7R^8A
M^?8'V::ST'UQYXFQZ'KPY=<:O9^WY?QT=G[?E_'6UR%\O=U'\>GY'QT 0H>&
M??\ G[M3K-^ MM?KX\_=B+'H<:O9^WY?QT=G[?E_'6URAD0Y>@!C.?W=X"'7
MK_#503 <\I1-RAS&Y0,;E+G',;ESRESTYC8*(],YU&L[</'ZN,+'H=^'CC4[
M/V_+^.F&<?FTD5:]F9_<9JBV;W7:J'F;57I!4@BDZ:MF1E)ZM2@%$#KPEFBT
M58U^@40405,TDV1DI*.9+HN3W)XA=G-JTER6F[1"TXFDFHWIE973M5YD.V4%
M!$K.J0:KN23346 2'?RA(R':@4ZK^39HIJ*E:'Q&\4.SFY_#=N76JI.3"FX5
MMJLU5H3:IW /6>YSJ=E69FK1$*X<PLPBNT<)F<VXDXI2VB *'<61-5(Z 5FR
MV;,:5XI,OEJZ*JU4DRFFDE@G29=+P,0I5BZ,05ON#RQ2I>U-+V=SBCK*?M!1
MY-G.434^;TLWZ1IZ6NH323)+'7HK3)-&D+JK=]8(I&YQ%)1:_88VQ+K0H.3M
M2N?Y G*8RO*8P'3(<I0R=8"B!3@!1$R@& I0Q@' )[Z0[AZI5&9G%DF&/K;-
MZZAD5WM<AIE@B+E:NV&TMT5X2%G3-".7B,4NZ/(+)LW;<&R;U-%LN@5>:6R[
MO'E66D63D?67:<Y3J/9'#*GQ *F%LI&[L;TQR!GL_(M@%15WMMM*T3<*@(Q]
MDEV1>PD3NVK.RM7@&<8L]<MIF3AQ,I!(,&"-=J-0,J0H*-Z738Y4[",(;ZPK
MS4RO/6V1[1521GC]NJD/R$G9C(^RM'4)VKS1)L^*S"F[*Y%4TU7-0S-<PGM%
MFJ-+1T8C)0RY=1&JKW5M,DM%(IM^L^;>F3MEZ6LYRP>C+LF*7L1'-2&O]*_;
MC+\QRJFSJ@0H*H^C_LO)'29OG;U*Z_LG:'.4RKL_$P[ZFASV!E5NQJ,^>18H
MG=I@@X,!3"D!3D N<="E4$%N3  )3*D*8X8.!"E$ TGNZT$JUD4+0U(8S=TF
MDS?B4 _D5D^;U98_D50IA2$1Z <"9$,@(]01D:,=<R8_5Y@P7H./$  1$,>S
MKT#("'4,]T!V<G'JM'R1%VKA,4E45  2G*( !N8!$.X  >G4!#.0$ '6F&59
M'=XU6-68VC4L50&UE4LS, M[7+$[7)XWZ/-2&F2 K++56C19)IA&LLS!0'=U
MB2.)7<@L0B*@)LJ:18-AK%OE*A8@GXMA"3*+^O6>E6>KV9.26K5SHMUCTXVS
MU:=+%/&$HF@\1;M'C"08.R.8J68,7Q4GB*:[-?[D39F,:%Q@D*"T':JYS%2L
MR^VP;K[MM)2&M=.@7->C;/#;M1LDTN"CZ29/736=A):,D:P^8@R3;13!ZT/(
MNOH6+:R59J*/*W_5-B(F.+(Q@*^0#.033$<%<$*40Y0$2J 4!#ZX]13=ZL\C
M0,B^:.6:H9+V;A!5$Q<9R  <I<B/<(AD,8]F<W09]FM!%'#35*+%$\KQ!Z>F
MF9.^ $\8>:&1Q#,0IEB#"-W57*E@&QI><]B.S&?54]9F.7R2U%3'3QU+15^8
MTBS-1D_9)Y(:6J@A:JI0S)!5&,SQQ.T2R]V[*<+9>7AZ]?*E!M8",A;UNMM[
MNL=!=[<; [@G^VCN9<0==:2]DGY>=F8=="3:LG<E/2CF7*W8CZL*2:C=LQ^O
M9+')V2RW2VRQ&2$G>+Q;+P_:1@. C6+FU3"\JLP9&=G4=*MF8K@@FX7$BBO)
MSF33$P$+QQI0O,(E$1'KT 0$<Y\@ 0ZY'(]X]V>H@.8B,R] H(L'!B'$0!PH
MF9!L7E !,85E"E)@H )C<O.(  CR#@=>JS.,TS.)::JJ#-&)5E5!# EY$[X@
M@Q1*Q"FHFLHV&JP6R);WDW8WLSV<JGS#*Z$4E0:=Z9YGK*R51!)]B#AA4U$L
M=V^PTH9V!?5&26)DDUWH%6D7K=@T(*SMTL"**8 ',)S9SGP A/Z9S8P! $1$
M=/0J\6A7X1C%-Q PMT2@JH'3M%S@!EU1Z9R=01'S  #23[=40D2(R#KD>2JA
M1 5P#F3;)C@3(MQ,4!ZX 3JB "; ?T2AC2VE;"F4"9'J !X>09#IY9Z]WF.>
MFL'(UR +D 'KN3:QWL1MPY[DDVX;9*@4Z&(!YJ-['8GH?&UN7C8<[,E[?F$W
M] GUN81''U<8'J 8 >\1R/G[-)1;=UV=9CEFK58@N2E,4 Y@R7 ".3=>XO?W
M@ 9$1Z:42^/20T ]<Y$IRI*8'FP.>\ Z8\<9Q[M-$V=VRMF_FYS:KPCQ9@HZ
M17G9RR=B@[3I-43D%HU"09MW15FSBYV.0:O6E21?MUHZ*91\I:':+U5O$-3U
M<NR7,>T694V390!]KK&L96)6*G@2S3U,T@U%8HDNS%0SN;1QH\CJK7]=VA[+
M]B>R6;=N>V4SQY%D(B$=/"HDJ\SKYV"T>74<995DJ:N7U5#LD:(&FF>.&.21
M.GVYHFX>_E[) 0 .$'S=PV4L5A$G,SVWC'B1'!))X"I#(N;N\9J$5J-8-_+,
M.W0MLZ5LQ:QK&8GGVSVZKVUE'KM#JK0&$'7(UO&L6X&,H?LD"  J+K*"*KAR
MLH)UW+E8QEW+E15=8YU5#&'4VGVAIFSM385.FQ*,<P:E,HLJ83N'\B^<'%9]
M*2K]P95Y)2D@X,HY?2+U9=T[<*'575.<<Z5#D+Y?,?QU];=C>R&6]B\J&7T-
MYZF8I+F%?* )JVH5;:B 2(X(KLM/ "PC5F9G>5Y))/RH],GI@[1>F7M1^F\V
MC3+LHR]9*3LUV>IF9J3)LO=U8@L;?::^ITQO75C(C32*B1I%3Q00QZO9^WY?
MQT=G[?E_'6WRAW<H9[NO3XCC1RE\@[_?^0^6MNUGH/C\\<DL>A]WUU&&<<;^
M\C_9#A^MMEA#IIV:6-'5&JKK)*+-VEBMC]&#BY%VDEE0[*(5=GF'Q2"!C,X]
M<A1 Q@'7FWW0=H;55R.VTJ$R_F)6U.8YY:Y)),P+"+"-37;-W:+< ,HJH_E7
M\K87XE(C(STI,.XY%%F9N*OIPXM]BW._VSTQ3(MRS9V!L_B+)67$BFX5BPL%
M;D$):.;2R34Z;I6'D3MSQDN1H=-V,:^=BU.1R"1P@:+Z/'B@GY[Z,=4N5;(Y
M]0,YF[]6B0$:P;E,DQ2"R1,=(VVRQK1(B"2*7Z-P4@JS(1!4[)8@G)LN0ST$
M:S-5U/V<W&H=V7:6,:2$C(4V97!)N0""IN",?2_\'OM?V"[&+G^9]IZ^*BS0
MS0=PE1#-*M301(CPI3B*&4M)'5=\TL(LSL::0 B':(^RRLG8'K&";1Z\G(HO
M'*;9K$H.'\BY745#M^9HFDNX6(H'*1LF4$P2$3<P&-S',I-$JTC%'5:R#RNQ
M<\R%!T>(=SZ2TLR*(E4!&2CH)*3=L^8I1 [9^FV52,!Q4(0YN0/1)L?Z)ZD5
MI(C[=F=&QJ.$T#/:?3VKJG4Q55)1%R(2;E%\ZNUI$'"7:E-8K4NS$HBB$6F@
M ):DTIVRFUM!B4H.GT6KUV+1+A-E#0D='-P$>JAC(M$$4SJJ&$QE%# *BAS&
M.H<QC".KZH[2446E*.B6?0?Y>J+7;A8]U&0  +VNQ\-P<;_VH_A;21UCKV.R
M)JF(,%^VYN[4T3J"MNYHZ<-+H:WJM+-$]K P@BP\D9F,/8:RN^3%.0=R,N6
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MI(;4U,YCJ;&16U+$R9SMY/<:-D+%N,_;&Y!1=0^S597"<CD7:)^U9/K]+4Y
M3%Y5VI@YM1=[B<65]W#=.B':[N[ICR'([6OEL4HU,R<1$'!*+MF[K2;!,"B
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MXHMX.)*U%4@GOJ%7CSB2-CTB=A&0L6TYA(@@!S B!BIF$QU!YESF.8P&$Q@
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M8RU4OC=JD8Y&R-LC45%7K-,QTXRQL;!#$.<D85120S'</4," Y 1# ^ Y#J
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M%HXS2Q3K51O! K+454DU34_:!,!W54_ZEEJC$ZZDG(C]6 !T'("4<B @;("
MAW@(?5$.4<A@>I1# ]V-4Y2Y#'V^(?'S]@=0[^F.K5."G<67W(X>ZD[LTI]+
M6VHOI_;NRNUGHOY)P[ITFJQAW\TX.8RRLO,5-6NS+Y=?"CQ9^9Z;(N,Z=<.
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MX<YU'1Q%</S!Z,CN1M2P3B9U#F?6:CQZ*:$?-ER8[N5K[-+D283 AE9S&-R
MRES"HHU3:R ]F][CV?[419CHH\Z[N*9K)#F42K'$[G2%6LB *1:C_3QV@4D=
MY%$H:3'*^TW9"LR37F>0F6JI8P7J<M8O+/%&I!:2CDOKF"KZQIW/?D*>ZDF=
MEBQS5%W(L^W$P2?@UVZK!PBM&RS51-*3KTW$/@%*0A)MBIEL]B)- 3(/8U^F
MGD!*9,J*R:"Z?IL]''Z1&$@8R)J-\LQDMI9!=.*A)RTS"2CO::Q>JF61HENG
M'ZJ9W56DD&[ESMY<)(Y#.6S=>JS;A2?BT'<SX_:3:9)ZZ;IQ!A/(*F*D9!0Z
M:38X"?E%.3*Y*HW]4$?JN$W**P'#F2]65,(I#*5PVUC:N@#.W.WJ+S4LN6,5
MAX1S)KJ4FMOD2EE73)A#KJ"595.38#.UJ9FRR,S'-$5(R)=0B\$HL^U_TG]B
M:+.:-%E@9<T4A:2KIHT>3274%*A"Z$Q6),;7/K!@- 9@VBU^;T&890TDT;3"
M-1)#,I >ED(6S=XPL86W$L.[ Z6TV]=/4GO]Z0\CM!_6.'A1))N45&\EO1/-
M2IQ#5,>4%3[?0CU,3S#LQ#B9E99MJ6.()!=1,',ME&<L$(MQXB:'2GA8MQ).
MY\SN0>R%D?/%@</I^4E7)W,O)2"ZAU7"[I^X457<N53JKKN5%73A9==990Z6
M4$^]O&SNN79G85@S6=MVR;V=F9!ZG$5FF5]PL=%.8F%A YVS-4R:H,6S9HZE
M)=9,4X]BZ$_K!?1IPM>B9X;-BH1-_N-7XKB!W,D$2'G;5N%$-Y&MMEQ$%#-:
MM2GQW<6P:(GR4DE+EE)QT =H9RQ14!@CR:6+LCZ-H>YS!I<QSJ9$,F64DJ"L
M (#*]?4E7BH(['5'3JK3-=9.YD%IASQ:JIKFM0JL<*[&KF4E&L0"(D!!EX$%
M@0FQ :^I3"GPY\9\-PUP4[7ML+A0[3M1*/)&9A=L[L\D*S9]OWTP^5EIB-@I
M0T%9H:8J[B3<NWL5%J,6+N#</'Z$=)C$.TXEG*!Z.#=^7XJ-Z[INK,5#]'8O
M:VJ.&=,>0)WSJ$"R7=P6&LA)2;5BH%LYFDZRV3/!,(Z-049QTA+/7RZXK,#&
MD,6X%N#M>3"7/PS[-E> ;F$J%,CFL<H;.>=:&:@A"KF'^V%://S]Q^8-.6A*
M]"5F+9P=;A8FOPL<D"$?#P<>RB8MBB4  J32/8(MVC=,   Y4D2!T#.1US_M
M'VL[/YI!6'+<BJZ7,,P*?::^JKHI& 5U>6T4%+$LSU 4I+*Y1F!9F1G=F.-I
M^R5!'F,&92QH9J6:2IIXXI:U*:*IE#:ZB.D>KDIHW)>1P%BLLKM,H60*V-LI
M *4"E+@@&.8I"@!2 =01,H<I"@! .J;)E3@4#JF^LH)AZZ.4<]<CX#D [N_
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M#92KZ"8VIE-FL\6G(/I]K&E>(0YF3.$18#'+%DWRW:'/T.?,,OI<MADIOL]
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MNJBDDPI6Y+@%"IJ0R_8P-N> J^J*Z#M8U79M*J=>K]6G91ZJY58D*@L5=A*
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M9BF,J0# <F2B/ULG[Q'(AUQCV],9#..JTV^PE>LE2G'GY3$-]4<B7]OFSUR
M@(&$>[(B/>(Z;[+OT\*8.'0 %/H \N0$<B'EW^\ ZACKK=<IB9$4."-(T_\
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M)1%%'%WDAM=Y.[4:W_OMJ;B"2#O@P(^ _/5IL@4W0>A1'W]!_P!FMG5!#("
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ME569?U;'U2NHEW;9I!ZI:V@J2+Z@ ;"HEBD#1RJ)4'$R?>&H AD:^H%3<BS
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M YE&YRM6XE%N8[I8YQ;(%+F?1C]NT<@H>.>]LDL[152%8_J9TE19<ZGU&W9
MLV6434(/:D42.4ZA! H6RQA78%Y -;]RRZ5%E56;=;!@H4BW%N*6&K&26)3"
M'6)=XUUJ"UPVH*"?V=1*L!:P/WE)"C$@O#1N6UI-AHL[$N4JC*UR8AJW$61U
M-NRR*"D[96!RH3+Q1VSCR5Y^Q86U].0JC16,2:Q[9XW;,WW(NY]HE&MD#=:W
M&3U<FHVP1KMJB9.2B7B#YDN8" !Q2<-E%$CX.!@$2F'J AD<:\!5(N3)"X0R
M3%LPBXI1W"/W+B491=M)%V"*&0%K,PZMD8'9-Y,471TF;]RW4;LG+Q4%5#,0
MYR>LOT4E^:63:>QQ4P5S#[@N+"[N5DJ#@8XZ4"TM)S+17T8[AA-"2T>NV:\Q
MYB(.+)_*!)*@1!<56R6)J4*-JX+(25#$ER;W.HFXOJ+;AB=)4D>M=M@RV1-+
MP*0SPG43K4($<1HJP0D*ZHK*9)'$8C665@PUR7,K.!\A^ Z,#Y#\!UGT:MO6
MZ#WGY>?T-\II/0?5N&VW ^\V'6^L@(7R(\/ZA3V<YZAZQ#^SS^_RSI==(=7
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MYIVV3LT E''9L%Y)W$5IF4.XJ;2"C$UDTP'D CTABAC&F6;?QH7+?+:6I*'
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M0$,^?A\M E'IC(YZ] Z?'^&LVC3#2.GC;ETX<,8<=0R ]1\O#Q^WV8U0 R.
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MRVI;Q:5IH"\0T(9-  8^NVG$AD[:O7Q8S#B/3* -FJ";)9J9NF1RHU3$J9$
M JG9-CJ%,5(ABIE, 9.=10P&1J_*F=QR3DAB-Q*LHS2!$P$21-)M54GS<J9P
M,7L_5DU"@0^ 356$Y1*<P8YVH6DR]6C"IN&)"L8Y%L*KI<#.B*($%JJ8@<RX
ME41*0Q"]F)4D.<02 JN5 V)U\V?5SZ$!0#E,4TB15(H\_K8"4P*@<2$.0 20
M*BD4!$B9 Y\=LH8!K0Q:4: *H*LR,5O95B>U@E[#[H73<LP<\3C+PU>NH@JR
M#:0I(QL 5610KD@$ !48VY"_*]L<09TX2>*/T5!1.NG_ #U AS$ IQ3*!@+R
MF QD%#)@J4X"'0YDSY  $?H15BI#*99SVX\S<(.EM(RSO7CR@5"%NL\U?QK!
MN:/.6#L,S!1RZ"AUGAE5!<K.4E6K,P(G344.3BW+=-HF"CJ69)&,0BGJ)/6E
M%DBJ%*H5%18B"34CDJ1B'60375[$3 5P!5!,0."MTNG)0DS!M%$$S+P4LRC4
MP.53M)%9DL1$RB@FP55\JH)5C"/*45,%.9)$@!XF5)(R(BY8KH:: $,D*VU
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M,J:0Q4]T0W>7#;7,8R]\VS!"T--#3H$IHXIHX(Z@&15>8S3,\;LD<A8JI!E
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M@"*93" ADH"(>0B'7/V]/R&;@#.>O7RP(Y^'=K/W:-8O&S!0 /#GS^O#&"$
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M)R$*F#0M$M#_ &Y5.7M0%O6)QW(;@;-3ZYC]#)$+(62I]JF/8H$K(MC"43%
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M0  *4H  %#'@ !X8#R#7R+Z8>TT><]HA04\@DI<J5H2ZFZR53D-4->]CI8Z
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MRA^A0$I"E*"D5K8R[V8J3I\'T$U7P)!=)G4?+$-U$4FA $Y<@(?6, " #D,
M&MMARJ@H$$E5(NH_SI+7)%AZB6)]P8C;?:^.R99V6R3(XUD:..2< 7J:D!Y"
MUA?NP;A!?>T2@\-S:YY&3N*+U4Z\F5Q(KB(B .7CE53S_E7"ZZIRY\"DR;N
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MG'E*H/\ 6P-^R80_H>\0QT'(AC6P&# !BB!BF+S%,40$IBB&0,4P")1 0[A
M1#R'7QU)(\SO+(Q=Y&9V=C<LS&[,2>)/$G%$J6)=R6=V+,W5C:_RWWM[,4P'
MD'P#1@/(/@&K@*(^'[OO]^C ^0]V?LUXN.HQ&A?'W_7T3X6MP'D'P#1@/(/@
M&KN4WD/PT8'R'X#I<=1]?XCWX:%\??\ 7T3X6MP'D'P#1@/(/@&K@ 1[OS^<
MAH$! <#^[3#0/'ZM^_WXMP'D'P#1@/(/@&KA*(!G'3WAHP/D/P'2XZC#0OC]
M?7Q\L6X#R#X!HP'D'P#5V!Z].[O]FC XSX>\!^/E]NF&A?'Z^OCY8MP'D'P#
M1@/(/@&K@ 1[OO#/P[]'*.<8'\^WNU%QU'OPT+X^_P"OHGPM;@/(/@&C >0?
M -7<H^0_#0("'@/EJ;CK]?1&&A?'W_7T3X6MP'D'P#1@/(/@&KL#TZ=_AX_#
MOU0?JADV #S$0 /CW:7'4;\/'#0OC[_KZ)\+4P'D'P#1@OD'P#3>MW.)O:[:
M!1M&3<NK*VN3[4D'2ZVS<V"V3:Z1#',G&P,6FXD'!2 4166!$K=N7*CA9)(I
MCA'AN5QL;M3R[A&(<5W:*"(HH10AD&FX>X@E*."E59QTJTV_K2ZQ#") F+A(
M2#,P 5W!<_,F6\I:"KK&"T\+R7MN =.YM>]MQ?C:]L9;+,@S7.7"9;0S5 O8
MRD%(%Y7:9K(/('>YMX3#N9"/9E$SITW0*&1$5%"$  #O$1,(!@-)U.[S[55L
M%#3M[JD4"13&4%_/1C/D*4.81-V[E/  40$>G3(9UYV;ANN\M"YB3,K<-Q'1
MECF!6];E33>/6 1SR&J6W!*K60;@'3LW"L@ %R11=0N3"G8VUW'@H1C";$UP
MIN8#I$JM0D')B]<@JI+1LZ_.I@1$P++B<1$0,. #6RT_8S,90#++!"2 0K-J
M)O:UM&MN!_9O?EC>Z3T39Q*JM5U]'2Z@#HC62=UX;&P5>9!(+6_&43?_ (W=
MJ)UR>)KNX]651$@IQZ2-BBLHH+=JD9^=,CH52OI1,3@V+_39Q!LEY',D;L6A
MA;X*>72383S"3>/%")I(1[I!X<3J !4B'50.+=( Z "93G%,H<O(&--B7O$X
MMG*FSTCG&4@H6W*P"&!+CE7J)!-@HB7I@<8P(!KC5EZNJ]"0D]H-HW<B \P2
M]?KR-)G4CY >T:2U&?5ET@MD!Y%4BB8!Q@!R(#N=#D"4-.(TCO(%N[BH1F>2
MPWTRT\&E=AMKN!_.N"3TS*NR]1DU''24?V)P@N[,TT;S2&UY'/=279CQ X
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MC;:'1N3H;,#L0?:,>CR-D&4LP:2;!5-PS>H)N6RZ8@8BJ2I0,0P" >(#U#O
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MA" 1H5PH874M]X@@D["P(Q\BRJ-Q;)=M)-'#,5RLX]NBF4%Y$$RJ&%<B9$2
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MHF5$H+?$[1[90-A<6N&HU8C+(ZY_69IG#,&\FOSCD_:O$D"N%.8W4W.H;(@
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M\A,0T.C.3?Z-PZTW,1C9Y&1",I8 &&8K2+MLFYD0,V3$QRFQTB3D1)D#X#F
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M8Q*%28K#4@;@.;".7D+G^38[7!!L;6P^\ZV 4,)N4 ]_,(!D,Y'R$0\>[IC
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MO_1BP!UOI+>6\O9PYS]L>M43M89B=4XE54^DK/)HK2[XXG%0BQH^/C!7 W:
M[YQ$=:_#EN7TQUYK7 $;FDH[33FQ!TNY!2(G868 $':1>..,:+6NU]CQ-N7
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M R[VTLR-YB+B21AJC!F20E:[$,)-9:064.]T':R(FN*FG5NGS48^V0V +O%
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M0=;#MV!2F,8P 7 @'41 .[(ACQZ9^_PTV_AGG%GFT\&S='.=U!IK5]<51_E
M6@G2T2?F 1$>;F9FYLX^L YQI;%W0"(AU,(#W>&>\>\,? ! ,"'3IGF[0@2-
M:Y75<<MB0=NMOH7QKM/>2&-C873?S  L?:/Q%KG%HRY!7 J3=V[,3F,8J*1@
M*4I"BH<1,;^U*0##T*/=WYQI,7;Z[SQI648-&4.F_?II)K.E$U%TD!*90A"@
ML54P\B1$@$2-0, %P AG(]]+/P;L?4TA'UJ1)RF O06[#.%A,4O<9T)>Q(.
M$4@6-[\*9 1CV2'0HG%5TI@ Y@ XE2)T\Q*F(%'KD1Q[KN$B,:]"DDA%+W)*
MJ0S$*++NU@+@DD="+V\T9=]&I@-0OI]7A:P+6)W-^!!OTVQS^VNR+FZW&))9
M;#)2BIESNS(L<C@Q"B@R*#EZ#CD$SI9(A"I,TP)V@"!LY#7I%VQV#VPV[B(8
MD53HDTNRC6*!IB43--295D6R::JB#B4,Z*S[0Q1,)6238@9#!>@8C8X(ML5+
M!;4+$];CZDR,5^<3%' -F!S%9IC_ &HE=R/U@#J(A'&.  40-J9GEQ@,"'@
M8\ QC_9KG7:W-9JBM%*DS"*GC",B'0FMK,P*I8&PTJ;]#MCA?I*K87S6GH*?
M_P"3A+3,&+$RS6.DDDFZHHVO_.&,() ..;(@  4I1$P\A0Z 4OUL 4  ,%
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M#ELU3*@$!&  !^)MR]MS]$X&2,VNM[  ; V!(N!X"WRMQQY;KOQA<0'%?)\
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MVBW%E*^QBW%SCK!],)]JUA*;*?3,M#S\0DU5(98L._E'3P8/4,>P3TB;:_L
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M-]G7PM?<X13:&9+$[@-F:IBE1L<>^@#F.( ';N0(\C^7/><\@R;H$ <_67$
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M!,5$13)T%=PW(/::D>VFX#(J"81@VA=),6R*( @!RRCHH$(7')S)HQC50!#
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MITZ#IAC!HUGP'B =^?X^_1@/(/AIAC!HUGY0#. #\_[/LT  !W &F&,&C6?
M!T#ID>O[_B'30( .,AW=VF&,&C6?E#J&._O_ #^<:,!\,!WCX=VF&,&C6;E#
MQ /L[OA]@=/OU7 =V.GEX![OSXCIAC!HUG  #N - !CR]GL#I^_3#&#1K/@
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M4\4V6]GG$U2P,<M<H_50 BQ[DG[[@<& LNQ%[[<EPS<-]2X=J&SKD(DH[EW
MB^L-@?B#B7G9MR(JR$K*/1*"CIZ\<'.JLJ<>HB!2%(D5-,CE-9\!Y>0?#NT
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M^$VP[H6VD^DVVO\ 1FU*OPV[T%7WFX%XW;V;3W.JU]2<S5)&*K+ )ITRJ<A
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MJB8,]H-Q7H*8 '%MLE0IK$HCW&61CPM\GV(=YNR%-0N.4O4,Z]< ,F@#D&R
M=W_X2?A_[.LQ4DR?T4R%_P#VE*'V= [O9JYE](G:21=(G@B\8X54CAPM:W#%
MW/Z6NU4J%$:C@O\ SD@N1Y:F(^!Z\<0 ;5>BEOIC-7%E>4/;A$"!VH5B*7N5
MG*(' 1.WLMU]9:L%P#ZH*,:X@8HY%,Y< ;4F.T' MLAM5()V,89Q;[H"92+6
M^XO5[%.C@!R1N\D#*^H-Q$>;U..39LB"(]FW* Z>CHUK%=G.9YD2:VMGGO\
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M,+#J/<WRQVNC7$_0-OQTO2^?^K\('3'^#CX]?X=-5^@K?C_CROG_ *OPF/\
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M#;O[^W'L#]'X/'_=\_GOZ]%S^R1[1X>/G[O'"PZCX_+':Z-<7]!6[^_EQ_\
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M^J?05O\ "\K^'?7X3VY_Y.'LTN?V3\/GA8=1[F^6.UT:XH(*W^-Z7'V_H_"
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?HT:88-&C1IA@T:-&F&#1HT:88-&C1IA@T:-&F&/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g449255.jpg
<DESCRIPTION>G449255.JPG
<TEXT>
begin 644 g449255.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]454U?4U1/4%\T0U]/4D<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M'R=IPE0'114=_,!N/DZD[ >KB+6:9XZT\Y%C.'O0%%*05;'8^<I2H)W)'50
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M<[$-Q]Y,3W<Q&QGP^H:(2J&R3Q$*\,\>A.2:)TD7G8-8FX('S@XR\@]7L/\
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M*E!19=GS5T;<M2.0O1J]AEPK:)0+H:>OA4=9!J83:&HM;!B0XS:0D<K;,9H
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MI+ F*2*1@;%>(%L"#LXO<CU>T\'<CU>T\=#NS\4?1P=V?BCZ.)/G^U_J_GM
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MVZ>WP^?@[KU)Z^/4_-MT]OA\_&_P<%QVCWC8X?V3[F^?CY&K7ZMP*J?I/JE
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M&YF..6DS$*U+K]S@G?2;-EFGA-(<EV.!.2EOV<2;61V9-E.Q*7,L(UO%2_\
M8XNMF,,54NYS2;4&KU#Q2JR"KELS(=C"BS(TAA27&7X\IAM]A]M:20IMUIQ"
MT*!V*%).YZ<=5;J[XX;O90FKP^1\T3".IIY1DJ*:4J&R2H"0+BY1U9HW&JN;
M$#Y;]*?1!O-T3XTN$[PQ0R15,9J,,Q6AD>?#<4I V3CTDS)$WJ,,LT,T<51
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M6DED )UO8@(.HQJ5JE=4\.PQ:TSO+5V;;=)C^29%>ZD7UC:J5M7(@X[9/U.
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M2/ZKMY=D&FC$[[6FH"-*++5_$L,:U&R[1*JUI7CXTUL=9<3P)]K+,BT\8O\
MWXKJM:FE=Y:L2:QD])AT_*KJP4>L#ZQ"D+SYD$$#K%B.8OX,/J=?^GF]5&E;
M\DP C1LKN=-$5E*LW)2I!-U.TG<@IG9\8%EUM"D)4E0>Z%8('(EGJE(=6LE(
M!4E*MTCQ'$.\VR^5B=I8UE=AU%9S+FE&/NVUGWKTAIZRG2A6+:II27Z6185U
M@TM:;"R8=CE"8]?)CNK>;=:FO9PS(9<3_O&G$$*:)/*KE!+2P0=T+:5LM*T%
M*DD @D;@QZS3"XURN1Y:%DJ6XR'AR*> ="2MMTN-J9>:<V3SLOM.MN* 5R=X
MA*Q$=Y:>HFB?T9C'*R%>(0'%B+$964@$K<7 )N2>0]:Q=Q:^BHZN$UL7'IXW
MS- "RDL"I5B4=6?*X5PA8*<H!.OJLEKE<X#E5=4XK%9DNV-+B-3$7=XO-I(V
M-FVK$]]:8RO'T!<2$_#Y@ZTXQ)0$*2W7Q ^RVTZ_#/&*>\PV]=R?'B69*&I<
M=)"'7_*:^<P]"EU\MF,MA<EF5$DN-2VT%*2 '&>Z4CI,&YPQ_%RBQF(%M1-+
M;3.+*DQYD)CF+:)/=/EQ@-L]X$++;XB,,\RG8B&N9UOBYQ4TM56HGU:5F'(J
MW'D/E+<=M1[DJ4I;2'' RZEM31<CJ4M4.0)#2W.=&ZJ>QG#)9:H5E2JT\]/E
M>-X@%;*E@CJP^ME.A8^L= XU!/3V[&/TL5"</PYY*RCJR8YTJ+LN>0 RQR1-
M_9<1;$(+QVS&(D!@(3VKOV-PW@I4,)A--MQVX[K:W5E+0006DI2MM8<"D; $
MK3U7R]1PE(4%N\B=_) 6Z\DK4E8&Y4X.8I))Z;D@'KMTY=]@#Q;/J1!RB=J
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M<'LX=JVZTLF2J./ MYF)UBVW<ST=LWXKF5:>B>^KN[[!I7,W7VV-3'R\[&1
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MHXM87,:HHOIUA;D\[W((L-JB2OJ%XOY.$\:*:%KJQRI/(\KA1GL+-(P4:KE
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MXF#$_!VOT?XGB'VB_P"!QOT!^Y/$P8GX.U^C_$\1"/ZB^&UG3?7/@-F4U)_
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M2#6YGG:$S[.U2I5C36^4QG!RKM=7\_DV%3SI5_OF,:J)V,8C"4K8$QV*N<E
M^!SK W,HPW=#>#$U$D=&E+"UBLU?(*16!M8JCWF<$'0B*QZB=I%2;IXA, TY
MBIE(O:0%I+"W-%.G+_$1S-QKMZ4,A[1.AN*N+9O]5\!K'V_]XQ*RFG0^@C<;
M%@2U.@[C;[SQ]?3A#*[9W9B"^[^W3@04#M_\^B%._P"GS! 'K*MMNN_'EQEZ
MR975$MP<]TNQ+EW'DV)8SCT1QL#?<)G5V-IDK4-MN=4UU9^^+A.Y*8D=H+4Q
M"E*8UILY0/\ RM.%QH^/_P!J<0E)&YZ@)ZIZ$>8RR'HKQ:107Q2A1B!HM+6N
MM]+C.40'KU L;<]G,;H4R@9Z]BPYY8D YJ-+OKW]G7U[>NC'NT=H;E3B&<?U
M4P.U>60$L0\HJ'GR2-P PF4723N-MD>?AW(EO63TI7#G19*%#=*V7VG4J&V_
M0MK5N/-OX;^?CQ12==<XEG_QB7@.8MJZ*;R3$L0FR7!L"=Y+M.Q9).P&RV)P
M<!Z@@[\.MI]VM[;%'V13V-M@<E'=MM+TSU MJ^ VM*@2M>#9XG(,0L%]"%1F
M7JH+W*4O-D@A%6]&.\=,A>GDH*\ 7*Q2O!)8?9G55][CV[)Y=TUL?1ZV-B.2
MRQE+ZK_B!8?#MOS-_8V$%75)!^3<_P ./O=+]'T'ZN*$=%O=+\^C3F*B[75Z
MN04]WSPX$%&#ZO1FB/AN+PBSG.X]EB6DA2UOX;DS\R0G;R2A6L]WQ;/HAVI=
M)M=JU4O"\EC2ID5U42TII;;U=>4U@WT?KKBGG(CV-;/87NAV),C,O(4G8CB!
MUM'7X;-P*^DFI)>I9XV0,/TD;5)%UT9&8'JVC]7@];0G\O$ E["10&0_5_Q
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MY]MN?E)Y>?8D<^W-MTWVZ<?.['Q3]/&[$,3?$)C*Z",9F8("6L6"*QS'NC0
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ME3CJU*6M0 !4H[  !(E.Z^[,^&UDM354T<*+8T]Y%DE#L'60@1ED565AJ7+
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M!/-)J&OFH94JZ9B,P42Q:B.HCYF*0<C:YR/8M&U[$@LI:L4PZ*NB*2@ \TD
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M2AAE2V6VDK#:&26DI2@G?N,:86;S+:4L=P@H2UNH<@4$#X*N51YB4A) (^]
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MRTD.PE2WI 5Y-'<4A*TF'L$.QQ51NMMI[QO<)!Y4-IV4H!75*MP?O@2D*W!
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MY35E&C1-Z5 Q$D(,:RI)=:B2.&.1E5[J@DD2TK*R*#<\[[)ZZH@]6TL9RE"
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MAV/@#U.WA\@XX5WD2W5J0A7,I1( !W\?4"/$^;QX:[-,YT\TUK(&0:M9YC^
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M0".HXLGXKO\ =*X//H%"OE =SA^I6F>4REG?9J'59E4.375;?>I1%6\I2CT
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MZ'G\?8-E,DHRV  ZK\K\K]Y&OMY:G;:3<N>^4/99V1( .QVVZ\HV\#MOL#U
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MBS(Q5@>HJ;'[N>T#EC>&1XI!E>-V1QV,I(.O6+C0C0C4:;'&J^YUY4GT@D^
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M)2E#$N]L9;\*,4U\-R/"::BHD!I_@]EEGE-= +$!RII9MH"ZMR/R,-R60BK
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M;Q8Q?ES$&LN^T!JW;U$F-/G_ .W6D&;638DNNN)A,JY@O1[205/2UJ,_-?\
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MD N)AN(2\IUIG9;H; *DMAUQ/U_J$533QR22\2,LW!("J2X11F*FS:VRBP)
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MTK^@IO1(F[N]F!/C$DD^'8J:C#L)F>G5:>@D@I*R3T>-9#6FFJ*V:I,[S0K
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MN?=C&8\0I8G5LQ95N;@D7 L>W^AMM2>\.&-23O9;"Y L.HV%^^W].1&RI!W
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MWG98KJ)GU5%THH+C%\#U URTMUE.*WF6/Y+ITY>T=,U(Q6M@M<B2]Y%ME'-
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M?L<'!P<&QL<:\B*Q*0IM]M+B5#8A0!&WR'IQL<'!L;1QU-[,VFFID-^/>8_
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M&06]6\K"V,;J&+:LDXN4>V9%8 Z9P#8FW41H>[GR]NR(S1&\4TD18 $QNR7
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M+<PK:E, I*T*>"?20M2N7Q\ %>)\=CT\.LCQ%,W T^IQ"#XY!U#N'OVDL#%
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M.X>4&NZ2I260W_N@I?<K"4@-H7W:D$<W( H$LO2]A7IN%5Z*K,3'*QN/6)8
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M)Z:D5QL)*U-LL4N51";'."Q+ %E L5!,<B@@Y3]4W (NN8$;2&-A&0#F!:Y
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M%F3I5:7I+_/!E6$AZ1<.IGO.A+[#SCUQN1P=PL[> 4/;T)\?2=M_5U\.*O\
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MQ(1L4D/LJ*>;8[=%@;@@;*VYAOOOPCF9SE5-;EMCF;&Z'VQO]T8<V+B3OYP
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MM"X<=OE6^VH6:.SI$MUV1ONI1">< CFWV0!UVZ'_ )1T'4]3QMZ@9XJ;*ER
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M[D\3!B?@[7Z/\3Q#[1?\#C?H#]R>)@Q/P=K]'^)X0Q_47PV4S?7/@-F4U)_
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MKJAQ*@2.BDJ;<3MX!7P5(]6Z5$>G;?CGN04GPZ[_ #C<?(D']W[^-AI[ZJQ
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M+G0K;0#LN+V%QRVRU:)D7FP '(7-P3[[=??;6QVD;P<1,L=>=18:E!G <:>
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M&L\ BW_JP[#UCJ]WNVV 2Z'4?^:]WVO;KKIRO;:6JX25 _!3U\3X>OP!._\
MKY..3)JD+!'*"#YBD>?;<;>'HZCZ.(OJ[0VI:M__ ,F^+;^D7EY_@^'7?;IQ
MB/:$U-\/M<8MZ.EY>G?Y?]G/"6:GI)5(87N.60GL/*WOO?\ V*F*HJHB,C'0
MZ>NO/3EKRTY;/],Q]"^;X&WU>??S[^H[\)Y[%DDJV;!)]*3X_(/W[^/AX<-
MKM :EJVWTVQ<^D&ZO2/'S?[/_KU].,*M>M1SN?M;XQZ__&,@Z^GQC; ?+\YX
MC59NOAE42S1*3_VSW7ZM>OJO_N_4V.UT( S<K?XUT\=0-.>MNK9TUXMU)#>W
MCU WZ'SG?<GIZ=NO0].$S::;TEO+@S+6D@6,JK<[^OD3(;,AZ&[NE7/'<6@J
M;5S(0O8';F2A>W.A*@BSKQJ.3N=-\7V]'OS?>'H_!MMM^OAXGC"K7/4<[_\
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( #Q )VPV_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g308280.jpg
<DESCRIPTION>G308280.JPG
<TEXT>
begin 644 g308280.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5].3TY?4D534%\T0U]30T%4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 5$"K ,!(@ "$0$#$0'_Q  ?  $  @(# 0$! 0          " D&!P$%
M"@0" PO_Q !Y$  !! (" 0$"!@41$ L, 14% P0&!P$"  @1"1(A$Q05%C%1
M%QA!89$B-E976'%V@926E[&VT=+5UB,D,C4W.%)5=Y*3E:&TM=0*,U1R=;.W
MN-?F\!DE)B<Y0F9S='BRP2A%4V+Q*31#1$=Y@IC8X6-E9X.&A\/_Q  = 0$
M @(# 0$              P0%!@$"!P@)_\0 9!$  @(! @,"!0@.%@H! @<
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M!2,@=,@L<8MA4;8 V88+H+W8!1B;9G&Q[^_QD$>8#;<?Q'X\W!ZC0@89]/\
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M*/:+&(T P\?68--GY<JB:&AMQ(N./F++!-VU=K:S%F70:B[5I6'4=>#FP;X
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M/T^^H?3"A+4DM;3[I]>]9WY >R:::[.PDYXC-LD[WE Y,4ZWT$O[)AL@FH4
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M="PX;CKI-.JS&U[H#US2Y_4_5=@F)G'!P4M&&\>D$J/R*MMP;XVR-#'0@G(
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M9D,>&,#LY@9%!9A*(6@MJ88/&[Q!+5ULP??%\<H[U@.E?:M[3T7I&Q9VW?\
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MBPOXB#%R6>19H9>_((DBX+90'#7;_&![,@[([91;IIO'#K;95136-X4-W [
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M\>\J2XX_+C^&WWRT#_Q^G_:Q^5F\%GN+6OX9G_%_#Z#OMM^W\JK\B\__ %"
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MJ[@"26;I3.Q)2)EG97KR[(L93@M7*(&[1[6U-JY3A4@CR$4$*&%DIE<YUO\
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MY]V??]'U^,^/HSXU%)?3,4E#&8?'KV+(';M'V]&NR1=I7@;+>QH7<5K K*,
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M[X^8':[\T%77[!G_ %[X[/I'U(;OD_0K@/S?]0>G?OXSLZVH?5&K>3Z>XO\
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M7&N5MT62*">ZN====<J;Z[;^SC&OM>,>.=WR.U#3V<'GUIU_93@,2F=3S5N
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M+":J6D!D@:R_LAG6#,96;N/GQ;*'I+_$RJS]BQEVW(#=@?Z][H+_ .H[:?\
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M&,<<<<8QQQQQC''''&,<<<<8QQQQQC'-;U9^-A?]%$T_=45YLCFMZL_&PO\
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M-Y5)G1=JT;PL]EX7CTBD+CY/PVF!&.FDR!=Y3G89UVX[-E:]6I&OHTU1)VU
M'90]*8[=DYGY2KI*#0IUHLI2+4 =&Y%LFS]D<4>/C++>2;9PFJE'T95")9@T
M(,R5O_ /6K=TG_XQI+LIIHY1T6UTWSC;?3X377?V=\Z9SI[6,^SG;'CG9XIK
M?&OL9?6[OCS_ .=8LHQGZ_'XC;7'C'YWGZ\YYU/#G&6H1I:BHP&.UIT=994M
MT)6FJROVI)FDM79YN9C(>0<ZQQ1D)%#&J*%Y&J<)U7:&2Y9YX+IG*/#=013Q
M[1-&(X*L4052O?ZTLY7=G;R7;9DP/WY^/HX]_GZ<^,>??C'T?1]7WOKYQF3
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M%>,(B7J@$PA^X4"$AQ"D HO=, ;/Z3)V8W)[DT/4E%)"VEL7C<J9CSHEI)@
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MQ/\ \IRY_P!:H+^5W'V8G_Y3ES_K5!?RNX]5*7Z:_P!PL>;]:\_IN-W8;/\
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M<4B=??6:KFP>U/:VK;[%TW6?6FH"D:;=8;>12ESY2T6+W*NK]TGJ\C[D4_\
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MT*.4VCBXXJS2U^  %X\NJW<V$,'(H"Y9&/E"0+-L2L&@Y+RGQGSC&?\ M_\
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M"DC_ -#/>=R#_I*'_P""Q_\ FB/.FGWXQIE^A21_Z&>\[D'_ $E#_P#!8_\
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MJ6"!NG5"B#X66J1Z02"8 IO7]CHRZ73Z;RN2/IU6-<R.IX7)C98X?>N#9,9
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M9L+60.R.X+<IY>4<HV+%F9BJJHVVYF8#F*@D [C7^).(8.&J":A8J6[<+6!
M_9>SJM=!!8L/9MSVIZ]:K55*[1&Q8FB@6Q+72:6&.1IHYB_,KNE^:(ZY_P#Z
MIM@?_M;_ '\<CU#^JW<2*=F;R["H=E^NRCNY*NH&N7(K/5>P5$V.E(D+?((O
M-&V>U"64-R*EJ.OA=_E-]A?#;37#,;AMKEYLN)3^YR/<H($D4XAS^F)IU\L*
M<5O$X,Q749NF(*;5 Q#SR3R0IG=X3D1YE+2GQ(0%PUC<>";MD='$A(NW)32+
MM*V9=5?3J S;M&8[;Q<+/IU:<6$#Y2]I0E43B1:[6"8B,;6KN&PU:[@X]W#P
M&%8"^<%W[HX?&H)OVB;8B.3?0M>160&.79I&C+D (@5H1SNW,556ZR%"Q!(W
M!Y3W9B9N-Z<-BO"^FZHD,NIV--FNR10BE2$$FE1K=N64FDBKU+0U>M)4>9HW
MDC67G2.11&9N?,KNG^:(ZY__ *IM@?\ [6_'S+[HXSKG;L/UTSKG?3&WL]39
M_C;V=M]==O9SGMOX\XQG.<>?=Y^GW<QZA>Y4'NRRK,KQE@H@YCLXR"@BN8!9
MXG!^-MZ[BLO?%9&^D41&B8R62)%33! 06=BGCMDP8N6K-?+]LHZF8I_0X_WZ
M?_&:\LQ31SISQ.'7F=-U((YD8J1W$^4;CVU(8=Q&;+I>K:;K59KFEW(+M9;%
MBJTM>5)46>K*T,T9*,P!#+S+N?7Q/'*N\<B,8T=/K;F-X=?X?8M@)1Q*8OS%
MCQP_M$1Q(/''CVOK2F]=8*"A!<S(2(IN7;Q- KN-='2V[%P\6;:D'2:6BNTF
MN0:].3^M.B']T7L?_P YNY.3EY+F0'>!\ QQQQQG.....,8XXXXQCCCCC&.:
MWJS\;"_Z*)I^ZHKS9'-;U9^-A?\ 11-/W5%>2+[%)]='^'D3>SQ_8IOOX,V1
MQQQR/)<Q*??C&F7Z%)'_ *&>\[D'_24/_P %C_\ -$>=-/OQC3+]"DC_ -#/
M>=R#_I*'_P""Q_\ FB/)S_LR_9Y/YN/*8^B#_:<7\_-G:<Z@^>!1<*5D<G,B
MH['@;!R5-'3I)F'#!QC%+9=X1*%2"[9B/8M$--UG+QVX1;MTM-E%5---<YQV
M_(S=PJOL:YNNMA5M5!.,B)Q)/FEJ.>2QN-6%Y&BIU&#LH9-79B(3\:!DA.*B
MS0V'2]U"Y-K"I<[!RW00[6#)XU@RYF1+]H.L[:#,[1<]A:.;UJ17)MA]A+VU
M D(.]<!'*;(RW:2I60Z 7"PEXLDT*HHOMU&#E1-![HDIMIKG7=D7KU>G;^?4
M>9/0FVY;!65,SN<4^+D,3?2$<%F-@Q]:LY<Z8G)( &[,F$F9@9/HOJ5^-,D$
MP#A!NZ>2&*#CL+*=]/NT!%QL[2LU:"%P[6].P-K"@$DGDSN.8"PMM]1*&ZYA
MFY693.),,')ADM6\V(2U='5 .WCTJ;CP[HOG=_C;]M.@UN#:O850UVJW&Y'J
M[Z?E3F9RS,E6#D/-NF]CMS\K;CV684L_*1V71S?1:&'5';1T/+@V8XU'&S/9
MJ008R5]^=X(50,]DT!)5)>EB+P*FF78&RY'5T8AQ^/5W5C^23..?..0:';#B
MLE*KMEZ_EQ1P#A,;EIW46'W7;#G#U=HQ6Q5;U&Z::2J3LR$&N(?5$-M2)4W)
M>RB\9BKFA@TWG<?KP_$-"9D=.WT^$Q<Y]E6!"<3LK7+&$C2L@0P=.C!B+LFA
MBQ+T[P,TO*72JVIE/+4JF0]88A1+D5)+@LH1+)FZ8W-==D2IA:C6OG<%C4]@
M3L!9 *," TBU+(?)K,V$>B/D]TLY*ZLG?2SLC+!/:2A!7V%(U0O:CLT/LN5V
M,C,)6[L:,T<O#Z1CLLKV*53BK4HLA.C#6IG\7!2)W9&(]$A$A;25$64)!4(Z
MX8R=E^]KJ;ZV/*X$V(5+[R*UYS$8+#HS%@1&2G73J7V%":RTDI5LPT^*QZ#Q
MZ4V#$V4GF1]X.#"U3 P6W7?'BH8*1D:Y7:M&[AX\60;-6Z*B[IRY5T1;H-T-
M=E%EEUE-M4TFZ*>JBJRBFVJ>B6%-U,XU]O/(!=DNO%S2BEX_4%7/FUE.-+MI
MRXC$WOBVB(T\Q;5+V7K*^MX>/5CM42#),<3&PHC%X]LLF-3CNZHK9Y@HAHX<
M);"[(C+/M&N8)1[:*+"'%^'FD.NPR#>+2.+UQ3Z(UW(+?:*R5P %[.WD\C(]
M>H(<[R$&O%#D^2.:-F* )VLW8S?=0V?'KHK:(6K$6AMK$YV)UD,55D W(D@6
MC+UPO\@2/1CNNNNB*E(G1G)0&SK*+UP *C'3YF/=K+,&VR>?*Q9-!K)H.8-6
MS%BQ;(,V3%FBDV9LVC5+1!LT:MT=$TD&S9!--!NDDGHFFBGIIIIKKKC&/JXQ
MFHKV_J62?\\%^Z8+RAZ/YQ]O4AC/W0$F_P!-OOI_[>.7PWM_4LD_YX+]TP7E
M#D>QG[>IOMY^B/R;.?/G^W;[SCW?1Y\_5]SZ,\T#PL?[A3?]WTW^EM$S:_!T
M-^-CYM&L'_\ @:]_GEH'/F>LVA%F['OVK=ZP?M7+%\R>()N6CQD\04:O&;ML
MMKNBX:NVRJK=RW6TW1705415TW3WVUS]&,^<8S]>,9YSSYF\7BSVTCQ@CS$'
M^0YT<:C$;AD>!Q*(1\)%8K&!;,)&HS&A+ #'HZ%'):HC@X(**;M1H@4P1UU1
M9#Q[9NT:):ZIMT4],8UQCLO$PD.X=7$9B $G+Z[@\V^2Y;N$$+S05%56&)#*
MHX!DKMODH+&R3< Q4*C6S]N.)O&0]<DBMEFCNGGW,<F(-231"6QI%=-JM(XI
M)X\BY6UWW1;+'@)$.DX6T3QE3=)#=[JJKHGC*FVFFVNF,[9QR6-_FRL[L [;
M2OS-S,DAVEYF'KCSJ6YO'S G???(Y%^9L$1254F->5>4.HW38'N&S ;>+;S9
M4I5GK<=4+.HBF.P&HF>Q&&V24OP3/!<C3#)R6A'W7ZASW8R28L .B[U5*)2V
ML0[ S EHSA?22I24"JGLFDHZRWR& ^JE()M'2S]QZ?G=./2@U4$-ORAX*H+K
M*0N[YJV>2<1%A!YE*X],W<'J0H&R>%22<QVV3@(Q$8.J\E+E)ZR&/$M8;N/0
M+#F1?5D<6ML.$0AG3.3]4^V Z(ACR0:Y9$GUPF/7NJ[SAK!SEBW93^O@<U?C
M'3J3MFJTAB8X,.4<M7+#?5S(N(]._5/95CO#)=W;ZWODZ[IJOZ+K2L1W7Z2F
M*'NR+1-ZT'S"2=L0DO(D):I++2KAE]CDK]B$F+&Q8<1*% ^CMRX^"WW:>MP=
MMO2L0MS2[NMZ?48S!'VN<1I"U>!Q.&01I,TBJ>QF*96@LO,Z:K%-Q'N!9BE'
M*A"M6BJL)#V>$LTBRRCID;NT8#-\\B2-E= B-E[_ -86KP74F[^SLEZ^]A69
MGKU9EETW8U)QL.!LLN*GE4@D)/+5]+8KHA(Z<Q6@H"Z3?$[4VDF(T/>:[Q[1
M%_)W L.3[SM'ZLM<]:9&A&-:<GUGF@_5<7W-L]L'G]0P!:#T63?:#4WP!&T9
M7&WEQ3I!RD1W5@%;MR!C1L/1^$72?&0S!W%AMZ6W<2,=#NQ74&N;@ZCQ!+MK
M8%L%+!A+.O[S;]?>O%761%Q8C2NNH\;;RQS(HTLE(AJTO,.)J@\C#LF5>;,8
MPW=?#O7^&=AO2([7=H$AQF\9GT:M27K]:1?6T/I*H-V7:1?K"ZB9\HK'[WZL
M_)$ZP=:6=((^Z"/K 9RU<4V+3:) UF!_2)8W I]H:7"!M<\MJ 51;MKR=HN,
M[P&.J( $"Q-&D;BX5YK19B(V:Q8#1Q/TDM<1B#E2O.9S7K$GH0;)()).KN_.
M0SNC0A^6+91S[1IRLP]$4?.,I,!!R0;H^3'2(((/CTR8]V)):#S@UJ58Z$A;
M]-%Z,(:-7:.KX:\23=L'>%6CG31='?7';^_W>_.?9U]G7SG.<:ZYSYSKKCZ-
M=<Y]^<8\8SGWY]_,*K:*$8'74 @QB7'; +0N#Q&(E)Y*-M=Y+-R,9CHT(^F$
MBVT46TV.R9TQ6-ELZK+^7SY?RX<;>5U,UYHD@02.$/,@=@C=_KE!(5O7!6&Z
M['O53W]X![LV]"Q1.<;.54N/(&(',.XL.X]W<Q'=W$CO+G7%_P"E9#_V1?\
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MR82Y5Y*I#8G7O2$I5I(#K\0P!L'.P]&O8HB59-13)@=P/45)MUG#YZLNQD+
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M].#HX]B@:#/NOD1(1*.T$YZO P;\S,GC031KN>L+2UA(_=Q)U'+55C88H9,
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M3=,2,T4UVTWT'L==]-]<Z[:[:M4==M=M=L8SKMKMC.-L9QC.,XSC./..??\
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M>>QIAH++[JM";!D118S8ARVQ40AD5E4U"GHZ^E2PT:WB/Q5N7DC>0/1CLJZ
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MM:]N:2E %Z2F;)Q@2QK]XT*!Q+%X\?O@T<<5!"["V2D;H6B1R2UT>2!VF@9
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M(*[33D\W?[CZZ$,5WYN-@HX@>E@QLJ/?R&ZTZ?U0E(X,2/21M\3PKM('"BH
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M8QCG]^.,8XXXXQCCCCC&....,8XXXXQCCCCC&....,8XXXXQCFJ+%_&[:O\
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*<<<8QQQQQC/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g296577.jpg
<DESCRIPTION>G296577.JPG
<TEXT>
begin 644 g296577.jpg
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M0T165UAWX?'_Q  = 0$  @(# 0$             !0<$!@,("0$"_\0 21$
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MQ&KN8Z4BI)DNB\82+%RNS>-5DG#995%0AQYC(%]++M]+3X     !PUXV
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M&,:^"BIT"^L5(%U8BKOH-NX\W#;L08ZG$.JEU%I :2ZRM+;K(>G1([2GT+4
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M4ERK-7CXJ35C,]L#@/?X^X._O*8._P"#N'O_  !W$>X?;#-0, _#O_B42_\
M(P!_OW?',#*N:=Y<VK7?)&?Z9VG^?^G++;NCE!1')F8W3+[EB9C=7.:3O&JY
MEG+ZFMNT)^5#8^Z9#1B&U',=L?2C]&HKUVT5:,J,G$R\U%1@7%]!#5MWU]:N
M7;^$B-R4#C?-M./[6@:OOG''DIQVUC$[4AZS:4]N6+4<#RYW;M3=DG,R)W$!
M"[KF%H:L4J:OT&A*UN2M+E66>MV,R0\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,XF>^LDO\ BN1_8E\Y;.)GOK)+_BN1_8E\8R$/2R_LT^ 'Y&O&
MS]T=4R>F0+Z67]FGP _(UXV?NCJF3TQC&,8QC(!,/[3^P_D+5G]_$WD_<@$P
M_M/[#^0M6?W\3>3]S7=<_0N?_>*X_P#R!EH=4O\ :=%_^%^B_P#ZK&,8S8LJ
M_&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC(VRO
M#KBG.[A;<@9GCII>5W8T<MG[?:,AKFK.[L239%2(PF!G5XT[M2;8$00383BI
ME)=BFBD1H]1*F0"R2S3N']_YA_AFO?O_ /X(?YYDR)DN6&$RI4F2F,RF/&3(
M?=>$>.CGL88#BE!IE/)[6F^U">3PD9P,Q8T8NF/'8CE]Q3SY99;:+SROTG72
MVE)<<5_Q.+[E'YG&,8S&SGS3L'O_ +_CFO;\/YQQC&,T$H#V[_8_O'_$!]_O
M ?L@/<!^R&:@';W8QC&<5.P<59867KLZR1DH6>BY"&EX]QY^@^C)5FO'R#-;
MTSIJ DZ9N%VZOIG(?P4-XG*;L8(GZUZ?W#C3_&>X<.];Z!H]6XW;!8VN/OFK
MVA9EU&79*\,DHRVNKA,R4N]M=GEY^.;M6$E.S4^]FUV;1FV"0(@S;$2F+C&,
MX6NUV$J<!"U>NQK:)K]<AXR A(IH4Q6D9#PS%O&Q<>U(<QS$;,F+5NV1()S"
M":1/(QC=S#S(  ?#[/Q$1$1'_$1$?=]@._N^QFN,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QG$SWUDE_Q7(_L2^<MG$SWUDE_Q7(_L2^,9"'I9
M?V:? #\C7C9^Z.J9/3(%]++^S3X ?D:\;/W1U3)Z8QC/PR<G&PL<^EYB0914
M3%LW,A)R<D[;L(^.8,TCKNWKYZZ42;-&C5!,ZSARX53102(=14Y"%$P?NR.7
M,  -Q2Y*%, "4=$;7 0$ $! :1- (" ^X0$/<(#[A#,6=(,.#,EI0'%18LB0
M$$E(66&5NA!4 2D**>"0"0#SP?ADSKE6B\V&BI''E1T7%S5U:Y"$!Q;"+"<Q
M$4\EM2DA:F@\5I05)"BD)*@#R(?,MX:6+U()^UFV]J\*NIPLKL G9!O]3" 4
MG4MV3,BK"DF!EODXTJG'J$?*1P.!>$9G(Y,B")BG&T",DXV:CF,O#R#*5B91
MFVD(R3C7;=_'R+!XD1=H]8O6JBK9VT=(*$6;N6ZJB*Z1RJ)'.0P&'^>'Z*'L
MWCZ"'CZ7EX>BEX>7I]O+P\/'R[  >7;OV]W?,[WA^ %XI<:RE  *&B-4
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MZID],8QE9?5UOZM&X/;)8M#F+([$EJCKE@!!'U5?EN;1E)5NF4/>8SB!@Y1
MQ>W?TU3=NPY9IE*/59GH.U;@X+Z%G)J/AJ]9-SI[!O+V8?-8V'CZQ67T-%>V
MR3UZN@T;M_8I&S!ZCE0B?DEX%.)S@0=+ZARS$TR^['4,NS8B*EEQ:DH"';F0
MS5-N=RB D-JF!PJY':$E7(XYR]OHSUL2?UQZ?S+)M*ZC5;23U N?4_4IJ>G5
M7.WFP]=1]U+2XVOK945^X2X$J\*XRT#CMKQ#6/'W3VMCM"I?-+6%-K\DV53
MQ5'S:OLB37JI'*(#[3(*/CJD. ]Q5,4P#W'O69TNUU-.;HYK</'ZJR:.N-K+
M; H[17N4%*E8U1BS+HI=Q!-(8M*DO.Q/<8TF(F !#N:S$O)?CIX ;Z.^G_ P
MB &^B/4?$1'N($[_ "OV\NP_U>_?M]CME6>T9^#U/U4^-.\ZO,,9C7'+37+S
M5DG8H.2:2$',6%@8(&-6:R3%55@\(5\CKLH'!941%)P4O8R8^,)>3:B)*TNR
MJK"!)10VL6HE-Q)<=\M4M\RW1E;J&'%E++5@NH=*E#M26D^?AD]T>NU=1(?T
M@-&FRF9EIU"T:WZ@UR6W4.OO;KTVL5[\A3*2I2E/3-;3NM>GSW+-AV#RHY=Y
MC- 'N #\/[OM?W?X9KEGYUKQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QG7+'3ZG<$&[6V5>NVALS6,X:-[%"1DV@U<'3%(R[=&3:ND
MT%C)B*9E4BD.9,1()A*/;.QXSC=::?;4T\VV\TL<+;=0EQM8!! 4A8*5 $ \
M$'R ?B,^*2E8*5)"DGXI4 0?GY!Y!\^<I9Y#=.W<VV-N6FY4U?2=-ISA1E'U
M2NL#S$'[%"1C1-!%6080U-%@$K(.S/)!^HDJX['<IMBN%4FR0A.+C-QH:ZYU
M56:KMRCZ?L5WJKIVV:6J$K4=+.)")0?"]@'CZ4F:Y'20S<>10&2B_IG,8K!H
M[!T==13PF)C*]I>EFHT.PV6S0HTE=E:F49B9<A,F&HRY*):RU#6T&6?3=;2(
M_I!/H-\M(X;4I)A(NO5L.<_8--N%^3ZGJAQSU&CZCB7#VM*3VI[5)'I]H'8G
ME*>$GC&>=;?UQ&[AU1LW4LT\=QT/M#7MUUW+/V!CD?LHR[UF4K#]VR426;JI
MNVK6557;'3<(*%63()%DA[*%]%QEC9.9CE\)*;UGN.=)X;\ !XW\?:?I_C#8
M*/1]I<Z76Z(*]5'<O&37*\FBE6=:\>&K6%VS3=O7BKHPD"[F[8]^;M1FVZTP
M0LG'R!D6$0ZMTKN8\5M&G:+7XIZ?:IU#JV_3$Y'JI%VE0CWJXZI)N61VBM0W
M5*0CB[W#=<Q5WP:GE(E<&VJ"5YLFZ-9GJ"JB8Y=_< [?;'X>[WCV_N^/N[_X
M=\UQC,4ZD])CD=6F?&6VLM':_KNTZ+_*"=L\XMC6F,LFMVMI#B!<[5M]1M-K
MVJ-D D)_Y2KDU14E-=D?N;$#-NQ8/H) 8E1JT\*XM]+'G+JFY=,W3ULX8:G8
MQG3[YY[:VYLOG9$[?U8ZM7)'6>S%MG2[2\Q].%4-H^UN_EZI1^QHN[.&4^2>
MK%3)5Z])P#=\ZK.9-C&,Q%^&'2YYA\:;MT:[C=N+E*O;_CQ&]1;5O(E^SV)I
M\\QI=ER0Y/VK;.DMN$?23]0]YC*I5YMY(M8F@/)6X0,S./6#9C&N'3Y97SWC
MUTM>;_%'7/3(V/=N$FKN<DGQNX=<F.+FT>']GV]IB)'6=^W#R&FMH5[=E%L6
MQRRNG[,C-T]PVH&QQ;2Q+##U)V=6$CK"^25BDLRK&,9BD<2NC1R!U38^!U>Y
M":^U5N.HZ#Z:W-O1MUEGLM6KA6*=M_D-OA?8&O-8U2+NP$L<C!TS65KFM81M
MP8PB,*WKT,\CC+QD=*MF+F%VU^E-U3)OAQHGB[&\?H&0=->E)&\6YFTTB\\,
M8*[5S=L=L>[6N4UGOS=.T:??-NS?'=&ON*PZUW2^-=LA8AY?Q70ML]78IZ^L
M\1G$"( '<1  #XB/N /\<8QE*/3;X=\A- \Q^;6[=O5!G6Z9O7C?TP:)1G9+
M;6+#)/;AQOX\VRB;BBI-C 2LDO'C7+5,-(]O).1^3;$4ZC^!=OV1#.,NNQC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,Q;NN+O7I^[T<[6XA;]XG;KW!<M0UK2K*?Y
M4ZBXV:IW',<:+UR#NU>MFD=)5:QWJ<86VOWGE%(4:)UZ(5EBC62%N];;7";:
MQTH\6C;2^F#R'TQL:H;?X]:ZX9O>GQ>^*MYB8#:O$A:I:LJL50W6W8$-I5.W
MU4-+.W>N9FM;&BI%],$EX<&3A6=9SK=^S$Z"+Y]4OU+]-ZCY7=0>\ZNT3TP(
MKFQR&UGH+5,WRFV'?N8MNXFZ4JE8OJ&Q&?'>&L-;KCN0^BON&,C(Z\3.N+D2
MKI2>J#'C).,L(R;"/7K$X^AXWU36:!RGU@TX[[2XV<KM9\ATH3F=4-V;]DN5
M.Q;#L>6UO4K%KJZEY$2SE=[L:ASFI)*M%HBAVD(6'8MG[08I=PLO8)YC+R\8
MQC&,XF>^LDO^*Y']B7SELXF>^LDO^*Y']B7QC(0]++^S3X ?D:\;/W1U3)Z9
M OI9?V:? #\C7C9^Z.J9/3&,?#*5I6)C-_=8UU$S4?&6.J<;^._H/HR2:MI.
M)4FK*U XH/&3I-=HY4!39)#BBND82KQI#"43-R]KIS? >_P'L _@$0 ?S .4
MR],!,-G;UY[<EU2F6;WC=JE'K#LW<Q?D*LO)>1%)-0?<=/Y->U1, )[@!L7O
MW#Q[:+MZ$S[32Z124N-S-@59RFU@*0N'00),\A:% A2#/-<DA0*>5 $>]G8;
MHJ$TNE?2#WE?@U/2O\BJX\ DVO5#9*?5W4))4.%+U0;:2D>5,H=(Y"2,DVUU
M3JX>;TQ71UM01@$N+L',)P@TVN#$DEC[4E&:DH2-^3?8BR)VB9&IWH( Y,W*
M5 512*4@>"=775Q(_BY3-H:^AF4++<:-GT^]U]&&9MX]G#PKJ13B'R+%@R21
M;-FR4VXK4DJ1%--,A6!U!+W[B,N6G_?XG/R3('][LOGM6]]:,]QZ8VCJQZFB
M=*^T2S5A$RX!Z;=_*13E"*>^\0 #L9063U,>X>*B!3=P$ '(:/KT6TUO>:V+
M%CQY,RXV6-%=98;:6W(;?2] (6A 4$L3&F'4I'NI4V" " <J_H3M['3GJEIV
MZ.--^Q4.[QG[=H-CB3K[LQ$2_@K">WN:FTDB?#<03VE#R@002,Y_5]ZC=G:X
MH>QH<R9HN]5"N6YB"2H+$30L,0TE"H>H B G;F<F;J%'L8BB1R& # (!WK*2
M^FMRR/6^)M0UY8]<[AO5HU7:[KK242UGK^2NIH1M$2B,M!LYY5HX0+'N#,YY
M6-C$#>9EF\(L( 0$?JI\:]YCT_9LI!L:OJCD&K'SE@/6R6ESJE^G4HN1;/U(
MR2&:GF\DZ:QK>&?)+-IA50#&CE452.4RF3.4)FDW[7K"!2F39QV+2R@0WEP5
M)=#R9+S,;VAH)2V02Q(D(9=*24MK6E*RDD#/QU9UR+TWZH[ST^=DI*]9VFXJ
M(1)6HRZUB:KZIG-JX/J-3ZQZ#,;<Y(4W*:43[XYEYC&,WK-,QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG1MG/'4=KF^OV+AP
MT>,J7;';1TT5.@Y;N6U>DEVZ[=9(Q5$ET5DR*HJ)F*=-4A#D,!B@(=YSC9F)
M8ST3)PDDF9:.EXY]%ODB*'1,JSD6BS)TF55(2J)&.W74(51,Q3D$0.00, "#
M&8/'2AYI\A>=MVZ6''CE?MWE;QQTI#\?[/L;4UIF=C6^M7'JK<C=/VA1GL&/
MN6Z8^TM[Q):GUG!/32##6#IXL?<:<3.RMGFG,:E$UYI:Y%=:+D<ZW# /GW%_
M433BHIU>[-T@)NVM=U6Q_O!?:*]_?TVD[BC*0KKAA2F.ODS$BTK-!N;=*61>
M3>/ B",H=@C(O;*I'I9<-I#0O%;CJ6A6*-HW"FZT_8?&:6AMA7*)V)JVW4AR
M^<PTI#;'92J5M<)K'D5R34;(2+J+GD4V2<LS=!',!;<D/3&X?_) P84&<)'?
MS^OIF!4D[]<DSI\N_G5\]"WU)8DL"B<(2P=G:="*8*<1( :%B0; "8,969K?
MK5;VM\SH#D//<8M:0W3HY4\VY'@=IS8\;N.R2G)IE?3["O6K*?MZ]:F<:[84
MAEK.WWW7TQ!+5J(NKN\U=LJ2;>EDF"* 27,Z6ZD?-3F%HBT\DJWQQU31.$>\
M=6\R5-'[5KG(I^AR;UTWT=6]G0]/V'L;6DK58&)>#LFSTE9.&@=266P6G63A
M=A)VTXL&[A\2;M2Z/W!JE<@V/(B#H-X)*P.VIOD'2]3/MR[5DN-VO>0UG._-
M9=[4'CP]M2VJZML^9"2<@><85\&D6KZ3VOQ<._2(Z#AJ!T8.!6M-I/\ :55H
M.P4%DT]V'HFO)'>&W)C3.EI7DC"S5>WQ8=&ZCE+:ZH^J9_:$/8)6/L,C5HIJ
M9NT<F;P24.B'AC&4N=.CKTOF?3@V5MN^4VQ[*I_3KX'\<Y;<%^V3LN:/R(Y$
M<E=BQ,?#1J,+69^)FY0-125I(^K$IR%MLW)N;#;64PO!UJ:BXI])9+C9'63Y
M:\4H7E53N8?$[2T'OS4' \O4,U+!Z3WK;+MK6YZH)M*OZBL>M[[8[-K>N3U4
MV91+59H1.3D8")L51M#9XY=5URFWCA6>6-1_22X*,8JH0!]0+2->JG#Q?@6X
M@I:YVZ1B[IQ<,Z3D8W7&P6RTL V]2LS!#SM.M<@H6WU";<.I.NSD>Z7,<.HT
M#HQ\#Z11=XT*6I&R]LM>0FHD./6P;/O/?6Y-OW]'C]%.E'E5TE2KW<[B_L>O
M=<4MT9!U6(6F/89PS?1\5)/'\A(Q;!T@QE:'5ZZM?([46G.=NL>-L+!:TV/I
M'@UQ.Y116[/G*#^?@&G(K>P:MM\1 5>3I4Y"+V"N0R;<U=?2+AF"WRV]E@<1
M4A"Q97N2+JEUL-[K6B.]LQ-3@MF.:G!+7N&HEDF[C38RTJ1Z!IEE6;39*Y4)
MZP0R#L5"L9:7K$'(/4NRSJ-:JF$F5B,^AYP'"E[VIMCK.YMC&Y*Z2I6@MT6_
M:W([=.SK]<J)KBQ-[10BJVZZVZ9DHN5J$I'PI:\ZAA8,8R+K\+!MHLD,S,Q6
ML]U9KR*U+KBCZR@YBX6"(H56A:G'3NP;A/[ O$PS@V23%"2MEVM#Q_8;3/O"
M)>O*3<N\7?/W1U%EC]S 4K&=^QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9C9;6X
MKZKW+U?.354X]\^NH!QTY-[0X^Z+V?R99<9Z]K0-%TJKZUAR:[T=7=CWZY:W
MM)X78]XA96T6VE5$[I9U)0;6URZBK%H6*:.??.BG6M(-S<W;M1M\\N=U;ULW
M(R'JW*=GS>IU9H6_J/L34NNXG7].8SE;K%:KC#YO6+6<?6YZGS")'R,I7#QY
M5%64JSEXMG"_J";DV1P4Y\[OWMQ<Y$:<XY6OD;2-#U??<1U&^,7*\_"_8,WJ
MZJ24;KO9^IN7^DJL[IU1M-<IMA-0KQ1;-8HF)4E67MCHJL@!#L;&.D3JR%:0
M/)/E-8^7''OF=R,YC;4J^Q]];1XLRL ]T56@H^O8?7&K=5:\:0\_89).!HE)
MA_9DY6W.D+;/.WKMW,MQ<(F<.&,N)QC-HF ! ![]Q^R!3" ?A, "4/\ $0_Y
MXQF[.)GOK)+_ (KD?V)?.4\@$WC[^_\ ZIO$>WQ #=O$1#[( (B'8?=[A[<7
M/?627_%<C^Q+XQD(>EE_9I\ /R->-G[HZID\Q[]A\1 ![#V$0$0 >WN$0 2B
M( /81#N'</=W#XA SI9?V:? #\C7C9^Z.J9/0?=_R_YCVQC*1>8V^.?7%:HP
M,Y<=K<;)6%O]@LE-9JU[4=XC)&%.E3;-96CP7$A?G2:KE9*')$LO32-X2SUF
MY5!=JDX2'V?H\:\ME%X<5^4L+B%/&[,LDWLFM,V3!\C/,XV8%&(.>SR3A\LS
MEGL@:!2D(Q2/8L"-(9PT:N3/'('6+5WU5^<6J^2-=C=,4: OD5:]2[DL_P O
M/[1%PC.!=FKT99J6N:(=1M@E7S@%)=4KA '<>R$8\@JG$C@0;!=1PMW%K^_<
M*ZA8-;FEZ95];4)WKX):X0\>16,DM85MO%3%E<14;,O&SR+)(-5Y9),TDS7?
MMRB#@K!14P)T3KEI5V'4VW5'O7[2'04#QJVY%E(E*#LQ4(6Z4+EN!/9&7#2E
M[U5I;0X^T5*X:;*/1/K#K6VZ5]#C4I5UTYKM0M]_ZA1Y&YRJW5Z:A:-;K42_
MDZ2N2*]II#3UO'O)#L%Q(2I<:MFDJ0)4OU_ "<H*ZGU*W$,0&WS<=5!MQW6F
M1$P][4SEG%I17((& A40MSE6GG^)3+"5QY@4H!EMH^\/=\>W<._VP]X?F'MF
M-UQ_X0WSD)K"S[M@+\I#V%O99]2C,9*(.1W<YB$41D?EMQ8?E9$M=<O[ HLW
M1<E92:;24;+K*J"DF(A;YPVY+GWO2GL!<TBPNYM<+%K^QZ\Y1!@\7=M%56!+
M(C'F$#((R#IJNVEFB9?")GT7C+Q(U5C3N,/I!N%W*D3(^VP5UB=VL;/:]*?6
MMA4:? D%#DNL96RXOM?AM!F9':D);D2HKS\I*5,H2M7EQK-I,<6ZBR9,<6ST
MBRJEE390\RLA3L=!03[[2>UU"5@..-*6X!VIY,(^*'_R!=3;F!Q^.<K2M;IC
M(S>M*:E(*;4[\[@DU)-V1 *0B8E):K(T."91 R==3()C B7QF_P6_P#,4O\
M_P M[T_>W;<A)U#4S:1YB\%>6+8ZC.+)=C:4V ^3(!$DJ]/NE ;F=*B)$Q#Y
M#LUT5[+&#N6/2[' $@[3=X,%]/1KI/R _I[>WLGYE$!*?PVY;B^91#W"4W;R
M*(>X2B A[AR=UH>P;VK73[HICO$B&@'P*R_EZ?=Q0@<DA#<B7.BI'P'LQ2/*
M2!VM^D%_XB>Z']4D?G%;]TC9J[Q\_IN[ATRDU_3Z[+WN@&1*JZ;6[AU7DK^M
MTN'PL%4Q<8QERY0V,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&48]>SDWS9XR<+[Y<.)6M8YPP2BZHXNV_FN\6&O[MI=ZMNS4\%!M*QK
M5YKFW&V4CL!I,RU6FG1)^L$JT8_<R*@2OB5DK8?PZHK^(I$[LB_\/='\.=[[
M2GGKK;U-TO8Z=L-.PFJ\I,1E(F[5M>J:VU:M?I-:NO3OVYYJMD=U[Y7>1*:R
MA?555H.ZI)^KF'-#92?'=/J#*Z\6U=J(G&T.(C?0*_'<NO"QM@5YS'W\.U"'
MDT.51(9-$W#E9D)%BW8*N$$?U320#.SHG)<EDZIR>#9)>=J/&,-LU$G#]MU-
M <?SUTZ^37,6.YE=A#,%):2T%;:1W/T*DK03Y5)#)R1TEEHY5KXL9>)E$_+[
M4E0VQS%4I.C+'M*W\Q9*Z<:=BVO<3O8\DSU;TWM&Z]G:^]<L8=M%NHN&8V[D
MG Q&PRU;0[QC;+-O.P7">LVT%HK0U5CEHF]CX_'(G73@=PEV-LA]N/8'$;C9
M=MLR<S"V*2V9:]*:\L%]D)^MMXMI79I];92ON9UW*032$AFD._7?*.8QK$QK
M9DJBBR;$38RG'2;YP38W$KD@VGK0/*C>?5=YR\>-[M%+;<)![(Z0I;_FM'-]
M+SU(>S\A&M]?Z2IFE-&SU-(2,9Q]1=PT?<8\S)Q>[ >QVW<D]Q<IZ#+C"Z5X
M?_1\J3ND+24G=/YPFMM4_)4ZL:9;NJ_\V;?%/95][&P;,)/Y7;K%8K_*'L9$
MP69.!-[!#\9N/%?W)/<AX+1^J8?>MG8*QEAV]&T*LLMBS+)PV8LG:4C;F\:G
M-.3OV,7$1\DX.[%U)Q\-#,)!=TSB(U!KZW/?627_ !7(_L2^,9!_I7B8>FAT
M_3&+X'-PRXTF.3N!O YM05(3I^0>XW@81)Y![C=O(/<(9/4?A_B7_,,@9TLO
M[-/@!^1KQL_='5,GH/\ ?]CW_FQ@>"#]V8"N_P!= -\;U.*Z $)NC:I#G]9+
MP3.%]GRB10_GXD.!O<)#"!@$0 0[B'>XWCOLQQ4^E0RI5;6%Q;MS[PV!KB!;
M,E@.NNS?V)FXGRI"D80,#IDFE!* '?L><2*( )NX2<:TNI;8ZR-DC!J=9<5;
M0^@@=S$:$##&B']JM#1NNI(2C+V(&LA)G6V0=473Y-P[%U'E5]0/9R>'KKJ
M@]Q=06KT>M0\1':SXJU]>T24;"1S2-A1V!+JM'Q_^$:(-F0/S3+NNE5$J(J*
M'JKX#"8Q#G+T\8TV=4O;#)@VZ%S-JV&SZ:5K;<12'2;*=&-S;-N>T+[&ZRNB
MW*NT-K(<AI<+B>X)'I!].'Z3<3<NAG2WHM'U.74W>QZWTOWIRT7=LRD5D>SH
M;F.Q5KA(K8[CS[FOS(E_[:)#2&D2D1?95E ?<L1TEK=EJ+4U ULQ*3PJ59CH
MQVH0WF1U+BF+J=? /VW\TYD'@_'_ .F[ /8 R"7,#5MKTO?8SFKHUD 3U:%-
M#<M5;@<C&W5(Y46SV:?-T0$3E*S1096-9-,ZK=)O$VI,I7, \5<6@9\'+9N\
M;KM':"+IJZ15;N6SE(B[=PW73,DL@NBH4R:R*R1SIJI*%,11,QB'*)3" ]E;
M[3Z^XUUBACJ56*JT0W->GQDCVBCGU:$IJYL0^/>C=B6W&^4ID1E/1G#Z;JL\
MS9E8Q*A(AH)8,<-&$\V!ZD-Z. ([S1^1;X *? 6V5MJ]U9RBKJK\B=7[.X1Z
MV?PT?*3(;:NT;(TJ5:.F""M"N%&;GDYAG9V:ZGM(NDHY>=K3E!AY*ING*3Y(
M56)TE3].Z:744KZHZ>XG2.O+:\N%JLMN([OYIJ"-"&?R86"YN'J[ Y@F%16]
ME615[$!0SIQZHB*??M$_JH\>+)QYD*U"5@\BOHB[7N:NM.BDO6>,:M;35WY/
MFH!0HD45:+HQ@HEB5Q,!92!1:-USN'L NH6'/!6WU_5O+GC]L#8#XU5I4;=G
M;>1LTNU=M(9D,G6IZ#06</U42-B-6\A)LRR+GU#)1K8ZCQZ*+5!95/K&_N>T
MP^JM9)N&8]+:QQ3ZQ>_FF##<KU3H1L9K#KR.! L%#V^)*<[7XT1]MCU4ALD^
MO/07H;T_ZJ_03:N-IU^3:[_K$7KCL>K1(=O:B8UM0:D5;*JNMA2VURXMJG3M
M;?;J3&=8DOL(<,=R1(D+>S@P'N #]L.^,^2"R3A%)=!1-9%9--5)5(Y5$E4U
M" =-1-0@F(HF<ABG(<AC$.0Q3$,)1 1^G</[_P P_P ,[E?'X9Y,D$$@^"#P
M0?B#SQQ_CSXS7&:=^_V_S"'^89KC/F,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&8;/4/W?P#V+U5>4.G.KSLGD3&<>M!Z7XML>)VJ==%Y<H:
MRL=UV-5KC>-Y[%FVW$ZOJOWMOB%)2@5^+D+A-(D3CRNX]BF_0:J-8VPOH&;?
MHUS2YXZJX[;4W!M[A+I;D1K]EP_L6\$]IGNM>U_?-$TRU7C7;![NB'@ME*4F
MC;2):HJGLK1'^VL8\RBB3Q^R?-7:WM%=YEV1KUB>36DM]\F*7HG2NCN,6CI'
M07'RX+4RE(<BWNYP?V'97(A*Y6]>.F[ .H[#3QU$VKE7?NX>(^5)%_,,63]S
M[3(_OZ1G);;6ZKCU!-5VS?L?R_U!QHY4MJ!H7EA&Q=6:H;!K]QUU [*M^LG4
MQ1SDJ=KE-!6BQ&H+JS131()!L=D19=?T446;&728QC&,9Q,]]9)?\5R/[$OG
M+9Q,]]9)?\5R/[$OC&0AZ67]FGP _(UXV?NCJF3S-V[" _ ?=^<>W_QR!G2R
M_LT^ 'Y&O&S]T=4R4^Z;NGK74.T-@JKD;EI.OKC:2JG$ *5:#K\A(-@#N)0$
MQW*"*9"B(>1SE+W 1[YQ/O-QF'I#JNUIAIQYQ7_*VT@K6H_@$I).9E?!DVD^
M#6PFR[,L9D:#$:3R5.R9;R([#:0 22MUQ"1P">3X!RG[@A=H9;:O4TYAS9S*
MP+?8TC"P[DYR!Z\!2/G%*I,D' D\1.]9)U-DV3(80.H= HE,84S#+/IN4N4#
M6%RWE:P,M<-^W>8MCMVL(G6-",9&0;QY/(X>94UYAS8'R0%'Q.T78CW$I$P+
M_.]VQRMY NI6=H,3MG8U2H$'<Y>3;4:L6Z>K5>6LJ:[=D_M$Q%Q+M@C-6%\K
M%H*A(S:;]9@D1%I'>RMD_3-G^=$_D=:N3?3MTG<KPW;%MM1-:-33,DS9-8YI
M81UK-K0,582,F2*#9!Y)P(11YKT$R)+SR<HZ2(D1<J9)&7]&G<-&U7IEU-V2
MTJ),)ZLLICU'$$@SJO:=]6N[]JD2%H$:8F/4F96+4PH&/*D/(:,F.XE]/WK'
MUFU;JK])G?:O6VIZ:'0VV-+U>1+;2VBPK= JZ;I^Q.;8!*XK3T2B3(B-/ .K
M9F.N/H8>[F1;#C&,P\PL@UU$[72ZSQ>NK6VQ\=+/+2XC*W36+XP$.E;G+CVQ
MC--%B'(NV<5MDSD)P%D3%!0K,6"YA;OE4E*NN%$7KKD?0]K<--OI!(5VWM5-
M@Z[D$U&YI>JVR,2393DC5':Z3DL?-M4%(V<;%(0&SM!"P-'Z+EC(O6ZN0-8Z
M;4;BBU;VZK5RTMV2QW#-"QP<7.(M%U4Q146:I2C5T1NJHD/I'42*0YT_J#&$
MONRLWFEJA+14_K#ESI>IPT,\U1-LX^_5^ BF,3&2M3E'"C CY5A'-6S9-00D
MW];D7Y0*X*TG(]V<X$AB&+0'4G5K:+M47J:7X4R@H:QFJO*!%>MR7-UB4\\W
ML#[[P64RQ$BS7YS<52 AM$)#C9#H4'((S-@U;::;J!K]J_5V&L2(4N)(KB['
ML8GLTGUUSV)32POUH:B)321P$^@"//<%>)<4M_;%X3;99<%.7$@=6G.5DF/&
MC=;IN="$F8-5Z#.(K4I(*++%;1*JJ[6.BP>+K.Z3-J!59AR>!=UF1)V3J&<0
M=!U+6DUN&O5>P1NPKAO;424].H[+V:=-TEL?<%<B+DDE#K6Y2$8I2T?,2#<$
MF,<W+&@L4T6#(R*0EFUOG1&F.?''V.8RAD7$=8H1.U:ROK1JFK.4N:D8_P#X
M.69%%0AU$^XA'6FN+KD;2[5%S&/ 1=(-73/'AWAS(Y :MUY*<%]XP,!?+1I7
M9VOG26ST[3*+2<E#:XM-<V!5XMX5>.<FF4I*/9L&3>>>.F4RSB'B#:7CGDQ&
MKN77ZV>5!U?7Y55?!JYUJ9725Z+?OL?6;T&2_#6J+3OO!M]P+;:(=J+1! <A
M-EM]T+CA:O3[H>Q:==NH.K]2.D<YS5.H\>^UV9U[T2BMTZQ2[AK;5Q"<G=1Z
M%EN9!KY-=9.*0C<=245I9NYS4ZJANQ;4L-9+^C^+ND^.KBRNM1U:2K:MM+'(
MSGM]VO5M(Y2AEI!2-(BG<;)/$8^SFD7?D=B#=1P"A2NCK BCX2$RO7I]\V)K
MFI5MDV*9U[%Z^/1;7$U]NSC+(\LA9%*5@PFC.5EW</#"W40.?V<J::*I%"AZ
M@F(/U 6%9<.MRZ2?2P9FNHCHIGTNKAIBQ#!8X#[J7BB*IEA37<^ETJY:05*)
M7P>[D]'^JE'U UK?=@H>J3]E(WRL=A1[]VWNT;%8>H:R$]!0_<MSK)N:&ZQV
M$AHHFOI992W'"D^EV)8QC)S*^QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8S'$_E'MTU5K_BBM;[IT\0Y=W*O,(N1HFYK3HS5NU=2:!4>;:UA69R-V
M%.VR^5&]5H^QH>Q/HJK,*7'3S.6L23!2?38M6IG:=O\ P9^AT3C?2VFJ>(UR
MX.T6.>V>-@^.-]UUKG5EFIJ,?87[160>TW5=IN5-9)6M9(]C:/65BD7<LVD"
M2,FH5\NL0M./5.ZM\'1.1J_3!@.,>BKE?=@U"M65SLSJ,[%IFCN##U)T,';:
MVA%N[*UFY;>\_#6((%-2DUE"ORR=N8%:PKU[)Q"HH3&Z)VT.5_)7AM4^8W*W
M?4'M2>Y8,XK:U)UK3M20>K:+QYJA0E*^.N*RX8S=@L%Z(^D(U:R2-KM\B>:,
MZ>EC"@HV9)N7#&7"8QC&,9Q,]]9)?\5R/[$OG+9Q,]]9)?\ %<C^Q+XQD(>E
ME_9I\ /R->-G[HZIG4>K->PHW!?<!$U/3>W7YL4!@ &\3JC9+%'C)(IAV$3G
M4@F$L'B'O GF?_T<[=TLO[-/@!^1KQL_='5,BYU:#%OUBX3\<_:?!KMGD3%R
M4^F!^P(UZN'BH5^[<%^P@W9W"1=^J;L1,C%=01 $Q'-/WZ2Y&TZ_]'_:)<$U
M<;CX^TW#K=5'[?C[P>F((X\\CG+S^C15Q+7KOTS-@D*K*/8F]RMN?T!4:'%D
M[I:EP_ -_5]#("^>!VDCY\'"ZZD_&1IJCD7L^OZ\9NY<=0:&T3LOD(NFT:1S
M*LW?9C"F,7K5NU;&73\C2=[I#-^NL8'<C/24O*NT$C&<$S^@'TZM'4?CQPTT
M3K76LLI/41*F,KA69AW%LHR6DH_8X!?S/)L[!PX;R<NX=6-PJ[E2F3]L Z8%
M02313+F,CH'4ZW-WBEU^N8[AH=V;?5EOD3JMRY\CB-6T$HONF%CVAQ#R4)[$
MWUS&)"0W@"\"F02F]/L7(3Z-^TAV]TS.']H5>IO7L3JAGKN0.4P&42>:KEI7
M7(I.  1\5_9:RT5, ^\2JD4[=CAG;SJBAYCIMIFJIG6+R.ELRHTZ<V]9V$E$
MF7-TBFFMNST/R74RY-9-@WU7!>EAUZ%&0^Q&6VAY_P!3I!IBV[3J5MV[2(Z$
M3>HZ=AW!E8YY91*W&P,QMKWN%(F(DUDYSPKWUI4GL20G+-,8QG7/+LQG VFM
M0MRKDY4[&P1E(&QQ3^%F(]P4#).XZ2;*-72)NX?4F,DJ84U"]CI*@14ABG(4
MP<]C/PXVV\VXRZA#K3J%MNMN)"T.-K24K0M"@4J0M)*5)4"% D$$'/BDI4DI
M4 I*@4J2H I4DC@@@^""/!!\$>#E6_":RS>D-I;,X57U^LY5K#Y_;]22;DP^
M$Q5)#QD7C)H B8?)=HY2LB;9+R(D^^=C<#%]A N45=0_2^]Y3EIO[8#C2FQV
MU2F-@1;&'LS.JSTI5I5):'KM>KRT?9$(Q.+=KV!5%J5!DBJ=5O*.CPGDN\:G
M$^0!U =9S[*)I?*/6Q#([(T%*-99X9!,QC2U)]N(N^1? F85'#.%<J++NT?
MQ/F]*V4J@"00 /W\C=F0.X>(5)V36E &,M6P]!2(-_5!16,??19J:$I#.C%
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M7%IW7CJ;IE8G78]ZWL6FDI#VB;Q7PMTTMYM(X*&]?V)F?$KE*!X]JIQ73D<
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MBTJ(:1\3X,KY<<_,OR.^C=:GNJ^MF]ZT5 D1]UZ0-R&FSP2 Y8:;O-^ZH \
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MMDUW_)^NG56TG(MG]YXX\:SD$IQ**C6M:$AA)W ![F*C/3M><]@]X'13$1
MRYCHJZ-'0W34XQ0#R/,PG[Q3W&Y+("A?!=:2VY*.[LP]H()2F*JSK$E78P0-
MW$I&!"^X"@ 8NW-YQ,[RXY="'AC6W)UY38_$SB8R,Q;B8ZC=?:<%1:F1PJF
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M4!#S0("7ID-[C$.01)G0W'2WXY@?U8:;VU6E ,0Q1A[NW$"=B"FH!#/H)VJ
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MH-VYC HCZ:OF):1('*FB8 ,BD1U_2'$5A],1,F;X%6ZI=?["9IQ]O )E1.)
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M,GW1?T@_CCS)]T7](/XXQF[&;?,GW1?T@_CCS)]T7](/XXQFH@ _$ '\(=\
M !\  /P  9IYD^Z+^D'\<>9/NB_I!_'&,U\0^/O_ $C?Y=^V<<]AXF2)X2,9
M'OR=SCXO635V7NH3TSCV<)*AW.01(8>WU1/J3=R^[.0\R?=%_2#^./,GW1?T
M@_CGY4A"P4K0E:3\0I(4#_B""#\!_P!L^$ C@@$'X@CD'_(YYA):0TS,]QE]
M3:UDQ'TNYGU%J[DY@0[^B G4BC'$J7<0(7R\2@(@ =A$,\RE>&'%B9\P>Z,U
M\3S*H0QHZ(-#'[*J>H<2J1#EB<A_+^JH02J$)W3(8J8B3).>9/NB_I!_''F3
M[HOZ0?QR&E:UKLX<3:"EF _'VJK@R.?//GU6%\^?)Y^)^.8SD&$[^MAQ7?\
MVD=E?_W(.0<E^G%Q"EA,8NKCQ9S'4.)HBVV]H "=/TRE*DI-.42$3'^D3(5(
M"@I[S <HB7.AN.EQQR X*0TSMBM*@)!*>'O"7<@E*)%3$%]!NU .X(/BJ85!
M "_4IE(7N4;'_,GW1?T@_CCS)]T7](/XYK\CIAT[DJ[G-*UI*N2>^/4PXB^3
MQY"XK3*P1QR"% @\GX^<PET%(L\FJ@ _>B,TT?\ NVE!Y_'X_/*S Z<:\0(#
M2N5'(.KF3*3T &P^V(HG;J>3(?29/(03)-4^Z9$BF)W-V,4Z9>Z8_13AORIA
M@[57G;L50A?6(FC981[) 5(W]*3R47M$D4RQE_<=4&Y3$1$2I=RB9(UE_F3[
MHOZ0?QQYD^Z+^D'\<Q?LITA (BU]E7?#CZKV79JX)X//"40[=EL#GR1V<$^?
MCQQQ_D]5#]6R^Q]WL\^P8X\@^ U*0GXC[N,J8V17NH!HRAVG8TORHUY.5JH1
MBDU()3-+:%?/.Q4VQ(YFF:GN 5=NWBC5G%-32"!7;]RF!U&X'-WCQTW>0LRV
MWS=:==Y99Z;>SE_91>O!(7U=EL#/)190  H(H'GXA62;>FD":0JQ44T3*(%0
M(%MO*.QZ!INC+[>>3;B ;:4HT:E;+FZL:;QU%MT8ETB>-_X".$SZ5DG$LJR9
MPD.Q1=/Y69<L&#!HY>KMTAI@X0]0OI%<J>0==U1J34,YJG;?RD>5U<^V726E
M7;7"=KH*S";>I3$'=+,BRLB+-@XEF$-8BPKV00:K(,".WZ9V!HO[!^IT[8*G
M>-%E75AJ&DK$FZ3>7&SWJ&E/AUNW2ER2W8,QFU4K@02EU2F$J,J0&V@E9U*U
M,6JV2@C_ )218C[ZP8=9;6LM^5-4XI3#P80\74H2\US'9)4/4?[DH[ECMR[;
M?6ES;VI;2FDVQNG3OLM@83_SJT1?1UU<W(,6DBU^174\$1-"M //E '+Z-]D
M)[0Z91ZX+D%KXJ5O:7Y#M>(%\ZA,!R?Y/;!MO';B_+\4Y. V1OA6#L]FH;'>
M]&9,7\/)V>AT*OS,]7UKRX@P8O;!'34K%&DGSN2FSL#.%6UJ]\V5KO5L&2S[
M+OE,U[7%'[:+3G[S:H&HPBDD\(LHTCR2UAD(V/.^=)MW!VS0K@7"Y$%C))G*
MDH)<<SD+0Y_G,EUF]=\2;-4]EVV[V;I?-ZA8:5<*+.0C.3H;V@WZR/T9Q[,&
MIKJ1I];@WUD4@Y.1\9$S)M%G;KJ2;9NXMG+(RW)UU+N(B=#4NC&\6R5EU-JR
MVB8C3S;46V6/(NP[KAZLUO*^K(7CQ/4N&W"M;5J-(Q5\0(]J+"&)KV7C-AOI
MAE2'9)_(T[9ZJ=KUFYO5B6XLS$=K+C=7^/%EYFKWW;=3KFV-'L^2=B.RK,/4
M:'3H795%VI:]>TQ:)V5M:,-N"EQ$?79R/AJ-8+U:R/XIGREVZ;6S=@TO;K:X
M;QT-==D<A]Z,-R;LGMD</OGSK5ZA2M55C3.J:_J?6:O(:%G]22E)J-+@97Z(
MJ.TK5?W5N<STM$3=<:NXF.A.BO>D;:I>(DZ18>5;ZRZYWA0^-M)YH0]AUA(6
M.V[W_FPSCA[4IBD;!MNW;/8M8O[W5@B-:[3>W=7><Y-TNNQ*]<GJQ<0=VAPQ
MDE>8/.>[:"NLIK;3&C8K>MZH7''8O+G:\18=L)ZB9P&C=<3:5=6:U&2&A[!^
M=6U[O+HSS:A569:TVE+DJ\RO;-CU8AXPK[Q6G=62/V#=M:6NG:=;2W#G9_)'
M7G$*#W^ILU!IL0-Y[0UK"WNK.BZ/&EK1CC5'SCL</J:6M9=MIW1E?57SQOKE
M[2V'SC<=NWIT^-S[>LLML.+Y91U0V9>]1;^XN[2M!M PTU'3_%O<NSY&_5.J
M5:M%V/%-:ON#2,1(+5*B[9EWUOK<Z5_.3U[U1//I)NVC^N47I006N+_2X&J[
M=!EP_P!?\CJ-R\JO')773%>V1>^==:W@J#5DT-T#:B)%U(TF*Y%[46I1=9A<
M%]CIKG'91*<Y6JAF,DCQ3YE6#D3;.8-0N.BK'HZ:XH[EAM8N("QW*JW&RV>&
MLFD-<[RK]EE&]-4?5FK2\A7MB,&ZU4CK9<21ATD@>6$9 [V,CXK?3'=I,:8:
MQRM5U29Z3@_QEYGHQ<7+SSJP.HS:NR&D5L:I2-9<NF@P01-4?(1-.F4I><25
ML)D+#.@5@[2JR,I>+?$_:>A]X<K]QWK>--V@GRNOU2V=8*U7])2.M3U.WTG5
MFN]+0?R/-N=S;#!] GH&M80).,?0Y7[JTKOYMK-,(U1*NI2!7T1H2"I:5>>:
MZH,92:W#PC?T7\5&MXZ+KE&FXRY0K)U).P*NE7:Y+UV*F$(]Z^&&9EB&@*MP
M9-"(D8R,?,HWER(Z6X]NW_SX;V7]'@+S8+W_ ,>W?+""$(41,!2@8_B)S
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MDIF;U$WJQZB[;9[1/AQ*Y$D1HU=7Q2MTPZZ)&;:::E2UALSI:W_:)#LH1XR
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M2_(;6_\ T]C_ #!L/X?O7\!F/,ZZ1'42%RN++KA\I4V@JG%L1Y3YE9T5#O\
M4%<*MMS-FZBP!_7.B@BF8?>5,N?#Z4/U'/OXW)S]2K!_K9F1!C.<=5=Q  ]3
M7#P /.C:.2>./B3KI))X\D_'D_?G >GVLDD^E<>3SXVC9P/B#X N. / X \
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MY%T?\/X=_#^I^_'V?:S^RN?E_:C9_EQ^^/[H_KF._P#2A^HY]_&Y.?J58/\
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M :#T3'6FY5!=09*FRM\G-06"WQU7GD&=GCJQ*P"EH81,\Z?0L;8%F@  !V
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I8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g212626.jpg
<DESCRIPTION>G212626.JPG
<TEXT>
begin 644 g212626.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]'3$E/34%?5%5-7S1#7TQ)3D4N15!3_]L
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M+IX8L"GE4FL:=HC(9'^3UJT4J!9*1LJ-WTA=Y4G,(,C*.,'RA,48(1+PY(=
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ME-'4I1/,MS2?GFBS[:J:16V\]&VA V%$^RB6V"O9[5KT5;5(ZFN\9:XFTPY
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MK5?(&MRALIBTT99H8?"X,OA>F5FJU"C1*8BQ$"FIL@$G 0M6-"=.>:D((MW
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M .K<LKA#KTW\1?WP_P#G"U_SQ?9O.WLZ^T7\,?\ YLL+^$OC/_!A?_I]H?\
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M0MW]+3HT2TS7O6B4N"8'H4N)U[LPX!^M^HA%Z!L A3W.8=?5Z[XB_P#DU?\
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MEL[?&F)1V1*1E-SL_+T[<C.-.%O0?EH1Y'N"['K&W[H@W7W/,GJF@ENF^YK
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MP"+4MJY42((@"#O0_00=Z^&4""O%9Y4H+QA9,U8JDD[UV31'2L4XKYV,)*3
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MMZW^WK?IO_7K+/\ +?&7>)U<?/M<OG<X-O%H7A/.OZ6@-VY+0HML0R2W]G7
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M5-"8=F-?UXPJG  DI%;6A777*=DP!OM:O>EZ G-7NTR;*[:K&B-QUW(8*Y6
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MI^=X.R02QI#0@C3 *4R=0X]+J" G%[4B:QA*4IG*VOKU]->OQWZ:]?V_RY2
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M$-.E+"5*Y$R)BCSU+PPQPQP"\O#4G)2J33W%M0JD1)2<\PP\("31 AI^Z/\
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M,U'DC,H8O?=ADY=<:F=G=#J4Z54"D,(*T%J2.*(3E.20F &86<S(G9ON3O\
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MMYB&1/+* M*K7 +5G ,);"SQ". $6C31@UZ@"'>]CLT'\7W^ ;SI_P!%W_\
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M\B9K+D3,T[1K]J%;?$EB\I2L C.-86I6XR,GW1K. \N4G.-ZT+7IO7KK[/\
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M^/"162;N5KMIRC%V]IP*=\,,KC%G:6.3XX:N21T'75AN3G4MBN%>'G/L]C,
MC?UZI"5*7UH<%B-V< @N(:^6OAZ?#7P^S\W^;Y81<XQC")D&?W1_^M ]'?OC
M<>?[Z'/^3F9!G]T?_K0/1W[XW'G^^AS_ (13E!^6_P!T/^6+.V=0_+?[H?\
M+%G;")C&,(F,8PB8QC")C&,(F,8PBK2>7+]=G\)?[\+]_P#[%JO++(/[P/[D
M/^S65IO+E^NS^$OY_P#UA?OR;_\ ZBU7_L_+]FOCO++(/[P/[D/^S66;VO\
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M8>>'B3IZ.;JKU38I,7 5[(33B\KID+ZAC222%S$X%FI9 G$B^DARU4DA[O\
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M:.'UL[2Y##FPV4-#&Z+4X*_)(.2 1&E/ $BG98#)._QE_D.U\?Q%_8?K]O\
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M6M:]=[W\/EK6O7?V:^.>-+/H9L109U&G0@(WE*&E6AJQ%*XB!2%' $8/(0@
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MIJC87^#L,HL!]O/F!V:XZ=8,XCU?1X]6W1:9OC\J JDTG:$ 0H&M1L)BH U
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MV\6@?8T_^O/9B4NJP'+\OC['#%Q:2437[Y*[.K]M<TJN1K8U'/YY^1/(A#^
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ME^+V\P'[/O9/\71Q;_0,?B]O,!^S[V3_ !='%O\ 0,G-QA%!COQZ^8#TW_\
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M%4_CK[0$_<(#UO+YWS WTY87D8YBF'4]$T/:%1V72?*%<P+F7H>"<PF]-RV
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$$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g831763.jpg
<DESCRIPTION>G831763.JPG
<TEXT>
begin 644 g831763.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ]1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]47U!%4D-?-$-?3$E.12Y%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" #] ;$# 2(  A$! Q$!_\0 'P !  (" @,! 0            D* 0@"!P0%
M!@L#_\0 71    8" 0(!! H*$ (%# ,   $#! 4& @<("1$A"A(5,1,4&E%8
M@927T]<6&#(Y055XEK&W%QDB4E1666%Q<G:1DK.XT:'6(S<X0L$H1D=38FB5
MHK+4V/"TMN'_Q  < 0$  P # 0$             !08' 0,(! +_Q !,$0 !
M! $" P,&!@T)"0       0(#! 4&$0<2$Q0A8146(C%QH2-1EI?A\ @7)B@R
M5E=F9Y&EIM8D05159&6!U?$8)S1"4I.4P=?_V@ , P$  A$#$0 _ +_
M       ?_O\ > P?J^/']) #6_2G+[C5R,ON[=8:1W%3MD7[CA:\*/O"K5MT
M\7E-;6Q24L<+A!V1-RQ:I(/LI2HV1B6+59VG[8AWN)JD6&.6>R(J">3FF9]3
M_P H[[F9_P#EO,/69G_Z:>7)?H(B_H(B_ +?8
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M'J\FN!<6^S>F_P ;:S_\?B?_ +P!!?\ M(]%_P#7J?/OR$_^_  3\
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M*<'+UQMW%K61Z9&U86Y;]WA8*U!0NC[1 \;]#;CT;J%SI:^M9GMLMYOV5O\
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MALQ6O4H+MC'3SP7,)D,E4<D5ZI9JR,69LC)H9&N8FVX  $N44
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MLJ4GJ]R/:][+K7=)[-G3UHT?W*U5:J*LZX#!&1^HR/\ H/O^@9&$&B@
M                       !1$\IG^_-=$K^W>L/]7>OQ>X3^Y/^NI_F9"B/
MY3/]^:Z)7]N]8?ZN]?B]PG]R?]=3_,R ',                         1
M"=:6=HV7%W7NH[9Q1T9S+L/)?D=K7CUJ?37(/9,+JBA9;2O4)>'L#;<+G(L'
MTTPGJ[&0,YA$MZ)G&WQ^I)J,JW*LG"ZAJ]9]&SIN<KN \3LY;D%RA1N%2O\
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M'445R[#0?C,Q0FGBGFA=D*;:\4C:Z1+*C'I-)NYO59W;>I47U*3!@ "BEA
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MXA;:T%M!YM<G$VY?(5J?<Z9J=?5P@8UCE]D<4^?N7,6[=.,CCL#5-3-,"=<
M  8,C,O ^W^W?Q+P\2[EX=R]7K\>W80P'PSYV[DM'&_6_++:/'V^:1XN<F67
M)=INVGQ4W#[]Y!O]?O;@YTO2[?J!K0:]I[2F,25LP0VY::3<+QALJ/@<8N#K
M-,;6VPJ,YH  $'7'7IW\HJ2[X.:&W#;=%3?$KIMWNQ7O15FJC[8#[=^Z%J[K
MS8>GN-T3L^GS-<BJ+K3'3NNMG3:MNDZ]<MD9[(ND!5)F"9:\C4I.,7DRY/\
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M[UA_J[U^+W"?W)_UU/\ ,R%$?RF?[\UT2O[=ZP_U=Z_%[A/[D_ZZG^9D .8
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MP+1KRWSUB<[^W7=*/!PE.D;LC /HS7]579>VI4ZJ@HSE466,>U6DP)XP
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M='NUX^.FX55UDU)!=[DS7<-5+8!$1%V+WS/XS,S,_C,S/WO>\!724,@
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M^/']) "H)Y.;]\_\H\_+>8?KJY="WX*@?DYOWS_RCS\MYA^NKET+?@
M                            #Q5F+-PX;.EVK=9RRR5R9N%44U%VF2Z?
ML*V35;/$U&^2R1^QJY(9)FJG^XS/+#P'E &ZIZEV]:?X*FRI_BG<O@%1%]:;
M^I>_XT7=%_P7O3Q./F8?O<?\)?[!YF'[W'_"7^PY !QLGQ)]?]$_4<?,P_>X
M_P"$O]@\S#][C_A+_8<@ ;)\2?7_ $3]1Q\S#][C_A+_ &#S,/WN/^$O]AR
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M%0/R<W[Y_P"4>?EO,/UU<NA;\
M
M  &#]7QX_I("RQ,^Q9$9^/@1EW\/7X?S?A]X#]7QX_I( 5!/)S?OG_E'GY;S
M#]=7+H6_!4#\G-^^?^4>?EO,/UU<NA;\
M
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M8\Y^R!C2SU^4KC?[U-7/%K]C&5IN)LSBL98H[)?T\Y)]DW-V230E2;)R1@
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M&+PE":QBUDC*DTGHATZE2SR\S#+,RR,L<3R,L<,U,NQ%W/S<$RRSSR[$?;#
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M^H66'9ZR?V642HN=Y+:2-,DD5(F1LQX8^;ACB9]_-QQQ[^_V(B[@#D
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MPKVWX&WRMBL&U(^4U*[LFO$]>5RJ/;%.0]F6BZRG8D
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M( R XEEB9]B/^@^QD1_T9&78_B,QR  .Q=^_;Q]7?\/;W@  8+'$O41%X=O
MB+P]?8O>+OX]O5W[GZS&0             !@L<2/N1$1^/CV]_U]O>[GXGV]
M9^L9  8+'$O$B(O67@1%X&?<R+WB,_$R]_Q]8R
M                                              "/WJPD9]+SJ+EC
M]T?!SE46/8^Q^=EI&ZECV/\  9F9$1^^*IMQY5\;.;' +H,\*.(FPX'=7/#5
M>V>G#.*5_7L;-2EJXXLM*:_AV^\[W>;&G756M.K5/;HIL+1B<JB;Y5$G"#>4
M2@E$Q>L>,VL@T<L'S9N\9/6ZS5VT=H).6KILX3R27;N&Z^"B*Z"R>>2:J*N&
M::F&66&>.6)F1^B@Z;4JRHLK7*Q7H%1RFFDX4A82+B<UTDLLLDDE\XYHVR62
M3RRRRP35//##(SRQQ+(^X H5\F>=$\7/F.VEI'D#NVG[#JO6KUWQQN&O]T=0
M*[R&T7>HF-_CJ'?J-7.G%1M;UC4&LN%<F2Z;*N[-VC:+!L2Q2\H@@Y?NK%(N
M\V&ZU6VAS!+J)1/1/>;JY'*/*+U)9_G6_P!XJ;!V!(6B4Z7C"A-=UTK2,ULU
MU/.;5.P$KN"<;Z&GF^<ADU4:-TZR;)*+P-L=NY36^OU9:;GU*14,YRRYPZEB
MF<ZQ YRL_E7E<5H(YJ2SCS>RIPZF)9Q63]=QE&YD6;$V^>..1:1<9>G51^/G
M)_?_ #$LFY-T<A>0.^8&)H!7/<TK4W:>K=+U^Q2%FK^FM91E1J=6;Q509RKQ
MNZDEY;*9F)UW$QLC(OLY+*4=R0%5#IW<M+U4NH[QIB+MRGN7-2W[YY+<C=?S
M6P] <V=R-K3),WK^\$A$<RNE7R-HB;K06O=/M6&?H:1UG6M11]-PK<9(PUIM
M\6ABE-7O\#[XXGX^.)'X^OQ+\/8B+O[_ (%_0/D(_7E#BK7*WN,I=3CKM.MD
M64W;V-;A&=IF&;<SR0:2MB;,$IF2;(Y&>22#UZNDF9F>.!&8^Q
E                                              '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g333345.jpg
<DESCRIPTION>G333345.JPG
<TEXT>
begin 644 g333345.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]'3$E/7T]615\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( ,X"J@,!(@ "$0$#$0'_Q  >  $  00# 0$             "08'" H!
M @4$ __$ '00   %!  " P4+$PT(#0T!  ,$!08'  $"" D1$B$Q"A,4%5$6
M%QHW05AA<7:QLQ@B.#E55W)T>(&4EIBUN+G3U=<9)#(U=Y&3E:&RM+?2(S-"
M5M'4UO E)R@I*E)B:&F2IZBV)D5&2%-496:"P<+%X?'_Q  < 0$  @,! 0$
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MU%WQ(L'V^K^*UE/$%*'/%RVEJ*4<[UGEW@\2,E\^0@65K 71I2J(DJ2F##C
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MCK7J.V4-Y[-3A&D%M1S+_F5;[@DYU)S325AQ^+#JS9%3SBD(&$94?%2:?/\
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MZ>,/G=,3[36S^:J>=/&'SNF)]IK9_-55_P!/'ESZ[]O9CE>_5VVO:UKWM?\
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M>W*_/J[+]+*V5O:RM?I<_+?GSOV7KFV-K<N7/JOS[;]=_9Z_CO\ ZN?7U]M
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M;)-,B@=\*W44X@<MA?HCE L\;]+9YO:U[7M>W.U^J]K]E[>2]?GWD+_V0?\
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MVQ=+ G)N@;$1\0DXG$<9K0/Q/.P3N173E$AAFC!)B0<6(H%9K"&B^2SQLTK
M+K7%5WRA/8BYW,@J &$3(XL<JRW&Q';)B,>(6_JBRGAH*PY92G4INQ8E%:5M
MRFU!3@?"LP7@EGT1GMXG .6R\8$;);D9;A#E0=#?]@W''MBB'D?O-#?$"FIY
M2;KLMO)EQB' &X\C;<1=!*"UK.<&:VRMZW 20Y&4KO%777!DR'F%-# A:1G
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MN9+XF \!A<,!K!V$PQ%$QQRQQSRM?[R)$DF$RR>G%"I @3!P+E"1(N"4*%@
M[=$,$N6+X!  !86ZL P@\,,;=6.-K5;#P\^NE*4 I2E *4I0"J*DGTO'U[D'
M']Z#E5K5%23Z7CZ]R#C^]!R@*=@WTI&%[GBOP@U77JU$&^E(PO<\5^$&JZ]
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M^UE>WM7OY;T!/.D]:6G7Y<N9 GU>3]:A=5>A7GI/[6)_TB3_ **%7H4 I2E
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M\P+[$:;E#90RYO%-^2,"[A$0_@V!U;' \)E=-!7<D\4]:P0W,K@-S!'MS"S
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M6T>:C\C:8M39AT-'!V*LBAN2%8SP;AFT.P::1<7BX<'\EK"R[5AZD$FS/,9
MWWTW&R?;YF$=X1>FP7&/%HB;AZ#0.)#![%YN>.)T7-?&F"^G%)QB1[&D*2X]
M<$Y@CD2"*VPFP;(-I43W$F+!]9)FF\!L*4KBW/E;GV]E^75;G;JOR[>KGV==
M<T I2E *4I0"E*4 I2E *4I0"J*DGTO'U[D'']Z#E5K5%23Z7CZ]R#C^]!R@
M*=@WTI&%[GBOP@U77JU$&^E(PO<\5^$&JZ] *4I0"E*4 I2E *L-.^MT6[%)
MS5+2$4=1)88:\:<K$?,<2$^XCDMDK"DAJ+76QFI),9.%K/1$+.)L+"HW7(FD
MUG!,7D@YD65"9G(N2%*WYI0%#QI&S%AV/V;%D9-E,9L?1\VTEI,]KHX8@:>B
M-]#*!D4T@7N.(.:'N$ %C<8V=,&3YXQD,=/FC1TP.8%KBE* 4JEGP]FC&K,=
MDB/]QHS.8S$;:V\'D['$? 2T!LM=N)QA77E];4C.6!=/24A,*&3Z@='SQ!*E
M0!1A<K887O6.L$;W:;[..<^R(!V7AF5WHF(EG,<9[-?2,INK!M=_#*YN0)N9
M#@+)MO@FQRQ0PMDB1E+*FC14L:- C&2^ H&6=+VM?M\MK_7M?G;^6U<=+&_J
MV[+W[?4MVW]FUO5OZGJTO>UNV_DZO5Z^?+J[>OE?]Z_DH##1Q:":R+\40]#9
M=I.MH-2 4XZB0\J1S+$K1S(;$;ZPD"MYRMM'E1E/)$D?)O.U &NDNQ&.N8V0
M<  "<94 !5-%1#Z;E PF(T(O9#1C>/F\F-)BL)M(;.9S712]BJ0W6PVTTLCH
M2*F%K99=Y(IB:3+%"P=\L\K!A8WSSS$OEGE]KJ=3;8[7<;V=ZXF-MHM!!6'0
MZ'(LG 2",@-UOIQE66UM5/CY8@$DQ*3"9H^?-C9XA%BI<483*V&&5[8MP;Q!
M-)=E7@%'L$;20E*3[,H!EU$6<T7ZC*#F5&R2\&\/<",B9C **TC)UCI')14D
MDN=*)X9\B*=% #.%LQ0,PZ5UZ6/_ !K=5K7[;=E^R_M7]2_9?U*\!<=K6; [
M=*N1R(* 9=SA :35+K2NGI8[E=)E.4U@LVT$$\8 $6%X=)15A4!2$_$PH")R
M4I'<2]RI$T*$!4-*Q'GS?33?5IT)S+V(V0B6&G0K(9!RIJ+(+K*MTX=0U54/
M(:8I%[&\+!9EU%83CJ61_NMA#:@!D4 #$&RPPSO-#LV11L$PTV3X6?K;DJ/U
M@VK$4QVM0_9213IQ!4C".L%P#=L [9BIRF4,D3>/1M<(P"('?KQYT!8^?=%H
M V3DIFR_)&$PITDQ^R73'30=D4;(;"04IHC.?"FEJ[Q1RV4+28PPL\7.=0D*
MZZ<'#%/J15#2$\T:$3T\L5P^98T&UE7Y&:4HK+4=JBYVK:*S!D Y+,KF&Q("
M_!M@/.;>\QLX5YYM::)"C08J5.M1_2@DNIV%%$@CJ)I6.G6^WATG,J^6-KWM
M?*UKV[>=[=7/LY^3GZGEY7Y=EZ=+'RV[;V]GG:W.]N7;SM;KO;MM;MH#FUN5
MN5O4^O?Z][]=[^6]^N_JTKCI6ZNNW7UVZ^?.WEMY;>SY.NJ2"?K+&?*A&83H
M1!) 2FFD/I29V*@!=Q$6<O+*VWD5S&4NV7A(**J+C;7DDBH9X6 ,'TA0+!Y7
M$+"6L!5U*XZ6/EMVVMV^K?LM[=^=N7EYVY<^=.ECRM?G;E>_*WLWZ^=O;MRO
MSMVVY7Y]EZ \=QMU!=[?7&HZD9+<;8<R.J-YQ-];(EE1%74);(CIBPC*Z8<#
M&)J*8J)QHR14")H$4L;*#C%QP\PA,\;X.MWAF:AMQK.]IALQ]+I1V-V/F:56
MWC.$V/-[1^RHA=MG[$#0AY^N=_JCRAYOQ2]\"[N8!2-UMMC(#E))JV&:'4$Q
M/'+9\WRQM:^5\K<K6Z5[\[<K6Y<^=[^3EU\ZHMIR0PGVI/M&9KN;[F58P>.4
M>R&GHBF74#;,>^+;;KQR:CC  RRS2U[%K.YL."Z:9MB8LDKR6=Z/>3@660%*
M0?!$:Z\,H1B1@D**>EGG$X7DX59PN1QO9Y/-[.Y0R574]7T^7DJKCM>3L<!_
M*PJBNN%8/G+@ DTXMD62DY.(%+PU;:0)CBF*B"VI21(S+8Y1N1\]Y86\W,Y$
MI(%38SC4!/,R"_C)4T9P.8M%E JR3FZ%_ OFFHGC1.P4#  AXI@-7B>HD%4B
M34DXV7.D% J6.DCA87$4N:*'0 S)0P +C>^(@1@N*&,#G;J$#SQSQYVO0'VT
MKCI8WORM>U[\^7;ZMK<[V]NUNOEV\NOLKF@%4+)<:LF8&"]8QD1" <3*D-G.
MI@NU(%'-D1%)J/5"/MIS)82FFCDU9,NIHJF=)9'4LZ2/E[#=^*F0# 88N%=4
MH##>1-!]7I2<[4=+N8:L..UVW'K-.(21(,B-IE2$SXD7!71%C5F1BMUTI;1F
M9OQXYAS*ZTTJ3$=SE$LZ>5 L0Q4]752)W,BUK6[.KKO?Z][\[_OWOSI2@%*4
MH!2E* 4I2@%*4H!2E* 4I2@%?(?($U0D<35$J =('RI@D=)F0\1BYHH;!$+F
M2PX6=KXB C@"B BAY6OCF'GEC>W*]Z^NE 8:0CP\-&];GFGR+!6J4$Q<_4=(
M--]">31CI 3G,W4)0 \%44=M+618=0;:8I%+8%%(D@CIP"B3"!*'<!RP086/
MT(>@FGC/?QR7&1KC#;6EC-Y*TDHS]*,1-%5FS(JT56PE9WMK"X@(3:45XTX5
ME1=8;6N@ NX^JJA]PV/*2@.>OF'2@(]X3X>45-:"99B78D@P=F5[8Z973L-L
M>XUN*D)FM&1IA<:BA&$YR(<<@JKHLRP&*ELYC)#"&L[%]VH8C137(.[SSL&-
M+(F6D0PA$D!L4K&D-QZUHY8Y4VJ*7F>:R4"G$SBNNFA#R^NJHMN^'5IPKY\4
M4^O.!9-'UM;/"B'%0^;,YY"7NI2@*+CN.F+$K%:D91FTD!B1\QD).;#.9K63
M2Z.W6RWDD'$LF(R*EE,<"R>G$ ,<0BI4#'$,$/&V.%K6M:K"-#173AAKLF.1
MI:RPDBJTPMMSLN21BT=MT4N[&6^#QA5?+*4$TV2,)8+-?*P;-+;V:2<2(MUW
MKADPM.1,4U080WEE?2@,-$/AY:1-V*WK"B5J]#0472,JM9;?30,LT@I)[K4V
M(=)J#!,KAA4\-5#]F 93D^[! %4+EF0"1*%&J"D%  P+9+2#'##E=ANF+Y*:
M* ^8\>Z ?:SN9CH32ZPW'(W%0O<HHHJREF\<RQ]-.EKW ,E1\,@Q@KWPSM>U
M5K2@,<YRU%UEV7,L\Y/D&QK+9E@A+15IC/EL$5P1(3'($0!<B"'D8Q_73:<>
M"4DW<#74/#&ZMBI"2.J)9L=,("%_W*ZFZTD4-U-HG!D8%T!\M:+&0\$<)H)6
M">Y6C"!3$A$+<6BU@>]J"/&Y/&Q9FD1[9 H0-K8$L0[5D+2@,?WSJIK?)A:4
MRK^A*-78%-BBRUF5LUMJIAPR^5V-TX@E1XX%T[F%8X,X6&12TP)F+X!@NLM?
M--(&$0\2,E"XP?2/M4-:XI"C$*-X.C)E><R"_@8N%;K22DTTR;RKF3&DXTAG
M  +&P5*1#) H=?*L..85'6?!L?73AX[D(8RR#I0%K9#A&(I:LI6DR-V<^K+$
M:R)#BI9T(1)8L?BN6\6_A)D?F_"P\^_--]XM5N8NE%SYDUBR(F6-X9^"!<J>
M=VLFO+_%< SYA2,7AFZXH)04YK.=F(:Z&O0ZFK!IP)T:*P*F4,@'F8173II8
M)H1@/,F54Q\SP& 9GHBXWSI0&)9+1'3U.AY5@,IKG% 43+KN"D)9:-VJ4%!5
M9&+&"9HE)*@KC9".(W)"<834P9+D$=9S>25FF)EDY<*XIQ/$&GW)PY=$W<UH
MV9#CU-@=6:$1(3E:\>-HS'2#XD;K8>BAXY>+;#30BX192;[M<%L7.YT1;#5$
MQP.L,)U*Q4VX@@U/'-2E 8H/71?4&1$9;0GCKM%*T1<.,5V4Q!6L5**60L')
M"HWX@.$EM.R)K:2I1L@KBVB,Q42%$@I(*.LJR61-AD5,Z .2M%-.$)+:J(AZ
MRPFB)+&DLQ,;.3D>/F^EE&S*1UIE6*HOQ%!(%"^">YU9HDRS?650OT!EE-"L
M"J^&999B997TH#$)?T$TL=)F)33AU@A-8S@QJ,QB14$>8*(.39S(C@P >CMG
M$2&1?P$XU8_4RQ=98S=62RFCM!=!P7&\33E>WAM[H#:W0(8)+B</$,?"D7--
M"'L6X"F;93LBZS.S:5VPO-^6E$.X71-/Y'666TU-.<HMLE$J>;J08#%L(1!O
MC>VE *4I0"E*4 I2E *4I0"E*4 I2E *HJ2?2\?7N0<?WH.56M47)%KWCU\V
MMVW:+BMU^RD&[4!3D&^E(PO<\5^$&JZ]6I@ZW*)6%;_Y=*7_ '\QKV_DO5UJ
M 4I2@%*4H!2E* 4I2@%*4H# #BNDCJGPO^(JG)Q4R>4%#1S:HD1)$P!3)LV<
M-0@]@"Q4J6 P$'',#C"8! @@X9BBB9XX!XY996M>.EP;$0IM[+'"[2-1'/:9
M93U=E$M-<QOZ+VRO.9,B'7\EJ?++%DYBN=] I8#=(+TW.M<84=($69KUG&Y5
MT,DZ[H6::Q#BHF["O^OD]ZNML;6OSZ[^WEEE;]Z][VY^ISY<^5[V[+T!ITZW
MS/L/LA+T-QQ#.P<MM<SN%I[N26D)V*FX<W[!R;$L[%FFS7C B[-K/$C>,==]
M/=CXV<^"X45=?(#+%@"+;(NYH.I&6FVGIJR;NB[MH-D-H893]IGW-BIJY'ZO
M/\):P'8;DF0]@=98-=+O@*)9.!VN090V;U[)*3\U3)KNW[J<S#;,WA"A-YX8
MZOL.-W$$<0I++IP^TX\VB4>C.=C,&5G*VP':WEQO#N!E+Z@TW@B67$\RGB+;
M6<Z4($I-YS)WA-SJ,OD,\3Z8I ECP&??0<:I&$H2CO7N)V9"L8(YE)8;%21$
MI(**BPJN57.YG#IQ66EMR.)?-J"VZ',YUY257&ZG&NG3RNXW"JJ:RJF3)TZ,
M+D!%(DOU<F#@1SNZ%0M,:BK*FE.YC= &F!Y%I0D9TEVRU)H:".ODY*3F!'(\
MIM-W)Z026(HDM0CQNN21HW4&>[W$E#.%9431RPUM5]YEG5/7?:0S-D=OZ5M,
M-'I(D;3:&H5U75F,[E38I^Z1JD3LH)_.&0IZF,1^!()%R'RY!@-]NQ^EO9\&
M$I1<-P2":GMD#8LM:UK<K<^77ZM[WZ_9O?GS]GGSKGEU<NVW9U]?[_EH#4^<
MTP"@LZ6$C3??;9IPP^:T39SZV4G&2%6?Y_*0=L@)L%!Q!K67W*G8K,M:[/6:
MXQ7-@F_LBP8@NVS>M#'02,T)L=QJ=8J>.JTVCO!/D0GH"X'HZY4$9$"<;I!9
MN,G)&YTM;4:\GDF0=)90$;0<$[2KC3C&1I,AT*65IM1AD;F()V.)IR0\9"A@
MO(Z^RW"(A!;<-@@\>?1QY=*_.][7O:]\K]N7.U^?2ORMTLN?2RY6YWORM7.
M> >&(>&-L,,+6MCAA\;CC:UN5L<<<>5L<;6MRMAC:V-O4M:@(O.,"GGE+2L
MJG$S9TU;;GASF+ER( YH:P!'B"ZS&SHU@2V @E@"A0 P9,B6Q[V7+ B#BY8
MA99XX/\ $)W%>VM4H\5-K."9'W'QQU<-.'7+HPV4PXY15)?G(N-MVVI(5("1
MT,J=-'Y"0UXW"QY_W;0(JTWD4NV':XPB#83?')?8FO;G_P#R][>]73(/#+*V
M5\>>6//HY<[VOCSZK]&]KVOCSMU97MRZ5K6M?G:UK4!K/285G]]R_L^]0]CM
MLF6H,SC%ZJ:I1VG,&67@@LAM:T3'%.HY&9D=(8%@C;$6PW*-+;[4BKX<2"X5
MB-W(03G'&BRR5E,4C"A0+;DMQM^4#T'[2[+;*Q7H;%>[W$-BVTIJ4V2^S%2Q
MQC,C5Q]ZHQ-*VX(#H3YF)LP(G(^RBTQSKEDZPDA.!AL]A.%SN+Q2DMA=VH>7
MM]O/MO\ Y>SV.SV*ZY!X9VO;/&V5KWYWMEUVOV=5[7ZN7.UK\NSG:U^7.UKT
M!K5:4KNQ^Q&S&F39FB<-M/.X:NG4YSVWPSR^\(14IL#B[B"XL/5&1)_06^3;
M)AS*S_U<,M5Q/=GN$JDD)%!<@Z@_&H9OF&03_=XJKFF"/YBW#>D+.A_1Z^OB
M&.'JVFY($=]_+.A"$<G$MD%MN<1OGO%ZD3NH!-%QJ>)PJ:)*!.Z:<%LK)YE+
M'&"%V.K6M;ERY]5N7;>_U[\[]=[^K>_7?KZ^N]+VY^7]^]NR_/U+_P#^VZK]
M5 :PLL.B3(.V%V$UH4Y[VH:^CS6VNT05IBE)5EB67D^HMA6=M==C5222&&Q[
M@6E.5XKB!Y[)1E!*.^7>@ODA:*4N1G9@A+,>-59$-H5*M^<5U3=<;-B7-IMB
MV]PIL]G=TD*.-J5>5)*BU6D=%9D40&MZ^,=Y[<(IE&E-7A<M*#BW!1XJDQ8D
M)'\^L6&XZ051\O\ !!023\VH\L<<K7ME;G:_5>U^?*]NNU[<NSE>U[VO;_"M
M>]K\[7Y5UN$'?#H7PQOA;E\;>W/'E;LM>W9>UN5N5K]5N6/*UNC;D!J7/K>9
M_P 21!O>BJ&R>SF:V_\ 0_2)V</\Y-*:NM;8&3SZNER^RG[)[.8S=;:*(4>I
MU=3FHN3 HMQM)(R D70W](!) 35"ZH)ZTGRD/&DV;@,=Q+3RC]J3+Q=Y;.J3
MM5=G'SI'!"FEL'AI::G4MM2YLG%S#>$S)PSA6SXQJ(XZB8XT3TM/EIJ:"N.K
M-)0S"$H[7EP\+Y8Y7Q^.QM>V.7._2M:_+I6M?GS^.Y6Z?7\?RMTN?*W)F'@)
M:UL\;96MECG:V77:V>&5LL,K6OSM;+#+&V6%[6YX9VMGC>V5K7H#1W$ER<#L
M51;LT^9+G-#V/2>#KQ\XQAAYF7?,J(Z%25-?=EB8<&H^9=QDVVX7-)Q*%6OB
M^N^R,V2<B/*[):TBO!($=K113"1GV^9PDPK(4GJ9W878=*WW1=Q]6&9J'K,G
MO1^%6!*&K;D)0%<X-YPQ10\[:6HHDAFJTZ/"?MAG.F'G)$;K0U<+-]1P:CY!
M;]]HZV-K=5N?J_X67._/MO>_/G>_DO?G>WJ<JXN'A?*V=\>>5K7M;+G?G:U[
MVOE:W7V97QQOE;LROCC?*U[XXWL!K4:^N.=D9T:+;"J$T;*/!U3EQ5]^M5I.
M:[VE*0EV*A]9&NXM_P M$Z)C$9\UYA4.[+%@N*UEH2*"A%'R,*:,)*B\59JJ
MJ>@%=EC"][X8WOVWQM>_MWM:]ZYY=G;U7Y]M_P"7KZ[>Q?J_>M7- *4I0"E*
*4 I2E *4I0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g162259.jpg
<DESCRIPTION>G162259.JPG
<TEXT>
begin 644 g162259.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#3TY44D],7S1#7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M4(@,;9XC#O.L8?+(M%1M)]61F(,DCNEDB=K=G4X]2V,# C\6WZ ;/@
M                       ^JM6HVU&J<7%6F0($*8]8M7+3RDJ-&D2E;GJ5
M2I2?N60G3)B"S#CSSM]"B22]S3-]=--ML?:'GULK(PWU;9*^;1%;8$-10*8J
MY;!&V(G6 Y32,IXZXFOT2;X&F2KE,W7R5JU5LJ.'ID2Q1)E*XMD*2G[KL%[
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MZ^K/PM_K[ #D
M                     *Q':PO:Z*3^/[QA^R64+.NOJS\+?Z^PK%=K"]KH
MI/X_O&'[)90LZZ^K/PM_K[ #D
M                                  *Q':PO:Z*3^/[QA^R64+.NOJS\
M+?Z^PK%=K"]KHI/X_O&'[)90LZZ^K/PM_K[ #D            #6#E-S2XJ<
M)8:VS_E;?%<T9%GQ>>U1];/'XM MDKFD(U5K&Z+L*4M;(9.N1)-RU2U*P-+B
M:B3FDG*]22SBMMP-GP'@7'+E-QTY=5^5:?&:YZ[NZ [KC6HZ25W)4$A2-KN0
M46>>RO9"??#A'WL@@\A0<ROJ)N="TQY"C9)@@\HS?WT
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M+TUQC7333&.[733&NFN/1KC ^0
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MO:Z*3^/[QA^R64+.NOJS\+?Z^PK%=K"]KHI/X_O&'[)90LZZ^K/PM_K[ #D
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MJT)G"'*7AM0)%3F['K;\0
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MIC4?;<+59Z]7A RLB- V(L*ERE2L4^3)2O'JE!RDWPSC3-]NS
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MHM&PK*37=IW1*#+D@QW8_P!_U_Z_V_Q$([KAJ/=9]2C=N6J*TK:6X)JJ1O\
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MR2/P*OVY\)E+KF0290UM:5ZELC?T+-C9*Q$J65B:V33!3R[JWA1HV6L
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M8F<_"PWRWQZF[MKZL_"W^OL .0
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M(ZPZ46 [MLO-E"^;E0Q\2(G]#'HNB2Y:&5\>$*!.^GRQQ\P><$:)<J)O6
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MC,Y(%C2X-2DC0Q"K;5:0[=*H0G$9TV3FI]]B=B^[!>>['=C]?S@A_P"=I?\
MK)'_ *@@\XX=&FG#Z8A"SD2AG1%P."%4Y2YLBUDN;6S,9B]P5*6M@)3M636T
MQ8T-&Z%([*D6YB90[ZKMB#U!&"CS/<M.C1PQTWTWU1VWX6F^F^O?;4CSCPB]
M]=]>_'B_3CPM<=^/UX]&?1D2NGL]U9J5;#^0QZ[K%>"9T%CJ;4$\*RQL>L4T
M'^,R_3+&KE;)%]LGUO:K%>[Q5Q2>_P '[<,?<VLJ'UU[W4CR]71SXM',]&<?
M0S-!E*W+79<S]%?5ZG^=2LMC^ZK>2G6;:@?'8;7B:_ZVRN@/C*+U)++*T[_
M+TT+U[\]^?!TUQIKWYSZ\]VN._/Z\^D?()T:X_\ C_[_ -@
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M1/OBBM,91>6^2F=^Y6<C;88QC&N.[&,8Q^S&,8Q\F!D
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MCW_DS]P=^/?^3/W #(#'?CW_ ),_<'?CW_DS]P R QWX]_Y,_<  R
MTRY^4M8%[\99)$JI1LCK9<6L*A;N@T=D;BF:&2823CK?5:WRWP1P=UJ%Q0LY
M<Z_HZ-B*=Z7I=V]F7/*1T<,Z(4BG?7I'#RN+<,N?F%R;MNMW2E#^1DUJ1'!Z
MBDS]!Y/.8W!:6JE#"4T@G3Q6LMF\$32"8R=SE*Y)'HW*9 F9HR@CYR]VW>'1
MQ;FR00 ! %U#^@C%NHY;<PL&UN??/.(0&2R&"2UHXZ0BSH[O0<#E, B:"+-$
MDA,!DT<>F]E?3=T[D_J'4K7R[5]D+ZK3GE:KS-,^?[=G]LS?;;?;K?\ 6?VV
MWVVVVVVY5ZYVVVVSG;;;;.67OSMMG.<YSGTYSG.<^D6/0 %<'V/Y9?NWW6>^
ME5I^"!['\LOW;[K/?2JT_!!8^  5P?8_EE^[?=9[Z56GX('L?RR_=ONL]]*K
M3\$%CX !7!]C^67[M]UGOI5:?@@>Q_++]V^ZSWTJM/P06/AJIRWY,F\9X7 E
M<?@"^UK3NBWX30E)5JD?"(HCE]GSDEZ=4VDDF*EM>R8;"HK$(K,)[.9/HPR!
M>U1.*.V[+')"^&-C*N AL]C^67[M]UGOI5:?@@UDYF=$+F#4?%N[[)XQ]6OK
M*W;?T/@JUYJFJEG*1<I23>6$+6\M,QJ4K2E:'-24>B-7&^)0NK>HSN3IMHHS
MX.23IU8ORQMVHFRX'+GW5E?T+$*MC4-FC=>]56+);6HV<-LXD2V)(H*U[2*O
M:_M9'<S3)RFAF_H_35Z_:S3$MAAL&=W5]?E$1:>S.'48X>-L=8I"X6FY$?E+
M;;Q0C1$=ZIN8RTE%UL45_+I?5"FFRZ[WMEML':%9)E[;$W2%(GA[C*QN?65*
MXM;DWJE($'7'7H4<F9[0%(SBZ^L3UEZVN.85-7LGM:O$O*8\E-!;%?8LV.4S
MB"<I<A<EA1,<D"E>TE%JG)P4::)-<'K5)GA&[>R^Q_++]V^ZSWTJM/P02$:=
M6+B3O.]FHF6+=ZB2\.9#S3<^0&D;F^:U9:QBME+*TD"%Y4:0[8]ED$?=6E\U
MDC(]&-LAC[HU'19PC^DBP>A2^A*.IMPG1I8XN7W&J:T<CC+9-]E3S5MSLJ:'
M0=^G2^MXW.K;4.M<HR:1@LLF#6XML.FEQ[P6,2]*A6/L:=72/)S7;4"+7V/Y
M9?NWW6>^E5I^"!['\LOW;[K/?2JT_!!-AQJO_P#.&8+1?/R6_)3^C;D7R#H/
MR;SSYZ\\?T%6B_UO^5'CO-C7Y#^4WF3SOYG\6K\T>4^0^<W+Q/E9FQP K@^Q
M_++]V^ZSWTJM/P0/8_EE^[?=9[Z56GX(+'P "N#['\LOW;[K/?2JT_! ]C^6
M7[M]UGOI5:?@@L?  *X/L?RR_=ONL]]*K3\$#V/Y9?NWW6>^E5I^""Q\  K@
M^Q_++]V^ZSWTJM/P0/8_EE^[?=9[Z56GX(+'P^NK5IT*50M5G%)TJ0DU2I4'
M;X+)(3$:;'*#S3-O\'0LDG3<W?;/=C&NF<YSC'I %<GV/Y9?NWW6>^E5I^"#
M0'E]T;NH;55Y\&X9QMZF_6.N6IKDNU=#^6$\6<H'E0HHJJR<Q3*6;MYS7LTH
MD*@_1QDN<J7E _HMMFHG35OUWQMHKEXXX]9>+6S1-Q<GY\W\:FBIJKHE/>9T
M%HGE.IOWD^D02):7BNXE/*7/IFM&*'R2>)%")H;#&^RI4RI+!7%PE8YZ&)'1
MT0;@U/=W.DVR:U9>1?$FK8= ;9T>--'FDN03M<4MX_/"&+K92T--]LT@J2MF
M)8T/GFY9#SYU4T@EK*R6)NSL6S>[QM[(FJ0",/'9_++SC'?UONL]C/=COQ^=
M5IZ_U_\ T49]C^67[M]UGOI5:?@@WY@?40G5G%\W<P;B)<B]^XOYJI/55927
M9#!K5OLRU8L:[L+VLB3X6:IIZ*JG73??7>:EFS=L@Z%?,W^"MRO9#%U/NW&+
MDS.K9LSD71%NUY"X-;G&QVJ\F6'U79+E:]8O#3<$)/G$2*;Y2_P*L9,TS5K;
MT2K,NA+_  Q(J;&AQA<L0.+DR3AL\E B0]C^67[M]UGOI5:?@@>Q_++]V^ZS
MWTJM/P06/@ %<'V/Y9?NWW6>^E5I^"!['\LOW;[K/?2JT_!!8^  5P?8_EE^
M[?=9[Z56GX('L?RR_=ONL]]*K3\$%CX !7#T[/[96N^NV>M[UG=L:[:[>#MR
MJTSKMX.<9\';'F7TZY[N[;'JSC.<9]&0%CP                        &
MGW,_C5)>1L$KM36TW:*WO"@KH@W(>B)I)HXNE\,;K%@Z9^85C%/(LTOD8>GN
M"6'7DQG5:RTABDC(^H&>7'OC*NPZM*,@X  U1G_$KG-R"8)9*KEO:DXE8$9F
M'&BP..%-US$YO*N/,*G'&B[4%W8EUIO\L/C=IV$_W J;D=?OAD:*@;17$)1H
MCF)FE\I(4OB[E6? 6W<\GHGS M^:5CI9BWDJ\7E/8/7C;)U,)88TT<*)9P\K
M6%PJ025,@D$ED:!+)54RFM@2=HCVS[LOWC[-&F5L9&S54  :PRKI!W2XPV:0
M%GMRJ#X_:W%OF1QUGFS[&YCLN;5-\\O9WREK:1QW*0\]$Y-S47.5<)L%D>DB
M8U86F+=8\X[Z;&MYVRW*/@;?EH37F&WT]8U01VINH)2$*HZ^C+#BDH>)]5*.
M-1*95<]R^HDK(HTBDY/DE730]M;(A/-XTW1";M*699?9,UK%D/U  -R>(O'5
MPXTPFR(<N?T,@)F'(B_[@9U",I:7NWQZVK*>9G'V-R,7[;'+'ED:5Z5O>'#3
M/DZ]P)/5I\8*-UQC:P              ?D/[:>\L;RT)E^S6H=&IQ;B'+1$W
MN6[><N1'I"EVC>[)EC6NW2;G:J-4;DD5(%62L)UJ<],8:5L  0M./3)O+D6F
M6MG,"TZ>:L1#A38_"^MI5Q8@K[7S^_&V3+ZBFZJ_I:PO1Q,2A+M#I+1%<OU;
MT5%$4G@,1D6TM<])@N;'EJCS!\K3T\^1]M<R>.G*SE03P7*G?&=\3/">]Z'J
M&T$/(>[T3+ [)@C'"GISG<L/8J5K4XZT7R8R*&,SC;QKD](&Q VOK0AR<IP
M ;,SSB]R18'[GQ9W&VTZTA5Q\H8W1#/3TDG<8?)"R52\5?!E,">I1(&9)@TF
M1N.B%R7/401:D*6DE[3->9&A<FPM8@4]DZ?7'NX>,M926M;09:);T9DF-E;4
M^U*_W),YM8,JD^ZQPL:Q+XL"[#E,LL&S94]>0*E<L4JU"A4E*PW[:H&IL8VI
1   ;]              #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g634913.jpg
<DESCRIPTION>G634913.JPG
<TEXT>
begin 644 g634913.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#3TY44D],7TU!0E\T0U]"05(N15!3_]L
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MEYBRT=(I0DA26(6'U=;8)29#14=566)EU_"9_\0 '@$!  (" @,!
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M1KK2@;%,ML,UE ;$COE;G2$9':[#*'5X%>=02 +$RKB:<Q\P&GKJ6\<[X(6
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M>W.U[7MX+VO:]KVO;P7M?G:@/M*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
M4I2@%*4H!2E* BPXR7D2A>F#PWOYP_6"I3 _%O\ '$^DRJ+/C)>1*%Z8/#>_
MG#]8*E,#\6_QQ/I,J M]V8VNUVTXCH"6MG)9:<,QP9<J4SP'<\C!PJD"N9<+
MJ)M*1\1")(^-W6=+)"D.#:X%@^UDA\LQ,+8VYV _L_/!QOU\077R_P#UVO\
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MT*VKOE>^5[[?B<[WO>]_N(QC;KO]ZUK?!:LSZ@%*4H!2E* 4I2@%*4H!2E*
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M!*!%6T7351+.%5%-4=M^&N>3U B8!.$CQ,UQ"M71BQLF;+9BES14P#G@, 8
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M4O%_3$Y&T53$A(($TM*2]MN&JGIJ:G%0"*>GD"?$*U=+E"1$D5#!*E"94 /
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M+H:&?1YEG] GM%FI^; B;7)K@CD:<EJ3)/9)*,G\;6R2O%ZI"IEJN"-$9KL
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M\LCT5ZY!B3QTK]UI8BY&JABGW,)XBR626*>$4<"=Q <E0NF#G9=")"G< >Z
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MC'YQI&G0R_J:1MXN7_P\97O7_P#P52]\,).3DF 7DG)*<G)*<4V%G4,JG)1
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M.R1_MLF?C C^E@UOU$?[4IGXO(_H@-:"M'^VR9^,"/Z6#6_41_M2F?B\C^B
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MJ9>BDY"3@3(*46>GFX^+HA)*-)Z@X\G:9+!"EW$,H&BB98GE?+$9*.=OO;I
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MMB(!=0!21UL-)NWN^&:0"J& $T53Q+7(AGQ@B>9C$R)@%EVGV)FTG_1OGO\
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M!2E* 5Y]SM1L/9%-MMXMU"=;>/\ :>[D)RHZ<O(QWN<; R7[K2E8L<(&NT&
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MR!$02I) .G<?YD[>;;.4F^[]@M<-2V#*NJ+1?+Z9[:[Y3RI-;9[8)&B]Z*+
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MA4JQY+LF8/=TIZ>N2#>0IM,BRB$L,@'#-JFP)HJ4I0"E*4 I2E *4I0"E*4
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MU",J; 2T>0V:P(VS9\T1R@A+)9;;\?+*PT!W"P6.OO)N%&ZVW0M(;H"PLF)
MIXN!(SKIM(P]CQ9&145LR?&\@1&O(+?DJ+)A:1ED/]I&':UD]ZM!0-IP2HMH
MZDB.ELJ02@D+""O*Q+NDLK(:@(0<*$LI)&YKM6/OB?Y87_?J*CANP,\(B?\
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M4Y6Y\^5N?O\ N_PTI0#E;GSY6Y^_[O\ #2E* 6M:UN5K6M;WK>"U*4H!2E*
M4I2@%*4H!2E* 4I2@%*4H#C?'&][7RQQO>U_!>]K7O:]^KE>_5?G[U6Y*&X6
MHZ4;<Q-5VBUS33S)3Q59XE5";HP)FVBE KP+6&4W, 9= 8R G!.8P W1#BI@
M4+X+HP*1F)90%P+Y7&YVO>UK6_YV%_S8YXWO_%:]0=P!PW'-'[WT;=+LC2+1
M!X5G/B<RM+:C;-!5E$R:VU?\AJ\?+1<85/S,.!45FVO(!)?P[;:Z(7*ETP7I
M@)17 $"^[9O?B M52\"'WX=6W"C;!.]/1VTX& 71G$WVPQ3&")=<G5Z+(BVG
MIZ="K0%=S) =+R2AUD8I=[MPP32U F:,F2WJS.Y^OJ'L(\]:'D^F[',D-1,A
MHZE@R"Z66T2,C'YP,/PJTFS&8:LY2ZR[W04-,(^ LHQ)(Q,!#K* $G=\A% 3
M$O#%#?"!GF28Z1HPV*F1\Z^,6.N'TR] 6RUX(4H(?1=Z,N02)QT[0*JU>5X9
MD\%HEEEQEHN8[1%88K0<0:)$H"J(H8!GT?%.\DMZ.<0)],C85ERO <.2))^W
M.@FN.DSHV,-RZT^Z8LD2%52>VTX)[.)2HVE)U'V>N$G@Q=@6\ALO(Z]4Z7T]
M+;1E' #(>SYL@9.ML<+6Y6QQM;GSY6M:UNE[_@MU_?ZZY5UJ,0%2DE,31U X
MK#)Z>2(BJBCG@(?4A2A4(N(?/"!X!X9G#N861HUEAAAAD8%$OCC;&]K5V5 ?
M+XXWO:][6O>W5>]K7O;X+]=OS4OCCE>U[XXWO;JO>UKWM\%[]7YJ^TH!>UK]
M=K7Y7YVY^Y?W_AKCT,.?/H8\^?/GT;<^?O\ /ESYURI0"G*W/GR\/5S]WE[U
M*4!\OCC>W1OCC?'WKVM>WAOSOX.KK\/PTOCC>UL;XXWQMRY6O:U[6Y=7*W5X
M/<]ZOM* <K>];P=7WN75_!7SHX\^ET;=+ERZ7*W/E[W/KY5]I0"E*4 I2E *
M4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
MI2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0
M"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g361630.jpg
<DESCRIPTION>G361630.JPG
<TEXT>
begin 644 g361630.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5])3D-214%3141?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 0@![P,!(@ "$0$#$0'_Q  ?  $  @(" P$!            "0H'" $"
M! 4&"P/_Q !J$   !00! 0(&!P\-"0T( P #! 4&!P ! @@)$2$Q$A,4%4%X
M"A8R.%%RN!<8&2(S-SEA<7F!L;*SM",U-EEUD927MK?(T=,:4E18<Y+4U_ E
M)R@I0D=59'>6F*'!)"9(4U978]AHB/'_Q  < 0$! 0$! 0$! 0
M" D&!PH%! /_Q !-$0 ! P,! P4&$ P' 0       @,$ 04&!P@1=B$Q-C>U
M$D%6876Q"1,6%S4X47>1E;*SM+;4\!@B0D5&5V)D<9*6T10R5%5CD]7Q_]H
M# ,!  (1 Q$ /P"_Q2E* 4I2@%>L63AU.2%,^FI)E>4"1 V:(HA,R0)FU<V
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M):4#Y? K:Q;$ V=.F# 6)>WB,<1+8@] [8VMF*@%*4H!2E* 4I2@%*4H!6#
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MR 0;I]-3S:"1==U8HC&")01-!*Y%PKX;/TH# [;U<UO9\A$9::L$Q*WI23&
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M\AWZ5!%3@5!_LU]G:XO_ %/^0[]*@BIP* 4I2@%*4H!2E* 4I2@%*4H!2E*
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M!""P)FF6F%)"L K FT\5= .6!)Y@2#0;(J[+<2L.2'+%;]A%=>"  L*<42>
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M=\=?RBT"IO:A"YXO>W:K??.^.OY1:!0$W0?N;_'$_.95WKH'[F_QQ/SF5=Z
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MF,I2E:.$2D.',LKQO$VMJ=+*MLE!>H3DRF..P<'G+^IS?VS0I\5DEMOHHU8
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M2E* 4I2@%*4H!2E* @_V:^SM<7_J?\AWZ5!%3@5!_LU]G:XO_4_Y#OTJ"*G
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MGD"98)XY#&#ATX. 5*E@L,AAS P0(6&0F>.-]]NMK]U^O?;\-K]+V_!?LO\
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MX8H6R1W&-]))FBV?F!/<,NB*(NTA?;IE:*9$2X.U><:NS$$B_P!L.1QDG U
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- I2E *4I0"E*4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g505554.jpg
<DESCRIPTION>G505554.JPG
<TEXT>
begin 644 g505554.jpg
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MT0@6)#,T0E)RX?%$4V*2TA=#5&23E++4&&-T@H.BM<0E)F9VAB<W1X33_]H
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M+4S=H4\<GML\GD$?  ('/()^/5;4,,EF4*7$7F<?<?SRS $!B>/M!)/R>?\
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MP9 (/\C4)I) "K\6<EF(('%SI_:@;&IY/36@%Y(_^3T'Q^A/%K[>?CCY_/\
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M.3S%YXI(X8:>-IQ+/(7E>5&FL+&8Z-,6;TP,-61?67WVOO-O9IX)52GIW+R
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MG)XJ!#[G6(0<;W&M*ON-P6ER"=]@< [9.W%GE_\ :SY>C(4;I=%.0.0T=^!
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M?C:AN]8KT:V1@] PBR\LF/OYS/9>[ A/V+:M8S%U:'G _P"52JUB%6Y6.Q(
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M5FT@(%<*-"(<Y4:@VHZM6E0IO>NV18DE+*]<%XPTB<J_/QY!\GX X'V_D_\
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M6@Q[X\X990<=(2W,=EHF4N+$:=JA@W)4+RWY!>3=*Z)<E"L.V.5E<+V\=Z\
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MG<OB*DU>">L/K9)+T,T:RJ8()R&4DL@!N='+5",48G'C&8#PC&%;);6"I4'
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MCL$CI:*D^11*>UYXE%CDRKW>4 K$(43[H_P&-ZL<NND1&4!X L9( 'TL$D$
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MIA+^>NXK$7K%3'5%Z'=7:<^5R(J1W(\/C'O6((A9O3QU(9K4%1K332Q"2QX
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M>D$FK9RCU=Z/]<]>ZC9#8\11S?2/,/FK=7.80XV;)T\U@88;;59\I/DPN/\
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MVMP""I'<> >2./D<<@D\A_M7IE!$BQ D@QJ C!'7M"E6*(2&"$]J+]G<''Z
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M8#D<,3R&9^2.%Y[SRBKPP ]$.!+WC2GK4VGF6U-1F^GIRO8D/,=BO).(E<L
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MH;N.[H\!G:,]JC82DMG*]0T4DDB1,!3L<UV2Y=)"U.Y.614=8P\F"RAQ]%0
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M@\\\_@GX_/R0>?T](V>H2"W [EY[>>X\\GY[B!\$#C@D@_D?(Y'I0V[BR+W
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M3&?"B1F((1,*2\CZL8"[GZ9 1<9QU&HG@E ZU(-34RI&"@G<%T$=/"$#'4X
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MT/C']6!(/A(& V#N#E1]$X( V'7/E^HUR%G5@U.N)"8SEH]151K4G(4.P17
M*ZF )U$#C7DLP@!R/*OPGB5BDC(Q!:)7![AR%8 GY3NY4_U%O4%L/D\9L632
M=F\M.1L=B1CTJ5,)62,+' KR/)&T=*'E(S$&-F1?JIYA(TA<IDLK),KAW21>
M1X@_"$\?',?XY_)_J^#\_) %JT\55@\"VUL-X9$E5#'V=I)CD5@RE3P05=2K
MCCD<<@HUT5//&L171+*#&J@X520,NRL2V%(.0I&0.O';3<I:&LIZDH)8Z:KI
M:MP=2NWNT@8*CK@!I%8J/$#H"0Q4E=YF?M74Q>S>XO1KV);&9T4.A^O1FQ3L
MTKZ02'=-WE\335Y91$_VQLRAA*$;O"]C L6^UBSJW5GVF>X_V>U]NUSI7U>Z
MA[/7Z@Z?D-INC!8'J3CXETV:YI]C*%(WNUXGU.?6-@QD!O7HM9S];*0XR_17
M(54@>YI56>2G0H8_O= PQU6M30@*$(D2M#"&=.YNV1^X$  =OR/2<S-C'6YG
MKV:Z6\>'1C6O1PV8D(0=LIAE22+R!R2C =R_S*0>>8][(AML-%XS&>!VE254
MS&6#NPU1:B"&60@$MT^+(&5.N0>U\I[1KYSLEC,EOY@H&M==9I*YA.**6AH:
M6=8*^*!?"G\6BCE200#"LT9 )$HLF]FO0K_%2]V&B[+[C+'2#7+F_P"A]3-4
MZ49/%]1=?SD-/J!BKFJ35I<G:_=JXW"7,WK5S+TM5R$MN>S)-)?Q7[O@N9".
MG8<GK!M&T8O<?91J'571<H,QCO>7K&8U3J[O_N(Z>]8=OKX>QE6R&VX$G3M9
MU=J.EWH7QW[O;,Q0C$2T\33:K&8*"TZ2\OC<) LRU*&.6O(C1RJF/J1^5206
M@F58P)8A\'QOWQ$_>%[N/399/]UT8I4%2GWNKQ-%#3JQI+$75NVQVP\,G>.1
M&P8<KW\!@/4;-R_/.XF>LBDDE U 0:,$*% "*Z@ #9CI V+;DDG0+'[=+)8[
M1%8[1R=6TUNI90]''+?$J92DD\514^\RSV]Y))/&5VA977P@8TV6)<]"NMYS
M%?X1/VX3'*8X17--QJXZ07JI6\PZ+;U'(M-A-VV769UB98#(RRE8V D(3US+
MOD&[4 4,&2+N4@=S HH[./ZR/D'@GGGCY_.2_;C:.6"(15XX>60D*B1$OW-X
MEC2/M/S^@ /Y)+<<I*:?M5F\R*2Z%&XXC4H3\!F(8DD_(X"_U?/SZ?V^@:VK
M4!Y5D>7P=(",I7PD(_M'.<_<,9SQ4?:#SW%SXUH:.UR6P6Q[NQ$E4M5XPNM;
M'5@96"'1X)4H?I"39O@ (.S=R=>N]A'E"K]%<60%FD18FA8LDD7*,[\D=G Y
M# <$^MKIA3\.+R&6\I>O=)BK(X?@0*I[2HD)8$R,Q8_ _//!''IG]GN3Y"_6
MQ]*4_57K(KGL'##Q_EP>.%0'[GY)'QP01R?3W4<C^ZL7!B:[1R!H:\%BU(%<
MQ1UNU_X2K\B2=SS*_:O**$XX9SZ4599%;2,>(Z @X!PA DU8&-7TAJ.Y '7;
MB@5"".!(P?BD + 9^$+N#T[D#&/7(W/"[&/&;,F3Q5^G6R..Q-BSD,5D(YEC
MOU\+6+RV,9<C2:N++T(V:Q2NM5,DL$CU9Y3.L"8*%RM&C^(#ZN=&1F4]T81U
M^Y8U^9" I*JI'Q\'GCGA.XG(73#,BV9%AG8H\7X6:'GF:-BJAC'(.WNC)"2<
M .I X]+#7,&D5OZREE:UI#(CI6EKV$LP+P)'CF=XOI6"GNC=8I7\T0\JJ.3&
MBCU)IQ)$6)5-!A722!U!1I-!V!V7/88SD;1PB!7?8K]60,8&,;;$=>O3IU7V
M'N"AC+$Y#!YP8U':>[@J26'()<@#DD'XY_V'TU>QM7RLZHZGN!)JR_#R0@GR
M,DB<\-$SAB 0'0L71ARR,Y^8P[VZ.0LX2U5LP8^E/=O8?ZEH,S3Q\78;URI!
M(OCR5&F75[$U.=IZM4":Q7$2-)Z9RMADF>S/AKZWG6G8R$U2SW092&O3A>U=
MEKJ7:#(05:L,T\L<4L=DUXY)A7?Q.%B'.KQ:E9A')D,-F7<@*%<C9%P3]($,
M!D%M^%(D (/IL=.<^N0-R,$8VSTW.W'A8UK7:JA9(E1#W#A/$5Y[B2.#\$\
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MXC 8W(;-I&EQ])^J4T^RXO7LE)K<6)JTMJP:6:=RUE=26>J#GK4='&P),<C
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M]_( >9$E(EA29/&X*^)HBT9]8;%.'RQ+-.&9 )(ZW@B*I*O"O.B<$QI-(Z,
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M)_&E96;R)" \DCE^4=&8B'N1V56I%//%54\%5"Q:&IABJ(6*LA:*:-98V*,
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M5M6'BBMF&:GS(9%:(F(VP1V#C\HLIJQV4,;-VK+1L3CMKE^\ /1M<!*N05C
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M]NT; 6/L3>!WROLU."?5K)SHMWH\34BJ^0M:R$EB.!*D:RFO][F4.)7>.O'
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M&5E+1K+C*\L@A%'*X'K\935'MXZO26OY3&O3;J$I[B>."KZHG !^2"WP!\D
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M<+:X[U/WH5^/2*FM37LA-)9EFE6)N^:S/-+--*&0*&>:5Y'E/8  68\(GP0
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MYZ]'5ALFIB<LMN><1J/MK6,U9H1:]2DD[A#?R\"Q1-;-16I1QGL#Z^;Y[?\
M%;/T[QU'9J5#JCD=HU>I7SXUW;_IM&WG,V9<)+#8AQVN9'![)>FRN M9^'.U
M+,.#DM5IM=SGEGFEZ8<IC,+M&(GP^WX##;#CK<31-0V"G7S.)R'$L<H:?'2U
M9JEBG&WA:)9H6E\D4$Q_C()HU#CIL1A,92Q."HTJ6*PU&*.KA\14I5<9CZ5,
M"M5QU&A72"K2KH.$AIP>**(P)&B *X%?N_*%)?;NE?<YY)Z.&WI34UO4>&*>
MN$\SFY1SJV\K03-3F)XWC(^)PQ556H7SD:EYCNRUMTJJB2ACMJT=-0PDPM35
MWO$LAN454K-^L,$STXBEADC(.J16*QJO(+U2Z&V>E%QLAO\ H'5;6]>RV(Q\
M6+TBS@MQH8O,[;:R65J3X#$PU!/C+++CH<4XP=;/PZ/'9N39K&8^S+^]+M>R
M7V.^S_"[7[5NJ.^;M1QDFX=5L'E-4UZ<SM)7P,6 6M!/9J <25(VVO 8O$UJ
MU&.I%3PFCT(JE6&M8*R3_P#>%[>-N]PJZ9+J.6P5"SI]G.1RXG9)<C#BXTS^
M..-BSL\^*JVK9RF%C^IDKXZ.#P9"K;R..-RD]F+(UGQZ-])DZ.](-9Z8XS.?
MOJ/#XNS7RVPSUS6L93(7[F0S62MQ4(#-!C89[F5G6E&9;+U*"5*UF>R\;V6@
M[)R5^B>9)9&6JK+/#;5--4W&MBJI7N4J^Z2JD*11.BB@::.IDD ]X9J<DO[O
M#X,%R_R +-S//(T=576:*VAZ6JN=9!4RO<JD+2S1I3Q11M'&M#XZ5#R+FH=X
M&+2>#"8^277\!;39-DPF.V#)Z9U'Q%V3(:R);MU:&9CQ\3QKA9X>]&S69QNS
M5<OIM<8K*Q[O@H1K=3#92LC8^!;J/9_U?]V];JQJ73WJ$O4/,4KUJ#$[;K?4
M7 6[MO7JTF#OO+N.)W"OA9J"T,79HUH;36]DNT\K6RAKRPML2JP</V]^S?J5
MTC]Q V>6;&V='US*;?E,'L?UY>_EL!M-+*)%J^0P]VDTL64KWKT3Y/,/E/HK
MZ8''W*\?U>1FCQ%L$%*A]TTE>2(36!=+232I"+8$:587$3%$9&/DB6 /!&W/
M+NP10ERKR?743R5=17W>UR4]Y<QT,-7$U+6V^C7W>!:I$3PZFGK(U25%D19*
M5A+X.@3?"7E+DJX4+R5M1<;S:):>]$Q6^"I@:DKK=0CP(A5)&/#J8*Z+2Z"5
M%>E99O""B;*J'H%Y#D^JQE1$D.WX?O6-WDC5AI^%!1'?AG1..T,0H;CE55>%
M"VUC_2YU2_N]TU_W6V^DIT061<[U=652L@W+#EE)4D%M.PK<=R*JMP""#V@D
M'N8 D^E7K'^ESJE_=[IK_NMM]:+)].7^ZOXIQ<7.9%/_ %VJ[Y[U7?\ /U<.
MSZ'H>AZ1X7X'KS@<\\#G^OCY]>^AZ' X''SS\_\ :>/^S\>O  /P /\ 8 /7
MOKPD#Y) ^0/G^LG@ ?UDGX _)/P/0X''OH>HQ0>\+H#DMVVCI_K>\U-QV/1*
M%K+;_%J%>QGJ>C8FE.E:SDMFOU$^EK5(9FD69\>^2>NM:S)9CACA+&16.S6'
MRZ++BLKCLG&]:I=23'WJMU&IWX18HVU>K+*K5;E=EGJV 3#8A9987="&]*R0
MS0Z?%BDBUHLB"1&0LC@,CJ& )1E965ALRD$$@@\':.1 I=&4,,J64C(\QGM^
M/!GZ'H \_(]#TEP3@>AZ'H>AP.!Z'H>AZ' X'H>AZ'H<#@>AZ'H>AP.!ZA;[
MC?\ /?%?W5H_\7SGJ:7J%ON-_P ]\5_=6C_Q?.>CIU/R_:.&=?\ T=O[R?CP
MT7[4#N_P"WNTGG]U[5P%_/<,2Q!'Z<__ (?_ ,/'+_'++7@:Q.LI!F3E>"H"
ML0#W-^I'/<0 WX/XY)]=2_[2&D<ET?2AW%!:I;8G=QSVE,'8F[N/[/$"W'^K
MR?T]<RVRP_N18L>U"O;M"O6LY#ZF.4?3BXOGJ4X%YC\5H5/'9GD=&=7L1PJH
M6,EY"U5;1"HA49+56LX(#!134XP"=]R,;;]>NV/&W\)B)FYKL;XPGZ!52QZ%
MA<*HZ?/.&SCN-^@(X2>0L49 5E4*&0E98RJ$$#Y#+\%N0.#_ *WZ \^D4M"-
MIG/G)KR2AB/UB/< [('Y!/8/Y/CN [1_-P%-;J,\"6:\;2065)A65@Q62-BL
ML/)([FC?A0.[DLP^WY'*>DCF8R1BK-%&04$A0\^7M8*!W$$LK'N*]H^T'DA>
M/5C%9K4+&I*-N264%,%<]2&R-]LG&_49SYO3X>YR-C\]L8&1OD=!G.#OOQDR
MFLE8K'A['EC*(TW:I5C$>X<Q<D]TB,O'(':O'P6Y);7.8W((IJUXI%7N!:1%
M[0$(Y,:#AN!W#ECSVGYY'Z>GBRDZ4*U"U:L,B9RE)=JN89$'-.9*%^ CCM<1
M7(S]/8C+1V:\D?!6:*Q%&A;.3FDN+$8F2*1>^*:63X?L_F(X^T'N*ANT_:#]
MWY'KL-4\:AR&D1"Q&&SD@J ""03N#@#X,'H!OPO'K4D$ [ C4,9!TG(.V3C&
MPSMGKMPT]C5,A'#-.!,[1&!W4AD7LE9D/=^ 3W %23^ R\? XWZ&O*1%8L.M
M:S"RR12Q6#%,LB,'CFC=&\D<B,O<C*058 @]P'I7[3?NP8[#UHRCULF;M^[.
MA)=KE"V:56FS ]K5ZT1-@(3W--:+N2.SA*/1N6:-V2(21=M>5U<(W:LB(6'>
M0/\ DRP(X[N5!)X (]+^]2,FMF4%FTXW.YPI4XPHSN ,'(QN<CAZ"S*A)"YZ
M-Y#('0D'.=^GGL.QG7BQ=>U>RENQ-<EIQS9"[-9G>2S;F,D<:"661GEG:>9X
M^]I"69>XDG\DCM;*K6(:L*.)9V\O<D?;'&LC]I<D\ET#/V'MY94!XYXX'SH.
M,&1RL='+V>:N7KS8J>5OM6 W8^*5SN=BH^EMBO+W,>TQ*XDY![O2PR^G3XK"
M82[FZ,N-R;YG-TX*LD0@FGQ<=/'&:PJ./*:D>54K7ME3%*S31P.X\O:W,T95
MS+)\494(H(P5 (R!@$X(\QL1GA72J2:3ER%&>NVPQTP",]3TZ;XX)#G=CDHS
M5HH;<D<7(L^&.6Q%43R",-8:-&$*,Y"*7"J7X4$L./3;6*_DOV(N^:Q92$V+
M3H1(E=9'5!&Y5N _<P##@J&=$;@L.'@S&2CR6#;#XS#V,+'-FX\YE9H<G8L_
MO:]!3FI5X!%X:XIXRN+-JRE-GMEK4XD,P$,2G!K>N4ULM];'/!6M5[52>S7K
M+<E@>Q&&CL_2&2N;B0V(X7EKK8BEEC#B*5).WF+:JBC+,2J9).C(9G "G<YZ
M9SA1DG !'4%U$ BD@'4RXPN% +$=SGH-CAL9SO@#*#K:1':S%G'9"<UZ]FTE
M0W&81+4CM(C4KL<S\(D<(>"['.0$6,!C]@8^OBOCI=2VO#Z?L]^I4RV8$E7%
MU([%:U!'D'^IOK&TU2U8@I1[*D4ES#UY)V,F2%G&0\3F&LL@GPU+(WH:=1;$
M5=*F.QE.U=*0RVGH5%K1W+L:F2&D]QU*BN)IDIP&"&2>9D>1D#UK]NFU[5JS
M9O7L!>J;?K-:2QADKUA5FV/&UY(\C9P%6^B!%S%>W6ASVIV8K"I!L=2&-V6O
ME+,L8MEYMTU7#:KO<!;K=7'P#6LB-';JWPWBH+A("-24L=1+$+EX>9&H6F*_
MKHX^)*VQQU-2*>JD>.";]7XZ@.L,IC(@E8%3^J$Q3Q2&5O"#8(/Q</1TMZ8R
M[)L^)H/]_P!7<@A,G_HXQYE:21G;X2-$#R2NPX5%=V^.>9"=.ING.QVKEB/$
M;?K55,MDXL7L.;PZV]=ST$60GBBRL>2P%C)V,/3R"H+=5,Q1K#Z*2!WL+)(T
M2-5[&^HD?7+I5N^1P-F"+JCB-,VS5\I4AC"-4V^U@++X;/U:LB(]*IM6-6Y:
MQBLI&,S(R.'<^;"S*MH72S7-?U[I_K4./JP"(8;'BLH11XX?HX1&OSW$2)'V
MJP^ #]O]A\A?PAO:3S1[-KW0\OI:X#<O?+G276GKA+X:>X^[1A()H)$!,GC&
MHCJ%\2*6!H98O$AE#'>_9?[-K1=[==J[F%)I)*>KAI:84U1X,E.!%)(\V-,D
M4HF*@1:T=6C$A^$C4$O@:F(K[1K%W&9'$YFQ7TV_C,A/B;*7H*<$&=:YC \D
M;,D+3_6WUCC?ML$PRN4\?80F_<A[=>EWNJZ:Y3I5U7P397"W6>]BLM3,=?8M
M/SZ5IJU39]8R+I(*63J1S/%-%82?%YFB\N*S-.Y1F*(^'TU>%F:O!%"7;N?P
MQJO)_!9NT LQ_')^0/@_!Y]'>.HLY3A?N8JW+ D%NX=JE3P2J\@D?V\?H"/)
M-)?+_=.>(N=[3+5<OW^"LM]?;ZVUUL\=;;:RWQTZ05=+71F&>.</ LP>/258
MZ1E02VXO'34MLI[,@,U#24STD:5"HYD@9W;1*@ 1LK(5)TX* ;=N.93&^[KW
M?>R2WNGLHL[7T^ZT;)HFPXK"])>K=HR9G+Z_TZAQ[238C:<98,\,5C$AZ&)H
M8S89,EF=8MULUAH)<MAZ>$NPV2>UOWQ=3]9?&W/<5G\#U"T'(20P;#MFL:S#
MA=KZ66;4X[,]F\7C*U>#:>GU=I/!F+5*@F<UNLB92/\ >%2&Q1L5C_M!/;+O
M_MP]T^S==+%.UFNDW6/-6LK1V:)6L+@,O9D:U=U_+,J#Z:U2ED94#<&W36+*
M1$P/9AHH'6.JL6%EJY7$YVO7<@, )HY$EC8$/%+"Q9)8I8R8Y8I5:.6-VC<,
M&8'[Q<G>PGV,^T;V56#F2W\L\M5_,'.EGH+MS3S=9;;3VVY_QTDH:=+][K%2
M@T_+DM/=4FDGL]!34UM>I:6:>WU$54XERBGO-;1W>X4]=//%%13^#144D@,:
M6_X335 +Z7JQ.-0::1W92AA1HY(V8]S>D5L?E*&.RN)M5,EB\G4JWL;D<5:K
M9#&Y&A=C66I?Q]VI+-5NT;,#+8K7*LTD$\,@DC=^[X>BC6$<$GD>5>V02-!_
MD_+PJBJT155=BH;Y1VXD#D2+Y(T"MRU>P']H/6Z$6AJ6QO)D?;[;L7+N7PF/
MKSY/,]$[MZ3RY#<-(JQ,]S*=,I;C-D-TTB);%S6O);V'58W[+V+R74YC;=/*
MXW'Y/'7H;^-R=/'Y'&9?%V4N8O*4KL45_&Y&E/6D9+N/R%26"S2MPR=MJK/%
M,OVR(OKS/?\ V77?V<7EK1<X_%IF+M;KBD?APU].C*"V"7\"JBU1K54S2/X3
M,K))-3R4\\NN<NR4]S19:=E;!3Q8PP+(3TQN-2-CX&  ;# J'5D0Q\DBP(*'
MFC(=DDA^EDEB"-Y(G[6E6$M'!*WD\G*"5%X"'N0$KGLORADL2I9@>&=9(JX1
M$J%XR4DO!?'65&3SR=WCDC"\(PC'+&$U:>S%99K@^F6.,H\Z%Y$NUY)"7DB4
M)"D"AHP\:]SB56'D"CU\QN[%U,I$;5W2\T4$;-YW1Y8I91-$9'N6%^V"@L9[
M?DL#'X.]Y31:% /3J=L^6V_VXSYC._&F4E/H1=AD?:,:3UP<]3M\AY<:HAGE
MD<3R6)VFM&S%'(GEIU##'V1K),)(7FDGG+V#*1,GED\?)XC93AP.P6/L;QI"
M7E3N8/'')WR.%;O<B IW=A <D,.X'\%=@7JDO8B\QRUI *Q%>-@QE\QFCYD4
MI,SN6L16.R%)&:)61"O&Q6R44TTB=[?4*H"0V>VO.S0LDECP4T9F"&)A-+96
M5H>]5"J51V9WQ(!.A&"!@D ]@5&1L!O]?U\?4BI(D%DUV2T>;#"-8DE91W1^
M3[/&_P!2T#J\7<KDQ]R!99#RNM-/X_()4'9Q75Y)2B4^)S(HHE%'D(=VB>7Q
MB91,QB6(]G!,_%$MUG53VSO':BL-90PF7M9/P \J%EC8QHJI$H5R6[W*>M&[
M%63Q7IUEG6C+,"\8-=(PI 42I6CD>V5+-(1"/ 5+3RB,(3Z'YQP<8&!@^@[Y
M/0'?N=AN.O?8<:ET2D.OCD6<LL4459RE<KXCY89)IPT,A8IXNXU9)$[Q$L3
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M$01"4\;"QWQ=X+,%0@LBO]K=OKYDQCV.V2-R)#6E2(%(ID+O*[2R*P"!VE(
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MP2TYJSBLBRFO;6,2^.P73Q5(APC.\ZR21O\ 5?$0C$R]W:>/2QL78ZZR_>%
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MD\AJ&3LO<SM#,;GK,:/)%K&SWKF<Q]C;:^1;!6,SDL7!FZF+OP056*U&OO\
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MA]NW;[]^G;UZ<#P2",DX.,87)W)&2,[#8[Y/;;!SQUB%U!X/=_:0K$#_ &L
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M8E1R0"H!'?P4^&)Y!!-:=.-(Y&A01^)E$T\JN8TCX+NT! #3R1=J=\?: _D
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M%UD\BH98BL<O>W!8RKQUQ#$L$44$;1OV+PH7L*AO(L:<+V\LS 2+Y''Y0*S
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M0X' ]0M]QO\ GOBO[JT?^+YSU-+U"WW&_P">^*_NK1_XOG/1TZGY?M'#.O\
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MC.Q]V^$1QM(3@*N<8M:R?6K'+;N#]\U44V[3<&PG':9Y2"/D#Y!YXX'Q^G'
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MB;QRS<GYL"(!2$:)%1V^XL3WG@]K%.^V^=^^X QD#Y[=?/TQP8#';.X([C?
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MP0-MF&V &Z8)..N=MQ>VIY'S_6P_[&(!_P"OCD^O?7RGX_\ XF/_ %%CP?\
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MD^0#VL#H+2$Q161?\E/; ?J9VF\3%F!E9>V/O>52W\2.0!>X*P8$^E@!WZY
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ML5+A!FN^S*HG#S4*KS/,:\<G>#Q&9HS&S1U/<Z&JKKC;H*A7K+5[K[]!H=3
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MJ*K'%S/2 R5/+$[,57WZ0U-AD+9:XT+8IQ,GJ[U'KXNI>O6K*0QP1RL[NZH
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MR%HPT<1DCD/$89!S(RD&4%UC?M8-P0Q7D2->Q'>!O*AD60J5*%_"ZQK7^2W
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M1R,?CB\$C/+&SP+P6L(MMSWO$ZQ/V*8P/$$[4B[G#GM4CT..=>H_?U!_9O\
MMZ\**+$0/$Q@C4M#YH8XX'XAXD!97=&($[ ,)/'W -*Y+,"2WHR \<;R+%\P
MH8I&[@$+QJ/L![>XQ0ABBL2?&0RHC_S'1DN"*N\;!(.WAVDC;PQQR,Q"D,R*
MK>5B79&(X+ '@\,/E;\TI"=RS>)R1(9.V9"D*\AD2/L?O=B)&D$1*]XCC<I&
M6X<_Y[YS]X^?SR.%U78'\] >N.^-AMW&_?;;D2Q,RF.1XP7F2-7B/8CO)PS/
MQ7[4!42,K%BRE">./66C:<HDD[!9>6C"13^2#LE9"IE2)$'F=4/C7L80=LB]
MZ*6XU#;@+U(99 TDBNJAP)!8X@*S([%(PK\AU=4!)[>& [B!J6.>T1*Y=WBC
M @BDBK,BABJR=Z'L 7^1&'W2]K1J2"W/?S^'Y[_/@,,CKWZ_,C(^1\NGR &#
M]V-ASY8_)!(0ZI*$[HI(P%4L.2>"5+ 1GO*L3)QP 2\^>1Y"A21)E61'64LH
M*]L4GB^YHHXY.?) %)9&$@F1CVGT5&\GW2QV?(U=K$4YB,K\2<E4#Q!D5529
M2)8PL[*O(3@!G]98\G(R--%%$!&5CG!F7EI1QYO#7C9F!4*Q(G*R.L2A0 "Q
M'">D@9[8ZGY#?OD;XZY/EU'&A(LE5#7>7ZN-7>6.65(88ZL$:HW$TL!B$H:<
MB);!C:4/Y&8?;]NV9!5![8U2)O-Y(8Y$1C.763RQLI\C"4LR,H("%E9@JANW
M%9=9X)IRTZ$Q-)VUE,,@,Y'C;QE9A&X$?)DDA<JZ]J<GEC@M-4KPCAK$L\<:
M^,A^9&928B_D*H)V[Y2) W=+("W9&7_(X )&WD<_([=<>FQ'SXSR6E>))H+#
M".-9>P1KY)4E+%(HZR,RB9S(9&E#K)%,I(4HH'&-EBL0R%4E2:SX>]C'"9:]
MKA) S31-)&63CDQEISW1*L8*<=VK!/+&D*(T?),<G:JQAHJQB)6M*T8$;%)2
MJIX>P".59)D 'W;*%F>)9"[K&#].CQ0Q1K88-^43L'DB*]G,;2$LX(';R?0X
MZ&/0>F,]3\]OVCKU/%4'O2Z8G1]ZEZUQ8IK'3SJ/4Q6J]2HYZ<$U/7]DJP#$
M83,9*E)'+%)K>SXQ*V#R%BV6J1YR"I5E@B7,5O+70OMEZ9XO=M9V*IF+>!Q,
M>4MY?":2,E7.-R69L8]*S28I<B)<Q]/0QD*1U,1CKYQ].JB=M5((XHUOJ]V_
M3G;^I_MOZIZ%I->IE-CV+!T:5;$9>1*D.6I5[V/OY/$%I?J*\=W+T:URCCQ.
M(J;79*L-V6O6#V8J/>COM\ZI])<+N&]]7M(R.BU,O0PW3C7$W!\3-D%MY#?:
MW4#-Y6E72]E)L+C\+KNHR5OJX[E*.Q:D@GKPS58UE-CMO.)>^<H<NUG)HOD]
M-4+):>9W2!UL,BNX0!Y:.H>GJ8@D,<$T,].98Y((RO\ )VD/C[VO>R9SS1?.
M:;5<;A9K)=+!>;US-)%!+)0+64=KN#U,;-%/!&4N_@PQSP3%G:KKYIX6E,C0
M)*2)_'@*VQ7F:8ONVOZIKN-D7OHG#Z2J=3]M:]69/!;H7-ER/3R"660EWOT&
MJ@K'W!JRO==NNSS=4(\-D)OW;@<93KY7 S78L@U+.[5GY<G26S=NP5S66G@:
ML5S)9*![/GM1RU8G2"!@;T[^KN[5M(TO3#:FF1L?JM6Y'7C>I9EDVGJM/?ZB
M6JV*)\U6W*FNC2\8&F6Q%3AQLEIXK,=-Z<[&]$>K.S]5)<7IE#IYMF\=4J]:
MTAN:KA:46(SV,Q]H4Y-E>P<A''K-1YC'#;K9<TJLEQ)+6$:WC9JPAF^9:[ER
M]4]SY J>9X^7+USM;ZVKBJ/#@9FLB5B4QA5ZJ2&#5=+;031R0F:.HFI&KY8F
M(C;&-7NTWU*_ER&W6J:^KRO16^R+:*1:FJKI+VE EWO<HHZ2">8K17B\5U+"
MPB8+[@ZZ46F>5&:Z*>U[&=:L1K,-3J?H>CRY;,6<?H]#,3YQ-MS$K69<=8L_
M7IBXX<5D-CLP6 D-?*KF,W4-?Z:T,?:K8V"3>P?LQ^O&GFEGL1M5?J:V/:[C
MUPO]/MHP=^A6NPPPSWL>V0>*G9L@(U2>I<R%.]-64%;DSQM 9]]%O:%N>0VW
M5^I77.:CB/Z'Y*OL.H=.,#<3-_2;# #/C<SN>=23Z.Y-098YZ& PD=NM)96.
M3(93Q=U$V)5F@62:&M+*6BF\UB%Y49C,\ D:*V[]XKFP$*O$B_"DMV)*6D;'
M[E[,.1;:8Z*U3U]QFCI=%7>DK[E2U$E=*K1U513NE:8BTRX>5EB]V>225$22
M#!;UQR!R;+=N715<V\J/RO=IGD6E6"_7.>[^[/30JUPKV%0*>CN-9.U1))2I
M%I2)D2>GC9I(!#OV;Z%U:Z?=/,CB>IHDJ?596M+K^)AV>_MUG7L77H8Z%*=[
M/7'GL6EOY.O;R_T=>T^)PM?)QX3&2S4JP=9A^!/X#@+(M:.RU::OVI!W2D).
M\I\SN70/))V$]A4_'C"@>LBU9%6R_;"9+!/TRHD7"1)#&]:!I6FC@[BG#*9
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M '[A\MP?C@?H3Z*&M%/U !)!YX)^6X7CGC@<'[CR1QQR3S\;]\'M4<+]W#
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M]+C7K30122K"L1J8WJ&=UU85$U1OI7>01RLT8(+* <\:7RS[5^4><+]4<O\
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MBR'4G:M:CQ6F8^M+_DUB?&S6*4%O;<C5C>2:KC-?6PDEF*.'(9'#P2+<6O\
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M^OU\)7+['KVK"*3.YG&8I;UD5JRW[E.H;3M&$K4:LMIZ\EFS^9EA3S6>YO&
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M-H-B<X^CT)W\L[\3'\1^4GII$/*W+I#1O'I:R6XCP9)EJI8R#3_S;SK[PZ9
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MR^=;$U+\D4V5@QW[RG:M26V8:TDLR11269*L,<D[B!%B)M=W+=-"R%W)=/\
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MDQ6:WQ>_U0RP"N+A(BT+1H6=HW=M/P'&!>UZ'FBHN5OJ;9:JNHH;#;)YK/-
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M>>5[P.02>0H_U>#P6'!/'V'Y]7__ .*GT1_Z*,/[1D;O/^]_3]/7I]JO1/\
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MK^P#S^[Y<*?^F:, #V<8Q@9_CADCI_\ I;N>H].^W'+!>V*!0W\4? X':R@
M=P/R3]S? _E)^"!SRI"^D5>SRRL55R5^1SWKQ\GDL!R?R3RQ!X)'P.22.M+_
M !3.A7_0Z/\ 7_Z[G_7\_K^OZ^O/\4SH3^NF0D ?@VI_U_M[O^KC_;_6?1&N
M^=A"X\SK3]W3Y>73?/",G\,@N,?\GA7(W'\;B3V[_P 5_G^>G)/5RE6$F>0Q
M2GM($3,/DM_9SS\$\\'X^/U_(]P&I;/U SM?":GA[67R>1G6*&*O%(]>'O<
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M2'&6*<#RL?EI#%W,223\GUK?X$.EW_1.M_WAFO\ X3]<PG]IO]T?\?#7,_\
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E,C&WE@$]>^_3@KQ-.-,X0(-_#1F;+=B7*H<#?"A=S@EML<?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g859618.jpg
<DESCRIPTION>G859618.JPG
<TEXT>
begin 644 g859618.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#3TQ,04=%3E\T0U]"05(N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M  P# 0 "$0,1 #\ O\
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MP7,J="]AXO&9G4[$FXDMNI!8U*V'(Y<#T\2IMR@I'321>B_^76EB"C0S@N*
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MVAY2& E@>":W4Z2"\9WXGTGIAA_'D'QR5M35"TYB.>)\?L7/QERVC<CB1KI
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M$0BJ7/-T97*GGB10D;QF#))%,DS6,Q2ZTWC,64+@2!
M
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M;24,
M                                    !Q6E*]E>OYJUI][MZ5IUI]ZO
M8.0                     <5I2O3KV].O9UKTKU]VGDK^>E>GEIVCD !Q2
ME*4Z4_\ O6O^^O;^#W*=E.R@Y             !Q6G6G2O7\U:TK^NE:5I^:
MH4MI3KTITZ_J_-3R4^_TI3K[?7H.0             <5I2ZG2M*5I[E>WR5Z
MT_57MI[E>T<@ .*6TMITI2E.M:UK]^M?+6M?+6M?;K7MJ.0
M
M                                        '5E9WI*,Y6HU#E#=51X^
M/O%%<)?OA6GH=3\2FH>&9^^6^#=2V6RA?]YD[]EZV?O.G=5[2'_/(?$5%541
M456KDY/W+DCLE\.3D7Q*@   ^@
M                                        !Q6M*4K6M:4I;Y:UK3I3
MLZ]ON=E:5[?:KU '(#Q[NSI2[NK>YKV4KW5.E:U\E*5Z]*]?O#FMUM*TI6ZE
M*U\E*UI2M>GEZ4\M>GW@!R
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M'/@R9,.7'=;?CONLNI6H'V@
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M[.WK[G;3M\G;3M[0!R        '6G7IUIUZ=>GM]/=Z>X
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M/&5R%+$OKES&<N7OMN6PN5F7$'^LOU]KE _(_P"/'^U3N)P
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MMSN=YJY5!0REA)-P*3L>:NONMPG,1?';;G5W"M*BN=OI7,=/&,UUV2H&0
M               &!W_Z]D _I6\T"0SP,#O_ ->R ?TK>:!(9X%3N1GDK[;B
MS%U]1YYN[P   4EX   #7O9+;#6W3]A>F;LY-D<PBR<IRY,3UJ07*10ZKJQ:
M7R'*(+72\E^1;=KAR%,.8U@;[835=9SE\.;-B(WX\5]U-&X5YSN*R?'VFQJQ
MMN6HBO1=4,:2VTB7V7*NOV-VJV?/B*E4EGJ\[,2.T-U*YPSG+EB22A*9U3.9
MS!?$5*9LF?%;?F[>/;GC_P!+KH=F#>-XQM')[T0NIN0F_GM'*V]UU#<!Y#)J
M#P)LY7;;*=ZTT<RHAIJ?59-EKT?"J%R1(GG,F;\6 O2,R/\ D]U-Y,.2.$]:
M=;YN8VT&KQO479QZ[ Q4KQF<462=D5K23KW;$"NX$Z5X]3C)TZCIRH]<J3C3
M,F4ACR9[S"AAJ:PIF2P"Q;_X_5Y0#_Q^OR@     @_UE^OM<H'Y'_'C_ &J=
MQ. (/]9?K[7*!^1_QX_VJ=Q.              UXVAVK@732)%6;]C9 (QW'
M:6II*#C4<R<M+ZPO.=P&+B;>:30:;835EU/%VKQJV_"D-MLHZFK'*83)BTM:
M3*&S.#8<0P\PL,S.YZZ&[,Q#%[PG\GHYNNQMC)-@*/L"4I2"_(YPM-TLE;7X
MR;JP8(DW;)<<WN+ Y6NU?&:6:6"]ZSC33V-4QD[;@-L]<.273O:-I3*[8[E>
MQO6:YF.\[ MF9FNZX&?<(X+TLRN%5:4F/,".SG&SFZH(I(ZJ)KF52.)OGRJ>
MI6EE*\REJ)<KG'639:(-OX,8&QT#.(T[8CDXFKJ#*<AI"6F[G6""(Y%IJ'#G
MB5?))ZR3P7*Z HV%JGB1>XR6LPF\=G>#&*Z[0K65S8N13]TDI["\:RA"VN"Z
MX8*+,+-MQ'2(UYSV2/Q@9PO'.JS!!*F05CJ4RXN?*0W<T79'NXEJU<I4P8Q(
M!# GY[,L'I;5'8-K\;'#>PYZUBV:DC6F'-B-C5/?/4J)6J]\TS+Z([GK.N;7
M-;7HN:2LWGD\H_:;]7FZZW*VT_(;Q>*5A%<1M+SIA&\P6 N8=:5IU[>GWZ5I
M7]5:4K^;IVC2MK\A^G;P3]MUY!F]K'FCHVJF479A\XJ'LC(CU236=5[KI2CJ
MP%LZ2Y<[<2,9DFX,37S*^5*<I(\U,UE7$4S)ML;7T/;:7=.BDWIBF@/Q'0S.
M].\S=*LF5W H.B06JU[):/I)%BOAPG%M?.*KD;:16UNKQZB\IU,*1,YEQJ1R
MZ_PS-II//&E*REK[]$3:U:PP!DBMJS-DU,LU%9S5:Q%@,61D6(]5X(SN9IQE
M6RJ&W#.%7<[,<S 435IK"2R.Y0/8EPUE-F#]^0"P5J%O/K5O,UG8ZM=GNJ.*
MU@N BV7TV'<Q7U%L@,U4640FYVY5RQ[)3>:SP24UUM=0(N-J+)A(HD.-',5-
M)1TS<6.XBNW/=4[*=+NVM:?4W>U[M>G2E/<K7LK[5:B"#BE;$KO_ &^Y+-X'
M- 4RZUQ-LUBT=CJ)8ZGQCF(NDX\>UBA%;94F.92CP_GJJ(K>L<[FPM-I*YTO
M3"ZDIMU5THQD2KB^+!6 U;V[W_NGW3-PL:/N0+8)CQ9R<<AZ#*SC02<U+</.
M!!GD\T8D@AM+#S4;%-CNAKPRXF6_7NMIJMD,-*.4XF:P7YTA45S%EH'Z+O=V
M_?IUK2G6MMU*=:U[FG;6G3MK6E*=O3MI[51A^"9YC39".R\K1&LFG&PSSKD9
MGIB]F1U-(Q*JG%LA.>,'6932ZH6+&C:-:[F>NE4=:QX?%R^GE\"RD9C26=)F
MLU!S7I[R! LP<9C]0-?-GES;9"1>6UV;#RUC?BC.$9\A>RD>ZG3.>CES0(>:
M$FOY)GB\LX%,BFDWHW&.CI[8*KI1@X%!5R)^0D0WMG+BEF?"0=T070]-CW;V
MOWT-XT6A#RPQ5&1DQK.3DECB194?"492+6>L)B4\INL>CD4G:@HZI@5SV"]T
MWGRQ2N<YASV 6Y]D-D(;U)A1^[$; .^K"B",B"<IO5VW(+C<7B8BK+R2V2&?
MQ(U4E:<"AW]:6TPGWM,2SF7%X30QELL+8LV;'F[%ELS8\>7'7NL>6RS)9=TK
M3K9DMI?;7I=2E:=;;J5Z5I2M.O2M*5[!1KVMX]]JFO ?)!$<)P9LX[4.?N+?
MC\=2PDF:2E(YR9-V$V?TM2G9=,9W(H+E[AG:YL)MZK(>!,OQJF$A2S.>)%RU
MY?NK4^H>[N3:1<<S3R:@;RZW7LMM(RO<X-K=?JP\UW/>=.Y$J](9ZM5W.*JV
MMD+BU3ZBGU+%:E4S,7-=^R=\[B@&^(                 " _F48DG/QM(Z
M5-+>U ?FFI!YL%UM9LO[?&8.."=*3@VTERF"F-)F9.37-%;_ ,!?%4^YVLS%
MG,Q\Y,TCW+&8Z9/H9%93_<<++MU(2T:8XJ@AJ2)%K^JHMA[O-DRCO+%6[ESF
M*7)6=%Q.N*G['NQT\F,[*1^]%DQPW*!%AF"BNJ(]BB@6FC>*N+M'.^R&TNZE
M1G([V5M0\K*UXV@BR<77&.\*X7;$ SRD(:"_&IZ3ZTY,B"Z,Z2Y%@\\";E:&
M/$W%Y/6UQJ%V^YT92:2DN%<D4/$7HN1EC9V+^16"2_&.QXM);.S])+\9&C"K
M5T'8<;ZCJ$AZZL75Y(>R(Q61XP2'>Z7&L[#RJT7$FHK/;;H1VLY8Y0NKZ4["
M8%PX IY*>V     #'LM>M=(WO#>7FRJC0#A2^M*<<_Y'D%>9*<-_Y:]:Z1O>
M&\O-E5&@'"E]:4XY_P CR"O,E. $H( .*UZ4K7W/<[:_FI[=?<I[8 Y 5Z=A
M_HF'CNUTGR7M=U5M;32>\8/>9Z/'^N0S!^%ZLI/>J/\ X%?;A9<,O1",F3S?
M4<9I(4[[DK 4N421S&GF3Y?!X5=A[Z;"XZ/XD]_?BPE/G* %G<!6(^FPN.C^
M)/?WXL)3YR@^FPN.C^)/?WXL)3YR@!9W 5B/IL+CH_B3W]^+"4^<H/IL+CH_
MB3W]^+"4^<H 6=P%8CZ;"XZ/XD]_?BPE/G*#Z;"XZ/XD]_?BPE/G* %G<!6(
M^FPN.C^)/?WXL)3YR@^FPN.C^)/?WXL)3YR@!9VNKTMNKY.E*UZ_@IU%=72O
M:Z79)^B">6_7!>F5WN6&8@AO6@[&D0JJV;R-)C+=&A'/HY5&BVC-,>!.SG5I
MU&KG(JIV&EJH:4RER@9-=RG5PXRN^BP..F^VMGI)[^T[NG<]?W,13LI=V5N[
M))K7LI7KTI2M:].E!72TLY*7=J[S![1<ND\:S[7I^E^_--AXSBU=1HH45YRJ
M)-DO.,U!AV944RM)Q&U30$)EHR0M%:*^0H0R**E@0,ZB515&\L!^E* K$?38
M7'1_$GO[\6$I\Y0?387'1_$GO[\6$I\Y0 L[@*Q'TV%QT?Q)[^_%A*?.4'TV
M%QT?Q)[^_%A*?.4 +.X"L1]-A<='\2>_OQ82GSE!]-A<='\2>_OQ82GSE "S
MN K$?387'1_$GO[\6$I\Y0?387'1_$GO[\6$I\Y0 L[@*Q'TV%QT?Q)[^_%A
M*?.4'TV%QT?Q)[^_%A*?.4 +.X"&;C_YV-'>1J:W!KS#F*:X_EY$8^>12+-G
MB,K(W/NUJ)Y\LGK1]HY<+C<193SH60Z2,**>:RIY_(GF,JBF8%$DF+.9-F9
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MNP!!IR9M!S.K#MI'#I;Z#K_R*0*40HQ-%D&UNY33I1INC",E6&'<[VRGD,>
MG0A/2XI*9=74S52*KGNR&L0%A\      !!_K+]?:Y0/R/^/'^U3N)P!!_K+]
M?:Y0/R/^/'^U3N)P   !X5RXZ5K2N2RE:>6E;[:5I^&E:@#S ?'W[%]MQ_#M
M^4._8OMN/X=OR@#Y 'Q]^Q?;<?P[?E#OV+[;C^';\H ^0<5I2M.E:4K2OEI6
MG6GZJCP[]B^VX_AV_*'?L7VW'\.WY0!YTI2G7I2E.M>M?OUZ4IUK[M>E*4ZU
M[>R@=S;6E*=S3I2M*TITITI6E>M*T]RM*^V/#OV+[;C^';\H=^Q?;<?P[?E
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M4I3_ .P\._8OMN/X=ORAW[%]MQ_#M^4 ?( ^/OV+[;C^';\H=^Q?;<?P[?E
M'R /C[]B^VX_AV_*'?L7VW'\.WY0!\@#X^_8OMN/X=ORCRMOLOZ]S=;=T\O<
MW4KT_#TK4 >0      "+[E,U+V$VLC[6[+K HZX)DO:Z;8L#9%OY=ID!Y.N*
MC5K-8LF-+.F'FVRRQH\JGU&K[QX,-3%"=Z47\)74!70W:EH"L4U(X_--.5C7
M3;N9)FG9R<:1R+=I7HAO;8E/U_8^QS7D# ;CR&[HUB](B1-<:D4CI&3B*@02
M3[N5G8G.)VN8L<7,AQQY\^)!*I>4^=28))A;4R,7)&&P;UU(6%C:J&&FJ[4(
M63"9CN F\N%WC:??&P#:RLI\T>T.'<Y<DS\[1S$D%+5I%<T>7N%XMAO%%,]=
MKGP?3 _)2V&Y'ZO'=MJ[_E\!S4U>3Y[A,PNH6M^-258]?S<7V>T8HR7J[!CR
M6\%[*3G3+IR+7BXVJ[R#E8!PPFM);3%),S@6+K[[,=EV3)=;999;6^^^ZZEM
MEMMM*W777775I2VVVE*UNNNK2EMM*UK6E*5J(Z4#E!UH>\9RY*D;VR%(J#&6
MPC/U=;A)M-*TJL3G,4@H<:++'1X2+.M3;)1RMIUWRFWRJ'(2\>:[!/IY-:>^
M!QWQN2P/$Y(Q=3K2M.RM*TK3I7R5ZTZ=OWA$'+.E,X**ILA)S(Q,5<>V7D4U
MSWBA%EK3M/MU&?2!"VOVNL2.B/GBY\+86LC#77-A8<F%FLJ8$AQI2<J7LM46
MJ>*#2P4)@9,,\GT;9$)-QMF"MD'U+^%4G1.D+7)I->.3<PQ'@UG-M$K-ZJ^;
MU*4TJ,CB<U:R%'N5MW,21WD;EC$_6G6)B;RN4\E"GW5GE&UY**;;/-I"E"0(
MB.H6N3B?NP;2;R!;$D.)FVOBC)K[GD6]SNQMR!EL?!)Q-M95,K$8;VP1NWG(
M@.&3<K22%3":MT_;6J&\4326M;E,>+X3>$[3J;VY3)&@9>FU5;K2BM(V!.:X
M>DRI)\G8(U5+'MGCXGK0W*3>3(H!&Y2R/9PYXON7?0FEDW;TPIQG[+1Q'*MI
M^S,<:OB#)Z8?'^UY1G55?"DTG?$V?3YA0]%,J7H\75:*[1_5DMAPDV3T4U+.
MA&QHCT<;BL?MQ- 14K*N@3J2S6E8ND:M/\@WG3\%:-I6I6GX:5I6E?OT&@/"
ME]:4XY_R/(*\R4X9#Y"98VUB>'KL^J>HJ+MF?<2>_DN0D]9V*:&O=D=-;T&*
MAG [2YUV-5TV/+)>>OO)W-Y,P$CM+<5N:IK'CRUR8<><*77U)/CGZTZ?]#R"
M_O\ 9Z"D_I7\].W[W7H )01]<WFL+ELQC)2ZN,OCO,7TLZ5OK87MKFNI;2ZZ
MVVMU;<=:4I==;2M:TI6M*=:T^P/@-%[31;.6ONK;88PYL%UUO3NJ6YL=V.ZM
MO7K3K2EU:TZTK3K3MIT %8?Z%(2BZ[H3/L_'K:F'?LOO?LA*;G5<]]]RF;R6
MF&NBE2ZADKW7^$P&BZP=ICL,&\5,JKGS4,5RY\MEEGWN:>[=\._^\(\N+OCY
M;7&3J0U]5&Q(*A*15OO*27H=?:JV2C14%P_(3O/N6MAE#(K*\6+W(Y PGH./
M/C4LGAN%,QFZX2E<W@N*0\ >/<T]V[X=_P#>#N:>[=\._P#O#R  >/<T]V[X
M=_\ >#N:>[=\._\ O#R  >/<T]V[X=_]X.YI[MWP[_[P\@ 'CW-/=N^'?_>#
MN:>[=\._^\/( !X]S3W;OAW_ -X.XM__ +?A[N[K7\->ZZUZ>U2OD[>G3K4>
M0 #Q[FGNW?#O_O!W-/=N^'?_ 'AY  /'N:>[=\._^\'<T]V[X=_]X>0 #Q[F
MGNW?#O\ [P=S3W;OAW_WAY  /'N:>[=\._\ O!W-/=N^'?\ WAY  /'N:>[=
M\._^\'<T]V[X=_\ >'D  J]\F):V)OHA3@EG!/LIB.2NA;3ZY.3+COORYCZ)
M@:1JJ 3S%K;RW4L25I?/'*9\IDQCQW4IDH2ON*6VF+06.O=6675\MUEM?UTI
M41P;>\=+<VTVRX^=K5.3EME+6@\CR,_4AHD&V06TR2L,AHC;33*,I*9E53C3
M9R)AUK)IW"IE"JU0R6R'2&1.Q9<I=1*R/V6]Q9;;UZ]S;;;U]WN:4IU_W #R
M              &!W_Z]D _I6\T"0SP,#O\ ]>R ?TK>:!(9X%3N1GDK[;BS
M%U]1YYN[P   4EX   #3KD)C.49FT9VYBF$B6!1E^0M=I;:,9$,[C4FAX6^E
MMFJA-LERSH251$-H"AE5KRUB8JW*R>3)*52F92-8DVTW44VD33F=Y->YM\\?
M6I')M "Q!L;L*/3QW8S=IQ>.L&\IC8.%L):24Q"*[ OYM.J.V1$N&85&8ZN-
M*2H\<C<4".)"C]N*MI+"IW'>12/93EK0_<&+X0(NA4F"1-<)?94:)K,=2(R7
M,H/9SLI61VZ2278Y%%'0T'.:43>'!D4E)62RV K>8I51)7WV&<=9;5& =[]2
MMJX5G777Z'NSZN-=KZ\+\"3(R8<W^UAO1IO6'4Y(V.I,AR1D7G(<S+A.(B[2
M<RPT\YE/4),<RR\3E[D=%"Z=A*J %S2VE:4[>OU5U>VO7LK=6M/S=.G2GM4Z
M4'D..O9UK3IVU_/V]*?GKV=*>[7H-"T?D'C%8?3M2;8UG$G#30.S6BGMK<[(
M2SFN^1P:[$UTS,2?G6D9SJD@-Y&:YMJ/%NITA.^.F]&;V>#-<;28KP<2YA2R
MBP!OJ C&2.4R(S;?73SAAW85B/2Y!@EVQ3$;N:K"PR5/[3V;>9N/8*78K3T:
M2UIO%JO1XD3",M(,F.6/'/%7<VJ<O(S'1[[5"NW6NFQ+3V09B\YD! =S(<#'
M?[OBB3XU?Y)&)OF,Y,8ILN7<;.<WH7774TE QB*'TA=2%UH.IS-5RME>0W"W
MUQ035/!EH!%]K+]?:Y0/R/\ CQ_M4[B< 0?:R5I7G9Y0*TZ]NG_'A7MI6VO:
M9G:ODK2E:>7MI6G6E>M*]*TK03@@#UBTK$4%(4UM3S4+)R0GG510,5MNO[P1
M3BV4Z=R]S9UNNKC*X,M]*6TK6M;:4I2M:TH*6''Y&?,#S)0^]]]F]S$RUIU'
MLK3W,B;$\&LN%F^\FVVHV:+EM14#&GGZO-EWDL9#+8>;G@1A/4CYJJ!<N*BZ
MH*:P;MP6Q=V5,VB:;[9+2>4J?4$?6>>E4B0MIENN/'$^)W<:+$[;<%MV>M3.
M;%9AI3!;=FK6_ICMK?TI6,KZ&I;6%K\)>BQ3%C,8[U-H2:YL]#6*S%ENRN>=
M906>^66VX<-;BV3$9PWD\M],EV8K7#D[]EMNLN &K'J-',;_ #B_8/XLZ!\\
M8>HT<QO\XOV#^+.@?/&+/( "L-ZC1S&_SB_8/XLZ!\\8>HT<QO\ .+]@_BSH
M'SQBSR  K#>HT<QO\XOV#^+.@?/&'J-',;_.+]@_BSH'SQBSR  K#>HT<QO\
MXOV#^+.@?/&'J-',;_.+]@_BSH'SQBSR  K#>HT<QO\ .+]@_BSH'SQA3AHY
MC>M*U^B+M@J]+K;NE=9F]6G6VZEU.M+ICK2O;2E>E:5I7VZ5IV"SR  I[Q;]
M"SS#K,Y$&7]1N6R<H&V2<K0?#;V0F,K#Z:XZ36;>#_H^O#T]NYY/(96:3PY2
MZ5@5DU46WMF6E9'+.7"I)!PR=)YMC_4:.8W^<7[!_%G0/GC%GD !6&]1HYC?
MYQ?L'\6= ^>,/4:.8W^<7[!_%G0/GC%GD !6&]1HYC?YQ?L'\6= ^>,/4:.8
MW^<7[!_%G0/GC%GD !6&]1HYC?YQ?L'\6= ^>,/4:.8W^<7[!_%G0/GC%GD
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MAO\ RUZUTC>\-Y>;*J- .%+ZTIQS_D>05YDIP E!
M                 !CR496C^%F<??\ )SD+--H)AE-)GEHV44CN$N95SV%-
M3L5Q=))*!VZIDZ8PX+;L9:^RRZ^EV6ZS'2Z^FKGJE.D7\?:#_JV_O^4QDZ.R
MWBX1+/;[3<ZZ!KUB=-1T%54Q-D:UKG1K)#$]B/:U['*Q5UD:YJJF3DSQ-=?[
M%:YDI[G>K3;JAT:2M@KKE1TDSHG.<ULB15$T;UC<YCVH]&ZJN:Y$7-JY;S -
M&*<E6D%U.ML^M^ZG6M.MK<?EU.MM>EU.MK3K3K;6E:74Z]:5I6E>E:5&5X@V
MZUTGMRG6A$DFICS<:<BF'"<3":0YR&3 C%3A%/SGKLRTAIA6ZS&<4B6"N/'G
MOSUNSVW6XJV6Y+K+M1AZ_P!+#)455CO%-3PMUI9ZBV5L,,3<T36DED@:QC<U
M1,W.1,U1,\U+%-BC#59/%34>(K%55,[M2&GIKM03SS/5%5&Q115#Y)'*B*NJ
MQJKDBKD;(  ##F=               P._P#U[(!_2MYH$AG@8'?_ *]D _I6
M\T"0SP*G<C/)7VW%F+KZCSS=W@   I+P   $4O)QR#.;0A3U,/V(D<ID62_,
M+R;$PR[,"T=;+ 9;<941NR0T5@$G3C/IB$TY4G!P(A5E1<YGX<LCU,5"BI8Y
M:5O-)]V/0#BAY<-A]R-D6+%T@/[2[8!IS-K$Y=D5@KINFR?8X=)5U)76$018
M7V-7'HO+S?7UEUX'DI(268)8VXY\3P8KC,Y$/,U5)*-XK&KN9S3?[>4VD^&R
MWGBUUHO4JKMMU(B8XD!5+75ZU+J:,LE3J:?+UK2E:X317-CZTI7N>M*5$6&D
M<;,31.?YNU6<3Q99A[[=S7L9M_K?'\<Q=<S6Y&VKS(LAMF6Q8:/(R&GMTIDC
MQR.S&83$ZW-C+FL3M.944O=874;K0)<;J=:=*>6E;:T^_6VZEU*5KV]*5K3I
M6O2O3W*BN.@<1LCT=CIC"QAP_&[14G3R'*3SW&:+P4C\U3Y$>[K0GE'9T(/2
M/:-=+,8",5NJ:FV[%=-7WBLQT248$8JS'27@5W@I8F78Z  0 *>EN[<IK++V
M"D"/H29LTZM-#3IGQ+%B#-2RX&9.BGKC+JU(DPN!8?>6+R1N+D"2D%4Q(,+D
M3S?<BV@+1>]5DK"3(&*$"TANIFO3]0(UV./3XFH[9>VW4X2G,SV8+">"DM$H
MW1'TS&=%3<92=(A1/;1U7<J=',>MQ0<[E14].)%'TJKN)JF3:.FI*L<WR  5
MMN,75Z+-0N83DRAN'?1SZ"T[5705:+^F');\EAQT/K)J;;C_ 'QW2,O.-R92
M?=E<=2B=<H^+TZRM^)/*E,%W>;;)(@_UE^OM<H'Y'_'C_:IW$X  \;[+;[;K
M+[:767VUMNMNI2ZVZVZE;;J5I6E:5I6E:TK2M*TK2M:5[!]<D2)II0L03RI8
MB1)X<98H3)X,)4J6+X;:68L!<O@LQX<&'%92EF/%BQV8\=M*6V6TI2E!]H
M                                     ?2S)R>9.$E$P2)YSZ;::L3S
MN8K@RFR-AZS'C.6DS.3'=G*VF\>+%89M+Y,=#%F/';FI?;9;2GW0
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ME.&_\M>M=(WO#>7FRJC0#A2^M*<<_P"1Y!7F2G "4$
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MP4\E/<H.0    $'^LOU]KE _(_X\?[5.XG $'^LOU]KE _(_X\?[5.XG
M                                 'KU:JI1+4:HEI"]9H0.52K%2\QC
M3;E*A;+4A:H7E;;C-A&XWWFAN\O;=GM+URUPVUR4MI7ZB9JB9HF:HF:KDB9K
MEFJ]Q$[J]Q#XY=5JNR5<D5<FIFY<DSR1.ZJ\B)W5/8 -$+#W)?W%G=H&D%+^
MXM[YW+FG3N:7]S3N^XZH'6MO==UW/7M[GIU[>HQ2UIOY!W=*TKQ FM/3O"Y8
M>(1ZH.4\<7IGQHI[%)*2HK")8BF,*=G.Y\I0LEF,:IX:0(68L]V*TI><QW79
M+=BBPS4S,J)(KE8WLI84GJ')=:?**%T\%*V1V>74K45,$299KK2-V99JFJRX
MNI('TT<UIQ%')63K34K'6:I19JAM//5K$S+-%>E-2U$RYJB:D3]N:(BRB@--
M6<<Y +W6W+'\B:AX61<L$K79F:+@F(PZ,2!7+_YQO;^!81<"5F5K<7:3QJ.7
M&3NR=F:^VWM&Y7X1B*VB6B>QBU-'4Z[-?6HJEE2QNU4U7N9L:_9GJKMR5%[I
MG+?<&W"-\C:2OH^+?J:EPI)*21^;4=K,9)M<S;DKDV:R*WE10  /QG[P   -
M)-]=G-9=6H;1G/M&V%:06I($BMJ+&5&#:B%2G9VR5)"^26UM&:[4C!+2%LRX
M%C&B-IQ+U]U2=F,HFHIW-X13/0N7,>DT(V5@+8QCO,QK[ <NZ_-=E.8HEJ+:
ME765PZPW*JHLIGC;QJWFNN(J'1>)TPT[P?5RI2ZW =Z%LU_=W65NU+YR2B/F
MUYUY.EY+V9CR74C<6+%#6\CI['K D7861)SR,>4TQ$8S((24=2FJA)^5G*+X
M<;[<BLL)B04C]ON5/<%51OJ2FAJ?W.'&6Y%D%J;&,^;YTVYD*=HGE%L-J2HC
MW0BR$HPEF#JK3#(.5LXDNV!+,S%>,?R4CG_16U'B44C5%'&4-E\> E0M?9G
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M,N*.?2W=<8)RS*\BY'.MM#&FR8IKT^I9%KI#L0%LLWR[>3J'L5,@%IL
M !!_K+]?:Y0/R/\ CQ_M4[B< 0?ZR_7VN4#\C_CQ_M4[B<
M                     1;<DN[$J:?W0]2-$%B+5) J^Z+/HT3EP_X-Z&*-
M6I&J=XF7D3O7??'9OPKPCPKN^]E^]=Z[G)WR+KU:S:;_ "&@O_5U[_\ /@V#
MYTOJ]9?PR]^S'HK]"5VC3!.%+O@NSW&YV.BK*VH6X<=43-D623BKG60QZVK(
MU.IBC8Q,D3J6IW=I#+2OC_&5DQ]?;9:<0W"AH*7]&<12P.C2*/CK1;ZB751T
M;EZN:61Z[>5[LLLR8+U:S:;_ "&@O_5U[_\ /@Q2UN4S8!HRK*\OIK2B7,Y)
M@(1\GN4D<179D126*-TI21T2]%+XG?A.X,IHLIF,BI4Z>/8\N>W%<5QE,=M;
M+HTP'08M'^"X65$<6';>QE5"VGJ&HV7*:%L\%2D;_P#-SU4J*:"79DNM&W;E
ML.:2Z2L>3OII)L3W.22CG6II7.="JPSNIYZ196?Y.QRTU340KGFFK,_9FJ*D
MP7JUFTW^0T%_ZNO?_GP/5K-IO\AH+_U=>_\ SX(?0%KXM\"_PS;?JS?C?G-?
M!E?^-/2'_%EU^O#X/]GP?^U_>74]&9\>&R^NC5EQ])S=2W&MK3R3C1-K%5 F
MC8\#?<ZDBDKB^!44E4Y;ER%2>.\S7(=R6WY[K[L=N*RMN.W;T1I<2/L(8\]]
M,G^?ZZ)+1#7%=+3T6)\0T=)$R"EI;S<J>GA9FC(H8JN5D<;,U5=5C&HU,U5<
MDVJI.K!5957#".&:ZMF?45=98K54U,\F2R33ST,$LLKU1$17/D<YSLD1,UV(
MB   :^;.0M<LQ7/+3.18G4-7]QW:M,23H5E+7N=M3I>UUB646M.>=.EHM:JP
MTJ3'*+5PJKO8382E-&>S36VZKDG2U)2QET9+6<!-P*#;^QP]L(DQTG9[,[(]
MVY;^P[NE)FN:>9"WDE7723-B9+/9(Y3$J/[E4MKF[7 W6&PF<S4K B1XS5%)
M;O@J28,GTG&KE3F=1&J?T0#K-K0ZL6I\^O\ @?8W8&>\<[H,4Q#%VO\ M*:U
MEL?IE#B^=IA/DW>Y%+(;0DRQOLMI2(IHSA9Q) F!45;DIC-QYE4M:-))WLWT
M/\:AC*V-HJQQJ@NZM.I96=;Y!<V-_;@K^Y,ERTP)4@%&D.#9(5WVMXLEJ&RS
M3$7\B2Q6\54SV4OF).G$K%497)&DO !8C'HG,V&V]$!7:CP0$1U-AP$#"6NM
MQQI*>NH*TF&[.]FDY61U4N;35(@9QUK88)G2V<MFL_>Y,5U.P>]  8D/P%!B
MJR6O&JG#44J,=,<^F*K+81Z.6:<9;14T7-D,HRBV&J91,J"WSR08RY#"8<2$
M\F8(9\F3,5R8LF2^Z[L*S%\;.-XM:1'!'[)7'^QL!\LRGPL--OJCP:!=5L[V
MJX&NYSR<87&_A4\?^#4,20?)XSMG[TQ;DI6M*]Z  :>;J:I:V;21&L$-C(-C
M";2+!;[X<[+)R8STAW%VNXL[04B>1:1,*N7,8T]2N+XL6+PO!;;FI;BQ5LOM
MOQV76X!X4J=.)/CGZ?R/(+K^MDI]:_[QO_+7K72-[PWEYLJHT X4OK2G'/\
MD>05YDIP E!                                 %0[EC]G')WO:B_S'
M31;Q%0[EC]G')WO:B_S'31V?05SRJ^@*W?;:<'X1',6C]9*#<+J1P  "7)"<
M   #X\W\ 8_HYC^IO%['7;V/\&_B>C+S)0Q1.S?P!C^CF/ZF\7L==O8_P;^)
MZ,O,E#$>^$!V/PSZ9<_N*,DQP:^RN*^C[9O-69C  $8R7           !@=_
M^O9 /Z5O- D,\# [_P#7L@']*WF@2&>!4[D9Y*^VXLQ=?4>>;N\   %)>
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MK:_[Z5&@7"E]:4XY_P CR"O,E. $H(
M   J'<L?LXY.][47^8Z:+>(J'<L?LXY.][47^8Z:.SZ"N>57T!6[[;3@_"(Y
MBT?K)0;A=2.   2Y(3@   ?'F_@#']',?U-XO8Z[>Q_@W\3T9>9*&*)V;^ ,
M?T<Q_4WB]CKM['^#?Q/1EYDH8CWP@.Q^&?3+G]Q1DF.#7V5Q7T?;-YJS,8
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M/TZ=?O\ 4;_RUZUTC>\-Y>;*J- .%+ZTIQS_ )'D%>9*< )00
M                     !4.Y8_9QR=[VHO\QTT6\14.Y8_9QR=[VHO\QTT=
MGT%<\JOH"MWVVG!^$1S%H_62@W"ZD<   ER0G    ^/-_ &/Z.8_J;Q>QUV]
MC_!OXGHR\R4,43LW\ 8_HYC^IO%['7;V/\&_B>C+S)0Q'OA =C\,^F7/[BC)
M,<&OLKBOH^V;S5F8P !&,EP           8'?_KV0#^E;S0)#/ P._\ U[(!
M_2MYH$AG@5.Y&>2OMN+,77U'GF[O   !27@   (GN5R(95EUA1(GQ9K#-NS9
MQ'>R^>64:$^0-7X_U-II^=L7X<*VN.Y(64;-(*<=-V6IA=LWYLMJ29OJMTMM
MM[Y6NC'$JP'L0V-5'8:U5FZ+FJ7CR0FX:D=Y<V&3D-9V%Q)KF:Z:?9V6&,3X
M<Y1/<=B@4.%C#PN+8S+/-)1U"-7ES*Y7#66+D=+,EX:@S' CKV!:VM:_M@T5
M_5.)Y%<ZU8E5NF"=T128[ 0$(KC/IRHOK2PK*%N"B&A&+%<TET4LQ?(7QE\I
MG%!=Q&:3RS#W("[K955N/F$'3JU'DZ)YW5_2A_/!P/5.;6Y"_"K[;* ^&B[&
M@TK6= S)RQ:9>D8%L-JRMJ#RD)3/+JAA,Y<OAX%K<      !!_K+]?:Y0/R/
M^/'^U3N)P!!_K+]?:Y0/R/\ CQ_M4[B<                 &O>VGL7-C/Q
M&RKYDK(V$&O>VGL7-C/Q&RKYDK(R-G[+6OI&BWF(Q=\["WCHNX;I,4<K?J;/
M\RS]B@Y'%OU-G^99^Q0<CT//,)O(GB3^0   ^@2N\-7LPC?XFG[_ ,;9 BB$
MKO#5[,(W^)I^_P#&V0-,TB<R,3=%5'])O.C/G_A+INC]LM9@ ""1Z+E?3G2^
MKUE_#+W[,>BOT+ O.E]7K+^&7OV8]%?H37T1=KZP^.Z>^*\@'IK[9N)?F?W#
M:P  .DG*P   +<?$C["&//?3)_G^NB2T1I<2/L(8\]],G^?ZZ)+1 ;&O/#%'
M3]VWZ<](-'W,;"'JW9?=M,  !K!N!#H]Y)R;E<C$X\=$NQ= #TT]AO4V*9<E
M>.ID:N![/B<9!FAZ+61@KK(05FF5 *QU#=D>&R[E7*)YM3+/QSH./$;)Y+4Z
M_!U_A^==C-7=[]([H1UFBK/I5LT0:N%S:C1Z5C"'Y-0)?CM#E5I*"FTBU3%2
M<P,UM**<S)5ORJ:C=<JIJ=CIGIWBM<N6.3K2GC%GIDDIZY$DAC,Q)AM*HDIV
MP:Q++F@!PLQ#6U6RW$ULTH,UV,U34$-86CU^),9BR<64XRN*F6]&1Z+!^[+E
MSGH!&>B\.03BC3C_ "<7I\-MQ<L-K)*-W)F=QVCT=K7;+UN4)'<2PJK;U5G^
MNLYQL]>,G9 4S3JSMQ3;F3+=C2JIF+&!O        Q[+7K72-[PWEYLJHT X
M4OK2G'/^1Y!7F2G#?^6O6ND;WAO+S951H!PI?6E..?\ (\@KS)3@!*"
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MH6!>=+ZO67\,O?LQZ*_0FOHB[7UA\=T]\5Y /37VS<2_,_N&U@  =).5@
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MQG_I4Y_W>-(>;^M;8(A[I6M.LRW4KTK6G9Z 7;V=GM"L_P!W?]E=\*ORCO&
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M9 _:0.78:]ZN,E*8<UV/_!WWW8^MM=-.%+ZTIQS_ )'D%^9*< )00
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MD1!0D4EG4E=96%0]EP$DU+2TXL9/*!\WFQ%29/!F,F,N/#BOOI[@:?\ (3[
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MW\<MWF"[16>%F'G ]8>'?QRW>8+M%9X3)T+\Q*/T^Y;PI!+3QVQKCZ!:MRC
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M_P#H4.M*<UNNE:UI2E(_V-K6M:]*4I2#GE6M:U^]3MJ+/7TDYH3_ "J]O_\
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M .O9 /Z5O- D,\# [_\ 7L@']*WF@2&>!4[D9Y*^VXLQ=?4>>;N\   %)>
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MU<JJV1'+Y[JV$LJHH7XJ4\*R4KD/U'&_[JAS*?'DK\UH F5NOLZ5_?6^2O\
M[U/<_"/R"?HH?Z^)NI^& ?\ _-$0#]&'U'&_[JAS*?'DK\UHTEESZ%%X\)_D
M%?EJ=)OWTE^4G5XL]$TAR'L0V7,\'!XE222"D>-EM0B/(;.^+$1-3DDCWV^O
M@Z>1*EL?3'BMI0#\GD!^I[])P\2O^4FW_P#MJ9OS0!])P\2O9_Z2;?U_?6]:
M>G2S?)W5.Z_ZH*>UU\E:5]RO4 ?EA /T@M%?H0/4QUZR,9<WE2]E(YV8-+LH
M8GPT65-T;9FVG(1"5'F0C$R2R(3+>R97.L1:69JRI4P.,[DM4SYRTUA33=,R
M62V[^DX>)7_*3;__ &U,WYH !^6);Y:_YM_[%P_>PB.ZWTK(W_?6_P#Z!9?M
MT]ML)-:>W[@K%?2</$K_ )2;?UI6E:5IZ=3-Z5I6G2M*_P"*#R5IV5I[=!(R
M2X9"R:3*IZ?RC<QI$@1+%R1(F5W?IA+%"A3#87*EB^&R+*68\)?!BQX<5EM*
M4MQV6VT\@ F@[NS[*WX5/E&O>VEUM=7-C>EUM?\ $;*GMT_R*6:>[[M:4$=O
MJ.-_W5#F4^/)7YK1ZU9X6$MQ)"HWU_D^YB%A#6T\XDK"2H;O4,D%-+4"^0J>
M3SI>^+>YS%3A;+E+F,5W9DQ9+[*]EU1^JAG;2UM'5/:KFTU53SN:W+6<V&5D
MBM;GDF:HU43-43-=I^.X4SJR@KJ1CFL?54=33->[-6M=/"^)KG(FU6M5R*N6
MW)-FTK+VUIW-G;3ZBSVZ?84'/6GNT_703S_2U.IW9_TP>33LI2E/^EF1IV4\
MG_5:'TM3J=_+!Y-/C9DOFM$G/C]L/>*\?:4/XY$I.#9B!$1/\1V78B?]"O\
MP2!CK3W:?KH'6GNT_7028[<_0Z.=KID 9-1=A>05^*:WM7!C:V PN_;1L4QM
M;5)87#^&='NWJK37:EE78VD.Q/,H5$[(O+%<^3)1.;*SD[O!;MM]+5:G=O\
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MS0)#/ P._P#U[(!_2MYH$AG@5.Y&>2OMN+,77U'GF[O   !27@
M        "$;;O;G95C23N0_XPD!#:<5\=K UU?;KB(\P6\XJ['9)/M77M*"2
MY'LIVY'&QRJ3&91(1XNSL4PAFDZ0KU)??&1VM>A1M";D:13?H)",^2G;*3P4
MI+2KEM.C=%EF/V<^3+<C&?D.'G@??<6H\U-+"0,^BHDS'*J*.7#5+46Z;<J
M=,,9\&G0P[J-FT#M.PFW;+UT=K99[I;;H6SSHA39R<"9I HD5*8&_JZWF.XW
M:DF?&2@2S>.G 4?:=A;E,6+(0J8)GO&AHCBH7OS:;2)RT(;:1W"\V)KQ(LEQ
MW&$::PR'.+G*.]@-@_&V7;C"AGHK;))MK1_(=>ZHC(3A2G3))E&-$R3<;ZB0
MN;=[V6\IM#(YRVKTG-;6; 0:Z'4Z59KPY&D-;-,AV8& ]EEGR*\U*?+HE;)]
MAJG>F^JI)N)W&P&P\;78;35=KR BNLLR5)FK9*F-3SXM$YPXCI'<JRWH\BI]
M%2,-*C'U48;_ )"<,SR<UY,6DG621R#G2#<J0^S&,:B#9!<(M5))->-%'$MZ
M[)S6*&<Z+)*'+K42F^E$P,Q.OD:E1BRD_F\W80<T[$WC)NV"1"K?1W+'T:)S
M;C[0YE1*WYU6W ZG3CM,JYQV38XI%;S5PV%3]<*BBHB88N2F^:4W&DX=?/*[
M)KX-:R$6!%3J@3TXYVXRGLC&WV>C5]&9+T^WDDY^,RRIQ.;YI>PQO(-:,(^4
M<"#4^HGVZ74T100'8H',JN41Y.TO2:%4RD7Y+[7<I'XF9>P[(;ZLI.7)F4E(
MAM&LHSAF-6<N7"3P8EAQN-;0RRKC5JX2U2)XRH9<&"M#=UMF%)$XK]9I#:L=
MMB]0EUG&(FCK56-8Z=C#DDXW'BTT?31U.EY08JIBU5+/6T<B(NO!9SJZOG)Y
MJKF+(7P&BUEA>WN@)),=]+[+;K;J7=:4ZUMK2M.O2E:^3L_,/,87@B&JP8R<
MK*NE299@KE7E)<HZYT?=9#>F*BCB)XJ(V%>JDHW<(1#P/OB:G>"5\%R&CE_?
MLG?^EF:  $0VZTN[:Q#.$>9HUG./*J4AR9#C'ULTJ0(Z272[]BT"Q?0;]J'M
M,#P6RM[QCQIQ6R%Q5<Q1_P <'49DQ4F-U'69%,/]:?"1'=TO(T!?_'LQWSLJ
MX-J"<[[5Q]([H38Y;RV0CF:*MUG&FA&!C(?;['P-\RUU;(F,P\JG5M9<S=2E
M(D0<BVX5E85+,RB8+F"@&#.26:=QH[=T6I6N"1-J3&:?%4^2I.<FPQKW$L]K
M*)5B&HT(,=N8DJ:9+BYK69<Z4O2(]C;?:ZDYI/=I=G%T5E,Q8S9CE<&VYK:Y
MAMEAZ<.;&HK,FHVW;QC".8]?*(D$D$LJF9#AMY2ZAOY90U'.GYT9"6T!B'C.
M1+)%\ZDG'EM.(T(4P8#60OT>4./R-I5-W*ZM+>S" XSE9G1%UU-*;EQ&<CCB
MJ=7M>^WA!RJJ94]0OPQ8BJE"R?&9-%QH[PB5OE+46.'HVRAQ5\8_3V4TSRRR
MB:7Q?%ZM9#D5ZT3:TY!R*##<!QK/]D-2+H/DY@1JBQ+<9;3Q;!V[&NN9M-MR
MHCT3;TDY&>9T8RAO&X+$K)4# "GRU-Y:8S9>$-Z\27*Q_-KS,.UT@-+T5QXR
M5EAP;#3_ '#&:DHV&W KYD=TOEXNIKKN%C,Y-.DB1P@C*QQQ.IL7XDXNJ^E=
M/)2\,,IQ^;C:-'!)S.DY%U-BIGQDGJ#/:INW83:J.Y:V)M.NJ0G'97&F-R+H
M/CMFF7+@3"QXQGPR5<I)J M*J<G)1K%&P?$4ZBS 08OU0<=I5MY8>V/@Q1<,
MA[#3+&$BM1BSXX*N; TS+LC!F.W'-D*M!845A7+10ZDEAR@87<117);-)^1?
M>N%:D0C[0N'V0WHN2SQ]UN=8BV8V%/B6X#BGA3KS<F1WKT1UF;YC(FIY6TM@
M:A*,B.).(-*F3.6(YK,&:A_/DP4NR 1>; \P\J9M/IUDI@0$]=?'OFT\W2F6
M!'^]W'$TCDK)3TD=:%&LUMA>9J&=72V$F@OE>IE8*ZI>,4:16^CJ2DHI;2S9
MDE*4["J?GJ9)%<U]]M^3*5+9<E;>Y[;LN#'DK=TM[*4NK=6ZE*4I3I7L[!'\
M]^,35M_Q12&5]+>]S+I'&WL66XB;T.%5.UJ[NO8D_P"<[**-">2_Q@=<1 MF
M:YZ[%6YM%K;BI?&9LNK<,ZZ[:V?N>K7592=]D)IL<]J%;CLV E2LE6MFQ#M4
MK+;&G2K?0_$UJI:HVT6?_:JG_%Z96M<52G7*!LP.*]>E>E.M>E>E*UZ4K7VJ
M5KTKTZ^[TKT]RHY  0_RQN3LO"NT6X":^D.,Z0A"/'A)NV$/LAL'E1:>#L58
MN=R\0.KDENA20T#$A&'271:)J.Q&I1436XE=VJ*SM7%Q6L)MKMVG4R;'I<[X
M=?\ 8N4T><5"1-1(JVW0'<E1XW(U] *\YG@>8TE1:036U9B+KL>$U,TV5>,E
M)>L./Y+3Z.!+>SG=YG(EJ>'=MQ:X14[I67I?<R'F77(Z(+5=<W$F*9NIMJK,
M5KCF,.I80E!O9<52IG(I*!HR7-F[\E;LJ;FR$;L?>[NZ&,=9-)8NU94EY=:C
MHEB0G&K,YAQ<DN2:) .R,O,F'(OS+6>/8B9JB=(D,J8S&QG<2R<N,'K51XNM
M3-XE5^NQUJ1!--DP,1I/)O")IN$'BM-M^-MJY85WNGA85CI1$.U0&/H!,2'#
MTLW'"2:KYS1M17U!:HOLTJ0MS6&4<F8PJ^9,4[\!2_"3BY&I;<+5DR.R^OCB
M@"?EF&=;GM")MW/..)'1#1O=29E'7R$#QXNVC!@G:Y6.\"IIP22T57#G0T_
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MH(#BE.GMUKVUKV]OEK6O3\%.O2GN4I2@Y
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MN0%FFE*TI3KTZ^WT\G6O;7I][KY/O #D
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MC^.)QIEY2A7 0+K9:J;FLU6TK2VVE:]:TMI2M?)UK2G2M>GM=0!R
M
M                              # [_\ 7L@']*WF@2&>!@=_^O9 /Z5O
M- D,\"IW(SR5]MQ9BZ^H\\W=X   *2\
M
M                                                         !@A
M_P!/\=D!?>I*W3_5$C3\_P"<9W !]7D;XO\ E2S%U]1YYN[P   ?"\
M
%   !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g988525.jpg
<DESCRIPTION>G988525.JPG
<TEXT>
begin 644 g988525.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#651/2TQ.15\T0U]"05(N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!!P*4 P$B  (1 0,1 ?_$ !\  0 " @(# 0$            )"@<( 08"
M!0L#!/_$ &X0   %! $! 04,$0L0!P@#  ,$!08'  $"" D1$A,4(3%1"A46
M&!DX07%WF+;6%QHB,C4Z6%EA<GF!D;&WN-(V-SE3DI.7LK77V",F*#-"4G9X
ME9:AM-'3U? E1U1SB)29)"=&@H:SQ=0I283_Q  = 0$  @,! 0$!
M    !P@" P8%"0$$_\0 3A$  0," P(&"@X(!04       $" P0%!A$2!Q,A
M-G6QM+4(%!4R,S=R=':"%A<B-4%15F%QD9*5U/ 8(S%5A:&RLT1E@=/51624
MT?'_V@ , P$  A$#$0 _ +_%*4H!2E* 56XY M_]U>._="^Q#B/6F+BG;BC%
MT:;-L1)8#9&E+6A7EA"N,ASJWW&WFZG.=QQRFK14D654AQ+"\-@<451"MB 9
M7V2<2;(]:PFM<"3L=.R(<K&F;)4/[%MEL-%:B=688X802 CM,ZT%U(<RX<=J
MNGO!,=">H&<ABN#4;>:7?L8!&#F>.)C "&'9+DFFAEI^F.O6O$NH4@2UR5;L
M3+$T-[*.U 8#K:$2:VQR]2-EF06FVV0W6TSI(<9!D+;=#CD%T8'$];5SQI;=
MAM9+$K)!F6E9"D/6PX'*D@['K[XUR9$3OLU)"?)+28YZ4C[^LILT5@+#35XR
M9#)"6+J9;!VMRT:)K5'5'"\G&TR31$OE<%O#:'8<&<%-C5[5. HHDQZQX]]"
M=@G_ +!:8S@*G$G6X8L4GM+SAE#T!O-L*2B42938&2<LIS&=2>H'V^LNM';:
M4J8KB(LYG!S&]L@:FG-H8]=D4;L+S-F"*7@@(20K1+';5=D3LH^LM]WH+W3G
MJ?70Y%<<I!N!,7VPD"MHF@OYOHJ$1N?+*15TGC0"J2 CNT=W8W)V2>7+^1?8
MK#C9QZR3<C,:!8\66R6?3:B=!*P86>."2]\VLK,1??;I5U#N*D_[>CP5,2':
M<5TEG*N;33$T$YJY!'*%LY*N@_"BM.E[%"4[\F>SY^,I5E%NLYJ)QEI1JV71
M,B\ZK1XWQ4@XST1R&4AHLMA(*DK-]=Q3$,XM+8A8^Z RRKAOII/PTP[Q_K>]
MRYKHZ0T03<I;2LV^EKR"['$E0PRT9K*:(F,G"ZS*:@JR&"365]PN;!?45-LK
MA@10!1S9D8@1 $KU,5</"7$NF^ANM:7->"_(7'/-R5.<!3$?C<--)+2P56'V
M976K(K$!>BF,=;#M;TD.5NJWH=>*(I%#!9MN).,!GD80HH 9IXF=N'[NUI82
MD"33P 4J,Z59[@![NENI*>B@KRS#$I.1AI+Z(HV0!U%3E=R-4HVW$M$"Q')O
MEG2:6 4U*+(V)5-!@;T"Y4N1Z>2NAR^CO8YL\\9:WQGR MHHA*08R"#3C+55
MF+Z<G%=AE%_Q<Q&R/$:VP2HE\2EGNX3Z'*II2%24A &4TD;NEF'2;3MK:/:U
M(4 Q\OC.-2*+<AOUT/QPI0)<9X2G*KS7)">SJ/(*6<+A$4D=SKXY5%;I54S%
M2&JGHZ'DMGC),17,XBXON/H;C;UZ6=>0Y=PF1%.RS(LKI;B&8%X_4R!N2UL-
M?644Z2">SS)J14B?#Z)9T+--&P+9Y!&2XPF.(]P,$-SG'U7<#>FU_CQ;M*W(
M>UN5=GVQ.TXK\1)F,21J^-6#+;*.EA+#L17NN!'GE(9ETI9:($5$ 4LWF>SR
M2QAD=5S )"]L=_,IK-&\/[9RI)+,F5GJ^E"+!COGN(QT-CJLG(;!V01VZNQ"
M^$(NER".SG(C+Q-Q6)J94B\<5MN+:$XDA52PQ2:<*K=-8_#:Q4_1[>G1R39>
M5GZS-X)OGZ=%QVH#++L=<CQQ3FN(3L!*H1 VZGD26L&"[6TC+*$94ABV"K@5
M[P5R-PA,Q+XRE#A!*3=#O(&UY&V%P"F7D#86KD3/24&O%'>;4CR-]3T5I)3*
M3FE&ZA(ILV?7G6>0%EQO!85GU8M8^X":<C)A1,;)>RJ![B1.?O5Z)[SQ\D2!
M-O6KAK0HZZGYK%48WCJX#%BC:<RUB4.S>K#%9=,X8,I;/O!'(GVB%<6:$8U9
M0P4HP+X)*MF1VA<G*[K"UYT4884,7L(DH.U,=:0.>9"R4C9Q8V]K979(SZ8\
M1*!G-PAO <R=)XI[>5W6FM ZT&V\U]%;JRLEL\U4XD:0;*<$%]DR^_A99VEN
MV ]]8LTBBYR>=<(AJ&<=$]*EAI+J(KH&1N60,5PR_3S5MBJE5/ D&A%3]PB0
MZB*4P'&RTYN%YENF;EUY'I9&+PV^.0&(>3!_1629.(2\K;)Q$P,FL C(K\'=
M9H)&B-XNXNC2&Y&Z;:RPYP#:<HM=)=99'7<C*6!^,8\T\<JK9W<DN78P>4;1
M[K3O\:X_XV#[[8RBY96ET@8CIC -< O=] %TYT."2'0N*88ZIYT,%LQN6(KB
MX][G4]S%DOORCR_Z^OEOM=EQ$0E!RSW)BGN*P2D:-!*CY;=\2.C2\HJ)TYN9
M\*IYWFXQR;[-<'H<!:)]%<+R+RD,Z&WDRDAR$!ESSHP#)?!$@OJ*MR8O3-G'
M.W0=CM_Q>2N)EX>+&RNJ,#;,&UE'7#XZJ :<@"?+["%'2AD\HUE FRQRR,JG
M@3BHJJ.!11+YGDKBVDU^R?K%L<G[+,AG['P='VQ,1O9:;^M2<1A:08SV/;=D
ME=0FW$)"4R"TPE%B+P!)XL9=5),?IPVKW5"+WLYT0Z034<#)'#AL9,VYW%IJ
MML+.3RNJ3)+K"=AYX/5OMYIMD015(R4^6J254UO)B'9HIYHJE(J=W,#!OYIH
MID"XQI/&N,.'G&YQR\Q3R2./%D;3[V+\E32YY;W]=FF3-'BR,8O*&R#@/O,Z
MTXL3LFBU<8Z"%**V:::Q6%4N&OJV2H,!B"2P+"!@X3"\>.F2IH#HY#.G23)Y
M&33L*ME?0$.2%-B#-<LJC+3J<#O!-JK-)O18$N 14G$9+9%RCJ*BG4\N7QR,
M%35Q3.<;<><$0C T]@_4</:6RJFPER&M+D#(/D6$,"A]P.%K/,\^/D:G4 .6
MQRI%&/*Q\4O=QEU4<\63L0PK)(X^.1@0#:EE\QVM+]BAGOU#9<S /Y_;BOG0
MYIZ]JZ RRDOJ&RL<G5C!VM(P*4?JA&:>@HJ$BFG8HO<Q(GH7)H@I,J*?NY#I
M1 'Z@X>;O79)!@HB@Z_;J/\ ?NQVM<C[-17$+,@,(Q+BN@1,K*".^X]4&&N/
M-#64F3D@RDJ0Q5-'!%:B\2*AF6\\%7)21@%+ YW@H.D8ZN78NV!IHSVR>3*2
M.3>"9DM"Q930V#(,IJ)4R[XH>D;&).QQDB-U), S2C I9W,E=&QL5&R'Q!!-
M$C^]"CH*Z'1O1K'O,]9T*K;N@#7R6(.7&<G18"AI+Z,R^K76UMR)*D&_#HK*
M3&^:!3DYK-DTFO10#1"5P5]WKRN9%6K >HQY;-5?3%E]=!C#M*J^4[H>JRB\
MS!9K6;"+LTXH<49Q3(5/) +L&D0PO^A%*-(A]PI+'4F4G2/F4CDRXL7,8N6"
MPLA\\.E2F6E926$N:FDCQCIH9WU+**\P2/?#XUQ*22>B$RMH3;3G,>=C;>($
MA$@4?-AR6AL9=N06$9Q!VS03)L^1[?%O%VXH.VWVMGN)]AR#>BS;B0#$XO*,
MUB"FB[),84[G&D;;BF[8JG%:<8H+=:B^HB)CE6VDK1DO*F"@B$BC==K>+#G1
MQ].]<N!R2H)D16F!:W:1Y9E)UZ*RUI=(#LD'5E%<^4G&9&FK"8P)BE8H[9@=
M!F672:%$-M.4",D*;BSDUM9%$@%89Z41*$@ -_E;E8@Q%8L0NH^S'_@N[#2N
M:B;7IH%UJ'#@,YF"$5D)C/R-&TFE95&AI4AXHS3@V(T@J4@I)4-S)YQFBIP+
MIN DB]:AKF3U.V-D&)XY@$G(DL+TJ11!4U8$V\G,U.66E',]NQ29J4YEIIN9
M\(CM7TJ,%='4;SV<CM%>P$0$K$CSAR&*',ARVFB;YG\:K!CJ("$&SBCQ/)FO
MV\4L[G0D$=B(Y)FO,?ITT(#;:+ZUT)PHZI1+N$:&U9NM8F/8$E*J0MISG5%Y
M:1C*: >+IY+9N8^)0G.FQ6I&P;\E1H^BG4Y[0H_6B[&="*7'$L%S,9GG@MOZ
M/$20&0\TDH6A";%IQI@:]%[H;+O+,Y&2%G!O+1QQ/EQ..@,P;/;-K<8\AW&W
MKV2E9RLQ(V();;FE2*B$.,UZ($\&(NB5.<R6F*DMJKT273"1R-C8N+G(BHC4
M74Z01E4%O*IY.+%# Q?&6JG-7J]MU+<#1*PH^V%:9K91N[#K$/O"2&.ST-GN
ME7U<<V+:F!H@F4*17.M@K:'E?-4**.:'9HJ1($<D6<GG^ 81@L\[%Z)C3WNS
MHAN6%*8;3.Z,X;"^<<?YL6Z\3D(;89@D8^7<E1RV>",.W0F\F)I4ZD!D414R
M,G;CXG1;E\PPPM&]0^$+TJ$DZ(R 5V9R>X>D V[-TY''AD-OYR,6W6<IYRN0
M)04@Y36+-D9C&3F)="'*IZS@J@@]5 N6N)>V &0=QMUIB4N3#4;BQU^<Y>(U
M>6HN>.S^P4[60$%TO)JPDR3+B2TABP^AO)&7F."_9#<C94$U4>+K0G(293?R
MP/)C<4E<P&,1SKLILBX>-5@ROLUL:\Y.G'5-K(<.(P ;58,?J<MQ@XU]YN!K
M/![/Q33S,:)#HC@T(NQL5"4B2<$MLZX2R<52*TFF!%9-]]M+Q]),V[-:Y;OQ
M5(.4,[;:S)[E9[7>Z@U\I"8$A1&]BJJ6=L12K'UW(T3BLW36:TJJ3<76R[6R
MY6DNJ ZJ7-J@6(:?AZG;I(>);7R06!L%'4J;@M3:PT2UL=D:ZT14CV1(@8L@
ML]Y(JG(R@D.%TJSW&0@%(P4L\WT*X7 ,@J(S./HS/;2.CKRH.!CK=SE*)ZQ$
MHO(L>&'K(ZY*>_6M.C+?6,#[#*L]77)N0FI)JLZ6FH#OLGFODR4:K!U%01%/
M)M)8DEY@IRZHIB FJ"L)W98Y9-94&:C,0*Q1_$TY'VCC725VRO=,;8\;,_;&
M6F,(_&9"ZR;*.HRXS2D(5L1:Z\[4)NJ[%;KX6T=O*+CPPS4E)+PFY.(1->.C
MO'QK$!-#C9<B:(S)K9LL@2JJ-\I)@[UFB#R"C=9$?B0HKS?,.!$=2@X%L.^1
M1S)YU+ !10R9L=.3K)X_K')PM,ARS8NNXU+A_"&7MR Q%R8/V,;,PMZ*ES9*
M(V%FUP4LA( ;A"(),6O9W (\CNQOW91Q>!42"HV4%PIR"NVS2 .M<9W(E+$P
MO/;F)YL-N*9'\T>5[<;52'4]EM6,T%78>NFOZ:Q#EG[)Q<H>8@.;'91USD&V
MX7\&G+;D4W>\V@V"R6JK"RGE:]+!'+NQX]B14>\X/.<]AC4G\L$Q<?\ %P;8
MUXC./W*QI'..4<.-8.-MIM2NHD7>WVP 4--M/E\-3,J[J,6",N%'(7QP.F/7
MQ?P4"PKLT;W&BW:@9I[%JF\VP6V#A>Q:&A,TYY1)LY9#'E745[MP.7BY-S1N
M,KM\BXFH\C0X3H:+@%.+"02#/B@&"OLD;@W\Z&A&K3OLY<QC'',#GR[%C_R&
M, \E1ZW6QUT.%QRUY5%L5:V)HV:"S> 9@99S+Y%[8HP0@(F8X&P;.YH-5WY"
ML*2JWV_*!=V3]/,JZU1]!+E+1TUY1SEN$KN@>3T9?5E:108C1$5II+5-+!UV
M"R:.WAP%5O)A$\:<"T62;>RAKF3U.V-D&)XY@$G(DL+TJ11!4U8$V\G,U.66
ME',]NQ29J4YEIIN9\(CM7TJ,%='4;SV<CM%>P$0$K$CSAR&*',ARVG9+@2':
MT8P<G,?:8B2F_6O=Z<]RH@DAUZ_D';'@@.Q)W Q)T-R5#P\IDQGBTU8GCYV@
M.!'D)H+Q(#  8H&7-89CY[*3'Q*$YTV*U(V#?DJ-'T4ZG/:%'ZT78SH12XXE
M@N9C,\\%M_1XB2 R'FDE"T(38M.-,#7HO=#9=Y9G(R0LX-Y:..)\N)QT!,K;
MPV\GV+^/[]*XM;I:UO!X+>Q;I;[UO#TMY+=;]+>#K7- *4I0"E*4 I2E *4I
M0"E*4 I2E *4I0"H/^8>9^1G7@2(IIT%/)$A)T3-.2IGV,U87F:V%LQ.L-Q<
M[(A(NDC'+ENVS3[;D@IJ%(BNI7+(*_AYZI:1@*BHRDX4\-#<\X%8<7HZ=:I.
M4>RH0=R"1;#-CR2&*JLTTT#R@MKHLA+D>+MUD@\@G@GDT*R*/&Z2"&FCLY=L
MH!*"ED(?)B8D\@ ( )WYTV5'^B^Q')+K\[SL]Q^N1IK,FZ\0XXR;03D./IZF
M9=D-HN1HR,H-9"2WJ6,L-6;(:B^FXN/!3$$P03:>TE<@1=:,M!RQQO$.XC4C
MF$%UX;;B/^2B[ACUR;'8.J-XN1HR7VH*7Q-2:V(E2&DSD!;C4!-S'O@S%5:<
M[S."(B:.4=1M25U4-THNJ[AX)]*7%&?(-!MT14;D)<@3]9LN.1A,S DW;0U+
M;42\;9OB(E'' X DY&GB6)/XDVU)*/-I)61%E!#3#3(4P6RG[EQKKUL(6CEF
M0_/>P31EMBMAK",IW*+?AL5AO2<6S=G*3)\[I/.J4BOI!1[*J8?P4G@8C=%:
MZ@ON,H >0E!D(^9UO' (^H>Y"IZG;F5,ZOMSSM:FIAWC5=VRD065FV7,+LLN
M878YKQ2WYQ7+C@)[D1V&=!2G7:+&NF+J:$\(^5R<B+F6 [K:Y=N:;%^77;&,
M.-#FJVKDU8CU]3)I9OW.FI4&XH4>!M*/4P!#7X4B*/#X[3LLKBTHIY)W2$=?
M:P6=#R<:H>$$,HH[@S2\"8)??'73@BU U%WX0MX-;B!F.2S2UK6X/:T+#'Y!
M=Z EO9=71QCTO"O-XR>N.$Z,,RA\V%=A#D[MHN1O=?(#DU_$,T'^S4X86;EJ
MAR1:E2W,AN0F?R-;%3+LVZ%]NQ\ PUJ+9#EP^UEX#!JESKT>Y);3F$Z&0UW"
MV;J_>QHT9(CEE@0R 9QN !DW0S:F2'SM[R4Z422ZS\CCZ3/'6!18\F.!);B2
M[G0QME->4221$IVA,Y$;;7.*;5?B6\RR:HIR"DC"-=20T\\$<.)0BF<A4V&Y
M/.0%H[&\Q450I,2N^I.TWF72M(TIUF3M>V)*!R< IE2Q%N58T=B:RH_)RBL(
MY1*R&5"SY27BUSC!(IN!M97#X1JV MBO5#3 KKY*.U&PKN=Q%_3[N&[HN<,N
MNE";(S,:@"1"D3H$01JU6HUS:\Z3Z>G)J*D*CB532BOJ)I2=3L6Q@;$DD!*3
M2F-M6>/A2UJW8WQW$^3&4>?I[EF)UQTQS>.1F\&P#<-MA3:+6P07;B_UK-;+
MGTI5,B+V"DVRF9@_8(9.S3B^(I08#JQ;E:8);9!9T[4M?-F'!L1'-]6L9O3(
MRC]"?$=Q.F;.IJ48 D-POL!Z%.]HIBU04LP),=)Q'*J**EEC*^GH:RBIRPHI
MO\<6<R&J<N9(AQL)TEAMN2(8V+GW7ISJ2&VB2?L=&VJ[M5&=+ZC&A/-W76$Q
M3(FTOS^;*-)">Q3;K9J@1<Z=? L"KETK*\5Z$EHZWMW0W249("=)3<B-(1C-
M<B@1E72BS03(2;AYL)QD!XX.X^*OW<J<K*=UDL(V4?O<40IWB9QP+"XF=(8-
MX,V?#@<2(6<X*#F9^J^MNW^M>II0VPP2B^R4'<)TN%9<[LE58 =N1637"QVR
MM ,%M (:9'B<J)1917EO#S]6 ;I 'Z)OF@S5Y<;[4<B#KON4J$)*U0?NY,0@
MX1Q%I0[*401,86PY9$0PCLU@ -I8C\FWE55/8R$9:",Z$\ K>/5=X'%MN%%K
M.#QYI]16VRV4^T,C*3^1'#I,C<B3O#:C62 U.)]1EI<06X7D=]$'&YD#,=7\
M]ED_@%'[.$=+S/$V>\#I!+,8)Z5@N:L,[@7]"#<UP;86T^1XOKKQY;'\?Z:.
M)"(0 KG1=B2SF)J$G'L<99%Q359KEUPEWHU@;G22J,FF1!ELA@IXA)WZ*G H
MDX18U(\;6R1U,5#W&:B\5DU.PY%90YZ.H$;SV3'6C/UEH6+[P#8,O)Z:&XVQ
M@=555\M$T6<)-4--^YAL%"BD!L$!S QD7VGW2CQPMLZB:RZ3:CPULW(&Q()I
M!6$M82Y>:SED],5$-#(.+-SJC:.QXGMXFSRJ$VUIU.5YJZ@GGD9 (%D4XN^T
M3^;'4HXR7<LF$B34^2F[)^K<0(D#"$&*IR:_GWNJVDUWZRI+1.(+^58WRM(2
M ;5C"D.NOY$P8IEE/@F[_.P5#+Y*G0'CP?1$Y7=N$&F2T[6W#&YFF,,:?/J+
MBS925%;:*;KXP3$=Q.]6/(AQ6QR*C(2/9*4E)NK3/5\%M?1RQD9=+))DXC"^
MN</#Y(K^U'@J"I%VK::M-.JDUZUSGKU.;0UB;[ 04]Y:LY'23%5)9C),DL^J
MR>L.]NJJDCR.? DMI)AT?SM5&DWFJ8+*^#A R+Q0;<3OL^^>39!FQ9.J!/6[
MD0E37Z*4=7;#(;ZZT(X;#::9],:ZX:890!+<YY-4U10M=RC'EHRJ%LP1PU@\
M4R+BWQ3H9N'+W)8^MXYOQFU=UTU9UKV9>>J$*--B(L6IZXZC,6IB(=>,V3$\
MI49\A"G#+@4G(F!LEDHP#+:S=1.^"KI(N]9'P5"NXV@.AKCTO<NYKO=$T$)?
M6MQMJ7CM0N8)D97C=.9#B>B<G)B@UT< 1^/DPK(A,NDD;)QD\8+GPL0\N^QE
M 840QEB!%XNE2%%3>!+U8EIJL2'M]U5YOR486E*+C\C-6/9FDAM'FG(DCQ*=
M;,@QR<3T=[IIDHH+\;.HNXDH)PII0ZW' WD;'T.X@>;YY)&?I%'4;,G:=_$=
MB9_<+7VEE0T9UY0V0BIRO"6N:HOO%RR$*D.!_I38;9E!B\ZS$G!C@NU6=CL?
MPQ]#:9%=Q)JJDGX^G#GTTL@XR^#!]J;!/UE1Y$&K&PKHE&.V"UU2/B<$;?.)
MJMB*)1"4%V06XNC)%E1Z-_!<0?0Z&\L0S8HJ"W5X(D?%*8B9/ N0@]K<=.>O
M>R1-M2CH$Q)>BD5SRO +;EB/)VC><W$J.I^)3TBPJ^V.(@+Q!PK!M893B17N
M8'2C6(-G" Y[!VSM[7<3@J VY6-R3ZEM&>9Y3;[7/4S7=4P"A1#5U%FI^J<H
MLV5DUVEA4M^,]O*JF]UIIY$E1&(-9K(2 GJ7<T8OE8B#@*!N?)'+%JI&6S9[
M5Y9/NDZYFS*VN<&2*\DPF@>@F.)?VR(*ZE S'<-E%R)[P4S+K+)A'S\6FBTG
M$W&'F[&EZ,E9)#4%41#QQ'',[KW)X$RKC?@_;X./-=S^UZ!.4L"0>&KQQ&SP
MU +(YV062K+C1=SF,*CK=A)9#-1BDMQ/5\W5B3.EC(B,?#P)Y_W,SC)<\:;\
MS'N@P)Y;1!O;.V@Y?V)B5S0(A/)3/R5!#?3FTBO.$9-6'M<U#Q5XHY#)->R*
MH-*01Q2B@>,-Q80EP! 6T#^2&.,![P3I]O#K/'FV;L9SYW F79:<D"?6&QA&
M:\(0>&QXA$TH6:Y(%_JQY0LT#A&UD5<(.AK.7$L8%&3U-&6RY!9*@8 V"Y[(
M:CO5;?F9XZB*3%J4M'$G7>SIC5YXLQ*)&1]PDANG]=7D*OMYZ.$F,RS^+L2S
M#Y1012\CM,VGJK=56F14<0S-N]N[DL;4&;F;'@;#S ^(VB& ^-E@[4/: 5^$
M8Z,EFH8.2<HH"I(J1-+#DIZ.-VO!T"FTN.R$-AIET+%2 (J2,X#1LWEF<U63
M_,Z"<:AK?J&G;M8&82=](CTJ9KG46-KVA,:[!DC3'-.'0I$1TKY)2Z37TJ03
MZ055WFVEH>SG55A2<BVIR*HK2Q8^6V>G[A70]II5V0DF=9^/+Q?9KC_:NC+R
M1&K&!-IFD8PSG^4E9#F1MJHSY7R8"JG/\B34"#*/H9U,P2")!+45U5,XGE4^
M!EEW\RFLT;P_MG*DDLR96>KZ4(L&.^>XC'0V.JR<AL'9!';J[$+X0BZ7(([.
M<B,O$W%8FIE2+QQ6VXMH3B2%5+#%)IPJML5J%OU%.Y#SV0CIELR5X\?FKCU9
M#0DIIRTW$! 5\B\F,,C(\?.E&Q;CK=I01"=+8.Y&"Y)6-I+K2310P3<3<2![
M@8#1YRGP@ 3=#W( V)#V'!!F7D#8FKL3/>4&U$V15JQ[&NIZ&U$EE)K/C<_)
M!@V=<#K4D!6<CP65=]7*]^KY5+1DLFFMPMDI[LZ?Z#FM5=C=T]@AY: ?P^Y*
MQ R\JM4*/[M,NPS\%18%%9'%-6,GNYA5XJXDT'!5.!&TY,$3C]KA%QC(&5Z
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MRV5K_8O:UZ]'N-=_W5<O_!JO]KYT^L\KN]8_WS:?O&C_ -XV(I77&F[VH_$
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MIDS*A)LHSPG/5;91\:ZN%Z([8 S2VNER,1(*1N,WU=+*&,$A)4W@RU1PDTW
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M[6/_ ,IK/JGQEX[^W?\ '5M-@_%&X^D57U;:2EO9&<=;9Z,T?6=W.*4I4V$
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MSQ+8_CQ%DM[:BW(;$K$OF=B%!U2X@[, /8RZ&J<:LTF'*L$W^V81/$3P :/
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M 4I2@/R%'!!Z7%%##MEU[-Q!, ^O3PWZ=O+'KTM?K?IUZ>S7X]_DO^U%O_,
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M!#.C?3);^^XGQI^?&_ZG.J#%&^F2W]]Q/C3\^-_U.=0"E*\>WA_?8_NK?[:
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M$B3.GM]TN<^X(C<SV66H_P! =I5N-]P/0V[";T9A6/D9$5,B[B"!4N\#>V?
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M.1$40$K,R#BHBIX0O<1#896^5ALRV O7#(7'&^%LK96_N<NE9;S79^P[O/\
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M?%4 /FES:&?M1.+YWR]K9*+FB"2P9EA9N%WHT129=<+(BZX3UED@6,G"AW
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ME8#Y*.7F4/FNRRRR]+G']NUE>_3TQL'7Z=;]>GZLJ_(7S*-S5@AB"B:Z1_;
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MC78[;G7R$I ,[1RVYP69)DHM=I.01NJC5BTHFK>"2J'@3ETP^93%$ F<N%8
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M#((9<J4*N),,&3(XF6=L0P0  Q!AA,KVQ##PRSRO;'&][?<W]*5JU]3= ?\
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MK64!G7+#'+Q];7\N.66-^EO8ZXWM?IX;^#KTKFUK6\%O^?LW\M_+>_AO7-*
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MN*  .IKS@C]Q)".G@CFABQ8$4ZI'"Q4,4P8  #S%QS&&"#QR$QK]PUQQ;21
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MOQ4^&\_$)LYS6LPM"C73EI>9ZHN(P:JIBD%08FWS@Y$_B3P%5OZN#8N'B!-
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M 663AM6+HV9RZ: IFC!\(M@;'%&S JWZ;.=D[D.G4N.-A9"6'?J7*4*[VSM
M"8H2@^6&TMC)9!Y$9/(Y"+&28XFJJ2*<B77D^RW&Q8W<"HH%FZB/=>=/H0L<
M:153;O\ +O)L$70=.%2)-6)2VV>>J<.KAUYY;+)32FZ5QI#=3'W&1VFWM16=
ML&C,10NL0U%1Q+<Y1U/UP.Q159"934C&(F])4B8N5^'<+)3KUCUO?<>I<2/6
M 85=T5HBL87D6-7+%C&7&"D+ILVIGS2TEL]20C+?3E<R>6EDX84R2>7/#FE9
M4'%'S%4#F0W>_D9QQZ!R<9W8#*O'">FIB.08%VH@W9))(11BIA'2B;4\[_.
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MXP9QQQ#;HZTR%K!*FJVX$ -9Y0?QFPOQUO+*7M9WM)B(\DV*9.=,FF'\WT]
MFZ/QVV,LJ2V0) I9\ZMY$BA$UW0<<0X"(4 FZV9?4T1O!DAO'7>%O3"S8DI)
M7".8B%>B!'9%V.%35TY("R6'HYS)1(0F^WRIXRYW"/W415,HJ*>(-\FH+QM-
M)#Z3<;FZTY[,O'<F#=C&5#9"6M+IF:D1.Z3=:G*[W7KQ(RL[HZ2I"-I++/OL
M@3=26]8QS4K-&4VJJBG!4%P=Z8]W!S-"$R^,9TXKG#)C<?6P$?RJAQ!RHR=
MB-!;KW4:MYRQ82$3/(J"SI <,<:W#3:88[/65%DI1Q*9*N#F8<;,631-V8+I
MY>3L3@^:^+C3&8M#X(RU_D)Z:[.ME-G%OAQT' <%NV&CES>*>9#?KNE53>,L
M2LKR;(<@+.*:OKCS.GT]1-*."CF=L:"-$@$X"3.E*4 I2E *4I0"E*4 I2E
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MS -J*SL8/%,AI32BV"DC$I5 4U)>?&&/>MCZD?-!Y8# B]JTM] *4I0"E*4
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:@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g809974.jpg
<DESCRIPTION>G809974.JPG
<TEXT>
begin 644 g809974.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#3TY44D],7TY#7S1#7TQ)3D4N15!3_]L
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MCWME&RRRWO6V6VP[ ]MMMM/4I2E*4I2GJ4%NT
M
M      !QJQZ$J?P>>^B9AR0XU8]"5/X//?1,P J3=1F>EK;"?'OE+ZGH(%NL
M5%.HS/2UMA/CWRE]3T$"W6
M                                                    XU8]"5/X
M//?1,PY(<:L>A*G\'GOHF8 5)NHS/2UMA/CWRE]3T$"W6*BG49GI:VPGQ[Y2
M^IZ"!;K                                !^ RJ)Q/.5*FCQ,L8/&:$
MB6#.9P8<QLY<7SFZ%2N+)DMR&#-2I8P9H7PVWYZE\&;/3'7%BR7V@?O >02%
M/T+Q2ZXV8<B2:S6D^IB<N!H16R5=<)X7A(3@S5K7(1:#6QWY5Y=QI^&EYQ:4
M""?F2T!/QYE)</)Q##E,V8[P%Q$M;-D)#3(ZCM2?Y8V\VHZW]#+J>\6OEA1_
ML,P6$L)" ^7I KU="0GHLD(+657 A5.Y$_*6/J* MH[Y;Q!98"LG.DT!G. P
M3F;B,:S03*JE%+[5GY4RSS,<%)??K;B]\.F)8",S&?PI<389QDQ%2#+8CN]^
M'3)2XC10-&*-](4$AT/BK4::TCKI[F8GWOAN;9N?,'1JV)X<*E'$A21%#QDB
MW7^5",&(TAQ-6N%\-3--1]NEX_R*B6H4[48,>%7OQJ:O6U/3LAG/?;2H&:8
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M2P^6Y&B9G+@NK==2E].C=6@$>W49GI:VPGQ[Y2^IZ"!;K%0_J,7-C,\-"?\
M/BK6['FWJD[-CNK2MM:V98;@;)96MM>_3G;=2M:5[]/!46\
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MI6M:6TI6OAK2E*5K^>OAJ %.?*G.O.O*G.M/!6OJU_6-0
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MX;"-M<1 UC,WY"LU8@_E/_"#-2?]&#ME_P 04+"<
M               !QJQZ$J?P>>^B9AR0XU8]"5/X//?1,P J3=1F>EK;"?'O
ME+ZGH(%NL5%.HS/2UMA/CWRE]3T$"W6                   "#%9_PDM@_
MZ$^2_P#CC8 G.&-QC56)C.W"9NOE*+OW<4C7A8UA)G[5S/:VJ18N2.ERF>*9
M&WUFI;(MW.Q()YL2W7/3/B(VY"-,5<>2M],D0
M       0?RG_ (09J3_HP=LO^(*%A. ,<%O5F*5_:=B;AJ!9>K,D=PR^H(;A
MK"MY,3<L84B.IMO%Q83J!V/=B-JMRRUDNXDIU-8[BI;L@O7#EIEMOQY'@
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M]:\ZUK^6M:UKZH
M           (3N)5 NZ<M+60JE:D:&\2W5+&IMIY(NK>Q9U4A>6X_D=#;IIM
MFEQG2:NI\CQ$]R:P74U\V7SNIKL9>:]J\;0RQQP)E]<V/'G236+>N/W[D-PS
MPUN&_P '^.G4O,S'.*\R7G@V8G61V2S5JJS8V&>AQ6T8KBM+S+&(RNHQ-VOY
MPK61FX' :5T]E+JE@Q8Z9+<2O;7BJZ\R_KRW-'N'@D[:Q.['FWLDEOLM,[<:
MJC86N37OB78J64AQ)10M#N YD)MASI6QBZIN:/TZS";9"XW22^NHQG-Z=H7.
M/$WG>6Y?<>Z6G[!TLA9)8<>I,3QJ3GB/-A)&<4B7+#E,2 \%-Z1KDQ)1%HYD
M2YNIR4@*J.E'R"D6,Y2QE:Q&3>8B!*E3GZM>?A_W]ZGZ*=[GZOA&H      #
MC5CT)4_@\]]$S#DAQJQZ$J?P>>^B9@!4FZC,]+6V$^/?*7U/00+=8J*=1F>E
MK;"?'OE+ZGH(%NL                 !$'QO>(?)_#!T67MIHB9;"?KQ29.
MC%DX6_)%CCR-K*FO56.D5,UDM:RVWU7LTM@*4N(W6*-,%F6^M^<N9MMIBN E
M\ ?-&^_8]]N5>6JFH'/E=6G_ $4V^&E*UIX9/IZOY:?GIX1]"'2^;5_974+5
MS8AU)2.A.>==>X=EYPHC>H>H@I"W(S 07:J)B+13-'5&B41.JV8L0H?.&SE"
MN/%V29SYNGEN R8
M         !6>XYZO-&R%K"U)2.&]O#LO"; V'@V8)@.1&HM1HP[LO%!!JN2Y
MX0UF?21*K6DM"S(:NZDEP4RET2TF:>K!))>8P1(G"[C(>Q<%G6W6.!G5/YZ
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M9X9T^F+;;K+<^],FYK;;^73MIEAJ!LE+;Z4[U+K:7<KJ4YTYTKR%O(
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M/UR:-6LUM&9?L*-?A4Y^4L+DYU6+17F9"QW>BWY*5Q=:L=U9A;':.JQ/3U0
M !J&\                              <:L>A*G\'GOHF8<D.-6/0E3^#
MSWT3, *DW49GI:VPGQ[Y2^IZ"!;K%13J,STM;83X]\I?4]! MU@
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M'GOHF8 5)NHS/2UMA/CWRE]3T$"W6*BG49GI:VPGQ[Y2^IZ"!;K
M        &E:\N_W_ -%*U_JI2M1ITJ>M=\B__N@#< _EFSX2^.N8QEQ8,5M;
M:5R9LEF*RE;JTMMI6_)=;;2M:UI2E*UI6M:TI3OUY#\7;A)_])I__P!<4_\
MW #D@'\\67'FQV9<.2S+BOITK,F.^W)9?;Z]M]E;K;J?EI6M!_0
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M*R]?9WHF.OW=8\X^)FEE=G64=7Z=.O=:&Z=8ZQUZ3/3K   &)F
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M[;:]*RMW1NYVV]^E>]3P4MY"HIU&9Z6ML)\>^4OJ>@@6ZP
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MK'H2I_!Y[Z)F %2;J,STM;83X]\I?4]! MUBHIU&9Z6ML)\>^4OJ>@@6ZP
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M1;5=5K,I;*;$MK:=YOVA7K:'295]HR-$,L3*NK*T>IHF)F)  "'DZ
M                   #C5CT)4_@\]]$S#DAQJQZ$J?P>>^B9@!4FZC,]+6V
M$^/?*7U/00+=8J*=1F>EK;"?'OE+ZGH(%NL
M                          K_ /S\]?!_6 -M>C7O7=&OJTI7E^OOC=3E
MR[W+EZG+P"J+NSQ!MD5W8.26O'TG.V,&%';P<#';R*RSMS>-*'F:/945277
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M(WL:4GQFY\1HN4QLO">L4;C^#)FO4,F"XG90M9FRRM]W9XXGO=38#QCESR(
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M.)[W4V \8Y<\B  N  *?_=V>.)[W4V \8Y<\B =W9XXGO=38#QCESR( "X
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MEI1T/9.2"SD7BU+R9.^["J*1JS)<3)W9:9+BA:N+UJMMM>_6VVM?7K2GV#<
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MWLYQ8,N9-5B-#& \5OID+9BQ].4TM2*$EA"7$DX06V^MD$];1%!/5B!,Y@
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MDQ\/9:>#B1HRQ'3A1I,E25<S(3BQU1M\SN7,JJN8]G=2E*4I2G@I3E3\U
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<$4A$()Y+#UFX  R#                  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g248496.jpg
<DESCRIPTION>G248496.JPG
<TEXT>
begin 644 g248496.jpg
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M)2<I-D)25I*3T? H9H8S-$9(4V*"A\'_Q  < 0$  @,! 0$
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M#>KD.G=CQ1JMJS/&O,:Z\S-KO")5XR!%A\1W209;KYFE^)+88#2()AAT#/Q
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M#@:3)!RDL(R/@<%,@7KHKE./YMCED2Y%3I37M'$D-='>;'=R-<QDE.1KKY3
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M)$;:,E-UNHZ6@M]"3$]%1$-%3R:6CHZ.DE02*4E)281!+D4Y-3"1<N33R!,
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MROEC>]_^V)C^3$3+&W^ZUJ WTI2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H"
M7NA3[1F@'XWKC_\ IRZ*GW#]C?X8GZ3*H".Z%/M&: ?C>N/_ .G+HJ?</V-_
MAB?I,J WTI2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
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M^R'TJB&O0^KSP>[A?MI<>/Q?[(?2J(: HBTI2@%*4H!2E* N?]Q.>?MM7\D
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MUD!MAYT6QWQZ2K]-%>L?ZL.PWL?$=EX_P<)6)G?;F9[5R/BYA2E*R1BA2E*
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MEW0"O/![N%^VEQX_%_LA]*HAKT/J\\'NX7[:7'C\7^R'TJB&@*(M*4H!2E*
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ME* 4I2@%*4H!2E* 5L$ZW#S[WKWW>9=[T[>O>WZ=/?ZUOI0%8I[J#"+3;.[
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M]K7_  VM?I>]O:O>U[V]J@-,+7MC>U^V^8E_R9"998_[KV\GM=E;Z4H!2E*
&4I2@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g902545.jpg
<DESCRIPTION>G902545.JPG
<TEXT>
begin 644 g902545.jpg
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M!_<:;J=\0/2+5XF*DY-L$NND717-O=S1VU "&><*G:NIBIC/3#K=9,-42D+
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MJD2U,U;6'I%!9?&$'6_*SK(R(@U]*T$Y2Q2=8*9/&4%Q5VLD!RFIF].[6FG
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M3+#GIO1%&6(N3G2R"PYL:8M6TK%() K6NDWDL>(.5')=@3MB!MTO5*50M^]
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M@$B& T01!WHL9?W0!F];WH R_P#YT(]A$5_\YH.(GOQF!9@#0!,+$$98PZ$
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M/]V/<E?BB_Y ?[L]F,1/7[DK\47_ " _W8]R5^*+_D!_NSV8Q$]?N2OQ1?\
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M(TY7GD3BEK3"L&VOZ/O&25Y/4%-$R:UV]DC2V/U/+[^K<%KUO$I\PMLD7RP
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M^2I_9-4:5&!]P5[)BD(P&!4##['H,_0RRQZ-%K9FAE@'[7M #O7N&6 SV?;
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M"_>'GFD^X$:#W7O! ,!5]KKX^#R]G7Z!L7'@J%VAJ:S;8$+K7[2M?1<_)U_
M_/KV?[37^ ^#][^)/F'!\&\8KRV][R/8</,KVZJ\65KQ1;H(NU6@I2GUTO\
MU,"/EZ7]S+&\90K,/,4\U_0'.%@'1&J;"L>U6F?*K'BK!.SXZ&OET6?R6YF3
M*6,&I<]-HGQ HVH 2^'ISA&)33$WO2C! (W+/O,72U9L]5&O$*D$U?)_3\-L
MQ[)J^1PR1,T/>)*G5"7P9R6KWQL7%O[(H2#"J3*T"10$A0D,.(),,$6'+)_$
MWP@_=]G<ISG-DYNS0-%.E!55U<].G&"XI:JRUJKZ_MKI>QJ'^27!&5@/8[_]
MD;_:#0\\Y?X>[NFO6[/E7"YC<W?R=#;-OAG2V\GO.M#;J]>;)3KY^G]+KW9\
MM/0H%6C"U]5U3-<+C*%KW\NLT@_3+;4M5,-+SFN'5=425+*S'QV>738I\1'Q
M/R42V,R03 -P8U3LI1!(*+%[A2FT4L"8((_:OHUOUU_&+7^C>]?^S+OB>4\;
MR'3U\G*TOHMXFH8]Y--E=:W%KD'TVNH2]":+/5E192 #[],)Y[_$'^#OGO\
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MH/UKCOWQQO\ M^\1)#%_<R_R _FZS/,"_N9?Y ?S=9GB(SP+7KK>OP_@^O\
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MN!L/&(EP2,I1"'2PD*8D(4QNE-C>>/77X=?Z=9TWYZM*JEP<JEE=RA+KJ?\
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M*4TM;KK*TVM75]E;Y:7NN^QEJM2G[%>6+]C_ .:3U!_!VO#_ &6RS->^-O\
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MB,CMU!^M<=^^.-_V_>2)R.W4'ZUQW[XXW_;]XB2&+^YE_D!_-UF>8%_<R_R
M_FZS/$1FK[KJY'=M2V+4;A,+!K]!9$0>X:NFE4RE1"+'C2-_1C0*7:%2]*G5
M*HW(TI)H]MCRF3FGH#Q:/*!LP(=ZVAGC?U;_ .[\._O:^_\ #?U;Q$JA\?O!
MGBNI(N637BZFJH>9I"[,L&J["NMT(=[4NHFVZXD2F.6?'Y%;5H"?Y\0_-DJ3
MJB9 C:W9 SC7Z]XB(VETGV&U_.C]8D:@\*Z&ZC[7B?/O9#/Q)"O)))8/T7?,
M(\J<Z@,A7W,3T/&*GLRQ&?C5BCA;"]UTQW"\H8:CASQ,2I=*("V:6MZ=,T'M
M*8ON_@]-ZWZ>OZH?U[]=^NABUO[^_AZ^OLZ^\'TUZ:^K$3+&/7X^GW_K_P#'
M_CX^F_P9C[0?3U]K7IKT^_\ A^K?[@OO;^_][UQ$JR\R7^9*5_#!\;W^\/Y@
MRTPO]3O\LS^L%E6?F1WK?$I6]?'_ )X/C>_U>1#F#6]?NZW\-Z^]OX9:87^I
MW^69_6"Q$SQC&(C&,?N8B,9&Q;,KI!>R:NTGV+OH@ICQLX L4(9@*2@C:&3L
M\>6-0O=.P6D3T:!Q/5IG#1.D)8RRB#FXP AGY)/(V?2F@WA$M3Z+FH;[%^/R
M=0"2GY/M?3 ^_P ?N/[^P+3I<F[F)SWMOR7CHX:]](RW&TUTVLR*MX*)]=H=
M'4I_405)]^B"6,UW9UM5M3,65S6TIHPPB,I! *$YOJT";2E4;O02&]L2!T8O
M>'54+>@(VEI2K7)89O1:5(:/>@Y4_P!9^11X@4(;I6\NKIR;5,U= 1BLWF3P
M998/9G2LD6:3%M\+Y.Y.;B'"1*Y,]G*TJ9L?9LV.!C:2XI'AXB+,V%'.9,3;
MU\N.T956[;T'0/7SL*+=K9"2%LM#/71CSL05&K==EREQ]8N-A5#><'PGK]S&
MW8NMQ>/^,TW-GT^5>076X>)7?6$:W)C:JC3T.YTJDLKM?C^.X.OUTH<:7PKE
M6R]++;DZ0JBC=-:"8O:M?,I*(1$+K"'-:V86E.EN@F; CB<$8RU3XXA$,L19
MSJ<G1L+=]V=79 F",X-!MJ=V=J>0";R?GC@"+-A8&EV7Q.S[#998:.E*)5$!
MT6N0=!]0Q 2E!)K%2@/3;4\Q<@'3&;)S#AII[=,&3$.*8',*5\=70/87SM*>
MIDDVY!YBGOJ9(^:V:R%TH[?ZJCA^B/<E]Y]:L3J%T@\,?$Q U+CRCSJX,D=1
MI'HUAFTV4*&PQE!?W5]5UO2D"B]6U%!8I6M<PIK*98E!X0PML:BT=:R=B&%$
MT,C2G2H$10S1F'G[*)T:J5&G*U9AZHXTX<3^7[^G_5V+QGS-^W(YMUJU,O\
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MFQZFVZ.GDWKN&ZI<M=>3/JH6AN>>>UUECC9<QO'2K52*P*#\6+^<8S PPLH
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MEE)TY( $D% #KV0%E   .O@$.M?#/TXQE<2222223[)/Y))_<D_W)EF
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M@Q]N2XE_%=@_T;WD/_PP8B6GXRK#[<EQ+^*[!_HWO(?_ (8,?;DN)?Q78/\
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MF]?@_P#V1_#GG]!IY*?V8FQOYC_&G_".=\[Y;)C*F_T&GDI_9B;&_F/\:?\
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MY?4_Z!Y;GW-517K%VYC4-UJ4$BJ;FU@@%@I!G>W&Y&T1.=QIN>7R,,6DJ)>
MDZ H-?-TU:(;NJ998RU"R.:. )K.AY\V5-LE;@O$<<$T3*?1/YZ&0-(@N;(J
M+;A$.K?O2U"8>EWHW>X/8#OZMC_]89_[V=7"%$2XOMREZ$#5U92&=,_E<N+L
M2Q)80.Q!WY6<8LZ@+I>I&6^QUYI>.,9=8PUSED5I"']"_9360"X:Y;:_:8*S
M&RQ2MAT![2 -;T &M_#>@AUO7[>M:]<1(H3CLFD()U'2_'JYU?7>[;L12IW9
MV:/,ZYS9H>R1:$2^=A=;$DFADLT4W)VZ$2!)"F0]6HD\J4MSFO:F,Z/,4A>V
MK;$VO2CZUD3'$+%N2KH%+).<SIHW&)I9$3BLBD*F0N*QG8$[&R/SVWN;L>^.
MS<X-C.4@2J!N;B@6(D6CE28XH&G+VHZ96-T7Q):<>,9"XUS[:-Q3&>EN"X]*
MZ*&J=<U6A4S)IA2%(E!+DM!)Y>T#6E*E2 *=I K5EG'FD@2'0H[V\?%@=23'
ML"21]HJYS^S5X[H?RI7:F:GATN;IVV7A:5ER #F8...PV>(KT,@A"G:Y":K.
M6/+*7LYK -H0*Q(EC.^H>9-0C=F;Z)H[5<:F Z]W/]W# =0G4_*&(LR#[E>Y
M+\P:F!9P!$CC.W#3V$T @"0ZV'?IHR0]F\[5!:_.7.419E;X5?!B!'!'BHDD
M/55;$TDAW.%,55/2UM?VU,D;9@IKZP?F$<6:WO2M1%WXX\HD!!IVZK^I:A/X
M^[/4]?2!DHU75,SN.:EP:M[&/F,-J8+=+N(>>J.?I*_S>*4G:<5KVU$#G3$A
MBT*B#VPB46[7<RE\;A[V.7@1P:3:3I3Q87OU)PQRA&;6$[\ZGFJ.2FU\8H))
M7JN)_6_-E0<E7M'"6:,@6,1S\P/J^[>EIZ:MK"5)6Q:.LEJF,2\Y L7NS*4B
M=BHSJ?F H,/&=T91A ;";W!U@6SKC@!7TV;&AR/9G=QB/MR8.I*@:7A,I:G)
M8R;7)D3DG/0*#2U1)A0=^>P'?U;'OZ]?=3/KUOTWK]7][?PW^WG3_P"F85<U
M<)K6H2P:DYUGW0O2U5^.>OVZ$1MML1C!&77FZVD\&2J^084V44JC$VKLUF;#
MKZ;HHR3Z$H>2IHZOK/:BD,12L,]E7< +UO0=^O\ US=_Q;,'O6_W-ZWK>OVM
MXB/=A_"/_P!89_[V>= UK?KZC^'X3![U_HV+>M_QZS+&(C&,8B,8QB(R.W4'
MZUQW[XXW_;]Y(G([=0?K7'?OCC?]OWB)(8O[F7^0'\W69Y@7]S+_ " _FZS/
M$1C&,1&,8Q$8WK6_AO\ \?W;U][?UZWC&(GC6M:^&O\ Q^WO\._P[W\=YYQC
M$1F(M^@1;U]>@[W_ *LRQO6MZWK?U;UZ;_<WB)UQIS:O4U?\^=Q=_LG7MSK7
MOF;KGJ1M9><)0VTR\\[S&H*'Z/5P1)306/[$R.SFEXE\%;!L$<F+#:B:4MLZ
M7M3KHQX;]K8RY2;D_E6EZ'IY[YQ@](UM9;LKG?0=0P!#$;_<GR:*[5I:C;2N
M&-,MF!C=,O\ 358D6@YU+((*DBRB[WVY8,K=(Z[3&K4J@4JCT2E1]K0Y#,L-
MTL9PAE@OBAXN9?T,N@$DZ Z D=%&W4XRLN='6,'GAYLU91H)$GFQ14P;3?L?
MB2-,I(32%N2)G=(E6$_7WP)S\PV"1<T,C4E(LV*V59E[5H@?[DNY=4\+O"UF
MJ=))Y-F6J 3TR!L [ 5V-,3IT4PQA,%W%*9 L*()<' TXQ$QY.[9CG83\_J*
MRB:LNLF&F.<+"/GCDZZ^5#L'H"%N=H**D&P$-@TY+Q6U:K*Y?9<YB?=C*=["
M1Q[YH3J&=<H' #H+K+LN@YQY03Y%.:V7%UES1RY/N7XQ&(<J-CE2:N^\^F:=
M02R;KW]4)TLV;?(XA$9W,BCBHW"DHV=-"6)D^;T+G+918WPSRJEY$HT< 4GQ
M-?.IS9%H7G;SM V!SBL'<;8NB:.DXEY,)C3P\R!S8X/&A."&%09K<'98N1PZ
M,,92TS2OWX [/FG-%'V(Z7$[S> MTF57[3\>H6W"G5<\'M\QJB*JK'6,<35M
M@7$M WE(E-M3XWYU9T[<^'B? [/<S-M;/M B1?Y!DMKQ3HSKGE:PKBF=^1ZE
M&?G*QJ_LJST$&36:6AO>/V4&2P>3KZWAT BCVBC\EJM7(HRX BB!V1-$T#'5
MIRY$QM2G=BV1ZY^Y@J7FANEJ:MD4M6/$_?D,CGDYLFQI];]ES-S9F!NB<=U)
MK'L^12J9.S?%HFSM<;C#0>[_ #4Q-200&]&4J7.:I=(7$1C&,1*YO)%*++:8
M9S3#*RMB=TNLN?L_GVG)7.JTW%"YNB@LQ52H^2(6!7-(K-&% J<@,R-,8M41
MU<:4GV:%/[DTS1H8C.W8=M<-6#U!2%BVTAZ98:XB_&,_J.R.DIO6U./T9+ZA
ME%YU_):YM*?UK6J$NP#XJJH1?8%=L]?T?*+QFK?+Q1(A@E(&<4J;[7.@^;ZI
MZ>A[+";:;I2J:HS.8K949<H18]B5/+XS.H2I4*XQ)H[.ZME$/F;(Y-9RM3[L
MQL?4P#RE!I"H!Y Q%[T2A\;O)+;#5L10PJ:DKW&THW=B^TC;NNYPO];:T.CB
MF&Q6;K>B'2PEUUK':/0M<XPMG)53DYK;8:YND61MQ#(Y+D1Z)"Z*^9)"HK)U
ML*=4=]'=DUAV*Y15(RSF0.":PKXX]O!KIISI&*IIG5E=SA(HM\$RKN6U<ZRN
M"1V1*$;Q*6Q[A* R'#7N\O\ R!SSJ"#\$7G9M#O5=5+=4*HBQ+"?9!*D#G9*
M"OBX?4DLE\B'!&M+]&VZ9S)"_-*)DB"R6":HF0(\R6OK*_$-8(0^Z^DOC4KI
M1,.7HY#4$:8N?*(Z4FG:4H9),XV98MP33I5P ^*HXZ(+&FLW>1-D5>)C,I!9
M=HE/!;\XRR5,[&G2%H4[J^K@V%V+7T2MBO)U5<^:MOT%LF&2>OYHR[6KV[;S
M$YDQKHW(VO;BU*4+HAVXLSDM2;6MRQ(O2[.]^C4IU)99H$2G;NJSNIJTHR,=
M8UG>5D)6JM:GI:1/E;P&%U(ZP"**79:2_P!PW[V$NE)#]:4QHY!7FQI00^@(
MHVV!%RFN62YD025Q6M[G7]W))@#2P&%C 869K0RS"Q:& PH?Z8H8!AWL(PC+
MV$01!WO0M;UO6]^N0QM3Q^<M7*_-#].(._F[1PF(5G)F./V594/B5L5K7RY>
MZP:O+QB,5EC/'KJAD5=75U6M#!93?(T18'F0-2@*EBDDA:G2:6M>G_C_ ,?_
M .OJU\,1&,8Q$Q'O>@#WKX;T$6];_;UK?IG7WM&6=1_13RP]9P_L^YH*]<26
MW<1E44RM9Z5D'-CE"Z,Y>I&[3(+/(J_569/E39/7-\EK,_29DM6/RACT_D.L
M;=&]0U$)CNP3O6MZWK?QUO6];U^UOX;R!4R\9_(5@V!/+!F<+L"1"M*?-=H6
M57+C?_0 J$L"=L[;$&I#()ISH39I-&2@W2. PW2Q"]P!<U.A\<:U3J@7*$_M
MB1(K+O+.I2=)5E21=3092SV':U24JLTAN1[?K>@<PN"GT]DL;S8<"BU.OM=5
MY'&Z1JR8.LB]CW9#KF6)25,S0UF8@5QIJD<B^2N]]]7RN%Q%EJ5SB;HGYY46
MET 4Z24E>;1%N_9@D=(HJ&6EIV8@$G>%$TJ?H 2F0Z-8MHV:LVASVP&DSE#\
MV[ <?'YR^Z6D&W543F(9*5=K3TDF94EQ7"WUNCOEG1I6TJV$E2H9R161$T7-
MJ7:%[<]13>GU.M=@NI*DQZ=35?JXQY47<Z!Z!GDV4P-TNGJ2^9/>]M.=:QYY
MC<)3."MH9(=$HW&6^1.SR];1,L2C*!P?7%<K)')+#D4[EP&YK#(OD"=$T&.Z
MNJ(UY"KXKZ62"%O]2M/#K]=-(4["FD+4K+?8Y;*N,)GF?6!+UR?;S-IJ$K3?
M\B1@B4"A+04C1:'(5QSG*S.!>-JW>BB9ZJHGM.9=-J.F7CFRK+W/AUS&<=.]
M:C:5CF.*60]U2Y\J5W$W*.*&&S%WT5?H-:#]+E2"/[A;I&9+(#EDH6([+Y#S
M_3\ML!]LV40=KD4ME%/.M!2,][,6NC,_5"^/BB1/,(=XJM5'1=Q:W5T5*1N!
MBIH-6JTAYS:<I&W&"2[U[SYQM1/,KB\/59,TM4/SM%XU7Y,BL:SK(MZ1QVL8
M2J=%L*JJ'OUHRF6.L1K*)JWMU5LL*CZI S%KEIK@M)6KPDJ2D24N,8Q$8QC$
M1C&,1&,8Q$8QC$1C&,1&,8Q$8QC$1C&,1&,8Q$8QC$1C&,1&8^SKVO:^/K^#
MVA>S^[L/K[.]_M^GU^F_KUK,L8B>O9Q6C0D;-+T<, C E;&'1@BP[T$0PE^O
MM[ $0@AV+6MAT+>M;WK>]:W^-0XMJ%&J<52](G0HP'F+%JA846C2%IO:VH&I
M4G&A3I2R/9W[X9IA8"M:]#-A]-:UU7?+>P=+E^7/F6\N25J]QNOCKQX7OU0T
MU(E4'$(^BX1#NFJ<AEQT OT2G5CVJL&IIY+1Q#8$QAVK 9(B)-[I:!&K25,4
M!9M5=%4[X\7>_59C'XN>E_,?Y0["Z1*L^0FPFN'%^>RWNQ^.83>SH6Y-S&&,
M/$X<G4]?'I*Y:BSK*&A&0Y$J2TY1Q")_0+;71N>$*=S:5Z-S;E9>C4J]O5$+
M42HK>]AT:F5I3#DZ@O8@B#H9)@P;$$0?7V@BUK\89&P":#G\+VTB9$^E8E#O
MIR0[:R H%!J1=L]PTHVC)TC5$G)U>S#PZ3'E&$G[+,+&$/56DES<S\U\P]1U
MQX4V?I:?1VV^V8MS_:TEY)K:U.FZAXV4S&!)9/>MO<K0."-CU'W$;5 RUR1B
M9J^=E4707X_Q'3XJ:&5N:&M95Y HBHNW_)+I:N06%T?6D1Y7%V <^5^>SIX+
M&^BY%OIQSD\!7SF2O4;/D5D5]!")4I%(6F%O+#&I!<[<_,,[^=%-?',8D3O[
MJW1M0&H25J]&D-<U.D;<4I5$)S%ZO91A^DJ(!Q@!JU.R"33M)TVC3ME%C,T7
M[ !"U^_.DSYXQ5>]=5=A&=(21&QNE'^%J-VMX^MOTH41DZ/=**^D78EZG]+J
M"%R11N\@RJ.57&=+8^>&6%QH:5  CYD7*CS.XQ2JV6N-/U6X3XM05.5U;P1;
M,BE902514K51-G42,M22'8@E* /1BX)Y81"T W0PZ%O6O7$39FPZ%O6]^OP_
M (0=;^/K\=!WK6_X];^_KZM[S+&,1,?9U[7M?'U_![0O9_=]GU]G6_V_3Z_7
M?U[WF6,8B,8QB)X$'0OAOU__ *1"#O\ TAWK?I^UZ^GKZ;^O6L\ZUK6O37U:
MQC$3'8=;WZ[]?XA"UK?[NM;UK?[?KK?KKX;^&98QB(QC&(C&,8B,8QB(R.W4
M'ZUQW[XXW_;]Y(G.$V!!6VPX\..NBM<B2B7-Z_W[?M/I1HUO4:/+!KY22>5[
M!GQ 9ZE^UK6_4 @BUK>(G,R_N9?Y ?S=9GG@.M!#H.OJ#K6M>OQWZ:UZ:]<\
MXB,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8
MQB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(Q
MC&(C&,8B,8QB(QC&(G&3(5#C9@DL,V)QHR?((XOAR&<&,+4.8(HDZN:!Z<XN
MDDPDFWM-'7%X:FQV7,A*X#8K<VY O4)3%2-.:7KTSF_GHZMG^FC:)IL=0RMS
M='J458*KX/NN)(\/;II[>G9_@^V+Z+O#F[O6M.[FO<6I0K7.FM.*DXU9K1VF
M,1.55I558TQ#6FNJ@KN#57 & !I;'!ZXB;#"(@S .,V<<!JC<90-C.@"<<(1
MQWR9&7LXX0C3=C,WL6_FDTA2Z>M5E,IZCK BH' EU3KZJ)@$3+K=:0^NZA_>
MR5<% T!BRDEX?5BMZ="CFH8'!W5*')6$Y:>:>-C$3\MC4'1MP.T$?[9IJJ[.
M?*M?2Y16;S8->Q&9NM>24G90B9#!W"1L[DKBCV4).0(MT8CD*P(B"!Z.T,@D
M1>VM:]/J_P#'_C[^,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8
MB,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8Q
<B(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g767357.jpg
<DESCRIPTION>G767357.JPG
<TEXT>
begin 644 g767357.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ _1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]#14Q?5%E015\T0U]&3$]7+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MFFFFE*::::4IIIII2FFFFE*::T$0 !$>@  B(^P._6,)O-N'*U)NH2Q97QK
M3+$X)/HF;OM2B91FH)0,";N/D)AN\;*"4P&["Z*9^! >.!#7HVTZ\2EIIQU0
M&2EM"ED#ADA() R0,\*J2E2CA*5*(U(2"3CQT!K*&FL->^*P#]F_$'W3J-^/
M]/?%8!^S?B#[IU&_'^O;R&;]9ROYN[_8JKN7?^4Y^ K]%99D' M&+QT!0.+9
MLX< 01[('%!$ZP$$W \ <2=D1 !$ $1#KQK^;#G/.F4MQF2+!E/+UMD+=;9Y
MX[."[LX$8PL69\Z<1]:KL<GPWAZW"IKBUB8ML7L-T2]M51=RHNX5_H:3&X?
M:D5)IDS=B$QSQSXI"ER;1S&,<S18"E*4L\(B8PB!2@ =1$/EU_-O/^J-[#'_
M /W#:^@NP>!W;VTDF1#*)#:+4U'?>8*74-NFX*?0RM:0I*7"VR70@@**&]_.
MZG&X[)L[JIKBVL+ 82E:T84$J[TK2DJ&0%%*2K'$I3G@*^=---?1E;G3334^
M_)O;<,;;H]P4YCG*C"XRM8B,,9+R&A%T2;& L<G.4XM?4BXYH_".E#"5\$DZ
M:^C%9*F6<*MC !O-^;4L;G<8]IM\NY2@X8\)A;[P:2E;I0C4A"5+0DJ/(*6D
M>*@-:\GGD,-./.9W&DE:MT G XX!(&?#) \2.-0$TU<%@K:A@+/&Z"G8FE=M
M^ZG;;4W^#,SY"DH3,EV>#;+-.TUA#.ZW)5F1>4&KG;0,2NN^CK V(P>I/GB[
M4AG#4S<Z2T4MJF J%F7"&][(5P&="P;?=O$9D^@!#RPQS ;.[E9=FL$\T]&7
M]UXSS+%'LL15;@4PJ&\[VC%,3$IVHMY;D+6U*:,5%J<>;4(KI2F\W%ZV0PER
M+*D,.'RAA:GN[>4EMHI(4I>\VGQ$UG=4I0<1N",5@I0HCRI]<=K!0XM*O?H)
M5A6$I(.IRD0JTU<)NMV"8BQWLKP[N!PM.VI]E-IA7#V:=P=(GYI"7:-:!F..
M?PT7D*LMSM8]6.AJ_D:"=PLS'M32HM8Z;:.GHM4FB"[SUEI\FYAE'>/D'&QK
MK<,>[:,$;6J+N;S5;'+I*TWI"$E*ZM(R\'4U7,9Z%[KSLF@X)% [CWJ42Q8O
M5$&,FZ.T9FM&MN+"ZPJ0')24(]TPXE491=0Y:WH+#K1:0I;BW92[E",!+27/
M*4OHP4*.[7D+G$*"YO+ '?[P+9*@J.ME"D[H)42LR&BU@'?"QC!JD_34\;#D
MCR;ZSJ/" VK[HF43"O'R;E=?<S7 F+M""QDDF;V60=4M^QJ5@1?!$22C6$.\
MC#-PD8M0YSBW7"1V[C ^R'"B&WBJT?%6X +IN9PGAC,E9L\[G.$E:_04,I6U
MM%+0,[72TUHZLKF.C$)!(7[!ZQ;JN7+9=)N4&YBFNE[2I:DPHDBRWJ.]/[[N
M XBUE(3'2''UN%NZN% 99(>6 %+W#NI2IX*:369P2XTVN++0I[>W<I8(P@;R
MR2F0K 2CWYYXT WL@5 ::N[NGDZMOU&W0;V3W.R9&K6S[933Z#9K/[C2L=,Y
M4N5AR'58Q_5,?P<]+,B,6+J=GEWI!EG,8N"")XR((JP4?'G(_!*^#=IVYO;Q
MN)RWMAJN5,$93VO51GDBWXGR'D!MENKY Q3V7*,K8J[: A8B5@K1#N&+]1XP
M767C5/16S9)BHE+)2D?;L[9VF0AAYEFX+AN)M7?SA&1Y+ =O345ZWQYJN_[U
M+SC<V(IXQVI#,4263)>:2L*JE-RC+"5)2\6E>3[SW=CNV52D-K90Z=_>"BEU
MLK*$K2V%H*U)"JJZTU<;N]\GWB?&&TS!V=\)S5GD[PEB;!F4=R=/GYL\P,/4
ML^Q!V51R)6T31K!*+K+;(5>LM9E6J;J2,T+)11U_,$9BL[QQN#V*5Z)\HS3=
MEV#ALB<)=0PL1%_89#ZI)B%:W.KMK3D"Q.W(HL!<,*U"HS<X1L"1/,M8_P!'
M**ACD#5<+;*R3D=XTX^VA+%XD/E]H-^3-6-4,352!OJ* IJ=&DQRD+#T9P.9
M2<))JY1'DA25J2-V2M>\G'=IB%OO2O!.,I>;<1C.\A6=",&KG35D/E$ML."L
M)1^)LO[39ZTVW;WE2,R=6F<];I=&;D&>5\/6^<K=MB3K@SC7:3*0:,49.+;.
MF9 50CY%VU7%JNDDEX#?KMZQ_MOR/B.JXY&?&+N^VC#>6IKZHI?W9=!:[TVG
ME9P&3@6K46T5VXUN+)@)5 ;!YP 5,!P*6\M^T=ON2;66$R4*NJ;D6&WV0TZP
MNTNH9G,3&RLJ8?:>7W9;]\=Y*LD  J]69C+X9*.\!?#Q2E:0E23'4$O)<&]E
M"D*.,:Y(-0=TU83Y.S;GBC<;=L^L\O0E^LT#B';+D'-L36L;6 :W:+)8*7)0
M(-8!H]+$3AUCS#1Z\CVK4D<L<9!PT5*184_,*R#MNR?;M(#Y/>\56 S[B&)W
M;9Z9XLOF!\VSL2MDB#JY+.VAW5XJ,TWK4!,H0,@C_HC*0FH-3SKF8BGC=)J)
M#M'5O-VLMD"Y.VN0W,#S*05NH::6QOJM\FYH:3A_R@K5$B/JW_)PPA:0AQY"
MEHS0Y/CM/JCK#N^D E24)4C)96^E.=\*R6VUZ[FX",%0R,TYZ:M WQX&P7@:
M0RM1J%M2W<TIY2LFJ4*LY\R;=W<MAZTHQLRHB+R,8KXYA&KXUMBVCWZG"-K*
MX4(<IG:9WR394ALKX-\G=B?)6S +A/V2T--WV6L89LSWMQI<;)B>MSF+<(2E
M6CW;&7KY(_SKZQ7<SZ3-!>;D?.^B2+&1:HG3AGJ3GR5MC:6[9#NSZ);$6?,:
MB1PI,9YX]ZQY49+B8<N2AJ*Q&2X_)4XX'6&V7%.,@[@72;C'2PU(6'$-O.);
M1E*%*RI <WU!MQ82VAO*UJ)"D)224\,TT::LAVE8+VY6G:GNTW+YYJF3[N3
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M9">4YK^49&9F+YLSJ^-YW&$["/BPD)9&-^E'B\789^!*$F*Z,K5U(IR,.,B
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MB_[70>JHP2^S_:6E%22J6U[;LFHG'OC)J$PEC,AR&*U6,4Q#%K &*8I@ Q1
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M*8KRW$)2RVZI:SNH !2594D*Q-[N,15LDH8F,*>6&DMI9?0IPD/M+5@-J*@
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MI33332E----*4TTTTI33332E----*4TTTTI33332E----*4TTTTI5>/E6OK
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M:R&^H]3>OKC7:U8:G6ZZ,I937Z]V2OSLDX?NX0(]55G$(NF1_GX>?\QZCQ%
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MKN!DSP\I'LWA&KY@]L 3R32E<D/,1ISK8V1(^E1>1GE8!%[Z8A29J?EJO&6
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M/VG:*X6K,Q9(*&C[?#D4(H@6PU5Q,0"KI%PU1DE%T%4R9?,!! #&$./4;M<
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M6C,UQFZ1TLX9Y >W=G9A"XFRT&2#RLC&N)YJO,/%RQKB)](8&9B:V00 0$!
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M9(> <RYH"NS&><5V*DPE6QJO(PR#VRH59V\A$']AG&M6=RYRS-A3CF2[M&)
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MVXVM)*5H6A04A220I)!!(-=G=A$M-M@E$2B%:GA 0$0$!")>" @(<" @/4!
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M^=/T>;*B[P;;1WQ)1'#@9W$O(4LM.)"T*%5_.NM2)4UMR\22S"<O <+GN=!
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MEXMHN%I")3K=R5#7(>6^H.E<(NKCJ0$D)3NF0YO#!"L@'A62_8W: 6\QU**
MKWRG3O*[Q*1DD  %.,IP /?*W@K3'[S\4>59VKY%]!:SMCDL9RKXPIHMKY'#
M$QRZQ1 #%9V5LM(5AXF(B I*)3("J40,4G'(!8/6[Q4+@Q1DZQ9(6=CW!0.@
M\BI)F_;*E, " IN&JRR)^0$..R<?IU_,\AK'/UM4RE?FI.&$3]LY(]XLW;K&
M !* N68&%DZ#@1 2NFZQ1 1 0XUGO&N[/+F+'Z+ZKSLE ND2B47]+EW](?J"
M8X*"JNTB15J3]83=3FDJH[%4!,!S (]K7/;OV$N>_78[J%\2F/-1NGS!U)P
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MNOW*PS;^NVF;EF<"T<6 T$#9%=!-K[;V2OUIB[+[.,3)S$)YNQVH%$]1@J<
MB,I[QCRL,^4LDY"9#'>,J*2$N$@X^Q=E-IK#"V7V;C3[I%MK[=BM([NY+-N+
MJ1"93WT;RU+"94=2@H)D1B\PI25)#A*5 3RVL$,?9532$*)CGHEX*4A"B)C'
M-+6L  I2@(F,8P]  !$QA]8CJ@E#H@AX@@C]Y,FOT-[)0 =K.(P$ $!AYH!
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M)=]!MGCR*-,(.VSUBX=&534D(H4WBGF&"W8*@=%F<JH^B(@'/J6X[)=,AYZ
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MJ*(:$I.)4]=;.QE<=B3&C) ^AK+92VC.\I9("05$IW0A!2$Z=T@)WA4.8Q3
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MB]#$%S?2B/4.!+R E'U<@)1Z@(::GAE"@4_%FT;*V/J#!,JU4*I@?)L3!0K
MJ@-V;1.DV!4XF46.JX=.W3E19X_?NUEWL@_<.7SUPNZ<+*G:V[;RWKM$;9.U
MN.)<<MUA8A..-Y"''(R66EK0%85NJ6@J3D XQD Z#8>T"W.6F+L?:WEH=>MV
MS[$%UQO.XMR*EEE:D;P"MQ2T$I*@E1&"4@Z#K]DGUK6(O]T37\K)_4J=16V2
M?6M8B_W1-?RLG]2IU]-77ZJ7+[OF?E#E=A[/_P!P>Q/\D=F__#0J:TY . $0
M 1[@Y[_D\=0.?;Q+NTWXP^SY/;?D5Q2)/&REV5W!$*\"GM7I8MS*BEYD(4T0
M>N-W#8E2>2REF0FTKJ]:QB5;6CSA(J1J\I%E/-N,\V[>;#B>]72&B,9XLSSN
M+O\ CJN2P-(7+50P?<<"R%UJ5CC#I*)S"BF+[%D(]?;E.W7)/"P!!PD903:Q
M^1KT.-/'3]-;@$DD#@2,C/AC(X</3PYU<-R < (@ CW!SW_)XZUU2/N3W*9&
MO.[K;HUPSD^T5[!^.,L;3*]?B521290.7K1NMEWUFBZK/J)"NM,5^M89K\39
MCL@]';G=9$BU3F6*)!'VC'RJ<2_S*PK:$+BD<:/MQJFVQ.-#+3M;<81^2WN<
M<DRVMB)K4'$*AC=6_-O0O05+E]5B-/61N[ID@@8\0FSCU@#KG'Z?SU/=JY:Z
M9(YCSYZ$&KA-:"(!QSZ^[H(_/T]0>L1Z!ZQ#51,OY0?/S5)&V1FVRFR>/Y/=
MO;MEE=*;,,G'W:=RDUNMIHE-N81RU 4KT9B]Y9(>-B;4[5G'=KBC*S\E#5Z8
M:1$6G/>+W [DLQVJD1=;G<:Q\7G[;_Y0_:MCR7I6.\D/E:3DDUG<56_4P86\
M34/77\=7[3 V^.;V=E:*^(08LY/TAI+HD;I+-X<M?8:>?7@?3@4W%9P=/2-.
M6OF.G^1S5U>FJLK[OPR]A2J[BHC*N#Z@]S5@N-P!;X*MX[R5+RE RO1-P&2F
MV,8!U7[59*7!SM=LT/:6ME@I*&GZT5D9VPAI%"3&(F5%F'J,_;N<P[?Z-C]>
MZL-I%9RM88.\6.:HMQW$W&%1D?J:=D4B*OC0&F)9*RVY\ZC%T6UGM4K U^JU
MB=\RV(>6:/VZR3(\WG_3P^/Y*C<)( QJ<#4:\#X^!%62Z:K$B=\F7,R6/!U6
MVX82J,TXS;M-@]TR<SEK)4G3(RBQLI86$&-4GT*O3;>^EY%RZD6T;&N80ID3
MO?2WKX&D6S\XYQC+>5:AI2D[;5ZO!8QQ_D#/..[KD:<2W#91?X_QKC9GCFVF
MQS8H!U<:_4;1*VF?F<A-Y.&J:,;7V2+F"AI>TRYXY-LVBWK(^+/3'GX<Z;BN
M&->>O#GDXY5<3IJ+F#-RS3.6UJ%W(1-9/#'DJA<)AU57<JF^;M+!17EBA)Z,
M9V%HU*G*P*\]6GWN%9$8] )B <1\R6.;F=>AIQ1PYOSS#9HW:%D;,&#J50,/
M[T'D#4\>2E4R=-W2ZTZ[V>DRMSIJ5\@'M"KL,6NWQO7IEM#O8*=D)&".K!A8
M6Q57T@C%LCX@>!X'A0))STTXCB-<#QT]LXJU'3526//*%9HMFW>N;B)7;Q5&
MS3,E]K>%]N6.X7*LDZM5\RG.9 L=".]NLI*T:-@*'C<IZ\_L2$ZW7L5B^IZ+
MD7BU=!TYC&*[.&[W=%3,=[K,;N\?XHHFXS#FWN0S_7[/!Y%LUEQY.8?>0MTC
MI.]T969Q>C*NLD8XMU;*Q/CVYU^-K,ZX<P[Q2UH1D@N1JWA\G+QX>WHXTW%9
MQIQQQ'B >?(G4C3CX&K;=?/:+SV>>OR#QSZ@$W' "/J 1Y'U:J:R'OUR1AF.
MP1C6^Q^W.O9JR1C.5RC.V/(V<+-4<,1-,AW41"0!26PV*RVF<R'>I*51,I6X
MZEH0U:19V.3<3DBPBV)9;@5#>#6,Q7+;/GB)Q]:XR8N&T#=SD!",?95LD?6J
M_)8AM^.X"W5*3I<7'FJ5[+(6A)TG6,H/F:$I%5]D#VOQ@M+4^;HL\/$\N8'C
MZ*G<5C.-,:8USX>O7U&K=M-5;XHWT9PL*FV&RY/VY0M7H.[O&]HMV+6E'R4[
MN^286Q5;$*V9&5=N-<D*G6X 2Y#K$3/FI:E<L<L\9O$H6/LK9D]E72<9FW8Y
MNBLFZ_'4GD6?C\2UWEU&)%HM#R).W*_XWDG35RXE\?YQ@)ZG5%>B9)K2I6K:
M1AD$WS5RJ9XHV5!JV;N'H$'A[<#^<5!2H#)&GB"".8Y=01Z*FWJ/]1^N0S-]
MK7"G_4LJZD!J/]1^N0S-]K7"G_4LJZO8O[3</N-/Y;#K6KY]4=DOY0O?^M[0
MU(#3335G6QU1SY2"!:6_.5*JMU:C(TQ[B^V3<<FJ4'#>,L-:L5=.N]19KD<-
M%G2T--+ 8'#-U^E,@\V!#%Y&F#.NU2XV)DM,4FZ2[^+\P )Q2$@]/6C()E(!
M4'$!'F\['*\=DRKAFC*MA$#"M'M"B/8_03Y1J%!&QX,L941-Z99;-17"H%$0
M20MU*FUDC&$ '@GI\"S)P;H)SD_UN-521TG(0ZXJ,7*B"A![!R=#(J]@>SPL
MB;E-0.2]X@!PX#LG+KL^P]SFP[?'=A.-I4QO!33K:5M.$NN9)R"6UE(1[\9S
M@$IR,CY_[1.VK;'L@V]@"$4W39F]6>'-E62<5*CAUAUV ^[ <"@[!>6F*%GN
M5I8<=47Y,>23A5"=GI=DI+WW/L4,O$JJ&,5NJ)$S,7P%$>18OVXG9O! /C&3
M25%PD AY]%(>FO-:_0U8:[C?*+%>+N<&Q:.G:8IJ/DT$#M7)C!V3"Y37(*"H
M@ "("\*18HCRA)(GX$*^LS[$)^NE>3V.7)96(*!G'N>H=15!!'CM#PY,*SV*
M+R8@)C)@[B0*(E)-IE*4H]JM.VT&6I$:XH]SI:L ;YS&=5H/H;N2!DG0$GGD
MC&*^B^S;MTV#[2VF6+?/3:KXL)"[#='4-25NG&40)![MFX G>W&T!J:I"2XN
M$VC4UU::[69@YBNOCQD[&/8E^F7MBU?('04,ER8"KHB/*;AN<2F%-PW450.
M<E4'75:W9*DK2%(4E25#*5)(4D@\"",@@^(-=EIIIIJ:4UT3B!AE5W3H(QD@
M^=IF(O(-6J+604,)# 551X@F1=99(QO.(J+&5%-0I3%#DH:[W6T?O^4/Z]2%
M*3]*2/'!(ST/B.AJW*4J]ZM(4 <X("@#D#(&#@XT!'CBK#*MY2#(@PU/J&3:
M:Y=4RA0ZS:N1.UW)$UL_+8)KL-"$>YE@*S&WS'N5(Q^W8IQ\@@I2H5TR3=R+
M]B@^.Y&."?FWS,L=D[#UXO6'IO#./,U90E"5.>V3^3PHF!\$;D[LUB2RS:*7
MRKEW<>I89RXQ+:$5<S$]/8FQSZ>W0EA?0SF4=*2B3#\]HAQZ^>_YN!X^_K85
M( G05 5$UVQP5:N4%EFKQFJ0P'(LR>M5$7C)8AP Q%FBZ"Q3?&*<!ZZU*X[&
M6B8C<AM-V]Q3S;J_H2Y4-Y"%E]3#L!UY#2&W7^[>4["5#EI<:2XU);65*5K\
MK9N)(PJ/AAU*^\!5ONH(XN-@%8*>]4 I;A[Q2<82-WWHN*A-GFWVOS+FM[N,
M4*;&XIW77*=,7E-],9F_<#+6M\@"--BH?;!4L.V&UWAJ\<@567!I&599)@3S
ML45^JJ5%#'-BV',8.D3"&/, >4:W$7ARFD2$R*RP GMHPVU!5J0ZCZ+I.38J
MZYSO[4CGM)@U6K=-)(M#@HT=M%NPL,:]FF\B[[),AW'(%&Q]C[(#B_5D:M:4
M+@:2@[<1NFY<.4):GY5B&LO9JG-B+UXF_75C)]I+ +!=VW3=Q#)R'IZ9?ML^
M4<KUE.;VS7VVWN\6]BR1G]SOE*K/'8Y8RTFY%1-W;\D)85A[RM'J.@$#F=V.
M.=R+A9O$-//OGK-NICW86U$"9+=,F=(MS3$>2E;,QEZ&^XR@N2$F+>-H6+S;
MTM$'O5>[\B)+1[XQT84V;%T7J$[(4X\^[&;0A\+0=YITH0%+;*W5NOLHYN*6
M\SD@J2@H*4U&JGVG.6U'**=FHDC>=OF9*\S=,5G8U9M6[8SCILB7IT?,5F]5
MEZBYBIA-HB8Z$O!N$7 -B*M%2*H^>+[YENIECVVV99R'@3;AN S];)Y2>=YN
MW 56U7J30 S%5N2,:8LC;35\.(I(KB0[596K+,$$Q5])@GKDP.@N<W]TE>[Y
M;H#G> QSON"R-!5!K$8_P+L$V]6J%Q+'5N<52>-VKW=+E9.;>WMVZ<,6[F<7
MK$>>9ACB5@UK<*HY=JN:V+ML.R$BZ?9%O]=QCY/3$DPC)NJE!;PMR$:6RJ*1
M2 &-%Q;-S6F.4K&Y?',F8AG- ;%CP,J8[EXV1!0;FW;0V*\1HLZZQHT2=,AH
M:<E,O=TN6A+JEBW1'MZ#?+K&64]^IAB%(MBU!6'I&$.N^[4RU7!+<B8R(SRF
MTA;X<<:0LI64AAJ0E33DC>*CE#06@ZH4HE(S+6T9CPWF+;3CR.JV<*YNFR@^
MA2QF3]L.Y'<?"^3YVZ8;,^;IO1CJUM?QS^@-0LLUYE(BZAF0*92LXMT$T; I
M.S'NFX;L\;8TP#LTM52M]6SU%[>Z%F)S7W$CA#%GDP,G9:W-YBF)M))^FM&9
M Q/"36XK&S6*7<C$+1,J6]UX5?//&\\YA4 ;RA840&P_>)>V;"1J>VK*MLK$
MK&.)V"N#.JKHT&>@$4S+IV&&MEF]PH5>&D6P%=P[QTHQ6EV:J+MDU40/VP\)
M&9UW181K%CP?5,VY2Q737#QZ6Q8_H5RA8*/%\Y%PG(I*6.B]NPHE=*+. D6,
M5=D&JB@F*NW(8"ZI9L+:FI$'9O:5(=3,\L=;C71425&2X\I:D*:MWE%N;82H
M%@QA88OE#:5-/RT2 I]5HFTO-$"UW-IQT/=X4)>=84EI2D[W>AF0['<PD!)4
MJ!OE7,$)164K%Y/3=?2JNE.7ZE4^A3[MO#NX?%MSR_BNNYGL[>66.V*ZK.*W
MMM&ROB-G9"H*L79&$NJ=3LL8Y[Z.[]'BUD/&&2L3S7U-91QY>,<6 2'6)#7J
MJ3M4D%VZ1_-*.6:$VP9>GM"*&*F9XP,Y: <P$\]VA !E+A/.>V:G.J.TEMH^
M$_T29*<B65WW3;K+5DG=76Z8HH^*A^B)#X$B*K5C/48H% F7T5*35A>-WJ9.
MU)O8QLY?ZLHSI14=V>>*$P7W*YM\IA'0<"VL22^#:#@]?;G16=C63A'E??T[
M!.Y&JY[Q*T!Y'0IIVT.:U/.BD%BB5Q9DB.V:%\YM)>+//2U?8[#<!;,R0N4(
M3T5:_)PA#:82X]QO=M*%N$?0[G<[=-(<2XF.$$('HJ^283_=7%E*&7-];:T,
MN(<5N)4D(:0''RM)6D_1'C&3NDJ5NI2"K\^?K#KX\AX_Y:XQN>!^;\_H[_5Q
MJ\[/.S38EBBL7>NYFS3C/!6XV)EVS.@8NVK9ARCO%G;<9]&F43A+SA.\4AMD
M''4PC,*-& ^B7MPP]$.K(NY-@0J+=U"VB^37W/SE;2R!EN)I^T[$Y5DF\CE+
M==;H[#< V459D=I!&U^>$MWGS.@.5O'D9UYLF]<F*BFY(;M"7+0=L[%+BF:X
M^];F.\0VRJYM"-Y<5I"TFV+0MYFZ;P(&Y;W9+J%E+;C:'%)0<HS>[=)86^72
MPA!2D^4#NB5!2M$$%2'>'!M2R-"0,IS7^;U>T $?E_/U>K7&$!Y'GQ'_ #XU
MDO*=/JE$N<G6:9EJD9L@X\032O\ CR+N<759-8#G*JC'DN\# 2#P$.R7F0C"
M2D"Z X&C9I^4JAB8V4Z=1$ * =XB   ]>\1Z!S[>_6V,O(?::>;WPAUL.([U
MIUAS=(!&^R^AMYM6#DH<0A:<'*0:OVUI=0AQ!WD+2%).",I4,@X4 1D'F :V
MS=P_(.N.( 8.# !@\# !@^@P"&LE4[%.1+^Z:LZI49F5.]-V&RI6BR+9<>>/
MTE94@"Y'GD *T3<',("!2B(#Q-"G; IENB24RU;HVHLT1$[J*25(60[  7])
M63'SC]JIVA[/:>(PY>V  54>HAJNU6WVQFQ$14W:K:2TV1A(44^6S&6WG2G&
M6V&"KOGW3D;K32%.*.B4DU:W&Y6ZT1E2[K/AVV* 3WTZ0U&;4!J0WWJDJ>6!
MJ&V4N.'3=2214$X6\6Z$3381DT],S4\VDG#/03FHM4"G[1$4X>42?-.IA^*#
M5NFKR/Q# (AJR7;-N2WG4R09FHK^Y5.,.Y*L)6,X^1A%"?%3$BM!LZ=G9F34
M$OZ4G'M*ZB E'ARD00/K(D'5MO6)TS(U"JC;Y=/@@RTF0A6ZATB<$565,905
MQ,<>>V1U)% ?]4 U\3.3;+)E.W9':UY@8.P#2#1*S,*?8['85=D*5P<O'J3\
MP'/J'O'XB[3OFS>SQQN1;]D=C?V7OD*2FZ7IKW*M@40,.M-%I5SDE"M2VZS#
M2H [KXR">$[5_-#['6P.1;+&?VIDIRE*E(\EMB#@#*7)+:Y#J1J%I3'BD_\
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MUTNZFIU\N=P("L!7+@#*@!1*/I+M59:0=<@(@)7+Q5,0X#S8% "ZQZ8W>!0
M 'OX  Y'QZ  ?X=_.OC3;WYL[M5VM+T39]<38NUK"DA%M2)=S+9Y.7&0V$I.
M-0J+$CNH/TKY WCP+:CYH[:.=WC&S<&-8HY!2F0L"=<% C!)>>0&6R>*5,1V
M7&R1A9-9XD\ZR+1JM%T. AZ1%JI @J2*9(-EW*91^*#L[?E=\/9 H'/*OY0Y
MC?&'N  PI*3,G+J^?E9!V_4 3"3TI8ZA$Q.(F-YI+HBB CST23( <!X:ZX1
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M>)K4A'&8K@Z3=R3-FMUIML^;<P9%N&3\^2^,JA(K;9LC;;Z'5L3.;+:HZ/\
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M+??K2M24J*$ %:@DE* I00DK4!A(4M24IR1O*(2,DU]B8 ^7P_/NUMB81]?
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ME$G ^F/J ]O;/'Y.8B9144,5-,#%)VU#%(0#G'LID[9A*7MJ&^*F3GM'-T(
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M5L=NXUQ>XZWW2Q-H%Y,%:.HZ+?NJ^T(A7V ,&=\@ID$1$0$>?^\;CGKU .>
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MCKK#*(H@*+<$BH(_I2)$NR1 B*?Q42I@3X@)%3 H)]C@G8[/8#L=G7"4=]1
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M=)RF9-4H&*8!#J #QS\NL466HG1[;IF43$ZF,0H"/'41#CV@'>'T<\AJG&.
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MLQH%V#.9R E^+( W%H.F4Z.-*/=O-MO!;:>(HY'D>1Y]O7_, #GQ#IKA'=B
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MKP(\CU$1 1YZASUYY'U^(]0X^3'#@"$*4J92@4A2E I2  < 4I0  *!0#@H
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M367K<ZW07\X1O*P\@X9/D03<)F)VQ3)S/?BUO[!N[?\ Y7LL_B34O0  #@
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M^L0J&4;'[*A#!P(@//> ].0$!'NX^D>[5XTI:%H=9<6TZ@A2%H44J2H8(*5
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MNG;;12@%]8B:,;%[O4')!#U\<:XNQM^5#+"C<1$3K_4NH'(\ )4K*@W./?\
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MBLX\A!\R4QP_5"(<B(].>>>X/O=..=9-8Q1" 4"D* !P//9#@ XZ=.[QXZ@
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>2E----*4TTTTI33332E----*4TTTTI33332E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g454639.jpg
<DESCRIPTION>G454639.JPG
<TEXT>
begin 644 g454639.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ ^1$E32S$P-CI;,3E:04@Q+C$Y6D%(
M-S@W,#$N3U544%5473,S.#=?,5]/3D5?1T5.7S1#7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M.#@X.&&#B'VT?NZO/JJ_YFKN)@\0^VC]W5Y]57_,U=PPPZ'+5]X;57\#JO\
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MV/)(Q^+/HBW$5@F,(5YZ84IUA'8,1&$(XD1C1C>PCU:US57D9FB7$?0/M<M
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M1ZN]6HED%%M$J9I SO@Z0489G@>7(1C"*Y*5$I2I02I9 )"$Y<RB!?*DK4A
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M0&EK"%*6A)!L" 2,.1VI^'U]_P IWK]:]>J_ZIQ56HOT^[IZ*J>B?4J?2O\
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MJL0E/LHLG&)0ZX,Z,0 'W>5]DE?*KW3/"2_5G1)+>]C.UBC56G(Q3=7I(Y;
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MI,:*RDHC14JM<-))4I2U  ./.*4XO072@!(RV6&V$Y6P=3=2U:K4?$]!R2+
M>)UP<'!P<:G%[!Q1R=45/I_E3YT_!U3TZ^].O5.*\'##$1= <KDK5.Q]O[IV
M!L*=MK;FVK)L$V53*6)CD+%]=T\^2;%<$QVFB2)C(42'%=!2ZE#E,%<2JRN,
MD*/Y57R))V.'8W:/5\RJBD>[KW.\-$5W7KU5>G3JJJO55^=??UX4_!QB1(,6
M"P(T9K(UVCSQ"EN/+6])>7(?=<=>6XZZZ\\XMUQQQ:EJ6HDDXVE8K52KTY51
MJL@2)1CPHB2VQ'B,LQ*=$8@0(D:)#:CQ(L6'#C,1H\>,PTRTTTE*$#4GDE[0
M_EQPJKPK&MS8AB\6NS#$\ZQB#97-6$427)QW(3DII/PT<+&$LX=;:%I94)DU
MYO(D=(\LX3)4D9X72YY0*V.]BC)&1[2(BKW.[E147HOHQ>U4ZKU^4B]?1$3C
MO!OG6C-P:BSO7*S75ILHH9$&#9-&XOP;:A,"QIK!X6.:0P8=O!@R)0!/8:1%
M&< GL*1CV\',BY3.:W:5Q#P>TK!:YIPB2-E65QIM9.+,%%5@T!2#J)[SWOFA
MIX8K*>_'(HH;$).CSY[75;O5^#.(:;3Z9(B52:F,U$?7(82I+CCBFY"&TJ9B
M,M@EQ0=;6LM I2%/]H2E)<6/F?TK<$U^M<34J=P_3%R_E&$B!-D-J::CQ'HC
M[CB951><4GLT.1GT-M.@+4H1"PFZRPVO>H8YL62]"9G6';OII(V.ZE1#0TL(
M9WHU511N1)(&O]5[A=J^Y.&HRK.H./59[6[G-APA.1KGN=WE,5ZJK @'^V*5
MRHJ]K>J]J.>O1K7.3WEV@\EY*LOAX?;7U]E6KMEU"%JK:\DAFV$#*Z?Q#V=:
M8T.)#C/EP $';06CBQ%F8]83A/\ -%QZ;+:VP, #O/>>EM:N\M;8Y)O37V20
M'A69"LZ*E&VRLP&1.X;!*T577E(9/"5UV*"Y7$FH-_?1JG3%4J57FEK>IS,>
M3,05I2Q(/8H5>$ZG.\EF2J2 PE.=P6<:<07$J3F\<G4&M-<74_@>2Z(]4DRX
MD-QQHNOQU,/A+GRG&SH96_&3$"GG-$Y7&7VG"VMM>6[5Y5AFV,>L(E=9Q;6D
MNXIX)3A)'DM"_JU&2@/C&D1RG@2?!*42$<K6_(,-&%:KNJ_LK=OV-QK6_P!'
M92YR9'I6Y^+<,SE<K+#$I?FCXZ\#RF*:0E0L:?0D.Y!#\I"JD"-&.7ID\TO(
MU7V.'5V?Z<HHT39>+Q8B6,&$R/#+G./@:YTFED/5\2(6^K'%?8XC+GD:QIDG
M8T:7%J\A.:(UGLZ=,;)Q_<&S-HYABE_AD7(*NFQR)59#"?639KZZ7,LIMG\&
M'<DV,$)"Q8$<LX07S2K8$C#6)'$>1PE>XAI'$?"BWG W"JL2;'4Q 6\EQX..
M+0R\J.K*VIV*]$4MQU61);=BM(6+H;4OV#@G@SB;@/TCJ@M>L5/ABKTF4X]5
MQ&4TP@QD]I'9FA*UM,U!F79IBRU"1&F.N-A/X=MGM?P<'!QYACZ'P<'!P<,,
M'$/MH_=U>?55_P S5W$P>(?;1^[J\^JK_F:NX88=#EJ^\-JK^!U7^@O#X\,=
MRU?>&U5_ ZK_ $%X?'AA@X.#@X88.("^T-M;$6I,1Q:',E0H.=;-H<>OWQ3F
M IZ:/39%?NB'\%X_'A2+&FKW2XA5=&F, V-*&6.0HGSY543WJG5?<GSK]2?/
M^3CFQ[07,L>(W2^MP3@2\PM=E1<B^ HI&&LH./5N/Y%5DN[&*QREA5LJWNJR
MG@GE(+X0G27BA-D,B3GQMK0D9ZS2TY.T'K\52D90L%"'D+65)((*4H2I2[BP
M2"3H#CE^-G2SP?Q.M+I97\AU-MIQ+A:6'GHCK3"6W$E*DNN.K0VUD4%EQ2$H
M[Q&(+2:[97+Q>R,PY<LKO154&P+,L<$O91;6FR:(@T&85[1QRPZRQ,9!J\4Z
MI#39)7*K25%R)4D19LJ&>U'I[3$H=?C>H<VE[@F(R$3%K5H!8G7V#E:-3CRB
M"\MIDD0CE>^OKZK&XEV96,!D4?#U(^2&T.B2TH@R'-[616RE5Z#:U7./)*Y_
M>1K4>17=&]O>KNQOR6=&JJ<(>)5RJB8Z;#'Y<B+Z2 !$.0J>J?V=!^.B=.O3
MM(G1'+TZ<>FRJ51*FI#LJ*1*C*R.+C.IB"6E.B43,K*PY?17:-=C)LHI+R@$
MD?/]+XCXKX<CN1:94,T"<V%L(J+#E252UN!)6Y3"[)06D)O9$>09$)*DA:8H
MNXE6)8\['--IW8.OR;TK<!9B>:6U3$N\>J:H<&PQ^LM9@XA),(T*WM9]9=5K
M)#;'X*O;&_%.!$-6E6N/,#91.T5;-980@2V*BH5O5>WW=4547I]*=4]%].OO
MZ)Q\W7-;B679?7XS<XK&#*M<6N(UKY.4TKPR5BD9("AV!13E"\X!,D(-%*H7
MF>-"$:T9)>UO.SS"97BD;'-?:>J<!M1C:.9DF379<Y97!>)RR#PX+:G"Z(!X
MY')X,B]LY<=S4\0M21W0'&CXAX6=>72WJ- 8;;<AK1/4R\&8S4EN0H(4L2Y*
MUMYF%MG,5J[2VA6L*QV/!GI(A0(M:9XLX@E2)#53"Z6W*BKE5)^$]%9(;8;I
MD!L2;24/Z-QTAC, KLVBW;L186E=4Q23;.?#KX8>B%ESI4>'%$JKT1"29)!
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MU;J7602O8<4V$6FP_P 1PY(T?#CE:Z(KA^9D-8\('(WS:M[V-<HT[J[= >H
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MMH/RRQFN>X?@I'>TB/1_80KW);C88EO!: ^:;*%$BSI8AL7*XJ.,@G,\LA9
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M'3"K%(@T:YSWRQ%<IA-\9KO-06MD$<1&M/PY$)97Q\O!BFF='+28XZ<%))"
M0B1;18Y$5SW(PSR]1#;W_P!=QD,1[2I%:0<B_4>UT_NB_+3PU\[ ZQ87-LP
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M*O1%]/GZKPI.&6YB[?X!T=L^Y[NSX-Q"TE=__!\-HUZ^OSIU]/P\2!F( W)
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M]I&D7U=$F6KG18(K.XOXUX.*M@5/+B/8R11SRG#"LA91@L?<2RZLA*4%2E$
M)2,RE$D"R4CO*WTL/V8M&0PD7*_.R38>_0?JO\<<IO:Z<Q6L:/F2P^,#8^'2
M&IIRC(5*_(ZJP49DS'-&D$]L&7(<TC6M8KQJU'L16N<B(Y%5$^RYYKM8)S.3
M1V&2S9 7ZLS!!)5XQEEZ\LIUSB*A$(5+1SR/<5J/\-W:K/3U>U')UC-[5/=>
MKLPYA<'N]'3M276+ TS10366LFX[8U,:V'E^:&/!-+I&H$$\<0T,QHQ5&=D<
MT9[AH,@U7+]E)S!TNO>9ZVR/9FQ\8P'&&:<SB"RYS&ZKJ*F2SD6^'E@P12[,
MXX[IQAQI)(L4?<<S(Y7C&Y!/Z=F*8KY$SEI?;>JDY<QS9LPT[/LBJ_*UQKSQ
MA^NI+MKG)F'*QMW01[5M[\N6HYX^L$/,7B<X3CTV&;GO@,)X2EK--;!:SQ$7
MHK46PI("].[T\14\-$]5?VHKN,4G,%)5SF0]%<P<U6IUZ_8\C0&.ZIU1&OM<
MA@M5?=U^CU1>B^G"7UYO3&]O8]\;=9[$I<^Q5;"=4-R/%93;"D-95JC981(M
MBD44::2"0K 2R0GR(X9*OC/,DD)@B7P[>S(OVR;(7JGI\OITZ?-Z-1.B(J^G
M3KU5/7Y^..+*D**7,R5#0I4,JDD&Q"@0"""#H1SN>@R?6T:603?4',#O:VU_
M'QL>>-/'WEF<Y'NA<N&ZT1KE:GPG'P"H<_M]ZM9+SQ7*U?\ >N5$1??Q?%MS
M:$@CAAY;-C,[4;\N;D^KH@U[G]GR7_'8JKV^CGHK$5K.KD[E3M10CG2U]\D_
M3T7^RNZKT7WJGN5?T+^#KQL0G,[KW&*Y47JG5[E_+[_P_P O%/9_WC\!]O\
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M,^6Y#1S(CVD5Z,:K'&:7HHG]7@'[D55:[Z^[\K?TIPT^L8#WX5@T]IAMZX=
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M+'@4SW,>BM;>6"**4C$>KJB#:C<@U.(B=-]+1:''X9[>YBQ"(Z,@H$9X0H(
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MSD[S&?\ (CQPM+)D/^0 )'=43@CRPYWS&VMF[!<-V%2Z_?"(^)+7*,?I;2:
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M<7(<9D.,".Q.C1":-O1.G1&M5J)TZ(B?3[N+1/?Z?\'_ "\>>H'<%]QE!_\
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MP2+;'L=Z-J;?$#G;EM_418]I10VRJ>XCF_1A$!Z3%2ADH0FY"\YTS ;* O8
M%"K+*0JP"3?3'S'0Y,=GL7'&WG5NET]HVRMT(6@YE9U)25!:VQE1E2LI%BH)
M2I*CZQV5K/>.2V>8X!C8*/.ZJAC9!4[ L=20:6+'E6@)M-CLR02FS"952K3R
M\$TFN277VSGP(DI\"0]@7'<_D"SD8_DE>=I$*QSF@DHQC1,DC>UC9?VKO*T0
MC,:\R"1Y$"005817A1[HVY3GFWZM\9^LI4S.(D>K%+SUDZ#7V)*^C,Q6$O\
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MEPRJA#:U$^TNZ%*^0U7(Y.Y>\:-1$:BJ+[8KT[48ZB^[\K?TIPT&MJ^43#L
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MG)V3[BB4EEU2B%-(;!3<W>39"B E>CK$JKQ2T:9&;E!3:RMM4=UU7:^L16D
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M]P/L6:R_>[P7\T,>_P!&\'V+-9)[M=X*G_SH8]_HWAVJS>]M0 ?MKU.FH^.
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MDBV;.[U2:DE$*\3!J]]CYA0RFM8Z3VF/XZ*(E2^IK9U=?A.-9<R173(Q([6
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M=5X#F>U,XJHDW(JVUJ=>:[CRY>=Y=&K;[':F;D%/B,6!+DY 7& 71ZV.!YI
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M8A;[ W+*J;V:.[UM@]'!-966797A=C5P,XKL<%$CG(*X3&S09CQK'AFD27,
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MJ;3-8>NG:A969J;(!9M/J!WT/'3SP8J3&H\V13E'/&\U\R(H7*CI+2-<Q/E
MWI[/GGER.)SFY; U#ON_U/&Y<_83Q]E\I-=K:-Y'GRQ'0>!4$7?VFZ#,65HM
MGXYL+1EK7_"Q :IR>FG/LAW&,Y977;I50")TZY:<5Y@]=>UCYX<@N8?M'=::
MSYD.;;$<QUV/7G+'C%YRC;%QF?RTXOBD?.=V;1S#64_.L''B61!;%./'<[Q&
M+#LL?AP+>#(F-GL'':*) -N0O;2VG57GT^.\EEL#<\_QAN+;]T]>778:8ZK9
M][6WV<.M=EYSJ++N;764/8&M Y"_8%)4@S++8N'S,3IYU]DM%?Y'AN*9#BM?
MEE'55EC)M,.)>+E4-\&9%-3LFQC1AH_#?;5>RUV #)Y>(<YNK[R)AD*FL,IE
MQZS8H(M)&R#.<4UI3K.DSL&B 8:;G6<8GC3(;"$F#GW459  Q6R) (>>QGR7
M9O)AHO3GLWN8#DWYIL3W3KC9>TZ3*M\8OI*VS?E<VR3(-A9ML:%S$R>8^HER
ML6B1,PH[6MB6(<QDQ,XK<@''Q]U2T+8XX\*,GY1^:.5[)?VCVJ \ONV)>S]D
M>VLRG>.O]>-PVV7+,ST_+Y[]%; C;"QVG\#S5CATC"J"ZR4=Y&:ZO6GK)T]"
MI'CD(D9U;@I-^64BWG<B^GTW\+@TW;4*W !S#O;:C??7QYX[V[I]J#[/OEWW
M&F@-U<V>H->[:$>AC7&*7=U8$;A\C*"B'C@-B9%5U5CB6LS7J'CGJA["R#&'
MS(<F+/&WR$D$DCR-YON69^\,[Y;6;GPM=YZRU7'W;G.M%ES4R*AU5)C1)@\W
M=U@)76-.D.? E&2FGV4Z-&G1#R88AR1.?\Z608EOOEDUM[:+DXR?D!YF.9W9
M'/OS"\U6S>7[;VK=81=A:6W7B/-;BS,>U;4;<V[(M$Q_3']3I8R75=_&V+,J
M8U)25#+K"HA&EB-+'6T]FISIZ@VAN[>6'ZVS/97,ER6\BGLS,,U-F0ZR2;'^
M;Q,'Y9=K<OO/)R_XIE,RMN)N2R\VPG)1S:P,)TRSK]G8QK.YE,6P8,[Y+BA:
MUC?<6.FMK;VOL;WV/@< R@[W%@+',.]JG4=!J1;W[6Q]166<_')U@F@=4\TN
M:<P> 8MR^[PM,+I=4[4OI%M6XUFEIL,<\^(0ZQ)-2RU 2WC55I+[[.L@!KH-
M=.G6Y*^'&*=KRW6\M38]N;"^7JZSBHK]S[$PK,MB87K\P[%UQD&%Z^G5E;F.
M00CA@EJ61**;<5L>2*791IAG2FNA190QF>/XZ1>SQ]H3SC<OGL]>4/[ .'8'
MK?E!]F%<XSGJ<X8MO:EQ(_,IS=8/E^E;-,1E8EKW-)V3[*Y;=71?C""#)@0(
M.$Y=F??<&6:.%'XDSIW.^<S7>\/96\S'-)R9\XN695R[<BG-URB\PS=-\OF>
M[3R%-HXOL7!,&PG,TA00Q7W%!N7%,$B[&H<JC2/@J_#<R)%>J!%(2'/:*T%K
M VUUM:_>M<\R+GIB"RCKKKI<7)-LOP^GPY_1SS1<Y?+%R5XGC.=<TFXL9TUB
M>8Y0["\8NLFC9!+!<Y2RGG7[J6$''*2]F++2GK)\_J6*('@Q2_;O$[1N8W8'
MM8_9RZQU=IS=69<W>I8.J^8%N7+IO-ZR9D.54N?DP$E>'-XM,_$,>OI0K#$I
M%K BY'66L6MLJB9(\I-B"D#.(46?:MZ2WUS,7_LK)G+^;;VM;?&^>.DV-DNV
M,-UMCF79-R[XY8\NNTH,;/\ -<2V#CV58771*2\NZS'KR%FU-+J66<XM(1S;
M,L(G'#K&^7+FNU+@_LHYQ]&^T TCL#EAVS[5:@YK=M<HV@P;BVU<;)VR;#1T
M_,!A^-;-PC/,+GZ]YH2M2UB2(&*R,:H0,OZ3"G5HJ ,D9;B@3EL1H!<:V.7>
MUCH/+GXX(;00"2;@ZBX&HY<^8/C?KS^LS.>=SE/UOA'+_LO/=[8+A^#\TEWA
M.-: R+(9-I60]H7FQJJ->877X^*15MG@)>54R),$6ZB5$:&.5&9:'@F,(;F_
MYE_:0<C7)WL'']5\S_,MKK2F>Y5C8<RI*#-W9)%?(Q.5?6&,"R.59UN/6=)5
M4WP]56-86=;V4 ()$0JR%$%1E?P-Y^.3OG]]J7MR;B&O]8UE=HO1?()CNJ]?
M;#Y^(6Q-$YOE?,QS-T.,9KL#>N%T6N->6U1.W=J:JU_@F(Y%XE%B>!X-FUWF
M6/0Y#>XD"IVF$[BYMZ/G&Y<^=SF,]G9SG[0N,O\ 8K_U+>Z-9:VY=;7*C&YI
MZKFGG6688'E47))<'&\9Q?/:G%IV70<BR*TE4)L.RVFL_'G1K$"$=H;'0"Y&
MMB;@$7MMISTZ6U.'9())!N=2H B]SJFYZ6N/'0[7QW^W=SU<GO+MK' ]S;AY
MB]78IK+:LF#%U3EL:^=F$3:A;"*R;%35\' HN5W6Q O@E#.-*PVKNH<.&<$F
M=(C"D >3"Q+GGY0-AX7I'8F"<P^L\PPGF4V5'TYI'),;N9-Q79[M<]=;6JZZ
MA>1KS2J3,HL&CMBV=%EL;'9M0^$\%L.%(+'$;YU^4;E!YJO9R77LT^9#=W+3
MM;:6':TT9SN:ISC1?+90/YA<^Y'\FYHM]/W5K4V+X;CUE+O<TQC'L)>;5>7Y
M!K1]G+QL["0R(>M+$29K7\LO-3629WM 8'*%NK&,#G^W4U[S_P!=R98[B@)W
M,I1\M]+I'*-)9EMM-.P+$A(VV-F9+?QMC9CJ<$UN3Q($!D@RG:\3@LZNG*]K
M&XV-]]B#M;337$=DC2ZB==P18F^B1N;@BYY'ZN^&[_:6\A_+E=9[CF[N9S7^
MNKO6&5X?A6P:Z[AYO)/A^4; P*7L_#*B\?18C< C&R#7\"7E4&2PI8#*R.1)
M<N+,[8BMH7VOOLSVZOA;B3G&U6775MFUCKNEO(\'8DF??YC4X[7Y9;T^/8A&
MP0V<Y .EQJVJKNZN:7&)^.T\&R@OLKB*69'"3F6FE^8C>NGO_"-N82!RY[NU
M_#Y\-*5&M^5C4FT,$LL0WSLA=*\F>4Z:)?.U%,\7+,8#L+,K6+'P2BO8D3(;
M82E5T!J,:XFQYV-/9WB7+9[.G:6LL-]H-@W/]RT<ET7$=%; Y2.7./S!TV*9
ME-T=J_&,RY?^9S7.10K+&H-%G&2P&162<@!0K2R:'(91\KB?!PZJ945*&HM:
MVAM_>YZCP-C:_P!5 ;:/=-RK,,W>%O9"B=- +W22+F_B!CZ%\8RC'LYQ?&<V
MQ&VBWV)YECE)EN+7T%#I"N\;R2JBWE#<0TE C24B6E3/ASXOF(T<_@2!^, 1
M.X;<TJK\WS-]Z?3Z]%7_ !=?\O#5<NUMN*]Y?]'WG,1CE-AV_+C4>O;3=>)8
M[X/P!C.U;#%*V3GE%3-C3[2,*OJ\B).B!!&L[&+&4;XL:=*C@&=[JE]SO3YO
MXOVWIQ>3[/4$@_'+I])QA$:D>8Z_R.-OBR?[/PT]$5125]/?_8'(B?4J]?3W
M(ON]W&JY5?N,V*G_ .D-S#K^3[+V6)QM,87KD,)4]WA2?7W>X+_\J<:OE6^X
MS8GT_P!4-S#]?P?^5_+5Z=?]4XM/$V1[OI2K]@QG1;67N?9.@V-[6/Q\,2;X
MA]M'[NKSZJO^9J[B8/$/MH_=U>?55_S-7<6,96'0Y:OO#:J_@=5_H+P^/#'<
MM7WAM5?P.J_T%X?'AA@X.#@X88.#BBN:B]%5$7Z%5.O%55$157T1$ZJOT(G#
M#&MN:>LR"JL:2Z@QK.IM84BOL:^6-"QID.4)P9$<PU_;#*-RM7HJ.1>CF.:]
MK7)PFYC-$66C\R6&%)<W"KUQY6(W4A%>_P $?1\BALS-:T:W-0US>K_DK8US
M@V T4B3F1^]'B,1.JKT3Z7(K6^J]$^4Y$3U7W>OK\W7A![-UMC6V,.M,+RD!
M'UUDT9 RXRC'855C&57P+>L.096 GP2JKPO>,@BC<6-($6,<PG]#P]77:++N
MHJ7"?*42F1KI?1YL;=JWN!H'$W02+I4FP^R'DZ6"T^R?K!\#]!UZ@\?^5?EX
M/N7)5OL@CE'KG%YH5MW*U[$R:S'V2&8O%*WMZ1T&HSY#)$_Q(T,H( ^R38H:
M+VYCQP1 !BQ@BCQHXA@CQP#8$  A8T8@A"-&C$$0VM&,0VM8-C6M:B-1$X3V
M&X?08%C-/B6,0!UU+1PV0X48?555$57FD'(ORY$R8=Q)4R457%DR2E,1RN>O
M"GXM5ZM/5J873=$9K,B*P3[#9(NM8!(+KM@IPB]K)0"4H&)892RBVZC8J/4]
M!X#D/,[DX.#@X.-'B]@X.#@X88.*.]R_4OZ.*\4=[E^I?T<,,-U@7[I;*_&)
M._5?$N'&X;G OW2V5^,2=^J^)<.-PPP<'!P<,,'!P<"JB>]43Z_3AA@XT]_D
M-%BM-9Y%DUS58_04L(UC<7=W81*JIJJ^,U7R)UC8SB@APH@&(KRR))AB8U%5
M7)PPNUN9/&L$R4>K\,I+;;V\Y\$-A7:CPDT1+6OK92N;&R+8&0S7)C^L\.<]
M$[L@RJ2 LQJ^'0U=W-4<0B%Q[EOR?9UQ5; YM;ZHV'<U-B*[P_3..#F1]$ZV
MF@>TM?+6HG=D[:V95WK_ ..>>C)7Q9*N/BV(XVJ(4FF?JJG'G(=)9$^8THMR
M'"LMT^ L6S)FRPE=WT@W]1BH?EW*.W1&8<]93W-/X/;C0HU<XQG+X<HDII,F
MG1DL)D\2\1,+OV;E"HSCK!%/=4"D\055Z!10AN4($BK5&*:4ZE+/8&V^:F35
MLY>1S]4:JJK-\Q.97,:!SKG* %KI]7-'HO6=]&"^XA3ZZT.&'L[.PP,: 1R3
M\9Q_+&A:?A#X3R "QS86WY=IFUIDF';#PC6])97&<0,+V)G&PK^EO<UOLEM]
MARLJQ&6(TR+*LL;6@LJY\:0%L1H8;*R-2U0A=+FM1J=$3HGI_(G1/R(GHB>Y
M$]$1$XKQ930([[L>757#5)S#BW4N/MH$5GM(TB*XQ%@GM6H\934EU*KJ>EO@
M-"9,E!ENV:[Z1ZE A5&B<'Q6^$>'ZC&CQ7XL&0Z]6)OJ=4IE7BU"L\0)3%F5
M.J-2Z3%<:*&H5&@+7,<HM$I*YL@KBE@'*['U5'LHNN,]G8:*Y((MP^FU_JI)
M=L^.U[(ZVEG.Q";:6#8PR$'%%,FF#$8\C8PPH0B/7T?6&?0V>%%WAE48?<K_
M  X^"ZC SO5$:KNP6#L;W*U$17=.JHB)UZ)TX>_C67-K%HZFQN)J%6+60I$T
MS -:^01D83BJ*.-SF(2096H( U>U"&>QBN1'=4W;++,=M+,=EIAE (0TPVAI
MI )*B$MMI2A(*B20 +DD[G'!S9TZIRG9U2F2JA-?*5/S)TAV7+?4E*4)4])D
M+<>=*4(0A)<6HA*4I!L  T4?5^>Q&N9$W?E45KW^(]L?!=1!:\B)T1[D'@[4
M<]$ZHCE17>J^O%(^KL[BJ18V[LHCJ9W<508)J(*E=U<O<3P\'9WNZN<O5_5>
MKG+U]5ZJX,#8U@-LR1D5'0DD-0B4\?&W6[:YKNKFQ2VLF[BOL)(FJULF2.%"
MCN,CV@CH)K7.N_ F??\ 'FK_ #*!_2'BYC%Z"PTMR'+;EA&#U=G@C%D"W?E(
MSG55.8>":B88ZJJ.52E;@Z/(JN1'*KW.ZJG7W]%X&:NSQD@LIF[\I9),G0LA
MN":C:<C5[>K2&3!T(1%[6HJ.<J=$3Z$7A9_ F??\>:O\R@_TAX/@3/O^/-7^
M90?Z0\,23?I\!^S"-35^>)(=,^S?E/FW-1CI7Q%U%YAS$1&]CCI@Z%5O:B-[
M5<J=J=.G1$X%U=GCI"2UW?E*RFL0;9*X)J)9#1HBHC&F7!U*C$151&H_MZ*J
M=.B\++X$S[_CS5_F4'^D/!\"9]UZ?'FJZ_1\2@=?XOC#PPOY? >'AX81I-7Y
MX4PI)=WY221'_L!WX+J)Y@^JN^U%?@[B#^4JN^0YOJJKTZJJ\4-J[/)#PE-N
M[*#%CJJQR%P3497@57(Y5"Y^#N<-5<B*JL5OJB+[TX6?P)GW_'FK_,H/](>#
MX$S[_CS5_F4'^D/#$>X? <K6Y> PC#ZNSR4HW2=WY3(4+E>%3X)J(RB>JM57
MC4F#.5CE5K55S>BJK6JJ^B<5DZOSR8UC9>[\IDM8]2L;(P749VL(J=%(U"X.
M]&OZ>G>U$<J>BJO"R^!,^_X\U?YE!_I#P? F??\ 'FJ_,H'](>&'N'Z(\/#P
M'PPGZ/6%M%RBGRG*=B9'FLK'HML&CB6-/AM+#@FNX\>%82W?%C'ZF1+*^'':
M 0Y)WQP]SRH)2(QS'>X0/P)GW_'FK_,H/](>#X$S[_CS5_F4'^D/#]>&%]P<
M('X$S[_CS5^GO_\ $H'](>#X$S[_ (\U?K[O_$H'](>&&%]P<(!:7/43JN=5
M2)[^JX6!$Z)[U]<A^;@2ESU55$SJJ541%5$PL"]$7W=?_&'Y^GI]/##"_P"#
MA _ F??\>:O\R@_TAX/@3/O^/-7^90?Z0\,,+[@X0/P)L!/5N<5"N145$)A(
MU8JHO7H]!Y()ZM7W.["#=TZ]KVKT5-SC%Q-M8TT%K$'"N:6Q)4VX8[R%@DE,
MC19H9E:4S6') GP9T26!#L0T=Q2PRN(6,\KV&%+P<'!PPP<'!P<,,-DS[[Y?
MQ<!_6R3PYO#9,^^^7\7 ?ULD\.;PPQ&3G$_W.^??7BW3Z_CGCO3A>2.J6MC[
MNGPG._+_ %R7T_ O5?I]Z?7T0?.'_N=\^]>B]<6Z?A7XZ8[Z<+J2O2ULO^4Y
MWT>_S)7?A^K\OS+TXK;O<]+FWP1?&-)%TIZW4-]=DD;]3I^N^F-I']Z?1T5/
MP>_HB?XD^CC<"&-$7H-C>JJBJUC47HY$ZIZ(BJB^Y4^?JOIQJ(Z>K5].BMZI
M^'Z%Z?@_3]?&Z9[OI]?3_)_'U_+Q>'V^(V^VU\6!M?6Q2?K1OXZ_7@[6]O;V
MIV].G:J(J=/=TZ+Z=.#PQ^J(QC4<ORD1J=%3\*=$1W1/<B_DX]]%5>B(J_@]
MZ_R)QKYMC70V/29/AQ'*UR(V1)")ZKVK[F.>A%__ %6JON_!P )V^WGX88:G
M&-XX!F>Z-JZ)QM]M:YEI;'M=76RIH*@K<4QV?M&+;6^(82;(2$8"5GI\6JX^
M:V6+Q(YI%)A^0XE=69X[<FJ@'MYOO?76N-N:4TQF,JQI<KY@R; KM6SY%6JX
MS?Y;K?'09E=X"2]:=?(9Q88:ESEF,T4J(WXQ4>)9>>OENDT$J([C)C-+S& C
M^UOT9H'/=<89S-9%S<YWS#&M=C:SS?;C]J<LW,/RU4E3I63@U;BVQ-56U'=0
M)V#3=(8]EI[RTQO$<GU9?T\F@M)<H86-XS%N;B'H_P!D#RU<PF48EE7,M)YJ
M>3W:N%1,(UCEFNLDU)I/E/TK7Y5S&OV](RK:&SY>3Y724<JST_FNQ0%QG&\D
MR?;-)C\7'89[)(Q+>95MM;Z'EN!E^/C?7WXR,C=_:S: $ DD=V^;2^AY<OC;
M'TCM9W+T&-SU_;J@AN>O_P NJ#:JHJ^Y'+ZJJ]$7JO3@\+JQ50+E9U57N03U
M9U3]MWN1O:U6]$ZHY45J^J]%7CB5[0O4UUL?F)TYE',5RV[TYH^2"GT3LRCC
MZ+Y?Q93E608IS8S\UQ>PQK9V;8?@6;8#=7@)^H(^1X3JO.R3;&GT]GA;&[G.
MQB3D%=E=<VG)KR5<QEMS"<O&U.=BAR[,<^Y?O9^<M4##LHS+/,ER/&,<YB*_
M>G- :Y9?.Q[)8>,;(WWK[1^2:SQ7,\^N(E\V7*L+NPJ[*<+(["9*G,<V4)&X
ML2>EC>P!/E:_N.* A.3,5*VO8)\;:7(O;\8>\8[.Y'O' <>W9K?E]D&M+39V
MS\/V!L&LIJ2J?:@Q_ M:/H(%[F6<3 E:W%<=FY'E&/X;C$^P$[XR9=8_ U6,
MCX5H>#XQK>NN\HW7M3E\C2["NVKJ?&M>YO?XY>UCZM;[7NSH]N/%,^PJ20Q!
MY5B#LAQO*,)M[.&T3Z'-,<L:.TBQU-4RK/FUE6/[;H/:E[9;79]B> 9GS*>S
MTU=C'*_L3+]?R\_P_'LDY;=Z[!R'?F& PPN9X8W(K672;?P'84NBAY?46%A4
MM)=J\D;%92)DX'4;(R/VJ&("L\PQ[.\YY;/9TY=@O,WM[#-=0L%Q&[S3F-Y@
M==9QHS7OQ4-EV:S,?NZC#]0[!V-\7)637<BDI,HJK=)0X^;C:1<WW&J[> &U
MNM^=]O'EB<B<M[*N$7OH"38$*WM;\6V][V%A?'4S&\[ILGRO86&U=7E\>UUI
M9X[3W\RWPC*:+';21DN,0<M@&PG*+2KC4.?5T.ML 0[RRQ*?:PL?R%DO&K8T
M6[A2X8LS)LRPS#I6)U^7Y)0XS-SO*XN"83"OI\:LE9;FL^IN,@B8GCD>6X9;
M?(I-%CU]="J832S'U5+:6'AI%@R"CX(<TW*AS'[HYA=K45CBNXKG2V?^TO\
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MX(':H:![,-I)=0H',D(4@A2L/?HCE9UAL;E?UEMS(7Y0F79=[1?37*U:N@9
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M,)AW,%0T>NLRU%CF08;9T%;&G6V+%G6PKBF'23,S);2(#JVL/)'CTN.)2P[
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M*_;X#X8/L4Z;_>+T%_@)U#\WN_\ M+XK]BG3?[Q>@O\  3J+^A?!P</E"?\
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L>5G>=<=6 $A3JU.*RB]DYEDFPN;"]A<XME2EDE2E*.@NHDFP L+DG3PQ_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
